

**UNITED STATES COURT OF APPEALS  
FOR THE NINTH CIRCUIT**

**Form 3. Petition for Review of Order of a Federal Agency, Board,  
Commission, or Officer**

Name of Federal Agency, Board, Commission, or Officer:

DEA; William Barr, Atty Gen; and Timothy Shea, Acting Administrator, DEA

Date of judgment or order you are challenging: 04/22/2020

Fee paid for petition?  Yes  No

**List all Petitioners** (*List each party filing the petition. Do not use "et al." or other abbreviations.*)

Suzanne Sisley, M.D.; Scottsdale Research Institute, LLC; Battlefield Foundation d/b/a Field To Healed; Lorenzo Sullivan; Kendrick Speagle; and Gary Hess

For immigration cases:

Alien Number(s):

Is petitioner(s) detained?  Yes  No

Has petitioner(s) moved the BIA to reopen?  Yes  No

Has petitioner(s) applied to the district director for an adjustment of status?  Yes  No

Have you filed a previous petition for review from this agency?  Yes  No

If Yes, what is the prior 9th Circuit case number?

Your mailing address:

Yetter Coleman LLP, 811 Main Street, Suite 4100

City: Houston State: TX Zip Code: 77002

Prisoner Inmate or A Number (if applicable):

Signature /s/Matthew C. Zorn Date May 21, 2020

*Complete and file with the attached representation statement and the order being challenged.  
See, e.g., Circuit Rule 15-4.*

Feedback or questions about this form? Email us at [forms@ca9.uscourts.gov](mailto:forms@ca9.uscourts.gov)

## Representation Statement for Petition for Review

**Petitioner(s)** *(List each party filing the petition, do not use “et al.” or other abbreviations.)*

Name(s) of party/parties:

Suzanne Sisley, M.D.; Scottsdale Research Institute, LLC; Battlefield Foundation d/b/a Field To Healed; Lorenzo Sullivan; Kendrick Speagle; and Gary Hess

Name(s) of counsel (if any):

Shane A. Pennington  
Matthew C. Zorn

Address: Yetter Coleman LLP, 811 Main Street, Suite 4100, Houston, TX 77002

Telephone number(s): Mr. Pennington: (713) 632-8081 Mr. Zorn: (713) 632-8064

Email(s): spennington@yettercoleman.com; mzorn@yettercoleman.com

Is counsel registered for Electronic Filing in the 9th Circuit?  Yes  No

**Respondent(s)** *(List only the names of parties and counsel (if known) who will oppose you in the petition. List separately represented parties separately.)*

Name(s) of party/parties:

Drug Enforcement Administration; William Barr, Attorney General of the United States; and Timothy Shea, Acting Administrator, Drug Enforcement Administration

Name(s) of counsel (if any known):

Dayle Elieson, Chief Counsel, Office of General Counsel, Drug Enforcement Administration

Address: 8701 Morrissette Dr., Springfield, VA 22152

Telephone number(s): 202-307-7322

Email(s):

*To list additional parties and/or counsel, attach additional pages as necessary.*

*Feedback or questions about this form? Email us at [forms@ca9.uscourts.gov](mailto:forms@ca9.uscourts.gov)*

**CONTINUATION OF FORM 3. REPRESENTATION STATEMENT FOR  
PETITION FOR REVIEW SERVICE LIST (NINTH CIR. RULE 3-2)**

PETITIONERS

Matthew C. Zorn  
Shane A. Pennington  
YETTER COLEMAN LLP  
811 Main Street, Suite 4100  
Houston, Texas 77002  
mzorn@yettercoleman.com  
spennington@yettercoleman.com  
Tel. (713) 632-8000  
Fax (713) 632-8002

RESPONDENTS

The Honorable William Barr  
Attorney General of the United States  
U.S. Department of Justice  
950 Pennsylvania, NW  
Washington, DC 20530

Robert C. Gleason  
Acting Chief Counsel  
Office of General Counsel  
Drug Enforcement Administration  
8701 Morrissette Dr.  
Springfield, VA 22152

Dayle Elieson  
Chief Counsel  
Office of General Counsel  
Drug Enforcement Administration  
8701 Morrissette Dr.  
Springfield, VA 22152

The Honorable Timothy Shea  
Drug Enforcement Administration  
7000 Army-Navy Dr.  
Arlington, VA 22202

No. \_\_\_\_\_

---

---

**In the United States Court of Appeals  
for the Ninth Circuit**

---

SUZANNE SISLEY, M.D.; SCOTTSDALE RESEARCH INSTITUTE, LLC; BATTLEFIELD  
FOUNDATION D/B/A FIELD TO HEALED; LORENZO SULLIVAN; KENDRICK SPEAGLE;  
AND GARY HESS,

*Petitioners,*

v.

DRUG ENFORCEMENT ADMINISTRATION; WILLIAM BARR, ATTORNEY GENERAL; AND  
TIMOTHY SHEA, ACTING ADMINISTRATOR, DRUG ENFORCEMENT ADMINISTRATION,

*Respondents*

---

**PETITION FOR REVIEW**

---

Matthew C. Zorn  
Shane A. Pennington  
YETTER COLEMAN LLP  
811 Main Street, Suite 4100  
Houston, Texas 77002  
(713) 632-8000  
(713) 632-8002  
mzorn@yettercoleman.com  
spennington@yettercoleman.com

ATTORNEYS FOR PETITIONERS SUZANNE SISLEY, M.D.; SCOTTSDALE RESEARCH  
INSTITUTE, LLC; BATTLEFIELD FOUNDATION D/B/A FIELD TO HEALED; LORENZO  
SULLIVAN; KENDRICK SPEAGLE; AND GARY HESS

## CORPORATE DISCLOSURE STATEMENT

Petitioner Scottsdale Research Institute, LLC is a privately held company and does not have any parent companies, subsidiaries, or affiliates that have issued shares to the public.

Petitioner Battlefield Foundation d/b/a Field to Healed is a private corporation and, other than Scottsdale Research Institute, LLC, does not have any parent companies, subsidiaries, or affiliates that have issued shares to the public.

May 21, 2020

/s/Matthew C. Zorn

Matthew C. Zorn

Shane A. Pennington

YETTER COLEMAN LLP

811 Main Street, Suite 4100

Houston, Texas 77002

(713) 632-8000

(713) 632-8002 Fax

*Attorneys for Petitioners*

*Suzanne Sisley, M.D.; Scottsdale Research Institute, LLC; Battlefield Foundation d/b/a Field To Healed; Lorenzo Sullivan; Kendrick Speagle; and Gary Hess*

Pursuant to 21 U.S.C. § 877 of the Controlled Substances Act (“CSA”), 5 U.S.C. §§ 702, 706 of the Administrative Procedure Act (“APA”), and Rule 15 of the Federal Rules of Appellate Procedure, Petitioners hereby petition the Court for review of the Drug Enforcement Administration’s (“DEA”) final determination denying Stephen Zyskiewicz’s January 3, 2020 petition to reschedule. Mr. Zyskiewicz’s petition is attached as **Exhibit 1** (the “2020 Petition”). A copy of the letter containing and memorializing DEA’s final determination (the “2020 Determination”), which was not publicly disclosed, followed by the cover e-mail and other attachments, is attached as **Exhibit 2**.

As grounds for denying Mr. Zyskiewicz’s petition, the 2020 Determination incorporates, reasserts, and applies the “Denial of Petition to Initiate Proceedings to Reschedule Marijuana,” 81 Fed. Reg. 53,767 (Aug. 12, 2016) (the “2016 Denial”), which in turn applies and relies on “Marijuana Scheduling Petition; Denial of Petition; Remand,” 57 Fed. Reg. 10,499 (Mar. 26, 1992) (the “1992 Rule”), attached as **Exhibit 3** and **Exhibit 4**, respectively.

Petitioners seek review of the 2020 Determination as well as the 2016 Denial and the 1992 Rule. *See Functional Music, Inc. v. F.C.C.*, 274 F.2d 543, 546 (D.C. Cir. 1958) (court may substantively examine propriety of a rule when further agency action applies it). *See also Wind River Min. Corp. v. United States*, 946 F.2d 710, 715 (9th Cir. 1991) (“The government should not be permitted to avoid all

challenges to its actions, even if *ultra vires*, simply because the agency took the action long before anyone discovered the true state of affairs.”).

Petitioners Seeking Review

1. Petitioner **Suzanne Sisley, M.D.** is an Arizona licensed physician who lives in Arizona and whose principal place of business is in Arizona, within this Circuit. Dr. Sisley is the President and Founder of Petitioner Scottsdale Research Institute, LLC.

In her private practice, Dr. Sisley treats approximately 40% military veterans, 20% police and fire, and 40% patients enrolled with 8 different Native American tribes based in Arizona. Her specialties include treating chronic pain, opioid dependence, and Post Traumatic Stress Disorder (“PTSD”).

Dr. Sisley is a pioneer in the field of marijuana research. Now more than a decade ago, her first-hand experience in private practice treating veteran clients that used marijuana to treat PTSD, which did not respond to conventional medications, inspired her to conduct clinical trials on the safety and efficacy of marijuana use. Through the company she founded, Scottsdale Research Institute, LLC, she recently completed the only federally authorized study of medical marijuana for PTSD for military veterans and first responders in the United States.

2. Petitioner **Scottsdale Research Institute, LLC (“SRI”)** is a non-commercial, Arizona limited liability company with its principal place of business in Arizona, within this Circuit.

Dr. Sisley formed SRI to conduct high-quality, controlled scientific studies to ascertain the general medical safety and efficacy of marijuana products and to examine various forms of marijuana administration. For its first clinical trial, SRI had to use marijuana from the University of Mississippi through the National Institute of Drug Abuse (“NIDA”), the only federally legal source of marijuana for research. The quality of the marijuana provided by the federal government was poor. It contained sticks and seeds. Third-party testing confirmed it had mold. The poor-quality marijuana had an adverse impact on the study results and on some study subjects. This marijuana was not only inadequate for the Phase II trial SRI completed, but it is inadequate for further studies SRI intends to conduct, such as Phase III clinical trials or other Phase II clinical trials.

In August 2016, toward the end of the Obama Administration, DEA announced a new policy to increase the number of entities permitted to manufacture cannabis for research. 81 Fed. Reg. 53,846 (Aug. 12, 2016) (the “2016 Policy Statement”). This announcement in the Federal Register reversed a longstanding agency policy related to medical marijuana research where DEA had determined that an exclusive supply arrangement with a single marijuana supplier was the best way



to fulfill our nation's obligations under the Single Convention of Narcotic Drugs of 1961 (the "Single Convention"). The Single Convention limits the manufacture and distribution of marijuana for medical or research purposes.

Because of the poor-quality marijuana provided by the federal government, in October 2016, SRI applied to cultivate its own marijuana for its clinical trials. SRI's application is still pending. To this day, DEA has not granted or denied a single application to cultivate marijuana for research that it received after the 2016 Policy Statement.

In June 2019, after years of delay and silence, SRI filed a mandamus petition in the United States Court of Appeals for the D.C. Circuit seeking to compel perfunctory, ministerial action on SRI's application. *See In re Scottsdale Research Institute, LLC*, Case No. 19-1120 (D.C. Cir.). The court ordered DEA to respond to SRI's petition by August 28, 2019. The day before the court deadline, DEA noticed SRI's application as well as all the other pending applications, mooting SRI's mandamus action. *See* 84 Fed. Reg. 44,920 (Aug. 27, 2019). At the same time, DEA indicated that new rules were needed to "evaluate the applications under the applicable legal standard and conform the program to relevant laws" before SRI's application or any of the other pending applications could move forward any further.

After seven months more delay, in late March 2020, in the middle of a national health crisis, DEA released its proposed rule. 85 Fed. Reg. 16,292 (Mar. 23, 2020).

DEA says the proposed rule would amend the agency's existing regulations "only to the extent necessary to comply with the CSA and to ensure DEA grants registrations that are consistent with the Single Convention as it pertains to marijuana."

Until April, neither DEA nor DOJ had fully explained its basis for delaying the applications. Unbeknownst to SRI, the other applicants, Congress, or the public, in secret, in June 2018, the Justice Department ("DOJ"), through the Office of Legal Counsel ("OLC"), had reinterpreted the relevant statutory provision governing the pending applications, 21 U.S.C. § 823(a), effectively blocking them. OLC concluded that DEA could register applicants to cultivate marijuana only if the registration scheme is consistent with the Single Convention on Narcotic Drugs. *See Licensing Marijuana Cultivation in Compliance with the Single Convention on Narcotic Drugs* 42 Op. O.L.C. -- (June 6, 2018). Therefore, according to the OLC memo, because the existing scheme was non-compliant, DEA could not register any of the pending applicants. DEA continued to register the University of Mississippi, however, into its purportedly non-compliant regime. *See* 84 Fed. Reg. 2,578 (Feb. 7, 2019). Despite almost a dozen congressional inquiries, DOJ only released this memo in late-April as part of a settlement after SRI brought claims against DOJ and DEA under the Freedom of Information Act. *See Scottsdale Research Institute, LLC*, 2:20-cv-00605-JJT (D. Ariz.).

Marijuana's schedule I status and DEA's determinations hinder SRI's clinical research—the very clinical research that DEA requires under its unlawful interpretation of 21 U.S.C. § 812(b)(1)(B) to consider removing marijuana from schedule I—in several key respects.

First, marijuana's schedule I status requires all cultivators be registered under 21 U.S.C. § 823(a). According to the statute and the OLC memo, because of that status, section 823(a) requires DEA and the federal government to severely restrict the quality and quantity of marijuana available for clinical research and comply with draconian international treaty obligations from 1961. A lower schedule could take marijuana out of section 823(a)'s ambit.

Second, because of marijuana's schedule I status, SRI has had to delay FDA-approved clinical trials to investigate the safety and efficacy of smoked marijuana in treating breakthrough pain in terminal cancer patients. SRI has been ready to do this research for more than a year. If marijuana were in a less restrictive schedule, SRI would have been able to complete its research by now. Instead, it has had to turn to importing marijuana from other countries because of inadequate supply, which is directly attributable to marijuana's schedule I status.

Third, SRI's research focuses on veterans. But because federal law prohibits the Department of Veterans Affairs (“VA”) from providing or researching marijuana regardless of state laws, the local VA has blocked SRI's recruitment efforts.

3. Petitioner **Battlefield Foundation d/b/a Field To Healed** is an Arizona non-profit corporation based in Arizona, within this Circuit. It is the 501(c)(3) non-profit arm of SRI and helps support SRI's mission.

Founded by Dr. Sisley and Roberto Pickering, Field to Healed is dedicated to medical research and charitable services for veterans and first responders.

4. Petitioner **L. Lorenzo Sullivan** is a disabled Army veteran who serves on the honorary board of Field to Healed. He lives in Arizona, within this Circuit.

Mr. Sullivan was honorably discharged from the Army after serving in the Vietnam War. Because of his service, he suffers from PTSD and has been classified by the VA as 85% unemployable. In addition, he was treated for prostate cancer resulting from Agent Orange exposure in Vietnam. Over the years, Mr. Sullivan has had difficulty with numerous VA-prescribed medications. He attempted to have a conversation with a VA doctor after a retired heart surgeon suggested marijuana, but because of marijuana's status under federal law, he was told that the VA could not help him or even discuss marijuana with him.

5. Petitioner **Kendric Speagle** is a Navy veteran who served as an aviation logistician onboard USS George Washington. He was deployed in the Persian Gulf enforcing No Fly Zones in Southern Iraq and in the Adriatic Sea, leading NATO missions over Bosnia Herzegovina. He lives in Arizona, within this Circuit.

In his late 30's, Mr. Speagle began to develop severe fluctuations in the intra-ocular pressure of his right eye, consistent with glaucoma. He reached out to the VA and inquired about using marijuana to reduce the pressure and the painful symptoms, but was told that the VA was legally unable to recommend or provide marijuana for medical purposes. Mr. Speagle had surgery and took multiple medications, but nothing seemed to reduce the painful pressure in his right eye. Mr. Speagle discovered that marijuana successfully, immediately, and drastically reduced his intra-ocular pressure and pain. Unfortunately, it was too late to prevent an acute episode of glaucoma, which left the muscles in the iris of his right eye completely dead. Had the VA been less encumbered by DEA's classification as a schedule I drug, Mr. Speagle would have avoided years of pain, and might have the ability to see clearly today.

6. Petitioner **Gary Hess** is a Marine Corps Veteran who served as an Infantry Officer during the heaviest levels of fighting in Iraq. He lives and works in Louisiana. Joinder of Mr. Hess in this action is practicable under Rule 15(a).

In 2008, Mr. Hess was honorably discharged with service-connected disabilities consisting of Traumatic Brain Injury, chronic pain, and PTSD, among others. For example, in December of 2006 while operating in Iraq, the house Mr. Hess was occupying was hit with a vehicle-born improvised explosive device, decapitating one of his Marines and wounding the remaining three, including Mr.

Hess. Mr. Hess reached out to the VA for help. From 2009 to 2017, he was prescribed the pharmaceutical “combat cocktail,” which was a failure. After trying medicinal marijuana, many of Mr. Hess’s most distressing and untreatable symptoms abated.

### Grounds for Review

Petitioners challenge and seek judicial review of the following aspects of the 2020 Determination, the 2016 Denial, and the 1992 Rule.

**1. Petitioners seek review of the agency’s interpretation of the statutory phrase “no currently accepted medical use in treatment in the United States” and its determination that marijuana has “no currently accepted medical use in treatment in the United States.”**

To determine whether a drug or other substance has a “currently accepted medical use in treatment in the United States,” 21 U.S.C. § 812(b)(1)(B), DEA applies a conjunctive five-part test that originated in the 1992 Rule:

- (1) whether a drug’s chemistry is known and reproducible;
- (2) whether there are adequate safety studies;
- (3) whether there are adequate and well controlled studies proving efficacy;
- (4) whether the drug is not accepted by qualified experts; *and*
- (5) whether the scientific evidence is not widely available.

2016 Denial at 53,779 & n.10 (citing 1992 Rule at 10504–06).

This agency created test has no basis in the statute; is contrary to the statutory text, structure, history, and purpose; departs from the original understanding of the statute; and rests on flawed and outdated case law.

In *Alliance for Cannabis Therapeutics v. Drug Enf't Admin.*, 15 F.3d 1131 (D.C. Cir. 1994) (“*Alliance II*”) and *All. for Cannabis Therapeutics v. Drug Enf't Admin.*, 930 F.2d 936, 939 (D.C. Cir. 1991) (“*Alliance I*”), the appellate court deferred to DEA’s five-part test under *Chevron U.S.A. Inc. v. Natural Resources Defense Council*, 467 U.S. 837 (1984) because “neither the statute nor its legislative history *precisely* defines the [statutory] term.” *Alliance I*, 930 F.2d 936 at 939 (emph. added); *Alliance II*, 15 F.3d at 1134 (relying on *Alliance I*).

But since then, the Supreme Court has clarified that courts do not defer to agency interpretations simply because a term is not “precisely” defined. Rather, courts must “exhaust” the traditional tools of statutory construction until the “legal toolkit is empty.” *Kisor v. Wilkie*, 139 S. Ct. 2400, 2415 (2019) (citing *Pauley v. BethEnergy Mines, Inc.*, 501 U.S. 680, 696 (1991)); *see also SAS Institute v. Iancu*, 138 S. Ct. 1348, 1359 (2018) (“Even under *Chevron*, we owe an agency’s interpretation of the law no deference unless, after ‘employing traditional tools of statutory construction,’ we find ourselves unable to discern Congress’s meaning.”). Here, applying the traditional tools of statutory construction as the Supreme Court

instructs, there is no uncertainty that warrants deference to DEA's test. *See Iancu*, 138 S. Ct. at 1358.

In any case, more recent Supreme Court precedent regarding *Chevron* deference refutes *Alliance I* and *II* and forecloses deference from the outset. *See, e.g., Gonzales v. Oregon*, 546 U.S. 243, 258 (2006) (explaining and holding that the Attorney General is not authorized to make a rule declaring illegitimate a medical standard for care and treatment of patients that is specifically authorized under state law). *Chevron* deference is also inappropriate because the CSA is a dual-application statute. *See generally Esquivel-Quintana v. Lynch*, 810 F.3d 1019, 1027-32 (6th Cir. 2016) (Sutton, J.) (concurring in part, dissenting in part).

Deference is also inappropriate because section 812(b)(1)(B) is unambiguous. Based on the statutory text, structure, history, purpose—and the original understanding the statute—“currently accepted medical use” means “legitimate” or “lawful medical purpose.” This is the only interpretation that captures the cooperative federalism vision of the CSA and respects state sovereignty. And under that interpretation, the 2020 Petition, the 2016 Denial itself, and judicially noticeable facts present conclusive evidence that precludes a finding that marijuana has “no currently accepted medical use in treatment in the United States.” The 2020 Petition should be granted.



Accordingly, Petitioners respectfully request the Court vacate and set aside the 1992 Rule and the five-factor test; reverse the agency's final determination that marijuana has "no currently accepted medical use in treatment in the United States"; and remand with instructions to initiate rulemaking under section 811(a).

**2. Petitioners seek review of the agency's final determination that rescheduling turns *solely* "on whether marijuana has a currently accepted medical use in treatment in the United States."**

The 2016 Denial concludes, "the only determinative issue in evaluating [a] petition is whether marijuana has a currently accepted medical use in treatment in the United States." 2016 Denial at 53,768. Thus, according to DEA, it need not consider the findings of sections 811(a) or 812(b) that have no bearing on that determination nor follow the procedures prescribed by sections 811(a) and (b), because schedule I is the only schedule for drugs with "no currently accepted medical use in treatment in the United States." This conclusion is arbitrary, capricious, and contrary to law.

A drug can meet the criteria for multiple schedules concurrently. For example, a drug may have "no currently accepted medical use in treatment in the United States" (schedule I, 21 U.S.C. § 812(b)(1)(B)) but a "currently accepted medical use with severe restrictions" (schedule II, 21 U.S.C. § 812(b)(2)(B)). For example, FDA in the past concluded that the criteria for both schedules I and II can be met

concurrently. *See* “Proposed Recommendation to the Drug Enforcement Administration Regarding the Scheduling Status of Tetrahydrocannabinol,” 47 Fed. Reg. 10,080, 10,084-85 (March 9, 1982) (concluding that THC met all three criteria for schedule I and schedule II and that placement of THC in IND Group C status, a means for the distribution of investigational agents to oncologists for the treatment of cancer under protocols outside a controlled clinical trial, met the definition of “currently accepted medical use with severe restrictions”).

Similarly, the conclusion that “the lack of accepted medical use for a specific, recognized disorder precludes the use of marijuana even under conditions where its use is severely restricted,” 2016 Denial at 53,786, is incorrect. This conclusion ignores the textual difference between “currently accepted medical use *in treatment* in the United States” and “currently accepted medical use with severe restrictions.” 21 U.S.C. § 812(b)(2)(B).

**3. Petitioners seek review of DEA’s final determination that “[t]here is a lack of accepted safety for use of marijuana under medical supervision.”**

DEA concludes that there is a “lack of accepted safety for use” of marijuana “under medical supervision” because there are no FDA-approved marijuana drug products, marijuana “does not have a currently accepted medical use in treatment in the United States,” and marijuana does not have “a currently accepted medical use with severe restrictions.” 2016 Denial at 53,786. This conclusion misconstrues the

statute and is arbitrary, capricious, and contrary to law because the agency has improperly imported a clinical efficacy requirement into section 812(b)(1)(C).

**4. Petitioners seek review of DEA’s final determination that marijuana must be placed in either schedule I or II.**

DEA has determined that, because 21 U.S.C. § 811(d) applies, marijuana cannot be placed in Schedules III, VI, or V. 2016 Denial at 53,768-70. But section 811(d)(1) is an unconstitutional delegation of legislative authority under Article I and violates core separation of powers principles.

Section 811(d)(1) impermissibly delegates to the Attorney General the power and obligation to issue an order placing a drug in the schedule “he deems most appropriate” to carry out international treaties, conventions, or protocols in effect on or before October 27, 1970, “without regard to the findings required by subsection (a) of this section or section 812(b) of this title and without regard to the procedures prescribed by subsections (a) and (b) of this section.” 21 U.S.C. § 811(d). Thus, the statute outsources regulatory power to create domestic criminal law to international organizations and subordinates domestic law to treaty obligations, conventions, and protocols. Then, it entrusts the Attorney General, a member of the executive branch, to execute non-self-executing international treaty obligations, providing him no intelligible principle, instructions, standards, or criteria whatsoever against which to measure what “he deems most appropriate.” This is unconstitutional. *See A.L.A.*

*Schechter Poultry Corp. v. United States*, 295 U.S. 495, 537-42 (1935) (holding unconstitutional a delegation of authority to unelected trade associations to propose poultry codes with criminal penalties, layered with delegation to President to approve code provisions “in his discretion” he thinks necessary “to effectuate the policy” unconstitutional).

Because section 811(d)(1) is invalid, it cannot constrain the Attorney General and DEA’s authority to reschedule a drug or other substance. DEA’s determination that placement of marijuana must be in either schedule I or II should be vacated and section 811(d)(1) should be held unconstitutional.

Dated: May 21, 2020

Respectfully submitted,

/s/Matthew C. Zorn

Matthew C. Zorn

Shane A. Pennington

YETTER COLEMAN LLP

811 Main Street, Suite 4100

Houston, Texas 77002

Tel. (713) 632-8000

Fax (713) 632-8002

mzorn@yettercoleman.com

spennington@yettercoleman.com

*Attorneys for Petitioners*

**CERTIFICATE OF SERVICE**

I certify that this Petition for Review was filed with the Court via the court's electronic filing system, on the 21st day of May, 2020, and copy of the Petition was served on all counsel of record, as listed below, via Federal Express:

The Honorable William Barr  
Attorney General of the United States  
U.S. Department of Justice  
950 Pennsylvania, NW  
Washington, DC 20530

*Respondent*

Robert C. Gleason  
Acting Chief Counsel  
Office of General Counsel  
Drug Enforcement Administration  
8701 Morrisette Dr.  
Springfield, VA 22152

*Respondent*

The Honorable Timothy Shea  
Drug Enforcement Administration  
7000 Army-Navy Dr.  
Arlington, VA 22202

*Respondent*

Dayle Elieson  
Chief Counsel  
Office of General Counsel  
Drug Enforcement Administration  
8701 Morrisette Dr.  
Springfield, VA 22152

*Respondent*

/s/ Matthew C. Zorn  
Matthew C. Zorn

# **Exhibit 1**

Re: petition to remove or reschedule cannabis from Schedule I

I hereby petition the US AG, DOJ, ONDCP, DEA and Congress to remove or reschedule cannabis (marijuana) in all its forms: THC and CBD (all naturally occurring equivalents, cannabinoids, terpenes in cannabis/hemp), hashish, marijuana, marihuana, flowering tops and leaves of Indian hemp (*Cannabis sativa*), hemp, *Cannabis indica*, *Cannabis ruderalis*, *Cannabis sativa* L., every extract and concentrate, crude or purified, compound, manufacture, salt, derivative, preparation, seeds, stalks, plants, cuttings, *Cannabis indica* Lam., etc.

Pursuant to 21 USCS §11, 812 any interested party can petition for removal and rescheduling. In November 2016, California voters passed Adult Use of Marijuana Act. The intent was to insure a comprehensive regulatory system that takes production and sales away from an illegal market. AUMA found that the majority of USA produced cannabis comes from California. Petitioner is in custody in state prison, CDCR CTF in Soledad, CA, for selling cannabis in line with the older model, CUA of 1996 (Prop 215) before the expiration of this older nonprofit collective model on January 9, 2019.

Petitioner finds the current situation of cannabis in Schedule I completely untenable. Half the states allow for medical use and the FDA allows CBD and THC pharmaceuticals as well as IND Compassionate Use.

Under the Constitution and 21 USCS §11, 812 the continued war on drugs (cannabis) must be corrected by removing or rescheduling cannabis.

DATED:  
1/3/2020

Respectively,

*St. Zyszkiewicz*

Stephen Zyszkiewicz

and

Medical cannabis  
epilepsy patient

*Jeremy Bowers*

Jeremy Bowers

# **Exhibit 2**





**U. S. Department of Justice**  
Drug Enforcement Administration  
8701 Morrissette Drive  
Springfield, Virginia 22152

---

*www.dea.gov*

Stephen Zyszkiewicz  
10446 West Sylvia Street  
Milwaukee, Wisconsin 53224

Dear Mr. Zyszkiewicz:

This responds to your letter to of the Drug Enforcement Administration (DEA) dated January 3, 2020, regarding removing marijuana and its derivatives out of schedule I into schedule II for medical use. Your letter is also signed by Mr. Jeremy Bowers and appears to be in the form of a petition. Although your letter is not in the proper format of a petition as outlined in Section 811 of the Federal Criminal Code, DEA appreciates the opportunity to address your concerns.

On August 12, 2016, the Federal Register addressed similar concerns from a petition submitted on November 30, 2011, from the Honorable Lincoln D. Chafee and the Honorable Christine O. Gregoire. The above judges petitioned DEA to initiate rulemaking proceedings under the rescheduling provisions of the Controlled Substances Act (CSA). Specifically, they petitioned DEA to have marijuana and “related items” removed from schedule I of the CSA and rescheduled as medical cannabis in schedule II. They requested that DEA remove marijuana and related items from schedule I based on their assertion that: (1) Cannabis has accepted medical use in the United States; (2) Cannabis is safe for use under medical supervision; (3) Cannabis for medical purposes has a relatively low potential for abuse, especially in comparison with other schedule II drugs.

In accordance with the CSA rescheduling provisions, after gathering the necessary data, DEA requested a scientific and medical evaluation and scheduling recommendation from the Department of Health and Human Services (HHS). HHS concluded that marijuana has a high potential for abuse, has no accepted medical use in the United States, and lacks an acceptable level of safety for use even under medical supervision. Therefore, HHS recommended that marijuana remain in schedule I. The scientific and medical evaluation and scheduling recommendation that HHS submitted to DEA is enclosed with this letter.

Based on HHS’s evaluation and all other relevant data, DEA has concluded that there is no substantial evidence that marijuana should be removed from schedule I. A document prepared by DEA addressing these materials in detail is also enclosed. In short, marijuana continues to meet the criteria for schedule I control under the CSA.

In sum, DEA recognizes the possibility that drugs containing marijuana or its derivatives might, in the future, be proven to be safe and effective for the treatment of certain conditions and thus approved be by the United States Food and Drug Administration for marketing. Until then, we will continue to identify opportunities to assist researchers in this area while never losing sight of the need to protect the public.

Stephen Zyskiewicz

Page 2

I trust this letter adequately addresses your inquiry. For information regarding DEA's Diversion Control Division, please visit [www.DEAdiversion.usdoj.gov](http://www.DEAdiversion.usdoj.gov). If you have any additional questions on this issue, or any other, please contact the Diversion Control Division Policy Section at (571) 362-3260.

Sincerely,

Thomas W. Prevoznik  
Deputy Assistant Administrator  
Diversion Control Division

**Pennington, Shane**

---

**From:** Stephen Zyskiewicz [REDACTED]  
**Sent:** Monday, May 4, 2020 7:24 PM  
**To:** Pennington, Shane  
**Subject:** Re: Your Petition to Re-/De-Schedule Cannabis  
**Attachments:** DPY-20-0143 Distributed.docx; Federal Register Notice MJ Petition Denial 2.pdf; FR Notice MJ Petition Denial.pdf

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

> Begin forwarded message:

>

> From: "Green, Tiffany T" <Tiffany.T.Green@usdoj.gov>

> Subject: DEA Response

> Date: April 22, 2020 at 10:27:47 AM CDT

> [REDACTED]

>

>

> Dear Mr. Zyszkiewicz:

>

>

>

> Thank you for contacting the Drug Enforcement Administration (DEA). This is in response to your letter dated January 3, 2020, regarding removing marijuana and its derivatives out of schedule I into schedule II for medical use

>

>

> Please see attachment.

>

>

>

> Sincerely,

>

>

>

> DEA Diversion Control Division, Policy Section

>

>

**DEPARTMENT OF JUSTICE****Drug Enforcement Administration****21 CFR Chapter II**

[Docket No. DEA-427]

**Denial of Petition To Initiate Proceedings To Reschedule Marijuana****AGENCY:** Drug Enforcement Administration, Department of Justice.**ACTION:** Denial of petition to initiate proceedings to reschedule marijuana.

**SUMMARY:** By letter dated July 19, 2016 the Drug Enforcement Administration (DEA) denied a petition to initiate rulemaking proceedings to reschedule marijuana. Because the DEA believes that this matter is of particular interest to members of the public, the agency is publishing below the letter sent to the petitioner which denied the petition, along with the supporting documentation that was attached to the letter.

**DATES:** August 12, 2016.

**FOR FURTHER INFORMATION CONTACT:** Michael J. Lewis, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrisette Drive, Springfield, Virginia 22152; Telephone: (202) 598-6812

**SUPPLEMENTARY INFORMATION:** July 19, 2016

Dear Mr. Krumm:

On December 17, 2009, you petitioned the Drug Enforcement Administration (DEA) to initiate rulemaking proceedings under the rescheduling provisions of the Controlled Substances Act (CSA). Specifically, you petitioned DEA to have marijuana removed from schedule I of the CSA and rescheduled in any schedule other than schedule I of the CSA.

You requested that DEA remove marijuana from schedule I based on your assertion that:

1. Marijuana has accepted medical use in the United States;
2. Studies have shown that smoked marijuana has proven safety and efficacy;
3. Marijuana is safe for use under medical supervision; and
4. Marijuana does not have the abuse potential for placement in schedule I

In accordance with the CSA scheduling provisions, after gathering the necessary data, DEA requested a scientific and medical evaluation and scheduling recommendation from the Department of Health and Human Services (HHS). HHS concluded that marijuana has a high potential for abuse, has no accepted medical use in the United States, and lacks an acceptable level of safety for use even under medical supervision. Therefore, HHS recommended that marijuana remain in schedule I. The scientific and medical evaluation and scheduling recommendation that HHS submitted to DEA is attached hereto.

Based on the HHS evaluation and all other relevant data, DEA has concluded that there is no substantial evidence that marijuana should be removed from schedule I. A document prepared by DEA addressing these materials in detail also is attached hereto. In short, marijuana continues to meet the criteria for schedule I control under the CSA because:

- (1) *Marijuana has a high potential for abuse.* The HHS evaluation and the additional data gathered by DEA show that marijuana has a high potential for abuse.
- (2) *Marijuana has no currently accepted medical use in treatment in the United States.* Based on the established five-part test for making such determination, marijuana has no “currently accepted medical use” because: As detailed in the HHS evaluation, the drug’s chemistry is not known and reproducible; there are no adequate safety studies; there are no adequate and well-controlled studies proving efficacy; the drug is not accepted by qualified experts; and the scientific evidence is not widely available.
- (3) *Marijuana lacks accepted safety for use under medical supervision.* At present, there are no U.S. Food and Drug Administration (FDA)-approved marijuana products, nor is marijuana under a New Drug Application (NDA) evaluation at the FDA for any indication. The HHS evaluation states that marijuana does not have a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. At this time, the known risks of marijuana use have not been shown to be outweighed by specific benefits in well-controlled clinical trials that scientifically evaluate safety and efficacy.

The statutory mandate of 21 U.S.C. 812(b) is dispositive. Congress established only one schedule, schedule I, for drugs of abuse with “no currently accepted medical use in treatment in the United States” and “lack of accepted safety for use under medical supervision.” 21 U.S.C. 812(b).

Although the HHS evaluation and all other relevant data lead to the conclusion that marijuana must remain in schedule I, it should also be noted that, in view of United States obligations under international drug control treaties, marijuana cannot be placed in a schedule less restrictive than schedule II. This is explained in detail in the accompanying document titled “Preliminary Note Regarding Treaty Considerations.”

Accordingly, and as set forth in detail in the accompanying HHS and DEA documents, there is no statutory basis under the CSA for DEA to grant your petition to initiate rulemaking proceedings to reschedule marijuana. Your petition is, therefore, hereby denied.

Sincerely,

Chuck Rosenberg,

*Acting Administrator*

Attachments:

**Preliminary Note Regarding Treaty Considerations**

Cover Letter from HHS to DEA  
Summarizing the Scientific and Medical Evaluation and Scheduling Recommendation for Marijuana.

U.S. Department of Health and Human Services (HHS)—Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act

U.S. Department of Justice—Drug Enforcement Administration (DEA), Schedule of Controlled Substances: Maintaining Marijuana in Schedule I of the Controlled Substances Act, Background, Data, and Analysis: Eight Factors Determinative of Control and Findings Pursuant to 21 U.S.C. 812(b)

Dated: July 19, 2016.

**Chuck Rosenberg,**  
*Acting Administrator.*

**Preliminary Note Regarding Treaty Considerations**

As the Controlled Substances Act (CSA) recognizes, the United States is a party to the Single Convention on Narcotic Drugs, 1961 (referred to here as the Single Convention or the treaty). 21 U.S.C. 801(7). Parties to the Single Convention are obligated to maintain various control provisions related to the drugs that are covered by the treaty. Many of the provisions of the CSA were enacted by Congress for the specific purpose of ensuring U.S. compliance with the treaty. Among these is a scheduling provision, 21 U.S.C. 811(d)(1). Section 811(d)(1) provides that, where a drug is subject to control under the Single Convention, the DEA Administrator (by delegation from the Attorney General) must “issue an order controlling such drug under the schedule he deems most appropriate to carry out such [treaty] obligations, without regard to the findings required by [21 U.S.C. 811(a) or 812(b)] and without regard to the procedures prescribed by [21 U.S.C. 811(a) and (b)].”

Marijuana is a drug listed in the Single Convention. The Single Convention uses the term “cannabis” to refer to marijuana.<sup>1</sup> Thus, the DEA Administrator is obligated under section 811(d) to control marijuana in the

<sup>1</sup> Under the Single Convention, “‘cannabis plant’ means any plant of the genus *Cannabis*.” Article 1(c). The Single Convention defines “cannabis” to include “the flowering or fruiting tops of the cannabis plant (excluding the seeds and leaves when not accompanied by the tops) from which the resin has not been extracted, by whatever name they may be designated.” Article 1(b). This definition of “cannabis” under the Single Convention is slightly less inclusive than the CSA definition of “marihuana,” which includes all parts of the cannabis plant except for the mature stalks, sterilized seeds, oil from the seeds, and certain derivatives thereof. See 21 U.S.C. 802(16). Cannabis and cannabis resin are included in the list of drugs in Schedule I and Schedule IV of the Single Convention. In contrast to the CSA, the drugs listed in Schedule IV of the Single Convention are also listed in Schedule I of the Single Convention and are subject to the same controls as Schedule I drugs as well as additional controls. Article 2, par. 5

schedule that he deems most appropriate to carry out the U.S. obligations under the Single Convention. It has been established in prior marijuana rescheduling proceedings that placement of marijuana in either schedule I or schedule II of the CSA is “necessary as well as sufficient to satisfy our international obligations” under the Single Convention. *NORML v. DEA*, 559 F.2d 735, 751 (D.C. Cir. 1977). As the United States Court of Appeals for the D.C. Circuit has stated, “several requirements imposed by the Single Convention would not be met if cannabis and cannabis resin were placed in CSA schedule III, IV, or V.”<sup>2</sup> *Id.* Therefore, in accordance with section 811(d)(1), DEA must place marijuana in either schedule I or schedule II.

Because schedules I and II are the only possible schedules in which marijuana may be placed, for purposes of evaluating this scheduling petition, it is essential to understand the differences between the criteria for placement of a substance in schedule I and those for placement in schedule II. These criteria are set forth in 21 U.S.C. 812(b)(1) and (b)(2), respectively. As indicated therein, substances in both schedule I and schedule II share the characteristic of “a high potential for abuse.” Where the distinction lies is that schedule I drugs have “no currently accepted medical use in treatment in the United States” and “a lack of accepted safety for use of the drug . . . under medical supervision,” while schedule II drugs do have “a currently accepted medical use in treatment in the United States.”<sup>3</sup>

Accordingly, in view of section 811(d)(1), this scheduling petition turns on whether marijuana has a currently accepted medical use in treatment in the United States. If it does not, DEA must, pursuant to section 811(d), deny the petition and keep marijuana in schedule I.

As indicated, where section 811(d)(1) applies to a drug that is the subject of a rescheduling petition, the DEA

Administrator must issue an order controlling the drug under the schedule he deems most appropriate to carry out United States obligations under the Single Convention, without regard to the findings required by sections 811(a) or 812(b) and without regard to the procedures prescribed by sections 811(a) and (b). Thus, since the only determinative issue in evaluating the present scheduling petition is whether marijuana has a currently accepted medical use in treatment in the United States, DEA need not consider the findings of sections 811(a) or 812(b) that have no bearing on that determination, and DEA likewise need not follow the procedures prescribed by sections 811(a) and (b) with respect to such irrelevant findings. Specifically, DEA need not evaluate the relative abuse potential of marijuana or the relative extent to which abuse of marijuana may lead to physical or psychological dependence.

As explained below, the medical and scientific evaluation and scheduling recommendation issued by the Secretary of Health and Human Services concludes that marijuana has no currently accepted medical use in treatment in the United States, and the DEA Administrator likewise so concludes. For the reasons just indicated, no further analysis beyond this consideration is required. Nonetheless, because of the widespread public interest in understanding all the facts relating to the harms associated with marijuana, DEA is publishing here the entire medical and scientific analysis and scheduling evaluation issued by the Secretary, as well as DEA’s additional analysis.

Department of Health and Human Services,  
Office of the Secretary Assistant Secretary for  
Health, Office of Public Health and Science  
Washington DC 20201.

June 25, 2015.

The Honorable Chuck Rosenberg  
*Acting Administrator, Drug Enforcement  
Administration, U.S. Department of  
Justice, 8701 Morrisette Drive, Springfield,  
VA 22152*

Dear Mr. Rosenberg:

Pursuant to the Controlled Substances Act (CSA), 21 U.S.C. 811(b), (c), and (f), the Department of Health and Human Services (HHS) is recommending that marijuana continue to be maintained in Schedule I of the CSA.

The Food and Drug Administration (FDA) has considered the abuse potential and dependence-producing characteristics of marijuana.

Marijuana meets the three criteria for placing a substance in Schedule I of the CSA under 21 U.S.C. 812(b)(1). As discussed in the enclosed analyses, marijuana has a high potential for abuse, no currently accepted

medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. Accordingly, HHS recommends that marijuana be maintained in Schedule I of the CSA. Enclosed are two documents prepared by FDA’s Controlled Substance Staff (in response to petitions filed in 2009 by Mr. Bryan Krumm and in 2011 by Governors Lincoln D. Chafee and Christine O. Gregoire) that form the basis for the recommendation. Pursuant to the requests in the petitions, FDA broadly evaluated marijuana, and did not focus its evaluation on particular strains of marijuana or components or derivatives of marijuana.

FDA’s Center for Drug Evaluation and Research’s current review of the available evidence and the published clinical studies on marijuana demonstrated that since our 2006 scientific and medical evaluation and scheduling recommendation responding to a previous DEA petition, research with marijuana has progressed. However, the available evidence is not sufficient to determine that marijuana has an accepted medical use. Therefore, more research is needed into marijuana’s effects, including potential medical uses for marijuana and its derivatives. Based on the current review, we identified several methodological challenges in the marijuana studies published in the literature. We recommend they be addressed in future clinical studies with marijuana to ensure that valid scientific data are generated in studies evaluating marijuana’s safety and efficacy for therapeutic use. For example, we recommend that studies need to focus on consistent administration and reproducible dosing of marijuana, potentially through the use of administration methods other than smoking. A summary of our review of the published literature on the clinical uses of marijuana, including recommendations for future studies, is attached to this document.

FDA and the National Institutes of Health’s National Institute on Drug Abuse (NIDA) also believe that work continues to be needed to ensure support by the federal government for the efficient conduct of clinical research using marijuana. Concerns have been raised about whether the existing federal regulatory system is flexible enough to respond to increased interest in research into the potential therapeutic uses of marijuana and marijuana-derived drugs. HHS welcomes an opportunity to continue to explore these concerns with DEA.

Should you have any questions regarding these recommendations, please contact Corinne P. Moody, Science Policy Analyst, Controlled Substances Staff, Center for Drug Evaluation and Research, FDA, at (301) 796–3152.

Sincerely yours,

Karen B. DeSalvo, MD, MPH, MSc  
*Acting Assistant Secretary for Health  
Enclosure:*

Basis for the Recommendation for  
Maintaining Marijuana in Schedule I of the  
Controlled Substances Act

<sup>2</sup> The Court further stated: “For example, [article 31 paragraph 4 of the Single Convention] requires import and export permits that would not be obtained if the substances were placed in CSA schedules III through V. In addition, the quota and [recordkeeping] requirements of Articles 19 through 21 of the Single Convention would be satisfied only by placing the substances in CSA schedule I or II.” *Id.* n. 71 (internal citations omitted).

<sup>3</sup> As DEA has stated in evaluating prior marijuana rescheduling petitions, “Congress established only one schedule, schedule I, for drugs of abuse with ‘no currently accepted medical use in treatment in the United States’ and ‘lack of accepted safety for use . . . under medical supervision.’ 21 U.S.C. 812(b).” 76 FR 40552 (2011); 66 FR 20038 (2001).

### Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act

On December 17, 2009, Mr. Bryan Krumm submitted a petition to the Drug Enforcement Administration (DEA) requesting that proceedings be initiated to repeal the rules and regulations that place marijuana<sup>4</sup> in Schedule I of the Controlled Substances Act (CSA). The petitioner contends that marijuana has an accepted medical use in the United States, has proven safety and efficacy, is safe for use under medical supervision, and does not have the abuse potential for placement in Schedule I. The petitioner requests that marijuana be rescheduled to any schedule other than Schedule I of the CSA. In May 2011, the DEA Administrator requested that the U.S. Department of Health and Human Services (HHS) provide a scientific and medical evaluation of the available information and a scheduling recommendation for marijuana, in accordance with the provisions of 21 U.S.C. 811(b).

In accordance with 21 U.S.C. 811(b), the DEA has gathered information related to the control of marijuana (*Cannabis sativa*)<sup>5</sup> under the CSA. Pursuant to 21 U.S.C. 811(b), the Secretary of HHS is required to consider in a scientific and medical evaluation eight factors determinative of control under the CSA. Following consideration of the eight factors, if it is appropriate, the Secretary must make three findings to recommend scheduling a substance in the CSA or transferring a substance from one schedule to another. The findings relate to a substance's abuse potential, legitimate medical use, and safety or dependence liability. Administrative responsibilities for evaluating a substance for control under the CSA are performed by the Food and Drug Administration (FDA), with the concurrence of the National Institute on Drug Abuse (NIDA), as described in the

<sup>4</sup>Note that "marihuana" is the spelling originally used in the Controlled Substances Act (CSA). This document uses the spelling that is more common in current usage, "marijuana."

<sup>5</sup>The CSA defines marihuana (marijuana) as the following:

All parts of the plant *Cannabis sativa* L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin. Such term does not include the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination (21 U.S.C. 802(16)).

Memorandum of Understanding (MOU) of March 8, 1985 (50 FR 9518–20).

In this document, FDA recommends continued control of marijuana in Schedule I of the CSA. Pursuant to 21 U.S.C. 811(c), the eight factors pertaining to the scheduling of marijuana are considered below.

#### 1. Its Actual or Relative Potential for Abuse

Under the first factor the Secretary must consider marijuana's actual or relative potential for abuse. The CSA does not define the term "abuse." However, the CSA's legislative history suggests the following in determining whether a particular drug or substance has a potential for abuse:<sup>6</sup>

a. There is evidence that individuals are taking the drug or drugs containing such a substance in amounts sufficient to create a hazard to their health or to the safety of other individuals or to the community.

b. There is a significant diversion of the drug or drugs containing such a substance from legitimate drug channels.

c. Individuals are taking the drug or drugs containing such a substance on their own initiative rather than on the basis of medical advice from a practitioner licensed by law to administer such drugs in the course of his professional practice.

d. The drug or drugs containing such a substance are new drugs so related in their action to a drug or drugs already listed as having a potential for abuse to make it likely that the drug will have the same potentiality for abuse as such drugs, thus making it reasonable to assume that there may be significant diversions from legitimate channels, significant use contrary to or without medical advice, or that it has a substantial capability of creating hazards to the health of the user or to the safety of the community.

In the development of this scientific and medical evaluation for the purpose of scheduling, the Secretary analyzed considerable data related to the substance's abuse potential. The data include a discussion of the prevalence and frequency of use, the amount of the substance available for illicit use, the ease of obtaining or manufacturing the substance, the reputation or status of the substance "on the street," and evidence relevant to at-risk populations. Importantly, the petitioners define marijuana as including all *Cannabis*

<sup>6</sup>Comprehensive Drug Abuse Prevention and Control Act of 1970, H.R. Rep. No. 91–1444, 91st Cong., Sess. 1 (1970) reprinted in U.S.C.C.A.N. 4566, 4603.

cultivated strains. Different marijuana samples derived from various cultivated strains may have very different chemical constituents, thus the analysis is based on what is known about the range of these constituents across all cultivated strains.

Determining the abuse potential of a substance is complex with many dimensions, and no single test or assessment provides a complete characterization. Thus, no single measure of abuse potential is ideal. Scientifically, a comprehensive evaluation of the relative abuse potential of a substance can include consideration of the following elements: Receptor binding affinity, preclinical pharmacology, reinforcing effects, discriminative stimulus effects, dependence producing potential, pharmacokinetics, route of administration, toxicity, data on actual abuse, clinical abuse potential studies, and public health risks. Importantly, abuse can exist independently from tolerance or physical dependence because individuals may abuse drugs in doses or patterns that do not induce these phenomena. Additionally evidence of clandestine population and illicit trafficking of a substance can shed light on both the demand for a substance as well as the ease of obtaining a substance. Animal and human laboratory data and epidemiological data are all used in determining a substance's abuse potential. Moreover, epidemiological data can indicate actual abuse.

The petitioner compares the effects of marijuana to currently controlled Schedule II substances and make repeated claims about their comparative effects. Comparisons between marijuana and the diverse array of Schedule II substances is difficult, because of the pharmacologically dissimilar actions of substances of Schedule II of the CSA. For example, Schedule II substances include stimulant-like drugs (*e.g.*, cocaine, methylphenidate, and amphetamine), opioids (*e.g.*, oxycodone, fentanyl), sedatives (*e.g.*, pentobarbital, amobarbital), dissociative anesthetics (*e.g.*, PCP), and naturally occurring plant components (*e.g.*, coca leaves and poppy straw). The mechanism(s) of action of the above Schedule II substances are wholly different from one another, and they are different from tetrahydrocannabinol (THC) and marijuana as well. For example, Schedule II stimulants typically function by increasing monoaminergic tone via an increase in dopamine and norepinephrine (Schmitt et al., 2013). In contrast, opioid analgesics function via mu-opioid receptor agonist effects.

These differing mechanism(s) of action result in vastly different behavioral and adverse effect profiles, making comparisons across the range of pharmacologically diverse C-II substances inappropriate.

In addition, many substances scheduled under the CSA are reviewed and evaluated within the context of commercial drug development, using data submitted in the form of a new drug application (NDA). A new analgesic drug might be compared to a currently scheduled analgesic drug as part of the assessment of its relative abuse potential. However, because the petitioners have not identified a specific indication for the use of marijuana, identifying an appropriate comparator based on indication cannot be done.

a. There is evidence that individuals are taking the substance in amounts sufficient to create a hazard to their health or to the safety of other individuals or to the community.

Evidence shows that some individuals are taking marijuana in amounts sufficient to create a hazard to their health and to the safety of other individuals and the community. A large number of individuals use marijuana. HHS provides data on the extent of marijuana abuse through NIDA and the Substance Abuse and Mental Health Services Administration (SAMHSA). According to the most recent data from SAMHSA's 2012 National Survey on Drug Use and Health (NSDUH), which estimates the number of individuals who have used a substance within a month prior to the study (described as "current use"), marijuana is the most commonly used illicit drug among American aged 12 years and older, with an estimated 18.9 million Americans having used marijuana within the month prior to the 2012 NSDUH.

Compared to 2004, when an estimated 14.6 million individuals reported using marijuana within the month prior to the study, the estimated rates in 2012 show an increase of approximately 4.3 million individuals. The 2013 Monitoring the Future (MTF) survey of 8th, 10th, and 12th grade students also indicates that marijuana is the most widely used illicit substance in this age group.

Specifically, current month use was at 7.0 percent of 8th graders, 18.0 percent of 10th, graders and 22.7 percent of 12th graders. Additionally, the 2011 Treatment Episode Data Set (TEDS) reported that primary marijuana abuse accounted for 18.1 percent of non-private substance-abuse treatment facility admissions, with 24.3 percent of those admitted reporting daily use. However, of these admissions for primary marijuana abuse, the criminal

justice system referred 51.6 percent to treatment. SAMHSA's Drug Abuse Warning Network (DAWN) was a national probability survey of U.S. hospitals with emergency departments (EDs) and was designed to obtain information on ED visits in which marijuana was mentioned, accounting for 36.4 percent of illicit drug related ED visits. There are some limitations related to DAWN data on ED visits, which are discussed in detail in Factor 4, "Its History and Current Pattern of Abuse;" Factor 5, "The Scope, Duration, and Significance of Abuse;" and Factor 6, "What, if any, Risk There is to the Public Health." These factors contain detailed discussions of these data.

A number of risks can occur with both acute and chronic use of marijuana. Detailed discussions of the risks are addressed in Factor 2, "Scientific Evidence of its Pharmacological Effect, if Known," and Factor 6, "What, if any, Risk There is to the Public Health."

b. There is significant diversion of the substance from legitimate drug channels.

There is a lack of evidence of significant diversion of marijuana from legitimate drug channels, but this is likely due to the fact that marijuana is more widely available from illicit sources rather than through legitimate channels. Marijuana is not an FDA-approved drug product, as an NDA or biologics license application (BLA) has not been approved for marketing in the United States. Numerous states and the District of Columbia have state-level medical marijuana laws that allow for marijuana use within that state. These state-level drug channels do not have sufficient collection of data related to medical treatment, including efficacy and safety.

Marijuana is used by researchers for nonclinical research as well as clinical research under investigational new drug (IND) applications; this represents the only legitimate drug channel in the United States. However, marijuana used for research represents a very small contribution of the total amount of marijuana available in the United States, and thus provides limited information about diversion. In addition, the lack of significant diversion of investigation supplies is likely because of the widespread availability of illicit marijuana of equal or greater amounts of delta<sup>9</sup>-THC. The data originating from the DEA on seizure statistics demonstrate the magnitude of the availability for illicit marijuana. DEA's System to Retrieve Information from Drug Evidence (STRIDE) provides information on total domestic drug seizures, STRIDE reports a total

domestic seizure of 573,195 kg of marijuana in 2011, the most recent year with complete data that is currently publically available (DEA Domestic Drug Seizures, n.d.).

c. Individuals are taking the substance on their own initiative rather than on the basis of medical advice from a practitioner licensed by law to administer such substances.

Because the FDA has not approved an NDA or BLA for a marijuana drug product for any therapeutic indication, the only way an individual can take marijuana on the basis of medical advice through legitimate channels at the federal level is by participating in research under an IND application. That said, numerous states and the District of Columbia have passed state-level medical marijuana laws allowing for individuals to use marijuana under certain circumstances. However, data are not yet available to determine the number of individuals using marijuana under these state-level medical marijuana laws. Regardless, according to the 2012 NSDUH data, 18.9 million American adults currently use marijuana (SAMHSA, 2013). Based on the large number of individuals reporting current use of marijuana and the lack of an FDA-approved drug product in the United States, one can assume that it is likely that the majority of individuals using marijuana do so on their own initiative rather than on the basis of medical advice from a licensed practitioner.

d. The substance is so related in its action to a substance already listed as having a potential for abuse to make it likely that it will have the same potential for abuse as such substance, thus making it reasonable to assume that there may be significant diversions from legitimate channels, significant use contrary to or without medical advice, or that it has a substantial capability of creating hazards to the health of the user or to the safety of the community.

FDA has approved two drug products containing cannabinoid compounds that are structurally related to the active components in marijuana. These two marketed products are controlled under the CSA. Once a specific drug product containing cannabinoids becomes approved, that specific drug product may be moved from Schedule I to a different Schedule (II-V) under the CSA. Firstly, Marinol—generically known as dronabinol—is a Schedule III drug product containing synthetic delta<sup>9</sup>-THC. Marinol, which is formulated in sesame oil in soft gelatin capsules, was first placed in Schedule II under the CSA following its approval by the FDA. Marinol was later rescheduled



to Schedule III under the CSA because of low numbers of reports of abuse relative to marijuana. Dronabinol is listed in Schedule I under the CSA. FDA approved Marinol in 1985 for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who failed to respond adequately to conventional anti-emetic treatments. In 1992, FDA approved Marional for anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS). Secondly, in 1985, FDA approved Cesamet, a drug product containing the Schedule II substance nabilone, for the treatment of nausea and vomiting associated with cancer chemotherapy. Besides the two cannabinoid-containing drug products FDA approved for marketing, other naturally occurring cannabinoids and their derivatives (from *Cannabis*) and their synthetic equivalents with similar chemical structure and pharmacological activity are included in the CSA as Schedule I substances.

## 2. Scientific Evidence of Its Pharmacological Effects, if Known

Under the second factor, the Secretary must consider the scientific evidence of marijuana's pharmacological effects. Abundant scientific data are available on the neurochemistry, toxicology, and pharmacology of marijuana. This section includes a scientific evaluation of marijuana's neurochemistry; pharmacology; and human and animal behavioral, central nervous system, cognitive, cardiovascular, autonomic, endocrinological, and immunological system effects. The overview presented below relies upon the most current research literature on cannabinoids.

### *Neurochemistry and Pharmacology of Marijuana*

Marijuana is a plant that contains numerous natural constituents, such as cannabinoids, that have a variety of pharmacological actions. The petition defines marijuana as including all *Cannabis* cultivated strains. Different marijuana samples derived from various cultivated strains may have very different chemical constituents including delta<sup>9</sup>-THC and other cannabinoids (Appendino et al., 2011). As a consequence, marijuana products from different strains will have different biological and pharmacological profiles.

According to ElSohly and Slade (2005) and Appendino et al. (2011), marijuana contains approximately 525 identified natural constituents, including approximately 100 compounds classified as cannabinoids. Cannabinoids primarily exist in

*Cannabis*, and published data suggests that most major cannabinoid compounds occurring naturally have been identified chemically. New and minor cannabinoids and other new compounds are continuously being characterized (Pollastro et al., 2011). So far, only two cannabinoids (cannabigerol and its corresponding acid) have been obtained from a non-*Cannabis* source. A South African *Helichrysum* (*H. umbraculigerum*) accumulates these compounds (Appendino et al., 2011). The chemistry of marijuana is described in more detail in Factor 3, "The State of Current Scientific Knowledge Regarding the Drug or Other Substance."

The site of cannabinoid action is at the cannabinoid receptors. Cloning of cannabinoid receptors, first from rat brain tissue (Matsuda et al., 1990) and then from human brain tissue (Gerard et al., 1991), has verified the site of action. Two cannabinoid receptors, CB<sub>1</sub> and CB<sub>2</sub>, were characterized (Battista et al., 2012; Piomelli, 2005). Evidence of a third cannabinoid receptor exists, but it has not been identified (Battista et al., 2012).

The cannabinoid receptors, CB<sub>1</sub> and CB<sub>2</sub>, belong to the family of G-protein-coupled receptors, and present a typical seven transmembrane-spanning domain structure. Cannabinoid receptors link to an inhibitory G-protein (G<sub>i</sub>), such that adenylate cyclase activity is inhibited when a ligand binds to the receptor. This, in turn, prevents the conversion of ATP to the second messenger, cyclic AMP (cAMP). Examples of inhibitory coupled receptors include opioid, muscarinic cholinergic, alpha<sub>2</sub>-adrenoreceptors, dopamine (D<sub>2</sub>), and serotonin (5-HT<sub>1</sub>).

Cannabinoid receptor activation inhibits N- and P/Q-type calcium channels and activates inwardly rectifying potassium channels (Mackie et al., 1995; Twitchell et al., 1997). N-type calcium channel inhibition decreases neurotransmitter release from several tissues. Thus, calcium channel inhibition may be the mechanism by which cannabinoids inhibit acetylcholine, norepinephrine, and glutamate release from specific areas of the brain. These effects may represent a potential cellular mechanism underlying cannabinoids' antinociceptive and psychoactive effects (Ameri, 1999).

CB<sub>1</sub> receptors are found primarily in the central nervous system, but are also present in peripheral tissues. CB<sub>1</sub> receptors are located mainly in the basal ganglia, hippocampus, and cerebellum of the brain (Howlett et al., 2004). The localization of these receptors may

explain cannabinoid interference with movement coordination and effects on memory and cognition. Additionally, CB<sub>1</sub> receptors are found in the immune system and numerous other peripheral tissues (Petrocellis and Di Marzo, 2009). However, the concentration of CB<sub>1</sub> receptors is considerably lower in peripheral tissues than in the central nervous system (Herkenharn et al., 1990 and 1992).

CB<sub>2</sub> receptors are found primarily in the immune system, but are also present in the central nervous system and other peripheral tissues. In the immune system, CB<sub>2</sub> receptors are found predominantly in B lymphocytes and natural killer cells (Bouaboula et al., 1993). CB<sub>2</sub> receptors may mediate cannabinoids' immunological effects (Galiegue et al., 1995). Additionally, CB<sub>2</sub> receptors have been localized in the brain, primarily in the cerebellum and hippocampus (Gong et al., 2006). The distribution of CB<sub>2</sub> receptors throughout the body is less extensive than the distribution of CB<sub>1</sub> receptors (Petrocellis and Di Marzo, 2009). However, both CB<sub>1</sub> and CB<sub>2</sub> receptors are present in numerous tissues of the body.

Cannabinoid receptors have endogenous ligands. In 1992 and 1995, two endogenous cannabinoid receptor agonists, anandamide and arachidonyl glycerol (2-AG), respectively, were identified (Di Marzo, 2006). Anandamide is a low efficacy agonist (Breivogel and Childers, 2000) and 2-AG is a high efficacy agonist (Gonsiorek et al., 2000). Cannabinoid endogenous ligands are present in central as well as peripheral tissues. A combination of uptake and hydrolysis terminate the action of the endogenous ligands. The endogenous cannabinoid system is a locally active signaling system that, to help restore homeostasis, is activated "on demand" in response to changes to the local homeostasis (Petrocellis and Di Marzo, 2009). The endogenous cannabinoid system, including the endogenous cannabinoids and the cannabinoid receptors, demonstrate substantial plasticity in response to several physiological and pathological stimuli (Petrocellis and Di Marzo, 2009). This plasticity is particularly evident in the central nervous system.

Delta<sup>9</sup>-THC and cannabidiol (CBD) are two abundant cannabinoids present in marijuana. Marijuana's major psychoactive cannabinoid is delta<sup>9</sup>-THC (Wachtel et al., 2002). In 1964, Gaoni and Mechoularn first described delta<sup>9</sup>-THC's structure and function. In 1963, Mechoularn and Shvo first described CBD's structure. The pharmacological actions of CBD have not been fully studied in humans.

Delta<sup>9</sup>-THC and CBD have varying affinity and effects at the cannabinoid receptors. Delta<sup>9</sup>-THC displays similar affinity for CB<sub>1</sub> and CB<sub>2</sub> receptors, but behaves as a weak agonist for CB<sub>2</sub> receptors. The identification of synthetic cannabinoid ligands that selectively bind to CB<sub>2</sub> receptors but do not have the typical delta<sup>9</sup>-THC-like psychoactive properties suggests that the activation of CB<sub>1</sub>-receptors mediates cannabinoids' psychotropic effects (Hanus et al., 1999). CBD has low affinity for both CB<sub>1</sub> and CB<sub>2</sub> receptors (Mechoulam et al., 2007). According to Mechoulam et al. (2007), CBD has antagonistic effects at CB<sub>1</sub> receptors and some inverse agonistic properties at CB<sub>2</sub> receptors. When cannabinoids are given subacutely to rats, CB<sub>1</sub> receptors down-regulate and the binding of the second messenger system coupled to CB<sub>1</sub> receptors, GTPγS, decreases (Breivogel et al., 2001).

### *Animal Behavioral Effects*

#### Self-Administration

Self-administration is a method that assesses the ability of a drug to produce rewarding effects. The presence of rewarding effects increases the likelihood of behavioral responses to obtain additional drug. Animal self-administration of a drug is often useful in predicting rewarding effects in humans, and is indicative of abuse liability. A good correlation is often observed between those drugs that rhesus monkeys self-administer and those drugs that humans abuse (Balster and Bigelow, 2003). Initially, researchers could not establish self-administration of cannabinoids, including delta<sup>9</sup>-THC, in animal models. However, self-administration of delta<sup>9</sup>-THC can now be established in a variety of animal models under specific training paradigms (Justinova et al., 2003, 2004, 2005).

Squirrel monkeys, with and without prior exposure to other drugs of abuse, self-administer delta<sup>9</sup>-THC under specific conditions. For instance, Tanda et al. (2000) observed that when squirrel monkeys are initially trained to self-administer intravenous cocaine, they will continue to bar-press delta<sup>9</sup>-THC at the same rate as they would with cocaine. The doses were notably comparable to those doses used by humans who smoke marijuana. SR141716, a CB<sub>1</sub> cannabinoid receptor agonist-antagonist, can block this rewarding effect. Other studies show that naïve squirrel monkeys can be successfully trained to self-administer delta<sup>9</sup>-THC intravenously (Justinova et al., 2003). The maximal responding rate

is 4 µg/kg per injection, which is 2–3 times greater than observed in previous studies using cocaine-experienced monkeys. Naltrexone, a mu-opioid antagonist, partially antagonizes these rewarding effects of delta<sup>9</sup>-THC (Justinova et al., 2004).

Additionally, data demonstrate that under specific conditions, rodents self-administer cannabinoids. Rats will self-administer delta<sup>9</sup>-THC when applied intracerebroventricularly (i.c.v.), but only at the lowest doses tested (0.01–0.02 µg/infusion) (Braidia et al., 2004). SR141716 and the opioid antagonist naloxone can antagonize this effect. However, most studies involve rodents self-administering the synthetic cannabinoid WIN 55212, a CB<sub>1</sub> receptor agonist with a non-cannabinoid structure (Deiana et al., 2007; Fattore et al., 2007; Martellotta et al., 1998; Mendizabal et al., 2006).

Aversive effects, rather than reinforcing effects, occur in rats that received high doses of WIN 55212 (Chaperon et al., 1998) or delta<sup>9</sup>-THC (Sanudo-Pena et al., 1997), indicating a possible critical dose-dependent effect. In both studies, SR141716 reversed these aversive effects.

#### Conditioned Place Preference

Conditioned place preference (CPP) is a less rigorous method than self-administration for determining whether or not a drug has rewarding properties. In this behavioral test, animals spend time in two distinct environments: One where they previously received a drug and one where they received a placebo. If the drug is reinforcing, animals will choose to spend more time in the environment paired with the drug, rather than with the placebo, when presented with both options simultaneously.

Animals show CPP to delta<sup>9</sup>-THC, but only at the lowest doses tested (0.075–1.0 mg/kg, intraperitoneal (i.p.)) (Braidia et al., 2004). SR141716 and naloxone antagonize this effect (Braidia et al., 2004). As a partial agonist, SR141716 can induce CPP at doses of 0.25, 0.5, 2 and 3 mg/kg (Cheer et al., 2000). In knockout mice, those without µ-opioid receptors do not develop CPP to delta<sup>9</sup>-THC (Ghozland et al., 2002).

#### Drug Discrimination Studies

Drug discrimination is a method where animals indicate whether a test drug produces physical or psychic perceptions similar to those produced by a known drug of abuse. In this test, an animal learns to press one bar when it receives the known drug of abuse and another bar when it receives placebo. To determine whether the test drug is like

the known drug of abuse, a challenge session with the test drug demonstrates which of the two bars the animal presses more often.

In addition to humans (Lile et al., 2009; Lile et al., 2011), it has been noted that animals, including monkeys (McMahon, 2009), mice (McMahon et al., 2008), and rats (Gold et al., 1992), are able to discriminate cannabinoids from other drugs or placebo. Moreover, the major active metabolite of delta<sup>9</sup>-THC, 11-hydroxy-delta<sup>9</sup>-THC, also generalizes (following oral administration) to the stimulus cues elicited by delta<sup>9</sup>-THC (Browne and Weissman, 1981). Twenty-two other cannabinoids found in marijuana also fully substitute for delta<sup>9</sup>-THC. However, CBD does not substitute for delta<sup>9</sup>-THC in rats (Vann et al., 2008).

Discriminative stimulus effects of delta<sup>9</sup>-THC are pharmacologically specific for marijuana containing cannabinoids (Balster and Prescott, 1992; Browne and Weissman, 1981; Wiley et al., 1993, 1995). The discriminative stimulus effects of the cannabinoid group appear to provide unique effects because stimulants, hallucinogens, opioids, benzodiazepines, barbiturates, NMDA antagonists, and antipsychotics do not fully substitute for delta<sup>9</sup>-THC.

### **Central Nervous System Effects**

#### *Human Physiological and Psychological Effects*

##### Psychoactive Effects

Below is a list of the common subjective responses to cannabinoids (Adams and Martin, 1996; Gonzalez, 2007; Hollister 1986, 1988; Institute of Medicine, 1982). According to Maldonado (2002), these responses to marijuana are pleasurable to many humans and are often associated with drug-seeking and drug-taking. High levels of positive psychoactive effects are associated with increased marijuana use, abuse, and dependence (Scherrer et al., 2009; Zeiger et al., 2010).

(1) Disinhibition, relaxation, increased sociability, and talkativeness.

(2) Increased merriment and appetite, and even exhilaration at high doses.

(3) Enhanced sensory perception, which can generate an increased appreciation of music, art, and touch.

(4) Heightened imagination, which can lead to a subjective sense of increased creativity.

(5) Initial dizziness, nausea, tachycardia, facial flushing, dry mouth, and tremor.

(6) Disorganized thinking, inability to converse logically, time distortions, and short-term memory impairment.

(7) Ataxia and impaired judgment, which can impede driving ability or lead to an increase in risk-tasking behavior.

(8) Illusions, delusions, and hallucinations that intensify with higher doses.

(9) Emotional lability, incongruity of affect, dysphoria, agitation, paranoia, confusion, drowsiness, and panic attacks, which are more common in inexperienced or high-dosed users.

As with many psychoactive drugs, a person's medical, psychiatric, and drug-taking history can influence the individual's response to marijuana. Dose preferences to marijuana occur in that marijuana users prefer higher concentrations of the principal psychoactive substance (1.95 percent delta<sup>9</sup>-THC) over lower concentrations (0.63 percent delta<sup>9</sup>-THC) (Chait and Burke, 1994). Nonetheless, frequent marijuana users (≤100 times of use) were able to identify a drug effect from low-dose delta<sup>9</sup>-THC better than occasional users (<10 times of use) while also experiencing fewer sedative effects from marijuana (Kirk and de Wit, 1999).

The petitioners contend that many of marijuana's naturally occurring cannabinoids mitigate the psychoactive effects of delta<sup>9</sup>-THC, and therefore that marijuana lacks sufficient abuse potential to warrant Schedule I placement, because Marinol, which is in Schedule III, contains only delta<sup>9</sup>-THC. This theory has not been demonstrated in controlled studies. Moreover, the concept of abuse potential encompasses all properties of a substance, including its chemistry, pharmacology, and pharmacokinetics, as well as usage patterns and diversion history. The abuse potential of a substance is associated with the repeated or sporadic use of a substance in nonmedical situations for the psychoactive effects the substance produces. These psychoactive effects include euphoria, perceptual and other cognitive distortions, hallucinations, and mood changes. However, as stated above, the abuse potential not only includes the psychoactive effects, but also includes other aspects related to a substance.

DEA's final published rule entitled "Rescheduling of the Food and Drug Administration Approved Product Containing Synthetic Dronabinol [(–)-delta<sup>9</sup>-(trans)-Tetrahydrocannabinol] in Sesame Oil and Encapsulated in Soft Gelatin Capsules From Schedule II to Schedule III" (64 FR 35928, July 2, 1999) rescheduled Marinol from Schedule II to Schedule III. The HHS assessment of the abuse potential and subsequent scheduling recommendation

compared Marinol to marijuana on different aspects related to abuse potential. Major differences in formulation, availability, and usage between marijuana and the drug product, Marinol, contribute to their differing abuse potentials.

Hollister and Gillespie (1973) estimated that delta<sup>9</sup>-THC by smoking is 2.6 to 3 times more potent than delta<sup>9</sup>-THC ingested orally. The intense psychoactive drug effect achieved, rapidly by smoking is generally considered to produce the effect desired by the abuser. This effect explains why abusers often prefer to administer certain drugs by inhalation, intravenously, or intranasally rather than orally. Such is the case with cocaine, opium, heroin, phencyclidine, methamphetamine, and delta<sup>9</sup>-THC from marijuana (0.1–9.5 percent delta<sup>9</sup>-THC range) or hashish (10–30 percent delta<sup>9</sup>-THC range) (Wesson and Washburn, 1990). Thus, the delayed onset and longer duration of action for Marinol may be contributing factors limiting the abuse or appeal of Marinol as a drug of abuse relative to marijuana.

The formulation of Marinol is a factor that contributes to differential scheduling of Marinol and marijuana. For example, extraction and purification of dronabinol from the encapsulated sesame oil mixture of Marinol is highly complex and difficult. Additionally, the presence of sesame oil mixture in the formulation may preclude the smoking of Marinol-laced cigarettes.

Additionally, there is a dramatic difference between actual abuse and illicit trafficking of Marinol and marijuana. Despite Marinol's availability in the United States, there have been no significant reports of abuse, diversion, or public health problems due to Marinol. By comparison, 18.9 million American adults report currently using marijuana (SAMHSA, 2013).

In addition, FDA's approval of an NDA for Marinol allowed for Marinol to be rescheduled to Schedule II, and subsequently to Schedule III of the CSA. In conclusion, marijuana and Marinol differ on a wide variety of factors that contribute to each substance's abuse potential. These differences are major reasons distinguishing the higher abuse potential for marijuana and the different scheduling determinations of marijuana and Marinol.

In terms of the petitioners' claim that different cannabinoids present in marijuana mitigate the psychoactive effects of delta<sup>9</sup>-THC, only three of the cannabinoids present in marijuana were simultaneously administered with delta<sup>9</sup>-THC to examine how the

combinations of these cannabinoids such as CBD, cannabichromene (CBC) and cannabitol (CBN) influence delta<sup>9</sup>-THC's psychoactive effects. Dalton et al. (1976) observed that smoked administration of placebo marijuana cigarettes containing injections of 0.15 mg/kg CBD combined with 0.025mg/kg of delta<sup>9</sup>-THC, in a 7:1 ratio of CBD to delta<sup>9</sup>-THC, significantly decreased ratings of acute subjective effects and "high" when compared to smoking delta<sup>9</sup>-THC alone. In contrast, Ilan et al. (2005) calculated the naturally occurring concentrations of CBC and CBD in a batch of marijuana cigarettes with either 1.8 percent or 3.6 percent delta<sup>9</sup>-THC concentration by weight. For each strength of delta<sup>9</sup>-THC in marijuana cigarettes, the concentrations of CBC and CBD were classified in groups of either low or high. The study varied the amount of CBC and CBD within each strength of delta<sup>9</sup>-THC marijuana cigarettes, with administrations consisting of either low CBC (between 0.1–0.2 percent CBC concentration by weight) and low CBD (between 0.1–0.4 percent CBD concentration by weight), high CBC (≤ 0.5 percent CBC concentration by weight) and low CBD, or low CBC and high CBD (≤1.0 percent CBD concentration by weight). Overall, all combinations scored significantly greater than placebo on ratings of subjective effects, and there was no significant difference between any combinations.

The oral administration of a combination of either 15, 30, or 60 mg CBD with 30 mg delta<sup>9</sup>-THC dissolved in liquid (in a ratio of at least 1:2 CBD to delta<sup>9</sup>-THC) reduced the subjective effects produced by delta<sup>9</sup>-THC alone (Karniol et al., 1974). Additionally, orally administering a liquid mixture combining 1 mg/kg CBD with 0.5 mg/kg of delta<sup>9</sup>-THC (ratio of 2:1 CBD to delta<sup>9</sup>-THC) decreased scores of anxiety and marijuana drug effect on the Addiction Research Center Inventory (ARCI) compared to delta<sup>9</sup>-THC alone (Zuardi et al., 1982). Lastly, oral administration of either 12.5, 25, or 50 mg CBN combined with 25 mg delta<sup>9</sup>-THC dissolved in liquid (ratio of at least 1:2 CBN to delta<sup>9</sup>-THC) significantly increased subjective ratings of "drugged," "drowsy," "dizzy," and "drunk," compared to delta<sup>9</sup>-THC alone (Karniol et al., 1975).

Even though some studies suggest that CBD may decrease some of delta<sup>9</sup>-THC's psychoactive effects, the ratios of CBD to delta<sup>9</sup>-THC administered in these studies are not present in marijuana used by most people. For example, in one study, researchers used smoked

marijuana with ratios of CBD to delta<sup>9</sup>-THC naturally present in marijuana plant material and they found out that varying the amount of CBD actually had no effect on delta<sup>9</sup>-THC's psychoactive effects (Ilan et al., 2005). Because most marijuana currently available on the street has high amounts of delta<sup>9</sup>-THC with low amounts of CBD and other cannabinoids, most individuals use marijuana with low levels of CBD present (Mehmedic et al., 2010). Thus, any possible mitigation of delta<sup>9</sup>-THC's psychoactive effects by CBD will not occur for most marijuana users. In contrast, one study indicated that another cannabinoid present in marijuana, CBN, may enhance delta<sup>9</sup>-THC's psychoactive effects (Karniol et al., 1975).

#### Behavioral Impairment

Marijuana induces various psychoactive effects that can lead to behavioral impairment. Marijuana's acute effects can significantly interfere with a person's ability to learn in the classroom or to operate motor vehicles. Acute administration of smoked marijuana impairs performance on learning, associative processes, and psychomotor behavioral tests (Block et al., 1992). Ramaekers et al. (2006a) showed that acute administration of 250 µg/kg and 500 µg/kg of delta<sup>9</sup>-THC in smoked marijuana dose-dependently impairs cognition and motor control, including motor impulsivity and tracking impairments (Ramaekers et al., 2006b). Similarly, administration of 290 µg/kg delta<sup>9</sup>-THC in a smoked marijuana cigarette resulted in impaired perceptual motor speed and accuracy: Two skills which are critical to driving ability (Kurzthaler et al., 1999). Lastly, administration of 3.95 percent delta<sup>9</sup>-THC in a smoked marijuana cigarette not only increased disequilibrium measures, but also increased the latency in a task of simulated vehicle braking at a rate comparable to an increase in stopping distance of five feet at 60 mph (Liguori et al., 1998). However, acute administration of marijuana containing 2.1 percent delta<sup>9</sup>-THC does not produce "hangover effects" (Chait, 1990).

In addition to measuring the acute effects immediately following marijuana administration, researchers have conducted studies to determine how long behavioral impairments last after abstinence. Some of marijuana's acute effects may not fully resolve until at least one day after the acute psychoactive effects have subsided. Heishman et al. (1990) showed that impairment on memory tasks persists for 24 hours after smoking marijuana

cigarettes containing 2.57 percent delta<sup>9</sup>-THC. However, Fant et al. (1998) showed that the morning after exposure to 1.8 percent or 3.6 percent smoked delta<sup>9</sup>-THC, subjects had minimal residual alterations in subjective or performance measures.

A number of factors may influence marijuana's behavioral effects including the duration of use (chronic or short term), frequency of use (daily, weekly, or occasionally), and amount of use (heavy or moderate). Researchers also have examined how long behavioral impairments last following chronic marijuana use. These studies used self-reported histories of past duration, frequency, and amount of past marijuana use, and administered a variety of performance and cognitive measures at different time points following marijuana abstinence. In chronic marijuana users, behavioral impairments may persist for up to 28 days of abstinence. Solowij et al. (2002) demonstrated that after 17 hours of abstinence, 51 adult heavy chronic marijuana users performed worse on memory and attention tasks than 33 non-using controls or 51 heavy, short-term users. Another study noted that heavy, frequent marijuana users, abstinent for at least 24 hours, performed significantly worse than the controls on verbal memory and psychomotor speed tests (Messinis et al., 2006). Additionally, after at least 1 week of abstinence, young adult frequent marijuana users, aged 18–28, showed deficits in psychomotor speed, sustained attention, and cognitive inhibition (Lisdahl and Price, 2012). Adult heavy, chronic marijuana users showed deficits on memory tests after 7 days of supervised abstinence (Pope et al., 2002). However, when these same individuals were again tested after 28 days of abstinence, they did not show significant memory deficits. The authors concluded, "cannabis-associated cognitive deficits are reversible and related to recent cannabis exposure, rather than irreversible and related to cumulative lifetime use."<sup>7</sup> However, other researchers reported neuropsychological deficits in memory, executive functioning, psychomotor speed and manual dexterity in heavy marijuana users abstinent for 28 days (Bolla et al., 2002). Furthermore, a follow-up study of heavy marijuana users noted decision-making deficits after 25 days of supervised abstinence. (Bolla et al., 2005). However, moderate marijuana users did not show decision-making deficits after 25 days of

abstinence, suggesting the amount of marijuana use may impact the duration of residual impairment.

The effects of chronic marijuana use do not seem to persist after more than 1 to 3 months of abstinence. After 3 months of abstinence, any deficits observed in IQ, immediate memory, delayed memory, and information-processing speeds following heavy marijuana use compared to pre-drug use scores were no longer apparent (Fried et al., 2005). Marijuana did not appear to have lasting effects on performance of a comprehensive neuropsychological battery when 54 monozygotic male twins (one of whom used marijuana, one of whom did not) were compared 1–20 years after cessation of marijuana use (Lyons et al., 2004). Similarly, following abstinence for a year or more, both light and heavy adult marijuana users did not show deficits on scores of verbal memory compared to non-using controls (Tait et al., 2011). According to a recent meta-analysis looking at non-acute and long-lasting effects of marijuana use on neurocognitive performance, any deficits seen within the first month following abstinence are generally not present after about 1 month of abstinence (Schreiner and Dunn, 2012).

Another aspect that may be a critical factor in the intensity and persistence of impairment resulting from chronic marijuana use is the age of first use. Individuals with a diagnosis of marijuana misuse or dependence who were seeking treatment for substance use, who initiated marijuana use before the age of 15 years, showed deficits in performance on tasks assessing sustained attention, impulse control, and general executive functioning compared to non-using controls. These deficits were not seen in individuals who initiated marijuana use after the age of 15 years (Fontes et al., 2011). Similarly, heavy, chronic marijuana users who began using marijuana before the age of 16 years had greater decrements in executive functioning tasks than heavy, chronic marijuana users who started using after the age of 16 years and non-using controls (Gruber et al., 2012). Additionally, in a prospective longitudinal birth cohort study of 1,037 individuals, marijuana dependence or chronic marijuana use was associated with a decrease in IQ and general neuropsychological performance compared to pre-marijuana exposure levels in adolescent onset users (Meier et al., 2012). The decline in adolescent-onset user's IQ persisted even after reduction or abstinence of marijuana use for at least 1 year. In contrast, the adult-onset chronic marijuana users showed no significant

<sup>7</sup> In this quotation the term *Cannabis* is used interchangeably for *marijuana*.

changes in IQ compared to pre-exposure levels whether they were current users or abstinent for at least 1 year (Meier et al., 2012).

In addition to the age of onset of use, some evidence suggests that the amount of marijuana used may relate to the intensity of impairments. In the above study by Gruber et al. (2012), where early-onset users had greater deficits than late-onset users, the early-onset users reported using marijuana twice as often and using three times as much marijuana per week than the late-onset users. Meier et al. (2012) showed that the deficits in IQ seen in adolescent-onset users increased with the amount of marijuana used. Moreover, when comparing scores for measures of IQ, immediate memory, delayed memory, and information-processing speeds to pre-drug-use levels, the current, heavy, chronic marijuana users showed deficits in all three measures while current, occasional marijuana users did not (Fried et al., 2005).

#### Behavioral Effects of Prenatal Exposure

Studies with children at different stages of development are used to examine the impact of prenatal marijuana exposure on performance in a series of cognitive tasks. However, many pregnant women who reported marijuana use were more likely to also report use of alcohol, tobacco, and cocaine (Goldschmidt et al., 2008). Thus, with potential exposure to multiple drugs, it is difficult to determine the specific impact of prenatal marijuana exposure.

Most studies assessing the behavioral effects of prenatal marijuana exposure included women who, in addition to using marijuana, also reported using alcohol and tobacco. However, some evidence suggests an association between heavy prenatal marijuana exposure and deficits in some cognitive domains. In both 4-year-old and 6-year-old children, heavy prenatal marijuana use is negatively associated with performance on tasks assessing memory, verbal reasoning, and quantitative reasoning (Fried and Watkinson, 1987; Goldschmidt et al., 2008). Additionally, heavy prenatal marijuana use is associated with deficits in measures of sustained attention in children at the ages of 6 years and 13–16 years (Fried et al., 1992; Fried, 2002). In 9- to 12-year-old children, prenatal marijuana exposure is negatively associated with executive functioning tasks that require impulse control, visual analysis, and hypothesis (Fried et al., 1998).

#### Association of Marijuana Use With Psychosis

This analysis evaluates only the evidence for a direct link between prior marijuana use and the subsequent development of psychosis. Thus, this discussion does not consider issues such as whether marijuana's transient effects are similar to psychotic symptoms in healthy individuals or exacerbate psychotic symptoms in individuals already diagnosed with schizophrenia.

Extensive research has been conducted to investigate whether exposure to marijuana is associated with the development of schizophrenia or other psychoses. Although many studies are small and inferential, other studies in the literature use hundreds to thousands of subjects. At present, the available data do not suggest a causative link between marijuana use and the development of psychosis (Minozzi et al., 2010). Numerous large, longitudinal studies show that subjects who used marijuana do not have a greater incidence of psychotic diagnoses compared to those who do not use marijuana (Fergusson et al., 2005; Kuepper et al., 2011; Van Os et al., 2002).

When analyzing the available evidence of the connection between psychosis and marijuana, it is critical to determine whether the subjects in the studies are patients who are already diagnosed with psychosis or individuals who demonstrate a limited number of symptoms associated with psychosis without qualifying for a diagnosis of the disorder. For example, instead of using a diagnosis of psychosis, some researchers relied on non-standard methods of representing symptoms of psychosis including "schizophrenic cluster" (Maremmani et al., 2004), "subclinical psychotic symptoms" (Van Gastel et al., 2012), "pre-psychotic clinical high risk" (Van der Meer et al., 2012), and symptoms related to "psychosis vulnerability" (Griffith-Lendering et al., 2012). These groupings do not conform to the criteria in the Diagnostic and Statistical Manual (DSM–5) or the International Classification of Diseases (ICD–10) for a diagnosis of psychosis. Thus, these groupings are not appropriate for use in evaluating marijuana's impact on the development of actual psychosis. Accordingly, this analysis includes only those studies that use subjects diagnosed with a psychotic disorder.

In the largest study evaluating the link between psychosis and drug use, 274 of the approximately 45,500 Swedish conscripts in the study population

(<0.01 percent) received a diagnosis of schizophrenia within the 14-year period following military induction from 1969 to 1983 (Andreasson et al., 1987). Of the conscripts diagnosed with psychosis, 7.7 percent (21 of the 274 conscripts with psychosis) had used marijuana more than 50 times at induction, while 72 percent (197 of the 274 conscripts with psychosis) had never used marijuana. Although high marijuana use increased the relative risk for schizophrenia to 6.0, the authors note that substantial marijuana use history "accounts for only a minority of all cases" of psychosis (Andreasson et al., 1987). Instead, the best predictor for whether a conscript would develop psychosis was a non-psychotic psychiatric diagnosis upon induction. The authors concluded that marijuana use increased the risk for psychosis only among individuals predisposed to develop the disorder. In addition, a 35-year follow up to this study reported very similar results (Manrique-Garcia et al., 2012). In this follow up study, 354 conscripts developed schizophrenia; of these 354 conscripts, 32 used marijuana more than 50 times at induction (9 percent, an odds ratio of 6.3), while 255 had never used marijuana (72 percent).

Additionally, the conclusion that the impact of marijuana may manifest only in individuals likely to develop psychotic disorders has been shown in many other types of studies. For example, although evidence shows that marijuana use may precede the presentation of symptoms in individuals later diagnosed with psychosis (Schimmelmann et al., 2011), most reports conclude that prodromal symptoms of schizophrenia appear prior to marijuana use (Schiffman et al., 2005). Similarly, a review of the gene-environment interaction model for marijuana and psychosis concluded that some evidence supports marijuana use as a factor that may influence the development of psychosis, but only in those individuals with psychotic liability (Pelayo-Teran et al., 2012).

A similar conclusion was drawn when the prevalence of schizophrenia was modeled against marijuana use across eight birth cohorts in Australia in individuals born between the years 1940 to 1979 (Degenhardt et al., 2003). Although marijuana use increased over time in adults born during the four-decade period, there was not a corresponding increase in diagnoses for psychosis in these individuals. The authors conclude that marijuana may precipitate schizophrenic disorders only in those individuals who are vulnerable to developing psychosis. Thus, marijuana *per se* does not appear to

induce schizophrenia in the majority of individuals who have tried or continue to use marijuana. However, in individuals with a genetic vulnerability for psychosis, marijuana use may influence the development of psychosis.

### Cardiovascular and Autonomic Effects

Single smoked or oral doses of delta<sup>9</sup>-THC produce tachycardia and may increase blood pressure (Capriotti et al., 1988; Benowitz and Jones, 1975). Some evidence associates the tachycardia produced by delta<sup>9</sup>-THC with excitation of the sympathetic and depression of the parasympathetic nervous systems (Malinowska et al., 2012). During chronic marijuana ingestion, a tolerance to tachycardia develops (Malinowska et al., 2012).

However, prolonged delta<sup>9</sup>-THC ingestion produces bradycardia and hypotension (Benowitz and Jones, 1975). Plant-derived cannabinoids and endocannabinoids elicit hypotension and bradycardia via activation of peripherally-located CB<sub>1</sub> receptors (Wagner et al., 1998). Specifically, the mechanism of this effect is through presynaptic CB<sub>1</sub> receptor-mediated inhibition of norepinephrine release from peripheral sympathetic nerve terminals, with possible additional direct vasodilation via activation of vascular cannabinoid receptors (Pacher et al., 2006). In humans, tolerance can develop to orthostatic hypotension (Jones, 2002; Sidney, 2002) possibly related to plasma volume expansion, but tolerance does not develop to the supine hypotensive effects (Benowitz and Jones, 1975). Additionally, electrocardiographic changes are minimal, even after large cumulative doses of delta<sup>9</sup>-THC are administered. (Benowitz and Jones, 1975).

Marijuana smoking by individuals, particularly those with some degree of coronary artery or cerebrovascular disease, poses risks such as increased cardiac work, catecholamines and carboxyhemoglobin, myocardial infarction, and postural hypotension (Benowitz and Jones, 1981; Hollister, 1988; Mittleman et al., 2001; Malinowska et al., 2012).

### Respiratory Effects

After acute exposure to marijuana, transient bronchodilation is the most typical respiratory effect (Gong et al., 1984). A recent 20-year longitudinal study with over 5,000 individuals collected information on the amount of marijuana use and pulmonary function data at years 0, 2, 5, 10, and 20 (Pletcher et al., 2012). Among the more than 5,000 individuals who participated in the study, almost 800 of them reported

current marijuana use but not tobacco use at the time of assessment. Pletcher et al. (2012) found that the occasional use of marijuana is not associated with decreased pulmonary function. However, some preliminary evidence suggests that heavy marijuana use may be associated with negative pulmonary effects (Pletcher et al., 2012). Long-term use of marijuana can lead to chronic cough and increased sputum, as well as an increased frequency of chronic bronchitis and pharyngitis. In addition, pulmonary function tests reveal that large-airway obstruction can occur with chronic marijuana smoking, as can cellular inflammatory histopathological abnormalities in bronchial epithelium (Adams and Martin 1996; Hollister 1986).

Evidence regarding marijuana smoking leading to cancer is inconsistent, as some studies suggest a positive correlation while others do not (Lee and Hancox, 2011; Tashkin, 2005). Several lung cancer cases have been reported in young marijuana users with no tobacco smoking history or other significant risk factors (Fung et al., 1999). Marijuana use may dose-dependently interact with mutagenic sensitivity, cigarette smoking, and alcohol use to increase the risk of head and neck cancer (Zhang et al., 1999). However, in a large study with 1,650 subjects, a positive association was not found between marijuana and lung cancer (Tashkin et al., 2006). This finding remained true, regardless of the extent of marijuana use, when controlling for tobacco use and other potential confounding variables. Overall, new evidence suggests that the effects of marijuana smoking on respiratory function and carcinogenicity differ from those of tobacco smoking (Lee and Hancox, 2011).

### Endocrine System

Experimental marijuana administration to humans does not consistently alter many endocrine parameters. In an early study, male subjects who experimentally received smoked marijuana showed a significant depression in luteinizing hormone and a significant increase in cortisol (Cone et al., 1986). However, two later studies showed no changes in hormones. Male subjects experimentally exposed to smoked delta<sup>9</sup>-THC (18 mg/marijuana cigarette) or oral delta<sup>9</sup>-THC (10 mg three times per day for 3 days and on the morning of the fourth day) showed no changes in plasma adrenocorticotrophic hormone (ACTH), cortisol, prolactin, luteinizing hormone, or testosterone levels (Dax et al., 1989). Similarly, a study with 93 men and 56

women showed that chronic marijuana use did not significantly alter concentrations of testosterone, luteinizing hormone, follicle stimulating hormone, prolactin, or cortisol (Block et al., 1991). Additionally, chronic marijuana use did not affect serum levels of thyrotropin, thyroxine, and triiodothyronine (Bonnet, 2013). However, in a double-blind, placebo-controlled, randomized clinical trial of HIV-positive men, smoking marijuana dose-dependently increased plasma levels of ghrelin and leptin, and decreased plasma levels of peptide YY (Riggs et al., 2012).

The effects of marijuana on female reproductive system functionality differ between humans and animals. In monkeys, delta<sup>9</sup>-THC administration suppressed ovulation (Asch et al., 1981) and reduced progesterone levels (Almirez et al., 1983). However, in women, smoked marijuana did not alter hormone levels or the menstrual cycle (Mendelson and Mello, 1984). Brown and Dobs (2002) suggest that the development of tolerance in humans may be the cause of the discrepancies between animal and human hormonal response to cannabinoids.

The presence of *in vitro* delta<sup>9</sup>-THC reduces binding of the corticosteroid, dexamethasone, in hippocampal tissue from adrenalectomized rats, suggesting an interaction with the glucocorticoid receptor (Eldridge et al., 1991). Although acute delta<sup>9</sup>-THC presence releases corticosterone, tolerance develops in rats with chronic administration (Eldridge et al., 1991).

Some studies support a possible association between frequent, long-term marijuana use and increased risk of testicular germ cell tumors (Trabert et al., 2011). On the other hand, recent data suggest that cannabinoid agonists may have therapeutic value in the treatment of prostate cancer, a type of carcinoma in which growth is stimulated by androgens. Research with prostate cancer cells shows that the mixed CB<sub>1</sub>/CB<sub>2</sub> agonist, WIN-55212-2, induces apoptosis in prostate cancer cells, as well as decreases the expression of androgen receptors and prostate-specific antigens (Sarfraz et al., 2005).

### Immune System

Cannabinoids affect the immune system in many different ways. Synthetic, natural, and endogenous cannabinoids often cause different effects in a dose-dependent biphasic manner (Croxford and Yamamura, 2005; Tanasescu and Constantinescu, 2010).

Studies in humans and animals give conflicting results about cannabinoid

effects on immune functioning in subjects with compromised immune systems. Abrams et al. (2003) investigated marijuana's effect on immunological functioning in 62 AIDS patients taking protease inhibitors. Subjects received one of the following three times a day: A smoked marijuana cigarette containing 3.95 percent delta<sup>9</sup>-THC, an oral tablet containing delta<sup>9</sup>-THC (2.5 mg oral dronabinol), or an oral placebo. The results showed no changes in CD4+ and CD8+ cell counts, HIV RNA levels, or protease inhibitor levels between groups. Thus, the use of cannabinoids showed no short-term adverse virologic effects in individuals with compromised immune systems. However, these human data contrast with data generated in immunodeficient mice, which demonstrated that exposure to delta<sup>9</sup>-THC *in vivo* suppresses immune function, increases HIV co-receptor expression, and acts as a cofactor to enhance HIV replication (Roth et al., 2005).

### 3. The State of Current Scientific Knowledge Regarding the Drug or Other Substance

Under the third factor, the Secretary must consider the state of current scientific knowledge regarding marijuana. Thus, this section discusses the chemistry, human pharmacokinetics, and medical uses of marijuana.

#### Chemistry

Marijuana is one of the common names of *Cannabis sativa* L. in the family Cannabaceae. *Cannabis* is one of the oldest cultivated crops, providing a source of fiber, food, oil, and drug. Botanists still debate whether *Cannabis* should be considered as a single (The Plant List, 2010) or three species, *i.e.*, *C. sativa*, *C. indica*, and *C. ruderalis* (Hillig, 2005). Specifically, marijuana is developed as *sativa* and *indica* cultivated varieties (strains) or various hybrids.

The petition defines marijuana as including all *Cannabis* cultivated strains. Different marijuana samples derived from various cultivated strains may have very different chemical constituents including delta<sup>9</sup>-THC and other cannabinoids (Appendino et al., 2011). As a consequence, marijuana products from different strains will have different safety, biological, pharmacological, and toxicological profiles. Thus, all *Cannabis* strains cannot be considered together because of the varying chemical constituents between strains.

Marijuana contains numerous naturally occurring constituents

including cannabinoids. Overall, various *Cannabis* strains contain more than 525 identified natural constituents. Among those constituents, the most important ones are the 21 (or 22) carbon terpenoids found in the plant, as well as their carboxylic acids, analogues, and transformation products, known as cannabinoids (Agurell et al., 1984, 1986; Mechoulam, 1973; Appendino et al., 2011). Thus far, more than 100 compounds classified as cannabinoids have been characterized (ElSohly and Slade, 2005; Radwan, ElSohly et al., 2009; Appendino et al. 2011).

Cannabinoids primarily exist in *Cannabis*, and published data suggest that most major cannabinoid compounds occurring naturally have been chemically identified. New and minor cannabinoids and other new compounds are continuously being characterized (Pollastro et al., 2011). So far, only two cannabinoids (cannabigerol and its corresponding acid) have been obtained from a *non-Cannabis* source. A South African *Helichrysum* (*H. umbraculigerum*) accumulates these compounds (Appendino et al. 2011).

Among the cannabinoids found in marijuana, delta<sup>9</sup>-THC (alternate name delta<sup>1</sup>-THC) and delta-8-tetrahydrocannabinol (delta<sup>8</sup>-THC, alternate name delta<sup>6</sup>-THC) produce marijuana's characteristic psychoactive effects. Because delta<sup>9</sup>-THC is more abundant than delta<sup>8</sup>-THC, marijuana's psychoactivity is largely attributed to the former. Only a few varieties of marijuana analyzed contain delta<sup>8</sup>-THC at significant amounts (Hively et al., 1966). Delta<sup>9</sup>-THC is an optically active resinous substance, insoluble in water, and extremely lipid soluble. Chemically, delta<sup>9</sup>-THC is (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo-[b,d]pyran-1-ol, or (–)-delta<sup>9</sup>-(trans)-tetrahydrocannabinol. The (–)-trans isomer of delta<sup>9</sup>-THC is pharmacologically 6–100 times more potent than the (+)-trans isomer (Dewey et al., 1984).

Other cannabinoids present in marijuana include CBD, CBC, and CBN. CBD, a major cannabinoid of marijuana, is insoluble in water and lipid-soluble. Chemically, CBD is 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol. CBD does not have cannabinol-like psychoactivity (Adams and Martin, 1996; Agurell et al., 1984, 1986; Hollister, 1986). CBC is another major cannabinoid in marijuana. Chemically, CBC is 2-methyl-2-(4-methylpent-3-enyl)-7-pentyl-5-chromenol. CBN, a major metabolite of delta<sup>9</sup>-THC, is also a minor naturally-occurring cannabinoid

with weak psychoactivity. Chemically, CBN is 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol.

Different marijuana samples derived from various cultivated strains may differ in chemical constituents including delta<sup>9</sup>-THC and other cannabinoids (Appendino et al. 2011). As a consequence, marijuana products from different strains may have different safety, biological, pharmacological, and toxicological profiles. In addition to differences between cultivated strains, the concentration of delta<sup>9</sup>-THC and other cannabinoids in marijuana may vary with growing conditions and processing after harvest. In addition to genetic differences among *Cannabis* species, the plant parts collected—for example, flowers, leaves, and stems—can influence marijuana's potency, quality, and purity (Adams and Martin, 1996; Agurell et al., 1984; Mechoulam, 1973). All these variations produce marijuana with potencies, as indicated by cannabinoid content, on average from as low as 1–2 percent to as high as 17 percent.

Overall, these variations in the concentrations of cannabinoids and other chemical constituents in marijuana complicate the interpretation of clinical data using marijuana. The lack of consistent concentrations of delta<sup>9</sup>-THC and other substances in marijuana from diverse sources makes interpreting the effect of different marijuana constituents difficult. In addition to different cannabinoid concentrations having different pharmacological and toxicological profiles, the non-cannabinoid components in marijuana, such as other terpenoids and flavonoids, might also contribute to the overall pharmacological and toxicological profiles of various marijuana strains and products derived from those strains.

The term marijuana is often used to refer to a mixture of the dried flowering tops and leaves from *Cannabis*. Marijuana in this limiting definition is one of three major derivatives sold as separate illicit products, which also include hashish and hash oil. According to the DEA, *Cannabis saliva* is the primary species of *Cannabis* currently marketed illegally in the United States.

Marijuana can vary in cannabinoid content and potency (Agurell et al., 1984, 1986; Mechoulam 1973, Cascini et al., 2012). In the usual mixture of leaves and stems distributed as marijuana, the concentration of delta<sup>9</sup>-THC averages over 12 percent by weight. However, specially grown and selected marijuana can contain 15 percent or greater delta<sup>9</sup>-THC (Appendino et al. 2011). Thus, a 1-gram marijuana cigarette might contain

delta<sup>9</sup>-THC in a range from as little as 3 milligrams to as much as 150 milligrams or more. Additionally, a recent systematic review and meta-analysis found that marijuana's delta<sup>9</sup>-THC content has increased significantly from 1979–2009 (Cascini et al., 2012). In addition to smoking marijuana, individuals ingest marijuana through food made with butter or oil infused with marijuana and its extracts. These marijuana butters are generally made by adding marijuana to butter and heating it. The resultant butter is then used to cook a variety of foods. There are no published studies measuring the concentrations of cannabinoids in these marijuana food products.

Hashish consists of the dried and compressed cannabinoid-rich resinous material of *Cannabis* and comes in a variety of forms (e.g. balls and cakes). Individuals may break off pieces, place it into a pipe and smoke it. DEA reports that cannabinoid content in hashish averages six percent (DEA, 2005). With the development and cultivation of more high potency *Cannabis* strains, the average cannabinoid content in hashish will likely increase.

Hash oil is produced by solvent extraction of the cannabinoids from plant material. The extract's color and odor vary, depending on the solvent type used. Hash oil is a viscous brown- or amber-colored liquid containing approximately 50 percent cannabinoids. One or two drops of the liquid placed on a cigarette purportedly produce the equivalent of a single marijuana cigarette (DEA, 2005).

In conclusion, marijuana has hundreds of cultivars containing variable concentrations of delta<sup>9</sup>-THC, cannabinoids, and other compounds. Thus, marijuana is not a single chemical with a consistent and reproducible chemical profile or predictable and consistent clinical effects. A guidance for industry, entitled *Botanical Drug Products*,<sup>8</sup> provides information on the approval of botanical drug products. To investigate marijuana for medical use in a manner acceptable as support for marketing approval under an NDA, clinical studies under an IND of consistent batches of a particular marijuana product for particular disease indications should be conducted. In addition, information and data regarding the marijuana product's chemistry, manufacturing and control, pharmacology, and animal toxicology data, among others must be provided

and meet the requirements for new drug approval (See 21 CFR 314.50).

#### Human Pharmacokinetics

Marijuana can be taken in a variety of formulations by multiple routes of administration. Individuals smoke marijuana as a cigarette, weighing between 0.5 and 1.0 gram, or in a pipe. Additionally, individuals take marijuana orally in foods or as an extract in ethanol or other solvents. More recently, access to vaporizers provides another means for abusers to inhale marijuana.

The absorption, metabolism, and pharmacokinetic profile of delta<sup>9</sup>-THC, cannabinoids, and drug products containing delta<sup>9</sup>-THC vary with route of administration and formulation (Adams and Martin, 1996; Agurell et al., 1984, 1986).

#### Pharmacokinetics of Smoked Administration of Cannabinoids

Characterization of the pharmacokinetics of delta<sup>9</sup>-THC and other cannabinoids from smoked marijuana is difficult because a subject's smoking behavior during an experiment varies (Agurell et al., 1986; Heming et al., 1986; Huestis et al., 1992a). Each puff delivers a discrete dose of delta<sup>9</sup>-THC. An experienced marijuana smoker can titrate and regulate the dose to obtain the desired acute psychological effects and minimize undesired effects. For example, under naturalistic conditions, users hold marijuana smoke in their lungs for an extended period of time which causes prolonged absorption and increases psychoactive effects. The effect of experience in the psychological response may explain why delta<sup>9</sup>-THC venous blood levels correlate poorly with intensity of effects and intoxication level (Agurell et al. 1986; Barnett et al. 1985; Huestis et al., 1992a). Puff and inhalation volumes should be recorded in studies as the concentration (dose) of cannabinoids administered can vary at different stages of smoking.

Smoked marijuana results in absorption of delta<sup>9</sup>-THC in the form of an aerosol within seconds. Psychoactive effects occur immediately following absorption, with mental and behavioral effects measurable for up to 6 hours (Grotenhermen, 2003; Hollister 1986, 1988). Delta<sup>9</sup>-THC is delivered to the brain rapidly and efficiently as expected of a very lipid soluble drug.

The bioavailability of the delta<sup>9</sup>-THC, from marijuana in a cigarette or pipe, can range from 1 to 24 percent with the fraction absorbed rarely exceeding 10 to 20 percent (Agurell et al., 1986; Hollister, 1988). The relatively low and variable bioavailability results from

significant loss of delta<sup>9</sup>-THC in side-stream smoke, variation in individual smoking behaviors, cannabinoid pyrolysis, incomplete absorption of inhaled smoke, and metabolism in the lungs. An individual's experience and technique with smoking marijuana also determines the dose absorbed (Heming et al., 1986; Johansson et al., 1989). After smoking, delta<sup>9</sup>-THC venous levels decline precipitously within minutes, and continue to go down to about 5 to 10 percent of the peak level within an hour (Agurell et al., 1986, Huestis et al., 1992a, 1992b).

#### Pharmacokinetics for Oral Administration of Cannabinoids

After oral administration of delta<sup>9</sup>-THC or marijuana, the onset of effects starts within 30 to 90 minutes, reaches its peak after 2 to 3 hours and then remains for 4 to 12 hours (Grotenhermen, 2003; Adams and Martin, 1996; Agurell et al., 1984, 1986). Due to the delay in onset of effects, users have difficulty in titrating oral delta<sup>9</sup>-THC doses compared to smoking marijuana. Oral bioavailability of delta<sup>9</sup>-THC, whether pure or in marijuana, is low and extremely variable, ranging between 5 and 20 percent (Agurell et al., 1984, 1986). Following oral administration of radioactive-labeled delta<sup>9</sup>-THC, delta<sup>9</sup>-THC plasma levels are low relative to plasma levels after smoking or intravenous administration. Inter- and intra-subject variability occurs even with repeated dosing under controlled conditions. The low and variable oral bioavailability of delta<sup>9</sup>-THC is a consequence of its first-pass hepatic elimination from blood and erratic absorption from stomach and bowel.

#### Cannabinoid Metabolism and Excretion

Cannabinoid metabolism is complex. Delta<sup>9</sup>-THC is metabolized via microsomal hydroxylation to both active and inactive metabolites (Lemberger et al., 1970, 1972a, 1972b; Agurell et al., 1986; Hollister, 1988). The primary active metabolite of delta<sup>9</sup>-THC following oral ingestion is 11-hydroxy-delta<sup>9</sup>-THC. This metabolite is approximately equipotent to delta<sup>9</sup>-THC in producing marijuana-like subjective effects (Agurell et al., 1986, Lemberger and Rubin, 1975). After oral administration, metabolite levels may exceed that of delta<sup>9</sup>-THC and thus contribute greatly to the pharmacological effects of oral delta<sup>9</sup>-THC or marijuana.

Plasma clearance of delta<sup>9</sup>-THC approximates hepatic blood flow at about 950 ml/min or greater. The rapid disappearance of delta<sup>9</sup>-THC from blood

<sup>8</sup> This guidance is available on the Internet at <http://www.fda.gov/Drugs/default.htm> under Guidance (Drugs).



is largely due to redistribution to other tissues in the body, rather than to metabolism (Agurell et al., 1984, 1986). Metabolism in most tissues is relatively slow or absent. Slow release of delta<sup>9</sup>-THC and other cannabinoids from tissues and subsequent metabolism results in a long elimination half-life. The terminal half-life of delta<sup>9</sup>-THC ranges from approximately 20 hours to as long as 10 to 13 days, though reported estimates vary as expected with any slowly cleared substance and the use of assays with variable sensitivities (Hunt and Jones, 1980). Lemberger et al. (1970) determined the half-life of delta<sup>9</sup>-THC to range from 23 to 28 hours in heavy marijuana users to 60 to 70 hours in naive users. In addition to 11-hydroxy-delta<sup>9</sup>-THC, some inactive carboxy metabolites have terminal half-lives of 50 hours to 6 days or more. The latter substances serve as long-term markers in urine tests for earlier marijuana use.

The majority of the absorbed delta<sup>9</sup>-THC dose is eliminated in feces, and about 33 percent in urine. Delta<sup>9</sup>-THC enters enterohepatic circulation and undergoes hydroxylation and oxidation to 11-nor-9-carboxy-delta<sup>9</sup>-THC. The glucuronide is excreted as the major urine metabolite along with about 18 non-conjugated metabolites. Frequent and infrequent marijuana users metabolize delta<sup>9</sup>-THC similarly (Agurell et al., 1986).

#### Status of Research Into the Medical Uses for Marijuana

State-level public initiatives, including laws and referenda in support of the medical use of marijuana, have generated interest in the medical community and the need for high quality clinical investigation as well as comprehensive safety and effectiveness data. In order to address the need for high quality clinical investigations, the state of California established the Center for Medicinal Cannabis Research (CMCR, [www.cmcr.ucsd.edu](http://www.cmcr.ucsd.edu)) in 2000 “in response to scientific evidence for therapeutic possibilities of cannabis<sup>9</sup> and local legislative initiatives in favor of compassionate use” (Grant, 2005). State legislation establishing the CMCR called for high quality medical research that would “enhance understanding of the efficacy and adverse effects of marijuana as a pharmacological agent,” but stressed the project “should not be construed as encouraging or sanctioning the social or recreational use of marijuana.” The CMCR funded many of the published studies on marijuana’s potential use for treating multiple

sclerosis, neuropathic pain, appetite suppression and cachexia. However, aside from the data produced by CMCR, no state-level medical marijuana laws have produced scientific data on marijuana’s safety and effectiveness.

FDA approves medical use of a drug following a submission and review of an NDA or BLA. The FDA has not approved any drug product containing marijuana for marketing. Even so, results of small clinical exploratory studies have been published in the current medical literature. Many studies describe human research with marijuana in the United States under FDA-regulated IND applications.

However, FDA approval of an NDA is not the only means through which a drug can have a currently accepted medical use in treatment in the United States. In general, a drug may have a “currently accepted medical use” in treatment in the United States if the drug meets a five-part test. Established case law (*Alliance for Cannabis Therapeutics v. DEA*, 15 F.3d 1131, 1135 (D.C. Cir. 1994)) upheld the Administrator of DEA’s application of the five-part test to determine whether a drug has a “currently accepted medical use.” The following describes the five elements that characterize “currently accepted medical use” for a drug:<sup>10</sup>

i. the drug’s chemistry must be known and reproducible

“The substance’s chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official compendia, as defined by section 201 G) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321G), is sufficient to meet this requirement.”

ii. there must be adequate safety studies

“There must be adequate pharmacological and toxicological studies, done by all methods reasonably applicable, on the basis of which it could fairly and responsibly be concluded, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, that the substance is safe for treating a specific, recognized disorder.”

iii. there must be adequate and well-controlled studies proving efficacy

“There must be adequate, well-controlled, well-designed, well-conducted, and well-documented studies, including clinical investigations, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of

drugs, on the basis of which it could be fairly and responsibly concluded by such experts that the substance will have the intended effect in treating a specific, recognized disorder.”

iv. the drug must be accepted by qualified experts

“The drug has a New Drug Application (NDA) approved by the Food and Drug Administration, pursuant to the Food, Drug and Cosmetic Act, 21 U.S.C. 355. Or, a consensus of the national community of experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, accepts the safety and effectiveness of the substance for use in treating a specific, recognized disorder. A material conflict of opinion among experts precludes a finding of consensus.” and

v. the scientific evidence must be widely available

“In the absence of NDA approval, information concerning the chemistry, pharmacology, toxicology, and effectiveness of the substance must be reported, published, or otherwise widely available, in sufficient detail to permit experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, to fairly and responsibly conclude the substance is safe and effective for use in treating a specific, recognized disorder.”

Marijuana does not meet any of the five elements necessary for a drug to have a “currently accepted medical use.”

Firstly, the chemistry of marijuana, as defined in the petition, is not reproducible in terms of creating a standardized dose. The petition defines marijuana as including all *Cannabis* cultivated strains. Different marijuana samples derived from various cultivated strains may have very different chemical constituents including delta<sup>9</sup>-THC and other cannabinoids (Appendino et al., 2011). As a consequence, marijuana products from different strains will have different safety, biological, pharmacological, and toxicological profiles. Thus, when considering all *Cannabis* strains together, because of the varying chemical constituents, reproducing consistent standardized doses is not possible. Additionally, smoking marijuana currently has not been shown to allow delivery of consistent and reproducible doses. However, if a specific *Cannabis* strain is grown and processed under strictly controlled conditions, the plant chemistry may be kept consistent enough to produce reproducible and standardized doses.

<sup>9</sup>In this quotation the term cannabis is interchangeable with marijuana.

<sup>10</sup> 57 FR I 0499, 10504–06 (March 26, 1992).

As to the second and third criteria; there are neither adequate safety studies nor adequate and well-controlled studies proving marijuana's efficacy. To support the petitioners' assertion that marijuana has accepted medical use, the petitioners cite the American Medical Association's (AMA) 2009 report entitled "Use of Cannabis for Medicinal Purposes." The petitioners claim the AMA report is evidence the AMA accepts marijuana's safety and efficacy. However, the 2009 AMA report clarifies that the report "should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the same and current standards for a prescription drug product."<sup>11</sup>

Currently, no published studies conducted with marijuana meet the criteria of an adequate and well-controlled efficacy study. The criteria for an adequate and well-controlled study for purposes of determining the safety and efficacy of a human drug are defined under the Code of Federal Regulations (CFR) in 21 CFR 314.126. In order to assess this element, FDA conducted a review of clinical studies published and available in the public domain before February, 2013. Studies were identified through a search of PubMed<sup>12</sup> for articles published from inception to February 2013, for randomized controlled trials using marijuana to assess marijuana's efficacy in any therapeutic indication. Additionally, the review included studies identified through a search of bibliographic references in relevant systematic reviews and identified studies presenting original research in any language. Selected studies needed to be placebo-controlled and double-blinded. Additionally, studies needed to encompass administered marijuana plant material. There was no requirement for any specific route of administration, nor any age limits on study subjects. Studies were excluded that used placebo marijuana supplemented by the addition of specific amounts of THC or other cannabinoids. Additionally, studies administering marijuana plant extracts were excluded.

The PubMed search yielded a total of 566 abstracts of scientific articles. Of

these abstracts, a full-text review was conducted with 85 papers to assess eligibility. Of the studies identified through the search of the references and the 566 abstracts from the PubMed search, only 11 studies met all the criteria for selection (Abrams et al., 2007; Corey-Bloom et al., 2012; Crawford and Merritt, 1979; Ellis et al., 2009; Haney et al., 2005; Haney et al., 2007; Merritt et al., 1980; Tashkin et al., 1974; Ware et al., 2010; Wilsey et al., 2008; Wilsey et al., 2013). These 11 studies were published between 1974 and 2013. Ten of these studies were conducted in the United States and one study was conducted in Canada. The identified studies examine the effects of smoked and vaporized marijuana for the indications of chronic neuropathic pain, spasticity related to Multiple Sclerosis (MS), appetite stimulation in human immunodeficiency virus (HIV) patients, glaucoma, and asthma. All studies used adult subjects.

The 11 identified studies were individually evaluated to determine if they successfully meet accepted scientific standards. Specifically, they were evaluated on study design including subject selection criteria, sample size, blinding techniques, dosing paradigms, outcome measures, and the statistical analysis of the results. The analysis relied on published studies, thus information available about protocols, procedures, and results were limited to documents published and widely available in the public domain. The review found that all 11 studies that examined effects of inhaled marijuana do not currently prove efficacy of marijuana in any therapeutic indication based on a number of limitations in their study design; however, they may be considered proof of concept studies. Proof of concept studies provide preliminary evidence on a proposed hypothesis involving a drug's effect. For drugs under development, the effect often relates to a short-term clinical outcome being investigated. Proof of concept studies often serve as the link between preclinical studies and dose ranging clinical studies. Thus, proof of concept studies generally are not sufficient to prove efficacy of a drug because they provide only preliminary information about the effects of a drug.

In addition to the lack of published adequate and well-controlled efficacy studies proving efficacy, the criteria for adequate safety studies has also not been met. Importantly, in its discussion of the five-part test used to determine whether a drug has a "currently accepted medical use," DEA said, "No drug can be considered safe in the abstract. Safety has meaning only when

judged against the intended use of the drug, its known effectiveness, its known and potential risks, the severity of the illness to be treated, and the availability of alternative remedies" (57 FR 10504). When determining whether a drug product is safe and effective for any indication, FDA performs an extensive risk-benefit analysis to determine whether the risks posed by the drug product's side effects are outweighed by the drug product's potential benefits for a particular indication. Thus, contrary to the petitioner's assertion that marijuana has accepted safety, in the absence of an accepted therapeutic indication which can be weighed against marijuana's risks, marijuana does not satisfy the element for having adequate safety studies such that experts may conclude that it is safe for treating a specific, recognized disorder.

The fourth of the five elements for determining "currently accepted medical use" requires that the national community of experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, accepts the safety and effectiveness of the substance for use in treating a specific, recognized disorder. A material conflict of opinion among experts precludes a finding of consensus. Medical practitioners who are not experts in evaluating drugs are not qualified to determine whether a drug is generally recognized as safe and effective or meets NDA requirements (57 FR 10499-10505).

There is no evidence that there is a consensus among qualified experts that marijuana is safe and effective for use in treating a specific, recognized disorder. As discussed above, there are not adequate scientific studies that show marijuana is safe and effective in treating a specific, recognized disorder. In addition, there is no evidence that a consensus of qualified experts have accepted the safety and effectiveness of marijuana for use in treating a specific, recognized disorder. Although medical practitioners are not qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, we also note that the AMA's report, entitled "Use of Cannabis for Medicinal Purposes," does not accept that marijuana currently has accepted medical use. Furthermore, based on the above definition of a "qualified expert", who is an individual qualified by scientific training and experience to evaluate the safety and effectiveness of a drug, state-level medical marijuana laws do not provide evidence of a consensus among qualified experts that marijuana is safe and effective for use in treating a specific, recognized disorder.

<sup>11</sup> In this quotation the term cannabis is used interchangeably for marijuana.

<sup>12</sup> The following search strategy was used, "(cannabis OR marijuana) AND (therapeutic use OR therapy) AND (RCT OR randomized controlled trial OR "systematic review" OR clinical trial OR clinical trials) NOT ("marijuana abuse"[Mesh] OR addictive behavior OR substance related disorders)."

As to the fifth part of the test, which requires that information concerning the chemistry, pharmacology, toxicology, and effectiveness of marijuana to be reported in sufficient detail, the scientific evidence regarding all of these aspects is not available in sufficient detail to allow adequate scientific scrutiny. Specifically, the scientific evidence regarding marijuana's chemistry in terms of a specific *Cannabis* strain that could produce standardized and reproducible doses is not currently available.

Alternately, a drug can be considered to have a "currently accepted medical use with severe restrictions" (21 U.S.C. 812(b)(2)(B)), as allowed under the stipulations for a Schedule II drug. Yet, as stated above, currently marijuana does not have any accepted medical use, even under conditions where its use is severely restricted.

In conclusion, to date, research on marijuana's medical use has not progressed to the point where marijuana is considered to have a "currently accepted medical use" or a "currently accepted medical use with severe restrictions."

#### 4. Its History and Current Pattern of Abuse

Under the fourth factor, the Secretary must consider the history and current pattern of marijuana abuse. A variety of sources provide data necessary to assess abuse patterns and trends of marijuana. The data indicators of marijuana use include the NSDUH, MTF, DAWN, and TEDS. The following briefly describes each data source, and summarizes the data from each source.

##### National Survey on Drug Use and Health (NSDUH)<sup>13</sup>

According to 2012 NSDUH<sup>14</sup> data, the most recent year with complete data, the

use of illicit drugs, including marijuana, is increasing. The 2012 NSDUH estimates that 23.9 million individuals over 12 years of age (9.2 percent of the U.S. population) currently use illicit drugs, which is an increase of 4.8 million individuals from 2004 when 19.1 million individuals (7.9 percent of the U.S. population) were current illicit drug users. NSDUH reports marijuana as the most commonly used illicit drug, with 18.9 million individuals (7.3 percent of the U.S. population) currently using marijuana in 2012. This represents an increase of 4.3 million individuals from 2004, when 14.6 million individuals (6.1 percent of the U.S. population) were current marijuana users.

The majority of individuals who try marijuana at least once in their lifetime do not currently use marijuana. The 2012 NSDUH estimates that 111.2 million individuals (42.8 percent of the U.S. population) have used marijuana at least once in their lifetime. Based on this estimate and the estimate for the number of individuals currently using marijuana, approximately 16.9 percent of those who have tried marijuana at least once in their lifetime currently use marijuana; conversely, 83.1 percent do not currently use marijuana. In terms of the frequency of marijuana use, an estimated 40.3 percent of individuals who used marijuana in the past month used marijuana on 20 or more days within the past month. This amount corresponds to an estimated 7.6 million individuals who used marijuana on a daily or almost daily basis.

Some characteristics of marijuana users are related to age, gender, and criminal justice system involvement. In observing use among different age cohorts, the majority of individuals who currently use marijuana are shown to be

between the ages of 18–25, with 18.7 percent of this age group currently using marijuana. In the 26 and older age group, 5.3 percent of individuals currently use marijuana. Additionally, in individuals aged 12 years and older, males reported more current marijuana use than females.

NSDUH includes a series of questions aimed at assessing the prevalence of dependence and abuse of different substances in the past 12 months.<sup>15</sup> In 2012, marijuana was the most common illicit drug reported by individuals with past year dependence or abuse. An estimated 4.3 million individuals meet the NSDUH criteria for marijuana dependence or abuse in 2012. The estimated rates and number of individuals with marijuana dependence or abuse has remained similar from 2002 to 2012. In addition to data on dependence and abuse, NSDUH includes questions aimed at assessing treatment for a substance use problem.<sup>16</sup> In 2012, an estimated 957,000 persons received treatment for marijuana use during their most recent treatment in the year prior to the survey.

##### Monitoring the Future (MTF)<sup>17</sup>

According to MTF,<sup>18</sup> rates of marijuana and illicit drug use declined for all three grades from 2005 through 2007. However, starting around 2008, rates of annual use of illicit drugs and marijuana increased through 2013 for all three grades. Marijuana remained the most widely used illicit drug during all time periods. The prevalence of annual and past month marijuana use in 10th and 12th graders in 2013 is greater than in 2005. Table 1 lists the lifetime, annual, and monthly prevalence rates of various drugs for 8th, 10th, and 12th graders in 2013.

<sup>13</sup> NSDUH provides national estimates of the prevalence and incidence of illicit drug, alcohol and tobacco use in the United States. NSDUH is an annual study conducted by SAMHSA. Prior to 2002, the database was known as the National Household Survey on Drug Abuse (NHSDA). NSDUH utilizes a nationally representative sample of United States civilian, non-institutionalized population aged 12 years and older. The survey excludes homeless people who do not use shelters, active military personnel, and residents of institutional group quarters such as jails and hospitals. The survey identifies whether an individual used a drug within a specific time period, but does not identify the amount of the drug used on each occasion. NSDUH defines "current use" as having used the substance within the month prior to the study.

<sup>14</sup> 2013; <http://www.samhsa.gov/data/NSDUH.aspx>.

<sup>15</sup> "These questions are used to classify persons as dependent on or abusing specific substances

based on criteria specified in the *Diagnostic and Statistical Manual of Mental Disorder*, 4th edition (DSM-IV). The questions related to dependence ask about health and emotional problems associated with substance use, unsuccessful attempts to cut down on use, tolerance, withdrawal, reducing other activities to use substances, spending a lot of time engaging in activities related to substance use, or using the substance in greater quantities or for longer time than intended. The questions on abuse ask about problems at work, home, and school; problems with family or friends; physical danger; and trouble with the law due to substance use. Dependence is considered to be a more severe substance use problem than abuse because it involves the psychological and physiological effects of tolerance and withdrawal." (NSDUH, 2013).

<sup>16</sup> "Estimates . . . refer to treatment received for illicit drug or alcohol use, or for medical problems associated with the use of illicit drugs or alcohol. This includes treatment received in the past year at any location, such as a hospital (inpatient),

rehabilitation facility (outpatient or inpatient), mental health center, emergency room, private doctor's office, prison or jail, or a self-help group, such as Alcoholics Anonymous or Narcotics Anonymous." (NSDUH, 2013).

<sup>17</sup> Monitoring the Future is a national survey that tracks drug use prevalence and trends among adolescents in the United States. MTF is reported annually by the Institute for Social Research at the University of Michigan under a grant from NIDA. Every spring, MTF surveys 8th, 10th, and 12th graders in randomly selected U.S. schools. MTF has been conducted since 1975 for 12th graders and since 1991 for 8th and 10th graders. The MTF survey presents data in terms of prevalence among the sample interviewed. For 2012, the latest year with complete data, the sample sizes were 15,200—8th graders; 13,300—10th graders; and 13,200—12th graders. In all, a total of about 41,700 students of 389 schools participated in the 2013 MTF.

<sup>18</sup> 2013; <http://www.monitoringthefuture.org/index.html>.

**Table 1: Trends in lifetime, annual, and monthly prevalence of use of various drugs for eighth, tenth, and twelfth graders. Percentages represent students in survey responding that they had used a drug at least once in their lifetime, in the past year, or in the past 30 days.**

	Lifetime			Annual			30-Day		
	2011	2012	2013	2011	2012	2013	2011	2012	2013
<b>Any illicit Drug (a)</b>									
8 <sup>th</sup> Grade	20.1	18.5	20.3	14.7	13.4	14.9	8.5	7.7	8.5
10 <sup>th</sup> Grade	37.7	36.8	38.8	31.1	30.1	31.8	19.2	18.6	19.4
12 <sup>th</sup> Grade	49.9	49.1	50.4	40.0	39.7	40.3	25.2	25.2	25.5
<b>Marijuana/Hashish</b>									
8 <sup>th</sup> Grade	16.4	15.2	16.5	12.5	11.4	12.7	7.2	6.5	7.0
10 <sup>th</sup> Grade	34.5	33.8	35.8	28.8	28.0	29.8	17.6	17.0	18.0
12 <sup>th</sup> Grade	45.5	45.2	45.5	36.4	36.4	36.4	22.6	22.9	22.7

SOURCE: The Monitoring the Future Study, the University of Michigan

a. For 12<sup>th</sup> graders only: "any illicit drug" includes any use of marijuana, LSD, other hallucinogens, crack, other cocaine, or heroin; or any narcotics use other than heroin, amphetamines, sedatives (barbiturates), or tranquilizers not under a doctor's orders. For 8<sup>th</sup> and 10<sup>th</sup> graders only: the use of narcotics other than heroin and sedatives (barbiturates) was excluded.

### Drug Abuse Warning Network (DAWN)<sup>19</sup>

Importantly, many factors can influence the estimates of ED visits, including trends in overall use of a substance as well as trends in the reasons for ED usage. For instance, some drug users may visit EDs for life-threatening issues while others may visit to seek care for detoxification because they needed certification before entering treatment. Additionally, DAWN data do not distinguish the drug responsible for the ED visit from other drugs that may have been used concomitantly. As stated in a DAWN report, "Since marijuana/hashish is frequently present in combination with other drugs, the reason for the ED visit may be more relevant to the other drug(s) involved in the episode."

For 2011, DAWN<sup>20</sup> estimates a total of 5,067,374 (95 percent confidence interval [CI]: 4,616,753 to 5,517,995) drug-related ED visits from the entire United States. Of these, approximately

2,462,948 ([CI]: 2,112,868 to 2,813,028) visits involved drug misuse or abuse.

During the same period, DAWN estimates that 1,252,500 (CI: 976,169 to 1,528,831) drug related ED visits involved illicit drugs. Thus, over half of all drug-related ED visits associated with drug misuse or abuse involved an illicit drug. For ED visits involving illicit drugs, 56.3 percent involved multiple drugs while 43.7 percent involved a single drug.

Marijuana was involved in 455,668 ED visits (CI: 370,995 to 540,340), while cocaine was involved in 505,224 (CI: 324,262 to 686,185) ED visits, heroin was involved in 258,482 (CI: 205,046 to 311,918) ED visits and stimulants including amphetamine and methamphetamine were involved in 159,840 (CI: 100,199 to 219,481) ED visits. Other illicit drugs, such as PCP, MDMA, GHB and LSD were much less frequently associated with ED visits. The number of ED visits involving marijuana has increased by 62 percent since 2004.

Marijuana-related ED visits were most frequent among young adults and minors. Individuals under the age of 18 accounted for 13.2 percent of these marijuana-related visits, whereas this age group accounted for approximately 1.2 percent of ED visits involving cocaine, and less than 1 percent of ED visits involving heroin. However, the age group with the most marijuana-related ED visits was between 25 and 29 years old. Yet, because populations differ between age groups, a standardized measure for population

size is useful to make comparisons. For marijuana, the rates of ED visits per 100,000 population were highest for patients aged 18 to 20 (443.8 ED visits per 100,000) and for patients aged 21 to 24 (446.9 ED visits per 100,000).

While DAWN provides estimates for ED visits associated with the use of medical marijuana for 2009–2011, the validity of these estimates is questionable. Because the drug is not approved by the FDA, reporting medical marijuana may be inconsistent and reliant on a number of factors including whether the patient self-reports the marijuana use as medicinal, how the treating health care provider records the marijuana use, and lastly how the SAMHSA coder interprets the report. All of these aspects will vary greatly between states with medical marijuana laws and states without medical marijuana laws. Thus, even though estimates are reported for medical marijuana related ED visits, medical marijuana estimates cannot be assessed with any acceptable accuracy at this time, as FDA has not approved marijuana treatment of any medical condition. These data show the difficulty in evaluating abuse of a product that is not currently approved by FDA, but authorized for medical use, albeit inconsistently, at the state level. Thus, we believe the likelihood of the treating health care provider or SAMHSA coder attributing the ED visit to "medical marijuana" versus "marijuana" to be very low. Overall, the available data are inadequate to

<sup>19</sup>DAWN is a national probability survey of the U.S. hospitals with ED designed to obtain information on drug related ED visits. DAWN is sponsored by SAMHSA. The DAWN system provides information on the health consequences of drug use in the United States, as manifested by drug-related visits to ED. The ED data from a representative sample of hospital emergency departments are weighted to produce national estimates. Importantly, DAWN data and estimates, starting in 2004, are not comparable to those for prior years because of vast changes in the methodology used to collect the data. Furthermore, estimates for 2004 are the first to be based on a redesigned sample of hospitals, which ended in 2011.

<sup>20</sup>2011; <http://www.samhsa.gov/data/dawn.aspx>.

characterize its abuse at the community level.

#### Treatment Episode Data Set (TEDS)<sup>21</sup>

Primary marijuana abuse accounted for 18.1 percent of all 2011 TEDS<sup>22</sup> admissions. Individuals admitted for primary marijuana abuse were nearly three-quarters (73.4 percent) male, and almost half (45.2 percent) were white. The average age at admission was 24 years old, and 31.1 percent of individuals admitted for primary marijuana abuse were under the age of 18. The reported frequency of marijuana use was 24.3 percent reporting daily use. Almost all (96.8 percent) primary marijuana users utilized the substance by smoking. Additionally, 92.9 percent reported using marijuana for the first time before the age of 18.

An important aspect of TEDS admission data for marijuana is of the referral source for treatment. Specifically, primary marijuana admissions were less likely than all other admissions to either be self-referred or referred by an individual for treatment. Instead, the criminal justice system referred more than half (51.6 percent) of primary marijuana admissions.

Since 2003, the percent of admissions for primary marijuana abuse increased from 15.5 percent of all admissions in 2003 to 18.1 percent in 2011. This increase is less than the increase seen for admissions for primary opioids other than heroin, which increased from 2.8 percent in 2003 to 7.3 percent in 2011. In contrast, the admissions for primary cocaine abuse declined from 9.8 percent in 2003 to 2.0 percent in 2011.

<sup>21</sup> The TEDS system is part of SAMHSA's Drug and Alcohol Services Information System (Office of Applied Science, SAMHSA). The TEDS report presents information on the demographic and substance use characteristics of the 1.8 million annual admissions to treatment for alcohol and drug abuse in facilities that report to individual state administrative data systems. Specifically, TEDS includes facilities licensed or certified by the states to provide substance abuse treatment and is required by the states to provide TEDS client-level data. Facilities that report TEDS data are those receiving State alcohol and drug agency funds for the provision of alcohol and drug treatment services. Since TEDS is based only on reports from these facilities, TEDS data do not represent the total national demand for substance abuse treatment or the prevalence of substance abuse in the general population. The primary goal for TEDS is to monitor the characteristics of treatment episodes for substance abusers. Importantly, TEDS is an admissions-based system, where admittance to treatment is counted as an anonymous tally. For instance, a given individual who is admitted to treatment twice within a given year would be counted as two admissions. The most recent year with complete data is 2011.

<sup>22</sup> 2011; <http://www.samhsa.gov/data/DASIS.aspx?qr=#TEDS>.

#### 5. The Scope, Duration, and Significance of Abuse

Under the fifth factor, the Secretary must consider the scope, duration, and significance of marijuana abuse. According to 2012 data from NSDUH and 2013 data from MTF, marijuana remains the most extensively used illegal drug in the United States, with 42.8 percent of U.S. individuals over age 12 (111.2 million) and 45.5 percent of 12th graders having used marijuana at least once in their lifetime. Although the majority of individuals over age 12 (83.1 percent) who have ever used marijuana in their lifetime do not use the drug monthly, 18.9 million individuals (7.3 percent of the U.S. population) report that they used marijuana within the past 30 days. An examination of use among various age cohorts through NSDUH demonstrates that monthly use occurs primarily among college-aged individuals, with use dropping off sharply after age 25. Additionally, NSDUH data show the number of individuals reporting past-month use of marijuana has increased by 4.3 million individuals since 2004. Data from MTF shows that annual prevalence of marijuana use declined for all three grades from 2005 through 2007, then began to rise through 2013. Additionally, in 2013, 1.1 percent of 8th graders, 4.0 percent of 10th graders, and 6.5 percent of 12th graders reported daily use of marijuana, defined as use on 20 or more days within the past 30 days.

The 2011 DAWN data show that marijuana use was mentioned in 455,668 ED visits, which amounts to approximately 36.4 percent of all illicit drug-related ED visits.<sup>23</sup>

TEDS data for 2011 show that 18.1 percent of all admissions were for primary marijuana abuse.<sup>24</sup> Between 2003 and 2011, there was a 2.6 percent increase in the number of TEDS admissions for primary marijuana use.

<sup>23</sup> Many factors can influence the estimates of ED visits, including trends in the reasons for ED usage. For instance, some drug users may visit EDs for life-threatening issues while others may visit to seek care for detoxification because they needed certification before entering treatment. Additionally, DAWN data do not distinguish the drug responsible for the ED visit from other drugs that may have been used concomitantly. As stated in a DAWN report, "Since marijuana/hashish is frequently present in combination with other drugs, the reason for the ED visit may be more relevant to the other drug(s) involved in the episode."

<sup>24</sup> An important aspect of TEDS admission data for marijuana is of the referral source for treatment. Specifically, primary marijuana admissions were less likely than all other admissions to either be self-referred or referred by an individual for treatment. Instead, the criminal justice system referred more than half (51.6 percent) of primary marijuana admissions.

Approximately 61.5 percent of primary marijuana admissions in 2011 were for individuals under the age of 25 years.

#### 6. What, if Any, Risk There Is to the Public Health

Under the sixth factor, the Secretary must consider the risks posed to the public health by marijuana. Factors 1, 4, and 5 include a discussion of the risk to the public health as measured by emergency room episodes and drug treatment admissions. Additionally, Factor 2 includes a discussion of marijuana's central nervous system, cognitive, cardiovascular, autonomic, respiratory, and immune system effects. Factor 6 focuses on the health risks to the individual user in terms of the risks from acute and chronic use of marijuana, as well as the "gateway hypothesis."

##### Risks From Acute Use of Marijuana

Acute use of marijuana impairs psychomotor performance, including complex task performance, which makes operating motor vehicles or heavy equipment after using marijuana inadvisable (Ramaekers et al., 2004; Ramaekers et al., 2006a). A meta-analysis conducted by Li et al. (2011) showed an association between marijuana use by the driver and a significantly increased risk of involvement in a car accident. Additionally, in a minority of individuals who use marijuana, some potential responses include dysphoria and psychological distress, including prolonged anxiety reactions (Haney et al., 1999).

##### Risks From Chronic Use of Marijuana

A distinctive marijuana withdrawal syndrome following long term or chronic use has been identified. The withdrawal syndrome indicates that marijuana produces physical dependence that is mild, short-lived, and comparable to tobacco withdrawal (Budney et al., 2008). Marijuana withdrawal syndrome is described in detail below under Factor 7.

The following states how the DSM-V (2013) of the American Psychiatric Association describes the consequences of *Cannabis*<sup>25</sup> abuse:

Individuals with cannabis use disorder may use cannabis throughout the day over a period of months or years, and thus may spend many hours a day under the influence. Others may use less frequently, but their use causes recurrent problems related to family,

<sup>25</sup> *Cannabis* is the term used in the DSM-V to refer to marijuana. In the following excerpt the term *Cannabis* is interchangeable for the term *marijuana*.

school, work, or other important activities (e.g., repeated absences at work; neglect of family obligations). Periodic cannabis use and intoxication can negatively affect behavioral and cognitive functioning and thus interfere with optimal performance at work or school, or place the individual at increased physical risk when performing activities that could be physically hazardous (e.g., driving a car; playing certain sports; performing manual work activities, including operating machinery). Arguments with spouses or parents over the use of cannabis in the home, or its use in the presence of children, can adversely impact family functioning and are common features of those with cannabis use disorder. Last, individuals with cannabis use disorder may continue using marijuana despite knowledge of physical problems (e.g., chronic cough related to smoking) or psychological problems (e.g., excessive sedation or exacerbation of other mental health problems) associated with its use.

#### Marijuana as a “Gateway Drug”

Kandel (1975) proposed nearly 40 years ago the hypothesis that marijuana is a “gateway drug” that leads to the use or abuse of other illicit drugs. Since that time, epidemiological research explored this premise. Overall, research does not support a direct causal relationship between regular marijuana use and other illicit drug use. The studies examining the gateway hypothesis are limited. First, in general, studies recruit individuals influenced by a myriad of social, biological, and economic factors that contribute to extensive drug abuse (Hall & Lynskey, 2005). Second, most studies that test the hypothesis that marijuana use causes abuse of illicit drugs use the determinative measure *any use of an illicit drug*, rather than DSM–5 criteria for drug abuse or dependence on an illicit drug (DSM–5, 2013). Consequently, although an individual who used marijuana may try other illicit drugs, the individual may not regularly use drugs, or have a diagnosis of drug abuse or dependence.

Little evidence supports the hypothesis that initiation of marijuana use leads to an abuse disorder with other illicit substances. For example, one longitudinal study of 708 adolescents demonstrated that early onset marijuana use did not lead to problematic drug use (Kandel & Chen, 2000). Similarly, Nace et al. (1975) examined Vietnam-era soldiers who extensively abused marijuana and heroin while they were in the military, and found a lack of correlation of a causal relationship demonstrating

marijuana use leading to heroin addiction. Additionally, in another longitudinal study of 2,446 adolescents, marijuana dependence was uncommon but when it did occur, the common predictors of marijuana dependence were the following: parental death, deprived socio-economic status, and baseline illicit drug use other than marijuana (von Sydow et al., 2002).

When examining the association between marijuana and illicit drugs, focusing on drug use versus abuse or dependence, different patterns emerge. For example, a study examining the possible causal relationship of the gateway hypothesis found a correlation between marijuana use in adolescents and other illicit drug use in early adulthood and, adjusting for age-linked experiences, did not effect this correlation (Van Gundy and Rebellon, 2010). However, when examining the association in terms of development of drug abuse; age-linked stressors and social roles moderated the correlation between marijuana use in adolescents and other illicit drug abuse. Similarly, Degenhardt et al. (2009) examined the development of drug dependence and found an association that did not support the gateway hypothesis. Specifically, drug dependence was significantly associated with the use of other illicit drugs prior to marijuana use.

Interestingly, the order of initiation of drug use seems to depend on the prevalence of use of each drug, which varies by country. Based on the World Health Organization (WHO) World Mental Health Survey that includes data from 17 different countries, the order of drug use initiation varies by country and relates to prevalence of drug use in each country (Degenhardt et al., 2010). Specifically, in the countries with the lowest prevalence of marijuana use, use of other illicit drugs before marijuana was common. This sequence of initiation is less common in countries with higher prevalence of marijuana use. A study of 9,282-households in the United States found that marijuana use often preceded the use of other illicit drugs; however, prior non-marijuana drug dependence was also frequently correlated with higher levels of illicit drug abuse (Degenhardt et al., 2009). Additionally, in a large 25-year longitudinal study of 1,256 New Zealand children, the author concluded that marijuana use correlated to an increased risk of abuse of other drugs, including cocaine and heroin (Fergusson et al., 2005).

Although many individuals with a drug abuse disorder may have used marijuana as one of their first illicit

drugs, this fact does not correctly lead to the reverse inference that most individuals who used marijuana will inherently go on to try or become regular users of other illicit drugs. Specifically, data from the 2011 NSDUH survey illustrates this issue (SAMHSA, 2012). NSDUH data estimates 107.8 million individuals have a lifetime history of marijuana use, which indicates use on at least one occasion, compared to approximately 36 million individuals having a lifetime history of cocaine use and approximately 4 million individuals having a lifetime history of heroin use. NSDUH data do not provide information about each individual’s specific drug history. However, even if one posits that every cocaine and heroin user previously used marijuana, the NSDUH data show that marijuana use at least once in a lifetime does not predict that an individual will also use another illicit drug at least once.

Finally, a review of the gateway hypothesis by Vanyukov et al. (2012) notes that because the gateway hypothesis only addresses the order of drug use initiation, the gateway hypothesis does not specify any mechanistic connections between drug “stages” following exposure to marijuana and does not extend to the risks for addiction. This concept contrasts with the concept of a common liability to addiction that involves mechanisms and biobehavioral characteristics pertaining to the entire course of drug abuse risk and disorders.

#### 7. Its Psychic or Physiologic Dependence Liability

Under the seventh factor, the Secretary must consider marijuana’s psychic or physiological dependence liability.

Psychic or psychological dependence has been shown in response to marijuana’s psychoactive effects. Psychoactive responses to marijuana are pleasurable to many humans and are associated with drug-seeking and drug-taking (Maldonado, 2002). Moreover, high levels of psychoactive effects, notably positive reinforcement, are associated with increased marijuana use, abuse, and dependence (Scherrer et al., 2009; Zeiger et al., 2010). Epidemiological data support these findings through 2012 NSDUH statistics that show that of individuals years 12 or older who used marijuana in the past month, an estimated 40.3 percent used marijuana on 20 or more days within the past month. This equates to approximately 7.6 million individuals aged 12 or older who used marijuana on a daily or almost daily basis.

Additionally, the 2013 MTF data report the prevalence of daily marijuana use, defined as use on 20 or more days within the past 30 days, in 8th, 10th, and 12th graders is 1.1 percent, 4.0 percent, and 6.5 percent, respectively.

Tolerance is a state of adaptation where exposure to a drug induces changes that result in a diminution of one or more of the drug's effects over time (American Academy of Pain Medicine, American Pain Society and American Society of Addiction Medicine consensus document, 2001). Tolerance can develop to some, but not all, of marijuana's effects. Specifically, tolerance does not seem to develop in response to many of marijuana's psychoactive effects. This lack of tolerance may relate to electrophysiological data demonstrating that chronic delta<sup>9</sup>-THC administration does not affect increased neuronal firing in the ventral tegmental area, a region known to play a critical role in drug reinforcement and reward (Wu and French, 2000). In the absence of other abuse indicators, such as rewarding properties, the presence of tolerance or physical dependence does not determine whether a drug has abuse potential.

However, humans can develop tolerance to marijuana's cardiovascular, autonomic, and behavioral effects (Jones et al., 1981). Tolerance to some of marijuana's behavioral effects seems to develop after heavy marijuana use, but not after occasional marijuana use. For instance, following acute administration of marijuana, heavy marijuana users did not exhibit impairments in tracking and attention tasks, as were seen in occasional marijuana users (Ramaekers et al., 2009). Furthermore, a neurophysiological assessment administered through an electroencephalograph (EEG) which measures event-related potentials (ERP) conducted in the same subjects as the previous study, found a corresponding effect in the P100<sup>26</sup> component of ERPs. Specifically, corresponding to performance on tracking and attention tasks, heavy marijuana users showed no changes in P100 amplitudes following acute marijuana administration, although occasional users showed a decrease in P100 amplitudes (Theunissen et al., 2012). A possible mechanism underlying tolerance to marijuana's effects may be the down-regulation of cannabinoid receptors (Hirvonen et al., 2012; Gonzalez et al.,

2005; Rodriguez de Fonseca et al., 1994; Oviedo et al., 1993).

Importantly, pharmacological tolerance alone does not indicate a drug's physical dependence liability. In order for physical dependence to exist, evidence of a withdrawal syndrome is needed. Physical dependence is a state of adaptation, manifested by a drug-class specific withdrawal syndrome produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist (*ibid*). Many medications not associated with abuse or addiction can produce physical dependence and withdrawal symptoms after chronic use.

Discontinuation of heavy, chronic marijuana use has been shown to lead to physical dependence and withdrawal symptoms (American Psychiatric Association DSM-V, 2013; Budney and Hughes, 2006; Haney et al., 1999). In heavy, chronic marijuana users, the most commonly reported withdrawal symptoms are sleep difficulties, decreased appetite or weight loss, irritability, anger, anxiety or nervousness, and restlessness. Some less commonly reported withdrawal symptoms are depressed mood, sweating, shakiness, physical discomfort, and chills (Budney and Hughes, 2006; Haney et al., 1999). The occurrence of marijuana withdrawal symptoms in light or non-daily marijuana users has not been established. The American Psychiatric Association's DSM-V (2013) includes a list of symptoms of "cannabis withdrawal." Most marijuana withdrawal symptoms begin within 24–48 hours of discontinuation, peak within 4–6 days, and last for 1–3 weeks. Marijuana withdrawal syndrome has been reported in adolescents and adults admitted for substance abuse treatment.

Based on clinical descriptions, this syndrome appears to be mild compared to classical alcohol and barbiturate withdrawal syndromes, which can include more serious symptoms such as agitation, paranoia, and seizures. Multiple studies comparing marijuana and tobacco withdrawal symptoms in humans demonstrate that the magnitude and time course of the two withdrawal syndromes are similar (Budney et al., 2008; Vandrey et al., 2005, 2008).

### **8. Whether the Substance is an Immediate Precursor of a Substance Already Controlled Under This Article**

Under the eight factor analysis, the Secretary must consider whether marijuana is an immediate precursor of a controlled substance. Marijuana is not an immediate precursor of another controlled substance.

### **Recommendation**

After consideration of the eight factors discussed above, FDA recommends that marijuana remain in Schedule I of the CSA. NIDA concurs with this scheduling recommendation. Marijuana meets the three criteria for placing a substance in Schedule I of the CSA under 21 U.S.C. 812(b)(1):

(1) Marijuana has a high potential for abuse:

A number of factors indicate marijuana's high abuse potential, including the large number of individuals regularly using marijuana, marijuana's widespread use, and the vast amount of marijuana available for illicit use. Approximately 18.9 million individuals in the United States (7.3 percent of the U.S. population) used marijuana monthly in 2012. Additionally, approximately 4.3 million individuals met diagnostic criteria for marijuana dependence or abuse in the year prior to the 2012 NSDUH survey. A 2013 survey indicates that by 12th grade, 36.4 percent of students report using marijuana within the past year, and 22.7 percent report using marijuana monthly. In 2011, 455,668 ED visits were marijuana-related, representing 36.4 percent of all illicit drug-related episodes. Primary marijuana use accounted for 18.1 percent of admissions to drug treatment programs in 2011. Additionally, marijuana has dose-dependent reinforcing effects, as demonstrated by data showing that humans prefer relatively higher doses to lower doses. Furthermore, marijuana use can result in psychological dependence.

(2) Marijuana has no currently accepted medical use in treatment in the United States:

FDA has not approved a marketing application for a marijuana drug product for any indication. The opportunity for scientists to conduct clinical research with marijuana exists, and there are active INDs for marijuana; however, marijuana does not have a currently accepted medical use for treatment in the United States, nor does marijuana have an accepted medical use with severe restrictions.

A drug has a "currently accepted medical use" if all of the following five elements have been satisfied:

- a. The drug's chemistry is known and reproducible;
- b. there are adequate safety studies;
- c. there are adequate and well-controlled studies proving efficacy;
- d. the drug is accepted by qualified experts; and
- e. the scientific evidence is widely available.

<sup>26</sup> The P100 component of ERPs is thought to relate to the visual processing of stimuli and can be modulated by attention.

[57 FR 10499, March 26, 1992]

Marijuana does not meet any of the elements for having a “currently accepted medical use.” First, FDA broadly evaluated marijuana, and did not focus its evaluation on particular strains of marijuana or components or derivatives of marijuana. Since different strains may have different chemical constituents, marijuana, as identified in this petition, does not have a known and reproducible chemistry, which would be needed to provide standardized doses. Second, there are not adequate safety studies on marijuana in the medical literature in relation to a specific, recognized disorder. Third, there are no published adequate and well controlled studies proving efficacy of marijuana. Fourth, there is no evidence that qualified experts accept marijuana for use in treating a specific, recognized disorder. Lastly, the scientific evidence regarding marijuana’s chemistry in terms of a specific *Cannabis* strain that could produce standardized and reproducible doses is not currently available, so the scientific evidence on marijuana is not widely available.

Alternately, a Schedule II drug can be considered to have a “currently accepted medical use with severe restrictions” (21 U.S.C. 812(b)(2)(B)). Yet as stated above, the lack of accepted medical use for a specific, recognized disorder precludes the use of marijuana even under conditions where its use is severely restricted.

In conclusion, to date, research on marijuana’s medical use has not developed to the point where marijuana is considered to have a “currently accepted medical use” or a “currently accepted medical use with severe restrictions.”

(3) There is a lack of accepted safety for use of marijuana under medical supervision:

There are currently no FDA-approved marijuana drug products. Marijuana does not have a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Thus, FDA has not determined that marijuana is safe for use under medical supervision.

In addition, FDA cannot conclude that marijuana has an acceptable level of safety relative to its effectiveness in treating a specific, recognized disorder without evidence that the substance is contamination free, and assurance of a consistent and predictable dose. Investigations into the medical use of marijuana should include information and data regarding the chemistry, manufacturing, and specifications of marijuana. Additionally, a procedure for

delivering a consistent dose of marijuana should also be developed. Therefore, FDA concludes marijuana does not currently have an accepted level of safety for use under medical supervision.

## References

- Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo controlled clinical trial. *Ann Intern Med.* 2003 Aug 19; 139(4):258–66.
- Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, and Petersen KL. 2007. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. *Neurology* 68(7): 515–521.
- Adams, I.B., and Martin, B.R. Cannabis: Pharmacology and toxicology in animals and humans. *Addiction* 1996, 91(11):1585–1614.
- Agurell, S., Dewey, W.L., and Willett, R.E., eds. *The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects.* New York: Academic Press, 1984.
- Agurell, S.; Halldin, M.; Lindgren, J.E.; Ohlsson, A.; Widman, M.; Gillespie, H.; and Hollister, L. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. *Pharmacol Rev* 1986, 38(1), 21–43.
- Almirez RG, Smith CG, Asch RH. The effects of marijuana extract and delta 9-tetrahydrocannabinol on luteal function in the rhesus monkey. *Fertil Steril.* 1983 Feb; 39(2):212–7.
- Ameri, A. The effects of cannabinoids on the brain. *Progress in Neurobiology* 1999, 58 (4), 315–348.
- American Academy of Pain Medicine, American Pain Society and American Society of Addiction Medicine Consensus Document. Definitions related to the use of opioids for the treatment of pain. 2001.
- Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. *Lancet.* 1987 Dec 26; 2(8574):1483–6.
- Appendino G, Chianese G, Tagliatalata-Scafati O. Cannabinoids: occurrence and medicinal chemistry. *Curr Med Chem.* 2011; 18(7):1085–99.
- Asch RH, Smith CG, Siler-Khodr TM, Pauerstein CJ. Effects of delta 9-tetrahydrocannabinol during the follicular phase of the rhesus monkey (*Macaca mulatta*). *J Clin Endocrinol Metab.* 1981 Jan; 52(1):50–5.
- Balster, R.L., Prescott, W.R., delta9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. *Neurosci. & Biobehav. Rev.* 1992, 16(1), 55–62.
- Balster RL and Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. *Drug and Alcohol Dependence.* 2003; 70: S13–S40.
- Barnett, G.; Licko, V.; and Thompson, T. Behavioral pharmacokinetics of marijuana. *Psychopharmacology* 1985, 85(1), 51–56.
- Battista N, Di TM, Bari M, Maccarrone M. The endocannabinoid system: an overview. *Front.Behav.Neurosci.* 2012; 6:9.
- Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. *Clin Pharmacol Ther.* 1975 Sep; 18(3):287–97.
- Benowitz NL, Jones RT. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. *J Clin Pharmacol.* 1981 Aug–Sep; 21(8–9 Suppl):214S–223S.
- Block RI, Farinpour R, Schlechte JA. Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. *Drug Alcohol Depend.* 1991 Aug; 28(2):121–8.
- Block RI, Farinpour R, Braverman K. Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. *Pharmacol Biochem Behav.* 1992 Nov; 43(3):907–17.
- Bolla KI, Brown K, Eldreth D, Tate K, and Cadet JL. Dose-related neurocognitive effects of marijuana use. *Neurology* 2002 59:1337–1343.
- Bolla KI, Eldreth DA, Matochik JA, and Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. *NeuroImage* 2005 26:480–492.
- Bonnet U. Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function. *Pharmacopsychiatry.* 2013 Jan; 46(1):35–6.
- Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P. Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem.* 1993 May 15; 214(1):173–80.
- Braida D, Iosue S, Pegorini S, Sala M. Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. *Eur J Pharmacol.* 2004 Dec 3; 506(1):63–9.
- Breivogel CS, Childers SR. Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. *J Pharmacol Exp Ther.* 2000. Oct; 295(1):328–36.
- Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. *Mol Pharmacol.* 2001 Jul; 60(1):155–63.
- Brown TT, Dobs AS. Endocrine effects of marijuana. *J Clin Pharmacol.* 2002 Nov; 42(11 Suppl):90S–96S.
- Browne RG, Weissman A. Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies. *J Clin Pharmacol.* 1981 Aug–Sep; 21(8–9 Suppl):227S–234S.
- Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal



- syndrome. *Am J Psychiatry*. 2004 Nov; 161(11):1967–77.
- Budney AJ, Hughes JR. The cannabis withdrawal syndrome. *Curr Opin Psychiatry* 2006 May; 19(3):233–8.
- Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursae Z. Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. *J Subst Abuse Treat*. 2008 Dec; 35(4):362–8.
- Capriotti RM, Foltin RW, Brady JV, Fischman MW. Effects of marijuana on the task-elicited physiological response. *Drug Alcohol Depend*. 1988 Jul; 21(3):183–7.
- Cascini F, Aiello C, Di Tanna G. Increasing delta-9-tetrahydrocannabinol ( $\Delta$ -9-THC) content in herbal cannabis over time: systematic review and meta-analysis. *Curr Drug Abuse Rev*. 2012 Mar; 5(1):32–40.
- Chait LD. Subjective and behavioral effects of marijuana the morning after smoking. *Psychopharmacology (Berl)* 1990; 100(3):328–33.
- Chait LD, Burke KA. Preference for high-versus low-potency marijuana. *Pharmacol Biochem Behav*. 1994 Nov; 49(3):643–7.
- Chaperon F, Soubrie P, Puech AJ, Thiebot MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. *Psychopharmacology (Berl)*. 1998 Feb; 135(4):324–32.
- Cheer JF, Kendall DA, Marsden CA. Cannabinoid receptors and reward in the rat: a conditioned place preference study. *Psychopharmacology (Berl)*. 2000 Jul; 151(1):25–30.
- Cone EJ, Johnson RE, Moore JD, Roache JD. Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. *Pharmacol Biochem Behav*. 1986 Jun; 24(6): 1749–54.
- Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, and Gouaux B. 2012. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *CMAJ* 184 (10): 1143–1150.
- Council on Science and Public Health Report 3. Use of cannabis for medicinal purposes. American Medical Association, Interim Meeting, Houston, Texas; November 2009.
- Crawford WJ, and Merritt JC. 1979. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. *International journal of clinical pharmacology and biopharmacy* 17 (5): 191–196.
- Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? *J Neuroimmunol*. 2005 Sep; 166(1–2):3–18. Review.
- Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. *Clin.Pharmacol. Ther*. 1976 Mar; 19(3):300–9.
- Dax EM, Pilotte NS, Adler WH, Nagel JE, Lange WR. The effects of 9-ene-tetrahydrocannabinol on hormone release and immune function. *J Steroid Biochem*. 1989; 34(1–6):263–70.
- Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. *Drug Alcohol Depend*. 2003 Jul 20; 71(1):37–48.
- Degenhardt L, Chiu WT, Conway K, Dierker L, Glantz M, Kalaydjian A, Merikangas K, Sampson N, Swendsen J, Kessler RC. Does the ‘gateway’ matter? Associations between the order of drug use initiation and the development of drug dependence in the National Comorbidity Study Replication. *Psychol. Med* 2009 Jan; 39(1):157–67.
- Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neumark Y, Sampson N, Alonso J, Angermeyer M, Anthony JC, Bruffaerts R, et al. Evaluating the drug use ‘gateway’ theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. *Drug Alcohol. Depend*. 2010 Apr 1; 108(1–2):84–97.
- Deiana S, Fattore L, Spano MS, Cossu G, Porcu E, Fadda P, Fratta W. Strain and schedule dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. *Neuropharmacology*. 2007 Feb; 52(2):646–54.
- Dewey, W.L., Martin, B.R., May, E.L. Cannabinoid stereoisomers: pharmacological effects. In Smith, D.F. (Ed.) *CRC Handbook of stereoisomers: drugs in psychopharmacology*, 317–326 (Boca Raton, FL, CRC Press), 1984.
- Di Marzo, V.A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. *Trends. Pharmacol. Sci* 2006 Mar; 27(3):134–40.
- DEA Statistics and Facts. (n.d.) DEA Domestic Drug Seizures. <http://www.justice.gov/dea/resource-center/statistics.shtml/> (accessed August 5, 2014)
- Drug Enforcement Administration, *Drugs of Abuse*, 2005.
- Drug Enforcement Administration. *Sourcebook of Criminal Justice Statistics*, 2003.
- DSM–V. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association. Washington, DC: American Psychiatric Publishing, 2013.
- Eldridge JC, Murphy LL, Landfield PW. Cannabinoids and the hippocampal glucocorticoid receptor: recent findings and possible significance. *Steroids*. 1991 May; 56(5):226–31. Review.
- Ellis RJ, Toperoff W, Vaida F, Van Den Brande G, Gonzales J, Gouaux B, Bentley H, and Atkinson JH. 2009. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology* 34(3): 672–680.
- ElSohly MA, Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. *Life Sciences*. 2005; 78:539–48.
- Fant RV, Heishman SJ, Bunker EB, Pickworth WB. Acute and residual effects of marijuana in humans. *Pharmacol Biochem Behav*. 1998 Aug; 60(4):777–84.
- Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. *Br.J Pharmacol*. 2007 Nov; 152(5):795–804.
- Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. *Addiction*. 2005 Mar; 100(3):354–66.
- Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL. Cannabis use before age 15 and subsequent executive functioning. *Br. J Psychiatry* 2011 Jun; 198(6):442–7.
- Fried, P.A., Watkinson, B. 36- and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes and alcohol. *J. Dev. Behav. Pediatr*. 1987, 8, 318–326.
- Fried, P.A., Watkinson, B., Gray, R. A follow-up study of attentional behavior in 6-year-old children exposed prenatally to marijuana, cigarettes and alcohol. *Neurotoxicol. Teratol*. 1992, 14, 299–311.
- Fried, P.A., Watkinson, B., Gray, R. Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marijuana. *Neurotoxicol. Teratol*. 1998, 20(3), 293–306.
- Fried PA. Adolescents prenatally exposed to marijuana: examination of facets of complex behaviors and comparisons with the influence of in utero cigarettes. *J. Clin. Pharmacol*. 2002 Nov; 42(11 Suppl):97S–102S.
- Fried PA, Watkinson B, Gray R. Neurocognitive consequences of marijuana—a comparison with pre-drug performance. *Neurotoxicol. Teratol*. 2005 Mar; 27(2):231–9.
- Fung, M., Gallagher, C., Machtay, M. Lung and aeo-digestive cancers in young marijuana smokers. *Tumori* 1999, 85 (2), 140–142.
- Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem*. 1995 Aug 15; 232(1):54–61.
- Gaoni, Y., Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent of hashish. *J. Am. Chem. Soc*. 1964, 86, 1646–1947.
- Gerard, C.M., Mollereau, C., Vassart, G., Parmentier, M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis.: *Biochem J*. 1991, 279, 129–34.
- Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. *J Neurosci*. 2002 Feb 1; 22(3):1146–54.
- Gold LH, Balster RL, Barrett RL, Britt DT, Martin BR. A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP

- 55,940 in rats and rhesus monkeys. *J Pharmacol Exp Ther.* 1992 Aug; 262(2):479–86.
- Goldschmidt L, Richardson GA, Willford J, Day NL. Prenatal marijuana exposure and intelligence test performance at age 6. *J. Am. Acad. Child. Adolesc. Psychiatry.* 2008 Mar; 47(3):254–63.
- Gong H Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. *Clin Pharmacol Ther.* 1984 Jan; 35(1):26–32.
- Gong JP, Onaivi ES, Lshiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. *Brain Res.* 2006 Feb 3; 1071(1):10–23.
- Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide. *Mol Pharmacol.* 2000 May; 57(5): 1045–50.
- Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. *Neuropsychol.Rev.* 2007 Sep; 17(3):347–61.
- Gonzalez S, Cebeira M, Fernandez-Ruiz J. Cannabinoid tolerance and dependence: A review of studies in laboratory animals. *Pharmacol.Biochem.Behav.* 2005 Jun; 81(2):300–18.
- Grant I. Foreword by Igor Grant, M.D., Director, Center for Medicinal Cannabis Research (CMCR). *Neuropharmacology.* 2005 Jun; 48(8): 1067.
- Griffith-Lendering MF, Wigman JT, Prince van LA, Huijbregts SC, Huizink AC, Ormel J, Verhulst FC, van OJ, Swaab H, Vollebergh WA. Cannabis use and vulnerability for psychosis in early adolescence—a TRAILS study. *Addiction* 2012 Dec 7.
- Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet.* 2003; 42(4):327–60.
- Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. *Psychol.Addict.Behav.* 2012 Sep; 26(3):496–506.
- Hall WD, Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. *Drug Alcohol Rev.* 2005 Jan; 24(1):39–48.
- Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, and Faltin RW. 2007. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. *Journal of acquired immune deficiency syndromes (1999)* 45 (5): 545–554.
- Haney M, Rabkin J, Gunderson E, and Foltin RW. 2005. Dronabinol and marijuana in HIV(+) marijuana smokers: Acute effects on caloric intake and mood. *Psychopharmacology* 181(1): 170–178.
- Haney M, Ward AS, Comer SD, Faltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. *Psychopharmacology (Berl)* 1999, 141(4):395–404.
- Hanus, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R.G., Roos, R.A., Mechoulam, R., Pride, E. HU–308: A specific agonist for CB(2), a peripheral Cannabinoid receptor. *Proc. Natl. Acad. Sci. USA* 1999, 96, 14228–33.
- Heishman SJ, Huestis MA, Benningfield JE, Cone EJ. Acute and residual effects of marijuana: Profiles of plasma THC levels, physiological, subjective, and performance measures. *Pharmacol Biochem Behav.* 1990 Nov; 37(3):561–5.
- Herkenham, M. Cannabinoid receptor localization in brain: Relationship to motor and reward systems. In: Kalivas, P.W., and Samson, H.H., eds. *The neurobiology of drug and alcohol addiction.* Ann NY Acad Sci 1992, 654, 19–32.
- Herkenham, M., Lynn, A.B., Little, M.D., Johnson, M.R., Melvin, L.S., de Costa, B.R., Rice, K.C. Cannabinoid receptor localization in Brain. *Proc. Natl. Acad. Sci. US A.* 1990, 87, 1932–1936.
- Herning, R.I.; Hooker, W.D.; and Jones, R.T. Tetrahydrocannabinol content and differences in marijuana smoking behavior. *Psychopharmacology* 1986, 90(2):160–162.
- Hillig, K.W. Genetic evidence for speciation in Cannabis (Cannabaceae). *Genetic Resources and Crop Evolution* 52: 161–180, 2005.
- Hirvonen, J., Goodwin, R.S., Li, C.T., Terry, G.E., Zoghbi, S.S., Morse, C., Pike, V.W., Volkow, N.D., Huestis, M.A., Innis, R.B. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. *Mol. Psychiatry.* 2012(Jun), 17(6), 643–649.
- Hively, R.L., Mosher, W.A., Hoffman, F.W. Isolation of trans-<sup>9</sup>-tetrahydrocannabinol from marijuana. *J. Am. Chem. Soc.* 1966, 88, 1832–1833.
- Hollister LE, Gillespie HK. Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration. *Clin.Pharmacol.Ther.* 1973 May;14(3):353–7.
- Hollister, L.E. Health aspects of cannabis. *Pharmacological Rev.* 1986, 38, 1–20.
- Hollister, L.E. Cannabis. (Literature review). *Acta Psychiatr Scand (Suppl)* 1988, 78, 108–118.
- Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Parrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. *Neuropharmacology.* 2004; 47 Suppl 1:345–58.
- Huestis, M.A., Sampson, A.H., Holicky, B.J., Benningfield, J.E., Cone, E.J. Characterization of the absorption phase of marijuana smoking. *Clin. Pharmacol Ther.* 1992a, 52, 31–41.
- Huestis, M.A.; Benningfield, J.E.; and Cone, E.J. Blood Cannabinoids. 1. Absorption of THC and formation of 11–OH-THC and THC COOH during and after smoking marijuana. *J Anal Toxicol* 1992b, 16(5), 276–282.
- Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. *J Pharmacol Exp Ther.* 1980 Oct; 215(1):35–44.
- Ilan AB, Gevins A, Coleman M, Elsohly MA, de WH. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. *Behav.Pharmacol.* 2005 Sep; 16(5–6):487–96.
- Institute of Medicine. Division of Health Sciences Policy. Marijuana and Health: Report of a Study by a Committee of the Institute of Medicine, Division of Health Sciences Policy. Washington, DC: National Academy Press, 1982.
- Institute of Medicine, Division of Neuroscience and Behavioral Health. Marijuana and Medicine: Assessing the Science Base. Washington DC: National Academy Press, 1999.
- Johansson, E.; Halldin, M.M.; Agurell, S.; Hollister, L.E.; and Gillespie, H.K. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. *Eur J Clin Pharmacol* 1989, 37(3), 273–277.
- Johnston, L.D., O'Malley, P.M., Miech, R.A., Bachman, J.G., & Schulenberg, J.E. (2014). *Monitoring the Future national survey results on drug use: 1975–2013: Overview, key findings on adolescent drug use.* Ann Arbor: Institute for Social Research, The University of Michigan, 84pp.
- Jones, R.T.; Benowitz, N.L.; and Heming, R.I. Clinical relevance of cannabis tolerance and dependence. *J Clin Pharmacol* 1981, 21,143S–152S.
- Jones RT. Cardiovascular system effects of marijuana. *J Clin Pharmacol.* 2002 Nov;42(11Suppl):58S–63S.
- Justinova Z, Goldberg SR, Heishman SJ, Tanda G. Self-administration of cannabinoids by experimental animals and human marijuana smokers. *Pharmacol Biochem Behav.* 2005 Jun; 81(2): 285–299.
- Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. *Psychopharmacology (Berl).* 2003 Sep; 169(2): 135–40.
- Justinova Z, Tanda G, Munzar P, Goldberg SR. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. *Psychopharmacology.(Berl.)* 2004 Apr;l 73(1–2):186–94.
- Kandel, D. Stages in adolescent involvement in drug use. *Science* 1975; 190:912–914.
- Kandel DB, Chen K. Types of marijuana users by longitudinal course. *J Stud Alcohol.* 2000 May; 61(3):367–78.
- Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. *Eur J Pharmacol.* 1974 Sep;28(1):172–7.
- Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE. Effects of delta9-tetrahydrocannabinol and cannabinalin in man. *Pharmacology* 1975; 13(6):502–12.
- Kirk JM, de Wit H. Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. *Pharmacol Biochem Behav.* 1999 May; 63(1):137–42.
- Kuepper R, van OJ, Lieb R, Wittchen HU, Hofer M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. *BMJ* 2011; 342:d738.
- Kurzthaler I, Hummer M, Miller C, Sperner-Unterwieser B, Gunther V, Wechdorn H, Battista HJ, Fleischhacker WW. Effect of cannabis use on cognitive functions and

- driving ability. *J Clin Psychiatry*. 1999 Jun; 60(6):395–9.
- Lee MH, Hancox RJ. Effects of smoking cannabis on lung function. *Expert Rev.Respir.Med* 2011 Aug; 5(4):537–46.
- Lemberger L., Silberstein, S. D., Axelrod, J., Kopin, I.J. Marihuana: Studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. *Science* 1970, 1 70, 1320–1322.
- Lemberger L., Weiss, J.L., Watanabe, A. M., Galanter, I.M., Wyatt, R.J., Cardon, P.V. Delta-9-tetrahydrocannabinol: Temporal correlation of the psychological effects and blood levels after various routes of administration. *New Eng. J. Med.* 1972a, 286(13), 685–688.
- Lemberger, L., Crabtree, R.E., Rowe, H.M. 11-Hydroxy-<sup>9</sup>-tetrahydrocannabinol: Pharmacology, disposition and metabolism of a major metabolite of marihuana in man. *Science* 1972b, 177, 62–63.
- Lemberger L., Rubin A. The physiologic disposition of marihuana in man, *Life Sci*. 1975,17, 1637–42.
- Li M–C., Brady, J.E., DiMaggio, C.J., Lusardi, A.R., Tzong, K.Y., Li, G. Marijuana use and motor vehicle crashes. *Epidemiologic Reviews*. 2012, 34, 65–72.
- Liguori A, Gatto CP, Robinson JH. Effects of marijuana on equilibrium, psychomotor performance, and simulated driving. *Behav Pharmacol*. 1998 Nov; 9(7):599–609.
- Lile JA, Kelly TH, Hays LR. Separate and combined effects of the cannabinoid agonists nabilone and Delta(9)-THC in humans discriminating Delta(9)-THC. *Drug Alcohol Depend*. 2011 Jul; 116(1–3):86–92.
- Lile JA, Kelly TH, Pinsky DJ, Hays LR. Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol. *Psychopharmacology (Berl.)* 2009 Apr; 203(2):241–50.
- Lisdahl KM, Price JS. Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. *J Int Neuropsychol.Soc* 2012 Jul; 18(4):678–88.
- Lyons MJ, Bar JL, Panizzon MS, Toomey R, Eisen S, Xian H, Tsuang MT. Neuropsychological consequences of regular marijuana use: A twin study. *Psychol Med*. 2004 Oct; 34(7):1239–50.
- Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. *J Neurosci*. 1995 Oct; 15(10):6552–61.
- Maldonado R. Study of cannabinoid dependence in animals. *Pharmacol Ther*. 2002 Aug; 95(2): 153–64.
- Malinowska B, Baranowska-Kuczko M, Schlicker E. Triphasic blood pressure responses to cannabinoids: Do we understand the mechanism? *Br J Pharmacol* 2012 Apr; 165(7):2073–88.
- Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreason S, Allebeck P. Cannabis, schizoprenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. *Psychol.Med* 2012 Jun; 42(6):1321–8.
- Maremmani I, Lazzeri A, Pacini M, Lovrecic M, Placidi GF, Perugi G. Diagnostic and symptomatological features in chronic psychotic patients according to cannabis use status. *J Psychoactive Drugs*. 2004 Jun; 36(2):235–41.
- “Marijuana Scheduling Petition; Denial of Petition; Remand; Final Order,” 57 Federal Register 59 (26 March 1992), pp. 10499–10508.
- Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W. Self-administration of the cannabinoid receptor agonist WIN 55,212–2 in drug-naïve mice. *Neuroscience*. 1998 Jul; 85(2):327–30.
- Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* 1990, 346, 561–564.
- McMahon LR. Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of discriminating Delta9-tetrahydrocannabinol. *Psychopharmacology (Berl.)* 2009 Apr; 203(2):219–28.
- McMahon LR, Ginsburg BC, Lamb RJ. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice. *Psychopharmacology (Berl.)* 2008 Jul; 198(4):487–95.
- Mechoulam, R. Cannabinoid chemistry. In Mechoulam, R. (ED.) *Marijuana*, pp.2–88 (New York, NY, Academic Press, Inc.), 1973.
- Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol—recent advances. *Chem.Biodivers*. 2007 Aug;4(8): 1678–92.
- Mechoulam R, Shvo Y. Hashish-I: The structure of Cannabidiol. *Tetrahedron*. 1963; 19: 2073–78.
- Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly MA. Potency Trends of  $\Delta^9$ -THC and other cainabinoids in confiscated cannabis preparations from 1993 to 2008. *J Forensic Sci*. 2010 Sept; 55(5): 1209–1217.
- Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE. Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc.Natl.Acad.Sci U.S.A* 2012 Oct 2; 109(40):E2657–E2664.
- Meijer JH, Dekker N, Koeter MW, Quee PI, van Beveren NJ, Meijer CJ. Cannabis and cognitive performance in psychosis: A cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. *Psychol.Med* 2012 Apr; 42(4):705–16.
- Mendelson JH, Mello NK. Effects of marijuana on neuroendocrine hormones in human males and females. *NIDA Res Monogr*. 1984; 44:97–114.
- Mendizabal V, Zimmer A, Maldonado R. Involvement of kappa/dynorphin system in WIN 55,212–2 self-administration in mice. *Neuropsychopharmacology*. 2006 Sep; 31(9):1957–66.
- Merritt JC, Crawford WJ, Alexander PC, Anduze AL, and Gelbart SS. 1980. Effect of marihuana on intraocular and blood pressure in glaucoma. *Ophthalmology* 87(3): 222–228.
- Messinis L, Kyprianidou A, Malefaki S, and Papathanasopoulos P. Neuropsychological deficits in long-term frequent cannabis users. *Neurology* 2006 66:737–739.
- Minozzi S, Davoli M, Bargagli AM, Amato L, Vecchi S, Perucci CA. An overview of systematic reviews on cannabis and psychosis: Discussing apparently conflicting results. *Drug Alcohol Rev*. 2010 May; 29(3):304–17.
- Mittleman MA, Lewis RA, Maclure M, Sherwood JB, and Muller JE. Triggering myocardial infarction by marijuana. *Circulation*. 2001; 103:2805–2809.
- Nace EP, Meyers AL, Rothberg JM, Maleson F. Addicted and nonaddicted drug users. A comparison of drug usage patterns. *Arch Gen Psychiatry*. 1975; 32(1):77–80.
- Oviedo, A., Glowa, J., Herkenham, M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study. *Brain Res*. 1993, 616, 293–302.
- Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol.Rev*. 2006 Sep; 58(3):389–462.
- Pelayo-Teran JM, Suarez-Pinilla P, Chadi N, Crespo-Pacorro B. Gene-environment interactions underlying the effect of cannabis in first episode psychosis. *Curr Pharm Des*. 2012; 18(32):5024–35.
- Petrocellis PL, Di Marzo V. An introduction to the endocannabinoid system: From the early to the latest concepts. *Best Pract.Res.Clin.Endocrinol.Metab*. 2009 Feb; 23(1):1–15.
- Piomelli D. The endocannabinoid system: A drug discovery perspective. *Curr Opin Investig Drugs*. 2005 Jul; 6(7):672–9.
- Pletcher MJ, Vittinghoff E, Kalhan R, Richman J, Safford M, Sidney S, Lin F, Kertesz S. Association between marijuana exposure and pulmonary function over 20 years. *JAMA* 2012 Jan 11; 307(2):173–81.
- Pollastro F, Tagliatela-Scafati O, Allara M, Munoz E, Di Marzo V, De Petrocellis L, Appendino G. Bioactive prenylogous cannabinoid from fiber hemp (*Cannabis sativa*). *J Nat Prod*. 2011 Sep 23;74(9):2019–22.
- Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Cognitive measures in long term cannabis users. *J Clin Pharmacol*. 2002 Nov; 42(11 Suppl):41S–47S. Review.
- Radwan MM, Elsohly MA, Slade D, Ahmed SA, Khan IA, Ross SA. Biologically active cannabinoids from high-potency *Cannabis sativa*. *J Nat Prod*. 2009 May 22; 72(5):906–11.
- Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. *Drug Alcohol Depend*. 2004 Feb 7; 73(2): 109–19.
- Ramaekers JG, Kauert G, van RP, Theunissen EL, Schneider E, Moeller MR. High-potency marijuana impairs executive function and inhibitory motor control. *Neuropsychopharmacology* 2006 Oct; 31(10):2296–303.

- Ramaekers JG, Kauert G, Theunissen EL, Toennes SW., Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. *J.Psychopharmacol.* 2009 May; 23(3):266–77.
- Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognitive and motor control as a function of  $\Delta^9$ -THC concentration in serum and oral fluid: Limits of impairment. *Drug and Alcohol Dependence.* 2006; 85:114–122.
- “Rescheduling of the Food and Drug Administration Approved Product Containing Synthetic Dronabinol [(–)-delta 9-(trans)-Tetrahydrocannabinol] in Sesame Oil and Encapsulated in Soft Gelatin Capsules From Schedule II to Schedule III; Final Rule,” 64 Federal Register 127 (2 July 1999), pp.35928–35930.
- Riggs PK, Vaida F, Rossi SS, Sorkin LS, Gouaux B, Grant I, Ellis RJ. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. *Brain Res* 2012 Jan 11; 1431:46–52.
- Rodriguez de Fonseca F, Gorriti, M.A., Fernandez-Ruiz, J.J., Palomo, T., Ramos, J.A. Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. *Pharmacol. Biochem. Behav.* 1994, 47 (1), 33–40.
- Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC. Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL–SCID mouse. *Life Sci.* 2005 Aug 19; 77(14):1711–22.
- Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol.* 2011 Aug; 163(7):1344–64.
- Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. *Cancer Res.* 2005 Mar 1; 65(5):1635–41.
- Sanudo-Peria M.C., Tsou, K., Delay, E.R., Hohman, A.G., Force, M., Walker, J.M. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. *Neurosci. Lett.*, 223, 125–128, 1997.
- Scherrer JF, Grant JD, Duncan AE, Sartor CE, Haber JR, Jacob T, Bucholz KK. Subjective effects to cannabis are associated with use, abuse and dependence after adjusting for genetic and environmental influences. *Drug Alcohol Depend.* 2009 Nov 1; 105(1–2):76–82.
- Schiffman J, Nakamura B, Earleywine Mj LaBrie J. Symptoms of schizotypy precede cannabis use. *Psychiatry Res.* 2005 Mar 30; 134(1):37–42.
- Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis. *Exp.Clin Psychopharmacol.* 2012 Oct; 20(5):420–9.
- Sidney S. Cardiovascular consequences of marijuana use. *J Clin Pharmacol.* 2002 Nov; 42(11 Suppl):64S–70S.
- Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J; Marijuana Treatment Project Research Group. Cognitive functioning of long-term heavy cannabis users seeking treatment. *JAMA.* 2002 Mar 6; 287(9): 1123–31.
- Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. *Schizophr Res.* 2005 Jun 1; 75(1):135–7.
- Substance Abuse and Mental Health Services Administration, *Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits.* HHS Publication No. (SMA) 13–4760, DAWN Series D–39. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
- Substance Abuse and Mental Health Services Administration, *Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H–46, HHS Publication No. (SMA) 13–4795.* Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
- Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. *Treatment Episode Data Set (FEDS): 2001–2011. National Admissions to Substance Abuse Treatment Services.* BHSIS Series S–65, HHS Publication No. (SMA) 13–4772. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
- Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. *Addiction* 2011 Dec; 106(12):2195–203.
- Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: An overview. *Immunobiology.* 2010 Aug; 215(8):588–97.
- Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. *Nat Neurosci.* 2000 Nov; 3(11):1073–4.
- Tashkin DP. Smoked marijuana as a cause of lung injury. *Monaldi Arch Chest Dis.* 2005 Jun; 63(2):93–100.
- Tashkin DP, Shapiro BJ, and Frank IM. 1974. Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. *The American review of respiratory disease* 109 (4): 420–428.
- Tashkin, DP, Zhang, ZF, Greenland, S, Cozen, W, Mack, TM, Morgenstern, H. Marijuana Use and Lung Cancer: Results of a Case-Control Study. Abstract #A 777, American Thoracic Society meeting, May 24, 2006.
- The Plant List (2010). Version 1. Published on the Internet; <http://www.theplantlist.org/> (accessed September 20, 2013)
- Theunissen EL, Kauert GF, Toennes SW., Moeller MR, Sambeth A, Blanchard MM, Ramaekers JG. Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. *Psychopharmacology (Berl.)* 2012 Mar;220(2):341–50.
- Trabert B, Sigurdson AJ, Sweeney AM, Strom SS, McGlynn KA. Marijuana use and testicular germ cell tumors. *Cancer.* 2011 Feb 15; 117: 848–853.
- Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. *J Neurophysiol.* 1997 Jul; 78(1):43–50.
- van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MW, de HL. Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. *Curr Pharm Des.* 2012; 18(32):5036–44.
- van Gastel WA, Wigman JT, Monshouwer K, Kahn RS, van OJ, Boks MP, Vollebergh WA. Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey. *Addiction* 2012 Feb; 107(2):381–7.
- Van Gundy K, Rebellon CJ. A Life-course Perspective on the “Gateway Hypothesis.” *J Health Soc Behav.* 2010 Sep; 51(3):244–59.
- van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. *Am J Epidemiol.* 2002 Aug 15; 156(4):319–27.
- Vandrey RG, Budney AJ, Moore BA, Hughes JR. A cross-study comparison of cannabis and tobacco withdrawal. *Am J Addict.* 2005 Jan-Feb; 14(1):54–63.
- Vandrey RG, Budney AJ, Hughes JR, Liguori A. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. *Drug Alcohol Depend.* 2008 Jan 1; 92(1–3):48–54.
- Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9) tetrahydrocannabinol. *Drug Alcohol Depend.* 2008 Apr 1; 94(1–3):191–8.
- Vanyukov MM, Tarter RE, Kirillova GP, Kirisci L, Reynolds MD, Kreek MJ, Conway KP, Maher BS, Iacono WG, Bierut L, Neale MC, Clark DB, Ridenour TA. Common liability to addiction and “gateway hypothesis”: theoretical, empirical and evolutionary perspective’. *Drug Alcohol Depend.* 2012 Jun; 123 Suppl 1:S3–17
- von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen HU. What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. *Drug Alcohol Depend.* 2002 Sep 1; 68(1):49–64.
- Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H. Comparison of the subjective effects of Delta (9)-tetrahydrocannabinol and marijuana in humans. *Psychopharmacology (Berl).* 2002 Jun; 161(4):331–9.
- Wagner JA, Varga K, Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. *J Mol Med.* 1998 Nov-Dec; 76(12):824–36.
- Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, and Collet JP. 2010. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ: Canadian Medical Association journal =journal de l'Association medicale canadienne* 182(14): E694–E701.

- Wesson DR, Washburn P. Current patterns of drug abuse that involve smoking. NIDA Res. Monogr. 1990; 99:5–11.
- Wiley JL, Barrett RL, Britt DT, Balster RL, Martin BR. Discriminative stimulus effects of delta 9-tetrahydrocannabinol and delta 9–11-tetrahydrocannabinol in rats and rhesus monkeys. *Neuropharmacology*. 1993 Apr; 32(4):359–65.
- Wiley JL, Huffman JW, Balster RL, Martin BR. Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys. *Drug Alcohol Depend*. 1995 Nov; 40(1):81–6.
- Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, and Donaghe H. 2013. Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain. *The journal of pain: official journal of the American Pain Society*.
- Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, and Fishman S. 2008. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *The journal of pain: official journal of the American Pain Society* 9 (6): 506–521.
- Wu X, French ED. Effects of chronic delta-9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. *Neuropharmacology*. 2000 Jan 28; 39(3):391–8.
- Yucel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, Takagi MJ, Fomito A, Wood SJ, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. *Schizophr.Bull*. 2012 Mar; 38(2):316–30.
- Zeiger JS, Haberstick BC, Corley RP, Ehringer MA, Crowley TJ, Hewitt JK, Hopfer CJ, Stallings MC, Young SE., Rhee SH. Subjective effects to marijuana associated with marijuana use in community and clinical subjects. *Drug Alcohol Depend*. 2010 Jun 1; 109(1–3):161–6.
- Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, Hsu TC, Schantz SP. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. *Cancer Epidemiol Biomarkers Prev*. 1999 Dec;8(12): 1071–8.
- Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9–THC in normal subjects. *Psychopharmacology (Berl.)*1982; 76(3):245–50.

### The Medical Application of Marijuana: A Review of Published Clinical Studies

March 19, 2015

Prepared by:

U.S. Food and Drug Administration  
Center for Drug Evaluation and Research  
(FDA/CDER)  
Controlled Substance Staff (CSS)

### TABLE OF CONTENTS

1. Introduction .....	71
2. Methods .....	73
2.1 Define the Objective of the Review .....	73
2.2 Define “Marijuana” .....	74
2.3 Define “Adequate and Well-Controlled Clinical Studies” .....	74
2.4 Search Medical Literature Databases and Identify Relevant Studies .....	75
2.5 Review and Analyze Qualifying Clinical Studies .....	77
3. Results and Discussion .....	77
3.1 Neuropathic Pain .....	77
3.1.1 Neuropathic Pain Associated with HIV-Sensory Neuropathy .....	77
3.1.2 Central and Peripheral Neuropathic Pain .....	81
3.2 Appetite Stimulation in HIV .....	86
3.3 Spasticity in Multiple Sclerosis .....	89
3.4 Asthma .....	90
3.5 Glaucoma .....	91
3.6 Conclusions .....	91
3.6.1 Conclusions for Chronic Neuropathic Pain .....	92
3.6.2 Conclusions for Appetite Stimulation in HIV .....	92
3.6.3 Conclusions for Spasticity in MS .....	92
3.6.4 Conclusions for Asthma .....	93
3.6.5 Conclusions for Glaucoma .....	93
3.7 Design Challenges for Future Studies .....	93
3.7.1 Sample Size .....	93
3.7.2 Marijuana Dose Standardization .....	94
3.7.3 Acute vs. Chronic Therapeutic Marijuana Use .....	96
3.7.4 Smoking as a Route of Administration .....	96
3.7.5 Difficulty in Blinding of Drug Conditions .....	96
3.7.6 Prior Marijuana Experience .....	97
3.7.7 Inclusion and Exclusion Criteria .....	98
3.7.8 Number of Female Subjects .....	99
Appendix (Tables) .....	103
List of Figure .....	
Figure 1: Identification of Studies From PubMed Search .....	76
List of Tables .....	
Table 1: Randomized, controlled, double-blind trials examining smoked marijuana in treatment of neuropathic pain .....	103
Table 2: Randomized, controlled, double-blind trials examining smoked marijuana in treatment of appetite stimulation in HIV/AIDS .....	109
Table 3: Randomized, controlled, double-blind trails examining smoked marijuana in treatment of spasticity in Multiple Sclerosis .....	112
Table 4: Randomized, controlled, double-blind trails examining smoked marijuana in treatment of intraocular pressure in Glaucoma .....	114
Table 5: Randomized, controlled, double-blind trails examining smoked marijuana in treatment of asthma .....	116

### Executive Summary

Marijuana is a Schedule I substance under the Controlled Substances Act (CSA). Schedule I indicates a high potential for abuse, no currently

accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. To date, marijuana has not been subject to an approved new drug application (NDA)

that demonstrates its safety and efficacy for a specific indication under the Food Drug and Cosmetic Act (FDCA).

Nevertheless, as of October 2014, twenty-three states and the District of

Columbia have passed state-level medical marijuana laws that allow for marijuana use within that state; similar bills are pending in other states.

The present review was undertaken by the Food and Drug Administration (FDA) to analyze the clinical studies published in the medical literature investigating the use of marijuana in any therapeutic areas. First, we discuss the context for this scientific review. Next, we describe the methods used in this review to identify adequate and well-controlled studies evaluating the safety and efficacy of marijuana for particular therapeutic uses.

The FDA conducted a systematic search for published studies in the medical literature that meet the described criteria for study design and outcome measures prior to February 2013. While not part of our systematic review, we have continued to routinely follow the literature beyond that date for subsequent studies. Studies were considered to be relevant to this review if the investigators administered marijuana to patients with a diagnosed medical condition in a well-controlled, double-blind, placebo-controlled clinical trial. Of the eleven studies that met the criteria for review, five different therapeutic areas were investigated:

- Five studies examined chronic neuropathic pain
- Two studies examined appetite stimulation in human immunodeficiency virus (HIV) patients
- Two studies examined glaucoma
- One study examined spasticity and pain in multiple sclerosis (MS)
- One study examined asthma.

For each of these eleven clinical studies, information is provided regarding the subjects studied, the drug conditions tested (including dose and method of administration), other drugs used by subjects during the study, the physiological and subjective measures collected, the outcome of these measures comparing treatment with marijuana to placebo, and the reported and observed adverse events. The conclusions drawn by the investigators are then described, along with potential limitations of these conclusions based on the study design. A brief summary of each study's findings and limitations is provided at the end of the section.

The eleven clinical studies that met the criteria and were evaluated in this review showed positive signals that marijuana may produce a desirable therapeutic outcome, under the specific experimental conditions tested. Notably, it is beyond the scope of this review to determine whether these data

demonstrate that marijuana has a currently accepted medical use in the United States. However, this review concludes that these eleven clinical studies serve as proof-of-concept studies, based on the limitations of their study designs, as described in the study summaries. Proof-of-concept studies provide preliminary evidence on a proposed hypothesis regarding a drug's effect. For drugs under development, the effect often relates to a short-term clinical outcome being investigated. Proof-of-concept studies serve as the link between preclinical studies and dose ranging clinical studies. Therefore, proof-of-concept studies are not sufficient to demonstrate efficacy of a drug because they provide only preliminary information about the effects of a drug. However, the studies reviewed produced positive results, suggesting marijuana should be further evaluated as an adjunct treatment for neuropathic pain, appetite stimulation in HIV patients, and spasticity in MS patients.

The main limitations identified in the eleven studies testing the medical applications of marijuana are listed below:

- The small numbers of subjects enrolled in the studies, which limits the statistical analyses of safety and efficacy.
- The evaluation of marijuana only after acute administration in the studies, which limits the ability to determine efficacy following chronic administration.
- The administration of marijuana typically through smoking, which exposes ill patients to combusted material and introduces problems with determining the doses delivered.
- The potential for subjects to identify whether they received marijuana or placebo, which breaks the blind of the studies.
- The small number of cannabinoid naïve subjects, which limits the ability to determine safety and tolerability in these subjects.
- The low number of female subjects, which makes it difficult to generalize the study findings to subjects of both genders.

Thus, this review discusses the following methodological changes that may be made in order to resolve these limitations and improve the design of future studies which examine the safety and efficacy of marijuana for specific therapeutic indications:

- Determine the appropriate number of subjects studied based on recommendations in various FDA *Guidances for Industry* regarding the

conduct of clinical trials for specific medical indications.

- Administer consistent and reproducible doses of marijuana based on recommendations in the FDA *Guidance for Industry: Botanical Drug Products (2004)*.<sup>27</sup>
- Evaluate the effects of marijuana under therapeutic conditions following both acute and chronic administration.
- Consider alternatives to smoked marijuana (e.g., vaporization).
- Address and improve whenever possible the difficulty in blinding of marijuana and placebo treatments in clinical studies.
- Evaluate the effect of prior experience with marijuana with regard to the safety and tolerability of marijuana.
- Strive for gender balance in the subjects used in studies.

In conclusion, the eleven clinical studies conducted to date do not meet the criteria required by the FDA to determine if marijuana is safe and effective in specific therapeutic areas. However, the studies can serve as proof-of-concept studies and support further research into the use of marijuana in these therapeutic indications. Additionally, the clinical outcome data and adverse event profiles reported in these published studies can beneficially inform how future research in this area is conducted. Finally, application of the recommendations listed above by investigators when designing future studies could greatly improve the available clinical data that can be used to determine if marijuana has validated and reliable medical applications.

## 1. Introduction

In response to citizen petitions submitted to the Drug Enforcement Administration (DEA) requesting DEA to reschedule marijuana, the DEA Administrator requested that the U.S. Department of Health and Human Services (HHS) provide a scientific and medical evaluation of the available information and a scheduling recommendation for marijuana, in accordance with 21 U.S.C. 811(b). The Secretary of HHS is required to consider in a scientific and medical evaluation eight factors determinative of control under the Controlled Substance Act (CSA). Administrative responsibilities for evaluating a substance for control under the CSA are performed by the Food and Drug Administration (FDA), with the concurrence of the National Institute on Drug Abuse (NIDA). Part of

<sup>27</sup> This Guidance is available on the internet at <http://www.fda.gov/Drugs/default.htm> under Guidance (Drugs).

this evaluation includes an assessment of whether marijuana has a currently accepted medical use in the United States. This assessment necessitated a review of the available data from published clinical studies to determine whether there is adequate scientific evidence of marijuana's effectiveness.

Under Section 202 of the CSA, marijuana is currently controlled as a Schedule I substance (21 U.S.C. 812). Schedule I includes those substances that have a high potential for abuse, have no currently accepted medical use in treatment in the United States, and lack accepted safety for use under medical supervision (21 U.S.C. 812(b)(1)(A)–(C)).

A drug product which has been approved by FDA for marketing in the United States is considered to have a “currently accepted medical use.” Marijuana is not an FDA-approved drug product, as a New Drug Application (NDA) or Biologics License application (BLA) for marijuana has not been approved by FDA. However, FDA approval of an NDA is not the only means through which a drug can have a currently accepted medical use in the United States.

In general, a drug may have a “currently accepted medical use” in the United States if the drug meets a five-part test. Established case law (*Alliance for Cannabis Therapeutics v. DEA*, 15 F.3d 1131, 1135 (D.C. Cir. 1994)) upheld the Administrator of DEA's application of the five-part test to determine whether a drug has a “currently accepted medical use.” The following describes the five elements that characterize “currently accepted medical use” for a drug:<sup>28</sup>

i. The drug's chemistry must be known and reproducible

“The substance's chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official compendia, as defined by section 201(j) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321(j), is sufficient to meet this requirement.”

ii. there must be adequate safety studies

“There must be adequate pharmacological and toxicological studies, done by all methods reasonably applicable, on the basis of which it could fairly and responsibly be concluded, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, that the substance is safe for treating a specific, recognized disorder.”

iii. there must be adequate and well-controlled studies proving efficacy

“There must be adequate, well-controlled, well-designed, well-conducted, and well-documented studies, including clinical investigations, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, on the basis of which it could be fairly and responsibly concluded by such experts that the substance will have the intended effect in treating a specific, recognized disorder.”

iv. the drug must be accepted by qualified experts

“The drug has a New Drug Application (NDA) approved by the Food and Drug Administration, pursuant to the Food, Drug and Cosmetic Act, 21 U.S.C. 355. Or, a consensus of the national community of experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, accepts the safety and effectiveness of the substance for use in treating a specific, recognized disorder. A material conflict of opinion among experts precludes a finding of consensus.” and

v. the scientific evidence must be widely available.

“In the absence of NDA approval, information concerning the chemistry, pharmacology, toxicology, and effectiveness of the substance must be reported, published, or otherwise widely available, in sufficient detail to permit experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, to fairly and responsibly conclude the substance is safe and effective for use in treating a specific, recognized disorder.”

One way to pass the five-part test for having “currently accepted medical use” is through submission of an NDA or BLA which is approved by FDA. However, FDA approval of an NDA or BLA is not required for a drug to pass the five-part test.

This review focuses on FDA's analysis of one element of the five-part test for determining whether a drug has “currently accepted medical use”.

Specifically, the present review assesses the 3rd criterion that addresses whether marijuana has “adequate and well-controlled studies proving efficacy”. Thus, this review evaluates published clinical studies that have been conducted using marijuana in subjects who have a variety of medical conditions by assessing the adequacy of the summarized study designs and the study data. The methodology for selecting the studies that were evaluated is delineated below.

FDA's evaluation and conclusions regarding the remaining four criteria for whether marijuana has a “currently accepted medical use,” as well as the eight factors pertaining to the scheduling of marijuana, are outside the scope of this review. A detailed discussion of these factors is contained in FDA's scientific and medical evaluation of marijuana.

## 2. Methods

The methods for selecting the studies to include in this review involved the following steps, which are described in detail in the subsections below:

1. Define the objective of the review.
2. Define “marijuana” in order to facilitate the medical literature search for studies that administered the substance,
3. Define “adequate and well-controlled studies” in order to facilitate the search for relevant data and literature,
4. Search medical literature databases and identify relevant adequate and well-controlled studies, and
5. Review and analyze the adequate and well-controlled clinical studies to determine if they demonstrate efficacy of marijuana for any therapeutic indication.

### 2.1 Define the Objective of the Review

The objective of this review is to assess the study designs and resulting data from clinical studies published in the medical literature that were conducted with marijuana (as defined below) as a treatment for any therapeutic indication, in order to determine if they meet the criteria of “adequate and well-controlled studies proving efficacy”.

### 2.2 Define “Marijuana”

In this review, the term “marijuana” refers to the flowering tops or leaves of the *Cannabis* plant. There were no restrictions on the route of administration used for marijuana in the studies.

Studies which administered individual cannabinoids (whether experimental substances or marketed drug products) or marijuana extracts were excluded from this review. Additionally, studies of administered neutral plant material or placebo marijuana (marijuana with all cannabinoids extracted) that had subsequently been supplemented by the addition of specific amounts of THC or other cannabinoids were also excluded (Chang et al., 1979).

<sup>28</sup> 57 FR 10499, 10504–06 (March 26, 1992).

### 2.3 Define “Adequate and Well-Controlled Clinical Studies”

The criteria for an “adequate and well-controlled study” for purposes of determining the safety and efficacy of a human drug is defined under the Code of Federal Regulations (CFR) in 21 CFR 314.126. The elements of an adequate and well-controlled study as described in 21 CFR 314.126 can be summarized as follows:

1. The main objective must be to assess a therapeutically relevant outcome.
2. The study must be placebo-controlled.
3. The subjects must qualify as having the medical condition being studied.
4. The study design permits a valid comparison with an appropriate control condition.
5. The assignment of subjects to treatment and control groups must be randomized.
6. There is minimization of bias through the use of a double-blind study design.
7. The study report contains a full protocol and primary data.
8. Analysis of the study data is appropriately conducted.

As noted above, the current review examines only those data available in the public domain and thus relies on clinical studies published in the medical literature. Published studies by their nature are summaries that do not include the level of detail required by studies submitted to FDA in an NDA.

While the majority of the elements defining an adequate and well-controlled study can be satisfied through a published paper (elements #1–6), there are two elements that cannot be met by a study published in the medical literature: element #7 (availability of a study report with full

protocol and primary data) and element #8 (a determination of whether the data analysis was appropriate). Thus, for purposes of this review, only elements #1–6 will be used to qualify a study as being adequate and well-controlled.

### 2.4 Search Medical Literature Databases and Identify Relevant Studies

We identified randomized, double-blind, placebo-controlled clinical studies conducted with marijuana to assess marijuana’s efficacy in any therapeutic indication. Two primary medical literature databases were searched for all studies posted to the databases prior to February 2013:<sup>29</sup>

- *PubMed*: PubMed is a database of published medical and scientific studies that is maintained by the U.S. National Library of Medicine (NLM) at NIH as a part of the Entrez system of information retrieval. PubMed comprises more than 24 million citations for biomedical literature from MEDLINE, life science journals, and online books (<http://www.ncbi.nlm.nih.gov/pubmed>).

- *ClinicalTrials.gov*: ClinicalTrials.gov is a database of publicly and privately supported clinical studies that is maintained by the NLM. Information about the clinical studies is provided by the Sponsor or Principal Investigator of the study. Information about the studies is submitted to the Web site (“registered”) when the studies begin, and is updated throughout the study. In some cases, results of the study or resulting publication citations are submitted to the Web site after the study ends

<sup>29</sup> While not a systematic review, we have followed the recent published literature on marijuana use for possible therapeutic purposes and, as of January 2015, we found only one new study that would meet our criteria (Naftali et al., 2013). This study examined the effects of smoked marijuana on Crohn’s disease.

(<https://clinicaltrials.gov/ct2/about-site/background>).

*ClinicalTrials.gov* was searched for all studies administering marijuana. The results of this search were used to confirm that no completed studies with published data were missed in the literature search. During the literature search, references found in relevant studies and systematic reviews were evaluated for additional relevant citations. All languages were included in the search. The PubMed search yielded a total of 566 abstracts.<sup>30</sup> Of these abstracts, a full-text review was conducted with 85 papers to assess eligibility. From this evaluation, only eleven of 85 studies met the 6 CFR elements for inclusion as adequate and well-controlled studies.

Figure 1 (below) provides an overview of the process used to identify studies from the PubMed search. The eleven studies reviewed were published between 1974 and 2013. Ten of these studies were conducted in the United States and one study was conducted in Canada. These eleven studies examined the effects of smoked and vaporized marijuana for the indications of chronic neuropathic pain, spasticity related to multiple sclerosis (MS), appetite stimulation in patients with human immunodeficiency virus (HIV), glaucoma, and asthma. All included studies used adult patients as subjects. All studies conducted in the United States were conducted under an IND as Phase 2 investigations.

<sup>30</sup> The following search strategy was used, “(cannabis OR marijuana) AND (therapeutic use OR therapy) AND (RCT OR randomized controlled trial OR “systematic review” OR clinical trial OR clinical trials) NOT (“marijuana abuse”[Mesh] OR addictive behavior OR substance related disorders)”.



safety in relation to its effectiveness in treating a specific and recognized disorder due to lack of evidence with respect to a consistent and reproducible dose that is contamination free. The HHS indicated that marijuana research investigating potential medical use should include information on the chemistry, manufacturing, and specifications of marijuana. The HHS further indicated that a procedure for delivering a consistent dose of marijuana should also be developed. Therefore, the HHS concluded that marijuana does not have an acceptable level of safety for use under medical supervision.

## References

- Abrams DI, Hilton JF, Reiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M (2003). Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial. *Ann Intern Med* 139(4):258–266.
- Adams IB, Martin BR (1996). Cannabis: Pharmacology and toxicology in animals and humans. *Addiction* 91:1585–1614.
- Agurell S, Dewey WL, and Willetts RE (eds.) (1984). *The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects*. New York: Academic Press.
- Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L (1986). Pharmacokinetics and metabolism of delta-9-tetrahydrocannabinol and other cannabinoids with emphasis on man. *Pharmacol Rev* 38(1):21–43.
- American College of Physicians [ACP]. (2008). Supporting Research Into the Therapeutic Role of Marijuana. Philadelphia: American College of Physicians; 2008: Position Paper (Available from American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106).
- American Medical Association [AMA]. (2009a). Use of Cannabis for Medical Purposes. *Report of the Council on Science and Public Health* 3.
- American Medical Association [AMA]. (2009b). AMA Policy: Medical Marijuana. H-95–952 Medical Marijuana.
- American Medical Association [AMA]. (2013). 2013 Interim Meeting. American Medical Association House of Delegates (I–13). Accessed at [www.ama-assn.org/assets/meeting/2013i/i13-refcommk-annotated.pdf](http://www.ama-assn.org/assets/meeting/2013i/i13-refcommk-annotated.pdf).
- American Society of Addiction Medicine [ASAM]. (2014). *New York Times* calls for legalization of marijuana, ASAM strongly objects. Accessed at [www.asam.org/docs/default-source/pressreleases/asam-press-release-nytimes-editorial-marijuana-2014-7-27.pdf?sfvrsn=2](http://www.asam.org/docs/default-source/pressreleases/asam-press-release-nytimes-editorial-marijuana-2014-7-27.pdf?sfvrsn=2)
- Andreasson S, Allebeck P, Engström A, Rydberg U (1987). Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. *Lancet* 1:483–1483.
- Appendino G, Chianese G, Tagliatala-Scafati O (2011). Cannabinoids: Occurrence and medicinal chemistry. *Curr Med Chem* 18(7):1085–1099.
- Asch RH, Smith CG, Siler-Khodr TM, Pauerstein CJ (1981). Effects of delta 9-tetrahydrocannabinol during the follicular phase of the rhesus monkey (Macaca mulatta). *J Clin Endocrinol Metab* 52(1):50–55.
- Balster RL (1991). Drug abuse potential evaluation in animals. *Br J Addict* 86(12):1549–1558.
- Balster RL, Prescott WR (1992). Delta9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. *Neurosci Biobehav Res* 16(1):55–62.
- Balster RL, Bigelow GE (2003). Guidelines and methodological reviews concerning drug abuse liability assessment. *Drug Alcohol Depend* 70:S13–S40.
- Barnett G, Licko V, Thompson T (1985). Behavioral pharmacokinetics of marijuana. *Psychopharmacology* 85(1):51–56.
- Benowitz NL, Jones RT (1975). Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. *Clin Pharmacol Ther* 18(3):287–297.
- Benowitz NL, Jones RT (1981). Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. *J Clin Pharmacol* 21(8–9 Suppl):214S–223S.
- Blanco C, Alderson D, Ogburn E, Grant BF, Nunes EV, Hatzenbuehler ML, Hasin DS (2007). Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991–1992 and 2001–2002. *Drug Alcohol Depend* 90(2–3):252–260.
- Block RI, Farinpour R, Schlechte JA (1991). Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. *Drug Alcohol Depend* 28(2):121–128.
- Block RI, Farinpour R, Braverman K (1992). Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. *Pharmacol Biochem Behav* 43(3):907–917.
- Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL (2002). Dose-related neurocognitive effects of marijuana use. *Neurology* 59:1337–1343.
- Bolla KI, Eldreth DA, Matochik JA, Cadet JL (2005). Neural substrates of faulty decision-making in abstinent marijuana users. *NeuroImage* 26:480–492.
- Bonnet U (2013). Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function. *Pharmacopsychiatry* 46(1):35–36.
- Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P (1993). Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem* 214(1):173–180.
- Braida D, Iosue S, Pegorini S, Sala M (2004). Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. *Eur J Pharmacol* 506(1):63–69.
- Brievogel CS, Childers SR (2000). Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. *J Pharmacol Exp Ther* 295(1):328–336.
- Brown TT, Dobs AS (2002). Endocrine effects of marijuana. *J Clin Pharmacol* 42(11 Suppl):90S–96S.
- Browne RG, Weisman A (1981). Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies. *J Clin Pharmacol* 21(8–9 Suppl):227S–234S.
- Budney AJ, Hughes JR (2006). The cannabis withdrawal syndrome. *Curr Opin Psychiatry* 19(3):233–238.
- Capriotti RM, Foltin RW, Brady JV, Fischman MW (1988). Effects of marijuana on the task-elicited physiological response. *Drug Alcohol Depend* 21(3):183–187.
- Cascini F, Aiello C, Di Tanna G (2012). Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. *Curr Drug Abuse Rev* 5(1):32–40.
- Chait LD, Burke KA (1994). Preference for “high” versus low-potency marijuana. *Pharmacol Biochem Behav* 7:357–364.
- Cheer JF, Kendall DA, Marsden CA (2000). Cannabinoid receptors and reward in the rat: a conditioned place preference study. *Psychopharmacology (Berl)* 151(1):25–30.
- Compton RP, Berning A (2015). Drug and Alcohol Crash Risk. *Traffic Safety Facts Research Note*. DOT HS 812 117. Washington, DC: National Highway Traffic Safety Administration.
- Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS (2004). Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. *JAMA* 291(17):2114–2121.
- Cone EJ, Johnson RE, Moore JD, Roache JD (1986). Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. *Pharmacol Biochem Behav* 24(6):1749–1754.
- Croxford JL, Yamamura T (2005). Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? *J Neuroimmunol* 166(1–2):3–18.
- Daling JR, Doody DR, Sun X, Trabert BL, Weiss NS, Chen C, Biggs ML, Starr JR, Dey SK, Schwartz SM (2009). Association of marijuana use and the incidence of testicular germ cell tumors. *Cancer*. 115(6):1215–1223.
- Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB (1976). Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. *Clin Pharmacol Ther* 19(3):300–309.
- Dax EM, Pilotte NS, Adler WH, Nagel JE, Lange WR (1989). The effects of 9-enetetrahydrocannabinol on hormone release and immune function. *J Steroid Biochem* 34(1–6):263–270.

42. Day NL, Wagener DK, Taylor PM (1985). Measurement of substance use during pregnancy: methodologic issues. *NIDA Res Monogr* 59:36–47.
43. Day NL, Leech SL, Goldschmidt L (2011). The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioning. *Neurotoxicol Teratol* 33(1):129–136.
44. Day NL, Goldschmidt L, Day R, Larkby C, Richardson GA (2015). Prenatal marijuana exposure, age of marijuana initiation, and the development of psychotic symptoms in young adults. *Psychol Med* 45(8):1779–1787.
45. Degenhardt L, Hall W, Lynskey M (2003). Testing hypotheses about the relationship between cannabis use and psychosis. *Drug Alcohol Depend* 71(1):37–48.
46. Degenhardt L, Hall WD, Lynskey M, McGrath J, McLaren J, Calabria B, Whiteford H, Vos T (2009). Should burden of disease estimates include cannabis use as a risk factor for psychosis? *PLoS Medicine* 6(9):e1000133.
47. Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neumark Y, Sampson N, Alonso J, Angermeyer M, Anthony JC, Bruffaerts R, et al (2010). Evaluating the drug use “gateway” theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. *Drug Alcohol Depend* 108(1–2):84–97.
48. De Petrocellis PL, Di Marzo V (2009). An introduction to the endocannabinoid system: from the early to the latest concepts. *Best Pract Res Clin Endocrinol Metab* 23(1):1–15.
49. Department of Health and Human Services [HHS] (2015). Basis for the recommendation for maintaining marijuana in Schedule I of the Controlled Substances Act.
50. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffing G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258(5090):1946–1949.
51. Dewey WL, Martin BR, May EL (1984). Cannabinoid stereoisomers: pharmacological effects. In Smith DF. (Ed.) *CRC Handbook of stereoisomers: drugs in psychopharmacology*, 317–26 (Boca Raton, FL, CRC Press).
52. Drug Enforcement Administration (2015). *Drugs of Abuse*.
53. DSM–5 (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association. Washington, DC: American Psychiatric Publishing.
54. Eisenstein TK, Meissler JJ (2015). Effects of cannabinoids on T-cell function and resistance to infection. *J Neuroimmune Pharmacol* 10(2):204–216.
55. Eldridge JC, Murphy LL, Landfield PW (1991). Cannabinoids and the hippocampal glucocorticoid receptor: recent findings and possible significance. *Steroids* 56(5):226–231.
56. ElSohly MA, Slade D (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. *Life Sci* 78:539–548.
57. Fant RV, Heishman SJ, Bunker EB, Pickworth WB (1998). Acute and residual effects of marijuana in humans. *Pharmacol Biochem Behav* 60(4):777–784.
58. **Federal Register** (1992). “Marijuana Scheduling Petition; Denial of Petition; Remand”—Drug Enforcement Administration, Final Order. *Fed Registr* 57(59):10499–10508.
59. **Federal Register** (1999). “Rescheduling of the Food and Drug Administration Approved Product Containing Synthetic Dronabinol [(–)-delta 9-(trans)-Tetrahydrocannabinol] in Sesame Oil and Encapsulated in Soft Gelatin Capsules From Schedule II to Schedule III; Final Rule.” *Fed Registr* 64(127):35928–35930.
60. **Federal Register** (2001). “Notice of Denial of Petition: Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act.” *Fed Registr* 66(75):20038–20076.
61. Fergusson DM, Horwood LJ, Ridder EM (2005). Tests of causal linkages between cannabis use and psychotic symptoms. *Addiction* 100(3):354–366.
62. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL (2011). Cannabis use before age 15 and subsequent executive functioning. *Br J Psychiatry* 198(6):442–447.
63. Fried PA, Watkinson B, Grant A, Knights RM (1980). Changing patterns of soft drug use prior to and during pregnancy: a prospective study. *Drug Alcohol Depend* 6(5):323–343.
64. Fried PA, Watkinson B (1990). 36- and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes and alcohol. *J Dev Behav Pediatr* 11:49–58.
65. Fried PA, Watkinson B, Gray R (1992). A follow-up study of attentional behavior in 6-year-old children exposed prenatally to marijuana, cigarettes and alcohol. *Neurotoxicol Teratol* 14:299–311.
66. Fried PA, Watkinson B, Gray R (1998). Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marijuana. *Neurotoxicol Teratol* 20(3):293–306.
67. Fried PA (2002). Adolescents prenatally exposed to marijuana: examination of facets of complex behaviors and comparisons with the influence of in utero cigarettes. *J Clin Pharmacol* 42(11 Suppl):97S–102S.
68. Fried PA, Watkinson B, Gray R (2005). Neurocognitive consequences of marijuana—a comparison with pre-drug performance. *Neurotoxicol Teratol* 27(2):231–239.
69. Fung M, Gallagher C, Machtay M (1999). Lung and aero-digestive cancers in young marijuana smokers. *Tumori* 85(2):140–142.
70. Gates P, Jaffe A, Copeland J (2014). Cannabis smoking and respiratory health: consideration of the literature. *Respirology* 19(5):655–662.
71. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R (2002). Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. *J Neurosci* 22(3):1146–1154.
72. Gold LH, Balster RL, Barrett RL, Britt DT, Martin BR (1992). A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. *J Pharmacol Exp Ther* 262(2):479–486.
73. Goldschmidt L, Richardson GA, Willford JA, Day NL (2008). Prenatal marijuana exposure and intelligence test performance at age 6. *J Am Acad Child Adolesc Psychiatry* 47(3):254–263.
74. Goldschmidt L, Richardson GA, Willford JA, Severtson SG, Day NL (2012). School achievement in 14-year-old youths prenatally exposed to marijuana. *Neurotoxicol Teratol* 34(1):161–167.
75. Gong H Jr, Tashkin DP, Simmons MS, Calvaresi B, Shapiro BJ (1984). Acute and subacute bronchial effects of oral cannabinoids. *Clin Pharmacol Ther* 35(1):26–32.
76. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. *Brain Res* 1071(1):10–23.
77. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. *Mol Pharmacol* 57(5):1045–1050.
78. Gonzalez R (2007). Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. *Neuropsychol Rev* 17(3):347–361.
79. Gonzalez S, Cebeira M, Fernandez-Ruiz J (2005). Cannabinoid tolerance and dependence: a review of studies in laboratory animals. *Pharmacol Biochem Behav* 81(2):300–318.
80. Gore RL, Earleywine M (2007). Marijuana’s perceived addictiveness: A survey of clinicians and researchers. In M. Earleywine, (Ed.) *Pot politics: The cost of prohibition*. New York: Oxford University Press.
81. Griffith-Lendering MF, Wigman JT, Prince van Leeuwen A, Huijbregts SC, Huizink AC, Ormel J, Verhulst FC, van Os J, Swaab H, Vollebergh WA (2013). Cannabis use and vulnerability for psychosis in early adolescence—a TRAILS study. *Addiction* 108(4):733–740.
82. Grotenhermen F (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet* 42(4):327–360.
83. Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE (2012). Age of onset of marijuana use and executive function. *Psychol Addict Behav* 26(3):496–506.
84. Hackam DG (2015). Cannabis and stroke: systematic appraisal of case reports. *Stroke* 46(3):852–856.


85. Hall WD, Lynskey M (2005). Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. *Drug Alcohol Rev* 24(1):39–48.
86. Hall W, Degenhardt L (2014). The adverse health effects of chronic cannabis use. *Drug Test Anal* 6(1–2):39–45.
87. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999). Abstinence symptoms following smoked marijuana in humans. *Psychopharmacology (Berl)* 141(4):395–404.
88. Harder S, Rietbrock S (1997). Concentration-effect relationship of delta-9-tetrahydrocannabinol and prediction of psychotropic effects after smoking marijuana. *International Journal of Clinical Pharmacology and Therapeutics*. 35(4):155–159.
89. Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF (2013). DSM-5 criteria for substance use disorders: recommendations and rationale. *Am J Psychiatry* 170(8):834–851.
90. Heishman SJ, Huestis MA, Henningfield JE, Cone EJ (1990). Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. *Pharmacol Biochem Behav* 37(3):561–565.
91. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990). Cannabinoid receptor localization in brain. *Proc Natl Acad Sci* 87:1932–1936.
92. Herkenham M (1992). Cannabinoid receptor localization in brain: relationship to motor and reward systems. *Ann N Y Acad Sci* 654:19–32.
93. Herning RI, Hooker WD, Jones RT (1986). Tetrahydrocannabinol content and differences in marijuana smoking behavior. *Psychopharmacology (Berl)* 90(2):160–162.
94. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB (2012). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. *Mol Psychiatry* 17(6):643–649.
95. Hively RL, Mosher WA, Hoffman FW (1966). Isolation of trans- $\Delta^9$ -tetrahydrocannabinol from marihuana. *J Am Chem Soc* 88:1832–1833.
96. Hollister LE, Gillespie HK (1973). Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration. *Clin Pharmacol Ther* 14(3):353–357.
97. Hollister LE (1986). Health aspects of cannabis. *Pharmacological Rev* 3:1–20.
98. Hollister LE (1988). Cannabis (Literature review). *Acta Psychiatr Scand (Suppl)* 78:108–118.
99. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ (2004). Cannabinoid physiology and pharmacology: 30 years of progress. *Neuropharmacology* 47 Suppl:345–358.
100. Huang YH, Zhang ZF, Tashkin DP, Feng B, Straif K, Hashibe K (2015). An epidemiologic review of marijuana and cancer: an update. *Cancer Epidemiol Biomarkers Prev* 24(1):15–31.
101. Huestis MA, Sampson AH, Holicky BJ, Benningfield JE, Cone EJ (1992a). Characterization of the absorption phase of marijuana smoking. *Clin Pharmacol Ther* 52:31–41.
102. Huestis MA, Benningfield JE, Cone EJ (1992b). Blood Cannabinoids. 1. Absorption of THC and formation of 11-OH-THC and THC COOH during and after smoking marijuana. *J Anal Toxicol* 16(5):276–282.
103. Hunt CA, Jones RT (1980). Tolerance and disposition of tetrahydrocannabinol in man. *J Pharmacol Exp Ther* 215(1):35–44.
104. Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H (2005). Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. *Behav Pharmacol* 16(5–6):487–496.
105. Institute of Medicine (1982). Division of Health Sciences Policy. Marijuana and Health: Report of a Study by a Committee of the Institute of Medicine, Division of Health Sciences Policy. Washington, DC: National Academy Press, 1982.
106. Institute of Medicine (1999). Division of Neuroscience and Behavioral Health. Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press, 1999.
107. Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK (1989). Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. *Eur J Clin Pharmacol* 37(3):273–277.
108. Jones RT, Benowitz NL, Heming RI (1981). Clinical relevance of cannabis tolerance and dependence. *J Clin Pharmacol* 21:143S–152S.
109. Jones RT (2002). Cardiovascular system effects of marijuana. *J Clin Pharmacol* 42(11Suppl):58S–63S.
110. Justinova Z, Tanda G, Redhi GH, Goldberg SR (2003). Self-administration of delta9-tetrahydrocannabinol (THC) by drug naïve squirrel monkeys. *Psychopharmacology (Berl)* 169(2):135–140.
111. Justinova Z, Tanda G, Munzar P, Goldberg SR (2004). The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. *Psychopharmacology (Berl)* 173(1–2):186–194.
112. Kandel D (1975). Stages in adolescent involvement in drug use. *Science* 190:912–914.
113. Kandel DB, Chen K (2000). Types of marijuana users by longitudinal course. *J Stud Alcohol* 61(3):367–378.
114. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974). Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. *Eur J Pharmacol* 28(1):172–177.
115. Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE (1975). Effects of delta9-tetrahydrocannabinol and cannabiniol in man. *Pharmacology* 13(6):502–512.
116. Keen L 2nd, Pereira D, Latimer W (2014). Self-reported lifetime marijuana use and interleukin-6 levels in middle-aged African Americans. *Drug Alcohol Depend* 140:156–160.
117. Kirk JM, de Wit H (1999). Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. *Pharmacol Biochem Behav* 63(1):137–142.
118. Kuepper R, van Os J, Lieb R, Wittchen HU, Henquet C (2011). Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. *Psychol Med* 41(10):2121–2129.
119. Kurtzthaler I, Hummer M, Miller C, Sperner-Unterweger B, Gunther V, Wechdorn H, Battista HJ, Fleischhacker WW (1999). Effects of cannabis use on cognitive functions and driving ability. *J Clin Psychiatry* 60(6):395–399.
120. Lacson JC, Carroll JD, Tuazon E, Castela EJ, Bernstein L, Cortessis VK (2012). Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. *Cancer* 118:5374–5383.
121. Lee MH, Hancox RJ (2011). Effects of smoking cannabis on lung function. *Exp Rev Res Med* 5(4):537–546.
122. Lemberger L, Silberstein SD, Axelrod J, Kopin IJ (1970). Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. *Science* 70:1320–1322.
123. Lemberger L, Weiss JL, Watanabe AM, Galanter IM, Wyatt RJ, Cardon PV (1972a). Delta-9-tetrahydrocannabinol: temporal correlation of the psychological effects and blood levels after various routes of administration. *New Eng J Med* 286(13):685–688.
124. Lemberger L, Crabtree RE, Rowe HM (1972b). 11-Hydroxy- $\Delta^9$ -tetrahydrocannabinol: pharmacology, disposition and metabolism of a major metabolite of marihuana in man. *Science* 77:62–63.
125. Lemberger L, Rubin A (1975). The physiological disposition of marihuana in man. *Life Sci* 17:1637–1642.
126. Li M-C, Brady JE, DiMaggio CJ, Lusardi AR, Tzong, KY, Li G (2012). Marijuana use and motor vehicle crashes. *Epidemiologic Rev* 34:65–72.
127. Liguori A, Gatto CP, Robinson JH (1998). Effects of marijuana on equilibrium, psychomotor performance, and simulated driving. *Behav Pharmacol* 9(7):599–609.
128. Lisdahl KM, Price JS (2012). Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. *J Int Neuropsychol Soc* 18(4):678–688.
129. Lyons MJ, Bar JL, Panizzon MS, Toomey R, Eisen S, Xian H, Tsuang MT (2004). Neuropsychological consequences of regular marijuana use: a twin study. *Psychol Med* 34(7):1239–1250.
130. Mackie K, Lai Y, Westenbroek R, Mitchell R (1995). Cannabinoids activate an inwardly rectifying potassium

- conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. *J Neurosci* 15(10):6552–6561.
131. Maldonado R (2002). Study of cannabinoid dependence in animals. *Pharmacol Ther* 95(2):153–164.
132. Malinowska B, Baranowska-Kuczko M, Schlicker E (2012). Triphasic blood pressure responses to cannabinoids: do we understand the mechanism? *Br J Pharmacol* 165(7):2073–2088.
133. Manrique-Garcia E, Zammit S, Dalman C, Hemmingston T, Andreasson S, Allebeck P (2012). Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. *Psychol Med* 42(6):1321–1328.
134. Maramba I, Lazzeri A, Pacini M, Lovrecic M, Placidi GF, Perugi G (2004). Diagnostic and symptomatological features in chronic psychotic patients according to cannabis use status. *J Psychoactive Drugs* 36(2):235–241.
135. McCart AT (2015). Marijuana and driving in the United States: prevalence, risks, and laws. Presented at the Casualty Actuarial Society Spring Meeting, Colorado Springs, CO. May 19, 2015.
136. McMahon LR, Ginsburg BC, Lamb RJ (2008). Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice. *Psychopharmacology (Berl)* 198(4):487–495.
137. McMahon LR (2009). Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol. *Psychopharmacology (Berl)* 203(2):219–228.
138. Mechoulam R (1973). Cannabinoid chemistry. In Mechoulam, R. (ed.) *Marijuana*, pp.2–88 (New York, NY, Academic Press, Inc.).
139. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE., Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol* 50(1):83–90.
140. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly MA (2010). Potency trends of Δ<sup>9</sup>-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. *J Forensic Sci* 55(5):1209–1217.
141. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci USA* 109(40):E2657–E2664.
142. Mendelson JH, Mello NK (1984). Effects of marijuana on neuroendocrine hormones in human males and females. *NIDA Res Monogr* 44:97–114.
143. Messinis L, Kyprianidou A, Malefaki S, Papanthasopoulos P (2006). Neuropsychological deficits in long-term frequent cannabis users. *Neurology* 66:737–739.
144. Minozzi S, Davoli M, Bargagli AM, Amato L, Vecchi S, Perucci CA (2010). An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. *Drug Alcohol Rev* 29(3):304–317.
145. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE (2001). Triggering myocardial infarction by marijuana. *Circulation* 103:2805–2809.
146. Nace EP, Meyers AL, Rothberg JM, Maleson F (1975). Addicted and nonaddicted drug users. A comparison of drug usage patterns. *Arch Gen Psychiatry* 32(1):77–80.
147. Oviedo A, Glowa J, Herkenham M (1993). Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. *Brain Res* 616:293–302.
148. Pacher P, Batkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev* 58(3):389–462.
149. Panayiotides IM (2015). What is the association between cannabis consumption and cardiovascular complications. *Subst Abuse* 9:1–3.
150. Pelayo-Teran JM, Suarez-Pinilla P, Chadi N, Crespo-Pacorro B (2012). Gene-environment interactions underlying the effect of cannabis in first episode psychosis. *Curr Pharm Des* 18(32):5024–5035.
151. Piomelli D (2005). The endocannabinoid system: a drug discovery perspective. *Curr Opin Investig* 6(7):672–679.
152. Pletcher MJ, Vittinghoff E, Kalhan R, Richman J, Safford M, Sidney S, Lin F, Kertesz S (2012). Association between marijuana exposure and pulmonary function over 20 years. *Journal of the American Medical Association*. 307(2):173–181.
153. Pollastro F, Tagliatalata-Scafati O, Allara M, Munoz E, Di Marzo V, De Petrocellis L, Appendino G (2011). Bioactive prenylogous cannabinoid from fiber hemp (*Cannabis sativa*). *J Nat Prod*. 74(9):2019–2022
154. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2002). Cognitive measures in long-term cannabis users. *J Clin Pharmacol* 42(11 Suppl):41S–47S.
155. Radwan MM, ElSohly MA, Slade D, Ahmed SA, Khan IA, Ross SA (2009). Biologically active cannabinoids from high-potency *Cannabis sativa*. *J Nat Prod* 72(5):906–911.
156. Ramaekers JG, Berghaus G, van Laar M, Drummer OH (2004). Dose related risk of motor vehicle crashes after cannabis use. *Drug and Alcohol Dependence*. 73(2):109–119.
157. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR (2006). High-potency marijuana impairs executive functions and inhibitory motor control. *Neuropsychopharmacology* 31(10):2296–2303.
158. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW., Moeller MR (2009). Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. *J Psychopharmacol* 23(3):266–277.
159. Riggs PK, Vaida F, Rossi SS, Sorkin LS, Gouaux B, Grant I, Ellis RJ (2012). A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. *Brain Res* 1431:46–52.
160. Rodriguez de Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA (1994). Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. *Pharmacol Biochem Behav* 47(1):33–40.
161. Roth MD, Arora A, Barsky SH, Kleerup EC, Simmons M, Tashkin DP (1998). Airway inflammation in young marijuana and tobacco smokers. *American Journal of Respiratory and Crit Care Med* 157:928–937.
162. Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC (2005). Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. *Life Sci* 77(14):1711–1722.
163. Russo E, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, Kirilin KA (2001). Chronic cannabis use in the compassionate investigational new drug program: An examination of benefits and adverse effects of legal clinical cannabis. *J Cannabis Ther* 2:3–57.
164. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H (2005). Cannabinoid receptor as a novel target for the treatment of prostate cancer. *Cancer Res* 65(5):1635–1641.
165. Scherrer JF, Grant JD, Duncan AE, Sartor CE, Haber JR, Jacob T, Bucholz KK (2009). Subjective effects to cannabis are associated with use, abuse and dependence after adjusting for genetic and environmental influences. *Drug Alcohol Depend* 105(1–2):76–82.
166. Schiffman J, Nakamura B, Earleywine MJ, LaBrie J (2005). Symptoms of schizotypy precede cannabis use. *Psychiatry Res* 134(1):37–42.
167. Schimmelmann BG, Conus P, Cotton SM, Kupferschmid S, Karow A, Schultze-Lutter F, McGorry PD, Lambert M (2011). Cannabis use disorder and age at onset of psychosis—a study in first episode patients. *Schizophr Res* 129(1):52–56.
168. Schreiner AM, Dunn ME (2012). Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. *Exp Clin Psychopharmacol* 20(5):420–429.
169. Sexton M, Cudaback E, Abdullah RA, Finnell J, Mischley LJ, Rozga M, Lichtman AH, Stella N (2014). Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. *Inflammopharmacology* 22(5):295–303.
170. Sidney S (2002). Cardiovascular consequences of marijuana use. *J Clin Pharmacol* 42(11Suppl):64S–70S.

171. Solinas M, Panlilio LV, Justinova Z, Yasar S, Goldberg SR (2006). Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. *Nat Protoc* 1(3):1194–1206.
172. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J (2002). Marijuana Treatment Project Research Group. Cognitive functioning of long-term heavy cannabis users seeking treatment. *Journal of the American Medical Association* 287(9):1123–1131.
173. Substance Abuse and Mental Health Services Administration (2013). *Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits*. HHS Publication No. (SMA) 13–4760, DAWN Series D–39. Rockville, MD.
174. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2015a). Results from the 2014 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD.
175. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2015b). *Treatment Episode Data Set (TEDS): 2003–2013. National Admissions to Substance Abuse Treatment Services*. BHSIS Series S–75, HHS Publication No. (SMA) 15–4934. Rockville, MD.
176. Tait RJ, MacKinnon A, Christensen H (2011). Cannabis use and cognitive functioning: 8-year trajectory in a young adult cohort. *Addiction* 106(12):2195–2203.
177. Tanasescu R, Constantinescu CS (2010). Cannabinoids and the immune system: an overview. *Immunobiology* 215(8):588–597.
178. Tanda G, Munzar P, Goldberg SR (2000). Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. *Nat Neurosci* 3(11):1073–1074.
179. Tanda G, Goldberg SR (2003). Cannabinoids: reward, dependence, and underlying neurochemical mechanisms—a review of recent preclinical data. *Psychopharmacology (Berl)* 169(2):115–134.
180. Tashkin DP (2005). Smoked marijuana as a cause of lung injury. *Monaldi Arch Chest Dis* 63(2):93–100.
181. Tashkin DP, Zhang ZF, Greenland S, Cozen W, Mack TM, and Morgenstern H (2006). Marijuana use and lung cancer: results of a case-control study. *American Thoracic Society International Conference*. Abstract A777.
182. Theunissen EL, Kauert GF, Toennes SW., Moeller MR, Sambeth A, Blanchard MM, Ramaekers JG (2012). Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. *Psychopharmacology (Berl)* 220(2):341–350.
183. Trabert B, Sigurdson AJ, Sweeney AM, Strom SS, McGlynn KA (2011). Marijuana use and testicular germ cell tumors. *Cancer* 117(4):848–853.
184. Twitchell W, Brown S, Mackie K (1997). Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. *J Neurophysiol* 78(1):43–50.
185. U.S. Food and Drug Administration (FDA), Center for Drug and Evaluation Research, Controlled Substances Staff (2015). *The Medical Application of Marijuana: A Review of Published Clinical Studies*. March 19, 2015.
186. van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MW, de Haan L (2012). Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. *Curr Pharm Des* 18(32):5036–5044.
187. van Gastel WA, Wigman JT, Monshouwer K, Kahn RS, van Os J, Boks MP, Volleburgh WA (2012). Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey. *Addiction* 107(2):381–387.
188. Van Gundy K, Rebellon CJ (2010). A Life-course Perspective on the “Gateway Hypothesis.” *J Health Soc Behav* 51(3):244–259.
189. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. (2002). Cannabis use and psychosis: a longitudinal population-based study. *Am J Epi* 156(4):319–327.
190. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL (2008). Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. *Drug Alcohol Depend* 94(1–3):191–198.
191. Volkow ND, Baler RD, Compton WM, Weiss SR (2014). Adverse health effects of marijuana use. *N Engl J Med* 370(23):2219–2227.
192. von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen HU (2002). What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. *Drug Alcohol Depend* 68(1):49–64.
193. Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H (2002). Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. *Psychopharmacology (Berl)* 161(4):331–339.
194. Wagner JA, Varga K, Kunos G (1998). Cardiovascular actions of cannabinoids and their generation during shock. *J Mol Med* 76(12):824–836.
195. Wang GS, Roosevelt G, Heard K (2013). Pediatric marijuana exposures in a medical marijuana state. *JAMA Pediatr* 167(7):630–633.
196. Wang GS, Roosevelt G, Le Lait MC, Martinez EM, Bucher-Bartelson B, Bronstein AC, Heard K (2014). Association of unintended pediatric exposures with decriminalization of marijuana in the United States. *Ann Emerg Med* 63(6):684–689.
197. Wang T, Collet JP, Shapiro S, Ware MA (2008). Adverse effects of medical cannabinoids: a systematic review. *CMAJ* 178(13):1669–1678.
198. Wesson DR, Washburn P (1990). Current patterns of drug abuse that involve smoking. *NIDA Res Monogr* 99:5–11.
199. Whitehill JM, Rivara FP, Moreno MA (2014). Marijuana-using drivers, alcohol-using drivers, and their passengers: prevalence and risk factors among underage college students. *JAMA Pediatr* 168(7):618–624.
200. Wiley JL, Barrett RL, Britt DL, Balster RL, Martin BR (1993). Discriminative stimulus effects of delta 9-tetrahydrocannabinol and delta 9–11-tetrahydrocannabinol in rats and rhesus monkeys. *Neuropharmacology* 32(4):359–365.
201. Wiley JL, Huffman JW, Balster RL, Martin BR (1995). Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys. *Drug Alcohol Depend* 40(1):81–86.
202. Wilkinson ST, Radhakrishnan R, D’Souza DC (2014). Impact of cannabis use on the development of psychotic disorders. *Curr Addict Rep* 1(2):115–128.
203. Wilson FA, Stimpson JP, Pagán JA (2014). Fatal crashes from drivers testing positive for drugs in the U.S., 1993–2010. *Public Health Rep* 129(4):342–350.
204. Wu X, French ED (2000). Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. *Neuropharmacology* 39(3):391–398.
205. Zeiger JS, Haberstick BC, Corley RP, Ehringer MA, Crowley TJ, Hewitt JK, Hopfer CJ, Stallings MC, Young SE., Rhee SH (2010). Subjective effects to marijuana associated with marijuana use in community and clinical subjects. *Drug Alcohol Depend* 109(1–3):161–66.
206. Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, Hsu TC, Schantz, SP (1999). Marijuana use and increased risk of squamous cell carcinoma of the head and neck. *Cancer Epidemiol Biomarkers Prev* 8(12):1071–1078.
207. Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, Woll PJ, Orlow I, Cox B on behalf of the Cannabis and Respiratory Disease Research Group of New Zealand, Brhane Y, Liu G, Hung RJ (2015). Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. *Int J Cancer* 136(4):894–903.
208. Zwardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9–THC in normal subject. *Psychopharmacology (Berl)* 76(3):245–250.

[FR Doc. 2016–17954 Filed 8–11–16; 8:45 am]

BILLING CODE 4410–09–P

**Figure 1: Identification of Studies from PubMed Search**

<sup>a</sup> Articles were deemed irrelevant if they examined safety or adverse event related outcomes, including psychoactive effects or other adverse events. <sup>b</sup> Excluded article types included comments, reviews, meta-analyses, and news articles. <sup>c</sup> Randomized Controlled Trials. <sup>d</sup> Cannabinoids administered included synthetic cannabinoids. <sup>e</sup> Rimonabant is a cannabinoid receptor antagonist. <sup>f</sup> An additional 2 studies meeting the inclusion criteria were found through the reference search.

Two qualifying studies, which assessed marijuana for glaucoma, were previously reviewed in the 1999 Institute of Medicine (IOM) report entitled “Marijuana and Medicine: Assessing the Science Base”.<sup>31</sup> We did our own analysis of these two studies and concurred with the conclusions in the IOM report. Thus, a detailed discussion of the two glaucoma studies is not included in the present review. The present review only discusses 9 of the identified 11 studies. For a summary of the study design for all eleven qualifying studies, see Tables 1–5 (located in the Appendix).

Based on the selection criteria for relevant studies described in Section 2.3

<sup>31</sup> In January 1997, the White House Office of National Drug Control Policy (ONDCP) requested that the IOM conduct a review of the scientific evidence to assess the potential health benefits and risks of marijuana and its constituent cannabinoids. Information for this study was gathered through scientific workshops, site visits to cannabis buyers’ clubs and HIV/Acquired Immunodeficiency Syndrome (AIDS) clinics, analysis of the relevant scientific literature, and extensive consultation with biomedical and social scientists. The report was finalized and published in 1999.

(Define Adequate and Well-Controlled Clinical Studies), a number of clinical studies that investigated marijuana, as defined in this review, were excluded from this review. Studies that examined the effects of marijuana in healthy subjects were excluded because they did not test a patient population with a medical condition (Flom et al., 1975; Foltin et al., 1986; Foltin et al., 1988; Hill et al., 1974; Milstein et al., 1974; Milstein et al., 1975; Soderpalm et al., 2001; Wallace et al., 2007; Greenwald and Stitzer, 2000). A 1975 study by Tashkin et al. was excluded because it had a single-blind, rather than double-blind, study design. Two other studies were excluded because the primary outcome measure assessed safety rather than a therapeutic outcome (Greenberg et al., 1994; Abrams et al., 2003).

### 2.5 Review and Analyze Qualifying Clinical Studies

Qualified clinical studies that evaluated marijuana for therapeutic purposes were examined in terms of adequacy of study design including method of drug administration, study

size, and subject inclusion and exclusion criteria. Additionally, the measures and methods of analysis used in the studies to assess the treatment effect were examined.

## 3. Results and Discussion

The eleven qualifying studies in this review assessed a variety of therapeutic indications. In order to better facilitate analysis and discussion of the studies, the following sections group the studies by therapeutic area. Within each section, each individual study is summarized in terms of its design, outcome data and important limitations. This information is also provided in the Appendix in tabular form for each study.

### 3.1 Neuropathic Pain

Five randomized, double-blind, placebo-controlled Phase 2 clinical studies have been conducted to examine the effects of inhaled marijuana smoke on neuropathic pain associated with HIV-sensory neuropathy (Abrams et al., 2007; Ellis et al., 2009) and chronic neuropathic pain from multiple causes

(Wilsey et al., 2008; Ware et al., 2010; Wilsey et al., 2013). Table 1 of the Appendix summarizes these studies.

### 3.1.1 Neuropathic Pain Associated With HIV-Sensory Neuropathy

Two studies examined the effect of marijuana to reduce the pain induced by HIV-sensory neuropathy.

Abrams et al. (2007) conducted the first study entitled, "Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial". The subjects were 50 adult patients with uncontrolled HIV-associated sensory neuropathy, who had at least 6 experiences with smoking marijuana. The subjects were split into two parallel groups of 25 subjects each. More than 68% of subjects were current marijuana users, but all individuals were required to discontinue using marijuana prior to the study. Most subjects were taking medication for pain during the study, with the most common medications being opioids and gabapentin. Upon entry into the study, subjects had an average daily pain score of at least 30 on a 0–100 visual analog scale (VAS).

Subjects were randomized to receive either smoked marijuana (3.56% THC<sup>32</sup>) or smoked placebo cigarettes three times per day for 5 days, using a standardized cued smoking procedure: (1) 5 second inhale, (2) 10 second holding smoke in the lungs, (3) 40 second exhale and breathing normally between puffs. The authors did not specify how many puffs the subjects smoked at each smoking session, but they stated that one cigarette was smoked per smoking session.

Primary outcome measures included daily VAS ratings of chronic pain and the percentage of subjects who reported a result of more than 30% reduction in pain intensity. The ability of smoked marijuana to induce acute analgesia was assessed using both thermal heat model and capsaicin sensitization model, while anti-hyperalgesia was assessed with brush and von Frey hair stimuli. The immediate analgesic effects of smoked marijuana was assessed using a 0–100 point VAS at 40-minute intervals three times before and three times after the first and last smoking sessions, which was done to correspond to the time of peak plasma cannabinoid levels. Notably, not all subjects completed the induced pain portion of the study ( $n = 11$  in marijuana group, 9 in placebo

group) because of their inability to tolerate the stimuli. Throughout the study, subjects also completed the Profile of Mood States (POMS) questionnaire, as well as subjective VAS measures of anxiety, sedation, disorientation, paranoia, confusion, dizziness, and nausea.

As a result, the median daily pain was reduced 34% by smoked marijuana compared to 17% by placebo ( $p = 0.03$ ). Fifty-two percent of subjects who smoked marijuana reported a >30% reduction in pain compared to 24% in the placebo group ( $p = 0.04$ ). Although marijuana reduced experimentally-induced hyperalgesia ( $p \leq 0.05$ ) during the first smoking sessions, marijuana did not alter responses to acutely painful stimuli.

There were no serious AEs and no episodes of hypertension, hypotension, or tachycardia requiring medical intervention. No subjects withdrew from the study for drug related reasons. Subjects in the marijuana group reported higher ratings on the subjective measures of anxiety, sedation, disorientation, confusion, and dizziness compared to the placebo group. There was one case of severe dizziness in a marijuana-treated subject. By the end of the study, subjects treated with marijuana and placebo reported a reduction in total mood disturbance as measured by POMS.

The authors conclude that smoked marijuana effectively reduced chronic neuropathic pain from HIV-associated sensory neuropathy with tolerable side effects. However, limitations of this study include: Maintenance of subjects on other analgesic medication while being tested with marijuana and a lack of information about the number of puffs during each inhalation of smoke. These limitations make it difficult to conclude that marijuana has analgesic properties on its own and that the actual AEs experienced during the study in response to marijuana are tolerable. However, the study produced positive results suggesting that marijuana should be studied further as an adjunct treatment for uncontrolled HIV-associated sensory neuropathy.

Ellis et al. (2009) conducted a more recent study entitled "Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial". The subjects were 28 HIV-positive adult male patients with intractable neuropathic pain that was refractory to the effects of at least two drugs taken for analgesic purposes. Upon entry into the study, subjects had a mean score of >5 on the Pain Intensity subscale of the Descriptor Differential Scale (DDS). Subjects were allowed to

continue taking their current routine of pain medications, which included opioids, non-narcotic analgesics, antidepressants, and anticonvulsants. Previous experience with marijuana was not required for participation in the study, but 27 of 28 subjects (96%) reported previous experience with marijuana. However, of these 27 experienced subjects, 63% ( $n = 18$ ) reported no marijuana use within the past year.

The study procedures compared the effects of the target dose of marijuana and placebo during two treatment periods lasting 5 days, with 2 weeks washout periods. The marijuana strengths available were 1%, 2%, 4%, 6%, or 8% THC concentration by weight. Subjects smoked marijuana or placebo cigarettes four times per day, approximately 90–120 minutes apart, using a standardized cued smoking procedure: (1) 5 second smoke inhalation, (2) 10 second hold of smoke in lungs, (3) 40 second exhale and normal breathing between puffs. The investigators did not provide a description of the number of puffs taken at any smoking session. All subjects practiced the smoking procedures using placebo marijuana prior to test sessions.

On the first day of each test period, dose titration occurred throughout the four smoking sessions scheduled for that day, with a starting strength of 4% THC concentration. Subjects were allowed to titrate to a personalized "target dose", which was defined as the dose that provided the best pain relief without intolerable adverse effects. This dose titration was accomplished by allowing subjects to either increase the dose incrementally (to 6% or 8% THC) to improve analgesia, or to decrease the dose incrementally (to 1% or 2% THC) if AEs were intolerable. For the next 4 days of each test period, the subjects smoked their target dose during each of the four daily smoking sessions. To maintain the blind, placebo marijuana was represented as containing 1%–8% THC, even though it did not contain any cannabinoids.

The primary outcome measure was the change in pain magnitude on the DDS at the end of each test period compared to baseline, with a clinically significant level of analgesia considered to be a reduction in pain of at least 30%. Additional measures included the POMS, the Sickness Impact Profile (SIP), the Brief Symptom Inventory (BSI) and the UKU Side Effect Rating Scale and a subjective highness/sedation VAS.

During the marijuana treatment week, 19 subjects titrated to the 2%–4% THC dose while the 6%–8% dose was

<sup>32</sup> The drug dose is reported as percentage of THC present in the marijuana rather than milligrams of THC present in each cigarette because of the difficulty in determining the amount of THC delivered by inhalation (see discussion in the section entitled "3.7.2 Marijuana Dose Standardization").

preferred by 8 subjects and 1 subject chose the 1% dose. In contrast, during the placebo treatment week, all 28 subjects titrated to the highest possible dose of “8% THC” that contained no actual cannabinoids, suggesting that placebo treatment provided little analgesic relief.

The degree of pain reduction was significantly greater after administration of marijuana compared to placebo (median change of 3.3 points on DDS,  $p = 0.016$ ). The median change from baseline in VAS pain scores was  $-17$  for marijuana treatment compared to  $-4$  for placebo treatment ( $p < 0.001$ ). A larger proportion of subjects who were treated with marijuana (0.46) reported a  $>30\%$  reduction in pain, compared to placebo (0.18). Additionally, the authors report improvements in total mood disturbance, physical disability, and quality of life as measured on POMS, SIP, and BSI scales after both placebo and marijuana treatment (data not provided in paper).

In terms of safety, there were no alterations in HIV disease parameters in response to marijuana or placebo. The authors report that marijuana led to a greater degree of UKU responses as well as AEs such as difficulty in concentration, fatigue, sleepiness or sedation, increased duration of sleep, reduced salivation and thirst compared to placebo (data not provided in paper). Two subjects withdrew from the study because of marijuana-related AEs: one subject developed an intractable smoking-related cough during marijuana administration and the sole marijuana-naïve subject in the study experienced an incident of acute cannabis-induced psychosis.<sup>33</sup>

The authors conclude that smoked marijuana effectively reduced chronic neuropathic pain from HIV-associated sensory neuropathy. The limitations of this study include: a lack of information about the number of puffs during each inhalation of smoke; a lack of information about the specific timing of the subjective assessments and collection of AEs relative to initiation of the smoking sessions; and the inclusion of only one marijuana-naïve subject. These limitations make it difficult to conclude that the actual AEs experienced during the study in

response to marijuana are tolerable. It is especially concerning that the only marijuana-naïve subject left the study because of serious psychiatric responses to marijuana exposure at analgesic doses. However, the study produced positive results suggesting that marijuana should be studied further as an adjunct treatment for uncontrolled HIV-associated sensory neuropathy.

### 3.1.2 Central and Peripheral Neuropathic Pain

Three studies examined the effect of marijuana on chronic neuropathic pain.

Wilsey et al. (2008) examined chronic neuropathic pain from multiple causes in the study entitled, “A Randomized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in Neuropathic Pain”. The subjects were 32 patients with a variety of neuropathic pain conditions, including 22 with complex regional pain syndrome, 6 with spinal cord injury, 4 with multiple sclerosis, 3 with diabetic neuropathy, 2 with ilioinguinal neuralgia, and 1 with lumbosacral plexopathy. All subjects reported a pain intensity of at least 30 on a 0–100 VAS and were allowed to continue taking their regular medications during the study period, which included opioids, antidepressants, anticonvulsants, and NSAIDs. All subjects were required to have experience with marijuana but could not use any cannabinoids for 30 days before study sessions.

The study consisted of three test sessions with an interval of 3–21 days between sessions. Treatment conditions were high-strength marijuana (7% delta-9-THC), low-strength marijuana (3.5% delta-9-THC), and placebo cigarettes, administered through a standardized cued-puff procedure: (1) “light the cigarette” (30 seconds), (2) “get ready” (5 seconds), (3) “inhale” (5 seconds), (4) “hold smoke in lungs” (10 seconds), (5) “exhale,” and (6) wait before repeating the puff cycle (40 seconds). Participants took 2 puffs after baseline measurements, 3 puffs an hour later, and 4 puffs an hour after that, for a cumulative dose of 9 puffs per test session.

Hourly assessment periods were scheduled before and after each set of puffs and for 2 additional hours during the recovery period. Plasma cannabinoids were measured at baseline, 5 minutes after the first puff and again at 3 hours after the last puff cycle.

The primary outcome measure was spontaneous pain relief, as measured by a 0–100 point VAS for current pain. Pain unpleasantness was measured on a 0–100 point VAS, and degree of pain

relief was measured on a 7-point Patient Global Impression of Change (PGIC) scale. Secondary measures included the Neuropathic Pain Scale (NPS), a 0–100 point VAS for allodynia, and changes in thermal pain threshold. Subjective measures were also evaluated with unipolar 0–100 point VAS for any drug effect, good drug effect, bad drug effect, high, drunk, impaired, stoned, like the drug effect, sedated, confused, nauseated, desire more of the drug, anxious, down, hungry, and bipolar 0–100 point VAS for sad/happy, anxious/relaxed, jittery/calm, bad/good, paranoid/self-assured, fearful/unafraid. Neurocognitive assessments measured attention and concentration, learning and memory, and fine motor speed.

Marijuana produced a reduction in pain compared to placebo, as measured by the pain VAS, the PGIC and on pain descriptors in the NPS, including sharp ( $P < .001$ ), burning ( $P < .001$ ), aching ( $P < .001$ ), sensitive ( $P = .03$ ), superficial ( $P < .01$ ) and deep pain ( $P < .001$ ). Notably, there were no additional benefits from the 7% THC strength of marijuana compared to the 3.5% THC strength, seemingly because of cumulative drug effects over time. There were no changes in allodynia or thermal pain responsivity following administration of either dose of marijuana.

Marijuana at both strengths produced increases on measures of any drug effect, good drug effect, high, stoned, impairment, sedation, confusion, and hunger. The 7% THC marijuana increased anxiety scores and bad drug effect (later in session) compared to placebo. Neither strength of marijuana affected the measures of mood. On neurocognitive measures, both the 3.5% THC and 7% THC marijuana produced impairment in learning and memory, while only the 7% THC marijuana impaired attention and psychomotor speed, compared to placebo. There were no adverse cardiovascular side effects and no subjects dropped out because of an adverse event related to marijuana.

The authors conclude that marijuana may be effective at ameliorating neuropathic pain at doses that induce mild cognitive effects, but that smoking is not an optimum route of administration. The limitations of this study include: Inclusion of subjects with many forms of neuropathic pain and maintenance of subjects on other analgesic medication while being tested with marijuana. These limitations make it difficult to conclude that marijuana has analgesic properties on its own and that the actual AEs experienced during the study in response to marijuana are tolerable. The authors compared pain score results by the type of pain

<sup>33</sup> At the time of the study, the following criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR, 2000) were used to diagnose substance-induced psychotic disorders: Prominent hallucinations or delusions; Hallucinations and/or delusions that develop during, or within one month of, intoxication or withdrawal; The disturbance is not better accounted for by a psychotic disorder that is not substance induced. The disturbance does not occur exclusively during the course of a delirium.



condition, with no significant differences found; however, the sample size of this study was small thus a type II error may have been present. Thus, it is difficult to determine if any particular subset of neuropathic pain conditions would benefit specifically from marijuana administration. However, the study produced positive results suggesting that marijuana should be studied further as an adjunct treatment for uncontrolled neuropathic pain.

The second study, conducted by Ware et al. (2010) in Canada is entitled, "Smoked cannabis for chronic neuropathic pain: a randomized controlled trial". The subjects were 21 adult patients with neuropathic pain caused by trauma or surgery compounded with allodynia or hyperalgesia, and a pain intensity score greater than 4 on a 10 point VAS. All subjects maintained their current analgesic medication and they were allowed to use acetaminophen for breakthrough pain. Eighteen subjects had previous experience with marijuana but none of them had used marijuana within a year before the study.

The study design used a four-period crossover design, testing marijuana (2.5%, 6.0% and 9.4% THC) and placebo marijuana. The 2.5% and 6.0% doses of marijuana were included to increase successful blinding. Each period was 14 days in duration, beginning with 5 days on the study drug followed by a 9-day washout period. Doses were delivered as 25 mg of marijuana that was smoked in a single inhalation using a titanium pipe. The first dose of each period was self-administered using a standardized puff procedure: (1) Inhale for 5 seconds, (2) hold the smoke in their lungs for 10 seconds, and (3) exhale. Subsequent doses were self-administered in the same manner for a total of three times daily at home on an outpatient basis for the first five days of each period.

The primary measure was an 11-point pain intensity scale, averaged over the 5 day treatment period, which was administered once daily for present, worst, least and average pain intensity during the previous 24 hours. Secondary measures included an acute pain 0–100 point VAS, pain quality assessed with the McGill Pain Questionnaire, sleep assessed with the Leeds Sleep Evaluation Questionnaire, mood assessed with the POMS, quality of life assessed using the EQ-5D health outcome instrument. Subjective measures included 0–100 point VAS scales for high, relaxed, stressed and happy.

Over the first three hours after smoking marijuana, ratings of pain,

high, relaxation, stress, happiness and heart rate were recorded. During the five days of each study period, participants were contacted daily to administer questionnaires on pain intensity, sleep, medication and AEs. Subjects returned on the fifth day to complete questionnaires on pain quality, mood, quality of life and assessments of potency. At the end of the study, participants completed final adverse event reports and potency assessments.

The average daily pain intensity was significantly lower on 9.4% THC marijuana (5.4) than on placebo marijuana (6.1) ( $p = 0.023$ ). The 9.4% THC strength also produced more drowsiness, better sleep, with less anxiety and depression, compared to placebo (all  $p < 0.05$ ). However, there were no significant differences on POMS scores or on VAS scores for high, happy, relaxed or stressed between THC doses.

The most frequent drug-related adverse events reported in the group receiving 9.4% THC marijuana were headache, dry eyes, burning sensation, dizziness, numbness and cough. Reports of high and euphoria occurred on only three occasions, once in each dose of THC. There were no significant changes in vital signs, heart-rate variability, or renal function. One subject withdrew from the study due to increased pain during administration of 6% THC marijuana.

The authors conclude that smoked marijuana reduces neuropathic pain, improves mood and aids in sleep, but that smoking marijuana is not a preferable route of administration. The limitations of this study include: The lack of information on timing of assessments during the outpatient portion of the study and maintenance of subjects on other analgesic medication while being tested with marijuana. These limitations make it difficult to conclude that marijuana has analgesic properties on its own and that the actual AEs experienced during the study in response to marijuana are tolerable. However, the study produced positive results suggesting that marijuana should be studied further as an adjunct treatment for uncontrolled neuropathic pain.

Wilsey et al. (2013) conducted the most recent study entitled, "Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain". This study is the only one in this review that utilized vaporization as a method of marijuana administration. The subjects were 36 patients with a neuropathic pain disorder (CRPS, thalamic pain, spinal cord injury, peripheral neuropathy, radiculopathy, or nerve

injury) who were maintained on their current medications (opioids, anticonvulsants, antidepressants, and NSAIDs). Although subjects were required to have a history of marijuana use, they refrained from use of cannabinoids for 30 days before study sessions.

Subjects participated in three sessions in which they received 1.29% or 3.53% THC marijuana or placebo marijuana. The marijuana was vaporized using the Volcano vaporizer and a standardized cued-puff procedure: (1) "hold the vaporizer bag with one hand and put the vaporizer mouthpiece in their mouth" (30 seconds), (2) "get ready" (5 seconds), (3) "inhale" (5 seconds), (4) "hold vapor in lungs" (10 seconds), (5) "exhale and wait" before repeating puff cycle (40 seconds). Subjects inhaled 4 puffs at 60 minutes. At 180 minutes, the vaporizer was refilled with marijuana vapor and subjects were allowed to inhale 4 to 8 puffs using the cued procedure. Thus, cumulative dosing allowed for a range of 8 to 12 puffs in total for each session, depending on the subjects desired response and tolerance. The washout time between each session ranged from 3–14 days.

The primary outcome variable was spontaneous pain relief, as assessed using a 0–100 point VAS for current pain. Secondary measures included the Patient Global Impression of Change (PGIC), the Neuropathic Pain Scale (NPS), a 0–100 point VAS for allodynia. Acute pain threshold was measured with a thermal pain model. Subjective measures included 0–100 point unipolar VAS for any drug effect, good drug effect, bad drug effect, high, drunk, impaired, stoned, drug liking, sedated, confused, nauseated, desire more drug, anxious, down and hungry. Bipolar 0–100 point VAS included sad/happy, anxious/relaxed, jittery/calm, bad/good, paranoid/self-assured, and fearful/unafraid.

Neurocognitive assessments assessed attention and concentration, learning and memory, and fine motor speed.

A 30% reduction in pain was achieved in 61% of subjects who received the 3.53% THC marijuana, in 57% of subjects who received the 1.29% THC marijuana and in 26% of subjects who received the placebo marijuana ( $p = 0.002$  for placebo vs. 3.53% THC,  $p = 0.007$  for placebo vs 1.29% THC;  $p \leq 0.05$  1.29% THC vs. 3.53% THC). Both strengths of marijuana significantly decreased pain intensity, unpleasantness, sharpness, and deepness on the NPS, as well as pain ratings on the PGIC, compared to placebo. These effects on pain were maximal with cumulative dosing over

the course of the study session, with maximal effects at 180 minutes. There were no effects of marijuana compared to placebo on measures of allodynia or thermal pain. Subjects correctly identified the study treatment 63% of the time for placebo, 61% of the time for 1.29% THC, and 89% of the time for 3.53% THC.

On subjective measures, marijuana produced dose-dependent increases compared to placebo on ratings for: any drug effect, good drug effect, drug liking, high, stoned, sedated, confused, and hungry. Both strengths of marijuana produced similar increases in drunk or impaired compared to placebo. In contrast, desire for drug was rated as higher for the 1.29% THC marijuana compared to the 3.53% THC marijuana. There were no changes compared to placebo for bad effect, nausea, anxiety, feeling down or any of the bipolar mood assessments. There was dose-dependent impairment on learning and memory from marijuana compared to placebo, but similar effects between the two strengths of marijuana on attention.

The authors conclude that vaporization of relatively low doses of marijuana can produce improvements in analgesia in neuropathic pain patients, especially when patients are allowed to titrate their exposure. However, this individualization of doses may account for the general lack of difference between the two strengths of marijuana. No data were presented regarding the total amount of THC consumed by each subject, so it is difficult to determine a proper dose-response evaluation. Additional limitations of this study are the inclusion of subjects with many forms of neuropathic pain and maintenance of subjects on other analgesic medication while being tested with marijuana. These limitations make it difficult to conclude that marijuana has analgesic properties on its own. It is also difficult to determine if any particular subset of neuropathic pain conditions would benefit specifically from marijuana administration. However, the study produced positive results suggesting that marijuana should be studied further as an adjunct treatment for uncontrolled neuropathic pain.

### 3.2 Appetite Stimulation in HIV

Two randomized, double-blind, placebo-controlled Phase 2 studies examined the effects of smoked marijuana on appetite in HIV-positive subjects (Haney et al., 2005; Haney et al., 2007). Table 2 of the Appendix summarizes both studies.

The first study, conducted by Haney et al. (2005) is entitled, “Dronabinol and marijuana in HIV+ marijuana smokers: Acute effects on caloric intake and mood”. The subjects were 30 HIV-positive patients who were maintained on two antiretroviral medications and either had clinically significant decreases in lean muscle mass<sup>34</sup> (low-BIA group, n = 15) or normal lean muscle mass (normal-BIA group, n = 15). All subjects had a history of smoking marijuana at least twice weekly for 4 weeks prior to entry into the study. On average, individuals had smoked 3 marijuana cigarettes per day, 5–6 times per week for 10–12 years.

Subjects participated in 8 sessions that tested the acute effects of 0, 10, 20, and 30 mg dronabinol oral capsules and marijuana cigarettes with 0%, 1.8%, 2.8%, and 3.9% THC concentration by weight, using a double-dummy design (with only one active drug per session). The doses of dronabinol are higher than those doses typically prescribed for appetite stimulation in order to help preserve the blinding. There was a one-day washout period between test sessions.

Marijuana was administered using a standardized cued procedure: (1) “light the cigarette” (30 seconds), (2) “prepare” (5 seconds), (3) “inhale” (5 seconds), (4) “hold smoke in lungs” (10 seconds), and (5) “exhale.” Each subject smoked three puffs in this manner, with a 40-second interval between each puff.

Caloric intake was used as a surrogate measure for weight gain. Subjects received a box containing a variety of food and beverage items and were told to record consumption of these items following that day’s administration of the test drug. Subjective measures included 0–100 point VAS for feel drug effect, good effect, bad effect, take drug again, drug liking, hungry, full, nauseated, thirsty, desire to eat. Neurocognitive measures and vital signs were monitored.

The low BIA group consumed significantly more calories in the 1.8% and 3.9% THC marijuana conditions ( $p < 0.01$ ) and the 10, 20, and 30 mg dronabinol conditions ( $p < 0.01$ ) compared with the placebo condition. In contrast, in the normal BIA group, neither marijuana nor dronabinol significantly affected caloric intake. This lack of effect may be accountable, however, by the fact that this group consumed approximately 200 calories

more than the low BIA group under baseline conditions.

Ratings of high and good drug effect were increased by all drug treatments in both the low-BIA and normal-BIA groups, except in response to the 10 mg dose of dronabinol. The 3.9% THC marijuana increased ratings of good drug effect, drug liking and desire to smoke again compared with placebo. Ratings of sedation were increased in both groups by 10 and 30 mg dronabinol, and in the normal BIA group by the 2.8% THC marijuana. Ratings of stimulation were increased in the normal BIA group by 2.8% and 3.9% THC marijuana and by 20 mg dronabinol. Increases in ratings of forgetfulness, withdrawn, dreaming, clumsy, heavy limbs, heart pounding, jittery, and decreases in ratings of energetic, social, and talkative were reported in the normal BIA group with 30 mg dronabinol. There were no significant changes in vital signs or performance on neurocognitive measures in response to marijuana. Notably, the time course of subjective effects peaked quickly and declined thereafter for smoked marijuana, while oral dronabinol responses took longer to peak and persisted longer. Additionally, marijuana but not dronabinol produced dry mouth and thirst.

In general, AEs reported in this study were low in both drug conditions for both subject groups. In the low BIA group, nausea was reported by one subject in both the 10 and 20 mg dronabinol conditions, while an uncomfortable level of intoxication was produced by the 30 mg dose in two subjects. There were no AEs reported in this group following marijuana at any dose. In the normal BIA group, the 30 mg dose of dronabinol produced an uncomfortable level of intoxication in three subjects and headache in one subject, while the 3.9% marijuana produced diarrhea in one subject.

The authors conclude that smoked marijuana can acutely increase caloric intake in low BIA subjects without significant cognitive impairment. However, it is possible that the low degree of cognitive impairment reported in this study may reflect the development of tolerance to cannabinoids in this patient population, since all individuals had current histories of chronic marijuana use. Additional limitations in this study include not utilizing actual weight gain as a primary measure. However, the study produced positive results suggesting that marijuana should be studied further as a treatment for appetite stimulation in HIV patients.

<sup>34</sup> Lean muscle mass was assessed using bioelectrical impedance analysis (BIA). The low-BIA group was classified with having <90% BIA, and the normal-BIA group was classified with having >90% BIA.

A second study conducted by Haney et al. (2007) is entitled, "Dronabinol and marijuana in HIV-positive marijuana smokers: Caloric intake, mood, and sleep". The design of this study was nearly identical to the one conducted by this laboratory in 2005 (see above), but there was no stratification of subjects by BIA. The subjects were 10 HIV-positive patients who were maintained on two antiretroviral medications and had a history of smoking marijuana at least twice weekly for 4 weeks prior to entry into the study. On average, individuals had smoked 3 marijuana cigarettes per day, 5 times per week for 19 years.

Subjects participated in 8 sessions that tested the acute effects of 0, 5 and 10 mg dronabinol oral capsules and marijuana cigarettes with 0, 2.0% and 3.9% THC concentration by weight, using a double-dummy design (with 4 sessions involving only one active drug and 4 interspersed placebo sessions). Both drug and placebo sessions lasted for 4 days each, with active drug administration occurring 4 times per day (every 4 hours). Testing occurred in two 16-day inpatient stays. In the intervening outpatient period, subjects were allowed to smoke marijuana prior to re-entry to the study unit for the second inpatient stay.

Marijuana was administered using a standardized cued procedure: (1) "light the cigarette" (30 seconds), (2) "prepare" (5 seconds), (3) "inhale" (5 seconds), (4) "hold smoke in lungs" (10 seconds), and (5) "exhale." Each subject smoked three puffs in this manner, with a 40-second interval between each puff.

Caloric intake was used as a surrogate measure for weight gain, but subjects were also weighed throughout the study (a measure which was not collected in the 2005 study by this group). Subjects received a box containing a variety of food and beverage items and were told to record consumption of these items following that day's administration of the test drug. Subjective measures included 0–100 point VAS for drug effect, good effect, bad effect, take drug again, drug liking, hungry, full, nauseated, thirsty, desire to eat. Neurocognitive measures and vital signs were monitored. Sleep was assessed using both the Nightcap sleep monitoring system and selected VAS measures related to sleep.

Both 5 and 10 mg dronabinol ( $p < 0.008$ ) and 2.0% and 3.9% THC marijuana ( $p < 0.01$ ) dose-dependently increased caloric intake compared with placebo. This increase was generally accomplished through increases in incidents of eating, rather than an increase in the calories consumed in each incident. Subjects also gained

similar amounts of weight after the highest dose of each cannabinoid treatment: 1.2 kg (2.6 lbs) after 4 days of 10 mg dronabinol, and 1.1 kg (2.4 lbs) after 4 days of 3.9% THC marijuana. The 3.9% THC marijuana dose also increased the desire to eat and ratings of hunger.

Ratings of good drug effect, high, drug liking, and desire to smoke again were significantly increased by 10 mg dronabinol and 2.0% and 3.9% THC marijuana doses compared to placebo. Both marijuana doses increased ratings of stimulated, friendly, and self-confident. The 10 mg dose of dronabinol increased ratings of concentration impairment, and the 2.0% THC marijuana dose increased ratings of anxious. Dry mouth was induced by 10 mg dronabinol (10 mg) and 2.0% THC marijuana. There were no changes in neurocognitive performance or objective sleep measures from administration of either cannabinoid. However, 3.9% THC marijuana increased subjective ratings of sleep.

The authors conclude that both dronabinol and smoked marijuana increase caloric intake and produce weight gain in HIV-positive patients. However, it is possible that the low degree of cognitive impairment reported in this study may reflect the development of tolerance to cannabinoids in this subject population, since all individuals had current histories of chronic marijuana use. This study produced positive results suggesting that marijuana should be studied further as a treatment for appetite stimulation in HIV patients.

### 3.3 Spasticity in Multiple Sclerosis

Only one randomized, double-blind, placebo-controlled Phase 2 study examined the effects of smoked marijuana on spasticity in MS.

This study was conducted by Corey-Bloom et al. (2012) and is entitled, "Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial". The subjects were 30 patients with MS-associated spasticity and had moderate increase in tone (score  $\geq 3$  points on the modified Ashworth scale). Participants were allowed to continue other MS medications, with the exception of benzodiazepines. Eighty percent of subjects had a history of marijuana use and 33% had used marijuana within the previous year.

Subjects participated in two 3-day test sessions, with an 11 day washout period. During each test session they smoked a 4.0% THC marijuana cigarette once per day or a placebo cigarette once per day. Smoking occurred through a

standardized cued-puff procedure: (1) Inhalation for 5 seconds, (2) breath-hold and exhalation for 10 seconds, (3) pause between puffs for 45 seconds. Subjects completed an average of four puffs per cigarette.

The primary outcome measure was change in spasticity on the modified Ashworth scale. Additionally, subjects were assessed using a VAS for pain, a timed walk, and cognitive tests (Paced Auditory Serial Addition Test) and AEs.

Treatment with 4.0% THC marijuana reduced subject scores on the modified Ashworth scale by an average of 2.74 points more than placebo ( $p < 0.0001$ ) and reduced VAS pain scores compared to placebo ( $p = 0.008$ ). Scores on the cognitive measure decreased by 8.7 points more than placebo ( $p = 0.003$ ). However, marijuana did not affect scores for the timed walk compared to placebo. Marijuana increased rating of feeling high compared to placebo.

7 subjects did not complete the study due to adverse events (two subjects felt uncomfortably "high", two had dizziness and one had fatigue). Of those 7 subjects who withdrew, 5 had little or no previous experience with marijuana. When the data were re-analyzed to include these drop-out subjects, with the presumption they did not have a positive response to treatment, the effect of marijuana was still significant on spasticity.

The authors conclude that smoked marijuana had usefulness in reducing pain and spasticity associated with MS. It is concerning that marijuana-naïve subjects dropped out of the study because they were unable to tolerate the psychiatric AEs induced by marijuana. The authors suggest that future studies should examine whether different doses can result in similar beneficial effects with less cognitive impact. However, the current study produced positive results suggesting that marijuana should be studied further as an adjunct treatment for spasticity in MS patients.

### 3.4 Asthma

Tashkin et al. (1974) examined bronchodilation in 10 subjects with bronchial asthma in the study entitled, "Acute Effects of Smoked Marijuana and Oral  $\Delta^9$ -Tetrahydrocannabinol on Specific Airway Conductance in Asthmatic Subjects". The study was a double-blind, placebo-controlled, crossover design. All subjects were clinically stable at the time of the study; four subjects were symptom free, and six subjects had chronic symptoms of mild to moderate severity. Subjects were tested with 0.25ml of isoproterenol HCl prior to the study to ensure they responded to bronchodilator

medications. Subjects were not allowed to take bronchodilator medication within 8 hours prior to the study. Previous experience with marijuana was not required for participation in the study, but 7 of the 10 subjects reported previous use of marijuana at a rate of less than 1 marijuana cigarette per month. No subjects reported marijuana use within 7 days of the study.

The study consisted of four test sessions with an interval of at least 48 hours between sessions. On two test sessions subjects smoked 7 mg/kg of body weight of either marijuana, with 2% THC concentration by weight, or placebo marijuana. During the other two test sessions, subjects ingested capsules with either 15 mg of synthetic THC or placebo. Marijuana was administered using a uniform smoking technique: subjects inhaled deeply for 2–4 seconds, held smoke in lungs for 15 seconds, and resumed normal breathing for approximately 5 seconds. The author did not provide a description of the number of puffs taken at any smoking session. The authors state that the smoking procedure was repeated until the cigarette was consumed, which took approximately 10 minutes.

The outcome measure used was specific airway conductance (SGaw), as calculated using measurements of thoracic gas volume (TGV) and airway resistance (Raw) using a variable-pressure body plethysmograph. Additionally, an assessment of degree of intoxication was administered only to those subjects reporting previous marijuana use. This assessment consisted of subjects rating “how ‘high’ they felt” on a scale of 0–7, 7 representing “the ‘highest’ they had ever felt after smoking marijuana”.

Marijuana produced a significant increase of 33–48% in average SGaw compared to both baseline and placebo ( $P < 0.05$ ). This significant increase in SGaw lasted for at least 2 hours after administration. The average TGV significantly decreased by 4–13% compared to baseline and placebo ( $P < 0.05$ ). The author stated that all subjects reported feelings of intoxication after marijuana administration.

The authors conclude that marijuana produced bronchodilation in clinically stable asthmatic subjects with minimal to moderate bronchospasms. Study limitations include: inclusion of subjects with varying severity of asthmatic symptoms, use of SGaw to measure lung responses to marijuana administration, and administration of smoke to asthmatic subjects. Smoke delivers a number of harmful substances and is not an optimal delivery symptom, especially for asthmatic patients. FEV1

via spirometry is the gold standard to assess changes in lung function, pre and post asthma treatment, by pharmacotherapy. SGaw has been shown to be a valid tool in bronchoconstriction lung assessment; however, since the FEV1 method was not utilized, it is unclear whether these results would correlate if the FEV1 method had been employed.

### 3.5 Glaucoma

Two randomized, double-blind, placebo-controlled Phase 2 clinical studies examined smoked marijuana in glaucoma (Crawford and Merritt, 1979; Merritt et al., 1980). In both studies, intraocular pressure (IOP) was significantly reduced 30 minutes after smoking marijuana. Maximal effects occurred 60–90 minutes after smoking, with IOP returning to baseline within 3–4 hours. These two studies were included in the 1999 IOM report on the medical uses of marijuana. Because our independent analysis of these studies concurred with the conclusions from the 1999 IOM report, these studies will not be discussed in further detail in this review. No recent studies have been conducted examining the effect of inhaled marijuana on IOP in glaucoma patients. This lack of recent studies may be attributed to the conclusions made in the 1999 IOM report that while cannabinoids can reduce intraocular pressure (IOP), the therapeutic effects require high doses that produce short-lasting responses, with a high degree of AEs. This high degree of AEs means that the potential harmful effects of chronic marijuana smoking may outweigh its modest benefits in the treatment of glaucoma.

### 3.6 Conclusions

Of the eleven randomized, double-blind, placebo-controlled Phase 2 clinical studies that met the criteria for review (see Sections 2.2 and 2.3), ten studies administered marijuana through smoking, while one study utilized marijuana vaporization. In these eleven studies, there were five different therapeutic indications: five examined chronic neuropathic pain, two examined appetite stimulation in HIV patients, two examined glaucoma, one examined spasticity in MS, and one examined asthma.

There are limited conclusions that can be drawn from the data in these published studies evaluating marijuana for the treatment of different therapeutic indications. The analysis relied on published studies, thus information available about protocols, procedures, and results were limited to documents published and widely available in the

public domain. The published studies on medical marijuana are effectively proof-of-concept studies. Proof-of-concept studies provide preliminary evidence on a proposed hypothesis regarding a drug’s effect. For drugs under development, the effect often relates to a short-term clinical outcome being investigated. Proof-of-concept studies serve as the link between preclinical studies and dose ranging clinical studies. Therefore, proof-of-concept studies are not sufficient to demonstrate efficacy of a drug because they provide only preliminary information about the effects of a drug. Although these studies do not provide evidence that marijuana is effective in treating a specific, recognized disorder, these studies do support future larger well-controlled studies to assess the safety and efficacy of marijuana for a specific medical indication. Overall, the conclusions below are preliminary, based on very limited evidence.

#### 3.6.1 Conclusions for Chronic Neuropathic Pain

In subjects with chronic neuropathic pain who are refractory to other pain treatments, five proof-of-concept studies produced positive results regarding the use of smoked marijuana for analgesia. However, the subjects in these studies continued to use their current analgesic drug regime, and thus no conclusions can be made regarding the potential efficacy of marijuana for neuropathic pain in patients not taking other analgesic drugs. Subjects also had numerous forms of neuropathic pain, making it difficult to identify whether a specific set of symptoms might be more responsive to the effects of marijuana. It is especially concerning that some marijuana-naïve subjects had intolerable psychiatric responses to marijuana exposure at analgesic doses.

#### 3.6.2 Conclusions for Appetite Stimulation in HIV

In subjects who were HIV-positive, two proof-of-concept studies produced positive results with the use of both dronabinol and smoked marijuana to increase caloric intake and produce weight gain in HIV-positive patients. However, the amount of THC in the marijuana tested in these studies is four times greater than the dose of dronabinol typically tested for appetite stimulation (10 mg vs. 2.5 mg; Haney et al., 2005). Thus, it is possible that the low degree of AEs reported in this study may reflect the development of tolerance to cannabinoids in this patient population, since all individuals had current histories of chronic marijuana use. Thus, individuals with little prior

exposure to marijuana may not respond similarly and may not be able to tolerate sufficient marijuana to produce appetite stimulation.

### 3.6.3 Conclusions for Spasticity in MS

In subjects with MS, a proof of concept study produced positive results using smoked marijuana as a treatment for pain and symptoms associated with treatment-resistant spasticity. The subjects in this study continued to take their current medication regiment, and thus no conclusions can be made regarding the potential efficacy of marijuana when taken on its own. It is also concerning that marijuana-naïve subjects dropped out of the study because they were unable to tolerate the psychiatric AEs induced by marijuana. The authors suggest that future studies should examine whether different doses can result in similar beneficial effects with less cognitive impact.

### 3.6.4 Conclusions for Asthma

In subjects with clinically stable asthma, a proof of concept study produced positive results of smoked marijuana producing bronchodilation. However, in this study marijuana was administered at rest and not while experiencing bronchospasms. Additionally, the administration of marijuana through smoking introduces harmful and irritating substances to the subject, which is undesirable especially in asthmatic patients. Thus the results suggest marijuana may have bronchodilator effects, but it may also have undesirable adverse effects in subjects with asthma.

### 3.6.5 Conclusions for Glaucoma

As noted in Sections 3.5, the two studies that evaluated smoked marijuana for glaucoma were conducted decades ago, and they have been thoroughly evaluated in the 1999 IOM report. The 1999 IOM report concludes that while the studies with marijuana showed positive results for reduction in IOP, the effect is short-lasting, requires a high dose, and is associated with many AEs. Thus, the potential harmful effects may outweigh any modest benefit of marijuana for this condition. We agree with the conclusions drawn in the 1999 IOM report.

## 3.7 Design Challenges for Future Studies

The positive results reported by the studies discussed in this review support the conduct of more rigorous studies in the future. This section discusses methodological challenges that have occurred in clinical studies with smoked marijuana. These design issues

should be addressed when larger-scale clinical studies are conducted to ensure that valid scientific data are generated in studies evaluating marijuana's safety and efficacy for a particular therapeutic use.

### 3.7.1 Sample Size

The ability for results from a clinical study to be generalized to a broader population is reliant on having a sufficiently large study sample size. However, as noted above, all of the 11 studies reviewed in this document were early Phase 2 proof of concept studies for efficacy and safety. Thus, the sample sizes used in these studies were inherently small, ranging from 10 subjects per treatment group (Tashkin et al., 1974; Haney et al., 2007) to 25 subjects per treatment group (Abrams et al., 2007). These sample sizes are statistically inadequate to support a showing of safety or efficacy. FDA's recommendations about sample sizes for clinical trials can be found in the *Guidance for Industry: E9 Statistical Principles for Clinical Trials (1998)*.<sup>35</sup> For example, "the number of subjects in a clinical trial should always be large enough to provide a reliable answer to the questions addressed. This number is usually determined by the primary objective of the trial. The method by which the sample size is calculated should be given in the protocol, together with the estimates of any quantities used in the calculations (such as variances, mean values, response rates, event rates, difference to be detected)." (pg. 21). Other clinical FDA *Guidance for Industry*<sup>36</sup> may also contain recommendations regarding the appropriate number of subjects that should be investigated for a specific medical indication.

### 3.7.2 Marijuana Dose Standardization

Dose standardization is critical for any clinical study in order to ensure that each subject receives a consistent exposure to the test drug. The *Guidance for Industry: Botanical Drug Products (2004)*<sup>37</sup> provides specific information on the development of botanical drug products. Specifically, this guidance

<sup>35</sup> The *Guidance for Industry: E9 Statistical Principles for Clinical Trials* can be found at: [www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073137.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073137.pdf).

<sup>36</sup> Other *Guidances for Industry* can be found at: [www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064981.htm](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064981.htm).

<sup>37</sup> The *Guidance for Industry: Botanical Drug Products* can be found at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070491.pdf>.

includes information about the need for well-characterized and consistent chemistry for the botanical plant product and for consistent and reliable dosing. Specifically for marijuana studies, dose standardization is important because if marijuana leads to plasma levels of cannabinoids that are significantly different between subjects, this variation may lead to differences in therapeutic responsiveness or in the prevalence of psychiatric AEs.

In most marijuana studies discussed in this review, investigators use a standardized cued smoking procedure. In this procedure, a subject is instructed to inhale marijuana smoke for 5 seconds, hold the smoke in the lungs for 10 seconds, exhale and breathe normally for 40 seconds. This process is repeated to obtain the desired dose of the drug. However, this procedure may not lead to equivalent exposure to marijuana and its constituent cannabinoids, based on several factors:

- Intentional or unintentional differences in the depth of inhalation may change the amount of smoke in the subject's lungs.
- Smoking results in loss from side stream smoke, such that the entire dose is not delivered to the subject.
- There may be differences in THC concentration along the length of a marijuana cigarette. According to Tashkin et al. (1991), the area of the cigarette closest to the mouth tends to accumulate a higher concentration of THC, but this section of the cigarette is not smoked during a study.

For example, Wilsey et al. (2008) used this standardized smoking procedure. The reported mean (range) of marijuana cigarettes consumed was 550 mg (200–830mg) for the low strength marijuana (3.5% THC) and 490 mg (270–870mg) for the high strength marijuana (7% THC). This wide range of amounts of marijuana cigarette smoked by the individual subjects, even with standardized smoking procedure and controlled number of puffs, supports the issues with delivering consistent doses with smoke marijuana.

In other marijuana studies that do not use a cued smoking procedure, subjects are simply told to smoke the marijuana cigarette over a specific amount of time (usually 10 minutes) without further instruction (Crawford and Merritt, 1979; Merritt et al., 1980; Ellis et al., 2009). The use of a nonstandardized procedure may lead to non-equivalent exposures to marijuana and its constituent cannabinoids between subjects because of additional factors that are not listed above, such as:

- Differences in absorption and drug response if subjects (especially

marijuana-naïve ones) are not instructed to hold marijuana smoke in their lungs for a certain period of time.

- Prolonged periods between puffs may increase loss to side stream smoke.
- Subjects may attempt to smoke the marijuana cigarette in the way they would smoke a tobacco cigarette, which relies primarily on short, shallow puffs.

In both standardized and non-standardized smoking procedures, subjects may seek to control the dose of THC through self-titration (Crawford and Merritt, 1979; Merritt et al., 1980; Tashkin et al., 1974; Abrams et al., 2007; Ellis et al., 2009). Self-titration involves an individual moderating the amount of marijuana smoke inhaled over time in order to obtain a preferred level of psychoactive or clinical response. The ability of an individual to self-titrate by smoking is one reason given by advocates of “medical marijuana” in support of smoking of marijuana rather than through its ingestion via edibles. However, for research purposes, self-titration interferes with the ability to maintain consistent dosing levels between subjects, and thus, valid comparisons between study groups.

All of these factors can make the exact dose of cannabinoids received by a subject in a marijuana study difficult to determine with accuracy. Testing whether plasma levels of THC or other cannabinoids are similar between subjects following the smoking procedure would establish whether the procedure is producing appropriate results. Additionally, studies could be conducted to determine if vaporization can be used to deliver consistent doses of cannabinoids from marijuana plant material. Specifically, vaporization devices that involve the collection of vapors in an enclosed bag or chamber may help with delivery of consistent doses of marijuana. Thus, more information could be collected on whether vaporization is comparable to or different than smoking in terms of producing similar plasma levels of THC in subjects using identical marijuana plant material.

### 3.7.3 Acute vs. Chronic Therapeutic Marijuana Use

The studies that were reviewed administered the drug for short durations lasting no longer than 5 days (Abrams et al., 2007; Ellis et al., 2009; Ware et al., 2010). Thus all studies examined the short-term effect of marijuana administration for therapeutic purposes. However, many of the medical conditions that have been studied are persistent or expected to last the rest of a patient’s life. Therefore, data on chronic exposure to smoked

marijuana in clinical studies is needed. In this way, more information will be available regarding whether tolerance, physical dependence, or specific adverse events develop over the course of time with continuing use of therapeutic marijuana.

### 3.7.4 Smoking as a Route of Administration

As has been pointed out by the IOM and other groups, smoking is not an optimum route of administration for marijuana-derived therapeutic drug products, primarily because introducing the smoke from a burnt botanical substance into the lungs of individuals with a disease state is not recommended when their bodies may be physically compromised. The 1999 IOM report on medicinal uses of marijuana noted that alternative delivery methods offering the same ability of dose titration as smoking marijuana will be beneficial and may limit some of the possible long-term health consequences of smoking marijuana. The primary alternative to smoked marijuana is vaporization, which can reduce exposure to combusted plant material containing cannabinoids. The only study to use vaporization as the delivery method was Wilsey et al. (2013). The results from Wilsey et al. (2013) showed a similar effect of decreased pain as seen in the other studies using smoking as the delivery method (Ware et al., 2010; Wilsey et al., 2008). This similar effect of decrease pain supports vaporization as a possibly viable route to administer marijuana in research, while potentially limiting the risks associated with smoking.

### 3.7.5 Difficulty in Blinding of Drug Conditions

An adequate and well-controlled clinical study involves double-blinding, where both the subjects and the investigators are unable to tell the difference between the test treatments (typically consisting of at least a test drug and placebo) when they are administered. All of the studies reviewed in this document administered study treatments under double-blind conditions and thus were considered to have an appropriate study design.

However, even under the most rigorous experimental conditions, blinding can be difficult in studies with smoked marijuana because the rapid onset of psychoactive effects readily distinguishes active from placebo marijuana. The presence of psychoactive effects also occurs with other drugs. However, most other drugs have a similar psychoactive effect with substances with similar mechanisms of

actions. These substances can be used as positive controls to help maintain blinding to the active drug being tested. Marijuana on the other hand, has a unique set of psychoactive effects which makes the use of appropriate positive controls difficult (Barrett et al., 1995). However, two studies did use Dronabinol as a positive control drug to help maintain blinding (Haney et al., 2005; Haney et al., 2007).

When blinding is done using only placebo marijuana, the ability to distinguish active from placebo marijuana may lead to expectation bias and an alteration in perceived responsiveness to the therapeutic outcome measures. With marijuana-experienced subjects, for example, there may be an early recognition of the more subtle cannabinoid effects that can serve as a harbinger of stronger effects, which is less likely to occur with marijuana-naïve subjects. To reduce this possibility, investigators have tested doses of marijuana other than the one they were interested in experimentally to maintain the blind (Ware et al., 2010).

Blinding can also be compromised by differences in the appearance of marijuana plant material based on THC concentration. Marijuana with higher concentrations of THC tends to be heavier and seemingly darker, with more “tar-like” substance. Subjects who have experience with marijuana have reported being able to identify marijuana from placebo cigarettes by sight alone when the plant material in a cigarette was visible (Tashkin et al., 1974; Ware et al., 2010). Thus, to maintain a double-blind design, many studies obscure the appearance of plant material by closing both ends of the marijuana cigarette and placing it in an opaque plastic tube.

While none of these methods to secure blinding may be completely effective, it is important to reduce bias as much as possible to produce consistent results between subjects under the same experimental conditions.

### 3.7.6 Prior Marijuana Experience

Marijuana use histories in test subjects may influence outcomes, related to both therapeutic responsiveness and psychiatric AEs. Marijuana-naïve subjects may also experience a marijuana drug product as so aversive that they would not want to use the drug product. Thus, subjects’ prior experience with marijuana may affect the conduct and results of studies.

Most of the studies reviewed in this document required that subjects have a history of marijuana use (see tables in Appendix that describe specific

requirements for each study). However, in studies published in the scientific literature, the full inclusion criteria with regard to specific amount of experience with marijuana may not be provided. For those studies that do provide inclusion criteria, acceptable experience with marijuana can range from once in a lifetime to use multiple times a day.

The varying histories of use might affect everything from scores on adverse event measures, safety measures, or efficacy measures. Additionally, varying amounts of experience can impact cognitive effect measures assessed during acute administration studies. For instance, Schreiner and Dunn (2012) contend cognitive deficits in heavy marijuana users continue for approximately 28 days after cessation of smoking. Studies requiring less than a month of abstinence prior to the study may still see residual effects of heavy use at baseline and after placebo marijuana administration, thus showing no significant effects on cognitive measures. However, these same measurements in occasional or naïve marijuana users may demonstrate a significant effect after acute marijuana administration. Therefore, the amount of experience and the duration of abstinence of marijuana use are important to keep in mind when analyzing results for cognitive and other adverse event measures. Lastly, a study population with previous experience with marijuana may underreport the incidence and severity of adverse events. Because most studies used subjects with prior marijuana experience, we are limited in our ability to generalize the results, especially for safety measures, to marijuana naïve populations.

Five of 11 studies reviewed in this document included both marijuana-naïve and marijuana-experienced subjects (Corey-Bloom et al., 2012; Ellis et al., 2009; Ware et al., 2010; Merritt et al., 1980; Tashkin et al., 1974). Since the number of marijuana-naïve subjects in these studies was low, it was not possible to conduct a separate analysis compared to experienced users. However, systematically evaluating the effect of marijuana experience on study outcomes is important, since many patients who might use a marijuana product for a therapeutic use will be marijuana-naïve.

Research shows that marijuana-experienced subjects have a higher ability to tolerate stronger doses of oral dronabinol than marijuana-naïve subjects (Haney et al., 2005). Possibly, this increased tolerance is also the case when subjects smoke or vaporize marijuana. Thus, studies could be

conducted that investigate the role of marijuana experience in determining tolerability of and responses to a variety of THC concentrations in marijuana.

#### 3.7.7 Inclusion and Exclusion Criteria

For safety reasons, all clinical studies have inclusion and exclusion criteria that restrict the participation of individuals with certain medical conditions. For studies that test marijuana, these criteria may be based on risks associated with exposure to smoked material and the effects of THC. Thus, most studies investigating marijuana require that subjects qualify for the study based on restrictive symptom criteria such that individuals do not have other symptoms that may be known to interact poorly with cannabinoids.

Similarly, clinical studies with marijuana typically exclude individuals with cardiac or pulmonary problems, as well as psychiatric disorders. These exclusion criteria are based on the well-known effects of marijuana smoke to produce increases in heart rate and blood pressure, lung irritation, and the exacerbation of psychiatric disturbances in vulnerable individuals. Although these criteria are medically reasonable for research protocols, it is likely that future marijuana products will be used in patients who have cardiac, pulmonary or psychiatric conditions. Thus, individuals with these conditions should be evaluated, whenever possible.

Additionally, all studies reviewed in this document allowed the subjects to continue taking their current regimen of medications. Thus all results evaluated marijuana as an adjunct treatment for each therapeutic indication.

#### 3.7.8 Number of Female Subjects

A common problem in clinical research is the limited number of females who participate in the studies. This problem is present in the 11 studies reviewed in this document, in which one study did not include any female subjects (Ellis et al., 2009), and three studies had a low percentage of female subjects (Abrams et al., 2007; Haney et al., 2005; Haney et al., 2007). However, each of these four studies investigated an HIV-positive patient population, where there may have been a larger male population pool from which to recruit compared to females.

Since there is some evidence that the density of CB1 receptors in the brain may vary between males and females (Crane et al., 2012), there may be differing therapeutic or subjective responsiveness to marijuana. Studies using a study population that is equal parts male and female may show whether and

how the effects of marijuana differ between male and female subjects.

#### 4. References

1999. *Marijuana and Medicine: Assessing the Science Base*. Washington, DC: National Academy Press.
- Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, and Schambelan M. 2003. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. *Annals of Internal Medicine* 139 (4): 258–266.
- Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, and Petersen KL. 2007. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. *Neurology* 68 (7): 515–521.
- Appendino G, Chianese G, Tagliatalata-Scafati O. 2011. Cannabinoids: occurrence and medicinal chemistry. *Curr Med Chem*. 18(7):1085–99.
- Barrett RL, Wiley JL, Balster RL, and Martin BR. 1995. Pharmacological specificity of  $\Delta^9$ -tetrahydrocannabinol discrimination in rats. *Psychopharmacology* 118(4): 419–424.
- Chait LD, and Pierrri J. 1989. Some physical characteristics of NIDA marijuana cigarettes. *Addictive Behaviors* 14 (1): 61–67.
- Chang AE, Shiling DJ, Stillman RC, Godlberg NH, Seipp CA, Barofsky I, Simon RM, and Rosenberg SA. 1979. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. *Annals of Internal Medicine* 91: 819–824.
- Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, and Gouaux B. 2012. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *Canadian Medical Association Journal* 184 (10): 1143–1150.
- Crane NA, Schuster RM, Fusar-Poli P, and Gonzalez R. 2012. Effects of Cannabis on Neurocognitive Functioning: Recent Advances, Neurodevelopmental Influences, and Sex Differences. *Neuropsychology Review*.
- Crawford WJ, and Merritt JC. 1979. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. *International Journal of Clinical Pharmacology and Biopharmacy* 17 (5): 191–196.
- Ellis RJ, Toperoff W, Vaida F, Van Den Brande G, Gonzales J, Gouaux B, Bentley H, and Atkinson JH. 2009. Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. *Neuropsychopharmacology* 34 (3): 672–680.
- Flom MC, Adams AJ, and Jones RT. 1975. Marijuana smoking and reduced pressure in human eyes: drug action or epiphenomenon? *Investigative Ophthalmology* 14(1): 52–55.
- Foltin RW, Brady JV, and Fischamn MW. 1986. Behavioral analysis of marijuana

- effects on food intake in humans. *Pharmacology Biochemistry and Behavior* 25: 577–582.
- Foltin RW, Fischman MW, and Byrne MF. 1988. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. *Appetite* 11: 1–14.
- Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, and Domino EF. 1994. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. *Clinical Pharmacology and Therapeutics* 55 (3): 324–328.
- Greenwald MK and Stitzer ML. 2000. Antinociceptive, subjective, and behavioral effects of smoked marijuana in humans. *Drug and Alcohol Dependence* 59: 261–275.
- Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, and Foltin RW. 2007. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. *Journal of Acquired Immune Deficiency Syndromes* (1999) 45 (5): 545–554.
- Haney M, Rabkin J, Gunderson E, and Foltin RW. 2005. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. *Psychopharmacology* 181 (1): 170–178.
- Hill SY, Schwin R, Goodwin DW, and Powell BJ. 1974. Marijuana and pain. *Journal of Pharmacology and Experimental Therapeutics* 188(2): 415–418.
- Jampel H. 2010. American glaucoma society position statement: marijuana and the treatment of glaucoma. *Journal of Glaucoma* 19 (2): 75–76.
- Merritt JC, Crawford WJ, Alexander PC, Anduze AL, and Gelbart SS. 1980. Effect of marijuana on intraocular and blood pressure in glaucoma. *Ophthalmology* 87 (3): 222–228.
- Milstein SL, MacCannell KL, Karr GW, and Clark S. 1974. Marijuana produced changes in cutaneous sensitivity and affect: users and non-users. *Pharmacology Biochemistry and Behavior* 2:367–374.
- Milstein SL, MacCannell K, Karr G, and Clark S. 1975. Marijuana-produced changes in pain tolerance: Experiences and non-experienced subjects. *Int. Pharmacopsychiat* 10: 177–182.
- Naftali T, Schleider LB, Dotan I, Lansky EP, Benjaminov FS, and Konikoff FM. 2013. Cannabis induces a clinical response in patients with Crohn's disease: A prospective placebo-controlled study. *Clinical Gastroenterology and Hepatology* 11: 1276–1280.
- Russo E, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, and Kirlin KA. 2002. Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis. *Journal of Cannabis Therapeutics* 2 (1): 3–57.
- Soderpalm AHV, Schuster A, and de Wit H. 2001. Antiemetic efficacy of smoked marijuana subjective and behavioral effects on nausea induced by syrup of ipecac. *Pharmacology Biochemistry and Behavior* 69: 343–350.
- Tashkin DP, Gliederer F, Rose J, Chang P, Hui KK, Yu JL, and Wu TC. 1991. Tar, CO and delta 9THC delivery from the 1st and 2nd halves of a marijuana cigarette. *Pharmacology Biochemistry and Behavior* 40 (3): 657–661.
- Tashkin DP, Shapiro BJ, Lee YE, Harper CE. 1975. Effects of smoked marijuana in experimentally induced asthma. *American Review of Respiratory Disease* 112: 377–386.
- Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, and Abramson I. 2007. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. *Anesthesiology* 107 (5): 785–796.
- Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, and Collet JP. 2010. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *Canadian Medical Association Journal* 182 (14): E694–E701.
- Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, and Fishman S. 2008. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *J. Pain* 9 (6): 506–521.
- Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, and Donaghe H. 2013. Low-dose vaporized cannabis significantly improves neuropathic pain. *J. Pain* 14(2):136–48.



## Appendix (Tables)

Table 1: Randomized, controlled, double-blind trials examining smoked marijuana in treatment of neuropathic pain

Author & Date <i>Indication</i>	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type <i>Duration</i>	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
Abrams et al. (2007)  <i>HIV-Sensory Neuropathy; Neuropathic Pain</i>	Marijuana Group: 25/27 22 males 5 females  Placebo Group: 25/28 26 males 2 females  <u>Inclusion Criteria:</u> -documented HIV -documented HIV-SN -pain score $\geq 30$ mm VAS -prior marijuana use of six or more times in lifetime  <u>Previous Marijuana Experience:</u> -marijuana group: 21 current users -placebo group: 19 current users  <u>Exclusion Criteria:</u> -substance abuse (including tobacco) -family history of neuropathy due to causes not HIV related -use of isoniazid,	NIDA marijuana, smoked 0%, 3.65% THC  <u>Smoking Procedure:</u> -signal light cued smoking of marijuana cigarette with each puff consisting of: 1) 5s inhale smoke, 2) 10s hold smoke in lungs 3) 40s exhale and breath normally 4) repeat procedure for desired number of puffs # of puffs not specified, only specified that subjects smoked the entire marijuana/placebo cigarette  On 1 <sup>st</sup> and last day of intervention period BID. For all other days TID	Parallel Group  <i>5-day treatment period</i>	VAS daily pain score	-52% of the marijuana group showed >30% decrease in pain score compared to 24% of placebo group. -Marijuana group had significantly greater reduction in daily pain score than placebo group.  -NNT=3.6	-Rating for adverse events of anxiety, sedation, disorientation, confusion, and dizziness were significantly higher in the marijuana group compared to placebo group. -Marijuana and placebo groups showed a reduction in total mood disturbance on POMS.  <u>AEs:</u> -1 grade 3 dizziness in marijuana group -2 grade 3 anxiety, 1 in each group.

Author & Date <i>Indication</i>	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type <i>Duration</i>	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
	dapsone, or metronidazole within 8 weeks of enrollment					
Ellis et al. (2009)  <i>HIV Sensory Neuropathy; Neuropathic Pain</i>	28/34 28 males  <u>Inclusion Criteria:</u> -documented HIV -documented neuropathic pain refractory to $\geq 2$ analgesics -pain score $\geq 5$ on pain intensity subscale of DDS  <u>Previous Marijuana Experience:</u> -27 subjects had previous experience -63% of subjects had no exposure for >1 year before study  <u>Exclusion Criteria:</u> -current DSM-IV substance abuse disorder -lifetime history of dependence on marijuana -previous psychosis with or intolerance to cannabinoids -concurrent use of approved cannabinoid medications -positive UDS for	NIDA marijuana, smoked 0%, 1%, 2%, 4%, 6%, 8% THC  <u>Smoking Procedures:</u> - Verbally cued smoking of marijuana cigarette with each puff consisting of: 1) 5s inhale smoke, 2) 10s hold smoke in lungs 3) 40s exhale and breath normally 4) repeat procedure for desired number of puffs -unknown number of puffs  QID	Crossover  Dose- titration (on 1 <sup>st</sup> day)  <i>2, 5-day treatment phase, with 2-week washout period</i>	Pain magnitud e on DDS	-Pain reduction was significantly greater after marijuana compared to placebo.  -NNT=3.5	-Mood disturbance, quality of life, and psychical disability improved for both marijuana and placebo. -Moderate to severe adverse events were more common with marijuana than placebo. -HIV disease parameters did not differ for marijuana or placebo. -Adverse events included: concentration difficulties, fatigue, sleepiness or sedation, increased duration of sleep, reduced salivation, and thirst. These adverse events were more frequent in marijuana compared to placebo.  <u>Withdrawals for drug related reasons:</u> -1 cannabis-naïve subject had acute cannabis-induced psychosis -1 subjects developed an intractable smoking-related cough during marijuana administration

Author & Date <i>Indication</i>	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type <i>Duration</i>	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
	cannabinoids during wash-in week -serious medical conditions that affect safety -alcohol or drug dependence within 12 months of study					
Wilsey et al. (2008)  <i>Neuropathic pain; Various Causes</i>	32/38 20 males 18 females  <u>Inclusion Criteria:</u> -CRPS type I, spinal cord injury, peripheral neuropathy, or nerve damage -previous marijuana use  <u>Previous Marijuana Experience:</u> -median (range) time from previous exposure: 1.7 years (31 days to 30 years) -median (range) exposure duration: 2 years (1 day to 22 years).  <u>Exclusion Criteria:</u> -no marijuana or cannabinoid medication use for 30 days prior to study; confirmed by UDS	NIDA marijuana, smoked 0%, 3.55%, 7% THC  <u>Smoking Procedure:</u> Verbally cued smoking of marijuana cigarette with each puff consisting of: 1) 5s inhale smoke, 2) 10s hold smoke in lungs 3) 40s exhale and breath normally 4) repeat procedure for desired number of puffs  Cumulative dosing procedure: -escalate the number of puffs from 2 to 4 puffs over 3 smoking sessions with 1 hour between sessions	Crossover  <i>3, 6-hour sessions, with 3-day between sessions</i>	VAS spontaneous pain intensity	-A significant decrease in pain intensity for both strengths of marijuana compared to placebo	-7% THC marijuana significantly decreased functioning on neurocognitive measures compared to placebo. -Subjective effects were greater for 7% THC marijuana than 3.55% THC marijuana with significantly more ratings of good drug effect, bad drug effect, feeling high, feeling stoned, impaired, sedation, confusion, and hunger compared to placebo.

Author & Date <i>Indication</i>	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type <i>Duration</i>	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
	-severe depression -history of schizophrenia or bipolar depression -uncontrolled hypertension, cardiovascular disease, and pulmonary disease -active substance abuse	TID				
Ware et al. (2010)  <i>Post- traumatic or postsurgical neuropathic pain</i>	21/23 11 males 12 females  <u>Inclusion Criteria:</u> -neuropathic pain for $\geq 3$ months caused by trauma or surgery -allodynia and hyperalgesia -pain score $>4$ cm VAS -no marijuana use for 1 year prior to study -stable analgesic regimen -normal liver and renal function  <u>Previous Marijuana Experience:</u> -18 subjects had used marijuana before  <u>Exclusion Criteria:</u> -pain due to cancer or nociceptive causes -significant cardiac or	NIDA placebo; Prairie Plant System Inc. (Canada) marijuana, smoked 0%, 2.5%, 6%, 9.4% THC  (25 mg of marijuana/placebo plant material was placed in opaque gelatin capsules)  <u>Smoking Procedures:</u> -1) Break one capsule open and tip content into the bowl of a titanium pipe 2) light marijuana material 3) 5s inhale smoke 4) 10s hold smoke in lungs 5) Exhale 1 puff burned all 25 mg of plant material	Crossover  <i>4, 5-day out- patient* treatment phase, with 9-day washout periods</i>	Pain intensity on 11- item NRS	-Average daily pain intensity was significantly lower after 9.4% THC compared to placebo.	-Anxiety and depression were significantly improved with 9.4% THC compared to placebo. -No significant difference between placebo and 9.4% THC for subjective effects.  <u>AEs:</u> -248 mild AEs were reported -6 moderate AEs were reported: 2 fall, 1 increased pain, 1 numbness, 1 drowsiness, 1 pneumonia -Most frequently reported drug- related AEs for 9.4% THC: headache, dry eyes, burning sensation, dizziness, numbness, and cough.  <u>Withdrawals for drug related reason:</u> -1 subject had increased pain after 6% THC administration -1 subject tested positive for cannabinoids in urine test during placebo treatment

Author & Date <i>Indication</i>	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type <i>Duration</i>	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
	pulmonary disease -current substance abuse or dependence (including marijuana) -history of psychotic disorders -current suicidal ideations	TID  Intermediate doses were used to help maintain blinding				
Wilsey et al. (2013)  <i>Neuropathic Pain; Various Causes</i>	36/39 28 males 11 females  <u>Inclusion Criteria:</u> -CRPS type 1, thalamic pain, spinal cord injury, peripheral neuropathy, radiculopathy, or nerve injury -previous marijuana use  <u>Previous Marijuana Experience:</u> - median (range) time from last exposure prior to screening: 9.6 years (1 day to 45 years) -16 current marijuana users and 23 past users -# smoked daily: 6 current users, 5 past users -# used approx. once every 2 weeks: 8 current users, 6 past users -# used once every 4 weeks or less: 2 current	NIDA marijuana, vaporized 0%, 1.29%, 3.53% THC  <u>Smoking Procedures:</u> - Verbally cued inhalation of vaporized material in the balloon with each puff consisting of: 1) 5s inhale vapors, 2) 10s hold vapors in lungs 3) 40s exhale and breath normally 4) repeat procedure for desired number of puffs  BID  Cumulative & Flexible Dosing: -1 <sup>st</sup> drug admin. consisted of 4 puffs from balloon.	Crossover  <i>3, 6-hour sessions, with at least 3 days between sessions</i>	VAS spontaneo us pain intensity	-Number of subjects that showed a 30% reduction in pain intensity was significantly greater for both strengths of marijuana compared to placebo. -Both strengths of marijuana showed a similar significant decrease in pain compared to placebo.  -NNT=3.2 for 1.29% THC marijuana vs. placebo. -NNT=2.9 for 3.53% THC marijuana vs. placebo.	-Scores for feeling stoned, feeling high, like the drug effect, feeling sedated, and feeling confused were significantly greater for 3.53% THC marijuana compared to 1.29% THC marijuana, and for both strengths of marijuana compared to placebo. -Scores for feeling drunk and feeling impaired are significantly greater in both strengths of marijuana compared to placebo. -Scores for desired more of the drug were significantly greater for 1.29% THC marijuana compared to placebo, with no significant difference seen for 3.53% THC marijuana. -3.53% THC marijuana had significantly worse performance than 1.29% THC marijuana for learning and memory. -Both strengths of marijuana significantly reduced scores on attention compared to placebo.

<b>Author &amp; Date Indication</b>	<b>Subjects (n) completed/randomized Subject characteristics</b>	<b>Drugs Admin. Methods</b>	<b>Study Type Duration</b>	<b>Primary Outcome Measure</b>	<b>Primary Outcome Measure Results</b>	<b>Adverse events/AEs</b>
	users, 12 past users  <u>Exclusion Criteria:</u> -no marijuana or cannabinoid medication use for 30 days prior to study; confirmed by UDS -severe depression -suicidal ideations -diagnoses of serious mental illness -uncontrolled hypertension, cardiovascular disease, or chronic pulmonary disease -active substance abuse	-Followed 2 hours later by 2 <sup>nd</sup> drug admin. -2 <sup>nd</sup> drug admin. consisted of 4 to 8 puffs from balloon; number of puffs taken was left up to the subject so they could self-titrate to their target does, which balanced desired response and tolerance levels.				

\*Out-patient: subjects were given enough doses of marijuana/placebo to last the 5-day treatment phase, and then were sent home for the remainder of the treatment phase. AE=Adverse Event; BID=drug administered two times per day; CRPS=complex regional pain syndrome; DDS=Descriptor Differential Scale; NIDA=National Institute of Drug Abuse; NNT=Number Needed to Treat; NRS=Numeric Rating Scale; QID=drug administered four times per day; THC=delta-9-tetrahydrocannabinol; TID=drug administered three times per day; UDS=urine drug screen; VAS=Visual Analog Scale.

**Table 2: Randomized, controlled, double-blind trials examining smoked marijuana in treatment of appetite stimulation in HIV/AIDS**

<b>Author &amp; Date Indication</b>	<b>Subjects (n) completed/randomized Subject characteristics</b>	<b>Drugs Admin. Methods</b>	<b>Study Type Duration</b>	<b>Primary Outcome Measure</b>	<b>Results (summary)</b>	<b>Adverse events/AEs</b>
Haney et al. (2005)  <i>HIV+ with either normal muscle mass (Normal-BIA) or clinically significant loss of muscle mass (Low-BIA)</i>	Low-BIA: 15/17 12 males 3 females Normal-BIA: 15/18 15 males  <u>Inclusion Criteria:</u> -21-50 years of age -prescribed at least 2 antiretroviral medications -currently under the care of a physician for HIV management -medically and psychiatrically stable -smoke marijuana $\geq$ 2x/week for past 4 weeks  <u>Previous Marijuana Experience:</u> -mean (SD) # of days/week of marijuana use: Low-BIA= 6 (2); Normal-BIA=5 (2) -mean (SD) # marijuana cigarettes/day: Low-BIA=3 (2); Normal-BIA=3 (1) -mean (SD) years of marijuana use: Low-BIA=12.2 (8.3);	NIDA marijuana, smoked 0%, 1.8%, 2.8%, 3.9% THC  Dronabinol, oral 0, 10, 20, 30mg  Double-dummy drug admin. Procedures: -only 1 active dose per session -one dronabinol/placebo capsule followed 1 hour later by marijuana/placebo smoking  <u>Smoking Procedures:</u> Verbally cued smoking of marijuana cigarette with each puff consisting of: 1) 5s inhale smoke, 2) 10s hold smoke in lungs 3) 40s exhale and breath normally	Crossover  <i>8, 7-hour session, with at least 1 day between sessions</i>	No primary outcome measure is specified  Related outcome measure was caloric intake	-In Low-BIA all dronabinol doses and 1.8% and 3.9% THC marijuana significantly increased caloric intake compared with placebo.	-Ratings of high and good drug effect were significantly increased for all strengths of marijuana and all doses of dronabinol except 10mg dronabinol. -3.9% THC significantly increased ratings of dry mouth and thirsty compared to placebo. -Low-BIA group showed no significant adverse event ratings, and in the normal-BIA group the only significant adverse events in response to marijuana included: diarrhea after 3.9% THC marijuana. -Dronabinol had more incidences of adverse events at all doses compared to marijuana.

Author & Date <i>Indication</i>	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type <i>Duration</i>	Primary Outcome Measure	Results (summary)	Adverse events/AEs
	Normal-BIA=10.8 (2.6)  <u>Exclusion Criteria:</u> -diagnosis of nutritional malabsorption, major depression, dementia, chronic diarrhea, weakness, fever, significant pulmonary disease -an opportunistic infection within past 3 months -obesity -use of steroids within past 3 weeks -drug dependence (excluding marijuana or nicotine)	4) repeat for 3 puffs per smoking session  QD				
Haney et al. (2007)  <i>HIV+</i>	10 9 males 1 female  <u>Inclusion Criteria:</u> -21-50 years of age -taking $\geq$ 2 antiretroviral medications -under the care of a physician for HIV management -medically and psychiatrically stable -smoke marijuana $\geq$	NIDA marijuana, smoked 0%, 2%, 3.9% THC  Dronabinol, oral 0, 5, 10mg  Double-dummy drug admin. Procedures: -only 1 active dose per session -one dronabinol/placebo	Crossover  <i>2, 16-day treatment phases, with 5-10 days between phases</i>  <i>Each 16-day treatment phase consisted of 2, 4-day active drug</i>	No primary outcome measure is specified  Related outcome measures were Caloric Intake & Body Weight	-Both strengths of marijuana significantly increased caloric intake compared to placebo. -3.9% THC marijuana significantly increased body weight compared to placebo.	-Both strengths of marijuana significantly increased ratings of: good drug effect, high, mellow, stimulate, friendly, and self-confident. Only 2% THC marijuana significantly increased ratings of anxious. -Both strengths of marijuana significantly increased subjective measures for satisfied sleep and estimated time of sleep.



Author & Date Indication	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type Duration	Primary Outcome Measure	Results (summary)	Adverse events/AEs
	<p>2x/week for the past 4 weeks</p> <p><u>Previous Marijuana Experience:</u>            -mean (SD) # of days/week of marijuana use: 4.6 (0.6)            -mean (SD) # marijuana cigarettes/day: 3.2 (0.8)            -mean (SD) years of marijuana use: 18.6 (3.3)</p> <p><u>Exclusion Criteria:</u>            -diagnosis of nutritional malabsorption, major depression, dementia, chronic diarrhea, weakness, fever, significant pulmonary disease            -an opportunistic infection within past 3 months            -obesity            -use of steroids within past 3 weeks            -drug dependence (excluding marijuana or nicotine)</p>	<p>capsule followed 1 hour later by marijuana/placebo smoking</p> <p><u>Smoking Procedures:</u>            Light cued smoking of marijuana cigarette with each puff consisting of:            1) 5s inhale smoke,            2) 10s hold smoke in lungs            3) 40s exhale and breath normally            4) repeat for 3 puffs per smoking session</p> <p>QID</p>	<p><i>period with 4-day placebo period between active drug periods.</i></p>			

AE=Adverse Event; BIA=Bioelectric Impedance Analysis; NIDA=National Institute of Drug Abuse; QD=drug administered one time per day; QID=drug administered four times per day; THC=delta-9-tetrahydrocannabinol

**Table 3: Randomized, controlled, double-blind trials examining smoked marijuana in treatment of spasticity in Multiple Sclerosis**

<b>Author &amp; Date Indication</b>	<b>Subjects (n) completed/randomized Subject characteristics</b>	<b>Drugs Admin. Methods</b>	<b>Study Type Duration</b>	<b>Primary Outcome Measure</b>	<b>Primary Outcome Measure Results</b>	<b>Adverse events/AEs</b>
Corey- Bloom et al. (2012)  <i>Multiple Sclerosis; Spasticity</i>	30/37 11 males 19 females  <u>Inclusion Criteria:</u> -documented MS -spasticity -moderate increase in tone (score $\geq 3$ on modified Ashworth scale  <u>Previous Marijuana Experience:</u> -24 subjects had previous exposure to marijuana -10 subjects used marijuana within the year  <u>Exclusion Criteria:</u> -no marijuana smoking for $\leq 1$ month prior to screening -psychiatric disorder (other than depression) -history of substance use -substantial neurological disease other than MS -severe or unstable	NIDA marijuana, smoked 0%, 4% THC  <u>Smoking Procedure:</u> smoking of marijuana cigarette with each puff consisting of: 1) 5s inhale smoke, 2) 10s hold smoke in lungs 3) 45s exhale and breath normally 4) repeat for an average of 4 puffs per smoking session  QD	Crossover  <i>2, 3-day treatment periods, with 11 day washout period</i>	Spasticity on the Modified Ashworth Scale	-Smoking marijuana significantly reduced spasticity scores compared to placebo	-Marijuana reduced scores on cognitive measure compared to placebo. -Marijuana significantly increased perceptions of “highness” compared to placebo  <u>Withdrawals for drug-related reasons:</u> -2 subjects felt uncomfortably high -2 dizziness -1 fatigue

<b>Author &amp; Date Indication</b>	<b>Subjects (n) completed/randomized Subject characteristics</b>	<b>Drugs Admin. Methods</b>	<b>Study Type Duration</b>	<b>Primary Outcome Measure</b>	<b>Primary Outcome Measure Results</b>	<b>Adverse events/AEs</b>
	medical illnesses -known pulmonary disorders -using high dose narcotic medication for pain -using benzodiazepines to control spasticity					

AE=Adverse Event; MS= Multiple Sclerosis; NIDA=National Institute of Drug Abuse; QD=drug administered one time per day; THC=delta-9-tetrahydrocannabinol

**Table 4: Randomized, controlled, double-blind trials examining smoked marijuana in treatment of intraocular pressure in Glaucoma**

<b>Author &amp; Date Indication</b>	<b>Subjects (n) completed/randomized Subject characteristics</b>	<b>Drugs Admin. Methods</b>	<b>Study Type Duration</b>	<b>Primary Outcome Measure</b>	<b>Results (summary)</b>	<b>Adverse events/AEs</b>
Crawford & Merritt (1979)  <i>Hypertensive and Normotensive Glaucoma</i>	HT group: 8 4 males 4 females  NT group: 8 4 males 4 females  <u>Inclusion Criteria:</u> -documented glaucoma  <u>Previous Marijuana Experience:</u> -all were marijuana naïve  <u>Exclusion Criteria:</u> -coronary artery disease	NIDA marijuana, smoked 0%, 2.8% THC  <u>Smoking Procedure:</u> -instructed to inhale 20 times deeply and retain smoke in lungs -smoke marijuana/placebo cigarette in 5 minutes  QD	Crossover  <i>4, 1-day sessions, no time between sessions</i>	No primary outcome measure is specified  Related outcome measure was IOP	-Marijuana decreased IOP by 37-44% from baseline. -The maximal decrease in IOP was significantly greater in HT (-14mmHg) than NT (-9mmHg) after marijuana .	-Placebo marijuana increased heart rate for 10 minutes in both groups. -The maximal increase in heart rate was significantly greater in NT than HT after marijuana. -The maximal decrease in blood pressure was significantly greater in HT than NT after marijuana.
Merritt et al. (1980)  <i>Glaucoma</i>	18 12 males 6 females (31 glaucoma eyes, analyzed results for each eye)  <u>Inclusion Criteria:</u> -documented glaucoma  <u>Previous Marijuana Experience:</u> -9 subjects had used marijuana at least once  <u>Exclusion Criteria:</u>	NIDA marijuana, smoked 0%, 2% THC  <u>Smoking Procedure:</u> -None described -smoked 1 marijuana/placebo cigarette over 10-20 minutes  QD	Crossover  <i>2, 1-day sessions</i>	No primary outcome measure is specified  Related outcome measure was IOP	-Marijuana significantly decreased IOP compared to placebo	-Marijuana significantly increased heart rate compared to placebo -Blood pressure significantly decreased after marijuana -All subjects experienced hunger, thirst, euphoria, drowsy, and feeling cold -Observed adverse events were greater in marijuana naïve subjects than in subjects with prior marijuana experience.  <u>AEs:</u> -5 subjects postural hypotension

<b>Author &amp; Date Indication</b>	<b>Subjects (n) completed/randomized Subject characteristics</b>	<b>Drugs Admin. Methods</b>	<b>Study Type Duration</b>	<b>Primary Outcome Measure</b>	<b>Results (summary)</b>	<b>Adverse events/AEs</b>
	-cardiac, neurological, and psychiatric dysfunction					-8 subjects anxiety with tachycardia and palpitations

AE=Adverse Event; HT=Hypertensive; IOP=Intraocular pressure; NIDA=National Institute of Drug Abuse; NT=Normotensive; QD=drug administered one time per day; THC=delta-9-tetrahydrocannabinol

**Table 5: Randomized, controlled, double-blind trials examining smoked marijuana in treatment of asthma**

<b>Author &amp; Date Indication</b>	<b>Subjects (n) completed/randomized Subject characteristics</b>	<b>Drugs Admin. Methods</b>	<b>Study Design Duration</b>	<b>Primary Outcome Measure</b>	<b>Results (summary)</b>	<b>Adverse events/AEs</b>
Tashkin et al. (1974)  <i>Bronchial Asthma</i>	10 5 males 5 females  <u>Inclusion Criteria:</u> -diagnosis of bronchial asthma -asthma relieved by bronchodilator medication -clinically stable  <u>Previous Marijuana Experience:</u> -7 subjects had previous exposure to marijuana -amount of exposure <1 cigarette/month  <u>Exclusion Criteria:</u> -no marijuana use $\leq$ 7 days of study -psychiatric illness	NIMH (NIDA) marijuana, smoked 0%, 2% THC  Dronabinol, oral 0, 15mg  Dosing is 7mg/kg of body weight of plant material  <u>Smoking Procedure:</u> smoking of marijuana cigarette with each puff consisting of: 1) 2-4s deep inhale smoke, 2) 15s hold smoke in lungs 3) 5s exhale and breath normally 4) repeat till entire cigarette is smoked  QD	Crossover  <i>4, 1-day sessions, with at least 48 hours between sessions</i>	No primary outcome measure is specified  Related outcome measure was sGaw	-Marijuana significantly increased sGaw (33-48%) compared to placebo and baseline	-Marijuana initially significantly increased pulse rate compared to placebo, and then at 90 minutes pulse rate was significantly decreased compared to baseline. -All subjects felt intoxicated after marijuana.

AE=Adverse Event; NIDA=National Institute of Drug Abuse; QD=drug administered one time per day; sGaw=Specific Airway Conductance; THC=delta-9-tetrahydrocannabinol

**U.S. Department of Justice—Drug Enforcement Administration**

**Schedule of Controlled Substances: Maintaining Marijuana in Schedule I of the Controlled Substances Act**

**Background, Data, and Analysis: Eight Factors Determinative of Control and Findings Pursuant to 21 U.S.C. 812(b)**

Prepared by: Office of Diversion  
Control, Drug and Chemical  
Evaluation Section, Washington, DC  
20537

July 2016

**Background**

On December 17, 2009, Bryan Krumm, CNP, submitted a petition to the Drug Enforcement Administration (DEA) to initiate proceedings for a repeal of the rules or regulations that place marijuana<sup>38</sup> in schedule I of the Controlled Substances Act (CSA). The petition requests that marijuana be rescheduled in any schedule other than schedule I of the CSA. The petitioner claims that:

1. Marijuana has accepted medical use in the United States;
  2. Studies have shown that smoked marijuana has proven safety and efficacy;
  3. Marijuana is safe for use under medical supervision; and
  4. Marijuana does not have the abuse potential for placement in schedule I
- The DEA accepted this petition for filing on April 3, 2010.

The Attorney General may by rule transfer a drug or other substance between schedules of the CSA if she finds that such drug or other substance has a potential for abuse, and makes the findings prescribed by 21 U.S.C. 812(b) for the schedule in which such drug is to be placed. 21 U.S.C. 811(a)(1). The Attorney General has delegated this responsibility to the Acting Administrator of the DEA. 28 CFR 0.100(b).

In accordance with 21 U.S.C. 811(b), after gathering the necessary data, the DEA submitted the petition and

necessary data to the Department of Health and Human Services (HHS) on May 6, 2011, and requested that HHS provide a scientific and medical evaluation and scheduling recommendation for marijuana. In documents dated June 3 and June 25, 2015, the acting Assistant Secretary for Health of the HHS<sup>39</sup> recommended to the DEA that marijuana continue to be controlled in Schedule I of the CSA, and provided to the DEA its scientific and medical evaluation titled “Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act.” The HHS’s recommendations are binding on the DEA as to scientific and medical matters. 21 U.S.C. 811(b).

Before initiating proceedings to reschedule a substance, the CSA requires the Acting Administrator to determine whether the HHS scheduling recommendation, scientific and medical evaluation, and “all other relevant data” constitute substantial evidence that the drug should be rescheduled as proposed. 21 U.S.C. 811(b). The Acting Administrator must determine whether there is substantial evidence to conclude that the drug meets the criteria for placement in another schedule based on the criteria set forth in 21 U.S.C. 812(b). The CSA requires that both the DEA and the HHS consider the eight factors specified by Congress in 21 U.S.C. 811(c). This document lays out those considerations and is organized according to the eight factors. As DEA sets forth in detail below, the evidence shows:

1. *Actual or relative potential for abuse.* Marijuana has a high potential for abuse. Preclinical and clinical data show that it has reinforcing effects characteristic of drugs of abuse. National databases on actual abuse show marijuana is the most widely abused drug, including significant numbers of substance abuse treatment admissions. Data on marijuana seizures show widespread availability and trafficking.

2. *Scientific evidence of its pharmacological effect.* The scientific understanding of marijuana, cannabinoid receptors, and the endocannabinoid system continues to be studied and elucidated. Marijuana

produces various pharmacological effects, including subjective (e.g., euphoria, dizziness, disinhibition), cardiovascular, acute and chronic respiratory, immune system, and prenatal exposure effects, as well as behavioral and cognitive impairment.

3. *Current scientific knowledge.* There is no currently accepted medical use for marijuana in the United States. Marijuana sources are derived from numerous cultivated strains and may have different levels of  $\Delta^9$ -THC and other cannabinoids. Under the five-element test for currently accepted medical use discussed in more detail below and upheld by the Court of Appeals for the District of Columbia in *Alliance for Cannabis Therapeutics v. DEA*, 15 F.3d 1131, 1135 (D.C. Cir. 1994) (hereinafter “ACT”), there is no complete scientific analysis of marijuana’s chemical components; there are not adequate safety studies; there are not adequate and well-controlled efficacy studies; there is not a consensus of medical opinion concerning medical applications of marijuana; and the scientific evidence regarding marijuana’s safety and efficacy is not widely available. To date, scientific and medical research has not progressed to the point that marijuana has a currently accepted medical use, even under conditions where its use is severely restricted.

4. *History and current pattern of abuse.* Marijuana continues to be the most widely used illicit drug. In 2014, there were 22.2 million current users. There were also 2.6 million new users, most of whom were less than 18 years of age. During the same period, marijuana was the most frequently identified drug exhibit in federal, state, and local forensic laboratories.

5. *Scope, duration, and significance of abuse.* Abuse of marijuana is widespread and significant. In 2014, for example, an estimated 6.5 million people aged 12 or older used marijuana on a daily or almost daily basis over a 12-month period. In addition, a significant proportion of all admissions for substance abuse treatment are for marijuana/hashish as their primary drug of abuse. In 2013, 16.8% of all such admissions—281,991 over the course of the year—were for primary marijuana/hashish abuse.

6. *Risk, if any, to public health.* Together with the health risks outlined in terms of pharmacological effects above, public health risks from acute use of marijuana include impaired psychomotor performance, impaired driving, and impaired performance on tests of learning and associative processes. Chronic use of marijuana

<sup>38</sup> The Controlled Substances Act (CSA) defines marijuana as the following: “All parts of the plant *Cannabis sativa L.*, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin. Such term does not include the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted there from), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. 21 U.S.C. 802(16). Note that “marihuana” is the spelling originally used in the CSA. This document uses the spelling that is more common in current usage, “marijuana.”

<sup>39</sup> As set forth in a memorandum of understanding entered into by the HHS, the Food and Drug Administration (FDA), and the National Institute on Drug Abuse (NIDA), the FDA acts as the lead agency within the HHS in carrying out the Secretary’s scheduling responsibilities under the CSA, with the concurrence of the NIDA. 50 FR 9518, Mar. 8, 1985. The Secretary of the HHS has delegated to the Assistant Secretary for Health of the HHS the authority to make domestic drug scheduling recommendations.

poses a number of other risks to the public health including physical as well as psychological dependence.

7. *Psychic or physiological dependence liability.* Long-term, heavy use of marijuana can lead to physical dependence and withdrawal following discontinuation, as well as psychic or psychological dependence. In addition, a significant proportion of all admissions for treatment for substance abuse are for primary marijuana abuse; in 2013, 16.8% of all admissions were for primary marijuana/hashish abuse, representing 281,991 individuals.

8. *Immediate precursor.* Marijuana is not an immediate precursor of any controlled substance.

As specified in 21 U.S.C. 812(b)(1), in order for a substance to be placed in schedule I, the Acting Administrator must find that:

A. The drug or other substance has a high potential for abuse.

B. The drug or other substance has no currently accepted medical use in treatment in the United States.

C. There is a lack of accepted safety for use of the drug or other substance under medical supervision.

To be classified in another schedule under the CSA (e.g., II, III, IV, or V), a substance must have a “currently accepted medical use in treatment in the United States.” 21 U.S.C. 812(b)(2)–(5). A substance also may be placed in schedule II if it is found to have “a currently accepted medical use with severe restrictions.” 21 U.S.C. 812(b)(2). If a controlled substance has no such currently accepted medical use, it must be placed in schedule I. See Notice of Denial of Petition, 66 FR 20038 (Apr. 18, 2001) (“Congress established only one schedule—schedule I—for drugs of abuse with ‘no currently accepted medical use in treatment in the United States’ and ‘lack of accepted safety for use . . . under medical supervision.’”).

A drug that is the subject of an approved new drug application (NDA) or abbreviated new drug application (ANDA) under Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), is considered to have a currently accepted medical use in treatment in the United States for purposes of the CSA. The HHS stated in its review, however, that FDA has not approved any NDA for marijuana for any indication.

In the absence of NDA or ANDA approval, DEA has established a five-element test for determining whether the drug has a currently accepted medical use in treatment in the United States. Under this test, a drug will be considered to have a currently accepted medical use only if the following five elements are satisfied:

1. The drug’s chemistry is known and reproducible;

2. There are adequate safety studies;

3. There are adequate and well-controlled studies proving efficacy;

4. The drug is accepted by qualified experts; and

5. The scientific evidence is widely available.

57 FR 10499, 10506 (March 26, 1992). See also *ACT*, 15 F.3d at 1135.

As discussed in Factor 3, below, HHS concluded, and DEA agrees, that the scientific evidence is insufficient to demonstrate that marijuana has a currently accepted medical use under the five-element test. The evidence was insufficient in this regard also when the DEA considered petitions to reschedule marijuana in 1992 (57 FR 10499),<sup>40</sup> in 2001 (66 FR 20038), and in 2011 (76 FR 40552).<sup>41</sup> Little has changed since 2011 with respect to the lack of clinical evidence necessary to establish that marijuana has a currently accepted medical use. No studies have scientifically assessed the efficacy and full safety profile of marijuana for any specific medical condition.

The limited existing clinical evidence is not adequate to warrant rescheduling of marijuana under the CSA. To the contrary, the data in this scheduling review document show that marijuana continues to meet the criteria for schedule I control under the CSA for the following reasons:

1. Marijuana has a high potential for abuse.

2. Marijuana has no currently accepted medical use in treatment in the United States.

3. Marijuana lacks accepted safety for use under medical supervision.

#### **Factor 1: The Drug’s Actual or Relative Potential for Abuse**

Marijuana is the most commonly abused illegal drug in the United States. It is also the most commonly used illicit drug by high school students in the United States. Further, marijuana is the most frequently identified drug by state, local and federal forensic laboratories. Marijuana’s main psychoactive ingredient,  $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC),<sup>42</sup> is an effective reinforcer in laboratory animals, including primates and rodents. These animal studies both predict and support the observations that marijuana produces reinforcing effects in humans. Such reinforcing

effects can account for the repeated abuse of marijuana.

#### *A. Indicators of Abuse Potential*

The HHS has concluded in its document, “Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act,” that marijuana has a high potential for abuse. The finding of “abuse potential” is critical for control under the Controlled Substances Act (CSA). Although the term is not defined in the CSA, guidance in determining abuse potential is provided in the legislative history of the Act (Comprehensive Drug Abuse Prevention and Control Act of 1970, H.R. Rep. No. 91–1444, 91st Cong., Sess. 2 (1970), reprinted in 1970 U.S.C.A.N. 4566, 4603). Accordingly, the following items are indicators that a drug or other substance has potential for abuse:

- *There is evidence that individuals are taking the drug or drugs containing such a substance in amounts sufficient to create a hazard to their health or to the safety of other individuals or of the community; or*

- *There is significant diversion of the drug or drugs containing such a substance from legitimate drug channels; or*

- *Individuals are taking the drug or drugs containing such a substance on their own initiative rather than on the basis of medical advice from a practitioner licensed by law to administer such drugs in the course of his professional practice; or*

- *The drug or drugs containing such a substance are new drugs so related in their action to a drug or drugs already listed as having a potential for abuse to make it likely that the drug will have the same potentiality for abuse as such drugs, thus making it reasonable to assume that there may be significant diversions from legitimate channels, significant use contrary to or without medical advice, or that it has a substantial capability of creating hazards to the health of the user or to the safety of the community.*

Of course, evidence of actual abuse of a substance is indicative that a drug has a potential for abuse.

In its recommendation, the HHS analyzed and evaluated data on marijuana as applied to each of the above four criteria. The analysis presented in the recommendation (HHS, 2015) is discussed below:

1. *There is evidence that individuals are taking the drug or drugs containing such a substance in amounts sufficient to create a hazard to their health or to the safety of other individuals or of the community.*

<sup>40</sup> See *Alliance for Cannabis Therapeutics v. DEA*, 15 F.3d 1131 (D.C. Cir. 1994).

<sup>41</sup> See *Americans for Safe Access v. DEA*, 706 F.3d 438 (D.C. Cir. 2013)(rhg den. 2013).

<sup>42</sup> The terms  $\Delta^9$ -THC and THC are used interchangeably throughout this document.



The HHS stated that some individuals are taking marijuana in amounts sufficient to create a hazard to their health and to the safety of other individuals and the community. Data from national databases on actual abuse of marijuana support the idea that a large number of individuals use marijuana. In its recommendation (HHS, 2015), the HHS presented data from the National Survey on Drug and Health (NSDUH) of the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Monitoring the Future (MTF) survey of the National Institute on Drug Abuse (NIDA), and the DEA has since updated this information. The most recent data from SAMHSA's NSDUH in 2014 reported that marijuana was the most used illicit drug. Among Americans aged 12 years and older, an estimated 22.2 million Americans used marijuana within the past month according to the 2014 NSDUH. In 2004, an estimated 14.6 million individuals reported using marijuana within the month prior to the study. The estimated rates in 2014 thus reflect an increase of approximately 7.6 million individuals over a 10-year period. According to the 2013 NSDUH report, an estimated 19.8 million individuals reported using marijuana. Thus, over a period of one year (2013 NSDUH–2014 NSDUH), there was an estimated increase of 2.4 million individuals in the United States using marijuana.

The results from the 2015 Monitoring the Future survey of 8th, 10th, and 12th grade students indicate that marijuana was the most widely used illicit drug in these age groups. Current monthly use was 6.5% of 8th graders, 14.8% of 10th graders, and 21.3% of 12th graders. The Treatment Episode Data Set (TEDS) in 2013 reported that marijuana abuse was the primary factor in 16.8 percent of non-private substance-abuse treatment facility admissions. In 2011, SAMHSA's Drug Abuse Warning Network (DAWN) reported that marijuana was mentioned in 36.4% (455,668 out of approximately 1.25 million) of illicit drug-related Emergency Department (ED) visits.

Data on the extent and scope of marijuana abuse are presented under Factors 4 and 5 of this analysis. Discussion of the health effects of marijuana is presented under Factor 2, and the assessment of risk to the public health posed by acute and chronic marijuana abuse is presented under Factor 6 of this analysis.

*2. There is significant diversion of the drug or drugs containing such a substance from legitimate drug channels.*

In accordance with the CSA, the only lawful source of marijuana in the United

States is that produced and distributed for research purposes under the oversight of NIDA and in conformity with United States obligations under the Single Convention on Narcotic Drugs.<sup>43</sup> The HHS stated that there is a lack of significant diversion from legitimate drug sources, but that this is likely due to high availability of marijuana from illicit sources. Marijuana is not an FDA-approved drug product. Neither a New Drug Application (NDA) nor a Biologics License Application (BLA) has been approved for marketing in the United States. However, the marijuana used for nonclinical and clinical research represents a very small amount of the total amount of marijuana available in the United States and therefore information about marijuana diversion from legitimate sources is limited or not available.

The DEA notes that the magnitude of the demand for illicit marijuana is evidenced by information presented from a number of databases presented under Factor 4. Briefly, marijuana is the most commonly used illegal drug in the United States. It is also the most commonly used illicit drug by American high schoolers. Marijuana is the most frequently identified drug in state, local, and federal forensic laboratories, with increasing amounts of both domestically grown and of illicitly smuggled marijuana.

Given that marijuana has long been the most widely trafficked and abused controlled substance in the United States, and that all aspects of such illicit activity are entirely outside of the closed system of distribution mandated by the CSA, it may well be the case that there is little thought given to diverting marijuana from the small supplies produced for legitimate research purposes. Thus, the lack of data indicating diversion of marijuana from legitimate channels to the illicit market is not indicative of a lack of potential for abuse of the drug.

*3. Individuals are taking the drug or drugs containing such a substance on their own initiative rather than on the basis of medical advice from a practitioner licensed by law to administer such drugs in the course of his professional practice.*

The HHS stated that the FDA has not evaluated or approved an NDA or BLA for marijuana for any therapeutic indication. Consistent with federal law, therefore, an individual legitimately can take marijuana based on medical advice from a practitioner only by participating

in research that is being conducted under an Investigational New Drug (IND) application. The HHS noted that there are several states as well as the District of Columbia which have passed laws allowing for individuals to use marijuana for purported "medical" use under certain circumstances, but data are not available yet to determine the number of individuals using marijuana under these state laws. Nonetheless, according to 2014 NSDUH data, 22.2 million American adults currently use marijuana (SAMHSA, 2015a). Based on the large number of individuals who use marijuana and the lack of an FDA-approved drug product, the HHS concluded that the majority of individuals using marijuana do so on their own initiative rather than by following medical advice from a licensed practitioner.

*4. The drug or drugs containing such a substance are new drugs so related in their action to a drug or drugs already listed as having a potential for abuse to make it likely that the drug will have the same potentiality for abuse as such drugs, thus making it reasonable to assume that there may be significant diversions from legitimate channels, significant use contrary to or without medical advice, or that it has a substantial capability of creating hazards to the health of the user or to the safety of the community.*

Marijuana and its primary psychoactive ingredient,  $\Delta^9$ -THC, are controlled substances in schedule I under the CSA.

The HHS stated that one approved, marketed drug product contains synthetic  $\Delta^9$ -THC, also known as dronabinol, and another approved, marketed drug product contains a cannabinoid-like synthetic compound that is structurally related to  $\Delta^9$ -THC, the main active component in marijuana. Both products are controlled under the CSA.

Marinol is a schedule III drug product containing synthetic  $\Delta^9$ -THC (dronabinol) formulated in sesame oil in soft gelatin capsules. Marinol was approved by the FDA in 1985 for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who did not respond to conventional anti-emetic treatments. In 1992, FDA approved Marinol for the treatment of anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS). Marinol was originally placed into schedule II and later rescheduled to schedule III under the CSA due to the low reports of abuse relative to marijuana.

<sup>43</sup> See 76 FR 51403, 51409–51410 (2011) (discussing cannabis controls required under the Single Convention).

Cesamet is a drug product containing the schedule II substance nabilone, a synthetic substance structurally related to  $\Delta^9$ -THC. Cesamet was approved for marketing by the FDA in 1985 for the treatment of nausea and vomiting associated with cancer chemotherapy. All other naturally occurring cannabinoids in marijuana and their synthetic equivalents with similar chemical structure and pharmacological activity are already included as schedule I drugs under the CSA.

### B. Abuse Liability Studies

In addition to the indicators suggested by the CSA's legislative history, data as to preclinical and clinical abuse liability studies, as well as actual abuse, including clandestine manufacture, trafficking, and diversion from legitimate sources, are considered in this factor.

Abuse liability evaluations are obtained from studies in the scientific and medical literature. There are many preclinical measures of a drug's effects that when taken together provide an accurate prediction of the human abuse liability. Clinical studies of the subjective and reinforcing effects in humans and epidemiological studies provide quantitative data on abuse liability in humans and some indication of actual abuse trends. Both preclinical and clinical studies have clearly demonstrated that marijuana and  $\Delta^9$ -THC possess the attributes associated with drugs of abuse: They function as a positive reinforcer to maintain drug-seeking behavior, they function as a discriminative stimulus, and they have dependence potential.

Preclinical and most clinical abuse liability studies have been conducted with the psychoactive constituents of marijuana, primarily  $\Delta^9$ -THC and its metabolite, 11-hydroxy- $\Delta^9$ -THC.  $\Delta^9$ -THC's subjective effects are considered to be the basis for marijuana's abuse liability. The following studies provide a summary of that data.

#### 1. Preclinical Studies

$\Delta^9$ -THC, the primary psychoactive component in marijuana, is an effective reinforcer in laboratory animals, including primates and rodents, as these animals will self-administer  $\Delta^9$ -THC. These animal studies both predict and support the observations that  $\Delta^9$ -THC, whether smoked as marijuana or administered by other routes, produces reinforcing effects in humans. Such reinforcing effects can account for the repeated abuse of marijuana.

#### a. Drug Discrimination Studies

The drug discrimination paradigm is used as an animal model of human subjective effects (Solinas et al., 2006) and is a method where animals are able to indicate whether a test drug is able to produce physical or psychological changes similar to a known drug of abuse. Animals are trained to press one bar (in an operant chamber) when they receive a known drug of abuse and another bar when they receive a placebo. When a trained animal receives a test drug, if the drug is similar to the known drug of abuse, it will press the bar associated with the drug.

Discriminative stimulus effects of  $\Delta^9$ -THC have specificity for the pharmacological effects of cannabinoids found in marijuana (Balster and Prescott, 1992; Browne and Weissman, 1981; Wiley et al., 1993; Wiley et al., 1995). As mentioned by the HHS, the discriminative stimulus effects of cannabinoids appear to be unique because abused drugs of other classes including stimulants, hallucinogens, opioids, benzodiazepines, barbiturates, NMDA antagonists, and antipsychotics do not fully substitute for  $\Delta^9$ -THC.

Laboratory animals including monkeys (McMahon et al., 2009), mice (McMahon et al., 2008), and rats (Gold et al., 1992) are able to discriminate cannabinoids from other drugs and placebo. The major active metabolite of  $\Delta^9$ -THC, 11-hydroxy- $\Delta^9$ -THC, generalizes to  $\Delta^9$ -THC (Browne and Weissman, 1981). In addition, according to the HHS, twenty-two other cannabinoids found in marijuana also substitute for  $\Delta^9$ -THC. At least one cannabinoid, CBD, does not substitute for  $\Delta^9$ -THC in rats (Vann et al., 2008).

#### b. Self-Administration Studies

Animal self-administration behavior associated with a drug is a commonly used method for evaluating if the drug produces rewarding effects and for predicting abuse potential (Balster, 1991; Balster and Bigelow, 2003). Drugs that are self-administered by animals are likely to produce rewarding effects in humans. As mentioned in the HHS review document, earlier attempts to demonstrate self-administration of  $\Delta^9$ -THC were unsuccessful and confounded by diet restrictions, animal restraint, and known analgesic activity of  $\Delta^9$ -THC at testing doses (Tanda and Goldberg, 2003; Justinova et al., 2003). Self-administration of  $\Delta^9$ -THC was first demonstrated by Tanda et al. (2000). Tanda et al. (2000) showed that squirrel monkeys that were initially trained to self-administer cocaine (30  $\mu$ g/kg, i.v.) self-administered 2  $\mu$ g/kg  $\Delta^9$ -THC (i.v.)

and at a rate of 30 injections per one hour session. Tanda et al. (2000) used a lower dose of  $\Delta^9$ -THC that was rapidly delivered (0.2 ml injection over 200 ms) than in previous self-administration studies such that analgesic activity of  $\Delta^9$ -THC was not a confounding factor. The authors also stated that the doses were comparable to those doses used by humans who smoke marijuana. A CB1 receptor antagonist (SR141716) blocked this rewarding effect of THC.

Justinova et al. (2003) were able to demonstrate self-administration of  $\Delta^9$ -THC in drug-naïve squirrel monkeys (no previous exposure to other drugs). The authors tested the monkeys with several doses of  $\Delta^9$ -THC (1, 2, 4, 8, and 16  $\mu$ g/kg, i.v.) and found that the maximal rates of self-administration were observed with the 4  $\mu$ g/kg/infusion. Subsequently, Braida et al. (2004) reported that rats will self-administer  $\Delta^9$ -THC when delivered intracerebroventricularly (i.c.v.), but only at the lowest doses tested (0.01–0.02  $\mu$ g/infusion, i.c.v.).

Self-administration behavior with  $\Delta^9$ -THC was found to be antagonized in rats and squirrel monkeys by rimonabant (SR141716A, CB1 antagonist) and the opioid antagonists (naloxone and naltrexone) (Tanda et al., 2000; Braida et al., 2004; Justinova et al., 2004).

#### c. Conditioned Place Preference Studies

Conditioned place preference (CPP) is a behavioral assay where animals are given the opportunity to spend time in two distinct environments: one where they previously received a drug and one where they received a placebo. If the drug is reinforcing, animals in a drug-free state will choose to spend more time in the environment paired with the drug when both environments are presented simultaneously.

CPP has been demonstrated with  $\Delta^9$ -THC in rats but only at low doses (0.075–1.0 mg/kg, i.p.; Braida et al., 2004). Rimonabant (0.25–1.0 mg/kg, i.p.) and naloxone (0.5–2.0 mg/kg, i.p.) antagonized  $\Delta^9$ -THC-mediated CPP (Braida et al., 2004). However, in another study with rats, rimonabant was demonstrated to induce CPP at doses ranging from 0.25–3.0 mg/kg (Cheer et al., 2000). Mice without  $\mu$ -opioid receptors did not exhibit CPP to  $\Delta^9$ -THC (paired with 1 mg/kg  $\Delta^9$ -THC, i.p.) (Ghozland et al., 2002).

#### 2. Clinical Studies

In its scientific review (HHS, 2015), the HHS provided a list of common subjective psychoactive responses to cannabinoids based on information from several references (Adams and Martin, 1996; Gonzalez, 2007; Hollister, 1986;

Hollister, 1988; Institute of Medicine, 1982). Furthermore, Maldonado (2002) characterized these subjective responses as pleasurable to most humans and are generally associated with drug-seeking and/or drug-taking. Later studies (Scherrer et al., 2009; Zeiger et al., 2010) reported that high levels of positive psychoactive effects correlate with increased marijuana use, abuse, and dependence. The list of the common subjective psychoactive effects provided by the HHS (HHS, 2015) is presented below:

(1) *Disinhibition, relaxation, increased sociability, and talkativeness.*

(2) *Increased merriment and appetite, and even exhilaration at high doses.*

(3) *Enhanced sensory perception, which can generate an increased appreciation of music, art, and touch.*

(4) *Heightened imagination, which can lead to a subjective sense of increased creativity.*

(5) *Initial dizziness, nausea, tachycardia, facial flushing, dry mouth, and tremor.*

(6) *Disorganized thinking, inability to converse logically, time distortions, and short-term memory impairment.*

(7) *Ataxia and impaired judgment, which can impede driving ability or lead to an increase in risk-taking behavior.*

(8) *Illusions, delusions, and hallucinations that intensify with higher doses.*

(9) *Emotional lability, incongruity of affect, dysphoria, agitation, paranoia, confusion, drowsiness, and panic attacks, which are more common in inexperienced or high-dosed users.*

The HHS mentioned that marijuana users prefer higher concentrations of the principal psychoactive component ( $\Delta^9$ -THC) over lower concentrations. In a clinical study with marijuana users ( $n = 12$ , usage ranged from once a month to 4 times a week), subjects were given a choice of 1.95%  $\Delta^9$ -THC marijuana or 0.63%  $\Delta^9$ -THC marijuana after sampling both marijuana cigarettes in two choice sessions. The marijuana cigarette with high THC was chosen in 21 out of 24 choice sessions or 87.5% of the time (Chait and Burke, 1994). Furthermore, in a double-blind study, frequent marijuana users ( $n = 11$ , usage at least 2 times per month with at least 100 occasions) when given a low-dose of oral  $\Delta^9$ -THC (7.5 mg) were able to distinguish the psychoactive effects better than occasional users ( $n = 10$ , no use within the past 4 years with 10 or fewer lifetime uses) and also experienced fewer sedative effects (Kirk and de Wit, 1999).

Marijuana has also been recognized by scientific experts to have withdrawal symptoms (negative reinforcement)

following moderate and heavy use. As discussed further in Factor 7, the DEA notes that the American Psychiatric Association's (APA) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) included a list of withdrawal symptoms following marijuana [cannabis] use (DSM-5, 2013).

### *C. Actual Abuse of Marijuana—National Databases Related to Marijuana Abuse and Trafficking*

Marijuana continues to be the most widely used illicit drug. Evidence of actual abuse can be defined by episodes/mentions in databases indicative of abuse/dependence. The HHS provided in its recommendation (HHS, 2015) information relevant to actual abuse of marijuana including data results from the National Survey on Drug Use and Health (NSDUH), a Monitoring the Future (MTF) survey, the Drug Abuse Warning Network (DAWN), and the Treatment Episode Data Set (TEDS). These data sources provide quantitative information on many factors related to abuse of a particular substance, including incidence and patterns of use, and profile of the abuser of specific substances. The DEA is providing updated information from these databases in this discussion. The DEA also includes data on trafficking and illicit availability of marijuana from DEA databases including the National Forensic Laboratory Information System (NFLIS) and the National Seizure System (NSS), formerly the Federal-wide Drug Seizure System (FDSS), as well as other sources of data specific to marijuana, including the Potency Monitoring Project and the Domestic Cannabis Eradication and Suppression Program (DCE/SP).

#### 1. National Survey on Drug Use and Health (NSDUH)

The National Survey on Drug Use and Health (NSDUH) is conducted annually by the Department of Health and Human Service's Substance Abuse and Mental Health Services Administration (SAMHSA). SAMHSA is the primary source of estimates of the prevalence and incidence of pharmaceutical drugs, illicit drugs, alcohol, and tobacco use in the United States. The survey is based on a nationally representative sample of the civilian, non-institutionalized population 12 years of age and older. The survey excludes homeless people who do not use shelters, active military personnel, and residents of institutional group quarters such as jails and hospitals.

According to the 2014 NSDUH report, marijuana was the most commonly used and abused illicit drug. That data showed that there were 22.2 million people who were past month users (8.4%) among those aged 12 and older in the United States. (Note: NSDUH figures on marijuana use include hashish use; the relative proportion of hashish use to marijuana use is very low). Marijuana had the highest rate of past-year dependence or abuse in 2014. The NSDUH report estimates that 3.0 million people aged 12 or older used an illicit drug for the first time in 2014; a majority (70.3%) of these past year initiates reported that their first drug used was marijuana. Among those who began using illicit drugs in the past year, 65.6%, 70.3%, and 67.6% reported marijuana as the first illicit drug initiated in 2012, 2013, and 2014 respectively. In 2014, the average age of marijuana initiates among 12- to 49-year-olds was 18.5 years. These usage rates and demographics are relevant in light of the risks presented.

Marijuana had the highest rate of past year dependence or abuse of any illicit drug in 2014. The 2014 NSDUH report stated that 4.2 million persons were classified with substance dependence or abuse of marijuana in the past year (representing 1.6% of the total population aged 12 or older, and 59.0% of those classified with illicit drug dependence or abuse) based on criteria specified in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV).

Among past year marijuana users age 12 or older, 18.5% used marijuana on 300 or more days within the previous 12 months in 2014. This translates into 6.5 million people using marijuana on a daily or almost daily basis over a 12-month period, significantly more than the estimated 5.7 million daily or almost daily users in just the year before. Among past month marijuana users, 41.6% (9.2 million) used the drug on 20 or more days in the past month, a significant increase from the 8.1 million who used marijuana 20 days or more in 2013.

#### 2. Monitoring the Future (MTF)

Monitoring the Future (MTF) is an ongoing study which is funded under a series of investigator-initiated competing research grants from the National Institute on Drug Abuse (NIDA). MTF tracks drug use trends among American adolescents in the 8th, 10th, and 12th grades. According to its 2015 survey results, marijuana was the most commonly used illicit drug, as was the case in previous years. Approximately 6.5% of 8th graders,

14.8% of 10th graders, and 21.3% of 12th graders surveyed in 2015 reported marijuana use during the past month prior to the survey. A number of high school students in 2015 also reported daily use in the past month, including 1.1%, 3.0%, and 6.0% of 8th, 10th, and 12th graders, respectively.

### 3. Drug Abuse Warning Network (DAWN), Emergency Department (ED) Visits

The Drug Abuse Warning Network (DAWN) is a public health surveillance system that monitors drug-related hospital emergency department (ED) visits to track the impact of drug use, misuse, and abuse in the United States. For the purposes of DAWN, the term “drug abuse” applies if the following conditions are met: (1) The case involved at least one of the following: use of an illegal drug, use of a legal drug contrary to directions, or inhalation of a non-pharmaceutical substance; and (2) the substance was used for one of the following reasons: because of drug dependence, to commit suicide (or attempt to commit suicide), for recreational purposes, or to achieve other psychic effects. Importantly, many factors can influence the estimates of ED visits, including trends in overall use of a substance as well as trends in the reasons for ED usage. For instance, some drug users may visit EDs for life-threatening issues while others may visit to seek care for detoxification because they needed certification before entering treatment. Additionally, DAWN data do not distinguish the drug responsible for the ED visit from other drugs that may have been used concomitantly. As stated in a DAWN report, “Since marijuana/hashish is frequently present in combination with other drugs, the reason for the ED visit may be more relevant to the other drug(s) involved in the episode.”

In 2011, marijuana was involved in 455,668 ED visits out of 2,462,948 total

ED visits involving all abuse or misuse in the United States and out of 1.25 million visits involving abuse or misuse of illicit drugs (excluding alcohol-related visits), as estimated by DAWN. This is lower than the number of ED visits involving cocaine (505,224) and higher than the number of ED visits involving heroin (258,482) and stimulants (e.g., amphetamine, methamphetamine) (159,840). Visits involving the other major illicit drugs, such as MDMA, GHB, LSD and other hallucinogens, PCP, and inhalants, were much less frequent, comparatively.

In young patients, marijuana is the illicit drug most frequently involved in ED visits, according to DAWN estimates, with 240.2 marijuana-related ED visits per 100,000 population ages 12 to 17, 443.8 per 100,000 population ages 18 to 20, and 446.9 per 100,000 population ages 21 to 24.

### 4. Treatment Episode Data Set (TEDS) System

The Treatment Episode Data Set (TEDS) system is part of the SAMHSA Drug and Alcohol Services Information System and is a national census of annual admissions to state licensed or certified, or administratively tracked, substance abuse treatment facilities. The TEDS system contains information on patient demographics and substance abuse problems of admissions to treatment for abuse of alcohol and/or drugs in facilities that report to state administrative data systems. For this database, the primary substance of abuse is defined as the main substance of abuse reported at the time of admission. TEDS also allows for the recording of two other substances of abuse (secondary and tertiary).

In 2011, the TEDS system included 1,928,792 admissions to substance abuse treatment; in 2012 there were 1,801,385 admissions; and in 2013 there were 1,683,451 admissions. Marijuana/hashish was the primary substance of

abuse for 18.3% (352,397) of admissions in 2011; 17.5% (315,200) in 2012; and 16.8% (281,991) in 2013. Of the 281,991 admissions for marijuana/hashish treatment in 2013, 24.3% used marijuana/hashish daily. Among those treated for marijuana/hashish as the primary substance in 2013, 27.4% were ages 12 to 17 years and 29.7% were ages 18 to 24 years. Those admitted for marijuana/hashish were mostly male (72.6%) and non-Hispanic (82.2%). Non-hispanic whites (43.2%) represented the largest ethnic group of marijuana admissions.

### 5. Forensic Laboratory Data

Data on marijuana seizures from federal, state, and local forensic laboratories have indicated that there is significant trafficking of marijuana. The National Forensic Laboratory System (NFLIS) is a program sponsored by the Drug Enforcement Administration’s Office of Diversion Control. NFLIS systematically collects drug identification results and associated information from drug exhibits encountered by law enforcement and analyzed in federal, state, and local forensic laboratories. NFLIS is a comprehensive information system that includes data from 278 individual forensic laboratories that report more than 91% of the drug caseload in the U.S. NFLIS captures data for all drugs and chemicals identified and reported by forensic laboratories. More than 1,700 unique substances are represented in the NFLIS database.

Data from NFLIS showed that marijuana was the most frequently identified drug in federal, state, and local laboratories from January 2004 through December 2014. Marijuana accounted for between 29.47% and 34.84% of all drug exhibits analyzed annually during that time frame (Table 1).

**Table 1. NFLIS Federal, State and Local Forensic Laboratory Data of Marijuana Reports (other than hashish)**

Year	Reports	Percent of Total Reports
2004	454,582	34.42%
2005	483,134	32.53%
2006	520,060	32.55%
2007	525,668	33.66%
2008	526,420	34.07%
2009	536,888	34.30%
2010	544,418	34.91%
2011	495,937	33.42%
2012	485,591	32.02%
2013	452,839	30.70%
2014	432,989	29.27%
2015*	341,162	26.73%

NFLIS database queried 03-23-2016, by date of submission, all drugs reported

\*2015 data are still being reported to NFLIS due to normal lag time.

Since 2004, the total number of reports of marijuana and the amount of marijuana encountered federally has remained high (see data from Federal-wide Drug Seizure System and Domestic Cannabis Eradication and Suppression Program below).

#### 6. Federal-Wide Drug Seizure System

The Federal-wide Drug Seizure System (FDSS) contains information about drug seizures made within the jurisdiction of the United States by the Drug Enforcement Administration, the

Federal Bureau of Investigation, United States Customs and Border Protection, and United States Immigration and Customs Enforcement. It also records maritime seizures made by the United States Coast Guard. Drug seizures made by other Federal agencies are included in the FDSS database when drug evidence custody is transferred to one of the agencies identified above. FDSS is now incorporated into the National Seizure System (NSS), which is a repository for information on

clandestine laboratory and contraband (chemicals and precursors, currency, drugs, equipment and weapons). FDSS reports total federal drug seizures [in kilograms (kg)] of substances such as cocaine, heroin, MDMA, methamphetamine, and cannabis (marijuana and hashish). The yearly volume of cannabis seized (Table 2), consistently exceeding a thousand metric tons per year, shows that cannabis is very widely trafficked in the United States.

**Table 2. Total Federal Seizures of Cannabis (Expressed in Kg)**  
(Source: NSS, U.S. Seizures, EPIC System Portal, queried 08-05-2015)

	2010	2011	2012	2013	2014
<b>Cannabis</b>	<b>4,071,328</b>	<b>3,622,256</b>	<b>2,756,439</b>	<b>2,622,494</b>	<b>1,768,277</b>
Marijuana	4,070,850	3,621,322	2,754,457	2,618,340	1,767,741
Hashish	478	934	1,982	4,154	536

#### 7. Potency Monitoring Project


The University of Mississippi's Potency Monitoring Project (PMP), through a contract with the National Institute on Drug Abuse (NIDA), analyzes and compiles data on the

$\Delta^9$ -THC concentrations of marijuana, hashish and hash oil samples provided by DEA regional laboratories and by state and local police agencies. After 2010, PMP has analyzed only marijuana samples provided by DEA regional laboratories. As indicated in Figure 1,

the percentage of  $\Delta^9$ -THC increased from 1995 to 2010 with an average THC content of 3.75% in 1995 and 9.53% in 2010. In examining marijuana samples only provided by DEA laboratories, the average  $\Delta^9$ -THC content was 3.96% in 1995 in comparison to 11.16% in 2015.

**Figure 1. Average Percentage of  $\Delta^9$ -THC in Samples of Seized Marijuana (1995 – 2015)\***

(Source: The University of Mississippi Potency Monitoring Program, Quarterly Report # 131)



\*PMP discontinued analysis of state samples after 2010.

\*\*Data for 2015 are incomplete. Figure 1 contains percentage of  $\Delta^9$ -THC data through Dec. 22. Due to lack of funding, 4,177 samples haven't yet been analyzed.

**8. The Domestic Cannabis Eradication and Suppression Program**

The Domestic Cannabis Eradication and Suppression Program (DCE/SP) was established in 1979 to reduce the supply of domestically cultivated marijuana in the United States. The program was designed to serve as a partnership between federal, state, and local

agencies. Only California and Hawaii were active participants in the program at its inception. However, by 1982 the program had expanded to 25 states and by 1985 all 50 states were participants. Cannabis is cultivated in remote locations and frequently on public lands and illicitly grown in all states. Data provided by the DCE/SP (Table 3) show

that in the United States in 2014, there were 3,904,213 plants eradicated in outdoor cannabis cultivation areas compared to 2,597,798 plants in 2000. Significant quantities of marijuana were also eradicated from indoor cultivation operations. There were 396,620 indoor plants eradicated in 2014 compared to 217,105 eradicated in 2000.

**Table 3. Domestic Cannabis Eradication, Outdoor and Indoor Plants Seized, 2000–2014** (Source: Domestic Cannabis Eradication/Suppression Program)

	2000	2001	2002	2003	2004
<b>Outdoor</b>	2,597,798	3,068,632	3,128,800	3,427,923	2,996,144
<b>Indoor</b>	217,105	236,128	213,040	223,183	203,896
<b>Total</b>	2,814,903	3,304,760	3,341,840	3,651,106	3,200,040

	2005	2006	2007	2008	2009
<b>Outdoor</b>	3,938,151	4,830,766	6,599,599	7,562,322	9,980,038
<b>Indoor</b>	270,935	400,892	434,728	450,986	414,604
<b>Total</b>	4,209,086	5,231,658	7,034,327	8,013,308	10,394,642

	2010	2011	2012	2013	2014
<b>Outdoor</b>	9,866,766	6,226,288	3,631,582	4,033,513	3,904,213
<b>Indoor</b>	462,419	509,231	302,377	361,727	396,620
<b>Total</b>	10,329,185	6,735,519	3,933,959	4,395,240	4,300,833

The recent statistics from these various surveys and databases show that marijuana continues to be the most commonly used illicit drug, with considerable rates of heavy abuse and dependence. They also show that marijuana is the most readily available illicit drug in the United States.

#### **Petitioners' Major Comment in Relation to Factor 1 and the Government's Responses**

(1) The petitioner states on pages 1–2 of the petition that “[p]ure THC (Marinol), the primary psychoactive ingredient in marijuana has been placed in Schedule III. However, unlike Marinol, marijuana has other cannabinoids that help to mitigate the psychoactive effects of THC and reduce the potential for abuse. Therefore, the THC in marijuana can not have the high potential for abuse required for placement in Schedule I.”

First, the petitioners failed to review the indicators of abuse potential, as discussed in the legislative history of the CSA. The petitioners did not use data on marijuana usage, diversion, psychoactive properties, and dependence in their evaluation of marijuana abuse potential. The HHS and the DEA discuss those indicators above in this factor. HHS's evaluation of the full range of data led HHS and DEA to conclude that marijuana has a high potential for abuse.

Second, the HHS indicated that modulating effects of the other cannabinoids in marijuana on  $\Delta^9$ -THC have not been demonstrated in controlled studies. Specifically, HHS concluded in its 8-factor analysis that

“any possible mitigation of delta-9-THC's psychoactive effects by CBD will not occur for most marijuana users.”

Marinol was rescheduled from schedule II to schedule III on July 2, 1999 (64 FR 35928, DEA 1999). In assessing Marinol, HHS compared Marinol to marijuana on several aspects of abuse potential and found that major differences between the two, such as formulation, availability, and usage, contribute to differences in abuse potential. The psychoactive effects from smoking are generally more rapid and intense than those that occur through oral administration (HHS, 2015; Wesson and Washburn, 1990; Hollister and Gillespie, 1973). Therefore, as concluded by both the HHS and the DEA, the delayed onset of action and longer duration of action from an oral dose of Marinol may contribute in limiting the abuse potential of Marinol relative to marijuana, which is most often smoked. The HHS also stated that the extraction and purification of dronabinol from the encapsulated sesame oil mixture of Marinol is highly complex and difficult and that the presence of sesame oil mixture may preclude the smoking of Marinol-laced cigarettes.

Additionally, the FDA approved a New Drug Application (NDA) for Marinol, indicating a legitimate medical use for Marinol in the United States and allowing for Marinol to be rescheduled into schedule II and subsequently into schedule III of the CSA. The HHS mentioned that marijuana and Marinol differ on a wide variety of factors and these differences are major reasons for

differential scheduling of marijuana and Marinol. Marijuana, as discussed more fully in Factors 3 and 6, does not have a currently accepted medical use in the United States, is highly abused, and has a lack of accepted safety.

Finally, the DEA notes that under the CSA, for a substance to be placed in schedule II, III, IV, or V, it must have a currently accepted medical use in treatment in the United States.<sup>44</sup> As DEA has previously stated, Congress established only one schedule, schedule I, for drugs of abuse with “no currently accepted medical use in treatment in the United States.” 76 FR 40552 (2011). Thus, any attempt to compare the relative abuse potential of schedule I substance to that of a substance in another schedule is inconsequential since a schedule I substance must remain in schedule I until it has been found to have a currently accepted medical use in treatment in the United States.

#### **Factor 2: Scientific Evidence of the Drug's Pharmacological Effects, if Known**

The HHS stated that there are large amounts of scientific data on the neurochemistry, mechanistic effects, toxicology, and pharmacology of marijuana. A scientific evaluation, as conducted by the HHS and the DEA, of marijuana's neurochemistry, human and animal behavioral pharmacology, central nervous system effects, and other pharmacological effects (e.g. cardiovascular, immunological effects) is presented below.

<sup>44</sup> See *Americans for Safe Access*, 706 F.3d at 440.

## Neurochemistry

Marijuana contains numerous constituents such as cannabinoids that have a variety of pharmacological actions. The HHS stated that different marijuana samples derived from various cultivated strains may differ in their chemical constituents including  $\Delta^9$ -THC and other cannabinoids. Therefore marijuana products from different strains will have different biological and pharmacological effects. The chemical constituents of marijuana are discussed further in Factor 3.

The primary site of action for cannabinoids such as  $\Delta^9$ -THC is at the cannabinoid receptor. Two cannabinoid receptors, CB1 and CB2, have been identified and characterized (Battista et al., 2012; Piomelli, 2005) and are G-protein-coupled receptors. Activation of these inhibitory G-protein-coupled receptors inhibits adenylate cyclase activity, which prevents conversion of ATP to cyclic AMP. Cannabinoid receptor activation also results in inhibition of N- and P/Q-type calcium channels and activates inwardly rectifying potassium channels (Mackie et al., 1995; Twitchell et al., 1997). The HHS mentioned that inhibition of N-type calcium channels decreases neurotransmitter release and this may be the underlying mechanism in the ability of cannabinoids to inhibit acetylcholine, norepinephrine and glutamate from specific areas of the brain. These cellular actions may underlie the antinociceptive and psychoactive effects of cannabinoids.  $\Delta^9$ -THC acts as an agonist at cannabinoid receptors.

CB1 receptors are primarily found in the central nervous system and are located mainly in the basal ganglia, hippocampus and cerebellum of the brain (Howlett et al., 2004). CB1 receptors are also located in peripheral tissues such as the immune system (De Petrocellis and Di Marzo, 2009), but the concentration of CB1 receptors there is considerably lower than in the central nervous system (Herkenham et al., 1990; 1992). CB2 receptors are found primarily in the immune system and predominantly in B lymphocytes and natural killer cells (Bouaboula et al., 1993). CB2 receptors are also found in the central nervous system, primarily in the cerebellum and hippocampus (Gong et al., 2006).

Two endogenous ligands to the cannabinoid receptors, anandamide and arachidonyl glycerol (2-AG), were identified in 1992 (Devane et al., 1992) and 1995 (Mechoulam et al., 1995), respectively. Anandamide is a low-efficacy agonist (Brievogel and Childers,

2000) and 2-AG is a high efficacy agonist (Gonsiorek et al., 2000) to the cannabinoid receptors. These endogenous ligands are present in both the central nervous system and in the periphery (HHS, 2015).

$\Delta^9$ -THC and cannabidiol (CBD) are two of the major cannabinoids in marijuana.  $\Delta^9$ -THC is the major psychoactive cannabinoid (Wachtel et al., 2002).  $\Delta^9$ -THC has similar affinity for CB1 and CB2 receptors and acts as a weak agonist at CB2 receptors. The HHS indicated that activation of CB1 receptors mediates psychotropic effects of cannabinoids. CBD has low affinity for both CB1 and CB2 receptors. CBD has antagonistic effects at CB1 receptors, and some inverse agonistic properties at CB2 receptors.

## Animal Behavioral Effects

Animal abuse potential studies (drug discrimination, self-administration, conditioned place preference) are discussed more fully in Factor 1. Briefly, it was consistently demonstrated that  $\Delta^9$ -THC, the primary psychoactive component in marijuana, and other cannabinoids in marijuana have a distinct drug discriminative profile. In addition, animals self-administer  $\Delta^9$ -THC, and  $\Delta^9$ -THC in low doses produces conditioned place preference.

## Central Nervous System Effects

### *Psychoactive Effects*

The clinical psychoactive effects of marijuana are discussed more fully in Factor 1. Briefly, the psychoactive effects from marijuana use are considered pleasurable and associated with drug-seeking or drug-taking (HHS, 2015; Maldonado, 2002). Further, it was noted by HHS that marijuana users prefer higher concentrations of the principal psychoactive component ( $\Delta^9$ -THC) over lower concentrations (HHS, 2015).

Studies have evaluated psychoactive effects of THC in the presence of high CBD, CBC, or CBN ratios. Even though some studies suggest that CBD may decrease some of  $\Delta^9$ -THC's psychoactive effects, the HHS found that the ratios of CBD to  $\Delta^9$ -THC administered in the studies were not comparable to the amounts found in marijuana used by most people (Dalton et al., 1976; Karniol et al., 1974; Zwardi et al., 1982). In fact, the CBD ratios in these studies are significantly higher than the CBD found in most marijuana currently found on the streets (Mehmedic et al., 2010). HHS indicated that most of the marijuana available on the street has a high THC and low CBD content and therefore any

lessening of THC's psychoactive effects by CBD will not occur for most marijuana users (HHS, 2015). Dalton et al. (1976) reported that when volunteers smoked cigarettes with a ratio of 7 CBD to 1  $\Delta^9$ -THC (0.15 mg/kg CBD and 0.025 mg/kg  $\Delta^9$ -THC), there was a significant decrease in ratings of acute subjective effects and achieving a "high" in comparison to smoking  $\Delta^9$ -THC alone. In oral administration studies, the subjective effects and anxiety produced by combination of CBD and THC in a ratio of at least 1:2 CBD to  $\Delta^9$ -THC (15, 30, 60 mg CBD to 30 mg  $\Delta^9$ -THC; Karniol et al., 1974) or a ratio of 2:1 CBD to  $\Delta^9$ -THC (1 mg/kg CBD to 0.5 mg/kg  $\Delta^9$ -THC; Zuardi et al., 1982) are less than those produced by  $\Delta^9$ -THC administered alone.

In one study (Ilan et al., 2005), the authors calculated the naturally occurring concentrations of CBC and CBD in marijuana cigarettes with either 1.8 or 3.6%  $\Delta^9$ -THC by weight. The authors varied the concentrations of CBC and CBD for each concentration of  $\Delta^9$ -THC in the marijuana cigarettes. Administrations in healthy marijuana users (n=23) consisted of either: (1) Low CBC (0.1% by weight) and low CBD (0.2% by weight); (2) high CBC (0.5% by weight) and low CBD; (3) low CBC and high CBD (1.0% by weight); or 4) high CBC and high CBD and the users were divided into low  $\Delta^9$ -THC (1.8% by weight) and high  $\Delta^9$ -THC (3.6% by weight) groups. Subjective psychoactive effects were significantly greater for all groups in comparison to placebo and there were no significant differences in effects among the treatments (Ilan et al., 2005).

The HHS also referred to a study with  $\Delta^9$ -THC and cannabitol (CBN) (Karniol et al., 1975). In this study, oral administration of either 12.5, 25, or 50 mg CBN combined with 25 mg  $\Delta^9$ -THC (ratio of at least 1:2 CBN to  $\Delta^9$ -THC) significantly increased subjective psychoactive ratings of  $\Delta^9$ -THC compared to  $\Delta^9$ -THC alone (Karniol et al., 1975).

### *Behavioral Impairment*

Several factors may influence marijuana's behavioral effects including the duration (chronic or short term), frequency (daily, weekly, or occasionally), and amount of use (heavy or moderate). Researchers have examined how long behavioral impairments persist following chronic marijuana use. These studies used self-reported histories of exposure duration, frequency, and amount of marijuana use, and administered several performance and cognitive tests at different time points following



marijuana abstinence. According to HHS, behavioral impairments may persist for up to 28 days of abstinence in chronic marijuana users.

Psychoactive effects of marijuana can lead to behavioral impairment including cognitive decrements and decreased ability to operate motor vehicles (HHS, 2015). Block et al. (1992) evaluated cognitive measures in 48 healthy male subjects following smoking a marijuana cigarette that contained 2.57% or 19 mg  $\Delta^9$ -THC by weight or placebo. Each subject participated in eight sessions (four sessions with marijuana; four sessions with placebo) and several cognitive and psychomotor tests were administered (e.g. verbal recall, facial recognition, text learning, reaction time). Marijuana significantly impaired performances in most of these cognitive and psychomotor tests (Block et al., 1992).

Ramaekers et al. (2006) reported that in 20 recreational users of marijuana, acute administration of 250  $\mu$ g/kg and 500  $\mu$ g/kg  $\Delta^9$ -THC in smoked marijuana resulted in dose-dependent impairments in cognition, motor impulsivity, motor control (tracking impairments), and risk taking. In another study (Kurzthaler et al., 1999), when 290  $\mu$ g/kg  $\Delta^9$ -THC was administered via a smoked marijuana cigarette in 30 healthy volunteers with no history of substance abuse there were significant impairments of motor speed and accuracy. Furthermore, administration of 3.95%  $\Delta^9$ -THC in a smoked marijuana cigarette increased the latency in a task of simulated braking in a vehicle (Liguori et al., 1998). The HHS noted that the motor impairments reported in these studies (Kurzthaler et al., 1999; Liguori et al., 1998) are critical skills needed for operating a vehicle.

As mentioned in the HHS document, some studies examined the persistence of the behavioral impairments immediately after marijuana administration. Some of marijuana's acute effects may still be present for at least 24 hours after the acute psychoactive effects have subsided. In a brief communication, Heishmann et al. (1990) reported that there were cognitive impairments (digit recall and arithmetic tasks) in two out of three experienced marijuana smokers for 24 hours after smoking marijuana cigarettes containing 2.57%  $\Delta^9$ -THC. However, Fant et al. (1998) evaluated subjective effects and performance measures for up to 25 hours in 10 healthy males after exposure to either 1.8% or 3.6%  $\Delta^9$ -THC in marijuana cigarettes. Peak decrements in subjective and performance measures were noted within 2 hours of marijuana exposure

but there were minimal residual alterations in subjective or performance measures at 23–25 hours after exposure.

Persistence of behavioral impairments following repeated and chronic use of marijuana has also been investigated and was reviewed in the HHS document (HHS, 2015). In particular, researchers examined how long behavioral impairments last following chronic marijuana use. In studies examining persistence of effects in chronic and heavy marijuana users, there were significant decrements in cognitive and motor function tasks in all studies of up to 27 days, and in most studies at 28 days (Solowij et al., 2002; Messinis et al., 2006; Lisdahl and Price, 2012; Pope et al., 2002; Bolla et al., 2002; Bolla et al., 2005). In studies that followed heavy marijuana users for longer than 28 days and up to 20 years of marijuana abstinence, cognitive and psychomotor impairments were no longer detected (Fried et al., 2005; Lyons et al., 2004; Tait et al., 2011). For example, Fried et al. (2005) reported that after 3 months of abstinence from marijuana, any deficits in intelligence (IQ), memory, and processing speeds following heavy marijuana use were no longer observed (Fried et al., 2005). In a meta-analysis that examined non-acute and long-lasting effects of marijuana, any deficits in neurocognitive performance that were observed within the first month were no longer apparent after approximately one month of abstinence (Schreiner and Dunn, 2012). HHS further notes that in moderate marijuana users deficits in decision-making skills were not observed after 25 days of abstinence and additionally IQ, immediate memory and delayed memory skills were not significantly impacted as observed with heavy and chronic marijuana users (Fried et al., 2005; HHS, 2015)

As mentioned in the HHS document (HHS, 2015), the intensity and persistence of neurological impairment from chronic marijuana use also may be dependent on the age of first use. In two separate smaller scale studies (less than 100 participants per exposure group), Fontes et al. (2011) and Gruber et al. (2012) compared neurological function in early onset (chronic marijuana use prior to age 15 or 16) and late onset (chronic marijuana use after age 15 or 16) heavy marijuana users and found that there were significant deficits in executive neurological function in early onset users which were not observed or were less apparent in late onset users. In a prospective longitudinal birth cohort study following 1,037 individuals (Meier et al., 2012), a significant decrease in IQ and

neuropsychological performance was observed in adolescent-onset users and persisted even after abstinence from marijuana for at least one year. However, Meier et al (2012) reported in there was no significant change in IQ in adult-onset users.

The HHS noted that there is some evidence that the severity of the persistent neurological impairments may also be due in part to the amount of marijuana usage. In the study mentioned above, Gruber et al. (2012) found that the early onset users consumed three times as much marijuana per week and used it twice as often as late onset users. Meier et al. (2012) reported in their study, mentioned above, that there was a correlation between IQ deficits in adolescent onset users and the increased amount of marijuana used.

#### *Behavioral Effects of Prenatal Exposure*

In studies that examined effects of prenatal marijuana exposure, many of the pregnant women also used alcohol and tobacco in addition to marijuana. Even though other drugs were used in conjunction with marijuana, there is evidence of an association between heavy prenatal marijuana exposure and deficits in some cognitive function. There have been two prospective longitudinal birth cohort studies following individuals prenatally exposed to marijuana from birth until adulthood: The Ottawa Prenatal Prospective Study (OPPS; Fried et al., 1980), and the Maternal Health Practices and Child Development Project (MHPCD; Day et al., 1985). Both longitudinal studies report that heavy prenatal marijuana use is associated with decreased performance on tasks assessing memory, verbal and quantitative reasoning in 4-year-olds (Fried and Watkinson, 1990) and in 6 year olds (Goldschmidt et al., 2008). In subsequent studies with the OPPS cohort, deficits in sustained attention were reported in children ages 6 and 13–16 years (Fried et al., 1992; Fried, 2002) and deficits in executive neurological function were observed in 9- and 12-year-old children (Fried et al., 1998). DEA further notes that with the MHPCD cohort, follow-up studies reported an increased rate of delinquent behavior (Day et al., 2011) and decreased achievement test scores (Goldschmidt et al., 2012) at age 14. When the MHPCD cohort was followed to age 22, there was a marginal ( $p = 0.06$ ) increase in psychosis with prenatal marijuana exposure and early onset of marijuana use (Day et al., 2015).

### *Association of Marijuana Use With Psychosis*

There has been extensive research to determine whether marijuana usage is associated with development of schizophrenia or other psychoses, and the HHS indicated that the available data do not suggest a causative link between marijuana and the development of psychosis (HHS, 2015; Minozzi et al., 2010). As mentioned in the HHS review (HHS, 2015), numerous large scale longitudinal studies demonstrated that subjects who used marijuana do not have a greater incidence of psychotic diagnoses compared to non-marijuana users (van Os et al., 2002; Fergusson et al., 2005; Kuepper et al., 2011). Further, the HHS commented that when analyzing the available data examining the association between marijuana and psychosis, it is critical to differentiate whether the patients in a study are already diagnosed with psychosis or if the individuals have a limited number of symptoms associated with psychosis without qualifying for a diagnosis of the disorder.

As mentioned by the HHS, some of the studies examining the association between marijuana and psychosis utilized non-standard methods to categorize psychosis and these methods did not conform to the criteria in the Diagnostic and Statistical Manual (DSM-5) or the International Classification of Diseases (ICD-10) and would not be appropriate for use in evaluating the association between marijuana use and psychosis. For example, researchers characterized psychosis as “schizophrenic cluster” (Maremmanni et al., 2004), “subclinical psychotic symptoms” (van Gastel et al., 2012), “pre-psychotic clinical high risk” (van der Meer et al., 2012), and symptoms related to “psychosis vulnerability” (Griffith-Lending et al., 2012).

The HHS discussed an early epidemiological study conducted by Andreasson et al. (1987), which examined the link between psychosis and marijuana use. In this study, about 45,000 18- and 19-year-old male Swedish subjects provided detailed information on their drug-taking history and 274 of these subjects were diagnosed with schizophrenia over a 14-year period (1969–1983). Out of the 274 subjects diagnosed with psychosis, 21 individuals (7.7%) had used marijuana more than 50 times, while 197 individuals (72%) never used marijuana. As presented by the authors (Andreasson et al., 1987), individuals who claimed to take marijuana on more

than 50 occasions were 6 times more likely to be diagnosed with schizophrenia than those who had never consumed the drug. The authors concluded that marijuana users who are vulnerable to developing psychoses are at the greatest risk for schizophrenia. In a 35 year follow up to the subjects evaluated in Andreasson et al. (1987), Manrique-Garcia et al. (2012) reported similar findings. In the follow up study, 354 individuals developed schizophrenia. Of those, 32 individuals (9%) had used marijuana more than 50 times and were 6.3 times more likely to develop schizophrenia. 255 of the 354 individuals (72%) never used marijuana.

The HHS also noted that many studies support the assertion that psychosis from marijuana usage may manifest only in individuals already predisposed to development of psychotic disorders. Marijuana use may precede diagnosis of psychosis (Schimmelmann et al., 2011), but most reports indicate that prodromal symptoms of schizophrenia are observed prior to marijuana use (Schiffman et al., 2005). In a review examining gene-environmental interaction between marijuana exposure and the development of psychosis, it was concluded that there is some evidence to support that marijuana use may influence the development of psychosis but only for susceptible individuals (Pelayo-Teran et al., 2012).

Degenhardt et al. (2003) modeled the prevalence of schizophrenia against marijuana use across eight birth cohorts in individuals born during 1940 to 1979 in Australia. Even though there was an increase in marijuana use in the adult subjects over this time period, there was not an increase in diagnoses of psychosis for these same subjects. The authors concluded that use of marijuana may increase schizophrenia only in persons vulnerable to developing psychosis.

### **Cardiovascular and Autonomic Effects**

The HHS stated that acute use of marijuana causes an increase in heart rate (tachycardia) and may increase blood pressure (Capriotti et al., 1988; Benowitz and Jones, 1975). There is some evidence that associates the increased heart rate from  $\Delta^9$ -THC exposure with excitation of the sympathetic and depression of the parasympathetic nervous systems (Malinowska et al., 2012). Tolerance to tachycardia develops with chronic exposure to marijuana (Jones, 2002; Sidney, 2002).

Prolonged exposure to  $\Delta^9$ -THC results in a decrease in heart rate (bradycardia) and hypotension (Benowitz and Jones,

1975). These effects are thought to be mediated through peripherally located, presynaptic CB1 receptor inhibition of norepinephrine release with possible direct activation of vascular cannabinoid receptors (Wagner et al., 1998; Pacher et al., 2006).

As stated in the HHS recommendation (HHS, 2015), marijuana exposure causes orthostatic hypotension (fainting-like feeling; sudden drop in blood pressure upon standing up) and tolerance can develop to this effect upon repeated, chronic exposure (Jones, 2002). Tolerance to orthostatic hypotension is potentially related to plasma volume expansion, but tolerance does not develop to supine hypotensive effects (Benowitz and Jones, 1975).

Marijuana smoking, particularly by those with some degree of coronary artery or cerebrovascular disease, poses risks such as increased cardiac work, increased catecholamines and carboxyhemoglobin, myocardial infarction and postural hypotension (Benowitz and Jones, 1981; Hollister, 1988; Mittleman et al., 2001; Malinowska et al., 2012). However, electrocardiographic changes were minimal after administration of large cumulative doses of  $\Delta^9$ -THC (Benowitz and Jones, 1975)

The DEA notes two recent reports that reviewed several case studies on marijuana and cardiovascular complications (Panayiotides, 2015; Hackam, 2015). Panayiotides (2015) reported that approximately 25.6% of the cardiovascular cases from marijuana use resulted in death from data provided by the French Addictovigilance Network during the period of 2006–2010. Several case studies on marijuana usage and cardiovascular events were discussed and it was concluded that although a causal link cannot be established due to not knowing exact amounts of marijuana used in the cases and confounding variables, the available evidence supports a link between marijuana and cardiotoxicity. Hackham (2015) reviewed 34 case reports or case series reports of marijuana and stroke/ ischemia in 64 stroke patients and reported that in 81% of the cases there was a temporal relationship between marijuana usage and stroke or ischemic event. The author concluded that collective analysis of the case reports supports a causal link between marijuana use and stroke.

### **Respiratory Effects**

The HHS stated that transient bronchodilation is the most typical respiratory effect of acute exposure to marijuana (Gong et al., 1984). In a recent

longitudinal study, information on marijuana use and pulmonary data function were collected from 5,115 individuals over 20 years from 4 communities in the United States (Oakland, CA; Chicago, IL; Minneapolis, MN; Birmingham, AL) (Pletcher et al., 2012). Of the 5,115 individuals, 795 individuals reported use of only marijuana (without tobacco). The authors reported that occasional use of marijuana (7 joint-years for lifetime or 1 joint/day for 7 years or 1 joint/week for 49 years) does not adversely affect pulmonary function. Pletcher et al. (2012) further concluded that there is some preliminary evidence suggesting that heavy marijuana use may have a detrimental effect on pulmonary function, but the sample size of heavy marijuana users in the study was too small. Further, as mentioned in the HHS recommendation document (HHS, 2015), long-term use of marijuana may lead to chronic cough, increased sputum, as well as increased frequency of chronic bronchitis and pharyngitis (Adams and Martin, 1996; Hollister, 1986).

The HHS stated that the evidence that marijuana may lead to cancer of the respiratory system is inconsistent, with some studies suggesting a positive correlation while others do not (Lee and Hancox, 2011; Tashkin, 2005). The HHS noted a case series that reported lung cancer occurrences in three marijuana smokers (age range 31–37 years) with no history of tobacco smoking (Fung et al., 1999). Furthermore, in a case-control study (n = 173 individuals with squamous cell carcinoma of the head and neck; n = 176 controls; Zhang et al., 1999), prevalence of marijuana use was 9.7% in controls and 13.9% in cases and the authors reported that marijuana use may dose-dependently interact with mutagenic sensitivity, cigarette smoking, and alcohol use to increase risk associated with head and neck cancers (Zhang et al., 1999). However, in a large clinical study with 1,650 subjects, no positive correlation was found between marijuana use and lung cancer (Tashkin et al., 2006). This finding held true regardless of the extent of marijuana use when both tobacco use and other potential confounding factors were controlled. The HHS concluded that new evidence suggests that the effects of smoking marijuana on respiratory function and cancer are different from the effects of smoking tobacco (Lee and Hancox, 2011).

The DEA further notes the publication of recent review articles critically evaluating the association between marijuana and lung cancer. Most of the reviews agree that the association is

weak or inconsistent (Huang et al., 2015; Zhang et al., 2015; Gates et al., 2014; Hall and Degenhardt, 2014). Huang et al. (2015) identified and reviewed six studies evaluating the association between marijuana use and lung cancer and the authors concluded that an association is not supported most likely due to the small amounts of marijuana smoked in comparison to tobacco. Zhang et al. (2015) examined six case control studies from the US, UK, New Zealand, and Canada within the International Lung Cancer Consortium and found that there was a weak association between smoking marijuana and lung cancer in individuals who never smoked tobacco, but precision of the association was low at high marijuana exposure levels. Hall and Degenhardt (2014) noted that even though marijuana smoke contains several of the same carcinogens and co-carcinogens as tobacco smoke (Roth et al., 1998) and has been found to be mutagenic and carcinogenic in the mouse skin test, epidemiological studies have been inconsistent, but more consistent positive associations have been reported in case control studies. Finally Gates et al. (2014), reviewed the studies evaluating marijuana use and lung cancer and concluded that there is evidence that marijuana produces changes in the respiratory system (precursors to cancer) that could lead to lung cancer, but overall association is weak between marijuana use and lung cancer especially when controlling for tobacco use.

## Endocrine System

### *Reproductive Hormones*

The HHS stated that administration of marijuana to humans does not consistently alter the endocrine system. In a controlled human exposure study (n = 4 males), subjects were acutely administered smoked marijuana containing 2.8%  $\Delta^9$ -THC or placebo and an immediate significant decrease in luteinizing hormone and an increase in cortisol was reported in the subjects that smoked marijuana (Cone et al., 1986). Furthermore, as cited by the HHS, two later studies (Dax et al., 1989; Block et al., 1991) reported no changes in hormone levels. Dax et al. (1989) recruited male volunteers (n = 17) that were occasional or heavy users of marijuana. Following exposure to smoked  $\Delta^9$ -THC (18 mg/cigarette) or oral  $\Delta^9$ -THC (10 mg three times per day for three days and on the morning of the fourth day), the subjects in that study showed no changes in plasma adrenocorticotrophic hormone (ACTH), cortisol, prolactin, luteinizing hormone,

or testosterone levels. Additionally, Block et al. (1991) compared plasma hormone levels amongst non-users as well as infrequent, moderate, and frequent users of marijuana (n = 93 men and 56 women) and found that chronic use of marijuana (infrequent, moderate, and frequent users) did not significantly alter concentrations of testosterone, luteinizing hormone, follicle stimulating hormone, prolactin, or cortisol.

The HHS noted that there is a discrepancy in the effect of marijuana on female reproductive system functionality between animals and humans (HHS, 2015). Female rhesus monkeys that were administered 2.5 mg/kg  $\Delta^9$ -THC, i.m., during days 1–18 of the menstrual cycle had reduced progesterone levels and ovulation was suppressed (Asch et al., 1981). However, women who smoked marijuana (1 gram marijuana cigarette with 1.8%  $\Delta^9$ -THC) during the periovulatory period (24–36 hours prior to ovulation) did not exhibit changes in reproductive hormone levels or their menstrual cycles (Mendelson and Mello, 1984). In a review article by Brown and Dobs (2002), the authors state that endocrine changes observed with marijuana are no longer observed with chronic administration and this may be due to drug tolerance.

### *Reproductive Cancers*

The HHS stated that recent studies support a possible association between frequent, long-term marijuana use and increased risk of testicular germ cell tumors. In a hospital-based case-control study, the frequency of marijuana use was compared between testicular germ cell tumor (TGCT) patients (n = 187) and controls (n = 148) (Trabert et al., 2011). TGCT patients were more likely to be frequent marijuana users than controls with an odds ratio (OR) of 2.2 (95% confidence limits of 1.0–5.1) and were less likely to be infrequent or short-term users with odds ratios of 0.5 and 0.6, respectively in comparison to controls (Trabert et al., 2011). The DEA further notes that in two population-based case-control studies (Daling et al., 2009; Lacson et al., 2012), marijuana use was compared between patients diagnosed with TGCT and matched controls in Washington State or Los Angeles County. In both studies, it was reported that TCGT patients were twice as likely as controls to use marijuana. Authors of both studies concluded that marijuana use is associated with an elevated risk of TGCT (Daling et al., 2009; Lacson et al., 2012).

The HHS cited a study (Sarfraz et al., 2005) demonstrating that WIN 55,212–2 (a mixed CB1/CB2 agonist) induces apoptosis (one form of cell death) in

prostate cancer cells and decreases expression of androgen receptors and prostate specific antigens, suggesting a potential therapeutic value for cannabinoid agonists in the treatment of prostate cancer, an androgen-stimulated type of carcinoma.

#### *Other hormones (e.g. Thyroid, Appetite)*

In more recent studies, as cited by the HHS, chronic marijuana use by subjects (n = 39) characterized as dependent on marijuana according to the ICD-10 criteria did not affect serum levels of thyroid hormones: TSH (thyrotropin), T4 (thyroxine), and T3 (triiodothyronine) (Bonnet, 2013). With respect to appetite hormones, in a pilot study with HIV-positive males, smoking marijuana dose-dependently increased plasma levels of ghrelin and leptin and decreased plasma levels of peptide YY (Riggs et al., 2012).

The HHS stated that  $\Delta^9$ -THC reduces binding of the corticosteroid dexamethasone in hippocampal tissue from adrenalectomized rats and acute  $\Delta^9$ -THC releases corticosterone, with tolerance developing to this effect with chronic administration (Eldridge et al., 1991). These data suggest that  $\Delta^9$ -THC may interact with the glucocorticoid receptor system.

#### **Immune System**

The HHS stated that cannabinoids alter immune function but that there can be differences between the effects of synthetic, natural, and endogenous cannabinoids (Croxford and Yamamura, 2005; Tanasescu and Constantinescu, 2010).

The HHS noted that there are conflicting results in animal and human studies with respect to cannabinoid effects on immune functioning in subjects with compromised immune systems. Abrams et al. (2003) examined the effects of marijuana and  $\Delta^9$ -THC in 62 HIV-1-infected patients. Subjects received one of three treatments, three times a day: smoked marijuana cigarette containing 3.95%  $\Delta^9$ -THC, oral tablet containing  $\Delta^9$ -THC (2.5 mg oral dronabinol), or oral placebo. There were no changes in CD4+ and CD8+ cell counts, HIV RNA levels, or protease inhibitor levels in any of the treatment groups (Abrams et al., 2003). Therefore, use of cannabinoids showed no short-term adverse virologic effects in individuals with compromised immune systems. Conversely, Roth et al. (2005) reported that in immunodeficient mice implanted with human blood cells infected with HIV, exposure to  $\Delta^9$ -THC *in vivo* suppresses immune function, increases HIV co-receptor expression,

and acts as a cofactor to enhance HIV replication.

The DEA notes two recent clinical studies reporting a decrease in cytokine and interleukin levels following marijuana use. Keen et al. (2014) compared the differences in the levels of IL-6 (interleukin-6), a proinflammatory cytokine, amongst non-drug users (n = 78), marijuana only users (n = 46) and marijuana plus other drug users (n = 45) in a community-based sample of middle-aged African Americans (Keen et al., 2014). After adjusting for confounders, analyses revealed that lifetime marijuana only users had significantly lower IL-6 levels than the nonuser group. Further, Sexton et al. (2014) compared several immune parameters in healthy individuals and subjects with multiple sclerosis (MS) and found that the chronic use of marijuana resulted in reduced monocyte migration, and decreased levels of CCL2 and IL-17 in both healthy and MS groups.

The DEA also notes a review suggesting that  $\Delta^9$ -THC suppresses the immune responses in experimental animal models and *in vitro* and that these changes may be primarily mediated through the CB2 cannabinoid receptor (Eisenstein and Meissler, 2015).

#### **Factor 3: The State of the Current Scientific Knowledge Regarding the Drug or Substance**

##### **Chemistry**

The HHS stated that marijuana, also known as *Cannabis sativa L.*, is part of the Cannabaceae plant family and is one of the oldest cultivated crops. The term “marijuana” is generally used to refer to a mixture of the dried flowering tops and leaves from *Cannabis*. Marijuana users primarily smoke the marijuana leaves, but individuals also ingest marijuana through food infused with marijuana and its extracts. *Cannabis sativa* is the primary species of *Cannabis* that is illegally marketed in the United States. Marijuana is one of three major derivatives sold as separate illicit products, the other two being hashish and hash oil. Hashish is composed of the dried and compressed cannabinoid-rich resinous material of *Cannabis* and is found as balls and cakes as well as other forms. Individuals may break off pieces and place them into a pipe to smoke. Hash oil, a viscous brown or amber colored liquid, is produced by solvent extraction of cannabinoids from *Cannabis* and contains approximately 50% cannabinoids. One to two drops of hash oil on a cigarette has been reported to

produce the equivalent of a single marijuana cigarette (DEA, 2015).

Different marijuana samples are derived from numerous cultivated strains and may have different chemical compositions including levels of  $\Delta^9$ -THC and other cannabinoids (Appendino et al., 2011). A consequence of having different chemical compositions in the various marijuana samples is that there will be significant differences in safety, biological, pharmacological, and toxicological profiles and therefore, according to the HHS, all *Cannabis* strains cannot be considered collectively because of the variations in chemical composition. Furthermore, the concentration of  $\Delta^9$ -THC and other cannabinoids present in marijuana may vary due to growing conditions and processing of the plant after harvesting. For example, the plant parts collected such as flowers, leaves and stems can influence marijuana's potency, quality, and purity (Adams and Martin, 1996; Agurell et al., 1984; Mechoulam, 1973). Variations in marijuana harvesting have resulted in potencies ranging from a low of 1 to 2% up to a high of 17% as indicated by cannabinoid content. The concentration of  $\Delta^9$ -THC averages approximately 12% by weight in a typical marijuana mixture of leaves and stems. However, some specifically grown and selected marijuana samples can contain 15% or greater  $\Delta^9$ -THC (Appendino et al., 2011). As a result, the  $\Delta^9$ -THC content in a 1 gram marijuana cigarette can range from as little as 3 milligrams to 150 milligrams or more. In a systematic review conducted by Cascini et al. (2012), it was reported that marijuana's  $\Delta^9$ -THC content has increased significantly from 1979–2009.

Since there is considerable variability in the cannabinoid concentrations and chemical constituency among marijuana samples, the interpretation of clinical data with marijuana is complicated. A primary issue is the lack of consistent concentrations of  $\Delta^9$ -THC and other substances in marijuana which complicates the interpretation of the effects of different marijuana constituents. An added issue is that the non-cannabinoid components in marijuana may potentially modify the overall pharmacological and toxicological properties of various marijuana strains and products.

Various *Cannabis* strains contain more than 525 identified natural constituents including cannabinoids, 21 (or 22) carbon terpenoids found in the plant, as well as their carboxylic acids, analogues, and transformation products (Agurell et al., 1984; 1986; Mechoulam, 1973; Appendino et al., 2011). To date,

more than 100 cannabinoids have been characterized (ElSohly and Slade, 2005; Radwan et al., 2009; Appendino et al., 2011), and most major cannabinoid compounds occurring naturally have been identified. There are still new and comparably more minor cannabinoids being characterized (Pollastro et al., 2011). The majority of the cannabinoids are found in *Cannabis*. One study reported accumulation of two cannabinoids, cannabigerol and its corresponding acid, in *Helichrysum (H. umbraculigerum)* which is a non-*Cannabis* source (Appendino et al., 2011).

Of the cannabinoids found in marijuana,  $\Delta^9$ -THC (previously known as  $\Delta^1$ -THC) and delta-8-tetrahydrocannabinol ( $\Delta^8$ -THC,  $\Delta^6$ -THC) have been demonstrated to produce marijuana's psychoactive effects. Psychoactive effects from marijuana usage have been mainly attributed to  $\Delta^9$ -THC because  $\Delta^9$ -THC is present in significantly more quantities than  $\Delta^8$ -THC in most marijuana varieties. There are only a few marijuana strains that contain  $\Delta^8$ -THC in significant amounts (Hively et al., 1966).  $\Delta^9$ -THC is an optically active resinous substance that is extremely lipophilic. The chemical name for  $\Delta^9$ -THC is (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo-[b,d]pyran-1-ol, or (-)-delta9-(trans)-tetrahydrocannabinol. The (-)-trans  $\Delta^9$ -THC isomer is pharmacologically 6 to 100 times more potent than the (+)-trans isomer (Dewey et al., 1984).

Other relatively well-characterized cannabinoids present in marijuana include cannabidiol (CBD), cannabichromene (CBC), and cannabinol (CBN). CBD and CBC are major cannabinoids in marijuana and are both lipophilic. The chemical name for CBD is 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol and the chemical name for CBC is 2-methyl-2-(4-methylpent-3-enyl)-7-pentyl-5-chromenol. CBN is a minor naturally-occurring cannabinoid with weak psychoactivity and is also a major metabolite of  $\Delta^9$ -THC. The chemical name for CBN is 6,6,9-trimethyl-3-pentyl-benzo[c]chromen-1-ol.

In summary, marijuana has several strains with high variability in the concentrations of  $\Delta^9$ -THC, the main psychoactive component, as well as other cannabinoids and compounds. Marijuana is not a single chemical and does not have a consistent and reproducible chemical profile with predictable or consistent clinical effects. In the HHS recommendation for marijuana scheduling (HHS, 2015), it

was recommended that investigators consult a guidance for industry entitled, *Botanical Drug Products*,<sup>45</sup> which provides information on the approval of botanical drug products. Specifically, in order to investigate marijuana in support of a New Drug Application (NDA), clinical studies under an Investigational New Drug (IND) application should include "consistent batches of a particular marijuana product for [a] particular disease." (HHS, 2015). Furthermore, the HHS noted that investigators must provide data meeting the requirements for new drug approval as stipulated in 21 CFR 314.50 (HHS, 2015).

#### Human Pharmacokinetics

Pharmacokinetics of marijuana in humans is dependent on the route of administration and formulation (Adams and Martin, 1996; Agurell et al., 1984; Agurell et al., 1986). Individuals primarily smoke marijuana as a cigarette (weighing between 0.5 and 1 gram) or in a pipe. More recently, vaporizers have been used as another means for individuals to inhale marijuana. Marijuana may also be ingested orally in foods or as an extract in ethanol or other solvents. Pharmacokinetic studies with marijuana focused on evaluating the absorption, metabolism, and elimination profile of  $\Delta^9$ -THC and other cannabinoids (Adams and Martin, 1996; Agurell et al., 1984; Agurell et al., 1986).

#### Absorption and Distribution of Inhaled Marijuana Smoke

There is high variability in the pharmacokinetics of  $\Delta^9$ -THC and other cannabinoids from smoked marijuana due to differences in individual smoking behavior even under controlled experimental conditions (Agurell et al., 1986; Herning et al., 1986; Huestis et al., 1992a). Experienced marijuana users can titrate and regulate the dose by holding marijuana smoke in their lungs for an extended period of time resulting in increased psychoactive effects by prolonging absorption of the smoke. This property may also help explain why there is a poor correlation between venous levels of  $\Delta^9$ -THC and the intensity of effects and intoxication (Agurell et al., 1986; Barnett et al., 1985; Huestis et al., 1992a). The HHS recommended that puff and inhalation volumes should be tracked in experimental studies because the concentration of cannabinoids can vary at different stages of smoking.

$\Delta^9$ -THC from smoked marijuana is rapidly absorbed within seconds.

<sup>45</sup> Available at <http://www.fda.gov/Drugs/default.htm> under Guidance (Drugs).

Psychoactive effects are observed immediately following absorption with measurable neurological and behavioral changes for up to 6 hours (Grotenhermen, 2003; Hollister, 1986; Hollister, 1988).  $\Delta^9$ -THC is distributed to the brain in a rapid and efficient manner. Bioavailability of  $\Delta^9$ -THC from marijuana (from a cigarette or pipe) ranges from 1 to 24% with the fraction absorbed rarely exceeding 10 to 20% (Agurell et al., 1986; Hollister, 1988). The low and variable bioavailability of  $\Delta^9$ -THC is due to loss in side-stream smoke, variation in individual smoking behaviors and experience, incomplete absorption of inhaled smoke, and metabolism in lungs (Herning et al., 1986; Johansson et al., 1989). After cessation of smoking,  $\Delta^9$ -THC venous levels decline within minutes and continue to decline to about 5% to 10% of the peak level within an hour (Agurell et al., 1986; Huestis et al., 1992a; Huestis et al., 1992b).

#### Absorption and Distribution of Orally Administered Marijuana

Following oral administration of  $\Delta^9$ -THC or marijuana, onset of effects start within 30 to 90 minutes, peak after 2 to 3 hours and effects remain for 4 to 12 hours (Grotenhermen, 2003; Adams and Martin, 1996; Agurell et al., 1984; Agurell et al., 1986). Dose titration of  $\Delta^9$ -THC from orally ingested marijuana is difficult for users in comparison to smoked or inhaled marijuana due to the delay in the onset of effects. Oral bioavailability of  $\Delta^9$ -THC, either in its pure form or in marijuana, is low and variable with a range from 5% to 20% (Agurell et al., 1984; Agurell et al., 1986). There is also inter- and intra-subject variability of orally administered  $\Delta^9$ -THC under experimental conditions and even under repeated dosing experiments (HHS, 2015). The HHS noted that in bioavailability studies using radiolabeled  $\Delta^9$ -THC,  $\Delta^9$ -THC plasma levels following oral administration of  $\Delta^9$ -THC were low relative to plasma levels after inhaled or intravenously administered  $\Delta^9$ -THC. The low and variable bioavailability of orally administered  $\Delta^9$ -THC is due to first pass hepatic elimination from blood and erratic absorption from stomach and bowel (HHS, 2015).

#### Metabolism and Excretion of Cannabinoids From Marijuana

Studies evaluating cannabinoid metabolism and excretion focused on  $\Delta^9$ -THC because it is the primary psychoactive component in marijuana.  $\Delta^9$ -THC is metabolized via microsomal hydroxylation and oxidation to both active and inactive

metabolites (Lemberger et al., 1970; Lemberger et al., 1972a; Lemberger et al., 1972b; Agurell et al., 1986; Hollister, 1988). Metabolism of  $\Delta^9$ -THC is consistent among frequent and infrequent marijuana users (Agurell et al., 1986). The primary active metabolite of  $\Delta^9$ -THC following oral ingestion is 11-hydroxy- $\Delta^9$ -THC which is equipotent to  $\Delta^9$ -THC in producing marijuana-like subjective effects (Agurell et al., 1986; Lemberger and Rubin, 1975). Metabolite levels following oral administration may be greater than that of  $\Delta^9$ -THC and may contribute greatly to the pharmacological effects of oral  $\Delta^9$ -THC or marijuana.

Plasma clearance of  $\Delta^9$ -THC approximates hepatic blood flow at a rate of approximately 950 ml/min or greater. Rapid clearance of  $\Delta^9$ -THC from blood is primarily due to redistribution to other tissues in the body rather than to metabolism (Agurell et al., 1984; Agurell et al., 1986). Outside of the liver, metabolism in most tissues is considerably slow or does not occur. The elimination half-life of  $\Delta^9$ -THC ranges from 20 hours to between 10 and 13 days (Hunt and Jones, 1980). Lemberger et al. (1970) reported that the half-life of  $\Delta^9$ -THC ranged from 23–28 hours in heavy marijuana users and up to 60 to 70 hours in naïve users. The long elimination half-life of  $\Delta^9$ -THC is due to slow release of  $\Delta^9$ -THC and other cannabinoids from tissues and subsequent metabolism. Inactive carboxy metabolites of  $\Delta^9$ -THC have terminal half-lives of 50 hours to 6 days or more and serve as long-term markers in urine tests for marijuana use.

Most of the absorbed  $\Delta^9$ -THC dose is eliminated in the feces and about 33% in urine. The glucuronide metabolite of  $\Delta^9$ -THC is excreted as the major urine metabolite along with 18 non-conjugated metabolites (Agurell et al., 1986).

#### Research Status and Test of Currently Accepted Medical Use for Marijuana

According to the HHS, there are numerous human clinical studies with marijuana in the United States under FDA-regulated IND applications. Results of small clinical exploratory studies have been published in the medical literature. Approval of a human drug for marketing, however, is contingent upon FDA approval of a New Drug Application (NDA) or a Biologics License Application (BLA). According to the HHS, the FDA has not approved any drug product containing marijuana for marketing.

The HHS noted that a drug may be found to have a medical use in treatment in the United States for

purposes of the CSA if the drug meets the five elements described by the DEA in 1992. Those five elements “are both necessary and sufficient to establish a prima facie case of currently accepted medical use” in treatment in the United States.” (57 FR 10499, 10504 (March 26, 1992)). This five-element test, which the HHS and DEA have utilized in all such analyses for more than two decades, has been upheld by the Court of Appeals. *ACT*, 15 F.3d at 1135. The five elements that characterize “currently accepted medical use” for a drug are summarized here and expanded upon in the discussion below:

1. *The drug's chemistry must be known and reproducible;*
2. *There must be adequate safety studies;*
3. *There must be adequate and well-controlled studies proving efficacy;*
4. *The drug must be accepted by qualified experts; and*
5. *Scientific evidence must be widely available.*

In its review (HHS, 2015), the HHS evaluated the five elements with respect to the currently available research for marijuana. The HHS concluded that marijuana does not meet any of the five elements—all of which must be demonstrated to find that a drug has a “currently accepted medical use.” A brief summary of the HHS’s evaluation is provided below.

*Element #1: The drug's chemistry must be known and reproducible.*

*“The substance's chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official compendia, as defined by section 201(j) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321(j), is sufficient generally to meet this requirement.” 57 FR 10499, 10506 (March 26, 1992).*

As defined by the CSA, marijuana includes all species of the genus *Cannabis*, including all strains therein.<sup>46</sup> Chemical constituents

<sup>46</sup> Although the CSA definition of marijuana refers only to the species “*Cannabis sativa* L.,” federal courts have consistently ruled that all species of the genus *cannabis* are included in this definition. See *United States v. Kelly*, 527 F.2d 961, 963–964 (9th Cir. 1976) (collecting and examining cases). The Single Convention (article 1, par. 1(c)) likewise defines the “cannabis plant” to mean “any plant of the genus *Cannabis*.” As explained above in the attachment titled “Preliminary Note Regarding Treaty Considerations,” 21 U.S.C. 811(d)(1) provides that, where a drug is subject to control under the Single Convention, the DEA Administrator must control the drug under the schedule he deems most appropriate to carry out such treaty obligations, without regard to the findings required by 21 U.S.C. 811(a) or 812(b) and without regard to the procedures prescribed by 21 U.S.C. 811(a) and (b).

including  $\Delta^9$ -THC and other cannabinoids vary significantly in marijuana samples derived from different strains (Appendino et al., 2011). As a result, there will be significant differences in safety, biological, pharmacological, and toxicological parameters amongst the various marijuana samples. Due to the variation of the chemical composition in marijuana samples, it is not possible to reproduce a standardized dose when considering all strains together. The HHS does advise that if a specific *Cannabis* strain is cultivated and processed under controlled conditions, the plant chemistry may be consistent enough to derive reproducible and standardized doses.

*Element #2: There must be adequate safety studies.*

*“There must be adequate pharmacological and toxicological studies, done by all methods reasonably applicable, on the basis of which it could fairly and responsibly be concluded, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, that the substance is safe for treating a specific, recognized disorder.” 57 FR 10499, 10506 (March 26, 1992).*

The HHS stated that there are no adequate safety studies on marijuana. As indicated in their evaluation of Element #1, the considerable variation in the chemistry of marijuana complicates the safety evaluation. The HHS concluded that marijuana does not satisfy Element #2 for having adequate safety studies such that medical and scientific experts may conclude that it is safe for treating a specific ailment.

*Element #3: There must be adequate and well-controlled studies of efficacy.*

*“There must be adequate, well-controlled, well-designed, well-conducted and well-documented studies, including clinical investigations, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, on the basis of which it could be fairly and responsibly concluded by such experts that the substance will have the intended effect in treating a specific, recognized disorder.” 57 FR 10499, 10506 (March 26, 1992).*

As indicated in the HHS’s review of marijuana (HHS, 2015), there are no adequate or well-controlled studies that prove marijuana’s efficacy. The FDA independently reviewed (FDA, 2015) publicly available clinical studies on marijuana published prior to February 2013 to determine if there were appropriate studies to determine marijuana’s efficacy (please refer to FDA, 2015 and HHS, 2015 for more

details). After review, the FDA determined that out of the identified articles, including those identified through a search of bibliographic references and 566 abstracts located on PubMed, 11 studies met the *a priori* selection criteria, including placebo control and double-blinding. FDA and HHS critically reviewed each of the 11 studies to determine if the studies met accepted scientific standards. FDA and HHS concluded that these studies do not “currently prove efficacy of marijuana” for any therapeutic indication due to limitations in the study designs. The HHS indicated that these studies could be used as proof of concept studies, providing preliminary evidence on a proposed hypothesis involving a drug’s effect.

*Element #4: The drug must be accepted by qualified experts.*

*“[A] consensus of the national community of experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, accepts the safety and effectiveness of the substance for use in treating a specific, recognized disorder. A material conflict of opinion among experts precludes a finding of consensus.” 57 FR 10499, 10506 (March 26, 1992).*

The HHS concluded that there is currently no evidence of a consensus among qualified experts that marijuana is safe and effective in treating a specific and recognized disorder. The HHS indicated that medical practitioners who are not experts in evaluating drugs cannot be considered qualified experts (HHS, 2015; 57 FR 10499, 10505). Further, the HHS noted that the 2009 American Medical Association (AMA) report entitled, “Use of Cannabis for Medicinal Purposes” does not conclude that there is a currently accepted medical use for marijuana. HHS also pointed out that state-level “medical marijuana” laws do not provide evidence of such a consensus among qualified experts.

*Element #5: The scientific evidence must be widely available.*

*“In the absence of NDA approval, information concerning the chemistry, pharmacology, toxicology, and effectiveness of the substance must be reported, published, or otherwise widely available, in sufficient detail to permit experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, to fairly and responsibly conclude the substance is safe and effective for use in treating a specific, recognized disorder.” 57 FR 10499, 10506 (March 26, 1992).*

The HHS concluded that the currently available data and information on

marijuana is not sufficient to allow scientific scrutiny of the chemistry, pharmacology, toxicology, and effectiveness. In particular, scientific evidence demonstrating the chemistry of a specific *Cannabis* strain that could provide standardized and reproducible doses is not available.

#### **Petitioners’ Major Comments in Relation to Factor 3 and the Government’s Responses**

(1) The petitioner states on page 2 of the petition, “*Marijuana has accepted medical use in the United States. Thirteen states accept the safety of marijuana for medical use . . . . Marijuana has been accepted as having medical use by dozens of professional medical and nursing organizations throughout the U.S. . . . Even the American Medical Association has now accepted the safety and efficacy of cannabinoid medicines and supports removal of marijuana from schedule I of the CSA in order to support further research.*”

As noted above, the HHS concluded that there is currently no evidence of a consensus among qualified experts that marijuana is safe and effective in treating a specific and recognized disorder, as required by the established standards. HHS pointed out that state-level “medical marijuana” laws do not provide evidence of such a consensus among qualified experts. HHS also indicated that medical practitioners who are not experts in evaluating drugs cannot be considered qualified experts (HHS, 2015; 57 FR 10499, 10505).

Further, the HHS pointed out that the 2009 AMA report entitled, “Use of Cannabis for Medicinal Purposes” does not conclude that there is a currently accepted medical use for marijuana. Instead, the AMA, like several other professional and medical associations, recommended further testing with marijuana to determine its medicinal value. The AMA official policy on medicinal use of marijuana is as follows: “*Our AMA urges that marijuana’s status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternative delivery methods. This should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product.*” (AMA, 2009). The DEA further notes that the 2013 AMA House of Delegates report states that, “*cannabis is a dangerous drug and as*

*such is a public health concern.*” (AMA, 2013).

(2) The petitioner asserts on page 3 of the petition that, “*Several recent studies of smoked marijuana have confirmed the safety and efficacy of smoked marijuana for medical use.*”

The HHS, in its scientific and medical evaluation, reviewed marijuana clinical studies evaluating therapeutic properties and concluded that there is not enough data to confirm the safety and efficacy of smoked marijuana for use in treating a specific and recognized disorder. Relevant to efficacy, for instance, the HHS concluded, for instance, that “smoking marijuana currently has not been shown to allow delivery of consistent and reproducible doses,” and that the bioavailability of the delta-9 -THC from marijuana in a cigarette or pipe can range from 1 percent to 24 percent with the fraction absorbed rarely exceeding 10 to 20%. Issues relating to the safety of smoked marijuana were discussed above in Factor 2.

(3) On page 3, the petitioner states that “*marijuana has been determined to be safe for use under medical supervision by the DEA’s own administrative law judge.*”

As described above, in the absence of NDA or ANDA approval, DEA has established a five-element test for determining whether the drug has a currently accepted medical use in treatment in the United States. 57 FR 10499, 10506 (March 26, 1992)). See also *ACT*, 15 F.3d at 1135. In response to this petition, HHS concluded, and DEA agrees, that the scientific evidence is insufficient to demonstrate that marijuana has a currently accepted medical use under the five-element test. The evidence was insufficient in this regard also when the DEA considered petitions to reschedule marijuana in 1992 (57 FR 10499), in 2001 (66 FR 20038), and in 2011 (76 FR 40552). Little has changed since 2011 with respect to the lack of clinical evidence necessary to establish that marijuana has a currently accepted medical use. No studies have scientifically assessed the efficacy and full safety profile of marijuana for any specific medical condition.

#### **Factor 4: Its History and Current Pattern of Abuse**

Marijuana continues to be the most widely used illicit drug. In 2013, an estimated 24.6 million Americans age 12 or older were current (past month) illicit drug users. Of those, 19.8 million were current (past month) marijuana users. As of 2013, an estimated 114.7 million Americans age 12 and older had

used marijuana or hashish in their lifetime and 33.0 million had used it in the past year.

According to the NSDUH estimates, 3.0 million people age 12 or older used an illicit drug for the first time in 2014. Marijuana initiates totaled 2.6 million in 2014. Nearly half (46.8%) of the 2.6 million new users were less than 18 years of age. In 2014, marijuana was used by 82.2% of current (past month) illicit drug users. In 2014, among past year marijuana users age 12 or older, 18.5% used marijuana on 300 or more days within the previous 12 months. This translates into 6.5 million people using marijuana on a daily or almost daily basis over a 12-month period, a significant increase from the 3.1 million daily or almost daily users in 2006 and from the 5.7 million in just the previous year. In 2014, among past month marijuana users, 41.6% (9.2 million people) used the drug on 20 or more days in the past month, a significant increase from the 8.1 million in 2013.

Marijuana is also the illicit drug with the highest numbers of past year dependence or abuse in the U.S. population. According to the 2014 NSDUH report, of the 7.1 million persons aged 12 or older who were classified with illicit drug dependence or abuse, 4.2 million of them abused or were dependent on marijuana (representing 59.0% of all those classified with illicit drug dependence or abuse and 1.6% of the total U.S. non-institutionalized population aged 12 or older).

According to the 2015 Monitoring the Future (MTF) survey, marijuana is used by a large percentage of American youths, and is the most commonly used illicit drug among American youth. Among students surveyed in 2015, 15.5% of 8th graders, 31.1% of 10th graders, and 44.7% of 12th graders reported that they had used marijuana in their lifetime. In addition, 11.8%, 25.4%, and 34.9% of 8th, 10th, and 12th graders, respectively, reported using marijuana in the past year. A number of high school students reported daily use in the past month, including 1.1%, 3.0%, and 6.0% of 8th, 10th, and 12th graders, respectively.

The prevalence of marijuana use and abuse is also indicated by criminal investigations for which drug evidence was analyzed in federal, state, and local forensic laboratories, as discussed above in Factor 1. The National Forensic Laboratory System (NFLIS), a DEA program, systematically collects drug identification results and associated information from drug cases submitted to and analyzed by federal, state, and local forensic laboratories. NFLIS data

shows that marijuana was the most frequently identified drug from January 2001 through December 2014. In 2014, marijuana accounted for 29.3% (432,989) of all drug exhibits in NFLIS.

The high consumption of marijuana is being fueled by increasing amounts of domestically grown marijuana as well as increased amounts of foreign source marijuana being illicitly smuggled into the United States. In 2014, the Domestic Cannabis Eradication and Suppression Program (DCE/SP) reported that 3,904,213 plants were eradicated in outdoor cannabis cultivation areas compared to 2,597,798 in 2000, as shown above in Table 3. Significant quantities of marijuana were also eradicated from indoor cultivation operations. There were 396,620 indoor plants eradicated in 2014 compared to 217,105 eradicated in 2000. As shown in Table 2 above, in 2014, the National Seizure System (NSS) reported seizures of 1,767,741 kg of marijuana.

#### **Factor 5: The Scope, Duration, and Significance of Abuse**

Abuse of marijuana is widespread and significant. As previously noted, according to the NSDUH, in 2014, an estimated 117.2 million Americans (44.2%) age 12 or older had used marijuana or hashish in their lifetime, 35.1 million (13.2%) had used it in the past year, and 22.2 million (8.4%) had used it in the past month. Past year and past month marijuana use has increased significantly since 2013. Past month marijuana use is highest among 18–21 year olds and it declines among those 22 years of age and older. In 2014, an estimated 18.5% of past year marijuana users age 12 or older used marijuana on 300 or more days within the past 12 months. This translates into 6.5 million persons using marijuana on a daily or almost daily basis over a 12-month period. In 2014, an estimated 41.6% (9.2 million) of past month marijuana users age 12 or older used the drug on 20 or more days in the past month (SAMHSA, NSDUH). Chronic use of marijuana is associated with a number of health risks (see Factors 2 and 6).

Furthermore, the average percentage of  $\Delta^9$ -THC in seized marijuana has increased over the past two decades (The University of Mississippi Potency Monitoring Project). Additional studies are needed to clarify the impact of greater potency, but one study shows that higher levels of  $\Delta^9$ -THC in the body are associated with greater psychoactive effects (Harder and Rietbrock, 1997), which can be correlated with higher abuse potential (Chait and Burke, 1994).

TEDS data show that in 2013, marijuana/hashish was the primary

substance of abuse in 16.8% of all admissions to substance abuse treatment among patients age 12 and older. TEDS data also show that marijuana/hashish was the primary substance of abuse for 77.0% of all 12- to 14-year-olds admitted for drug treatment and 75.5% of all 15- to 17-year-olds admitted for drug treatment in 2013. Among the 281,991 admissions to drug treatment in 2013 in which marijuana/hashish was the primary drug, the average age at admission was 25 years and the peak age cohort was 15 to 17 years (22.5%). Thirty-nine percent of the 281,991 primary marijuana/hashish admissions (35.9%) were under the age of 20.

In summary, the recent statistics from these various surveys and databases (see Factor 1 for more details) demonstrate that marijuana continues to be the most commonly used illicit drug, with large incidences of heavy use and dependence in teenagers and young adults.

#### **Factor 6: What, if Any, Risk There Is to the Public Health**

In its recommendation, the HHS discussed public health risks associated with acute and chronic marijuana use in Factor 6. Public health risks as measured by emergency department visits and drug treatment admissions are discussed by HHS and DEA in Factors 1, 4, and 5. Similarly, Factor 2 discusses marijuana's pharmacology and presents some of the adverse health effects associated with use. Marijuana use may affect the physical and/or psychological functioning of an individual user, but may also have broader public impacts including driving impairments and fatalities from car accidents.

#### **Risks From Acute Use of Marijuana**

As discussed in the HHS review document (HHS, 2015), acute use of marijuana impairs psychomotor performance including motor control and impulsivity, risk taking and executive function (Ramaekers et al., 2004; Ramaekers et al., 2006). In a minority of individuals using marijuana, dysphoria, prolonged anxiety, and psychological distress may be observed (Haney et al., 1999). The DEA further notes a recent review of acute marijuana effects (Wilkinson et al., 2014) that reported impaired neurological function including altered perception, paranoia, delayed response time, and memory deficits.

In its recommendation, HHS references a meta-analysis conducted by Li et al. (2012) where the authors concluded that psychomotor impairments associated with acute marijuana usage have also been



associated with increased risk of car accidents with individuals experiencing acute marijuana intoxication (Li et al., 2012; HHS, 2015). The DEA further notes more recent studies examining the risk associated with marijuana use and driving. Younger drivers (under 21) have been characterized as the highest risk group associated with marijuana use and driving (Whitehill et al., 2014). Furthermore, in 2013, marijuana was found in 13% of the drivers involved in automobile-related fatal accidents (McCartt, 2015). The potential risk of automobile accidents associated with marijuana use appears to be increasing since there has been a steady increase in individuals intoxicated with marijuana over the past 20 years (Wilson et al., 2014). However, a recent study commissioned by the National Highway Traffic Safety Administration (NHTSA) reported that when adjusted for confounders (e.g., alcohol use, age, gender, ethnicity), there was not a significant increase in crash risk (fatal and nonfatal,  $n = 2,682$ ) associated with marijuana use (Compton and Berning, 2015).

The DEA also notes recent studies examining unintentional exposures of children to marijuana (Wang et al., 2013; 2014). Wang et al. (2013) reviewed emergency department (ED) visits at a children's hospital in Colorado from January 1, 2005 to December 31, 2011. As stated by the authors, in 2000 Colorado passed Amendment 20 which allowed for the use of marijuana. Following the passage of "a new Justice Department policy" instructing "federal prosecutors not to seek arrest of medical marijuana users and suppliers as long as they conform to state laws" (as stated in Wang et al., 2013), 14 patients in Colorado under the age of 12 were admitted to the ED for the unintended use of marijuana over a 27 month period. Prior to the passage of this policy, from January 1, 2005 to September 30, 2009 (57 months), there were no pediatric ED visits due to unintentional marijuana exposure (Wang et al., 2013). The DEA also notes a larger scale evaluation of pediatric exposures using the National Poison Data System (Wang et al., 2014). That study reported that there were 985 unintentional marijuana exposures in children (9 years and younger) between January 1, 2005 to December 31, 2011. The authors stratified the ED visits by states with laws allowing medical use of marijuana, states transitioning to legalization for medical use, and states with no such laws. Out of the 985 exposures, 495 were in non-legal states ( $n=33$  states), 93 in transitional states

( $n=8$  states), and 396 in "legal" states ( $n=9$  states). The authors reported that there was a twofold increase ( $OR = 2.1$ ) in moderate or major effects in children with unintentional marijuana use and a threefold increase ( $OR = 3.4$ ) in admissions to critical care units in states allowing medical use of marijuana, in comparison to non-legal states.

#### Risks Associated With Chronic Use of Marijuana

The HHS noted that a major risk from chronic marijuana use is a distinctive withdrawal syndrome, as described in the 2013 DSM-5. The HHS analysis also quoted the following description of risks associated with marijuana [cannabis] abuse from the DSM-5:

*Individuals with cannabis use disorder may use cannabis throughout the day over a period of months or years, and thus may spend many hours a day under the influence. Others may use less frequently, but their use causes recurrent problems related to family, school, work, or other important activities (e.g., repeated absences at work; neglect of family obligations). Periodic cannabis use and intoxication can negatively affect behavioral and cognitive functioning and thus interfere with optimal performance at work or school, or place the individual at increased physical risk when performing activities that could be physically hazardous (e.g. driving a car; playing certain sports; performing manual work activities, including operating machinery). Arguments with spouses or parents over the use of cannabis in the home, or its use in the presence of children, can adversely impact family functioning and are common features of those with cannabis use disorder. Last, individuals with cannabis use disorder may continue using marijuana despite knowledge of physical problems (e.g. chronic cough related to smoking) or psychological problems (e.g. excessive sedation or exacerbation of other mental health problems) associated with its use. (HHS 2015, page 34).*

The HHS stated that chronic marijuana use produces acute and chronic adverse effects on the respiratory system, memory and learning. Regular marijuana smoking can produce a number of long-term pulmonary consequences, including chronic cough and increased sputum (Adams and Martin, 1996), and histopathologic abnormalities in bronchial epithelium (Adams and Martin, 1996).

#### Marijuana as a "Gateway Drug"

The HHS reviewed the clinical studies evaluating the gateway hypothesis in marijuana and found them to be limited. The primary reasons were: (1) Recruited participants were influenced by social, biological, and economic factors that contribute to

extensive drug abuse (Hall and Lynskey, 2005), and (2) most studies testing the gateway drug hypothesis for marijuana use the determinative measure *any use of an illicit drug* rather than applying DSM-5 criteria for drug abuse or dependence (DSM-5, 2013).

The HHS cited several studies where marijuana use did not lead to other illicit drug use (Kandel and Chen, 2000; von Sydow et al., 2002; Nace et al., 1975). Two separate longitudinal studies with adolescents using marijuana did not demonstrate an association with use of other illicit drugs (Kandel and Chen, 2000; von Sydow et al., 2002).

It was noted by the HHS that, when evaluating the gateway hypothesis, differences appear when examining use versus abuse or dependence of other illicit drugs. Van Gundy and Rebellon (2010) reported that there was a correlation between marijuana use in adolescence and other illicit drug use in early adulthood, but when examined in terms of drug abuse of other illicit drugs, age-linked stressors and social roles were confounders in the association. Degenhardt et al. (2009) reported that marijuana use often precedes use of other illicit drugs, but dependence involving drugs other than marijuana frequently correlated with higher levels of illicit drug abuse. Furthermore, Degenhardt et al. (2010) reported that in countries with lower prevalence of marijuana usage, use of other illicit drugs before marijuana was often documented.

Based on these studies among others, the HHS concluded that although many individuals with a drug abuse disorder may have used marijuana as one of their first illicit drugs, this does not mean that individuals initiated with marijuana inherently will go on to become regular users of other illicit drugs.

#### Factor 7: Its Psychic or Physiological Dependence Liability

##### Physiological (Physical) Dependence in Humans

The HHS stated that heavy and chronic use of marijuana can lead to physical dependence (DSM-5, 2013; Budney and Hughes, 2006; Haney et al., 1999). Tolerance is developed following repeated administration of marijuana and withdrawal symptoms are observed as following discontinuation of marijuana usage (HHS, 2015).

The HHS mentioned that tolerance can develop to some of marijuana's effects, but does not appear to develop with respect to the psychoactive effects. It is believed that lack of tolerance to

psychoactive effects may relate to electrophysiological data demonstrating that chronic  $\Delta^9$ -THC administration does not affect increased neuronal firing in the ventral tegmental area, a brain region that plays a critical role in drug reinforcement and reward (Wu and French, 2000). Humans can develop tolerance to marijuana's cardiovascular, autonomic, and behavioral effects (Jones et al., 1981). Tolerance to some behavioral effects appears to develop with heavy and chronic use, but not with occasional usage. Ramaekers et al. (2009) reported that following acute administration of marijuana, occasional marijuana users still exhibited impairments in tracking and attention tasks whereas performance of heavy users on the these tasks was not affected. In a follow-up study with the same subjects that participated in the study by Ramaekers et al. (2009), a neurophysiological assessment was conducted where event-related potentials (ERPs) were measured using electroencephalography (EEG) (Theunissen et al., 2012). Similar to the earlier results, the heavy marijuana users (n = 11; average of 340 marijuana uses per year) had no changes in their ERPs with the acute marijuana exposure. However, occasional users (n = 10; average of 55 marijuana uses per year) had significant decreases in the amplitude of an ERP component (categorized as P100) on tracking and attention tasks and ERP amplitude change is indicative of a change in brain activity (Theunissen et al., 2012).

The HHS indicated that down-regulation of cannabinoid receptors may be a possible mechanism for tolerance to marijuana's effects (Hirvonen et al., 2012; Gonzalez et al., 2005; Rodriguez de Fonseca et al., 1994; Oviedo et al., 1993).

As indicated by the HHS, the most common withdrawal symptoms in heavy, chronic marijuana users are sleep difficulties, decreased appetite or weight loss, irritability, anger, anxiety or nervousness, and restlessness (Budney and Hughes, 2006; Haney et al., 1999). As reported by HHS, most marijuana withdrawal symptoms begin within 24–48 hours of discontinuation, peak within 4–6 days, and last for 1–3 weeks.

The HHS pointed out that the American Psychiatric Association's (APA's) Diagnostic and Statistical Manual of Mental Disorders—5 (DSM–5) included a list of withdrawal symptoms following marijuana [cannabis] use (DSM–5, 2013). The DEA notes that a DSM–5 working group report indicated that marijuana withdrawal symptoms were added to DSM–5 (they were not previously

included in DSM–IV) because marijuana withdrawal has now been reliably presented in several studies (Hasin et al., 2013). In short, marijuana withdrawal signs are reported in up to one-third of regular users and between 50% and 90% of heavy users (Hasin et al., 2013). According to DSM–5 criteria, in order to be characterized as having marijuana withdrawal, an individual must develop at least three of the seven symptoms within one week of decreasing or stopping the heavy and prolonged use (DSM–5, 2013). These seven symptoms are: (1) Irritability; anger or aggression, (2) nervousness or anxiety, (3) sleep difficulty, (4) decreased appetite or weight loss, (5) restlessness, (6) decreased mood, (7) somatic symptoms causing significant discomfort (DSM–5, 2013).

#### Psychological (Psychic) Dependence in Humans

High levels of psychoactive effects such as positive reinforcement correlate with increased marijuana abuse and dependence (Scherrer et al., 2009; Zeiger et al., 2010). Epidemiological marijuana use data reported by NSDUH, MTF, and TEDS support this assertion as presented in the HHS 2015 review of marijuana and updated by the DEA. According to the findings in the 2014 NSDUH survey, an estimated 9.2 million individuals 12 years and older used marijuana daily or almost daily (20 or more days within the past month). In the 2015 MTF report, daily marijuana use (20 or more days within the past 30 days) in 8th, 10th, and 12th graders is 1.1%, 3.0%, and 6.0%, respectively.

The 2014 NSDUH report stated that 4.2 million persons were classified with dependence on or abuse of marijuana in the past year (representing 1.6% of the total population age 12 or older, and 59.0% of those classified with illicit drug dependence or abuse) based on criteria specified in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM–IV). Furthermore, of the admissions to licensed substance abuse facilities, as presented in TEDS, marijuana/hashish was the primary substance of abuse for; 18.3% (352,297) of 2011 admissions; 17.5% (315,200) of 2012 admissions; and 16.8% (281,991) of 2013 admissions. Of the 281,991 admissions in 2013 for marijuana/hashish as the primary substance, 24.3% used marijuana/hashish daily. Among admissions to treatment for marijuana/hashish as the primary substance in 2013, 27.4% were ages 12 to 17 years and 29.7% were ages 20 to 24 years.

#### Factor 8: Whether the Substance is an Immediate Precursor of a Substance Already Controlled Under the CSA

Marijuana is not an immediate precursor of another controlled substance.

#### Determination

After consideration of the eight factors discussed above and of the HHS's Recommendation, the DEA finds that marijuana meets the three criteria for placing a substance in schedule I of the CSA under 21 U.S.C. 812(b)(1):

1. Marijuana has a high potential for abuse.

The HHS concluded that marijuana has a high potential for abuse based on a large number of people regularly using marijuana, its widespread use, and the vast amount of marijuana that is available through illicit channels.

Marijuana is the most abused and trafficked illicit substance in the United States. Approximately 22.2 million individuals in the United States (8.4% of the United States population) were past month users of marijuana according to the 2014 NSDUH survey. A 2015 national survey (Monitoring the Future) that tracks drug use trends among high school students showed that by 12th grade, 21.3% of students reported using marijuana in the past month, and 6.0% reported having used it daily in the past month. In 2011, SAMHSA's Drug Abuse Warning Network (DAWN) reported that marijuana was mentioned in 36.4% of illicit drug-related emergency department (ED) visits, corresponding to 455,668 out of approximately 1.25 million visits. The Treatment Episode Data Set (TEDS) showed that 16.8% of non-private substance-abuse treatment facility admissions in 2013 were for marijuana as the primary drug.

Marijuana has dose-dependent reinforcing effects that encourage its abuse. Both clinical and preclinical studies have demonstrated that marijuana and its principle psychoactive constituent,  $\Delta^9$ -THC, possess the pharmacological attributes associated with drugs of abuse. They function as discriminative stimuli and as positive reinforcers to maintain drug use and drug-seeking behavior. Additionally, use of marijuana can result in psychological dependence.

2. Marijuana has no currently accepted medical use in treatment in the United States.

The HHS stated that the FDA has not approved an NDA for marijuana. The HHS noted that there are opportunities for scientists to conduct clinical research with marijuana and there are active INDs for marijuana, but marijuana

does not have a currently accepted medical use in the United States, nor does it have an accepted medical use with severe restrictions.

FDA approval of an NDA is not the sole means through which a drug can be determined to have a “currently accepted medical use” under the CSA. Applying the five-part test summarized below, a drug has a currently accepted medical use if all of the following five elements have been satisfied. As detailed in the HHS evaluation and as set forth below, none of these elements has been fulfilled for marijuana:

i. The drug’s chemistry must be known and reproducible

Chemical constituents including  $\Delta^9$ -THC and other cannabinoids in marijuana vary significantly in different marijuana strains. In addition, the concentration of  $\Delta^9$ -THC and other cannabinoids may vary between strains. Therefore the chemical composition among different marijuana samples is not reproducible. Due to the variation of the chemical composition in marijuana strains, it is not possible to derive a standardized dose. The HHS does advise that if a specific *Cannabis* strain is cultivated and processed under controlled conditions, the plant chemistry may be consistent enough to derive standardized doses.

ii. There must be adequate safety studies

There are not adequate safety studies on marijuana for use in any specific, recognized medical condition. The considerable variation in the chemistry of marijuana results in differences in safety, biological, pharmacological, and toxicological parameters amongst the various marijuana samples.

iii. There must be adequate and well-controlled studies proving efficacy

There are no adequate and well-controlled studies that determine marijuana’s efficacy. In an independent review performed by the FDA of publicly available clinical studies on marijuana (FDA, 2015), FDA concluded that these studies do not have enough information to “currently prove efficacy of marijuana” for any therapeutic indication.

iv. The drug must be accepted by qualified experts

At this time, there is no consensus of opinion among experts concerning the medical utility of marijuana for use in treating specific recognized disorders.

v. The scientific evidence must be widely available

The currently available data and information on marijuana is not sufficient to address the chemistry, pharmacology, toxicology, and

effectiveness. The scientific evidence regarding marijuana’s chemistry with regard to a specific cannabis strain that could be formulated into standardized and reproducible doses is not currently available.

3. There is a lack of accepted safety for use of marijuana under medical supervision.

Currently, there are no FDA-approved marijuana products. The HHS also concluded that marijuana does not have a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. According to the HHS, the FDA is unable to conclude that marijuana has an acceptable level of safety in relation to its effectiveness in treating a specific and recognized disorder due to lack of evidence with respect to a consistent and reproducible dose that is contamination free. The HHS indicated that marijuana research investigating potential medical use should include information on the chemistry, manufacturing, and specifications of marijuana. The HHS further indicated that a procedure for delivering a consistent dose of marijuana should also be developed. Therefore, the HHS concluded that marijuana does not have an acceptable level of safety for use under medical supervision.

## References

- Abrams DI, Hilton JF, Reiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M (2003). Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. *Ann Intern Med* 139(4):258–266.
- Adams IB, Martin BR (1996). Cannabis: Pharmacology and toxicology in animals and humans. *Addiction* 91:1585–1614.
- Agurell S, Dewey WL, and Willetts RE (eds.) (1984). *The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects*. New York: Academic Press
- Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L (1986). Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on man. *Pharmacol Rev* 38(1):21–43.
- American College of Physicians [ACP]. (2008). Supporting Research Into the Therapeutic Role of Marijuana. Philadelphia: American College of Physicians; 2008: Position Paper (Available from American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106).
- American Medical Association [AMA]. (2009a). Use of Cannabis for Medical Purposes. *Report of the Council on Science and Public Health* 3.
- American Medical Association [AMA]. (2009b). AMA Policy: Medical Marijuana. H-95–952 Medical Marijuana.
- American Medical Association [AMA]. (2013). 2013 Interim Meeting. American Medical Association House of Delegates (1–13). Accessed at [www.ama-assn.org/assets/meeting/2013i/113-refcommk-annotated.pdf](http://www.ama-assn.org/assets/meeting/2013i/113-refcommk-annotated.pdf).
- American Society of Addiction Medicine [ASAM]. (2014). *New York Times* calls for legalization of marijuana, ASAM strongly objects. Accessed at [www.asam.org/docs/default-source/pressreleases/asam-press-release-nytimes-editorial-marijuana-2014-7-27.pdf?sfvrsn=2](http://www.asam.org/docs/default-source/pressreleases/asam-press-release-nytimes-editorial-marijuana-2014-7-27.pdf?sfvrsn=2).
- Andreasson S, Allebeck P, Engström A, Rydberg U (1987). Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. *Lancet* 1:483–1483.
- Appendino G, Chianese G, Tagliatalata-Scafati O (2011). Cannabinoids: occurrence and medicinal chemistry. *Curr Med Chem* 18(7):1085–1099.
- Asch RH, Smith CG, Siler-Khodr TM, Pauerstein CJ (1981). Effects of delta 9-tetrahydrocannabinol during the follicular phase of the rhesus monkey (*Macaca mulatta*). *J Clin Endocrinol Metab* 52(1):50–55.
- Balster RL (1991). Drug abuse potential evaluation in animals. *Br J Addict* 86(12):1549–1558.
- Balster RL, Prescott WR (1992). Delta9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. *Neurosci Biobehav Res* 16(1):55–62.
- Balster RL, Bigelow GE (2003). Guidelines and methodological reviews concerning drug abuse liability assessment. *Drug Alcohol Depend* 70:S13–S40.
- Barnett G, Licko V, Thompson T (1985). Behavioral pharmacokinetics of marijuana. *Psychopharmacology* 85(1):51–56.
- Benowitz NL, Jones RT (1975). Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. *Clin Pharmacol Ther* 18(3):287–297.
- Benowitz NL, Jones RT (1981). Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. *J Clin Pharmacol* 21(8–9 Suppl):214S–223S.
- Block RI, Farinpour R, Schlechte JA (1991). Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. *Drug Alcohol Depend* 28(2):121–128.
- Block RI, Farinpour R, Braverman K (1992). Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. *Pharmacol Biochem Behav* 43(3):907–917.
- Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL (2002). Dose-related neurocognitive effects of marijuana use. *Neurology* 59:1337–1343.
- Bolla KI, Eldreth DA, Matochik JA, Cadet JL (2005). Neural substrates of faulty decision-making in abstinent marijuana users. *NeuroImage* 26:480–492.

23. Bonnet U (2013). Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function. *Pharmacopsychiatry* 46(1):35–36.
24. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P (1993). Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem* 214(1):173–180.
25. Braida D, Iosue S, Pegorini S, Sala M (2004). Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. *Eur J Pharmacol* 506(1):63–69.
26. Brievogel CS, Childers SR (2000). Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. *J Pharmacol Exp Ther* 295(1):328–336.
27. Brown TT, Dobs AS (2002). Endocrine effects of marijuana. *J Clin Pharmacol* 42(11 Suppl):90S–96S.
28. Browne RG, Weisman A (1981). Discriminative stimulus properties of delta 9-tetrahydrocannabinol: Mechanistic studies. *J Clin Pharmacol* 21(8–9 Suppl):227S–234S.
29. Budney AJ, Hughes JR (2006). The cannabis withdrawal syndrome. *Curr Opin Psychiatry* 19(3):233–238.
30. Capriotti RM, Foltin RW, Brady JV, Fischman MW (1988). Effects of marijuana on the task-elicited physiological response. *Drug Alcohol Depend* 21(3):183–187.
31. Cascini F, Aiello C, Di Tanna G (2012). Increasing delta-9-tetrahydrocannabinol  $\Delta$ -9-THC content in herbal cannabis over time: systematic review and meta-analysis. *Curr Drug Abuse Rev* 5(1):32–40.
32. Chait LD, Burke KA (1994). Preference for “high” versus low-potency marijuana. *Pharmacol Biochem Behav* 7:357–364.
33. Cheer JF, Kendall DA, Marsden CA (2000). Cannabinoid receptors and reward in the rat: a conditioned place preference study. *Psychopharmacology (Berl)* 151(1):25–30.
34. Compton RP, Berning A (2015). Drug and Alcohol Crash Risk. *Traffic Safety Facts Research Note*. DOT HS 812 117. Washington, DC: National Highway Traffic Safety Administration.
35. Cone EJ, Johnson RE, Moore JD, Roache JD (1986). Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. *Pharmacol Biochem Behav* 24(6):1749–1754.
36. Croxford JL, Yamamura T (2005). Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? *J Neuroimmunol* 166(1–2):3–18.
37. Daling JR, Doody DR, Sun X, Trabert BL, Weiss NS, Chen C, Biggs ML, Starr JR, Dey SK, Schwartz SM (2009). Association of marijuana use and the incidence of testicular germ cell tumors. *Cancer*. 115(6):1215–1223.
38. Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB (1976). Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. *Clin Pharmacol Ther* 19(3):300–309.
39. Dax EM, Pilotte NS, Adler WH, Nagel JE, Lange WR (1989). The effects of 9-enetetrahydrocannabinol on hormone release and immune function. *J Steroid Biochem* 34(1–6):263–270.
40. Day NL, Wagener DK, Taylor PM (1985). Measurement of substance use during pregnancy: methodologic issues. *NIDA Res Monogr* 59:36–47.
41. Day NL, Leech SL, Goldschmidt L (2011). The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioning. *Neurotoxicol Teratol* 33(1):129–136.
42. Day NL, Goldschmidt L, Day R, Larkby C, Richardson GA (2015). Prenatal marijuana exposure, age of marijuana initiation, and the development of psychotic symptoms in young adults. *Psychol Med* 45(8):1779–1787.
43. Degenhardt L, Hall W, Lynskey M (2003). Testing hypotheses about the relationship between cannabis use and psychosis. *Drug Alcohol Depend* 71(1):37–48.
44. Degenhardt L, Hall WD, Lynskey M, McGrath J, McLaren J, Calabria B, Whiteford H, Vos T (2009). Should burden of disease estimates include cannabis use as a risk factor for psychosis? *PLoS Medicine*. 6(9):e1000133.
45. Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neumark Y, Sampson N, Alonso J, Angermeyer M, Anthony JC, Bruffaerts R, et al (2010). Evaluating the drug use “gateway” theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. *Drug Alcohol Depend* 108(1–2):84–97.
46. De Petrocellis PL, Di Marzo V (2009). An introduction to the endocannabinoid system: From the early to the latest concepts. *Best Pract Res Clin Endocrinol Metab* 23(1):1–15.
47. Department of Health and Human Services [HHS] (2015). Basis for the recommendation for maintaining marijuana in Schedule I of the Controlled Substances Act.
48. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258(5090):1946–1949.
49. Dewey WL, Martin BR, May EL (1984). Cannabinoid stereoisomers: pharmacological effects. In Smith DF. (Ed.) *CRC Handbook of stereoisomers: drugs in psychopharmacology*, 317–26 (Boca Raton, FL, CRC Press).
50. Drug Enforcement Administration (2015). *Drugs of Abuse*.
51. DSM-5 (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association. Washington, DC: American Psychiatric Publishing.
52. Eisenstein TK, Meissler JJ (2015). Effects of cannabinoids on T-cell function and resistance to infection. *J Neuroimmune Pharmacol* 10(2):204–216.
53. Eldridge JC, Murphy LL, Landfield PW (1991). Cannabinoids and the hippocampal glucocorticoid receptor: Recent findings and possible significance. *Steroids* 56(5):226–231.
54. ElSohly MA, Slade D (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. *Life Sci* 78:539–548.
55. Fant RV, Heishman SJ, Bunker EB, Pickworth WB (1998). Acute and residual effects of marijuana in humans. *Pharmacol Biochem Behav* 60(4):777–784.
56. Federal Register (1992). “Marijuana Scheduling Petition; Denial of Petition; Remand”—Drug Enforcement Administration, Final Order. *Fed Registr* 57(59):10499–10508.
57. Federal Register (1999). “Rescheduling of the Food and Drug Administration Approved Product Containing Synthetic Dronabinol [(–)-delta 9-(trans)-Tetrahydrocannabinol] in Sesame Oil and Encapsulated in Soft Gelatin Capsules From Schedule II to Schedule III; Final Rule,” *Fed Registr* 64(127):35928–35930.
58. Federal Register (2001). “Notice of Denial of Petition: Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act,” *Fed Registr* 66(75):20038–20076.
59. Fergusson DM, Horwood LJ, Ridder EM (2005). Tests of causal linkages between cannabis use and psychotic symptoms. *Addiction*. 100(3):354–366.
60. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL (2011). Cannabis use before age 15 and subsequent executive functioning. *Br J Psychiatry* 198(6):442–447.
61. Fried PA, Watkinson B, Grant A, Knights RM (1980). Changing patterns of soft drug use prior to and during pregnancy: a prospective study. *Drug Alcohol Depend* 6(5):323–343.
62. Fried PA, Watkinson B (1990). 36- and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes and alcohol. *J Dev Behav Pediatr* 11:49–58.
63. Fried PA, Watkinson B, Gray R (1992). A follow-up study of attentional behavior in 6-year-old children exposed prenatally to marijuana, cigarettes and alcohol. *Neurotoxicol Teratol* 14:299–311.
64. Fried PA, Watkinson B, Gray R (1998). Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marijuana. *Neurotoxicol Teratol* 20(3):293–306.
65. Fried PA (2002). Adolescents prenatally exposed to marijuana: Examination of facets of complex behaviors and comparisons with the influence of in utero cigarettes. *J Clin Pharmacol* 42(11 Suppl):97S–102S.
66. Fried PA, Watkinson B, Gray R (2005). Neurocognitive consequences of

- marihuana—a comparison with pre-drug performance. *Neurotoxicol Teratol* 27(2):231–239.
67. Fung M, Gallagher C, Machtay M (1999). Lung and aero-digestive cancers in young marijuana smokers. *Tumori* 85(2):140–142.
68. Gates P, Jaffe A, Copeland J (2014). Cannabis smoking and respiratory health: Consideration of the literature. *Respirology* 19(5):655–662.
69. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R (2002). Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. *J Neurosci* 22(3):1146–1154.
70. Gold LH, Balster RL, Barrett RL, Britt DT, Martin BR (1992). A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. *J Pharmacol Exp Ther* 262(2):479–486.
71. Goldschmidt L, Richardson GA, Willford JA, Day NL (2008). Prenatal marijuana exposure and intelligence test performance at age 6. *J Am Acad Child Adolesc Psychiatry* 47(3):254–263.
72. Goldschmidt L, Richardson GA, Willford JA, Severtson SG, Day NL (2012). School achievement in 14-year-old youths prenatally exposed to marijuana. *Neurotoxicol Teratol* 34(1):161–167.
73. Gong H Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ (1984). Acute and subacute bronchial effects of oral cannabinoids. *Clin Pharmacol Ther* 35(1):26–32.
74. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR (2006). Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. *Brain Res* 1071(1):10–23.
75. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide. *Mol Pharmacol* 57(5):1045–1050.
76. Gonzalez R (2007). Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. *Neuropsychol Rev* 17(3):347–361.
77. Gonzalez S, Cebeira M, Fernandez-Ruiz J (2005). Cannabinoid tolerance and dependence: A review of studies in laboratory animals. *Pharmacol Biochem Behav* 81(2):300–318.
78. Griffith-Lendering MF, Wigman JT, Prince van Leeuwen A, Huijbregts SC, Huizink AC, Ormel J, Verhulst FC, van Os J, Swaab H, Vollebergh WA (2013). Cannabis use and vulnerability for psychosis in early adolescence—a TRAILS study. *Addiction* 108(4):733–740.
79. Grotenhermen F (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet* 42(4):327–360.
80. Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE (2012). Age of onset of marijuana use and executive function. *Psychol Addict Behav* 26(3):496–506.
81. Hackam DG (2015). Cannabis and stroke: Systematic appraisal of case reports. *Stroke* 46(3):852–856.
82. Hall WD, Lynskey M (2005). Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. *Drug Alcohol Rev* 24(1):39–48.
83. Hall W, Degenhardt L (2014). The adverse health effects of chronic cannabis use. *Drug Test Anal* 6(1–2):39–45.
84. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999). Abstinence symptoms following smoked marijuana in humans. *Psychopharmacology (Berl)* 141(4):395–404.
85. Harder S, Rietbrock S (1997). Concentration-effect relationship of delta-9-tetrahydrocannabinol and prediction of psychotropic effects after smoking marijuana. *International Journal of Clinical Pharmacology and Therapeutics*. 35(4):155–159.
86. Hasin DS, O'Brien CP, Auriacombe M, Borges G, Buchholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF (2013). DSM-5 criteria for substance use disorders: Recommendations and rationale. *Am J Psychiatry* 170(8):834–851.
87. Heishman SJ, Huestis MA, Henningfield JE, Cone EJ (1990). Acute and residual effects of marijuana: Profiles of plasma THC levels, physiological, subjective, and performance measures. *Pharmacol Biochem Behav* 37(3):561–565.
88. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990). Cannabinoid receptor localization in brain. *Proc Natl Acad Sci* 87:1932–1936.
89. Herkenham M (1992). Cannabinoid receptor localization in brain: Relationship to motor and reward systems. *Ann N Y Acad Sci* 654:19–32.
90. Herning RI, Hooker WD, Jones RT (1986). Tetrahydrocannabinol content and differences in marijuana smoking behavior. *Psychopharmacology (Berl)* 90(2):160–162.
91. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB (2012). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. *Mol Psychiatry* 17(6):643–649.
92. Hively RL, Mosher WA, Hoffman FW (1966). Isolation of trans- $\Delta^9$ -tetrahydrocannabinol from marihuana. *J Am Chem Soc* 88:1832–1833.
93. Hollister LE, Gillespie HK (1973). Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration. *Clin Pharmacol Ther* 14(3):353–357.
94. Hollister LE (1986). Health aspects of cannabis. *Pharmacological Rev* 3:1–20.
95. Hollister LE (1988). Cannabis (Literature review). *Acta Psychiatr Scand (Suppl)* 78:108–118.
96. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ (2004). Cannabinoid physiology and pharmacology: 30 years of progress. *Neuropharmacology* 47 Suppl:345–358.
97. Huang YH, Zhang ZF, Tashkin DP, Feng B, Straif K, Hashibe K (2015). An epidemiologic review of marijuana and cancer: An update. *Cancer Epidemiol Biomarkers Prev* 24(1):15–31.
98. Huestis MA, Sampson AH, Holicky BJ, Benningfield JE, Cone EJ (1992a). Characterization of the absorption phase of marijuana smoking. *Clin Pharmacol Ther* 52:31–41.
99. Huestis MA, Benningfield JE, Cone EJ (1992b). Blood Cannabinoids. 1. Absorption of THC and formation of 11-OH-THC and THC COOH during and after smoking marijuana. *J Anal Toxicol* 16(5):276–282.
100. Hunt CA, Jones RT (1980). Tolerance and disposition of tetrahydrocannabinol in man. *J Pharmacol Exp Ther* 215(1):35–44.
101. Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H (2005). Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. *Behav Pharmacol* 16(5–6):487–496.
102. Institute of Medicine (1982). Division of Health Sciences Policy. Marijuana and Health: Report of a Study by a Committee of the Institute of Medicine, Division of Health Sciences Policy. Washington, DC: National Academy Press, 1982.
103. Institute of Medicine (1999). Division of Neuroscience and Behavioral Health. Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press, 1999.
104. Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK (1989). Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. *Eur J Clin Pharmacol* 37(3):273–277.
105. Jones RT, Benowitz NL, Heming RI (1981). Clinical relevance of cannabis tolerance and dependence. *J Clin Pharmacol* 21:143S–152S.
106. Jones RT (2002). Cardiovascular system effects of marijuana. *J Clin Pharmacol* 42(11Suppl):58S–63S.
107. Justinova Z, Tanda G, Redhi GH, Goldberg SR (2003). Self-administration of delta9-tetrahydrocannabinol (THC) by drug naïve squirrel monkeys. *Psychopharmacology (Berl)* 169(2):135–140.
108. Justinova Z, Tanda G, Munzar P, Goldberg SR (2004). The opioid antagonist naltrexone reduces the reinforcing effects of delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. *Psychopharmacology (Berl)* 173(1–2):186–194.
109. Kandel D (1975). Stages in adolescent involvement in drug use. *Science* 190:912–914.
110. Kandel DB, Chen K (2000). Types of marijuana users by longitudinal course. *J Stud Alcohol* 61(3):367–378.
111. Karniol IG, Shirakawa I, Kasinski N, Pfefferman A, Carlini EA (1974). Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. *Eur J Pharmacol* 28(1):172–177.
112. Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE (1975). Effects of delta9-tetrahydrocannabinol and cannabiniol in man. *Pharmacology* 13(6):502–512.

113. Keen L 2nd, Pereira D, Latimer W (2014). Self-reported lifetime marijuana use and interleukin-6 levels in middle-aged African Americans. *Drug Alcohol Depend* 140:156–160.
114. Kirk JM, de Wit H (1999). Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. *Pharmacol Biochem Behav* 63(1):137–142.
115. Kuepper R, van Os J, Lieb R, Wittchen HU, Henquet C (2011). Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. *Psychol Med* 41(10):2121–2129.
116. Kurtzthaler I, Hummer M, Miller C, Sperner-Unterwieser B, Gunther V, Wechdorn H, Battista HJ, Fleischhacker WW (1999). Effects of cannabis use on cognitive functions and driving ability. *J Clin Psychiatry* 60(6):395–399.
117. Lacson JC, Carroll JD, Tuazon E, Castela E, Bernstein L, Cortessis VK (2012). Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. *Cancer* 118:5374–5383.
118. Lee MH, Hancox RJ (2011). Effects of smoking cannabis on lung function. *Exp Rev Res Med* 5(4):537–546.
119. Lemberger L, Silberstein SD, Axelrod J, Kopin IJ (1970). Marijuana: Studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. *Science* 70:1320–1322.
120. Lemberger L, Weiss JL, Watanabe AM, Galanter IM, Wyatt RJ, Cardon PV (1972a). Delta-9-tetrahydrocannabinol: Temporal correlation of the psychological effects and blood levels after various routes of administration. *New Eng J Med* 286(13):685–688.
121. Lemberger L, Crabtree RE, Rowe HM (1972b). 11-Hydroxy-delta-9-tetrahydrocannabinol: Pharmacology, disposition and metabolism of a major metabolite of marijuana in man. *Science* 77:62–63.
122. Lemberger L, Rubin A (1975). The physiologic disposition of marijuana in man. *Life Sci* 17:1637–1642.
123. Li M-C, Brady JE, DiMaggio CJ, Lusardi AR, Tzong, KY, Li G (2012). Marijuana use and motor vehicle crashes. *Epidemiologic Rev* 34:65–72.
124. Liguori A, Gatto CP, Robinson JH (1998). Effects of marijuana on equilibrium, psychomotor performance, and simulated driving. *Behav Pharmacol* 9(7):599–609.
125. Lisdahl KM, Price JS (2012). Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. *J Int Neuropsychol Soc* 18(4):678–688.
126. Lyons MJ, Bar JL, Panizzon MS, Toomey R, Eisen S, Xian H, Tsuang MT (2004). Neuropsychological consequences of regular marijuana use: a twin study. *Psychol Med* 34(7):1239–1250.
127. Mackie K, Lai Y, Westenbroek R, Mitchell R (1995). Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. *J Neurosci* 15(10):6552–6561.
128. Maldonado R (2002). Study of cannabinoid dependence in animals. *Pharmacol Ther* 95(2):153–164.
129. Malinowska B, Baranowska-Kuczek M, Schlicker E (2012). Triphasic blood pressure responses to cannabinoids: Do we understand the mechanism? *Br J Pharmacol* 165(7):2073–2088.
130. Manrique-Garcia E, Zammit S, Dalman C, Hemmingson T, Andreasson S, Allebeck P (2012). Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. *Psychol Med* 42(6):1321–1328.
131. Maremmani I, Lazzeri A, Pacini M, Lovrecic M, Placidi GF, Perugi G (2004). Diagnostic and symptomatological features in chronic psychotic patients according to cannabis use status. *J Psychoactive Drugs* 36(2):235–241.
132. McCart AT (2015). Marijuana and driving in the United States: Prevalence, risks, and laws. Presented at the Casualty Actuarial Society Spring Meeting. Colorado Springs, CO. May 19, 2015.
133. McMahon LR, Ginsburg BC, Lamb RJ (2008). Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice. *Psychopharmacology (Berl)* 198(4):487–495.
134. McMahon LR (2009). Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta-9-tetrahydrocannabinol. *Psychopharmacology (Berl)* 203(2):219–228.
135. Mechoulam R (1973). Cannabinoid chemistry. In Mechoulam, R. (ed.) Marijuana, pp.2–88 (New York, NY, Academic Press, Inc.).
136. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE., Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol* 50(1):83–90.
137. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly MA (2010). Potency trends of Δ<sup>9</sup>-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. *J Forensic Sci* 55(5):1209–1217.
138. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci USA* 109(40):E2657–E2664.
139. Mendelson JH, Mello NK (1984). Effects of marijuana on neuroendocrine hormones in human males and females. *NIDA Res Monogr* 44:97–114.
140. Messinis L, Kyprianidou A, Malefaki S, Papathanasopoulos P (2006). Neuropsychological deficits in long-term frequent cannabis users. *Neurology* 66:737–739.
141. Minozzi S, Davoli M, Bargagli AM, Amato L, Vecchi S, Perucci CA (2010). An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. *Drug Alcohol Rev* 29(3):304–317.
142. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE (2001). Triggering myocardial infarction by marijuana. *Circulation* 103:2805–2809.
143. Nace EP, Meyers AL, Rothberg JM, Maleson F (1975). Addicted and nonaddicted drug users. A comparison of drug usage patterns. *Arch Gen Psychiatry* 32(1):77–80.
144. Oviedo A, Glowa J, Herkenham M (1993). Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study. *Brain Res* 616:293–302.
145. Pacher P, Batkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev* 58(3):389–462.
146. Panayiotides IM (2015). What is the association between cannabis consumption and cardiovascular complications. *Subst Abuse* 9:1–3.
147. Pelayo-Teran JM, Suarez-Pinilla P, Chadi N, Crespo-Pacorro B (2012). Gene-environment interactions underlying the effect of cannabis in first episode psychosis. *Curr Pharm Des* 18(32):5024–5035.
148. Piomelli D (2005). The endocannabinoid system: A drug discovery perspective. *Curr Opin Investig* 6(7):672–679.
149. Pletcher MJ, Vittinghoff E, Kalhan R, Richman J, Safford M, Sidney S, Lin F, Kertesz S (2012). Association between marijuana exposure and pulmonary function over 20 years. *Journal of the American Medical Association*. 307(2):173–181.
150. Pollastro F, Tagliatalata-Scafati O, Allara M, Munoz E, Di Marzo V, De Petrocellis L, Appendino G (2011). Bioactive prenylogous cannabinoid from fiber hemp (*Cannabis sativa*). *J Nat Prod*. 74(9):2019–2022.
151. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2002). Cognitive measures in long-term cannabis users. *J Clin Pharmacol* 42(11 Suppl):41S–47S.
152. Radwan MM, ElSohly MA, Slade D, Ahmed SA, Khan IA, Ross SA (2009). Biologically active cannabinoids from high-potency Cannabis sativa. *J Nat Prod* 72(5):906–911.
153. Ramaekers JG, Berghaus G, van Laar M, Drummer OH (2004). Dose related risk of motor vehicle crashes after cannabis use. *Drug and Alcohol Dependence*. 73(2):109–119.
154. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR (2006). High-potency marijuana impairs executive functions and inhibitory motor control.

- Neuropsychopharmacology* 31(10):2296–2303.
155. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW., Moeller MR (2009). Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. *J Psychopharmacol* 23(3):266–277.
  156. Riggs PK, Vaida F, Rossi SS, Sorkin LS, Gouaux B, Grant I, Ellis RJ (2012). A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. *Brain Res* 1431:46–52.
  157. Rodriguez de Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA (1994). Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. *Pharmacol Biochem Behav* 47(1):33–40.
  158. Roth MD, Arora A, Barsky SH, Kleerup EC, Simmons M, Tashkin DP (1998). Airway inflammation in young marijuana and tobacco smokers. *American Journal of Respiratory and Crit Care Med* 157:928–937.
  159. Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC (2005). Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL–SCID mouse. *Life Sci* 77(14):1711–1722.
  160. Russo E, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, Kirilin KA (2001). Chronic cannabis use in the compassionate investigational new drug program: An examination of benefits and adverse effects of legal clinical cannabis. *J Cannabis Ther* 2:3–57.
  161. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H (2005). Cannabinoid receptor as a novel target for the treatment of prostate cancer. *Cancer Res* 65(5):1635–1641.
  162. Scherrer JF, Grant JD, Duncan AE, Sartor CE, Haber JR, Jacob T, Bucholz KK (2009). Subjective effects to cannabis are associated with use, abuse and dependence after adjusting for genetic and environmental influences. *Drug Alcohol Depend* 105(1–2):76–82.
  163. Schiffrman J, Nakamura B, Earleywine MJ, LaBrie J (2005). Symptoms of schizotypy precede cannabis use. *Psychiatry Res* 134(1):37–42.
  164. Schimmelmann BG, Conus P, Cotton SM, Kupferschmid S, Karow A, Schultze-Lutter F, McGorry PD, Lambert M (2011). Cannabis use disorder and age at onset of psychosis—a study in first episode patients. *Schizophr Res* 129(1):52–56.
  165. Schreiner AM, Dunn ME (2012). Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis. *Exp Clin Psychopharmacol* 20(5):420–429.
  166. Sexton M, Cudaback E, Abdullah RA, Finnell J, Mischley LJ, Rozga M, Lichtman AH, Stella N (2014). Cannabis use by individuals with multiple sclerosis: Effects on specific immune parameters. *Inflammopharmacology* 22(5):295–303.
  167. Sidney S (2002). Cardiovascular consequences of marijuana use. *J Clin Pharmacol* 42(11Suppl):64S–70S.
  168. Solinas M, Panlilio LV, Justinova Z, Yasar S, Goldberg SR (2006). Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. *Nat Protoc* 1(3):1194–1206.
  169. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J (2002). Marijuana Treatment Project Research Group. Cognitive functioning of long-term heavy cannabis users seeking treatment. *Journal of the American Medical Association* 287(9):1123–1131.
  170. Substance Abuse and Mental Health Services Administration (2013). *Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits*. HHS Publication No. (SMA) 13–4760, DAWN Series D–39. Rockville, MD.
  171. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2015a). Results from the 2014 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD.
  172. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2015b). *Treatment Episode Data Set (TEDS): 2003–2013. National Admissions to Substance Abuse Treatment Services*. BHSIS Series S–75, HHS Publication No. (SMA) 15–4934. Rockville, MD.
  173. Tait RJ, MacKinnon A, Christensen H (2011). Cannabis use and cognitive functioning: 8-year trajectory in a young adult cohort. *Addiction* 106(12):2195–2203.
  174. Tanasescu R, Constantinescu CS (2010). Cannabinoids and the immune system: An overview. *Immunobiology* 215(8):588–597.
  175. Tanda G, Munzar P, Goldberg SR (2000). Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. *Nat Neurosci* 3(11):1073–1074.
  176. Tanda G, Goldberg SR (2003). Cannabinoids: Reward, dependence, and underlying neurochemical mechanisms—a review of recent preclinical data. *Psychopharmacology (Berl)* 169(2):115–134.
  177. Tashkin DP (2005). Smoked marijuana as a cause of lung injury. *Monaldi Arch Chest Dis* 63(2):93–100.
  178. Tashkin DP, Zhang ZF, Greenland S, Cozen W, Mack TM, and Morgenstern H (2006). Marijuana use and lung cancer: Results of a case-control study. *American Thoracic Society International Conference*. Abstract A777.
  179. Theunissen EL, Kauert GF, Toennes SW., Moeller MR, Sambeth A, Blanchard MM, Ramaekers JG (2012). Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. *Psychopharmacology (Berl)* 220(2):341–350.
  180. Trabert B, Sigurdson AJ, Sweeney AM, Strom SS, McGlynn KA (2011). Marijuana use and testicular germ cell tumors. *Cancer* 117(4):848–853.
  181. Twitchell W, Brown S, Mackie K (1997). Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. *J Neurophysiol* 78(1):43–50.
  182. U.S. Food and Drug Administration (FDA), Center for Drug and Evaluation Research, Controlled Substances Staff (2015). *The Medical Application of Marijuana: A Review of Published Clinical Studies*. March 19, 2015.
  183. van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MW, de Haan L (2012). Cannabis use in patients at clinical high risk of psychosis: Impact on prodromal symptoms and transition to psychosis. *Curr Pharm Des* 18(32):5036–5044.
  184. van Gastel WA, Wigman JT, Monshouwer K, Kahn RS, van Os J, Boks MP, Volleburch WA (2012). Cannabis use and subclinical positive psychotic experiences in early adolescence: Findings from a Dutch survey. *Addiction* 107(2):381–387.
  185. Van Gundy K, Rebellon CJ (2010). A Life-course Perspective on the “Gateway Hypothesis.” *J Health Soc Behav* 51(3):244–259.
  186. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. (2002). Cannabis use and psychosis: A longitudinal population-based study. *Am J Epi* 156(4):319–327.
  187. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL (2008). Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of  $\Delta(9)$ -tetrahydrocannabinol. *Drug Alcohol Depend* 94(1–3):191–198.
  188. Volkow ND, Baler RD, Compton WM, Weiss SR (2014). Adverse health effects of marijuana use. *N Engl J Med* 370(23):2219–2227.
  189. von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen HU (2002). What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. *Drug Alcohol Depend* 68(1):49–64.
  190. Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H (2002). Comparison of the subjective effects of  $\Delta(9)$ -tetrahydrocannabinol and marijuana in humans. *Psychopharmacology (Berl)* 161(4):331–339.
  191. Wagner JA, Varga K, Kunos G (1998). Cardiovascular actions of cannabinoids and their generation during shock. *J Mol Med* 76(12):824–836.
  192. Wang GS, Roosevelt G, Heard K (2013). Pediatric marijuana exposures in a medical marijuana state. *JAMA Pediatr* 167(7):630–633.
  193. Wang GS, Roosevelt G, Le Lait MC, Martinez EM, Bucher-Bartelson B, Bronstein AC, Heard K (2014). Association of unintended pediatric exposures with decriminalization of marijuana in the United States. *Ann Emerg Med* 63(6):684–689.
  194. Wang T, Collet JP, Shapiro S, Ware MA (2008). Adverse effects of medical cannabinoids: A systematic review. *CMAJ* 178(13):1669–1678.

195. Wesson DR, Washburn P (1990). Current patterns of drug abuse that involve smoking. *NIDA Res Monogr* 99:5–11.
196. Whitehill JM, Rivara FP, Moreno MA (2014). Marijuana-using drivers, alcohol-using drivers, and their passengers: Prevalence and risk factors among underage college students. *JAMA Pediatr* 168(7):618–624.
197. Wiley JL, Barrett RL, Britt DL, Balster RL, Martin BR (1993). Discriminative stimulus effects of  $\Delta$  9-tetrahydrocannabinol and  $\Delta$  9-11-tetrahydrocannabinol in rats and rhesus monkeys. *Neuropharmacology* 32(4):359–365.
198. Wiley JL, Huffman JW, Balster RL, Martin BR (1995). Pharmacological specificity of the discriminative stimulus effects of  $\Delta$  9-tetrahydrocannabinol in rhesus monkeys. *Drug Alcohol Depend* 40(1):81–86.
199. Wilkinson ST, Radhakrishnan R, D'Souza DC (2014). Impact of cannabis use on the development of psychotic disorders. *Curr Addict Rep* 1(2):115–128.
200. Wilson FA, Stimpson JP, Pagán JA (2014). Fatal crashes from drivers testing positive for drugs in the U.S., 1993–2010. *Public Health Rep* 129(4):342–350.
201. Wu X, French ED (2000). Effects of chronic  $\Delta$ 9-tetrahydrocannabinol on rat midbrain dopamine neurons: An electrophysiological assessment. *Neuropharmacology* 39(3):391–398.
202. Zeiger JS, Haberstick BC, Corley RP, Ehringer MA, Crowley TJ, Hewitt JK, Hopfer CJ, Stallings MC, Young SE., Rhee SH (2010). Subjective effects to marijuana associated with marijuana use in community and clinical subjects. *Drug Alcohol Depend* 109(1–3):161–66.
203. Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, Hsu TC, Schantz, SP (1999). Marijuana use and increased risk of squamous cell carcinoma of the head and neck. *Cancer Epidemiol Biomarkers Prev* 8(12):1071–1078.
204. Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, Woll PJ, Orlow I, Cox B on behalf of the Cannabis and Respiratory Disease Research Group of New Zealand, Brhane Y, Liu G, Hung RJ (2015). Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. *Int J Cancer* 136(4):894–903.
205. Zwardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982). Action of cannabidiol on the anxiety and other effects produced by  $\Delta$  9-THC in normal subject. *Psychopharmacology (Berl)* 76(3):245–250.

[FR Doc. 2016–17960 Filed 8–11–16; 8:45 am]

**BILLING CODE 4410–09–P**



# **Exhibit 3**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**21 CFR Chapter II**

[Docket No. DEA-427]

**Denial of Petition To Initiate Proceedings To Reschedule Marijuana**

**AGENCY:** Drug Enforcement Administration, Department of Justice.

**ACTION:** Denial of petition to initiate proceedings to reschedule marijuana.

**SUMMARY:** By letter dated July 19, 2016 the Drug Enforcement Administration (DEA) denied a petition to initiate rulemaking proceedings to reschedule marijuana. Because the DEA believes that this matter is of particular interest to members of the public, the agency is publishing below the letter sent to the petitioner which denied the petition, along with the supporting documentation that was attached to the letter.

**DATES:** August 12, 2016.

**FOR FURTHER INFORMATION CONTACT:** Michael J. Lewis, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrisette Drive, Springfield, Virginia 22152; Telephone: (202) 598-6812

**SUPPLEMENTARY INFORMATION:** July 19, 2016

Dear Mr. Krumm:

On December 17, 2009, you petitioned the Drug Enforcement Administration (DEA) to initiate rulemaking proceedings under the rescheduling provisions of the Controlled Substances Act (CSA). Specifically, you petitioned DEA to have marijuana removed from schedule I of the CSA and rescheduled in any schedule other than schedule I of the CSA.

You requested that DEA remove marijuana from schedule I based on your assertion that:

1. Marijuana has accepted medical use in the United States;
2. Studies have shown that smoked marijuana has proven safety and efficacy;
3. Marijuana is safe for use under medical supervision; and
4. Marijuana does not have the abuse potential for placement in schedule I

In accordance with the CSA scheduling provisions, after gathering the necessary data, DEA requested a scientific and medical evaluation and scheduling recommendation from the Department of Health and Human Services (HHS). HHS concluded that marijuana has a high potential for abuse, has no accepted medical use in the United States, and lacks an acceptable level of safety for use even under medical supervision. Therefore, HHS recommended that marijuana remain in schedule I. The scientific and medical evaluation and scheduling recommendation that HHS submitted to DEA is attached hereto.

Based on the HHS evaluation and all other relevant data, DEA has concluded that there is no substantial evidence that marijuana should be removed from schedule I. A document prepared by DEA addressing these materials in detail also is attached hereto. In short, marijuana continues to meet the criteria for schedule I control under the CSA because:

- (1) *Marijuana has a high potential for abuse.* The HHS evaluation and the additional data gathered by DEA show that marijuana has a high potential for abuse.
- (2) *Marijuana has no currently accepted medical use in treatment in the United States.* Based on the established five-part test for making such determination, marijuana has no “currently accepted medical use” because: As detailed in the HHS evaluation, the drug’s chemistry is not known and reproducible; there are no adequate safety studies; there are no adequate and well-controlled studies proving efficacy; the drug is not accepted by qualified experts; and the scientific evidence is not widely available.
- (3) *Marijuana lacks accepted safety for use under medical supervision.* At present, there are no U.S. Food and Drug Administration (FDA)-approved marijuana products, nor is marijuana under a New Drug Application (NDA) evaluation at the FDA for any indication. The HHS evaluation states that marijuana does not have a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. At this time, the known risks of marijuana use have not been shown to be outweighed by specific benefits in well-controlled clinical trials that scientifically evaluate safety and efficacy.

The statutory mandate of 21 U.S.C. 812(b) is dispositive. Congress established only one schedule, schedule I, for drugs of abuse with “no currently accepted medical use in treatment in the United States” and “lack of accepted safety for use under medical supervision.” 21 U.S.C. 812(b).

Although the HHS evaluation and all other relevant data lead to the conclusion that marijuana must remain in schedule I, it should also be noted that, in view of United States obligations under international drug control treaties, marijuana cannot be placed in a schedule less restrictive than schedule II. This is explained in detail in the accompanying document titled “Preliminary Note Regarding Treaty Considerations.”

Accordingly, and as set forth in detail in the accompanying HHS and DEA documents, there is no statutory basis under the CSA for DEA to grant your petition to initiate rulemaking proceedings to reschedule marijuana. Your petition is, therefore, hereby denied.

Sincerely,

Chuck Rosenberg,

*Acting Administrator*

Attachments:

**Preliminary Note Regarding Treaty Considerations**

Cover Letter from HHS to DEA Summarizing the Scientific and Medical Evaluation and Scheduling Recommendation for Marijuana.

U.S. Department of Health and Human Services (HHS)—Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act

U.S. Department of Justice—Drug Enforcement Administration (DEA), Schedule of Controlled Substances: Maintaining Marijuana in Schedule I of the Controlled Substances Act, Background, Data, and Analysis: Eight Factors Determinative of Control and Findings Pursuant to 21 U.S.C. 812(b)

Dated: July 19, 2016.

**Chuck Rosenberg,**

*Acting Administrator.*

**Preliminary Note Regarding Treaty Considerations**

As the Controlled Substances Act (CSA) recognizes, the United States is a party to the Single Convention on Narcotic Drugs, 1961 (referred to here as the Single Convention or the treaty). 21 U.S.C. 801(7). Parties to the Single Convention are obligated to maintain various control provisions related to the drugs that are covered by the treaty. Many of the provisions of the CSA were enacted by Congress for the specific purpose of ensuring U.S. compliance with the treaty. Among these is a scheduling provision, 21 U.S.C. 811(d)(1). Section 811(d)(1) provides that, where a drug is subject to control under the Single Convention, the DEA Administrator (by delegation from the Attorney General) must “issue an order controlling such drug under the schedule he deems most appropriate to carry out such [treaty] obligations, without regard to the findings required by [21 U.S.C. 811(a) or 812(b)] and without regard to the procedures prescribed by [21 U.S.C. 811(a) and (b)].”

Marijuana is a drug listed in the Single Convention. The Single Convention uses the term “cannabis” to refer to marijuana.<sup>1</sup> Thus, the DEA Administrator is obligated under section 811(d) to control marijuana in the

<sup>1</sup> Under the Single Convention, “‘cannabis plant’ means any plant of the genus *Cannabis*.” Article 1(c). The Single Convention defines “cannabis” to include “the flowering or fruiting tops of the cannabis plant (excluding the seeds and leaves when not accompanied by the tops) from which the resin has not been extracted, by whatever name they may be designated.” Article 1(b). This definition of “cannabis” under the Single Convention is slightly less inclusive than the CSA definition of “marihuana,” which includes all parts of the cannabis plant except for the mature stalks, sterilized seeds, oil from the seeds, and certain derivatives thereof. See 21 U.S.C. 802(16). Cannabis and cannabis resin are included in the list of drugs in Schedule I and Schedule IV of the Single Convention. In contrast to the CSA, the drugs listed in Schedule IV of the Single Convention are also listed in Schedule I of the Single Convention and are subject to the same controls as Schedule I drugs as well as additional controls. Article 2, par. 5

schedule that he deems most appropriate to carry out the U.S. obligations under the Single Convention. It has been established in prior marijuana rescheduling proceedings that placement of marijuana in either schedule I or schedule II of the CSA is “necessary as well as sufficient to satisfy our international obligations” under the Single Convention. *NORML v. DEA*, 559 F.2d 735, 751 (D.C. Cir. 1977). As the United States Court of Appeals for the D.C. Circuit has stated, “several requirements imposed by the Single Convention would not be met if cannabis and cannabis resin were placed in CSA schedule III, IV, or V.”<sup>2</sup> *Id.* Therefore, in accordance with section 811(d)(1), DEA must place marijuana in either schedule I or schedule II.

Because schedules I and II are the only possible schedules in which marijuana may be placed, for purposes of evaluating this scheduling petition, it is essential to understand the differences between the criteria for placement of a substance in schedule I and those for placement in schedule II. These criteria are set forth in 21 U.S.C. 812(b)(1) and (b)(2), respectively. As indicated therein, substances in both schedule I and schedule II share the characteristic of “a high potential for abuse.” Where the distinction lies is that schedule I drugs have “no currently accepted medical use in treatment in the United States” and “a lack of accepted safety for use of the drug . . . under medical supervision,” while schedule II drugs do have “a currently accepted medical use in treatment in the United States.”<sup>3</sup>

Accordingly, in view of section 811(d)(1), this scheduling petition turns on whether marijuana has a currently accepted medical use in treatment in the United States. If it does not, DEA must, pursuant to section 811(d), deny the petition and keep marijuana in schedule I.

As indicated, where section 811(d)(1) applies to a drug that is the subject of a rescheduling petition, the DEA

Administrator must issue an order controlling the drug under the schedule he deems most appropriate to carry out United States obligations under the Single Convention, without regard to the findings required by sections 811(a) or 812(b) and without regard to the procedures prescribed by sections 811(a) and (b). Thus, since the only determinative issue in evaluating the present scheduling petition is whether marijuana has a currently accepted medical use in treatment in the United States, DEA need not consider the findings of sections 811(a) or 812(b) that have no bearing on that determination, and DEA likewise need not follow the procedures prescribed by sections 811(a) and (b) with respect to such irrelevant findings. Specifically, DEA need not evaluate the relative abuse potential of marijuana or the relative extent to which abuse of marijuana may lead to physical or psychological dependence.

As explained below, the medical and scientific evaluation and scheduling recommendation issued by the Secretary of Health and Human Services concludes that marijuana has no currently accepted medical use in treatment in the United States, and the DEA Administrator likewise so concludes. For the reasons just indicated, no further analysis beyond this consideration is required. Nonetheless, because of the widespread public interest in understanding all the facts relating to the harms associated with marijuana, DEA is publishing here the entire medical and scientific analysis and scheduling evaluation issued by the Secretary, as well as DEA’s additional analysis.

Department of Health and Human Services, Office of the Secretary Assistant Secretary for Health, Office of Public Health and Science Washington DC 20201.

June 25, 2015.

The Honorable Chuck Rosenberg  
*Acting Administrator, Drug Enforcement Administration, U.S. Department of Justice, 8701 Morrisette Drive, Springfield, VA 22152*

Dear Mr. Rosenberg:

Pursuant to the Controlled Substances Act (CSA), 21 U.S.C. 811(b), (c), and (f), the Department of Health and Human Services (HHS) is recommending that marijuana continue to be maintained in Schedule I of the CSA.

The Food and Drug Administration (FDA) has considered the abuse potential and dependence-producing characteristics of marijuana.

Marijuana meets the three criteria for placing a substance in Schedule I of the CSA under 21 U.S.C. 812(b)(1). As discussed in the enclosed analyses, marijuana has a high potential for abuse, no currently accepted

medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. Accordingly, HHS recommends that marijuana be maintained in Schedule I of the CSA. Enclosed are two documents prepared by FDA’s Controlled Substance Staff (in response to petitions filed in 2009 by Mr. Bryan Krumm and in 2011 by Governors Lincoln D. Chafee and Christine O. Gregoire) that form the basis for the recommendation. Pursuant to the requests in the petitions, FDA broadly evaluated marijuana, and did not focus its evaluation on particular strains of marijuana or components or derivatives of marijuana.

FDA’s Center for Drug Evaluation and Research’s current review of the available evidence and the published clinical studies on marijuana demonstrated that since our 2006 scientific and medical evaluation and scheduling recommendation responding to a previous DEA petition, research with marijuana has progressed. However, the available evidence is not sufficient to determine that marijuana has an accepted medical use. Therefore, more research is needed into marijuana’s effects, including potential medical uses for marijuana and its derivatives. Based on the current review, we identified several methodological challenges in the marijuana studies published in the literature. We recommend they be addressed in future clinical studies with marijuana to ensure that valid scientific data are generated in studies evaluating marijuana’s safety and efficacy for therapeutic use. For example, we recommend that studies need to focus on consistent administration and reproducible dosing of marijuana, potentially through the use of administration methods other than smoking. A summary of our review of the published literature on the clinical uses of marijuana, including recommendations for future studies, is attached to this document.

FDA and the National Institutes of Health’s National Institute on Drug Abuse (NIDA) also believe that work continues to be needed to ensure support by the federal government for the efficient conduct of clinical research using marijuana. Concerns have been raised about whether the existing federal regulatory system is flexible enough to respond to increased interest in research into the potential therapeutic uses of marijuana and marijuana-derived drugs. HHS welcomes an opportunity to continue to explore these concerns with DEA.

Should you have any questions regarding these recommendations, please contact Corinne P. Moody, Science Policy Analyst, Controlled Substances Staff, Center for Drug Evaluation and Research, FDA, at (301) 796–3152.

Sincerely yours,

Karen B. DeSalvo, MD, MPH, MSc  
*Acting Assistant Secretary for Health*

Enclosure:  
Basis for the Recommendation for  
Maintaining Marijuana in Schedule I of the  
Controlled Substances Act

<sup>2</sup> The Court further stated: “For example, [article 31 paragraph 4 of the Single Convention] requires import and export permits that would not be obtained if the substances were placed in CSA schedules III through V. In addition, the quota and [recordkeeping] requirements of Articles 19 through 21 of the Single Convention would be satisfied only by placing the substances in CSA schedule I or II.” *Id.* n. 71 (internal citations omitted).

<sup>3</sup> As DEA has stated in evaluating prior marijuana rescheduling petitions, “Congress established only one schedule, schedule I, for drugs of abuse with ‘no currently accepted medical use in treatment in the United States’ and ‘lack of accepted safety for use . . . under medical supervision.’ 21 U.S.C. 812(b).” 76 FR 40552 (2011); 66 FR 20038 (2001).

### Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act

On December 17, 2009, Mr. Bryan Krumm submitted a petition to the Drug Enforcement Administration (DEA) requesting that proceedings be initiated to repeal the rules and regulations that place marijuana<sup>4</sup> in Schedule I of the Controlled Substances Act (CSA). The petitioner contends that marijuana has an accepted medical use in the United States, has proven safety and efficacy, is safe for use under medical supervision, and does not have the abuse potential for placement in Schedule I. The petitioner requests that marijuana be rescheduled to any schedule other than Schedule I of the CSA. In May 2011, the DEA Administrator requested that the U.S. Department of Health and Human Services (HHS) provide a scientific and medical evaluation of the available information and a scheduling recommendation for marijuana, in accordance with the provisions of 21 U.S.C. 811(b).

In accordance with 21 U.S.C. 811(b), the DEA has gathered information related to the control of marijuana (*Cannabis sativa*)<sup>5</sup> under the CSA. Pursuant to 21 U.S.C. 811(b), the Secretary of HHS is required to consider in a scientific and medical evaluation eight factors determinative of control under the CSA. Following consideration of the eight factors, if it is appropriate, the Secretary must make three findings to recommend scheduling a substance in the CSA or transferring a substance from one schedule to another. The findings relate to a substance's abuse potential, legitimate medical use, and safety or dependence liability. Administrative responsibilities for evaluating a substance for control under the CSA are performed by the Food and Drug Administration (FDA), with the concurrence of the National Institute on Drug Abuse (NIDA), as described in the

<sup>4</sup>Note that "marihuana" is the spelling originally used in the Controlled Substances Act (CSA). This document uses the spelling that is more common in current usage, "marijuana."

<sup>5</sup>The CSA defines marihuana (marijuana) as the following:

All parts of the plant *Cannabis sativa* L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin. Such term does not include the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination (21 U.S.C. 802(16)).

Memorandum of Understanding (MOU) of March 8, 1985 (50 FR 9518–20).

In this document, FDA recommends continued control of marijuana in Schedule I of the CSA. Pursuant to 21 U.S.C. 811(c), the eight factors pertaining to the scheduling of marijuana are considered below.

#### 1. Its Actual or Relative Potential for Abuse

Under the first factor the Secretary must consider marijuana's actual or relative potential for abuse. The CSA does not define the term "abuse." However, the CSA's legislative history suggests the following in determining whether a particular drug or substance has a potential for abuse:<sup>6</sup>

a. There is evidence that individuals are taking the drug or drugs containing such a substance in amounts sufficient to create a hazard to their health or to the safety of other individuals or to the community.

b. There is a significant diversion of the drug or drugs containing such a substance from legitimate drug channels.

c. Individuals are taking the drug or drugs containing such a substance on their own initiative rather than on the basis of medical advice from a practitioner licensed by law to administer such drugs in the course of his professional practice.

d. The drug or drugs containing such a substance are new drugs so related in their action to a drug or drugs already listed as having a potential for abuse to make it likely that the drug will have the same potentiality for abuse as such drugs, thus making it reasonable to assume that there may be significant diversions from legitimate channels, significant use contrary to or without medical advice, or that it has a substantial capability of creating hazards to the health of the user or to the safety of the community.

In the development of this scientific and medical evaluation for the purpose of scheduling, the Secretary analyzed considerable data related to the substance's abuse potential. The data include a discussion of the prevalence and frequency of use, the amount of the substance available for illicit use, the ease of obtaining or manufacturing the substance, the reputation or status of the substance "on the street," and evidence relevant to at-risk populations. Importantly, the petitioners define marijuana as including all *Cannabis*

<sup>6</sup>Comprehensive Drug Abuse Prevention and Control Act of 1970, H.R. Rep. No. 91–1444, 91st Cong., Sess. 1 (1970) reprinted in U.S.C.C.A.N. 4566, 4603.

cultivated strains. Different marijuana samples derived from various cultivated strains may have very different chemical constituents, thus the analysis is based on what is known about the range of these constituents across all cultivated strains.

Determining the abuse potential of a substance is complex with many dimensions, and no single test or assessment provides a complete characterization. Thus, no single measure of abuse potential is ideal. Scientifically, a comprehensive evaluation of the relative abuse potential of a substance can include consideration of the following elements: Receptor binding affinity, preclinical pharmacology, reinforcing effects, discriminative stimulus effects, dependence producing potential, pharmacokinetics, route of administration, toxicity, data on actual abuse, clinical abuse potential studies, and public health risks. Importantly, abuse can exist independently from tolerance or physical dependence because individuals may abuse drugs in doses or patterns that do not induce these phenomena. Additionally evidence of clandestine population and illicit trafficking of a substance can shed light on both the demand for a substance as well as the ease of obtaining a substance. Animal and human laboratory data and epidemiological data are all used in determining a substance's abuse potential. Moreover, epidemiological data can indicate actual abuse.

The petitioner compares the effects of marijuana to currently controlled Schedule II substances and make repeated claims about their comparative effects. Comparisons between marijuana and the diverse array of Schedule II substances is difficult, because of the pharmacologically dissimilar actions of substances of Schedule II of the CSA. For example, Schedule II substances include stimulant-like drugs (e.g., cocaine, methylphenidate, and amphetamine), opioids (e.g., oxycodone, fentanyl), sedatives (e.g., pentobarbital, amobarbital), dissociative anesthetics (e.g., PCP), and naturally occurring plant components (e.g., coca leaves and poppy straw). The mechanism(s) of action of the above Schedule II substances are wholly different from one another, and they are different from tetrahydrocannabinol (THC) and marijuana as well. For example, Schedule II stimulants typically function by increasing monoaminergic tone via an increase in dopamine and norepinephrine (Schmitt et al., 2013). In contrast, opioid analgesics function via mu-opioid receptor agonist effects.

These differing mechanism(s) of action result in vastly different behavioral and adverse effect profiles, making comparisons across the range of pharmacologically diverse C-II substances inappropriate.

In addition, many substances scheduled under the CSA are reviewed and evaluated within the context of commercial drug development, using data submitted in the form of a new drug application (NDA). A new analgesic drug might be compared to a currently scheduled analgesic drug as part of the assessment of its relative abuse potential. However, because the petitioners have not identified a specific indication for the use of marijuana, identifying an appropriate comparator based on indication cannot be done.

a. There is evidence that individuals are taking the substance in amounts sufficient to create a hazard to their health or to the safety of other individuals or to the community.

Evidence shows that some individuals are taking marijuana in amounts sufficient to create a hazard to their health and to the safety of other individuals and the community. A large number of individuals use marijuana. HHS provides data on the extent of marijuana abuse through NIDA and the Substance Abuse and Mental Health Services Administration (SAMHSA). According to the most recent data from SAMHSA's 2012 National Survey on Drug Use and Health (NSDUH), which estimates the number of individuals who have used a substance within a month prior to the study (described as "current use"), marijuana is the most commonly used illicit drug among American aged 12 years and older, with an estimated 18.9 million Americans having used marijuana within the month prior to the 2012 NSDUH.

Compared to 2004, when an estimated 14.6 million individuals reported using marijuana within the month prior to the study, the estimated rates in 2012 show an increase of approximately 4.3 million individuals. The 2013 Monitoring the Future (MTF) survey of 8th, 10th, and 12th grade students also indicates that marijuana is the most widely used illicit substance in this age group.

Specifically, current month use was at 7.0 percent of 8th graders, 18.0 percent of 10th, graders and 22.7 percent of 12th graders. Additionally, the 2011 Treatment Episode Data Set (TEDS) reported that primary marijuana abuse accounted for 18.1 percent of non-private substance-abuse treatment facility admissions, with 24.3 percent of those admitted reporting daily use. However, of these admissions for primary marijuana abuse, the criminal

justice system referred 51.6 percent to treatment. SAMHSA's Drug Abuse Warning Network (DAWN) was a national probability survey of U.S. hospitals with emergency departments (EDs) and was designed to obtain information on ED visits in which marijuana was mentioned, accounting for 36.4 percent of illicit drug related ED visits. There are some limitations related to DAWN data on ED visits, which are discussed in detail in Factor 4, "Its History and Current Pattern of Abuse;" Factor 5, "The Scope, Duration, and Significance of Abuse;" and Factor 6, "What, if any, Risk There is to the Public Health." These factors contain detailed discussions of these data.

A number of risks can occur with both acute and chronic use of marijuana. Detailed discussions of the risks are addressed in Factor 2, "Scientific Evidence of its Pharmacological Effect, if Known," and Factor 6, "What, if any, Risk There is to the Public Health."

b. There is significant diversion of the substance from legitimate drug channels.

There is a lack of evidence of significant diversion of marijuana from legitimate drug channels, but this is likely due to the fact that marijuana is more widely available from illicit sources rather than through legitimate channels. Marijuana is not an FDA-approved drug product, as an NDA or biologics license application (BLA) has not been approved for marketing in the United States. Numerous states and the District of Columbia have state-level medical marijuana laws that allow for marijuana use within that state. These state-level drug channels do not have sufficient collection of data related to medical treatment, including efficacy and safety.

Marijuana is used by researchers for nonclinical research as well as clinical research under investigational new drug (IND) applications; this represents the only legitimate drug channel in the United States. However, marijuana used for research represents a very small contribution of the total amount of marijuana available in the United States, and thus provides limited information about diversion. In addition, the lack of significant diversion of investigation supplies is likely because of the widespread availability of illicit marijuana of equal or greater amounts of delta<sup>9</sup>-THC. The data originating from the DEA on seizure statistics demonstrate the magnitude of the availability for illicit marijuana. DEA's System to Retrieve Information from Drug Evidence (STRIDE) provides information on total domestic drug seizures, STRIDE reports a total

domestic seizure of 573,195 kg of marijuana in 2011, the most recent year with complete data that is currently publically available (DEA Domestic Drug Seizures, n.d.).

c. Individuals are taking the substance on their own initiative rather than on the basis of medical advice from a practitioner licensed by law to administer such substances.

Because the FDA has not approved an NDA or BLA for a marijuana drug product for any therapeutic indication, the only way an individual can take marijuana on the basis of medical advice through legitimate channels at the federal level is by participating in research under an IND application. That said, numerous states and the District of Columbia have passed state-level medical marijuana laws allowing for individuals to use marijuana under certain circumstances. However, data are not yet available to determine the number of individuals using marijuana under these state-level medical marijuana laws. Regardless, according to the 2012 NSDUH data, 18.9 million American adults currently use marijuana (SAMHSA, 2013). Based on the large number of individuals reporting current use of marijuana and the lack of an FDA-approved drug product in the United States, one can assume that it is likely that the majority of individuals using marijuana do so on their own initiative rather than on the basis of medical advice from a licensed practitioner.

d. The substance is so related in its action to a substance already listed as having a potential for abuse to make it likely that it will have the same potential for abuse as such substance, thus making it reasonable to assume that there may be significant diversions from legitimate channels, significant use contrary to or without medical advice, or that it has a substantial capability of creating hazards to the health of the user or to the safety of the community.

FDA has approved two drug products containing cannabinoid compounds that are structurally related to the active components in marijuana. These two marketed products are controlled under the CSA. Once a specific drug product containing cannabinoids becomes approved, that specific drug product may be moved from Schedule I to a different Schedule (II-V) under the CSA. Firstly, Marinol—generically known as dronabinol—is a Schedule III drug product containing synthetic delta<sup>9</sup>-THC. Marinol, which is formulated in sesame oil in soft gelatin capsules, was first placed in Schedule II under the CSA following its approval by the FDA. Marinol was later rescheduled

to Schedule III under the CSA because of low numbers of reports of abuse relative to marijuana. Dronabinol is listed in Schedule I under the CSA. FDA approved Marinol in 1985 for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who failed to respond adequately to conventional anti-emetic treatments. In 1992, FDA approved Marional for anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS). Secondly, in 1985, FDA approved Cesamet, a drug product containing the Schedule II substance nabilone, for the treatment of nausea and vomiting associated with cancer chemotherapy. Besides the two cannabinoid-containing drug products FDA approved for marketing, other naturally occurring cannabinoids and their derivatives (from *Cannabis*) and their synthetic equivalents with similar chemical structure and pharmacological activity are included in the CSA as Schedule I substances.

## 2. Scientific Evidence of Its Pharmacological Effects, if Known

Under the second factor, the Secretary must consider the scientific evidence of marijuana's pharmacological effects. Abundant scientific data are available on the neurochemistry, toxicology, and pharmacology of marijuana. This section includes a scientific evaluation of marijuana's neurochemistry; pharmacology; and human and animal behavioral, central nervous system, cognitive, cardiovascular, autonomic, endocrinological, and immunological system effects. The overview presented below relies upon the most current research literature on cannabinoids.

### *Neurochemistry and Pharmacology of Marijuana*

Marijuana is a plant that contains numerous natural constituents, such as cannabinoids, that have a variety of pharmacological actions. The petition defines marijuana as including all *Cannabis* cultivated strains. Different marijuana samples derived from various cultivated strains may have very different chemical constituents including delta<sup>9</sup>-THC and other cannabinoids (Appendino et al., 2011). As a consequence, marijuana products from different strains will have different biological and pharmacological profiles.

According to ElSohly and Slade (2005) and Appendino et al. (2011), marijuana contains approximately 525 identified natural constituents, including approximately 100 compounds classified as cannabinoids. Cannabinoids primarily exist in

*Cannabis*, and published data suggests that most major cannabinoid compounds occurring naturally have been identified chemically. New and minor cannabinoids and other new compounds are continuously being characterized (Pollastro et al., 2011). So far, only two cannabinoids (cannabigerol and its corresponding acid) have been obtained from a non-*Cannabis* source. A South African *Helichrysum* (*H. umbraculigerum*) accumulates these compounds (Appendino et al., 2011). The chemistry of marijuana is described in more detail in Factor 3, "The State of Current Scientific Knowledge Regarding the Drug or Other Substance."

The site of cannabinoid action is at the cannabinoid receptors. Cloning of cannabinoid receptors, first from rat brain tissue (Matsuda et al., 1990) and then from human brain tissue (Gerard et al., 1991), has verified the site of action. Two cannabinoid receptors, CB<sub>1</sub> and CB<sub>2</sub>, were characterized (Battista et al., 2012; Piomelli, 2005). Evidence of a third cannabinoid receptor exists, but it has not been identified (Battista et al., 2012).

The cannabinoid receptors, CB<sub>1</sub> and CB<sub>2</sub>, belong to the family of G-protein-coupled receptors, and present a typical seven transmembrane-spanning domain structure. Cannabinoid receptors link to an inhibitory G-protein (G<sub>i</sub>), such that adenylate cyclase activity is inhibited when a ligand binds to the receptor. This, in turn, prevents the conversion of ATP to the second messenger, cyclic AMP (cAMP). Examples of inhibitory coupled receptors include opioid, muscarinic cholinergic, alpha<sub>2</sub>-adrenoreceptors, dopamine (D<sub>2</sub>), and serotonin (5-HT<sub>1</sub>).

Cannabinoid receptor activation inhibits N- and P/Q-type calcium channels and activates inwardly rectifying potassium channels (Mackie et al., 1995; Twitchell et al., 1997). N-type calcium channel inhibition decreases neurotransmitter release from several tissues. Thus, calcium channel inhibition may be the mechanism by which cannabinoids inhibit acetylcholine, norepinephrine, and glutamate release from specific areas of the brain. These effects may represent a potential cellular mechanism underlying cannabinoids' antinociceptive and psychoactive effects (Ameri, 1999).

CB<sub>1</sub> receptors are found primarily in the central nervous system, but are also present in peripheral tissues. CB<sub>1</sub> receptors are located mainly in the basal ganglia, hippocampus, and cerebellum of the brain (Howlett et al., 2004). The localization of these receptors may

explain cannabinoid interference with movement coordination and effects on memory and cognition. Additionally, CB<sub>1</sub> receptors are found in the immune system and numerous other peripheral tissues (Petrocellis and Di Marzo, 2009). However, the concentration of CB<sub>1</sub> receptors is considerably lower in peripheral tissues than in the central nervous system (Herkenharn et al., 1990 and 1992).

CB<sub>2</sub> receptors are found primarily in the immune system, but are also present in the central nervous system and other peripheral tissues. In the immune system, CB<sub>2</sub> receptors are found predominantly in B lymphocytes and natural killer cells (Bouaboula et al., 1993). CB<sub>2</sub> receptors may mediate cannabinoids' immunological effects (Galiegue et al., 1995). Additionally, CB<sub>2</sub> receptors have been localized in the brain, primarily in the cerebellum and hippocampus (Gong et al., 2006). The distribution of CB<sub>2</sub> receptors throughout the body is less extensive than the distribution of CB<sub>1</sub> receptors (Petrocellis and Di Marzo, 2009). However, both CB<sub>1</sub> and CB<sub>2</sub> receptors are present in numerous tissues of the body.

Cannabinoid receptors have endogenous ligands. In 1992 and 1995, two endogenous cannabinoid receptor agonists, anandamide and arachidonyl glycerol (2-AG), respectively, were identified (Di Marzo, 2006). Anandamide is a low efficacy agonist (Breivogel and Childers, 2000) and 2-AG is a high efficacy agonist (Gonsiorek et al., 2000). Cannabinoid endogenous ligands are present in central as well as peripheral tissues. A combination of uptake and hydrolysis terminate the action of the endogenous ligands. The endogenous cannabinoid system is a locally active signaling system that, to help restore homeostasis, is activated "on demand" in response to changes to the local homeostasis (Petrocellis and Di Marzo, 2009). The endogenous cannabinoid system, including the endogenous cannabinoids and the cannabinoid receptors, demonstrate substantial plasticity in response to several physiological and pathological stimuli (Petrocellis and Di Marzo, 2009). This plasticity is particularly evident in the central nervous system.

Delta<sup>9</sup>-THC and cannabidiol (CBD) are two abundant cannabinoids present in marijuana. Marijuana's major psychoactive cannabinoid is delta<sup>9</sup>-THC (Wachtel et al., 2002). In 1964, Gaoni and Mechoulam first described delta<sup>9</sup>-THC's structure and function. In 1963, Mechoulam and Shvo first described CBD's structure. The pharmacological actions of CBD have not been fully studied in humans.

Delta<sup>9</sup>-THC and CBD have varying affinity and effects at the cannabinoid receptors. Delta<sup>9</sup>-THC displays similar affinity for CB<sub>1</sub> and CB<sub>2</sub> receptors, but behaves as a weak agonist for CB<sub>2</sub> receptors. The identification of synthetic cannabinoid ligands that selectively bind to CB<sub>2</sub> receptors but do not have the typical delta<sup>9</sup>-THC-like psychoactive properties suggests that the activation of CB<sub>1</sub>-receptors mediates cannabinoids' psychotropic effects (Hanus et al., 1999). CBD has low affinity for both CB<sub>1</sub> and CB<sub>2</sub> receptors (Mechoulam et al., 2007). According to Mechoulam et al. (2007), CBD has antagonistic effects at CB<sub>1</sub> receptors and some inverse agonistic properties at CB<sub>2</sub> receptors. When cannabinoids are given subacutely to rats, CB<sub>1</sub> receptors down-regulate and the binding of the second messenger system coupled to CB<sub>1</sub> receptors, GTPγS, decreases (Breivogel et al., 2001).

### *Animal Behavioral Effects*

#### Self-Administration

Self-administration is a method that assesses the ability of a drug to produce rewarding effects. The presence of rewarding effects increases the likelihood of behavioral responses to obtain additional drug. Animal self-administration of a drug is often useful in predicting rewarding effects in humans, and is indicative of abuse liability. A good correlation is often observed between those drugs that rhesus monkeys self-administer and those drugs that humans abuse (Balster and Bigelow, 2003). Initially, researchers could not establish self-administration of cannabinoids, including delta<sup>9</sup>-THC, in animal models. However, self-administration of delta<sup>9</sup>-THC can now be established in a variety of animal models under specific training paradigms (Justinova et al., 2003, 2004, 2005).

Squirrel monkeys, with and without prior exposure to other drugs of abuse, self-administer delta<sup>9</sup>-THC under specific conditions. For instance, Tanda et al. (2000) observed that when squirrel monkeys are initially trained to self-administer intravenous cocaine, they will continue to bar-press delta<sup>9</sup>-THC at the same rate as they would with cocaine. The doses were notably comparable to those doses used by humans who smoke marijuana. SR141716, a CB<sub>1</sub> cannabinoid receptor agonist-antagonist, can block this rewarding effect. Other studies show that naïve squirrel monkeys can be successfully trained to self-administer delta<sup>9</sup>-THC intravenously (Justinova et al., 2003). The maximal responding rate

is 4 µg/kg per injection, which is 2–3 times greater than observed in previous studies using cocaine-experienced monkeys. Naltrexone, a mu-opioid antagonist, partially antagonizes these rewarding effects of delta<sup>9</sup>-THC (Justinova et al., 2004).

Additionally, data demonstrate that under specific conditions, rodents self-administer cannabinoids. Rats will self-administer delta<sup>9</sup>-THC when applied intracerebroventricularly (i.c.v.), but only at the lowest doses tested (0.01–0.02 µg/infusion) (Braidia et al., 2004). SR141716 and the opioid antagonist naloxone can antagonize this effect. However, most studies involve rodents self-administering the synthetic cannabinoid WIN 55212, a CB<sub>1</sub> receptor agonist with a non-cannabinoid structure (Deiana et al., 2007; Fattore et al., 2007; Martellotta et al., 1998; Mendizabal et al., 2006).

Aversive effects, rather than reinforcing effects, occur in rats that received high doses of WIN 55212 (Chaperon et al., 1998) or delta<sup>9</sup>-THC (Sanudo-Pena et al., 1997), indicating a possible critical dose-dependent effect. In both studies, SR141716 reversed these aversive effects.

#### Conditioned Place Preference

Conditioned place preference (CPP) is a less rigorous method than self-administration for determining whether or not a drug has rewarding properties. In this behavioral test, animals spend time in two distinct environments: One where they previously received a drug and one where they received a placebo. If the drug is reinforcing, animals will choose to spend more time in the environment paired with the drug, rather than with the placebo, when presented with both options simultaneously.

Animals show CPP to delta<sup>9</sup>-THC, but only at the lowest doses tested (0.075–1.0 mg/kg, intraperitoneal (i.p.)) (Braidia et al., 2004). SR141716 and naloxone antagonize this effect (Braidia et al., 2004). As a partial agonist, SR141716 can induce CPP at doses of 0.25, 0.5, 2 and 3 mg/kg (Cheer et al., 2000). In knockout mice, those without µ-opioid receptors do not develop CPP to delta<sup>9</sup>-THC (Ghozland et al., 2002).

#### Drug Discrimination Studies

Drug discrimination is a method where animals indicate whether a test drug produces physical or psychic perceptions similar to those produced by a known drug of abuse. In this test, an animal learns to press one bar when it receives the known drug of abuse and another bar when it receives placebo. To determine whether the test drug is like

the known drug of abuse, a challenge session with the test drug demonstrates which of the two bars the animal presses more often.

In addition to humans (Lile et al., 2009; Lile et al., 2011), it has been noted that animals, including monkeys (McMahon, 2009), mice (McMahon et al., 2008), and rats (Gold et al., 1992), are able to discriminate cannabinoids from other drugs or placebo. Moreover, the major active metabolite of delta<sup>9</sup>-THC, 11-hydroxy-delta<sup>9</sup>-THC, also generalizes (following oral administration) to the stimulus cues elicited by delta<sup>9</sup>-THC (Browne and Weissman, 1981). Twenty-two other cannabinoids found in marijuana also fully substitute for delta<sup>9</sup>-THC. However, CBD does not substitute for delta<sup>9</sup>-THC in rats (Vann et al., 2008).

Discriminative stimulus effects of delta<sup>9</sup>-THC are pharmacologically specific for marijuana containing cannabinoids (Balster and Prescott, 1992; Browne and Weissman, 1981; Wiley et al., 1993, 1995). The discriminative stimulus effects of the cannabinoid group appear to provide unique effects because stimulants, hallucinogens, opioids, benzodiazepines, barbiturates, NMDA antagonists, and antipsychotics do not fully substitute for delta<sup>9</sup>-THC.

### **Central Nervous System Effects**

#### *Human Physiological and Psychological Effects*

##### Psychoactive Effects

Below is a list of the common subjective responses to cannabinoids (Adams and Martin, 1996; Gonzalez, 2007; Hollister 1986, 1988; Institute of Medicine, 1982). According to Maldonado (2002), these responses to marijuana are pleasurable to many humans and are often associated with drug-seeking and drug-taking. High levels of positive psychoactive effects are associated with increased marijuana use, abuse, and dependence (Scherrer et al., 2009; Zeiger et al., 2010).

(1) Disinhibition, relaxation, increased sociability, and talkativeness.

(2) Increased merriment and appetite, and even exhilaration at high doses.

(3) Enhanced sensory perception, which can generate an increased appreciation of music, art, and touch.

(4) Heightened imagination, which can lead to a subjective sense of increased creativity.

(5) Initial dizziness, nausea, tachycardia, facial flushing, dry mouth, and tremor.

(6) Disorganized thinking, inability to converse logically, time distortions, and short-term memory impairment.

(7) Ataxia and impaired judgment, which can impede driving ability or lead to an increase in risk-tasking behavior.

(8) Illusions, delusions, and hallucinations that intensify with higher doses.

(9) Emotional lability, incongruity of affect, dysphoria, agitation, paranoia, confusion, drowsiness, and panic attacks, which are more common in inexperienced or high-dosed users.

As with many psychoactive drugs, a person's medical, psychiatric, and drug-taking history can influence the individual's response to marijuana. Dose preferences to marijuana occur in that marijuana users prefer higher concentrations of the principal psychoactive substance (1.95 percent delta<sup>9</sup>-THC) over lower concentrations (0.63 percent delta<sup>9</sup>-THC) (Chait and Burke, 1994). Nonetheless, frequent marijuana users (≤100 times of use) were able to identify a drug effect from low-dose delta<sup>9</sup>-THC better than occasional users (<10 times of use) while also experiencing fewer sedative effects from marijuana (Kirk and de Wit, 1999).

The petitioners contend that many of marijuana's naturally occurring cannabinoids mitigate the psychoactive effects of delta<sup>9</sup>-THC, and therefore that marijuana lacks sufficient abuse potential to warrant Schedule I placement, because Marinol, which is in Schedule III, contains only delta<sup>9</sup>-THC. This theory has not been demonstrated in controlled studies. Moreover, the concept of abuse potential encompasses all properties of a substance, including its chemistry, pharmacology, and pharmacokinetics, as well as usage patterns and diversion history. The abuse potential of a substance is associated with the repeated or sporadic use of a substance in nonmedical situations for the psychoactive effects the substance produces. These psychoactive effects include euphoria, perceptual and other cognitive distortions, hallucinations, and mood changes. However, as stated above, the abuse potential not only includes the psychoactive effects, but also includes other aspects related to a substance.

DEA's final published rule entitled "Rescheduling of the Food and Drug Administration Approved Product Containing Synthetic Dronabinol [(–)-delta<sup>9</sup>-(trans)-Tetrahydrocannabinol] in Sesame Oil and Encapsulated in Soft Gelatin Capsules From Schedule II to Schedule III" (64 FR 35928, July 2, 1999) rescheduled Marinol from Schedule II to Schedule III. The HHS assessment of the abuse potential and subsequent scheduling recommendation

compared Marinol to marijuana on different aspects related to abuse potential. Major differences in formulation, availability, and usage between marijuana and the drug product, Marinol, contribute to their differing abuse potentials.

Hollister and Gillespie (1973) estimated that delta<sup>9</sup>-THC by smoking is 2.6 to 3 times more potent than delta<sup>9</sup>-THC ingested orally. The intense psychoactive drug effect achieved, rapidly by smoking is generally considered to produce the effect desired by the abuser. This effect explains why abusers often prefer to administer certain drugs by inhalation, intravenously, or intranasally rather than orally. Such is the case with cocaine, opium, heroin, phencyclidine, methamphetamine, and delta<sup>9</sup>-THC from marijuana (0.1–9.5 percent delta<sup>9</sup>-THC range) or hashish (10–30 percent delta<sup>9</sup>-THC range) (Wesson and Washburn, 1990). Thus, the delayed onset and longer duration of action for Marinol may be contributing factors limiting the abuse or appeal of Marinol as a drug of abuse relative to marijuana.

The formulation of Marinol is a factor that contributes to differential scheduling of Marinol and marijuana. For example, extraction and purification of dronabinol from the encapsulated sesame oil mixture of Marinol is highly complex and difficult. Additionally, the presence of sesame oil mixture in the formulation may preclude the smoking of Marinol-laced cigarettes.

Additionally, there is a dramatic difference between actual abuse and illicit trafficking of Marinol and marijuana. Despite Marinol's availability in the United States, there have been no significant reports of abuse, diversion, or public health problems due to Marinol. By comparison, 18.9 million American adults report currently using marijuana (SAMHSA, 2013).

In addition, FDA's approval of an NDA for Marinol allowed for Marinol to be rescheduled to Schedule II, and subsequently to Schedule III of the CSA. In conclusion, marijuana and Marinol differ on a wide variety of factors that contribute to each substance's abuse potential. These differences are major reasons distinguishing the higher abuse potential for marijuana and the different scheduling determinations of marijuana and Marinol.

In terms of the petitioners' claim that different cannabinoids present in marijuana mitigate the psychoactive effects of delta<sup>9</sup>-THC, only three of the cannabinoids present in marijuana were simultaneously administered with delta<sup>9</sup>-THC to examine how the

combinations of these cannabinoids such as CBD, cannabichromene (CBC) and cannabitol (CBN) influence delta<sup>9</sup>-THC's psychoactive effects. Dalton et al. (1976) observed that smoked administration of placebo marijuana cigarettes containing injections of 0.15 mg/kg CBD combined with 0.025mg/kg of delta<sup>9</sup>-THC, in a 7:1 ratio of CBD to delta<sup>9</sup>-THC, significantly decreased ratings of acute subjective effects and "high" when compared to smoking delta<sup>9</sup>-THC alone. In contrast, Ilan et al. (2005) calculated the naturally occurring concentrations of CBC and CBD in a batch of marijuana cigarettes with either 1.8 percent or 3.6 percent delta<sup>9</sup>-THC concentration by weight. For each strength of delta<sup>9</sup>-THC in marijuana cigarettes, the concentrations of CBC and CBD were classified in groups of either low or high. The study varied the amount of CBC and CBD within each strength of delta<sup>9</sup>-THC marijuana cigarettes, with administrations consisting of either low CBC (between 0.1–0.2 percent CBC concentration by weight) and low CBD (between 0.1–0.4 percent CBD concentration by weight), high CBC (≤ 0.5 percent CBC concentration by weight) and low CBD, or low CBC and high CBD (≤1.0 percent CBD concentration by weight). Overall, all combinations scored significantly greater than placebo on ratings of subjective effects, and there was no significant difference between any combinations.

The oral administration of a combination of either 15, 30, or 60 mg CBD with 30 mg delta<sup>9</sup>-THC dissolved in liquid (in a ratio of at least 1:2 CBD to delta<sup>9</sup>-THC) reduced the subjective effects produced by delta<sup>9</sup>-THC alone (Karniol et al., 1974). Additionally, orally administering a liquid mixture combining 1 mg/kg CBD with 0.5 mg/kg of delta<sup>9</sup>-THC (ratio of 2:1 CBD to delta<sup>9</sup>-THC) decreased scores of anxiety and marijuana drug effect on the Addiction Research Center Inventory (ARCI) compared to delta<sup>9</sup>-THC alone (Zuardi et al., 1982). Lastly, oral administration of either 12.5, 25, or 50 mg CBN combined with 25 mg delta<sup>9</sup>-THC dissolved in liquid (ratio of at least 1:2 CBN to delta<sup>9</sup>-THC) significantly increased subjective ratings of "drugged," "drowsy," "dizzy," and "drunk," compared to delta<sup>9</sup>-THC alone (Karniol et al., 1975).

Even though some studies suggest that CBD may decrease some of delta<sup>9</sup>-THC's psychoactive effects, the ratios of CBD to delta<sup>9</sup>-THC administered in these studies are not present in marijuana used by most people. For example, in one study, researchers used smoked



marijuana with ratios of CBD to delta<sup>9</sup>-THC naturally present in marijuana plant material and they found out that varying the amount of CBD actually had no effect on delta<sup>9</sup>-THC's psychoactive effects (Ilan et al., 2005). Because most marijuana currently available on the street has high amounts of delta<sup>9</sup>-THC with low amounts of CBD and other cannabinoids, most individuals use marijuana with low levels of CBD present (Mehmedic et al., 2010). Thus, any possible mitigation of delta<sup>9</sup>-THC's psychoactive effects by CBD will not occur for most marijuana users. In contrast, one study indicated that another cannabinoid present in marijuana, CBN, may enhance delta<sup>9</sup>-THC's psychoactive effects (Karniol et al., 1975).

#### Behavioral Impairment

Marijuana induces various psychoactive effects that can lead to behavioral impairment. Marijuana's acute effects can significantly interfere with a person's ability to learn in the classroom or to operate motor vehicles. Acute administration of smoked marijuana impairs performance on learning, associative processes, and psychomotor behavioral tests (Block et al., 1992). Ramaekers et al. (2006a) showed that acute administration of 250 µg/kg and 500 µg/kg of delta<sup>9</sup>-THC in smoked marijuana dose-dependently impairs cognition and motor control, including motor impulsivity and tracking impairments (Ramaekers et al., 2006b). Similarly, administration of 290 µg/kg delta<sup>9</sup>-THC in a smoked marijuana cigarette resulted in impaired perceptual motor speed and accuracy: Two skills which are critical to driving ability (Kurzthaler et al., 1999). Lastly, administration of 3.95 percent delta<sup>9</sup>-THC in a smoked marijuana cigarette not only increased disequilibrium measures, but also increased the latency in a task of simulated vehicle braking at a rate comparable to an increase in stopping distance of five feet at 60 mph (Liguori et al., 1998). However, acute administration of marijuana containing 2.1 percent delta<sup>9</sup>-THC does not produce "hangover effects" (Chait, 1990).

In addition to measuring the acute effects immediately following marijuana administration, researchers have conducted studies to determine how long behavioral impairments last after abstinence. Some of marijuana's acute effects may not fully resolve until at least one day after the acute psychoactive effects have subsided. Heishman et al. (1990) showed that impairment on memory tasks persists for 24 hours after smoking marijuana

cigarettes containing 2.57 percent delta<sup>9</sup>-THC. However, Fant et al. (1998) showed that the morning after exposure to 1.8 percent or 3.6 percent smoked delta<sup>9</sup>-THC, subjects had minimal residual alterations in subjective or performance measures.

A number of factors may influence marijuana's behavioral effects including the duration of use (chronic or short term), frequency of use (daily, weekly, or occasionally), and amount of use (heavy or moderate). Researchers also have examined how long behavioral impairments last following chronic marijuana use. These studies used self-reported histories of past duration, frequency, and amount of past marijuana use, and administered a variety of performance and cognitive measures at different time points following marijuana abstinence. In chronic marijuana users, behavioral impairments may persist for up to 28 days of abstinence. Solowij et al. (2002) demonstrated that after 17 hours of abstinence, 51 adult heavy chronic marijuana users performed worse on memory and attention tasks than 33 non-using controls or 51 heavy, short-term users. Another study noted that heavy, frequent marijuana users, abstinent for at least 24 hours, performed significantly worse than the controls on verbal memory and psychomotor speed tests (Messinis et al., 2006). Additionally, after at least 1 week of abstinence, young adult frequent marijuana users, aged 18–28, showed deficits in psychomotor speed, sustained attention, and cognitive inhibition (Lisdahl and Price, 2012). Adult heavy, chronic marijuana users showed deficits on memory tests after 7 days of supervised abstinence (Pope et al., 2002). However, when these same individuals were again tested after 28 days of abstinence, they did not show significant memory deficits. The authors concluded, "cannabis-associated cognitive deficits are reversible and related to recent cannabis exposure, rather than irreversible and related to cumulative lifetime use."<sup>7</sup> However, other researchers reported neuropsychological deficits in memory, executive functioning, psychomotor speed and manual dexterity in heavy marijuana users abstinent for 28 days (Bolla et al., 2002). Furthermore, a follow-up study of heavy marijuana users noted decision-making deficits after 25 days of supervised abstinence. (Bolla et al., 2005). However, moderate marijuana users did not show decision-making deficits after 25 days of

abstinence, suggesting the amount of marijuana use may impact the duration of residual impairment.

The effects of chronic marijuana use do not seem to persist after more than 1 to 3 months of abstinence. After 3 months of abstinence, any deficits observed in IQ, immediate memory, delayed memory, and information-processing speeds following heavy marijuana use compared to pre-drug use scores were no longer apparent (Fried et al., 2005). Marijuana did not appear to have lasting effects on performance of a comprehensive neuropsychological battery when 54 monozygotic male twins (one of whom used marijuana, one of whom did not) were compared 1–20 years after cessation of marijuana use (Lyons et al., 2004). Similarly, following abstinence for a year or more, both light and heavy adult marijuana users did not show deficits on scores of verbal memory compared to non-using controls (Tait et al., 2011). According to a recent meta-analysis looking at non-acute and long-lasting effects of marijuana use on neurocognitive performance, any deficits seen within the first month following abstinence are generally not present after about 1 month of abstinence (Schreiner and Dunn, 2012).

Another aspect that may be a critical factor in the intensity and persistence of impairment resulting from chronic marijuana use is the age of first use. Individuals with a diagnosis of marijuana misuse or dependence who were seeking treatment for substance use, who initiated marijuana use before the age of 15 years, showed deficits in performance on tasks assessing sustained attention, impulse control, and general executive functioning compared to non-using controls. These deficits were not seen in individuals who initiated marijuana use after the age of 15 years (Fontes et al., 2011). Similarly, heavy, chronic marijuana users who began using marijuana before the age of 16 years had greater decrements in executive functioning tasks than heavy, chronic marijuana users who started using after the age of 16 years and non-using controls (Gruber et al., 2012). Additionally, in a prospective longitudinal birth cohort study of 1,037 individuals, marijuana dependence or chronic marijuana use was associated with a decrease in IQ and general neuropsychological performance compared to pre-marijuana exposure levels in adolescent onset users (Meier et al., 2012). The decline in adolescent-onset user's IQ persisted even after reduction or abstinence of marijuana use for at least 1 year. In contrast, the adult-onset chronic marijuana users showed no significant

<sup>7</sup> In this quotation the term *Cannabis* is used interchangeably for *marijuana*.

changes in IQ compared to pre-exposure levels whether they were current users or abstinent for at least 1 year (Meier et al., 2012).

In addition to the age of onset of use, some evidence suggests that the amount of marijuana used may relate to the intensity of impairments. In the above study by Gruber et al. (2012), where early-onset users had greater deficits than late-onset users, the early-onset users reported using marijuana twice as often and using three times as much marijuana per week than the late-onset users. Meier et al. (2012) showed that the deficits in IQ seen in adolescent-onset users increased with the amount of marijuana used. Moreover, when comparing scores for measures of IQ, immediate memory, delayed memory, and information-processing speeds to pre-drug-use levels, the current, heavy, chronic marijuana users showed deficits in all three measures while current, occasional marijuana users did not (Fried et al., 2005).

#### Behavioral Effects of Prenatal Exposure

Studies with children at different stages of development are used to examine the impact of prenatal marijuana exposure on performance in a series of cognitive tasks. However, many pregnant women who reported marijuana use were more likely to also report use of alcohol, tobacco, and cocaine (Goldschmidt et al., 2008). Thus, with potential exposure to multiple drugs, it is difficult to determine the specific impact of prenatal marijuana exposure.

Most studies assessing the behavioral effects of prenatal marijuana exposure included women who, in addition to using marijuana, also reported using alcohol and tobacco. However, some evidence suggests an association between heavy prenatal marijuana exposure and deficits in some cognitive domains. In both 4-year-old and 6-year-old children, heavy prenatal marijuana use is negatively associated with performance on tasks assessing memory, verbal reasoning, and quantitative reasoning (Fried and Watkinson, 1987; Goldschmidt et al., 2008). Additionally, heavy prenatal marijuana use is associated with deficits in measures of sustained attention in children at the ages of 6 years and 13–16 years (Fried et al., 1992; Fried, 2002). In 9- to 12-year-old children, prenatal marijuana exposure is negatively associated with executive functioning tasks that require impulse control, visual analysis, and hypothesis (Fried et al., 1998).

#### Association of Marijuana Use With Psychosis

This analysis evaluates only the evidence for a direct link between prior marijuana use and the subsequent development of psychosis. Thus, this discussion does not consider issues such as whether marijuana's transient effects are similar to psychotic symptoms in healthy individuals or exacerbate psychotic symptoms in individuals already diagnosed with schizophrenia.

Extensive research has been conducted to investigate whether exposure to marijuana is associated with the development of schizophrenia or other psychoses. Although many studies are small and inferential, other studies in the literature use hundreds to thousands of subjects. At present, the available data do not suggest a causative link between marijuana use and the development of psychosis (Minozzi et al., 2010). Numerous large, longitudinal studies show that subjects who used marijuana do not have a greater incidence of psychotic diagnoses compared to those who do not use marijuana (Fergusson et al., 2005; Kuepper et al., 2011; Van Os et al., 2002).

When analyzing the available evidence of the connection between psychosis and marijuana, it is critical to determine whether the subjects in the studies are patients who are already diagnosed with psychosis or individuals who demonstrate a limited number of symptoms associated with psychosis without qualifying for a diagnosis of the disorder. For example, instead of using a diagnosis of psychosis, some researchers relied on non-standard methods of representing symptoms of psychosis including "schizophrenic cluster" (Maremmani et al., 2004), "subclinical psychotic symptoms" (Van Gastel et al., 2012), "pre-psychotic clinical high risk" (Van der Meer et al., 2012), and symptoms related to "psychosis vulnerability" (Griffith-Lendering et al., 2012). These groupings do not conform to the criteria in the Diagnostic and Statistical Manual (DSM-5) or the International Classification of Diseases (ICD-10) for a diagnosis of psychosis. Thus, these groupings are not appropriate for use in evaluating marijuana's impact on the development of actual psychosis. Accordingly, this analysis includes only those studies that use subjects diagnosed with a psychotic disorder.

In the largest study evaluating the link between psychosis and drug use, 274 of the approximately 45,500 Swedish conscripts in the study population

(<0.01 percent) received a diagnosis of schizophrenia within the 14-year period following military induction from 1969 to 1983 (Andreasson et al., 1987). Of the conscripts diagnosed with psychosis, 7.7 percent (21 of the 274 conscripts with psychosis) had used marijuana more than 50 times at induction, while 72 percent (197 of the 274 conscripts with psychosis) had never used marijuana. Although high marijuana use increased the relative risk for schizophrenia to 6.0, the authors note that substantial marijuana use history "accounts for only a minority of all cases" of psychosis (Andreasson et al., 1987). Instead, the best predictor for whether a conscript would develop psychosis was a non-psychotic psychiatric diagnosis upon induction. The authors concluded that marijuana use increased the risk for psychosis only among individuals predisposed to develop the disorder. In addition, a 35-year follow up to this study reported very similar results (Manrique-Garcia et al., 2012). In this follow up study, 354 conscripts developed schizophrenia; of these 354 conscripts, 32 used marijuana more than 50 times at induction (9 percent, an odds ratio of 6.3), while 255 had never used marijuana (72 percent).

Additionally, the conclusion that the impact of marijuana may manifest only in individuals likely to develop psychotic disorders has been shown in many other types of studies. For example, although evidence shows that marijuana use may precede the presentation of symptoms in individuals later diagnosed with psychosis (Schimmelmann et al., 2011), most reports conclude that prodromal symptoms of schizophrenia appear prior to marijuana use (Schiffman et al., 2005). Similarly, a review of the gene-environment interaction model for marijuana and psychosis concluded that some evidence supports marijuana use as a factor that may influence the development of psychosis, but only in those individuals with psychotic liability (Pelayo-Teran et al., 2012).

A similar conclusion was drawn when the prevalence of schizophrenia was modeled against marijuana use across eight birth cohorts in Australia in individuals born between the years 1940 to 1979 (Degenhardt et al., 2003). Although marijuana use increased over time in adults born during the four-decade period, there was not a corresponding increase in diagnoses for psychosis in these individuals. The authors conclude that marijuana may precipitate schizophrenic disorders only in those individuals who are vulnerable to developing psychosis. Thus, marijuana *per se* does not appear to

induce schizophrenia in the majority of individuals who have tried or continue to use marijuana. However, in individuals with a genetic vulnerability for psychosis, marijuana use may influence the development of psychosis.

#### Cardiovascular and Autonomic Effects

Single smoked or oral doses of delta<sup>9</sup>-THC produce tachycardia and may increase blood pressure (Capriotti et al., 1988; Benowitz and Jones, 1975). Some evidence associates the tachycardia produced by delta<sup>9</sup>-THC with excitation of the sympathetic and depression of the parasympathetic nervous systems (Malinowska et al., 2012). During chronic marijuana ingestion, a tolerance to tachycardia develops (Malinowska et al., 2012).

However, prolonged delta<sup>9</sup>-THC ingestion produces bradycardia and hypotension (Benowitz and Jones, 1975). Plant-derived cannabinoids and endocannabinoids elicit hypotension and bradycardia via activation of peripherally-located CB<sub>1</sub> receptors (Wagner et al., 1998). Specifically, the mechanism of this effect is through presynaptic CB<sub>1</sub> receptor-mediated inhibition of norepinephrine release from peripheral sympathetic nerve terminals, with possible additional direct vasodilation via activation of vascular cannabinoid receptors (Pacher et al., 2006). In humans, tolerance can develop to orthostatic hypotension (Jones, 2002; Sidney, 2002) possibly related to plasma volume expansion, but tolerance does not develop to the supine hypotensive effects (Benowitz and Jones, 1975). Additionally, electrocardiographic changes are minimal, even after large cumulative doses of delta<sup>9</sup>-THC are administered. (Benowitz and Jones, 1975).

Marijuana smoking by individuals, particularly those with some degree of coronary artery or cerebrovascular disease, poses risks such as increased cardiac work, catecholamines and carboxyhemoglobin, myocardial infarction, and postural hypotension (Benowitz and Jones, 1981; Hollister, 1988; Mittleman et al., 2001; Malinowska et al., 2012).

#### Respiratory Effects

After acute exposure to marijuana, transient bronchodilation is the most typical respiratory effect (Gong et al., 1984). A recent 20-year longitudinal study with over 5,000 individuals collected information on the amount of marijuana use and pulmonary function data at years 0, 2, 5, 10, and 20 (Pletcher et al., 2012). Among the more than 5,000 individuals who participated in the study, almost 800 of them reported

current marijuana use but not tobacco use at the time of assessment. Pletcher et al. (2012) found that the occasional use of marijuana is not associated with decreased pulmonary function. However, some preliminary evidence suggests that heavy marijuana use may be associated with negative pulmonary effects (Pletcher et al., 2012). Long-term use of marijuana can lead to chronic cough and increased sputum, as well as an increased frequency of chronic bronchitis and pharyngitis. In addition, pulmonary function tests reveal that large-airway obstruction can occur with chronic marijuana smoking, as can cellular inflammatory histopathological abnormalities in bronchial epithelium (Adams and Martin 1996; Hollister 1986).

Evidence regarding marijuana smoking leading to cancer is inconsistent, as some studies suggest a positive correlation while others do not (Lee and Hancox, 2011; Tashkin, 2005). Several lung cancer cases have been reported in young marijuana users with no tobacco smoking history or other significant risk factors (Fung et al., 1999). Marijuana use may dose-dependently interact with mutagenic sensitivity, cigarette smoking, and alcohol use to increase the risk of head and neck cancer (Zhang et al., 1999). However, in a large study with 1,650 subjects, a positive association was not found between marijuana and lung cancer (Tashkin et al., 2006). This finding remained true, regardless of the extent of marijuana use, when controlling for tobacco use and other potential confounding variables. Overall, new evidence suggests that the effects of marijuana smoking on respiratory function and carcinogenicity differ from those of tobacco smoking (Lee and Hancox, 2011).

#### Endocrine System

Experimental marijuana administration to humans does not consistently alter many endocrine parameters. In an early study, male subjects who experimentally received smoked marijuana showed a significant depression in luteinizing hormone and a significant increase in cortisol (Cone et al., 1986). However, two later studies showed no changes in hormones. Male subjects experimentally exposed to smoked delta<sup>9</sup>-THC (18 mg/marijuana cigarette) or oral delta<sup>9</sup>-THC (10 mg three times per day for 3 days and on the morning of the fourth day) showed no changes in plasma adrenocorticotrophic hormone (ACTH), cortisol, prolactin, luteinizing hormone, or testosterone levels (Dax et al., 1989). Similarly, a study with 93 men and 56

women showed that chronic marijuana use did not significantly alter concentrations of testosterone, luteinizing hormone, follicle stimulating hormone, prolactin, or cortisol (Block et al., 1991). Additionally, chronic marijuana use did not affect serum levels of thyrotropin, thyroxine, and triiodothyronine (Bonnet, 2013). However, in a double-blind, placebo-controlled, randomized clinical trial of HIV-positive men, smoking marijuana dose-dependently increased plasma levels of ghrelin and leptin, and decreased plasma levels of peptide YY (Riggs et al., 2012).

The effects of marijuana on female reproductive system functionality differ between humans and animals. In monkeys, delta<sup>9</sup>-THC administration suppressed ovulation (Asch et al., 1981) and reduced progesterone levels (Almirez et al., 1983). However, in women, smoked marijuana did not alter hormone levels or the menstrual cycle (Mendelson and Mello, 1984). Brown and Dobs (2002) suggest that the development of tolerance in humans may be the cause of the discrepancies between animal and human hormonal response to cannabinoids.

The presence of *in vitro* delta<sup>9</sup>-THC reduces binding of the corticosteroid, dexamethasone, in hippocampal tissue from adrenalectomized rats, suggesting an interaction with the glucocorticoid receptor (Eldridge et al., 1991). Although acute delta<sup>9</sup>-THC presence releases corticosterone, tolerance develops in rats with chronic administration (Eldridge et al., 1991).

Some studies support a possible association between frequent, long-term marijuana use and increased risk of testicular germ cell tumors (Trabert et al., 2011). On the other hand, recent data suggest that cannabinoid agonists may have therapeutic value in the treatment of prostate cancer, a type of carcinoma in which growth is stimulated by androgens. Research with prostate cancer cells shows that the mixed CB<sub>1</sub>/CB<sub>2</sub> agonist, WIN-55212-2, induces apoptosis in prostate cancer cells, as well as decreases the expression of androgen receptors and prostate-specific antigens (Sarfraz et al., 2005).

#### Immune System

Cannabinoids affect the immune system in many different ways. Synthetic, natural, and endogenous cannabinoids often cause different effects in a dose-dependent biphasic manner (Croxford and Yamamura, 2005; Tanasescu and Constantinescu, 2010).

Studies in humans and animals give conflicting results about cannabinoid

effects on immune functioning in subjects with compromised immune systems. Abrams et al. (2003) investigated marijuana's effect on immunological functioning in 62 AIDS patients taking protease inhibitors. Subjects received one of the following three times a day: A smoked marijuana cigarette containing 3.95 percent delta<sup>9</sup>-THC, an oral tablet containing delta<sup>9</sup>-THC (2.5 mg oral dronabinol), or an oral placebo. The results showed no changes in CD4+ and CD8+ cell counts, HIV RNA levels, or protease inhibitor levels between groups. Thus, the use of cannabinoids showed no short-term adverse virologic effects in individuals with compromised immune systems. However, these human data contrast with data generated in immunodeficient mice, which demonstrated that exposure to delta<sup>9</sup>-THC *in vivo* suppresses immune function, increases HIV co-receptor expression, and acts as a cofactor to enhance HIV replication (Roth et al., 2005).

### 3. The State of Current Scientific Knowledge Regarding the Drug or Other Substance

Under the third factor, the Secretary must consider the state of current scientific knowledge regarding marijuana. Thus, this section discusses the chemistry, human pharmacokinetics, and medical uses of marijuana.

#### Chemistry

Marijuana is one of the common names of *Cannabis sativa* L. in the family Cannabaceae. *Cannabis* is one of the oldest cultivated crops, providing a source of fiber, food, oil, and drug. Botanists still debate whether *Cannabis* should be considered as a single (The Plant List, 2010) or three species, *i.e.*, *C. sativa*, *C. indica*, and *C. ruderalis* (Hillig, 2005). Specifically, marijuana is developed as *sativa* and *indica* cultivated varieties (strains) or various hybrids.

The petition defines marijuana as including all *Cannabis* cultivated strains. Different marijuana samples derived from various cultivated strains may have very different chemical constituents including delta<sup>9</sup>-THC and other cannabinoids (Appendino et al., 2011). As a consequence, marijuana products from different strains will have different safety, biological, pharmacological, and toxicological profiles. Thus, all *Cannabis* strains cannot be considered together because of the varying chemical constituents between strains.

Marijuana contains numerous naturally occurring constituents

including cannabinoids. Overall, various *Cannabis* strains contain more than 525 identified natural constituents. Among those constituents, the most important ones are the 21 (or 22) carbon terpenoids found in the plant, as well as their carboxylic acids, analogues, and transformation products, known as cannabinoids (Aguirell et al., 1984, 1986; Mechoulam, 1973; Appendino et al., 2011). Thus far, more than 100 compounds classified as cannabinoids have been characterized (ElSohly and Slade, 2005; Radwan, ElSohly et al., 2009; Appendino et al. 2011).

Cannabinoids primarily exist in *Cannabis*, and published data suggest that most major cannabinoid compounds occurring naturally have been chemically identified. New and minor cannabinoids and other new compounds are continuously being characterized (Pollastro et al., 2011). So far, only two cannabinoids (cannabigerol and its corresponding acid) have been obtained from a *non-Cannabis* source. A South African *Helichrysum* (*H umbraculigerum*) accumulates these compounds (Appendino et al. 2011).

Among the cannabinoids found in marijuana, delta<sup>9</sup>-THC (alternate name delta<sup>1</sup>-THC) and delta-8-tetrahydrocannabinol (delta<sup>8</sup>-THC, alternate name delta<sup>6</sup>-THC) produce marijuana's characteristic psychoactive effects. Because delta<sup>9</sup>-THC is more abundant than delta<sup>8</sup>-THC, marijuana's psychoactivity is largely attributed to the former. Only a few varieties of marijuana analyzed contain delta<sup>8</sup>-THC at significant amounts (Hively et al., 1966). Delta<sup>9</sup>-THC is an optically active resinous substance, insoluble in water, and extremely lipid soluble. Chemically, delta<sup>9</sup>-THC is (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo-[b,d]pyran-1-ol, or (–)-delta<sup>9</sup>-(trans)-tetrahydrocannabinol. The (–)-trans isomer of delta<sup>9</sup>-THC is pharmacologically 6–100 times more potent than the (+)-trans isomer (Dewey et al., 1984).

Other cannabinoids present in marijuana include CBD, CBC, and CBN. CBD, a major cannabinoid of marijuana, is insoluble in water and lipid-soluble. Chemically, CBD is 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol. CBD does not have cannabinol-like psychoactivity (Adams and Martin, 1996; Agurell et al., 1984, 1986; Hollister, 1986). CBC is another major cannabinoid in marijuana. Chemically, CBC is 2-methyl-2-(4-methylpent-3-enyl)-7-pentyl-5-chromenol. CBN, a major metabolite of delta<sup>9</sup>-THC, is also a minor naturally-occurring cannabinoid

with weak psychoactivity. Chemically, CBN is 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol.

Different marijuana samples derived from various cultivated strains may differ in chemical constituents including delta<sup>9</sup>-THC and other cannabinoids (Appendino et al. 2011). As a consequence, marijuana products from different strains may have different safety, biological, pharmacological, and toxicological profiles. In addition to differences between cultivated strains, the concentration of delta<sup>9</sup>-THC and other cannabinoids in marijuana may vary with growing conditions and processing after harvest. In addition to genetic differences among *Cannabis* species, the plant parts collected—for example, flowers, leaves, and stems—can influence marijuana's potency, quality, and purity (Adams and Martin, 1996; Agurell et al., 1984; Mechoulam, 1973). All these variations produce marijuana with potencies, as indicated by cannabinoid content, on average from as low as 1–2 percent to as high as 17 percent.

Overall, these variations in the concentrations of cannabinoids and other chemical constituents in marijuana complicate the interpretation of clinical data using marijuana. The lack of consistent concentrations of delta<sup>9</sup>-THC and other substances in marijuana from diverse sources makes interpreting the effect of different marijuana constituents difficult. In addition to different cannabinoid concentrations having different pharmacological and toxicological profiles, the non-cannabinoid components in marijuana, such as other terpenoids and flavonoids, might also contribute to the overall pharmacological and toxicological profiles of various marijuana strains and products derived from those strains.

The term marijuana is often used to refer to a mixture of the dried flowering tops and leaves from *Cannabis*. Marijuana in this limiting definition is one of three major derivatives sold as separate illicit products, which also include hashish and hash oil. According to the DEA, *Cannabis saliva* is the primary species of *Cannabis* currently marketed illegally in the United States.

Marijuana can vary in cannabinoid content and potency (Aguirell et al., 1984, 1986; Mechoulam 1973, Cascini et al., 2012). In the usual mixture of leaves and stems distributed as marijuana, the concentration of delta<sup>9</sup>-THC averages over 12 percent by weight. However, specially grown and selected marijuana can contain 15 percent or greater delta<sup>9</sup>-THC (Appendino et al. 2011). Thus, a 1-gram marijuana cigarette might contain

delta<sup>9</sup>-THC in a range from as little as 3 milligrams to as much as 150 milligrams or more. Additionally, a recent systematic review and meta-analysis found that marijuana's delta<sup>9</sup>-THC content has increased significantly from 1979–2009 (Cascini et al., 2012). In addition to smoking marijuana, individuals ingest marijuana through food made with butter or oil infused with marijuana and its extracts. These marijuana butters are generally made by adding marijuana to butter and heating it. The resultant butter is then used to cook a variety of foods. There are no published studies measuring the concentrations of cannabinoids in these marijuana food products.

Hashish consists of the dried and compressed cannabinoid-rich resinous material of *Cannabis* and comes in a variety of forms (e.g. balls and cakes). Individuals may break off pieces, place it into a pipe and smoke it. DEA reports that cannabinoid content in hashish averages six percent (DEA, 2005). With the development and cultivation of more high potency *Cannabis* strains, the average cannabinoid content in hashish will likely increase.

Hash oil is produced by solvent extraction of the cannabinoids from plant material. The extract's color and odor vary, depending on the solvent type used. Hash oil is a viscous brown- or amber-colored liquid containing approximately 50 percent cannabinoids. One or two drops of the liquid placed on a cigarette purportedly produce the equivalent of a single marijuana cigarette (DEA, 2005).

In conclusion, marijuana has hundreds of cultivars containing variable concentrations of delta<sup>9</sup>-THC, cannabinoids, and other compounds. Thus, marijuana is not a single chemical with a consistent and reproducible chemical profile or predictable and consistent clinical effects. A guidance for industry, entitled *Botanical Drug Products*,<sup>8</sup> provides information on the approval of botanical drug products. To investigate marijuana for medical use in a manner acceptable as support for marketing approval under an NDA, clinical studies under an IND of consistent batches of a particular marijuana product for particular disease indications should be conducted. In addition, information and data regarding the marijuana product's chemistry, manufacturing and control, pharmacology, and animal toxicology data, among others must be provided

<sup>8</sup> This guidance is available on the Internet at <http://www.fda.gov/Drugs/default.htm> under Guidance (Drugs).

and meet the requirements for new drug approval (See 21 CFR 314.50).

#### Human Pharmacokinetics

Marijuana can be taken in a variety of formulations by multiple routes of administration. Individuals smoke marijuana as a cigarette, weighing between 0.5 and 1.0 gram, or in a pipe. Additionally, individuals take marijuana orally in foods or as an extract in ethanol or other solvents. More recently, access to vaporizers provides another means for abusers to inhale marijuana.

The absorption, metabolism, and pharmacokinetic profile of delta<sup>9</sup>-THC, cannabinoids, and drug products containing delta<sup>9</sup>-THC vary with route of administration and formulation (Adams and Martin, 1996; Agurell et al., 1984, 1986).

#### Pharmacokinetics of Smoked Administration of Cannabinoids

Characterization of the pharmacokinetics of delta<sup>9</sup>-THC and other cannabinoids from smoked marijuana is difficult because a subject's smoking behavior during an experiment varies (Agurell et al., 1986; Heming et al., 1986; Huestis et al., 1992a). Each puff delivers a discrete dose of delta<sup>9</sup>-THC. An experienced marijuana smoker can titrate and regulate the dose to obtain the desired acute psychological effects and minimize undesired effects. For example, under naturalistic conditions, users hold marijuana smoke in their lungs for an extended period of time which causes prolonged absorption and increases psychoactive effects. The effect of experience in the psychological response may explain why delta<sup>9</sup>-THC venous blood levels correlate poorly with intensity of effects and intoxication level (Agurell et al. 1986; Barnett et al. 1985; Huestis et al., 1992a). Puff and inhalation volumes should be recorded in studies as the concentration (dose) of cannabinoids administered can vary at different stages of smoking.

Smoked marijuana results in absorption of delta<sup>9</sup>-THC in the form of an aerosol within seconds. Psychoactive effects occur immediately following absorption, with mental and behavioral effects measurable for up to 6 hours (Grotenhermen, 2003; Hollister 1986, 1988). Delta<sup>9</sup>-THC is delivered to the brain rapidly and efficiently as expected of a very lipid soluble drug.

The bioavailability of the delta<sup>9</sup>-THC, from marijuana in a cigarette or pipe, can range from 1 to 24 percent with the fraction absorbed rarely exceeding 10 to 20 percent (Agurell et al., 1986; Hollister, 1988). The relatively low and variable bioavailability results from

significant loss of delta<sup>9</sup>-THC in side-stream smoke, variation in individual smoking behaviors, cannabinoid pyrolysis, incomplete absorption of inhaled smoke, and metabolism in the lungs. An individual's experience and technique with smoking marijuana also determines the dose absorbed (Heming et al., 1986; Johansson et al., 1989). After smoking, delta<sup>9</sup>-THC venous levels decline precipitously within minutes, and continue to go down to about 5 to 10 percent of the peak level within an hour (Agurell et al., 1986, Huestis et al., 1992a, 1992b).

#### Pharmacokinetics for Oral Administration of Cannabinoids

After oral administration of delta<sup>9</sup>-THC or marijuana, the onset of effects starts within 30 to 90 minutes, reaches its peak after 2 to 3 hours and then remains for 4 to 12 hours (Grotenhermen, 2003; Adams and Martin, 1996; Agurell et al., 1984, 1986). Due to the delay in onset of effects, users have difficulty in titrating oral delta<sup>9</sup>-THC doses compared to smoking marijuana. Oral bioavailability of delta<sup>9</sup>-THC, whether pure or in marijuana, is low and extremely variable, ranging between 5 and 20 percent (Agurell et al., 1984, 1986). Following oral administration of radioactive-labeled delta<sup>9</sup>-THC, delta<sup>9</sup>-THC plasma levels are low relative to plasma levels after smoking or intravenous administration. Inter- and intra-subject variability occurs even with repeated dosing under controlled conditions. The low and variable oral bioavailability of delta<sup>9</sup>-THC is a consequence of its first-pass hepatic elimination from blood and erratic absorption from stomach and bowel.

#### Cannabinoid Metabolism and Excretion

Cannabinoid metabolism is complex. Delta<sup>9</sup>-THC is metabolized via microsomal hydroxylation to both active and inactive metabolites (Lemberger et al., 1970, 1972a, 1972b; Agurell et al., 1986; Hollister, 1988). The primary active metabolite of delta<sup>9</sup>-THC following oral ingestion is 11-hydroxy-delta<sup>9</sup>-THC. This metabolite is approximately equipotent to delta<sup>9</sup>-THC in producing marijuana-like subjective effects (Agurell et al., 1986; Lemberger and Rubin, 1975). After oral administration, metabolite levels may exceed that of delta<sup>9</sup>-THC and thus contribute greatly to the pharmacological effects of oral delta<sup>9</sup>-THC or marijuana.

Plasma clearance of delta<sup>9</sup>-THC approximates hepatic blood flow at about 950 ml/min or greater. The rapid disappearance of delta<sup>9</sup>-THC from blood

is largely due to redistribution to other tissues in the body, rather than to metabolism (Agurell et al., 1984, 1986). Metabolism in most tissues is relatively slow or absent. Slow release of delta<sup>9</sup>-THC and other cannabinoids from tissues and subsequent metabolism results in a long elimination half-life. The terminal half-life of delta<sup>9</sup>-THC ranges from approximately 20 hours to as long as 10 to 13 days, though reported estimates vary as expected with any slowly cleared substance and the use of assays with variable sensitivities (Hunt and Jones, 1980). Lemberger et al. (1970) determined the half-life of delta<sup>9</sup>-THC to range from 23 to 28 hours in heavy marijuana users to 60 to 70 hours in naive users. In addition to 11-hydroxy-delta<sup>9</sup>-THC, some inactive carboxy metabolites have terminal half-lives of 50 hours to 6 days or more. The latter substances serve as long-term markers in urine tests for earlier marijuana use.

The majority of the absorbed delta<sup>9</sup>-THC dose is eliminated in feces, and about 33 percent in urine. Delta<sup>9</sup>-THC enters enterohepatic circulation and undergoes hydroxylation and oxidation to 11-nor-9-carboxy-delta<sup>9</sup>-THC. The glucuronide is excreted as the major urine metabolite along with about 18 non-conjugated metabolites. Frequent and infrequent marijuana users metabolize delta<sup>9</sup>-THC similarly (Agurell et al., 1986).

#### Status of Research Into the Medical Uses for Marijuana

State-level public initiatives, including laws and referenda in support of the medical use of marijuana, have generated interest in the medical community and the need for high quality clinical investigation as well as comprehensive safety and effectiveness data. In order to address the need for high quality clinical investigations, the state of California established the Center for Medicinal Cannabis Research (CMCR, [www.cmcr.ucsd.edu](http://www.cmcr.ucsd.edu)) in 2000 “in response to scientific evidence for therapeutic possibilities of cannabis<sup>9</sup> and local legislative initiatives in favor of compassionate use” (Grant, 2005). State legislation establishing the CMCR called for high quality medical research that would “enhance understanding of the efficacy and adverse effects of marijuana as a pharmacological agent,” but stressed the project “should not be construed as encouraging or sanctioning the social or recreational use of marijuana.” The CMCR funded many of the published studies on marijuana’s potential use for treating multiple

sclerosis, neuropathic pain, appetite suppression and cachexia. However, aside from the data produced by CMCR, no state-level medical marijuana laws have produced scientific data on marijuana’s safety and effectiveness.

FDA approves medical use of a drug following a submission and review of an NDA or BLA. The FDA has not approved any drug product containing marijuana for marketing. Even so, results of small clinical exploratory studies have been published in the current medical literature. Many studies describe human research with marijuana in the United States under FDA-regulated IND applications.

However, FDA approval of an NDA is not the only means through which a drug can have a currently accepted medical use in treatment in the United States. In general, a drug may have a “currently accepted medical use” in treatment in the United States if the drug meets a five-part test. Established case law (*Alliance for Cannabis Therapeutics v. DEA*, 15 F.3d 1131, 1135 (D.C. Cir. 1994)) upheld the Administrator of DEA’s application of the five-part test to determine whether a drug has a “currently accepted medical use.” The following describes the five elements that characterize “currently accepted medical use” for a drug:<sup>10</sup>

- i. the drug’s chemistry must be known and reproducible  
 “The substance’s chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official compendia, as defined by section 201 G) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321G), is sufficient to meet this requirement.”
- ii. there must be adequate safety studies  
 “There must be adequate pharmacological and toxicological studies, done by all methods reasonably applicable, on the basis of which it could fairly and responsibly be concluded, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, that the substance is safe for treating a specific, recognized disorder.”
- iii. there must be adequate and well-controlled studies proving efficacy  
 “There must be adequate, well-controlled, well-designed, well-conducted, and well-documented studies, including clinical investigations, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of

drugs, on the basis of which it could be fairly and responsibly concluded by such experts that the substance will have the intended effect in treating a specific, recognized disorder.”

- iv. the drug must be accepted by qualified experts

“The drug has a New Drug Application (NDA) approved by the Food and Drug Administration, pursuant to the Food, Drug and Cosmetic Act, 21 U.S.C. 355. Or, a consensus of the national community of experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, accepts the safety and effectiveness of the substance for use in treating a specific, recognized disorder. A material conflict of opinion among experts precludes a finding of consensus.” and

- v. the scientific evidence must be widely available

“In the absence of NDA approval, information concerning the chemistry, pharmacology, toxicology, and effectiveness of the substance must be reported, published, or otherwise widely available, in sufficient detail to permit experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, to fairly and responsibly conclude the substance is safe and effective for use in treating a specific, recognized disorder.”

Marijuana does not meet any of the five elements necessary for a drug to have a “currently accepted medical use.”

Firstly, the chemistry of marijuana, as defined in the petition, is not reproducible in terms of creating a standardized dose. The petition defines marijuana as including all *Cannabis* cultivated strains. Different marijuana samples derived from various cultivated strains may have very different chemical constituents including delta<sup>9</sup>-THC and other cannabinoids (Appendino et al., 2011). As a consequence, marijuana products from different strains will have different safety, biological, pharmacological, and toxicological profiles. Thus, when considering all *Cannabis* strains together, because of the varying chemical constituents, reproducing consistent standardized doses is not possible. Additionally, smoking marijuana currently has not been shown to allow delivery of consistent and reproducible doses. However, if a specific *Cannabis* strain is grown and processed under strictly controlled conditions, the plant chemistry may be kept consistent enough to produce reproducible and standardized doses.

<sup>9</sup>In this quotation the term cannabis is interchangeable with marijuana.

<sup>10</sup> 57 FR I 0499, 10504–06 (March 26, 1992).

As to the second and third criteria; there are neither adequate safety studies nor adequate and well-controlled studies proving marijuana's efficacy. To support the petitioners' assertion that marijuana has accepted medical use, the petitioners cite the American Medical Association's (AMA) 2009 report entitled "Use of Cannabis for Medicinal Purposes." The petitioners claim the AMA report is evidence the AMA accepts marijuana's safety and efficacy. However, the 2009 AMA report clarifies that the report "should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the same and current standards for a prescription drug product."<sup>11</sup>

Currently, no published studies conducted with marijuana meet the criteria of an adequate and well-controlled efficacy study. The criteria for an adequate and well-controlled study for purposes of determining the safety and efficacy of a human drug are defined under the Code of Federal Regulations (CFR) in 21 CFR 314.126. In order to assess this element, FDA conducted a review of clinical studies published and available in the public domain before February, 2013. Studies were identified through a search of PubMed<sup>12</sup> for articles published from inception to February 2013, for randomized controlled trials using marijuana to assess marijuana's efficacy in any therapeutic indication. Additionally, the review included studies identified through a search of bibliographic references in relevant systematic reviews and identified studies presenting original research in any language. Selected studies needed to be placebo-controlled and double-blinded. Additionally, studies needed to encompass administered marijuana plant material. There was no requirement for any specific route of administration, nor any age limits on study subjects. Studies were excluded that used placebo marijuana supplemented by the addition of specific amounts of THC or other cannabinoids. Additionally, studies administering marijuana plant extracts were excluded.

The PubMed search yielded a total of 566 abstracts of scientific articles. Of

these abstracts, a full-text review was conducted with 85 papers to assess eligibility. Of the studies identified through the search of the references and the 566 abstracts from the PubMed search, only 11 studies met all the criteria for selection (Abrams et al., 2007; Corey-Bloom et al., 2012; Crawford and Merritt, 1979; Ellis et al., 2009; Haney et al., 2005; Haney et al., 2007; Merritt et al., 1980; Tashkin et al., 1974; Ware et al., 2010; Wilsey et al., 2008; Wilsey et al., 2013). These 11 studies were published between 1974 and 2013. Ten of these studies were conducted in the United States and one study was conducted in Canada. The identified studies examine the effects of smoked and vaporized marijuana for the indications of chronic neuropathic pain, spasticity related to Multiple Sclerosis (MS), appetite stimulation in human immunodeficiency virus (HIV) patients, glaucoma, and asthma. All studies used adult subjects.

The 11 identified studies were individually evaluated to determine if they successfully meet accepted scientific standards. Specifically, they were evaluated on study design including subject selection criteria, sample size, blinding techniques, dosing paradigms, outcome measures, and the statistical analysis of the results. The analysis relied on published studies, thus information available about protocols, procedures, and results were limited to documents published and widely available in the public domain. The review found that all 11 studies that examined effects of inhaled marijuana do not currently prove efficacy of marijuana in any therapeutic indication based on a number of limitations in their study design; however, they may be considered proof of concept studies. Proof of concept studies provide preliminary evidence on a proposed hypothesis involving a drug's effect. For drugs under development, the effect often relates to a short-term clinical outcome being investigated. Proof of concept studies often serve as the link between preclinical studies and dose ranging clinical studies. Thus, proof of concept studies generally are not sufficient to prove efficacy of a drug because they provide only preliminary information about the effects of a drug.

In addition to the lack of published adequate and well-controlled efficacy studies proving efficacy, the criteria for adequate safety studies has also not been met. Importantly, in its discussion of the five-part test used to determine whether a drug has a "currently accepted medical use," DEA said, "No drug can be considered safe in the abstract. Safety has meaning only when

judged against the intended use of the drug, its known effectiveness, its known and potential risks, the severity of the illness to be treated, and the availability of alternative remedies" (57 FR 10504). When determining whether a drug product is safe and effective for any indication, FDA performs an extensive risk-benefit analysis to determine whether the risks posed by the drug product's side effects are outweighed by the drug product's potential benefits for a particular indication. Thus, contrary to the petitioner's assertion that marijuana has accepted safety, in the absence of an accepted therapeutic indication which can be weighed against marijuana's risks, marijuana does not satisfy the element for having adequate safety studies such that experts may conclude that it is safe for treating a specific, recognized disorder.

The fourth of the five elements for determining "currently accepted medical use" requires that the national community of experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, accepts the safety and effectiveness of the substance for use in treating a specific, recognized disorder. A material conflict of opinion among experts precludes a finding of consensus. Medical practitioners who are not experts in evaluating drugs are not qualified to determine whether a drug is generally recognized as safe and effective or meets NDA requirements (57 FR 10499-10505).

There is no evidence that there is a consensus among qualified experts that marijuana is safe and effective for use in treating a specific, recognized disorder. As discussed above, there are not adequate scientific studies that show marijuana is safe and effective in treating a specific, recognized disorder. In addition, there is no evidence that a consensus of qualified experts have accepted the safety and effectiveness of marijuana for use in treating a specific, recognized disorder. Although medical practitioners are not qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, we also note that the AMA's report, entitled "Use of Cannabis for Medicinal Purposes," does not accept that marijuana currently has accepted medical use. Furthermore, based on the above definition of a "qualified expert", who is an individual qualified by scientific training and experience to evaluate the safety and effectiveness of a drug, state-level medical marijuana laws do not provide evidence of a consensus among qualified experts that marijuana is safe and effective for use in treating a specific, recognized disorder.

<sup>11</sup> In this quotation the term cannabis is used interchangeably for marijuana.

<sup>12</sup> The following search strategy was used, "(cannabis OR marijuana) AND (therapeutic use OR therapy) AND (RCT OR randomized controlled trial OR "systematic review" OR clinical trial OR clinical trials) NOT ("marijuana abuse"[Mesh] OR addictive behavior OR substance related disorders)."

As to the fifth part of the test, which requires that information concerning the chemistry, pharmacology, toxicology, and effectiveness of marijuana to be reported in sufficient detail, the scientific evidence regarding all of these aspects is not available in sufficient detail to allow adequate scientific scrutiny. Specifically, the scientific evidence regarding marijuana's chemistry in terms of a specific *Cannabis* strain that could produce standardized and reproducible doses is not currently available.

Alternately, a drug can be considered to have a "currently accepted medical use with severe restrictions" (21 U.S.C. 812(b)(2)(B)), as allowed under the stipulations for a Schedule II drug. Yet, as stated above, currently marijuana does not have any accepted medical use, even under conditions where its use is severely restricted.

In conclusion, to date, research on marijuana's medical use has not progressed to the point where marijuana is considered to have a "currently accepted medical use" or a "currently accepted medical use with severe restrictions."

#### 4. Its History and Current Pattern of Abuse

Under the fourth factor, the Secretary must consider the history and current pattern of marijuana abuse. A variety of sources provide data necessary to assess abuse patterns and trends of marijuana. The data indicators of marijuana use include the NSDUH, MTF, DAWN, and TEDS. The following briefly describes each data source, and summarizes the data from each source.

##### National Survey on Drug Use and Health (NSDUH)<sup>13</sup>

According to 2012 NSDUH<sup>14</sup> data, the most recent year with complete data, the

use of illicit drugs, including marijuana, is increasing. The 2012 NSDUH estimates that 23.9 million individuals over 12 years of age (9.2 percent of the U.S. population) currently use illicit drugs, which is an increase of 4.8 million individuals from 2004 when 19.1 million individuals (7.9 percent of the U.S. population) were current illicit drug users. NSDUH reports marijuana as the most commonly used illicit drug, with 18.9 million individuals (7.3 percent of the U.S. population) currently using marijuana in 2012. This represents an increase of 4.3 million individuals from 2004, when 14.6 million individuals (6.1 percent of the U.S. population) were current marijuana users.

The majority of individuals who try marijuana at least once in their lifetime do not currently use marijuana. The 2012 NSDUH estimates that 111.2 million individuals (42.8 percent of the U.S. population) have used marijuana at least once in their lifetime. Based on this estimate and the estimate for the number of individuals currently using marijuana, approximately 16.9 percent of those who have tried marijuana at least once in their lifetime currently use marijuana; conversely, 83.1 percent do not currently use marijuana. In terms of the frequency of marijuana use, an estimated 40.3 percent of individuals who used marijuana in the past month used marijuana on 20 or more days within the past month. This amount corresponds to an estimated 7.6 million individuals who used marijuana on a daily or almost daily basis.

Some characteristics of marijuana users are related to age, gender, and criminal justice system involvement. In observing use among different age cohorts, the majority of individuals who currently use marijuana are shown to be

between the ages of 18–25, with 18.7 percent of this age group currently using marijuana. In the 26 and older age group, 5.3 percent of individuals currently use marijuana. Additionally, in individuals aged 12 years and older, males reported more current marijuana use than females.

NSDUH includes a series of questions aimed at assessing the prevalence of dependence and abuse of different substances in the past 12 months.<sup>15</sup> In 2012, marijuana was the most common illicit drug reported by individuals with past year dependence or abuse. An estimated 4.3 million individuals meet the NSDUH criteria for marijuana dependence or abuse in 2012. The estimated rates and number of individuals with marijuana dependence or abuse has remained similar from 2002 to 2012. In addition to data on dependence and abuse, NSDUH includes questions aimed at assessing treatment for a substance use problem.<sup>16</sup> In 2012, an estimated 957,000 persons received treatment for marijuana use during their most recent treatment in the year prior to the survey.

##### Monitoring the Future (MTF)<sup>17</sup>

According to MTF,<sup>18</sup> rates of marijuana and illicit drug use declined for all three grades from 2005 through 2007. However, starting around 2008, rates of annual use of illicit drugs and marijuana increased through 2013 for all three grades. Marijuana remained the most widely used illicit drug during all time periods. The prevalence of annual and past month marijuana use in 10th and 12th graders in 2013 is greater than in 2005. Table 1 lists the lifetime, annual, and monthly prevalence rates of various drugs for 8th, 10th, and 12th graders in 2013.

<sup>13</sup> NSDUH provides national estimates of the prevalence and incidence of illicit drug, alcohol and tobacco use in the United States. NSDUH is an annual study conducted by SAMHSA. Prior to 2002, the database was known as the National Household Survey on Drug Abuse (NHSDA). NSDUH utilizes a nationally representative sample of United States civilian, non-institutionalized population aged 12 years and older. The survey excludes homeless people who do not use shelters, active military personnel, and residents of institutional group quarters such as jails and hospitals. The survey identifies whether an individual used a drug within a specific time period, but does not identify the amount of the drug used on each occasion. NSDUH defines "current use" as having used the substance within the month prior to the study.

<sup>14</sup> 2013; <http://www.samhsa.gov/data/NSDUH.aspx>.

<sup>15</sup> "These questions are used to classify persons as dependent on or abusing specific substances

based on criteria specified in the *Diagnostic and Statistical Manual of Mental Disorder*, 4th edition (DSM-IV). The questions related to dependence ask about health and emotional problems associated with substance use, unsuccessful attempts to cut down on use, tolerance, withdrawal, reducing other activities to use substances, spending a lot of time engaging in activities related to substance use, or using the substance in greater quantities or for longer time than intended. The questions on abuse ask about problems at work, home, and school; problems with family or friends; physical danger; and trouble with the law due to substance use. Dependence is considered to be a more severe substance use problem than abuse because it involves the psychological and physiological effects of tolerance and withdrawal." (NSDUH, 2013).

<sup>16</sup> "Estimates . . . refer to treatment received for illicit drug or alcohol use, or for medical problems associated with the use of illicit drugs or alcohol. This includes treatment received in the past year at any location, such as a hospital (inpatient),

rehabilitation facility (outpatient or inpatient), mental health center, emergency room, private doctor's office, prison or jail, or a self-help group, such as Alcoholics Anonymous or Narcotics Anonymous." (NSDUH, 2013).

<sup>17</sup> Monitoring the Future is a national survey that tracks drug use prevalence and trends among adolescents in the United States. MTF is reported annually by the Institute for Social Research at the University of Michigan under a grant from NIDA. Every spring, MTF surveys 8th, 10th, and 12th graders in randomly selected U.S. schools. MTF has been conducted since 1975 for 12th graders and since 1991 for 8th and 10th graders. The MTF survey presents data in terms of prevalence among the sample interviewed. For 2012, the latest year with complete data, the sample sizes were 15,200—8th graders; 13,300—10th graders; and 13,200—12th graders. In all, a total of about 41,700 students of 389 schools participated in the 2013 MTF.

<sup>18</sup> 2013; <http://www.monitoringthefuture.org/index.html>.



**Table 1: Trends in lifetime, annual, and monthly prevalence of use of various drugs for eighth, tenth, and twelfth graders. Percentages represent students in survey responding that they had used a drug at least once in their lifetime, in the past year, or in the past 30 days.**

	Lifetime			Annual			30-Day		
	2011	2012	2013	2011	2012	2013	2011	2012	2013
<b>Any illicit Drug (a)</b>									
8 <sup>th</sup> Grade	20.1	18.5	20.3	14.7	13.4	14.9	8.5	7.7	8.5
10 <sup>th</sup> Grade	37.7	36.8	38.8	31.1	30.1	31.8	19.2	18.6	19.4
12 <sup>th</sup> Grade	49.9	49.1	50.4	40.0	39.7	40.3	25.2	25.2	25.5
<b>Marijuana/Hashish</b>									
8 <sup>th</sup> Grade	16.4	15.2	16.5	12.5	11.4	12.7	7.2	6.5	7.0
10 <sup>th</sup> Grade	34.5	33.8	35.8	28.8	28.0	29.8	17.6	17.0	18.0
12 <sup>th</sup> Grade	45.5	45.2	45.5	36.4	36.4	36.4	22.6	22.9	22.7

SOURCE: The Monitoring the Future Study, the University of Michigan

a. For 12<sup>th</sup> graders only: "any illicit drug" includes any use of marijuana, LSD, other hallucinogens, crack, other cocaine, or heroin; or any narcotics use other than heroin, amphetamines, sedatives (barbiturates), or tranquilizers not under a doctor's orders. For 8<sup>th</sup> and 10<sup>th</sup> graders only: the use of narcotics other than heroin and sedatives (barbiturates) was excluded.

### Drug Abuse Warning Network (DAWN)<sup>19</sup>

Importantly, many factors can influence the estimates of ED visits, including trends in overall use of a substance as well as trends in the reasons for ED usage. For instance, some drug users may visit EDs for life-threatening issues while others may visit to seek care for detoxification because they needed certification before entering treatment. Additionally, DAWN data do not distinguish the drug responsible for the ED visit from other drugs that may have been used concomitantly. As stated in a DAWN report, "Since marijuana/hashish is frequently present in combination with other drugs, the reason for the ED visit may be more relevant to the other drug(s) involved in the episode."

For 2011, DAWN<sup>20</sup> estimates a total of 5,067,374 (95 percent confidence interval [CI]: 4,616,753 to 5,517,995) drug-related ED visits from the entire United States. Of these, approximately

2,462,948 ([CI]: 2,112,868 to 2,813,028) visits involved drug misuse or abuse.

During the same period, DAWN estimates that 1,252,500 (CI: 976,169 to 1,528,831) drug related ED visits involved illicit drugs. Thus, over half of all drug-related ED visits associated with drug misuse or abuse involved an illicit drug. For ED visits involving illicit drugs, 56.3 percent involved multiple drugs while 43.7 percent involved a single drug.

Marijuana was involved in 455,668 ED visits (CI: 370,995 to 540,340), while cocaine was involved in 505,224 (CI: 324,262 to 686,185) ED visits, heroin was involved in 258,482 (CI: 205,046 to 311,918) ED visits and stimulants including amphetamine and methamphetamine were involved in 159,840 (CI: 100,199 to 219,481) ED visits. Other illicit drugs, such as PCP, MDMA, GHB and LSD were much less frequently associated with ED visits. The number of ED visits involving marijuana has increased by 62 percent since 2004.

Marijuana-related ED visits were most frequent among young adults and minors. Individuals under the age of 18 accounted for 13.2 percent of these marijuana-related visits, whereas this age group accounted for approximately 1.2 percent of ED visits involving cocaine, and less than 1 percent of ED visits involving heroin. However, the age group with the most marijuana-related ED visits was between 25 and 29 years old. Yet, because populations differ between age groups, a standardized measure for population

size is useful to make comparisons. For marijuana, the rates of ED visits per 100,000 population were highest for patients aged 18 to 20 (443.8 ED visits per 100,000) and for patients aged 21 to 24 (446.9 ED visits per 100,000).

While DAWN provides estimates for ED visits associated with the use of medical marijuana for 2009–2011, the validity of these estimates is questionable. Because the drug is not approved by the FDA, reporting medical marijuana may be inconsistent and reliant on a number of factors including whether the patient self-reports the marijuana use as medicinal, how the treating health care provider records the marijuana use, and lastly how the SAMHSA coder interprets the report. All of these aspects will vary greatly between states with medical marijuana laws and states without medical marijuana laws. Thus, even though estimates are reported for medical marijuana related ED visits, medical marijuana estimates cannot be assessed with any acceptable accuracy at this time, as FDA has not approved marijuana treatment of any medical condition. These data show the difficulty in evaluating abuse of a product that is not currently approved by FDA, but authorized for medical use, albeit inconsistently, at the state level. Thus, we believe the likelihood of the treating health care provider or SAMHSA coder attributing the ED visit to "medical marijuana" versus "marijuana" to be very low. Overall, the available data are inadequate to

<sup>19</sup>DAWN is a national probability survey of the U.S. hospitals with ED designed to obtain information on drug related ED visits. DAWN is sponsored by SAMHSA. The DAWN system provides information on the health consequences of drug use in the United States, as manifested by drug-related visits to ED. The ED data from a representative sample of hospital emergency departments are weighted to produce national estimates. Importantly, DAWN data and estimates, starting in 2004, are not comparable to those for prior years because of vast changes in the methodology used to collect the data. Furthermore, estimates for 2004 are the first to be based on a redesigned sample of hospitals, which ended in 2011.

<sup>20</sup>2011; <http://www.samhsa.gov/data/dawn.aspx>.

characterize its abuse at the community level.

#### Treatment Episode Data Set (TEDS)<sup>21</sup>

Primary marijuana abuse accounted for 18.1 percent of all 2011 TEDS<sup>22</sup> admissions. Individuals admitted for primary marijuana abuse were nearly three-quarters (73.4 percent) male, and almost half (45.2 percent) were white. The average age at admission was 24 years old, and 31.1 percent of individuals admitted for primary marijuana abuse were under the age of 18. The reported frequency of marijuana use was 24.3 percent reporting daily use. Almost all (96.8 percent) primary marijuana users utilized the substance by smoking. Additionally, 92.9 percent reported using marijuana for the first time before the age of 18.

An important aspect of TEDS admission data for marijuana is of the referral source for treatment. Specifically, primary marijuana admissions were less likely than all other admissions to either be self-referred or referred by an individual for treatment. Instead, the criminal justice system referred more than half (51.6 percent) of primary marijuana admissions.

Since 2003, the percent of admissions for primary marijuana abuse increased from 15.5 percent of all admissions in 2003 to 18.1 percent in 2011. This increase is less than the increase seen for admissions for primary opioids other than heroin, which increased from 2.8 percent in 2003 to 7.3 percent in 2011. In contrast, the admissions for primary cocaine abuse declined from 9.8 percent in 2003 to 2.0 percent in 2011.

<sup>21</sup> The TEDS system is part of SAMHSA's Drug and Alcohol Services Information System (Office of Applied Science, SAMHSA). The TEDS report presents information on the demographic and substance use characteristics of the 1.8 million annual admissions to treatment for alcohol and drug abuse in facilities that report to individual state administrative data systems. Specifically, TEDS includes facilities licensed or certified by the states to provide substance abuse treatment and is required by the states to provide TEDS client-level data. Facilities that report TEDS data are those receiving State alcohol and drug agency funds for the provision of alcohol and drug treatment services. Since TEDS is based only on reports from these facilities, TEDS data do not represent the total national demand for substance abuse treatment or the prevalence of substance abuse in the general population. The primary goal for TEDS is to monitor the characteristics of treatment episodes for substance abusers. Importantly, TEDS is an admissions-based system, where admittance to treatment is counted as an anonymous tally. For instance, a given individual who is admitted to treatment twice within a given year would be counted as two admissions. The most recent year with complete data is 2011.

<sup>22</sup> 2011; <http://www.samhsa.gov/data/DASIS.aspx?qr=#TEDS>.

#### 5. The Scope, Duration, and Significance of Abuse

Under the fifth factor, the Secretary must consider the scope, duration, and significance of marijuana abuse. According to 2012 data from NSDUH and 2013 data from MTF, marijuana remains the most extensively used illegal drug in the United States, with 42.8 percent of U.S. individuals over age 12 (111.2 million) and 45.5 percent of 12th graders having used marijuana at least once in their lifetime. Although the majority of individuals over age 12 (83.1 percent) who have ever used marijuana in their lifetime do not use the drug monthly, 18.9 million individuals (7.3 percent of the U.S. population) report that they used marijuana within the past 30 days. An examination of use among various age cohorts through NSDUH demonstrates that monthly use occurs primarily among college-aged individuals, with use dropping off sharply after age 25. Additionally, NSDUH data show the number of individuals reporting past-month use of marijuana has increased by 4.3 million individuals since 2004. Data from MTF shows that annual prevalence of marijuana use declined for all three grades from 2005 through 2007, then began to rise through 2013. Additionally, in 2013, 1.1 percent of 8th graders, 4.0 percent of 10th graders, and 6.5 percent of 12th graders reported daily use of marijuana, defined as use on 20 or more days within the past 30 days.

The 2011 DAWN data show that marijuana use was mentioned in 455,668 ED visits, which amounts to approximately 36.4 percent of all illicit drug-related ED visits.<sup>23</sup>

TEDS data for 2011 show that 18.1 percent of all admissions were for primary marijuana abuse.<sup>24</sup> Between 2003 and 2011, there was a 2.6 percent increase in the number of TEDS admissions for primary marijuana use.

<sup>23</sup> Many factors can influence the estimates of ED visits, including trends in the reasons for ED usage. For instance, some drug users may visit EDs for life-threatening issues while others may visit to seek care for detoxification because they needed certification before entering treatment. Additionally, DAWN data do not distinguish the drug responsible for the ED visit from other drugs that may have been used concomitantly. As stated in a DAWN report, "Since marijuana/hashish is frequently present in combination with other drugs, the reason for the ED visit may be more relevant to the other drug(s) involved in the episode."

<sup>24</sup> An important aspect of TEDS admission data for marijuana is of the referral source for treatment. Specifically, primary marijuana admissions were less likely than all other admissions to either be self-referred or referred by an individual for treatment. Instead, the criminal justice system referred more than half (51.6 percent) of primary marijuana admissions.

Approximately 61.5 percent of primary marijuana admissions in 2011 were for individuals under the age of 25 years.

#### 6. What, if Any, Risk There Is to the Public Health

Under the sixth factor, the Secretary must consider the risks posed to the public health by marijuana. Factors 1, 4, and 5 include a discussion of the risk to the public health as measured by emergency room episodes and drug treatment admissions. Additionally, Factor 2 includes a discussion of marijuana's central nervous system, cognitive, cardiovascular, autonomic, respiratory, and immune system effects. Factor 6 focuses on the health risks to the individual user in terms of the risks from acute and chronic use of marijuana, as well as the "gateway hypothesis."

##### Risks From Acute Use of Marijuana

Acute use of marijuana impairs psychomotor performance, including complex task performance, which makes operating motor vehicles or heavy equipment after using marijuana inadvisable (Ramaekers et al., 2004; Ramaekers et al., 2006a). A meta-analysis conducted by Li et al. (2011) showed an association between marijuana use by the driver and a significantly increased risk of involvement in a car accident. Additionally, in a minority of individuals who use marijuana, some potential responses include dysphoria and psychological distress, including prolonged anxiety reactions (Haney et al., 1999).

##### Risks From Chronic Use of Marijuana

A distinctive marijuana withdrawal syndrome following long term or chronic use has been identified. The withdrawal syndrome indicates that marijuana produces physical dependence that is mild, short-lived, and comparable to tobacco withdrawal (Budney et al., 2008). Marijuana withdrawal syndrome is described in detail below under Factor 7.

The following states how the DSM-V (2013) of the American Psychiatric Association describes the consequences of *Cannabis*<sup>25</sup> abuse:

Individuals with cannabis use disorder may use cannabis throughout the day over a period of months or years, and thus may spend many hours a day under the influence. Others may use less frequently, but their use causes recurrent problems related to family,

<sup>25</sup> *Cannabis* is the term used in the DSM-V to refer to marijuana. In the following excerpt the term *Cannabis* is interchangeable for the term *marijuana*.

school, work, or other important activities (e.g., repeated absences at work; neglect of family obligations). Periodic cannabis use and intoxication can negatively affect behavioral and cognitive functioning and thus interfere with optimal performance at work or school, or place the individual at increased physical risk when performing activities that could be physically hazardous (e.g., driving a car; playing certain sports; performing manual work activities, including operating machinery). Arguments with spouses or parents over the use of cannabis in the home, or its use in the presence of children, can adversely impact family functioning and are common features of those with cannabis use disorder. Last, individuals with cannabis use disorder may continue using marijuana despite knowledge of physical problems (e.g., chronic cough related to smoking) or psychological problems (e.g., excessive sedation or exacerbation of other mental health problems) associated with its use.

#### Marijuana as a “Gateway Drug”

Kandel (1975) proposed nearly 40 years ago the hypothesis that marijuana is a “gateway drug” that leads to the use or abuse of other illicit drugs. Since that time, epidemiological research explored this premise. Overall, research does not support a direct causal relationship between regular marijuana use and other illicit drug use. The studies examining the gateway hypothesis are limited. First, in general, studies recruit individuals influenced by a myriad of social, biological, and economic factors that contribute to extensive drug abuse (Hall & Lynskey, 2005). Second, most studies that test the hypothesis that marijuana use causes abuse of illicit drugs use the determinative measure *any use of an illicit drug*, rather than DSM-5 criteria for drug abuse or dependence on an illicit drug (DSM-5, 2013). Consequently, although an individual who used marijuana may try other illicit drugs, the individual may not regularly use drugs, or have a diagnosis of drug abuse or dependence.

Little evidence supports the hypothesis that initiation of marijuana use leads to an abuse disorder with other illicit substances. For example, one longitudinal study of 708 adolescents demonstrated that early onset marijuana use did not lead to problematic drug use (Kandel & Chen, 2000). Similarly, Nace et al. (1975) examined Vietnam-era soldiers who extensively abused marijuana and heroin while they were in the military, and found a lack of correlation of a causal relationship demonstrating

marijuana use leading to heroin addiction. Additionally, in another longitudinal study of 2,446 adolescents, marijuana dependence was uncommon but when it did occur, the common predictors of marijuana dependence were the following: parental death, deprived socio-economic status, and baseline illicit drug use other than marijuana (von Sydow et al., 2002).

When examining the association between marijuana and illicit drugs, focusing on drug use versus abuse or dependence, different patterns emerge. For example, a study examining the possible causal relationship of the gateway hypothesis found a correlation between marijuana use in adolescents and other illicit drug use in early adulthood and, adjusting for age-linked experiences, did not effect this correlation (Van Gundy and Rebellon, 2010). However, when examining the association in terms of development of drug abuse; age-linked stressors and social roles moderated the correlation between marijuana use in adolescents and other illicit drug abuse. Similarly, Degenhardt et al. (2009) examined the development of drug dependence and found an association that did not support the gateway hypothesis. Specifically, drug dependence was significantly associated with the use of other illicit drugs prior to marijuana use.

Interestingly, the order of initiation of drug use seems to depend on the prevalence of use of each drug, which varies by country. Based on the World Health Organization (WHO) World Mental Health Survey that includes data from 17 different countries, the order of drug use initiation varies by country and relates to prevalence of drug use in each country (Degenhardt et al., 2010). Specifically, in the countries with the lowest prevalence of marijuana use, use of other illicit drugs before marijuana was common. This sequence of initiation is less common in countries with higher prevalence of marijuana use. A study of 9,282-households in the United States found that marijuana use often preceded the use of other illicit drugs; however, prior non-marijuana drug dependence was also frequently correlated with higher levels of illicit drug abuse (Degenhardt et al., 2009). Additionally, in a large 25-year longitudinal study of 1,256 New Zealand children, the author concluded that marijuana use correlated to an increased risk of abuse of other drugs, including cocaine and heroin (Fergusson et al., 2005).

Although many individuals with a drug abuse disorder may have used marijuana as one of their first illicit

drugs, this fact does not correctly lead to the reverse inference that most individuals who used marijuana will inherently go on to try or become regular users of other illicit drugs. Specifically, data from the 2011 NSDUH survey illustrates this issue (SAMHSA, 2012). NSDUH data estimates 107.8 million individuals have a lifetime history of marijuana use, which indicates use on at least one occasion, compared to approximately 36 million individuals having a lifetime history of cocaine use and approximately 4 million individuals having a lifetime history of heroin use. NSDUH data do not provide information about each individual’s specific drug history. However, even if one posits that every cocaine and heroin user previously used marijuana, the NSDUH data show that marijuana use at least once in a lifetime does not predict that an individual will also use another illicit drug at least once.

Finally, a review of the gateway hypothesis by Vanyukov et al. (2012) notes that because the gateway hypothesis only addresses the order of drug use initiation, the gateway hypothesis does not specify any mechanistic connections between drug “stages” following exposure to marijuana and does not extend to the risks for addiction. This concept contrasts with the concept of a common liability to addiction that involves mechanisms and biobehavioral characteristics pertaining to the entire course of drug abuse risk and disorders.

#### 7. Its Psychic or Physiologic Dependence Liability

Under the seventh factor, the Secretary must consider marijuana’s psychic or physiological dependence liability.

Psychic or psychological dependence has been shown in response to marijuana’s psychoactive effects. Psychoactive responses to marijuana are pleasurable to many humans and are associated with drug-seeking and drug-taking (Maldonado, 2002). Moreover, high levels of psychoactive effects, notably positive reinforcement, are associated with increased marijuana use, abuse, and dependence (Scherrer et al., 2009; Zeiger et al., 2010). Epidemiological data support these findings through 2012 NSDUH statistics that show that of individuals years 12 or older who used marijuana in the past month, an estimated 40.3 percent used marijuana on 20 or more days within the past month. This equates to approximately 7.6 million individuals aged 12 or older who used marijuana on a daily or almost daily basis.

Additionally, the 2013 MTF data report the prevalence of daily marijuana use, defined as use on 20 or more days within the past 30 days, in 8th, 10th, and 12th graders is 1.1 percent, 4.0 percent, and 6.5 percent, respectively.

Tolerance is a state of adaptation where exposure to a drug induces changes that result in a diminution of one or more of the drug's effects over time (American Academy of Pain Medicine, American Pain Society and American Society of Addiction Medicine consensus document, 2001). Tolerance can develop to some, but not all, of marijuana's effects. Specifically, tolerance does not seem to develop in response to many of marijuana's psychoactive effects. This lack of tolerance may relate to electrophysiological data demonstrating that chronic delta<sup>9</sup>-THC administration does not affect increased neuronal firing in the ventral tegmental area, a region known to play a critical role in drug reinforcement and reward (Wu and French, 2000). In the absence of other abuse indicators, such as rewarding properties, the presence of tolerance or physical dependence does not determine whether a drug has abuse potential.

However, humans can develop tolerance to marijuana's cardiovascular, autonomic, and behavioral effects (Jones et al., 1981). Tolerance to some of marijuana's behavioral effects seems to develop after heavy marijuana use, but not after occasional marijuana use. For instance, following acute administration of marijuana, heavy marijuana users did not exhibit impairments in tracking and attention tasks, as were seen in occasional marijuana users (Ramaekers et al., 2009). Furthermore, a neurophysiological assessment administered through an electroencephalograph (EEG) which measures event-related potentials (ERP) conducted in the same subjects as the previous study, found a corresponding effect in the P100<sup>26</sup> component of ERPs. Specifically, corresponding to performance on tracking and attention tasks, heavy marijuana users showed no changes in P100 amplitudes following acute marijuana administration, although occasional users showed a decrease in P100 amplitudes (Theunissen et al., 2012). A possible mechanism underlying tolerance to marijuana's effects may be the down-regulation of cannabinoid receptors (Hirvonen et al., 2012; Gonzalez et al.,

2005; Rodriguez de Fonseca et al., 1994; Oviedo et al., 1993).

Importantly, pharmacological tolerance alone does not indicate a drug's physical dependence liability. In order for physical dependence to exist, evidence of a withdrawal syndrome is needed. Physical dependence is a state of adaptation, manifested by a drug-class specific withdrawal syndrome produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist (*ibid*). Many medications not associated with abuse or addiction can produce physical dependence and withdrawal symptoms after chronic use.

Discontinuation of heavy, chronic marijuana use has been shown to lead to physical dependence and withdrawal symptoms (American Psychiatric Association DSM-V, 2013; Budney and Hughes, 2006; Haney et al., 1999). In heavy, chronic marijuana users, the most commonly reported withdrawal symptoms are sleep difficulties, decreased appetite or weight loss, irritability, anger, anxiety or nervousness, and restlessness. Some less commonly reported withdrawal symptoms are depressed mood, sweating, shakiness, physical discomfort, and chills (Budney and Hughes, 2006; Haney et al., 1999). The occurrence of marijuana withdrawal symptoms in light or non-daily marijuana users has not been established. The American Psychiatric Association's DSM-V (2013) includes a list of symptoms of "cannabis withdrawal." Most marijuana withdrawal symptoms begin within 24–48 hours of discontinuation, peak within 4–6 days, and last for 1–3 weeks. Marijuana withdrawal syndrome has been reported in adolescents and adults admitted for substance abuse treatment.

Based on clinical descriptions, this syndrome appears to be mild compared to classical alcohol and barbiturate withdrawal syndromes, which can include more serious symptoms such as agitation, paranoia, and seizures. Multiple studies comparing marijuana and tobacco withdrawal symptoms in humans demonstrate that the magnitude and time course of the two withdrawal syndromes are similar (Budney et al., 2008; Vandrey et al., 2005, 2008).

### **8. Whether the Substance is an Immediate Precursor of a Substance Already Controlled Under This Article**

Under the eight factor analysis, the Secretary must consider whether marijuana is an immediate precursor of a controlled substance. Marijuana is not an immediate precursor of another controlled substance.

### **Recommendation**

After consideration of the eight factors discussed above, FDA recommends that marijuana remain in Schedule I of the CSA. NIDA concurs with this scheduling recommendation. Marijuana meets the three criteria for placing a substance in Schedule I of the CSA under 21 U.S.C. 812(b)(1):

(1) Marijuana has a high potential for abuse:

A number of factors indicate marijuana's high abuse potential, including the large number of individuals regularly using marijuana, marijuana's widespread use, and the vast amount of marijuana available for illicit use. Approximately 18.9 million individuals in the United States (7.3 percent of the U.S. population) used marijuana monthly in 2012. Additionally, approximately 4.3 million individuals met diagnostic criteria for marijuana dependence or abuse in the year prior to the 2012 NSDUH survey. A 2013 survey indicates that by 12th grade, 36.4 percent of students report using marijuana within the past year, and 22.7 percent report using marijuana monthly. In 2011, 455,668 ED visits were marijuana-related, representing 36.4 percent of all illicit drug-related episodes. Primary marijuana use accounted for 18.1 percent of admissions to drug treatment programs in 2011. Additionally, marijuana has dose-dependent reinforcing effects, as demonstrated by data showing that humans prefer relatively higher doses to lower doses. Furthermore, marijuana use can result in psychological dependence.

(2) Marijuana has no currently accepted medical use in treatment in the United States:

FDA has not approved a marketing application for a marijuana drug product for any indication. The opportunity for scientists to conduct clinical research with marijuana exists, and there are active INDs for marijuana; however, marijuana does not have a currently accepted medical use for treatment in the United States, nor does marijuana have an accepted medical use with severe restrictions.

A drug has a "currently accepted medical use" if all of the following five elements have been satisfied:

- a. The drug's chemistry is known and reproducible;
- b. there are adequate safety studies;
- c. there are adequate and well-controlled studies proving efficacy;
- d. the drug is accepted by qualified experts; and
- e. the scientific evidence is widely available.

<sup>26</sup> The P100 component of ERPs is thought to relate to the visual processing of stimuli and can be modulated by attention.

[57 FR 10499, March 26, 1992]

Marijuana does not meet any of the elements for having a “currently accepted medical use.” First, FDA broadly evaluated marijuana, and did not focus its evaluation on particular strains of marijuana or components or derivatives of marijuana. Since different strains may have different chemical constituents, marijuana, as identified in this petition, does not have a known and reproducible chemistry, which would be needed to provide standardized doses. Second, there are not adequate safety studies on marijuana in the medical literature in relation to a specific, recognized disorder. Third, there are no published adequate and well controlled studies proving efficacy of marijuana. Fourth, there is no evidence that qualified experts accept marijuana for use in treating a specific, recognized disorder. Lastly, the scientific evidence regarding marijuana’s chemistry in terms of a specific *Cannabis* strain that could produce standardized and reproducible doses is not currently available, so the scientific evidence on marijuana is not widely available.

Alternately, a Schedule II drug can be considered to have a “currently accepted medical use with severe restrictions” (21 U.S.C. 812(b)(2)(B)). Yet as stated above, the lack of accepted medical use for a specific, recognized disorder precludes the use of marijuana even under conditions where its use is severely restricted.

In conclusion, to date, research on marijuana’s medical use has not developed to the point where marijuana is considered to have a “currently accepted medical use” or a “currently accepted medical use with severe restrictions.”

(3) There is a lack of accepted safety for use of marijuana under medical supervision:

There are currently no FDA-approved marijuana drug products. Marijuana does not have a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Thus, FDA has not determined that marijuana is safe for use under medical supervision.

In addition, FDA cannot conclude that marijuana has an acceptable level of safety relative to its effectiveness in treating a specific, recognized disorder without evidence that the substance is contamination free, and assurance of a consistent and predictable dose. Investigations into the medical use of marijuana should include information and data regarding the chemistry, manufacturing, and specifications of marijuana. Additionally, a procedure for

delivering a consistent dose of marijuana should also be developed. Therefore, FDA concludes marijuana does not currently have an accepted level of safety for use under medical supervision.

#### References

- Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo controlled clinical trial. *Ann Intern Med.* 2003 Aug 19; 139(4):258–66.
- Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, and Petersen KL. 2007. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. *Neurology* 68(7): 515–521.
- Adams, I.B., and Martin, B.R. Cannabis: Pharmacology and toxicology in animals and humans. *Addiction* 1996, 91(11):1585–1614.
- Agurell, S., Dewey, W.L., and Willett, R.E., eds. *The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects.* New York: Academic Press, 1984.
- Agurell, S.; Halldin, M.; Lindgren, J.E.; Ohlsson, A.; Widman, M.; Gillespie, H.; and Hollister, L. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. *Pharmacol Rev* 1986, 38(1), 21–43.
- Almirez RG, Smith CG, Asch RH. The effects of marijuana extract and delta 9-tetrahydrocannabinol on luteal function in the rhesus monkey. *Fertil Steril.* 1983 Feb; 39(2):212–7.
- Ameri, A. The effects of cannabinoids on the brain. *Progress in Neurobiology* 1999, 58 (4), 315–348.
- American Academy of Pain Medicine, American Pain Society and American Society of Addiction Medicine Consensus Document. Definitions related to the use of opioids for the treatment of pain. 2001.
- Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. *Lancet.* 1987 Dec 26; 2(8574):1483–6.
- Appendino G, Chianese G, Tagliatalata-Scafati O. Cannabinoids: occurrence and medicinal chemistry. *Curr Med Chem.* 2011; 18(7):1085–99.
- Asch RH, Smith CG, Siler-Khodr TM, Pauerstein CJ. Effects of delta 9-tetrahydrocannabinol during the follicular phase of the rhesus monkey (*Macaca mulatta*). *J Clin Endocrinol Metab.* 1981 Jan; 52(1):50–5.
- Balster, R.L., Prescott, W.R., delta9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. *Neurosci. & Biobehav. Rev.* 1992, 16(1), 55–62.
- Balster RL and Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. *Drug and Alcohol Dependence.* 2003; 70: S13–S40.
- Barnett, G.; Licko, V.; and Thompson, T. Behavioral pharmacokinetics of marijuana. *Psychopharmacology* 1985, 85(1), 51–56.
- Battista N, Di TM, Bari M, Maccarrone M. The endocannabinoid system: an overview. *Front.Behav.Neurosci.* 2012; 6:9.
- Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. *Clin Pharmacol Ther.* 1975 Sep; 18(3):287–97.
- Benowitz NL, Jones RT. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. *J Clin Pharmacol.* 1981 Aug–Sep; 21(8–9 Suppl):214S–223S.
- Block RI, Farinpour R, Schlechte JA. Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. *Drug Alcohol Depend.* 1991 Aug; 28(2):121–8.
- Block RI, Farinpour R, Braverman K. Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. *Pharmacol Biochem Behav.* 1992 Nov; 43(3):907–17.
- Bolla KI, Brown K, Eldreth D, Tate K, and Cadet JL. Dose-related neurocognitive effects of marijuana use. *Neurology* 2002 59:1337–1343.
- Bolla KI, Eldreth DA, Matochik JA, and Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. *NeuroImage* 2005 26:480–492.
- Bonnet U. Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function. *Pharmacopsychiatry.* 2013 Jan; 46(1):35–6.
- Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P. Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem.* 1993 May 15; 214(1):173–80.
- Braida D, Iosue S, Pegorini S, Sala M. Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. *Eur J Pharmacol.* 2004 Dec 3; 506(1):63–9.
- Breivogel CS, Childers SR. Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. *J Pharmacol Exp Ther.* 2000. Oct; 295(1):328–36.
- Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. *Mol Pharmacol.* 2001 Jul; 60(1):155–63.
- Brown TT, Dobs AS. Endocrine effects of marijuana. *J Clin Pharmacol.* 2002 Nov; 42(11 Suppl):90S–96S.
- Browne RG, Weissman A. Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies. *J Clin Pharmacol.* 1981 Aug–Sep; 21(8–9 Suppl):227S–234S.
- Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal

- syndrome. *Am J Psychiatry*. 2004 Nov; 161(11):1967–77.
- Budney AJ, Hughes JR. The cannabis withdrawal syndrome. *Curr Opin Psychiatry* 2006 May; 19(3):233–8.
- Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursae Z. Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. *J Subst Abuse Treat*. 2008 Dec; 35(4):362–8.
- Capriotti RM, Foltin RW, Brady JV, Fischman MW. Effects of marijuana on the task-elicited physiological response. *Drug Alcohol Depend*. 1988 Jul; 21(3):183–7.
- Cascini F, Aiello C, Di Tanna G. Increasing delta-9-tetrahydrocannabinol ( $\Delta$ -9-THC) content in herbal cannabis over time: systematic review and meta-analysis. *Curr Drug Abuse Rev*. 2012 Mar; 5(1):32–40.
- Chait LD. Subjective and behavioral effects of marijuana the morning after smoking. *Psychopharmacology (Berl)* 1990; 100(3):328–33.
- Chait LD, Burke KA. Preference for high-versus low-potency marijuana. *Pharmacol Biochem Behav*. 1994 Nov; 49(3):643–7.
- Chaperon F, Soubrie P, Puech AJ, Thiebot MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. *Psychopharmacology (Berl)*. 1998 Feb; 135(4):324–32.
- Cheer JF, Kendall DA, Marsden CA. Cannabinoid receptors and reward in the rat: a conditioned place preference study. *Psychopharmacology (Berl)*. 2000 Jul; 151(1):25–30.
- Cone EJ, Johnson RE, Moore JD, Roache JD. Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. *Pharmacol Biochem Behav*. 1986 Jun; 24(6): 1749–54.
- Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, and Gouaux B. 2012. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *CMAJ* 184 (10): 1143–1150.
- Council on Science and Public Health Report 3. Use of cannabis for medicinal purposes. American Medical Association, Interim Meeting, Houston, Texas; November 2009.
- Crawford WJ, and Merritt JC. 1979. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. *International journal of clinical pharmacology and biopharmacy* 17 (5): 191–196.
- Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? *J Neuroimmunol*. 2005 Sep; 166(1–2):3–18. Review.
- Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. *Clin.Pharmacol. Ther*. 1976 Mar; 19(3):300–9.
- Dax EM, Pilotte NS, Adler WH, Nagel JE, Lange WR. The effects of 9-ene-tetrahydrocannabinol on hormone release and immune function. *J Steroid Biochem*. 1989; 34(1–6):263–70.
- Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. *Drug Alcohol Depend*. 2003 Jul 20; 71(1):37–48.
- Degenhardt L, Chiu WT, Conway K, Dierker L, Glantz M, Kalaydjian A, Merikangas K, Sampson N, Swendsen J, Kessler RC. Does the ‘gateway’ matter? Associations between the order of drug use initiation and the development of drug dependence in the National Comorbidity Study Replication. *Psychol. Med* 2009 Jan; 39(1):157–67.
- Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neumark Y, Sampson N, Alonso J, Angermeyer M, Anthony JC, Bruffaerts R, et al. Evaluating the drug use ‘gateway’ theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. *Drug Alcohol. Depend*. 2010 Apr 1; 108(1–2):84–97.
- Deiana S, Fattore L, Spano MS, Cossu G, Porcu E, Fadda P, Fratta W. Strain and schedule dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. *Neuropharmacology*. 2007 Feb; 52(2):646–54.
- Dewey, W.L., Martin, B.R., May, E.L. Cannabinoid stereoisomers: pharmacological effects. In Smith, D.F. (Ed.) *CRC Handbook of stereoisomers: drugs in psychopharmacology*, 317–326 (Boca Raton, FL, CRC Press), 1984.
- Di Marzo, V.A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. *Trends. Pharmacol. Sci* 2006 Mar; 27(3):134–40.
- DEA Statistics and Facts. (n.d.) DEA Domestic Drug Seizures. <http://www.justice.gov/dea/resource-center/statistics.shtml/> (accessed August 5, 2014)
- Drug Enforcement Administration, *Drugs of Abuse*, 2005.
- Drug Enforcement Administration. *Sourcebook of Criminal Justice Statistics*, 2003.
- DSM–V. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association. Washington, DC: American Psychiatric Publishing, 2013.
- Eldridge JC, Murphy LL, Landfield PW. Cannabinoids and the hippocampal glucocorticoid receptor: recent findings and possible significance. *Steroids*. 1991 May; 56(5):226–31. Review.
- Ellis RJ, Toperoff W, Vaida F, Van Den Brande G, Gonzales J, Gouaux B, Bentley H, and Atkinson JH. 2009. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology* 34(3): 672–680.
- ElSohly MA, Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. *Life Sciences*. 2005; 78:539–48.
- Fant RV, Heishman SJ, Bunker EB, Pickworth WB. Acute and residual effects of marijuana in humans. *Pharmacol Biochem Behav*. 1998 Aug; 60(4):777–84.
- Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. *Br.J Pharmacol*. 2007 Nov; 152(5):795–804.
- Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. *Addiction*. 2005 Mar; 100(3):354–66.
- Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL. Cannabis use before age 15 and subsequent executive functioning. *Br. J Psychiatry* 2011 Jun; 198(6):442–7.
- Fried, P.A., Watkinson, B. 36- and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes and alcohol. *J. Dev. Behav. Pediatr*. 1987, 8, 318–326.
- Fried, P.A., Watkinson, B., Gray, R. A follow-up study of attentional behavior in 6-year-old children exposed prenatally to marihuana, cigarettes and alcohol. *Neurotoxicol. Teratol*. 1992, 14, 299–311.
- Fried, P.A., Watkinson, B., Gray, R. Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. *Neurotoxicol. Teratol*. 1998, 20(3), 293–306.
- Fried PA. Adolescents prenatally exposed to marijuana: examination of facets of complex behaviors and comparisons with the influence of in utero cigarettes. *J. Clin. Pharmacol*. 2002 Nov; 42(11 Suppl):97S–102S.
- Fried PA, Watkinson B, Gray R. Neurocognitive consequences of marihuana—a comparison with pre-drug performance. *Neurotoxicol. Teratol*. 2005 Mar; 27(2):231–9.
- Fung, M., Gallagher, C., Machtay, M. Lung and aeo-digestive cancers in young marijuana smokers. *Tumori* 1999, 85 (2), 140–142.
- Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem*. 1995 Aug 15; 232(1):54–61.
- Gaoni, Y., Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent of hashish. *J. Am. Chem. Soc*. 1964, 86, 1646–1947.
- Gerard, C.M., Mollereau, C., Vassart, G., Parmentier, M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis.: *Biochem J*. 1991, 279, 129–34.
- Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. *J Neurosci*. 2002 Feb 1; 22(3):1146–54.
- Gold LH, Balster RL, Barrett RL, Britt DT, Martin BR. A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP

- 55,940 in rats and rhesus monkeys. *J Pharmacol Exp Ther.* 1992 Aug; 262(2):479–86.
- Goldschmidt L, Richardson GA, Willford J, Day NL. Prenatal marijuana exposure and intelligence test performance at age 6. *J. Am. Acad. Child. Adolesc. Psychiatry.* 2008 Mar; 47(3):254–63.
- Gong H Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. *Clin Pharmacol Ther.* 1984 Jan; 35(1):26–32.
- Gong JP, Onaivi ES, Lshiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. *Brain Res.* 2006 Feb 3; 1071(1):10–23.
- Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide. *Mol Pharmacol.* 2000 May; 57(5): 1045–50.
- Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. *Neuropsychol.Rev.* 2007 Sep; 17(3):347–61.
- Gonzalez S, Cebeira M, Fernandez-Ruiz J. Cannabinoid tolerance and dependence: A review of studies in laboratory animals. *Pharmacol.Biochem.Behav.* 2005 Jun; 81(2):300–18.
- Grant I. Foreword by Igor Grant, M.D., Director, Center for Medicinal Cannabis Research (CMCR). *Neuropharmacology.* 2005 Jun; 48(8): 1067.
- Griffith-Lendering MF, Wigman JT, Prince van LA, Huijbregts SC, Huizink AC, Ormel J, Verhulst FC, van OJ, Swaab H, Vollebergh WA. Cannabis use and vulnerability for psychosis in early adolescence—a TRAILS study. *Addiction* 2012 Dec 7.
- Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet.* 2003; 42(4):327–60.
- Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. *Psychol.Addict.Behav.* 2012 Sep; 26(3):496–506.
- Hall WD, Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. *Drug Alcohol Rev.* 2005 Jan; 24(1):39–48.
- Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, and Faltin RW. 2007. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. *Journal of acquired immune deficiency syndromes (1999)* 45 (5): 545–554.
- Haney M, Rabkin J, Gunderson E, and Foltin RW. 2005. Dronabinol and marijuana in HIV(+) marijuana smokers: Acute effects on caloric intake and mood. *Psychopharmacology* 181(1): 170–178.
- Haney M, Ward AS, Comer SD, Faltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. *Psychopharmacology (Berl)* 1999, 141(4):395–404.
- Hanus, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R.G., Roos, R.A., Mechoulam, R., Pride, E. HU-308: A specific agonist for CB(2), a peripheral Cannabinoid receptor. *Proc. Natl. Acad. Sci. USA* 1999, 96, 14228–33.
- Heishman SJ, Huestis MA, Benningfield JE, Cone EJ. Acute and residual effects of marijuana: Profiles of plasma THC levels, physiological, subjective, and performance measures. *Pharmacol Biochem Behav.* 1990 Nov; 37(3):561–5.
- Herkenham, M. Cannabinoid receptor localization in brain: Relationship to motor and reward systems. In: Kalivas, P.W., and Samson, H.H., eds. *The neurobiology of drug and alcohol addiction.* Ann NY Acad Sci 1992, 654, 19–32.
- Herkenham, M., Lynn, A.B., Little, M.D., Johnson, M.R., Melvin, L.S., de Costa, B.R., Rice, K.C. Cannabinoid receptor localization in Brain. *Proc. Natl. Acad. Sci. US A.* 1990, 87, 1932–1936.
- Herning, R.I.; Hooker, W.D.; and Jones, R.T. Tetrahydrocannabinol content and differences in marijuana smoking behavior. *Psychopharmacology* 1986, 90(2):160–162.
- Hillig, K.W. Genetic evidence for speciation in Cannabis (Cannabaceae). *Genetic Resources and Crop Evolution* 52: 161–180, 2005.
- Hirvonen, J., Goodwin, R.S., Li, C.T., Terry, G.E., Zoghbi, S.S., Morse, C., Pike, V.W., Volkow, N.D., Huestis, M.A., Innis, R.B. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. *Mol. Psychiatry.* 2012(Jun), 17(6), 643–649.
- Hively, R.L., Mosher, W.A., Hoffman, F.W. Isolation of trans-<sup>9</sup>-tetrahydrocannabinol from marihuana. *J. Am. Chem. Soc.* 1966, 88, 1832–1833.
- Hollister LE, Gillespie HK. Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration. *Clin.Pharmacol.Ther.* 1973 May;14(3):353–7.
- Hollister, L.E. Health aspects of cannabis. *Pharmacological Rev.* 1986, 38, 1–20.
- Hollister, L.E. Cannabis. (Literature review). *Acta Psychiatr Scand (Suppl)* 1988, 78, 108–118.
- Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Parrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. *Neuropharmacology.* 2004; 47 Suppl 1:345–58.
- Huestis, M.A., Sampson, A.H., Holicky, B.J., Benningfield, J.E., Cone, E.J. Characterization of the absorption phase of marijuana smoking. *Clin. Pharmacol Ther.* 1992a, 52, 31–41.
- Huestis, M.A.; Benningfield, J.E.; and Cone, E.J. Blood Cannabinoids. 1. Absorption of THC and formation of 11–OH-THC and THC COOH during and after smoking marijuana. *J Anal Toxicol* 1992b, 16(5), 276–282.
- Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. *J Pharmacol Exp Ther.* 1980 Oct; 215(1):35–44.
- Ilan AB, Gevins A, Coleman M, Elsohly MA, de WH. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. *Behav.Pharmacol.* 2005 Sep; 16(5–6):487–96.
- Institute of Medicine. Division of Health Sciences Policy. Marijuana and Health: Report of a Study by a Committee of the Institute of Medicine, Division of Health Sciences Policy. Washington, DC: National Academy Press, 1982.
- Institute of Medicine, Division of Neuroscience and Behavioral Health. Marijuana and Medicine: Assessing the Science Base. Washington DC: National Academy Press, 1999.
- Johansson, E.; Halldin, M.M.; Agurell, S.; Hollister, L.E.; and Gillespie, H.K. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. *Eur J Clin Pharmacol* 1989, 37(3), 273–277.
- Johnston, L.D., O'Malley, P.M., Miech, R.A., Bachman, J.G., & Schulenberg, J.E. (2014). *Monitoring the Future national survey results on drug use: 1975–2013: Overview, key findings on adolescent drug use.* Ann Arbor: Institute for Social Research, The University of Michigan, 84pp.
- Jones, R.T.; Benowitz, N.L.; and Heming, R.I. Clinical relevance of cannabis tolerance and dependence. *J Clin Pharmacol* 1981, 21,143S–152S.
- Jones RT. Cardiovascular system effects of marijuana. *J Clin Pharmacol.* 2002 Nov;42(11Suppl):58S–63S.
- Justinova Z, Goldberg SR, Heishman SJ, Tanda G. Self-administration of cannabinoids by experimental animals and human marijuana smokers. *Pharmacol Biochem Behav.* 2005 Jun; 81(2): 285–299.
- Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. *Psychopharmacology (Berl).* 2003 Sep; 169(2): 135–40.
- Justinova Z, Tanda G, Munzar P, Goldberg SR. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. *Psychopharmacology.(Berl.)* 2004 Apr; 173(1–2):186–94.
- Kandel, D. Stages in adolescent involvement in drug use. *Science* 1975; 190:912–914.
- Kandel DB, Chen K. Types of marijuana users by longitudinal course. *J Stud Alcohol.* 2000 May; 61(3):367–78.
- Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. *Eur J Pharmacol.* 1974 Sep;28(1):172–7.
- Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE. Effects of delta9-tetrahydrocannabinol and cannabinalin in man. *Pharmacology* 1975; 13(6):502–12.
- Kirk JM, de Wit H. Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. *Pharmacol Biochem Behav.* 1999 May; 63(1):137–42.
- Kuepper R, van OJ, Lieb R, Wittchen HU, Hofer M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. *BMJ* 2011; 342:d738.
- Kurzthaler I, Hummer M, Miller C, Sperner-Unterwieser B, Gunther V, Wechdorn H, Battista HJ, Fleischhacker WW. Effect of cannabis use on cognitive functions and

- driving ability. *J Clin Psychiatry*. 1999 Jun; 60(6):395–9.
- Lee MH, Hancox RJ. Effects of smoking cannabis on lung function. *Expert Rev. Respir. Med* 2011 Aug; 5(4):537–46.
- Lemberger L., Silberstein, S. D., Axelrod, J., Kopin, I.J. Marihuana: Studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. *Science* 1970, 1 70, 1320–1322.
- Lemberger L., Weiss, J.L., Watanabe, A. M., Galanter, I.M., Wyatt, R.J., Cardon, P.V. Delta-9-tetrahydrocannabinol: Temporal correlation of the psychological effects and blood levels after various routes of administration. *New Eng. J. Med.* 1972a, 286(13), 685–688.
- Lemberger, L., Crabtree, R.E., Rowe, H.M. 11-Hydroxy-<sup>9</sup>-tetrahydrocannabinol: Pharmacology, disposition and metabolism of a major metabolite of marihuana in man. *Science* 1972b, 177, 62–63.
- Lemberger L., Rubin A. The physiologic disposition of marihuana in man, *Life Sci*. 1975,17, 1637–42.
- Li M-C., Brady, J.E., DiMaggio, C.J., Lusardi, A.R., Tzong, K.Y., Li, G. Marijuana use and motor vehicle crashes. *Epidemiologic Reviews*. 2012, 34, 65–72.
- Liguori A, Gatto CP, Robinson JH. Effects of marijuana on equilibrium, psychomotor performance, and simulated driving. *Behav Pharmacol*. 1998 Nov; 9(7):599–609.
- Lile JA, Kelly TH, Hays LR. Separate and combined effects of the cannabinoid agonists nabilone and Delta(9)-THC in humans discriminating Delta(9)-THC. *Drug Alcohol Depend*. 2011 Jul; 116(1–3):86–92.
- Lile JA, Kelly TH, Pinsky DJ, Hays LR. Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol. *Psychopharmacology (Berl.)* 2009 Apr; 203(2):241–50.
- Lisdahl KM, Price JS. Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. *J Int Neuropsychol. Soc* 2012 Jul; 18(4):678–88.
- Lyons MJ, Bar JL, Panizzon MS, Toomey R, Eisen S, Xian H, Tsuang MT. Neuropsychological consequences of regular marijuana use: A twin study. *Psychol Med*. 2004 Oct; 34(7):1239–50.
- Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. *J Neurosci*. 1995 Oct; 15(10):6552–61.
- Maldonado R. Study of cannabinoid dependence in animals. *Pharmacol Ther*. 2002 Aug; 95(2): 153–64.
- Malinowska B, Baranowska-Kuczko M, Schlicker E. Triphasic blood pressure responses to cannabinoids: Do we understand the mechanism? *Br J Pharmacol* 2012 Apr; 165(7):2073–88.
- Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andresson S, Allebeck P. Cannabis, schizoprenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. *Psychol. Med* 2012 Jun; 42(6):1321–8.
- Maremmani I, Lazzeri A, Pacini M, Lovrecic M, Placidi GF, Perugi G. Diagnostic and symptomatological features in chronic psychotic patients according to cannabis use status. *J Psychoactive Drugs*. 2004 Jun; 36(2):235–41.
- “Marijuana Scheduling Petition; Denial of Petition; Remand; Final Order,” 57 Federal Register 59 (26 March 1992), pp. 10499–10508.
- Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W. Self-administration of the cannabinoid receptor agonist WIN 55,212–2 in drug-naïve mice. *Neuroscience*. 1998 Jul; 85(2):327–30.
- Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* 1990, 346, 561–564.
- McMahon LR. Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of discriminating Delta9-tetrahydrocannabinol. *Psychopharmacology (Berl.)* 2009 Apr; 203(2):219–28.
- McMahon LR, Ginsburg BC, Lamb RJ. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice. *Psychopharmacology (Berl.)* 2008 Jul; 198(4):487–95.
- Mechoulam, R. Cannabinoid chemistry. In Mechoulam, R. (ED.) *Marijuana*, pp.2–88 (New York, NY, Academic Press, Inc.), 1973.
- Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol—recent advances. *Chem. Biodivers*. 2007 Aug; 4(8): 1678–92.
- Mechoulam R, Shvo Y. Hashish-I: The structure of Cannabidiol. *Tetrahedron*. 1963; 19: 2073–78.
- Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly MA. Potency Trends of  $\Delta^9$ -THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. *J Forensic Sci*. 2010 Sept; 55(5): 1209–1217.
- Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE. Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc. Natl. Acad. Sci U.S.A* 2012 Oct 2; 109(40):E2657–E2664.
- Meijer JH, Dekker N, Koeter MW, Quee PI, van Beveren NJ, Meijer CJ. Cannabis and cognitive performance in psychosis: A cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. *Psychol. Med* 2012 Apr; 42(4):705–16.
- Mendelson JH, Mello NK. Effects of marijuana on neuroendocrine hormones in human males and females. *NIDA Res Monogr*. 1984; 44:97–114.
- Mendizabal V, Zimmer A, Maldonado R. Involvement of kappa/dynorphin system in WIN 55,212–2 self-administration in mice. *Neuropsychopharmacology*. 2006 Sep; 31(9):1957–66.
- Merritt JC, Crawford WJ, Alexander PC, Anduze AL, and Gelbart SS. 1980. Effect of marihuana on intraocular and blood pressure in glaucoma. *Ophthalmology* 87(3): 222–228.
- Messinis L, Kyprianidou A, Malefaki S, and Papathanasopoulos P. Neuropsychological deficits in long-term frequent cannabis users. *Neurology* 2006 66:737–739.
- Minuzzi S, Davoli M, Bargagli AM, Amato L, Vecchi S, Perucci CA. An overview of systematic reviews on cannabis and psychosis: Discussing apparently conflicting results. *Drug Alcohol Rev*. 2010 May; 29(3):304–17.
- Mittleman MA, Lewis RA, Maclure M, Sherwood JB, and Muller JE. Triggering myocardial infarction by marijuana. *Circulation*. 2001; 103:2805–2809.
- Nace EP, Meyers AL, Rothberg JM, Maleson F. Addicted and nonaddicted drug users. A comparison of drug usage patterns. *Arch Gen Psychiatry*. 1975; 32(1):77–80.
- Oviedo, A., Glowa, J., Herkenham, M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study. *Brain Res*. 1993, 616, 293–302.
- Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol. Rev.* 2006 Sep; 58(3):389–462.
- Pelayo-Teran JM, Suarez-Pinilla P, Chadi N, Crespo-Pacorro B. Gene-environment interactions underlying the effect of cannabis in first episode psychosis. *Curr Pharm Des*. 2012; 18(32):5024–35.
- Petrocellis PL, Di Marzo V. An introduction to the endocannabinoid system: From the early to the latest concepts. *Best Pract. Res. Clin. Endocrinol. Metab*. 2009 Feb; 23(1):1–15.
- Piomelli D. The endocannabinoid system: A drug discovery perspective. *Curr Opin Investig Drugs*. 2005 Jul; 6(7):672–9.
- Pletcher MJ, Vittinghoff E, Kalhan R, Richman J, Safford M, Sidney S, Lin F, Kertesz S. Association between marijuana exposure and pulmonary function over 20 years. *JAMA* 2012 Jan 11; 307(2):173–81.
- Pollastro F, Tagliatela-Scafati O, Allara M, Munoz E, Di Marzo V, De Petrocellis L, Appendino G. Bioactive prenylogous cannabinoid from fiber hemp (*Cannabis sativa*). *J Nat Prod*. 2011 Sep 23; 74(9):2019–22.
- Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Cognitive measures in long term cannabis users. *J Clin Pharmacol*. 2002 Nov; 42(11 Suppl):41S–47S. Review.
- Radwan MM, Elsohly MA, Slade D, Ahmed SA, Khan IA, Ross SA. Biologically active cannabinoids from high-potency *Cannabis sativa*. *J Nat Prod*. 2009 May 22; 72(5):906–11.
- Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. *Drug Alcohol Depend*. 2004 Feb 7; 73(2): 109–19.
- Ramaekers JG, Kauert G, van RP, Theunissen EL, Schneider E, Moeller MR. High-potency marijuana impairs executive function and inhibitory motor control. *Neuropsychopharmacology* 2006 Oct; 31(10):2296–303.



- Ramaekers JG, Kauert G, Theunissen EL, Toennes SW., Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. *J.Psychopharmacol.* 2009 May; 23(3):266–77.
- Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognitive and motor control as a function of  $\Delta^9$ -THC concentration in serum and oral fluid: Limits of impairment. *Drug and Alcohol Dependence.* 2006; 85:114–122.
- “Rescheduling of the Food and Drug Administration Approved Product Containing Synthetic Dronabinol [(–)-delta 9-(trans)-Tetrahydrocannabinol] in Sesame Oil and Encapsulated in Soft Gelatin Capsules From Schedule II to Schedule III; Final Rule,” 64 Federal Register 127 (2 July 1999), pp.35928–35930.
- Riggs PK, Vaida F, Rossi SS, Sorkin LS, Gouaux B, Grant I, Ellis RJ. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. *Brain Res* 2012 Jan 11; 1431:46–52.
- Rodriguez de Fonseca F, Gorriti, M.A., Fernandez-Ruiz, J.J., Palomo, T., Ramos, J.A. Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. *Pharmacol. Biochem. Behav.* 1994, 47 (1), 33–40.
- Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC. Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL–SCID mouse. *Life Sci.* 2005 Aug 19; 77(14):1711–22.
- Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol.* 2011 Aug; 163(7):1344–64.
- Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. *Cancer Res.* 2005 Mar 1; 65(5):1635–41.
- Sanudo-Peria M.C., Tsou, K., Delay, E.R., Hohman, A.G., Force, M., Walker, J.M. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. *Neurosci. Lett.*, 223, 125–128, 1997.
- Scherrer JF, Grant JD, Duncan AE, Sartor CE, Haber JR, Jacob T, Bucholz KK. Subjective effects to cannabis are associated with use, abuse and dependence after adjusting for genetic and environmental influences. *Drug Alcohol Depend.* 2009 Nov 1; 105(1–2):76–82.
- Schiffman J, Nakamura B, Earleywine Mj LaBrie J. Symptoms of schizotypy precede cannabis use. *Psychiatry Res.* 2005 Mar 30; 134(1):37–42.
- Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis. *Exp.Clin Psychopharmacol.* 2012 Oct; 20(5):420–9.
- Sidney S. Cardiovascular consequences of marijuana use. *J Clin Pharmacol.* 2002 Nov; 42(11 Suppl):64S–70S.
- Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J; Marijuana Treatment Project Research Group. Cognitive functioning of long-term heavy cannabis users seeking treatment. *JAMA.* 2002 Mar 6; 287(9): 1123–31.
- Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. *Schizophr Res.* 2005 Jun 1; 75(1):135–7.
- Substance Abuse and Mental Health Services Administration, *Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits.* HHS Publication No. (SMA) 13–4760, DAWN Series D–39. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
- Substance Abuse and Mental Health Services Administration, *Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H–46, HHS Publication No. (SMA) 13–4795.* Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
- Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. *Treatment Episode Data Set (FEDS): 2001–2011. National Admissions to Substance Abuse Treatment Services.* BHSIS Series S–65, HHS Publication No. (SMA) 13–4772. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
- Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. *Addiction* 2011 Dec; 106(12):2195–203.
- Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: An overview. *Immunobiology.* 2010 Aug; 215(8):588–97.
- Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. *Nat Neurosci.* 2000 Nov; 3(11):1073–4.
- Tashkin DP. Smoked marijuana as a cause of lung injury. *Monaldi Arch Chest Dis.* 2005 Jun; 63(2):93–100.
- Tashkin DP, Shapiro BJ, and Frank IM. 1974. Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. *The American review of respiratory disease* 109 (4): 420–428.
- Tashkin, DP, Zhang, ZF, Greenland, S, Cozen, W, Mack, TM, Morgenstern, H. Marijuana Use and Lung Cancer: Results of a Case-Control Study. Abstract #A 777, American Thoracic Society meeting, May 24, 2006.
- The Plant List (2010). Version 1. Published on the Internet; <http://www.theplantlist.org/> (accessed September 20, 2013)
- Theunissen EL, Kauert GF, Toennes SW., Moeller MR, Sambeth A, Blanchard MM, Ramaekers JG. Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. *Psychopharmacology (Berl.)* 2012 Mar;220(2):341–50.
- Trabert B, Sigurdson AJ, Sweeney AM, Strom SS, McGlynn KA. Marijuana use and testicular germ cell tumors. *Cancer.* 2011 Feb 15; 117: 848–853.
- Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. *J Neurophysiol.* 1997 Jul; 78(1):43–50.
- van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MW, de HL. Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. *Curr Pharm Des.* 2012; 18(32):5036–44.
- van Gastel WA, Wigman JT, Monshouwer K, Kahn RS, van OJ, Boks MP, Vollebergh WA. Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey. *Addiction* 2012 Feb; 107(2):381–7.
- Van Gundy K, Rebellon CJ. A Life-course Perspective on the “Gateway Hypothesis.” *J Health Soc Behav.* 2010 Sep; 51(3):244–59.
- van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. *Am J Epidemiol.* 2002 Aug 15; 156(4):319–27.
- Vandrey RG, Budney AJ, Moore BA, Hughes JR. A cross-study comparison of cannabis and tobacco withdrawal. *Am J Addict.* 2005 Jan-Feb; 14(1):54–63.
- Vandrey RG, Budney AJ, Hughes JR, Liguori A. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. *Drug Alcohol Depend.* 2008 Jan 1; 92(1–3):48–54.
- Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9) tetrahydrocannabinol. *Drug Alcohol Depend.* 2008 Apr 1; 94(1–3):191–8.
- Vanyukov MM, Tarter RE, Kirillova GP, Kirisci L, Reynolds MD, Kreek MJ, Conway KP, Maher BS, Iacono WG, Bierut L, Neale MC, Clark DB, Ridenour TA. Common liability to addiction and “gateway hypothesis”: theoretical, empirical and evolutionary perspective’. *Drug Alcohol Depend.* 2012 Jun; 123 Suppl 1:S3–17
- von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen HU. What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. *Drug Alcohol Depend.* 2002 Sep 1; 68(1):49–64.
- Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H. Comparison of the subjective effects of Delta (9)-tetrahydrocannabinol and marijuana in humans. *Psychopharmacology (Berl).* 2002 Jun; 161(4):331–9.
- Wagner JA, Varga K, Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. *J Mol Med.* 1998 Nov-Dec; 76(12):824–36.
- Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, and Collet JP. 2010. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ: Canadian Medical Association journal =journal de l’Association medicale canadienne* 182(14): E694–E701.

- Wesson DR, Washburn P. Current patterns of drug abuse that involve smoking. NIDA Res. Monogr. 1990; 99:5–11.
- Wiley JL, Barrett RL, Britt DT, Balster RL, Martin BR. Discriminative stimulus effects of delta 9-tetrahydrocannabinol and delta 9–11-tetrahydrocannabinol in rats and rhesus monkeys. *Neuropharmacology*. 1993 Apr; 32(4):359–65.
- Wiley JL, Huffman JW, Balster RL, Martin BR. Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys. *Drug Alcohol Depend*. 1995 Nov; 40(1):81–6.
- Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, and Donaghe H. 2013. Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain. *The journal of pain: official journal of the American Pain Society*.
- Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, and Fishman S. 2008. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *The journal of pain: official journal of the American Pain Society* 9 (6): 506–521.
- Wu X, French ED. Effects of chronic delta-9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. *Neuropharmacology*. 2000 Jan 28; 39(3):391–8.
- Yucel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, Takagi MJ, Fomito A, Wood SJ, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. *Schizophr.Bull*. 2012 Mar; 38(2):316–30.
- Zeiger JS, Haberstick BC, Corley RP, Ehringer MA, Crowley TJ, Hewitt JK, Hopfer CJ, Stallings MC, Young SE., Rhee SH. Subjective effects to marijuana associated with marijuana use in community and clinical subjects. *Drug Alcohol Depend*. 2010 Jun 1; 109(1–3):161–6.
- Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, Hsu TC, Schantz SP. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. *Cancer Epidemiol Biomarkers Prev*. 1999 Dec;8(12): 1071–8.
- Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9–THC in normal subjects. *Psychopharmacology (Berl.)*1982; 76(3):245–50.

### The Medical Application of Marijuana: A Review of Published Clinical Studies

March 19, 2015

Prepared by:

U.S. Food and Drug Administration  
Center for Drug Evaluation and Research  
(FDA/CDER)  
Controlled Substance Staff (CSS)

### TABLE OF CONTENTS

1. Introduction .....	71
2. Methods .....	73
2.1 Define the Objective of the Review .....	73
2.2 Define “Marijuana” .....	74
2.3 Define “Adequate and Well-Controlled Clinical Studies” .....	74
2.4 Search Medical Literature Databases and Identify Relevant Studies .....	75
2.5 Review and Analyze Qualifying Clinical Studies .....	77
3. Results and Discussion .....	77
3.1 Neuropathic Pain .....	77
3.1.1 Neuropathic Pain Associated with HIV-Sensory Neuropathy .....	77
3.1.2 Central and Peripheral Neuropathic Pain .....	81
3.2 Appetite Stimulation in HIV .....	86
3.3 Spasticity in Multiple Sclerosis .....	89
3.4 Asthma .....	90
3.5 Glaucoma .....	91
3.6 Conclusions .....	91
3.6.1 Conclusions for Chronic Neuropathic Pain .....	92
3.6.2 Conclusions for Appetite Stimulation in HIV .....	92
3.6.3 Conclusions for Spasticity in MS .....	92
3.6.4 Conclusions for Asthma .....	93
3.6.5 Conclusions for Glaucoma .....	93
3.7 Design Challenges for Future Studies .....	93
3.7.1 Sample Size .....	93
3.7.2 Marijuana Dose Standardization .....	94
3.7.3 Acute vs. Chronic Therapeutic Marijuana Use .....	96
3.7.4 Smoking as a Route of Administration .....	96
3.7.5 Difficulty in Blinding of Drug Conditions .....	96
3.7.6 Prior Marijuana Experience .....	97
3.7.7 Inclusion and Exclusion Criteria .....	98
3.7.8 Number of Female Subjects .....	99
Appendix (Tables) .....	103
List of Figure .....	
Figure 1: Identification of Studies From PubMed Search .....	76
List of Tables .....	
Table 1: Randomized, controlled, double-blind trials examining smoked marijuana in treatment of neuropathic pain .....	103
Table 2: Randomized, controlled, double-blind trials examining smoked marijuana in treatment of appetite stimulation in HIV/AIDS .....	109
Table 3: Randomized, controlled, double-blind trails examining smoked marijuana in treatment of spasticity in Multiple Sclerosis .....	112
Table 4: Randomized, controlled, double-blind trails examining smoked marijuana in treatment of intraocular pressure in Glaucoma .....	114
Table 5: Randomized, controlled, double-blind trails examining smoked marijuana in treatment of asthma .....	116

### Executive Summary

Marijuana is a Schedule I substance under the Controlled Substances Act (CSA). Schedule I indicates a high potential for abuse, no currently

accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. To date, marijuana has not been subject to an approved new drug application (NDA)

that demonstrates its safety and efficacy for a specific indication under the Food Drug and Cosmetic Act (FDCA).

Nevertheless, as of October 2014, twenty-three states and the District of

Columbia have passed state-level medical marijuana laws that allow for marijuana use within that state; similar bills are pending in other states.

The present review was undertaken by the Food and Drug Administration (FDA) to analyze the clinical studies published in the medical literature investigating the use of marijuana in any therapeutic areas. First, we discuss the context for this scientific review. Next, we describe the methods used in this review to identify adequate and well-controlled studies evaluating the safety and efficacy of marijuana for particular therapeutic uses.

The FDA conducted a systematic search for published studies in the medical literature that meet the described criteria for study design and outcome measures prior to February 2013. While not part of our systematic review, we have continued to routinely follow the literature beyond that date for subsequent studies. Studies were considered to be relevant to this review if the investigators administered marijuana to patients with a diagnosed medical condition in a well-controlled, double-blind, placebo-controlled clinical trial. Of the eleven studies that met the criteria for review, five different therapeutic areas were investigated:

- Five studies examined chronic neuropathic pain
- Two studies examined appetite stimulation in human immunodeficiency virus (HIV) patients
- Two studies examined glaucoma
- One study examined spasticity and pain in multiple sclerosis (MS)
- One study examined asthma.

For each of these eleven clinical studies, information is provided regarding the subjects studied, the drug conditions tested (including dose and method of administration), other drugs used by subjects during the study, the physiological and subjective measures collected, the outcome of these measures comparing treatment with marijuana to placebo, and the reported and observed adverse events. The conclusions drawn by the investigators are then described, along with potential limitations of these conclusions based on the study design. A brief summary of each study's findings and limitations is provided at the end of the section.

The eleven clinical studies that met the criteria and were evaluated in this review showed positive signals that marijuana may produce a desirable therapeutic outcome, under the specific experimental conditions tested. Notably, it is beyond the scope of this review to determine whether these data

demonstrate that marijuana has a currently accepted medical use in the United States. However, this review concludes that these eleven clinical studies serve as proof-of-concept studies, based on the limitations of their study designs, as described in the study summaries. Proof-of-concept studies provide preliminary evidence on a proposed hypothesis regarding a drug's effect. For drugs under development, the effect often relates to a short-term clinical outcome being investigated. Proof-of-concept studies serve as the link between preclinical studies and dose ranging clinical studies. Therefore, proof-of-concept studies are not sufficient to demonstrate efficacy of a drug because they provide only preliminary information about the effects of a drug. However, the studies reviewed produced positive results, suggesting marijuana should be further evaluated as an adjunct treatment for neuropathic pain, appetite stimulation in HIV patients, and spasticity in MS patients.

The main limitations identified in the eleven studies testing the medical applications of marijuana are listed below:

- The small numbers of subjects enrolled in the studies, which limits the statistical analyses of safety and efficacy.
- The evaluation of marijuana only after acute administration in the studies, which limits the ability to determine efficacy following chronic administration.
- The administration of marijuana typically through smoking, which exposes ill patients to combusted material and introduces problems with determining the doses delivered.
- The potential for subjects to identify whether they received marijuana or placebo, which breaks the blind of the studies.
- The small number of cannabinoid naïve subjects, which limits the ability to determine safety and tolerability in these subjects.
- The low number of female subjects, which makes it difficult to generalize the study findings to subjects of both genders.

Thus, this review discusses the following methodological changes that may be made in order to resolve these limitations and improve the design of future studies which examine the safety and efficacy of marijuana for specific therapeutic indications:

- Determine the appropriate number of subjects studied based on recommendations in various FDA *Guidances for Industry* regarding the

conduct of clinical trials for specific medical indications.

- Administer consistent and reproducible doses of marijuana based on recommendations in the FDA *Guidance for Industry: Botanical Drug Products (2004)*.<sup>27</sup>

- Evaluate the effects of marijuana under therapeutic conditions following both acute and chronic administration.

- Consider alternatives to smoked marijuana (e.g., vaporization).

- Address and improve whenever possible the difficulty in blinding of marijuana and placebo treatments in clinical studies.

- Evaluate the effect of prior experience with marijuana with regard to the safety and tolerability of marijuana.

- Strive for gender balance in the subjects used in studies.

In conclusion, the eleven clinical studies conducted to date do not meet the criteria required by the FDA to determine if marijuana is safe and effective in specific therapeutic areas. However, the studies can serve as proof-of-concept studies and support further research into the use of marijuana in these therapeutic indications.

Additionally, the clinical outcome data and adverse event profiles reported in these published studies can beneficially inform how future research in this area is conducted. Finally, application of the recommendations listed above by investigators when designing future studies could greatly improve the available clinical data that can be used to determine if marijuana has validated and reliable medical applications.

## 1. Introduction

In response to citizen petitions submitted to the Drug Enforcement Administration (DEA) requesting DEA to reschedule marijuana, the DEA Administrator requested that the U.S. Department of Health and Human Services (HHS) provide a scientific and medical evaluation of the available information and a scheduling recommendation for marijuana, in accordance with 21 U.S.C. 811(b). The Secretary of HHS is required to consider in a scientific and medical evaluation eight factors determinative of control under the Controlled Substance Act (CSA). Administrative responsibilities for evaluating a substance for control under the CSA are performed by the Food and Drug Administration (FDA), with the concurrence of the National Institute on Drug Abuse (NIDA). Part of

<sup>27</sup> This Guidance is available on the internet at <http://www.fda.gov/Drugs/default.htm> under Guidance (Drugs).

this evaluation includes an assessment of whether marijuana has a currently accepted medical use in the United States. This assessment necessitated a review of the available data from published clinical studies to determine whether there is adequate scientific evidence of marijuana's effectiveness.

Under Section 202 of the CSA, marijuana is currently controlled as a Schedule I substance (21 U.S.C. 812). Schedule I includes those substances that have a high potential for abuse, have no currently accepted medical use in treatment in the United States, and lack accepted safety for use under medical supervision (21 U.S.C. 812(b)(1)(A)–(C)).

A drug product which has been approved by FDA for marketing in the United States is considered to have a "currently accepted medical use." Marijuana is not an FDA-approved drug product, as a New Drug Application (NDA) or Biologics License application (BLA) for marijuana has not been approved by FDA. However, FDA approval of an NDA is not the only means through which a drug can have a currently accepted medical use in the United States.

In general, a drug may have a "currently accepted medical use" in the United States if the drug meets a five-part test. Established case law (*Alliance for Cannabis Therapeutics v. DEA*, 15 F.3d 1131, 1135 (D.C. Cir. 1994)) upheld the Administrator of DEA's application of the five-part test to determine whether a drug has a "currently accepted medical use." The following describes the five elements that characterize "currently accepted medical use" for a drug:<sup>28</sup>

i. The drug's chemistry must be known and reproducible

"The substance's chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official compendia, as defined by section 201(j) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321(j), is sufficient to meet this requirement."

ii. there must be adequate safety studies

"There must be adequate pharmacological and toxicological studies, done by all methods reasonably applicable, on the basis of which it could fairly and responsibly be concluded, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, that the substance is safe for treating a specific, recognized disorder."

iii. there must be adequate and well-controlled studies proving efficacy

"There must be adequate, well-controlled, well-designed, well-conducted, and well-documented studies, including clinical investigations, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, on the basis of which it could be fairly and responsibly concluded by such experts that the substance will have the intended effect in treating a specific, recognized disorder."

iv. the drug must be accepted by qualified experts

"The drug has a New Drug Application (NDA) approved by the Food and Drug Administration, pursuant to the Food, Drug and Cosmetic Act, 21 U.S.C. 355. Or, a consensus of the national community of experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, accepts the safety and effectiveness of the substance for use in treating a specific, recognized disorder. A material conflict of opinion among experts precludes a finding of consensus." and

v. the scientific evidence must be widely available.

"In the absence of NDA approval, information concerning the chemistry, pharmacology, toxicology, and effectiveness of the substance must be reported, published, or otherwise widely available, in sufficient detail to permit experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, to fairly and responsibly conclude the substance is safe and effective for use in treating a specific, recognized disorder."

One way to pass the five-part test for having "currently accepted medical use" is through submission of an NDA or BLA which is approved by FDA. However, FDA approval of an NDA or BLA is not required for a drug to pass the five-part test.

This review focuses on FDA's analysis of one element of the five-part test for determining whether a drug has "currently accepted medical use". Specifically, the present review assesses the 3rd criterion that addresses whether marijuana has "adequate and well-controlled studies proving efficacy". Thus, this review evaluates published clinical studies that have been conducted using marijuana in subjects who have a variety of medical conditions by assessing the adequacy of the summarized study designs and the study data. The methodology for selecting the studies that were evaluated is delineated below.

FDA's evaluation and conclusions regarding the remaining four criteria for whether marijuana has a "currently accepted medical use," as well as the eight factors pertaining to the scheduling of marijuana, are outside the scope of this review. A detailed discussion of these factors is contained in FDA's scientific and medical evaluation of marijuana.

## 2. Methods

The methods for selecting the studies to include in this review involved the following steps, which are described in detail in the subsections below:

1. Define the objective of the review.
2. Define "marijuana" in order to facilitate the medical literature search for studies that administered the substance,
3. Define "adequate and well-controlled studies" in order to facilitate the search for relevant data and literature,
4. Search medical literature databases and identify relevant adequate and well-controlled studies, and
5. Review and analyze the adequate and well-controlled clinical studies to determine if they demonstrate efficacy of marijuana for any therapeutic indication.

### 2.1 Define the Objective of the Review

The objective of this review is to assess the study designs and resulting data from clinical studies published in the medical literature that were conducted with marijuana (as defined below) as a treatment for any therapeutic indication, in order to determine if they meet the criteria of "adequate and well-controlled studies proving efficacy".

### 2.2 Define "Marijuana"

In this review, the term "marijuana" refers to the flowering tops or leaves of the *Cannabis* plant. There were no restrictions on the route of administration used for marijuana in the studies.

Studies which administered individual cannabinoids (whether experimental substances or marketed drug products) or marijuana extracts were excluded from this review. Additionally, studies of administered neutral plant material or placebo marijuana (marijuana with all cannabinoids extracted) that had subsequently been supplemented by the addition of specific amounts of THC or other cannabinoids were also excluded (Chang et al., 1979).

<sup>28</sup> 57 FR 10499, 10504–06 (March 26, 1992).

### 2.3 Define “Adequate and Well-Controlled Clinical Studies”

The criteria for an “adequate and well-controlled study” for purposes of determining the safety and efficacy of a human drug is defined under the Code of Federal Regulations (CFR) in 21 CFR 314.126. The elements of an adequate and well-controlled study as described in 21 CFR 314.126 can be summarized as follows:

1. The main objective must be to assess a therapeutically relevant outcome.
2. The study must be placebo-controlled.
3. The subjects must qualify as having the medical condition being studied.
4. The study design permits a valid comparison with an appropriate control condition.
5. The assignment of subjects to treatment and control groups must be randomized.
6. There is minimization of bias through the use of a double-blind study design.
7. The study report contains a full protocol and primary data.
8. Analysis of the study data is appropriately conducted.

As noted above, the current review examines only those data available in the public domain and thus relies on clinical studies published in the medical literature. Published studies by their nature are summaries that do not include the level of detail required by studies submitted to FDA in an NDA.

While the majority of the elements defining an adequate and well-controlled study can be satisfied through a published paper (elements #1–6), there are two elements that cannot be met by a study published in the medical literature: element #7 (availability of a study report with full

protocol and primary data) and element #8 (a determination of whether the data analysis was appropriate). Thus, for purposes of this review, only elements #1–6 will be used to qualify a study as being adequate and well-controlled.

### 2.4 Search Medical Literature Databases and Identify Relevant Studies

We identified randomized, double-blind, placebo-controlled clinical studies conducted with marijuana to assess marijuana’s efficacy in any therapeutic indication. Two primary medical literature databases were searched for all studies posted to the databases prior to February 2013:<sup>29</sup>

- *PubMed*: PubMed is a database of published medical and scientific studies that is maintained by the U.S. National Library of Medicine (NLM) at NIH as a part of the Entrez system of information retrieval. PubMed comprises more than 24 million citations for biomedical literature from MEDLINE, life science journals, and online books (<http://www.ncbi.nlm.nih.gov/pubmed>).

- *ClinicalTrials.gov*: ClinicalTrials.gov is a database of publicly and privately supported clinical studies that is maintained by the NLM. Information about the clinical studies is provided by the Sponsor or Principal Investigator of the study. Information about the studies is submitted to the Web site (“registered”) when the studies begin, and is updated throughout the study. In some cases, results of the study or resulting publication citations are submitted to the Web site after the study ends


<sup>29</sup> While not a systematic review, we have followed the recent published literature on marijuana use for possible therapeutic purposes and, as of January 2015, we found only one new study that would meet our criteria (Naftali et al., 2013). This study examined the effects of smoked marijuana on Crohn’s disease.

(<https://clinicaltrials.gov/ct2/about-site/background>).

*ClinicalTrials.gov* was searched for all studies administering marijuana. The results of this search were used to confirm that no completed studies with published data were missed in the literature search. During the literature search, references found in relevant studies and systematic reviews were evaluated for additional relevant citations. All languages were included in the search. The PubMed search yielded a total of 566 abstracts.<sup>30</sup> Of these abstracts, a full-text review was conducted with 85 papers to assess eligibility. From this evaluation, only eleven of 85 studies met the 6 CFR elements for inclusion as adequate and well-controlled studies.

Figure 1 (below) provides an overview of the process used to identify studies from the PubMed search. The eleven studies reviewed were published between 1974 and 2013. Ten of these studies were conducted in the United States and one study was conducted in Canada. These eleven studies examined the effects of smoked and vaporized marijuana for the indications of chronic neuropathic pain, spasticity related to multiple sclerosis (MS), appetite stimulation in patients with human immunodeficiency virus (HIV), glaucoma, and asthma. All included studies used adult patients as subjects. All studies conducted in the United States were conducted under an IND as Phase 2 investigations.

<sup>30</sup> The following search strategy was used, “(cannabis OR marijuana) AND (therapeutic use OR therapy) AND (RCT OR randomized controlled trial OR “systematic review” OR clinical trial OR clinical trials) NOT (“marijuana abuse”[Mesh] OR addictive behavior OR substance related disorders)”.

**Figure 1: Identification of Studies from PubMed Search**

<sup>a</sup> Articles were deemed irrelevant if they examined safety or adverse event related outcomes, including psychoactive effects or other adverse events. <sup>b</sup> Excluded article types included comments, reviews, meta-analyses, and news articles. <sup>c</sup> Randomized Controlled Trials. <sup>d</sup> Cannabinoids administered included synthetic cannabinoids. <sup>e</sup> Rimonabant is a cannabinoid receptor antagonist. <sup>f</sup> An additional 2 studies meeting the inclusion criteria were found through the reference search.

Two qualifying studies, which assessed marijuana for glaucoma, were previously reviewed in the 1999 Institute of Medicine (IOM) report entitled “Marijuana and Medicine: Assessing the Science Base”.<sup>31</sup> We did our own analysis of these two studies and concurred with the conclusions in the IOM report. Thus, a detailed discussion of the two glaucoma studies is not included in the present review. The present review only discusses 9 of the identified 11 studies. For a summary of the study design for all eleven qualifying studies, see Tables 1–5 (located in the Appendix).

Based on the selection criteria for relevant studies described in Section 2.3

<sup>31</sup> In January 1997, the White House Office of National Drug Control Policy (ONDCP) requested that the IOM conduct a review of the scientific evidence to assess the potential health benefits and risks of marijuana and its constituent cannabinoids. Information for this study was gathered through scientific workshops, site visits to cannabis buyers’ clubs and HIV/Acquired Immunodeficiency Syndrome (AIDS) clinics, analysis of the relevant scientific literature, and extensive consultation with biomedical and social scientists. The report was finalized and published in 1999.

(Define Adequate and Well-Controlled Clinical Studies), a number of clinical studies that investigated marijuana, as defined in this review, were excluded from this review. Studies that examined the effects of marijuana in healthy subjects were excluded because they did not test a patient population with a medical condition (Flom et al., 1975; Foltin et al., 1986; Foltin et al., 1988; Hill et al., 1974; Milstein et al., 1974; Milstein et al., 1975; Soderpalm et al., 2001; Wallace et al., 2007; Greenwald and Stitzer, 2000). A 1975 study by Tashkin et al. was excluded because it had a single-blind, rather than double-blind, study design. Two other studies were excluded because the primary outcome measure assessed safety rather than a therapeutic outcome (Greenberg et al., 1994; Abrams et al., 2003).

### 2.5 Review and Analyze Qualifying Clinical Studies

Qualified clinical studies that evaluated marijuana for therapeutic purposes were examined in terms of adequacy of study design including method of drug administration, study

size, and subject inclusion and exclusion criteria. Additionally, the measures and methods of analysis used in the studies to assess the treatment effect were examined.

## 3. Results and Discussion

The eleven qualifying studies in this review assessed a variety of therapeutic indications. In order to better facilitate analysis and discussion of the studies, the following sections group the studies by therapeutic area. Within each section, each individual study is summarized in terms of its design, outcome data and important limitations. This information is also provided in the Appendix in tabular form for each study.

### 3.1 Neuropathic Pain

Five randomized, double-blind, placebo-controlled Phase 2 clinical studies have been conducted to examine the effects of inhaled marijuana smoke on neuropathic pain associated with HIV-sensory neuropathy (Abrams et al., 2007; Ellis et al., 2009) and chronic neuropathic pain from multiple causes

(Wilsey et al., 2008; Ware et al., 2010; Wilsey et al., 2013). Table 1 of the Appendix summarizes these studies.

### 3.1.1 Neuropathic Pain Associated With HIV-Sensory Neuropathy

Two studies examined the effect of marijuana to reduce the pain induced by HIV-sensory neuropathy.

Abrams et al. (2007) conducted the first study entitled, “Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial”. The subjects were 50 adult patients with uncontrolled HIV-associated sensory neuropathy, who had at least 6 experiences with smoking marijuana. The subjects were split into two parallel groups of 25 subjects each. More than 68% of subjects were current marijuana users, but all individuals were required to discontinue using marijuana prior to the study. Most subjects were taking medication for pain during the study, with the most common medications being opioids and gabapentin. Upon entry into the study, subjects had an average daily pain score of at least 30 on a 0–100 visual analog scale (VAS).

Subjects were randomized to receive either smoked marijuana (3.56% THC<sup>32</sup>) or smoked placebo cigarettes three times per day for 5 days, using a standardized cued smoking procedure: (1) 5 second inhale, (2) 10 second holding smoke in the lungs, (3) 40 second exhale and breathing normally between puffs. The authors did not specify how many puffs the subjects smoked at each smoking session, but they stated that one cigarette was smoked per smoking session.

Primary outcome measures included daily VAS ratings of chronic pain and the percentage of subjects who reported a result of more than 30% reduction in pain intensity. The ability of smoked marijuana to induce acute analgesia was assessed using both thermal heat model and capsaicin sensitization model, while anti-hyperalgesia was assessed with brush and von Frey hair stimuli. The immediate analgesic effects of smoked marijuana was assessed using a 0–100 point VAS at 40-minute intervals three times before and three times after the first and last smoking sessions, which was done to correspond to the time of peak plasma cannabinoid levels. Notably, not all subjects completed the induced pain portion of the study ( $n = 11$  in marijuana group, 9 in placebo

group) because of their inability to tolerate the stimuli. Throughout the study, subjects also completed the Profile of Mood States (POMS) questionnaire, as well as subjective VAS measures of anxiety, sedation, disorientation, paranoia, confusion, dizziness, and nausea.

As a result, the median daily pain was reduced 34% by smoked marijuana compared to 17% by placebo ( $p = 0.03$ ). Fifty-two percent of subjects who smoked marijuana reported a >30% reduction in pain compared to 24% in the placebo group ( $p = 0.04$ ). Although marijuana reduced experimentally-induced hyperalgesia ( $p \leq 0.05$ ) during the first smoking sessions, marijuana did not alter responses to acutely painful stimuli.

There were no serious AEs and no episodes of hypertension, hypotension, or tachycardia requiring medical intervention. No subjects withdrew from the study for drug related reasons. Subjects in the marijuana group reported higher ratings on the subjective measures of anxiety, sedation, disorientation, confusion, and dizziness compared to the placebo group. There was one case of severe dizziness in a marijuana-treated subject. By the end of the study, subjects treated with marijuana and placebo reported a reduction in total mood disturbance as measured by POMS.

The authors conclude that smoked marijuana effectively reduced chronic neuropathic pain from HIV-associated sensory neuropathy with tolerable side effects. However, limitations of this study include: Maintenance of subjects on other analgesic medication while being tested with marijuana and a lack of information about the number of puffs during each inhalation of smoke. These limitations make it difficult to conclude that marijuana has analgesic properties on its own and that the actual AEs experienced during the study in response to marijuana are tolerable. However, the study produced positive results suggesting that marijuana should be studied further as an adjunct treatment for uncontrolled HIV-associated sensory neuropathy.

Ellis et al. (2009) conducted a more recent study entitled “Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial”. The subjects were 28 HIV-positive adult male patients with intractable neuropathic pain that was refractory to the effects of at least two drugs taken for analgesic purposes. Upon entry into the study, subjects had a mean score of >5 on the Pain Intensity subscale of the Descriptor Differential Scale (DDS). Subjects were allowed to

continue taking their current routine of pain medications, which included opioids, non-narcotic analgesics, antidepressants, and anticonvulsants. Previous experience with marijuana was not required for participation in the study, but 27 of 28 subjects (96%) reported previous experience with marijuana. However, of these 27 experienced subjects, 63% ( $n = 18$ ) reported no marijuana use within the past year.

The study procedures compared the effects of the target dose of marijuana and placebo during two treatment periods lasting 5 days, with 2 weeks washout periods. The marijuana strengths available were 1%, 2%, 4%, 6%, or 8% THC concentration by weight. Subjects smoked marijuana or placebo cigarettes four times per day, approximately 90–120 minutes apart, using a standardized cued smoking procedure: (1) 5 second smoke inhalation, (2) 10 second hold of smoke in lungs, (3) 40 second exhale and normal breathing between puffs. The investigators did not provide a description of the number of puffs taken at any smoking session. All subjects practiced the smoking procedures using placebo marijuana prior to test sessions.

On the first day of each test period, dose titration occurred throughout the four smoking sessions scheduled for that day, with a starting strength of 4% THC concentration. Subjects were allowed to titrate to a personalized “target dose”, which was defined as the dose that provided the best pain relief without intolerable adverse effects. This dose titration was accomplished by allowing subjects to either increase the dose incrementally (to 6% or 8% THC) to improve analgesia, or to decrease the dose incrementally (to 1% or 2% THC) if AEs were intolerable. For the next 4 days of each test period, the subjects smoked their target dose during each of the four daily smoking sessions. To maintain the blind, placebo marijuana was represented as containing 1%–8% THC, even though it did not contain any cannabinoids.

The primary outcome measure was the change in pain magnitude on the DDS at the end of each test period compared to baseline, with a clinically significant level of analgesia considered to be a reduction in pain of at least 30%. Additional measures included the POMS, the Sickness Impact Profile (SIP), the Brief Symptom Inventory (BSI) and the UKU Side Effect Rating Scale and a subjective highness/sedation VAS.

During the marijuana treatment week, 19 subjects titrated to the 2%–4% THC dose while the 6%–8% dose was

<sup>32</sup> The drug dose is reported as percentage of THC present in the marijuana rather than milligrams of THC present in each cigarette because of the difficulty in determining the amount of THC delivered by inhalation (see discussion in the section entitled “3.7.2 Marijuana Dose Standardization”).

preferred by 8 subjects and 1 subject chose the 1% dose. In contrast, during the placebo treatment week, all 28 subjects titrated to the highest possible dose of “8% THC” that contained no actual cannabinoids, suggesting that placebo treatment provided little analgesic relief.

The degree of pain reduction was significantly greater after administration of marijuana compared to placebo (median change of 3.3 points on DDS,  $p = 0.016$ ). The median change from baseline in VAS pain scores was  $-17$  for marijuana treatment compared to  $-4$  for placebo treatment ( $p < 0.001$ ). A larger proportion of subjects who were treated with marijuana (0.46) reported a  $>30\%$  reduction in pain, compared to placebo (0.18). Additionally, the authors report improvements in total mood disturbance, physical disability, and quality of life as measured on POMS, SIP, and BSI scales after both placebo and marijuana treatment (data not provided in paper).

In terms of safety, there were no alterations in HIV disease parameters in response to marijuana or placebo. The authors report that marijuana led to a greater degree of UKU responses as well as AEs such as difficulty in concentration, fatigue, sleepiness or sedation, increased duration of sleep, reduced salivation and thirst compared to placebo (data not provided in paper). Two subjects withdrew from the study because of marijuana-related AEs: one subject developed an intractable smoking-related cough during marijuana administration and the sole marijuana-naïve subject in the study experienced an incident of acute cannabis-induced psychosis.<sup>33</sup>

The authors conclude that smoked marijuana effectively reduced chronic neuropathic pain from HIV-associated sensory neuropathy. The limitations of this study include: a lack of information about the number of puffs during each inhalation of smoke; a lack of information about the specific timing of the subjective assessments and collection of AEs relative to initiation of the smoking sessions; and the inclusion of only one marijuana-naïve subject. These limitations make it difficult to conclude that the actual AEs experienced during the study in

response to marijuana are tolerable. It is especially concerning that the only marijuana-naïve subject left the study because of serious psychiatric responses to marijuana exposure at analgesic doses. However, the study produced positive results suggesting that marijuana should be studied further as an adjunct treatment for uncontrolled HIV-associated sensory neuropathy.

### 3.1.2 Central and Peripheral Neuropathic Pain

Three studies examined the effect of marijuana on chronic neuropathic pain.

Wilsey et al. (2008) examined chronic neuropathic pain from multiple causes in the study entitled, “A Randomized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in Neuropathic Pain”. The subjects were 32 patients with a variety of neuropathic pain conditions, including 22 with complex regional pain syndrome, 6 with spinal cord injury, 4 with multiple sclerosis, 3 with diabetic neuropathy, 2 with ilioinguinal neuralgia, and 1 with lumbosacral plexopathy. All subjects reported a pain intensity of at least 30 on a 0–100 VAS and were allowed to continue taking their regular medications during the study period, which included opioids, antidepressants, anticonvulsants, and NSAIDs. All subjects were required to have experience with marijuana but could not use any cannabinoids for 30 days before study sessions.

The study consisted of three test sessions with an interval of 3–21 days between sessions. Treatment conditions were high-strength marijuana (7% delta-9-THC), low-strength marijuana (3.5% delta-9-THC), and placebo cigarettes, administered through a standardized cued-puff procedure: (1) “light the cigarette” (30 seconds), (2) “get ready” (5 seconds), (3) “inhale” (5 seconds), (4) “hold smoke in lungs” (10 seconds), (5) “exhale,” and (6) wait before repeating the puff cycle (40 seconds). Participants took 2 puffs after baseline measurements, 3 puffs an hour later, and 4 puffs an hour after that, for a cumulative dose of 9 puffs per test session.

Hourly assessment periods were scheduled before and after each set of puffs and for 2 additional hours during the recovery period. Plasma cannabinoids were measured at baseline, 5 minutes after the first puff and again at 3 hours after the last puff cycle.

The primary outcome measure was spontaneous pain relief, as measured by a 0–100 point VAS for current pain. Pain unpleasantness was measured on a 0–100 point VAS, and degree of pain

relief was measured on a 7-point Patient Global Impression of Change (PGIC) scale. Secondary measures included the Neuropathic Pain Scale (NPS), a 0–100 point VAS for allodynia, and changes in thermal pain threshold. Subjective measures were also evaluated with unipolar 0–100 point VAS for any drug effect, good drug effect, bad drug effect, high, drunk, impaired, stoned, like the drug effect, sedated, confused, nauseated, desire more of the drug, anxious, down, hungry, and bipolar 0–100 point VAS for sad/happy, anxious/relaxed, jittery/calm, bad/good, paranoid/self-assured, fearful/unafraid. Neurocognitive assessments measured attention and concentration, learning and memory, and fine motor speed.

Marijuana produced a reduction in pain compared to placebo, as measured by the pain VAS, the PGIC and on pain descriptors in the NPS, including sharp ( $P < .001$ ), burning ( $P < .001$ ), aching ( $P < .001$ ), sensitive ( $P = .03$ ), superficial ( $P < .01$ ) and deep pain ( $P < .001$ ). Notably, there were no additional benefits from the 7% THC strength of marijuana compared to the 3.5% THC strength, seemingly because of cumulative drug effects over time. There were no changes in allodynia or thermal pain responsivity following administration of either dose of marijuana.

Marijuana at both strengths produced increases on measures of any drug effect, good drug effect, high, stoned, impairment, sedation, confusion, and hunger. The 7% THC marijuana increased anxiety scores and bad drug effect (later in session) compared to placebo. Neither strength of marijuana affected the measures of mood. On neurocognitive measures, both the 3.5% THC and 7% THC marijuana produced impairment in learning and memory, while only the 7% THC marijuana impaired attention and psychomotor speed, compared to placebo. There were no adverse cardiovascular side effects and no subjects dropped out because of an adverse event related to marijuana.

The authors conclude that marijuana may be effective at ameliorating neuropathic pain at doses that induce mild cognitive effects, but that smoking is not an optimum route of administration. The limitations of this study include: Inclusion of subjects with many forms of neuropathic pain and maintenance of subjects on other analgesic medication while being tested with marijuana. These limitations make it difficult to conclude that marijuana has analgesic properties on its own and that the actual AEs experienced during the study in response to marijuana are tolerable. The authors compared pain score results by the type of pain

<sup>33</sup> At the time of the study, the following criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR, 2000) were used to diagnose substance-induced psychotic disorders: Prominent hallucinations or delusions; Hallucinations and/or delusions that develop during, or within one month of, intoxication or withdrawal; The disturbance is not better accounted for by a psychotic disorder that is not substance induced. The disturbance does not occur exclusively during the course of a delirium.



condition, with no significant differences found; however, the sample size of this study was small thus a type II error may have been present. Thus, it is difficult to determine if any particular subset of neuropathic pain conditions would benefit specifically from marijuana administration. However, the study produced positive results suggesting that marijuana should be studied further as an adjunct treatment for uncontrolled neuropathic pain.

The second study, conducted by Ware et al. (2010) in Canada is entitled, "Smoked cannabis for chronic neuropathic pain: a randomized controlled trial". The subjects were 21 adult patients with neuropathic pain caused by trauma or surgery compounded with allodynia or hyperalgesia, and a pain intensity score greater than 4 on a 10 point VAS. All subjects maintained their current analgesic medication and they were allowed to use acetaminophen for breakthrough pain. Eighteen subjects had previous experience with marijuana but none of them had used marijuana within a year before the study.

The study design used a four-period crossover design, testing marijuana (2.5%, 6.0% and 9.4% THC) and placebo marijuana. The 2.5% and 6.0% doses of marijuana were included to increase successful blinding. Each period was 14 days in duration, beginning with 5 days on the study drug followed by a 9-day washout period. Doses were delivered as 25 mg of marijuana that was smoked in a single inhalation using a titanium pipe. The first dose of each period was self-administered using a standardized puff procedure: (1) Inhale for 5 seconds, (2) hold the smoke in their lungs for 10 seconds, and (3) exhale. Subsequent doses were self-administered in the same manner for a total of three times daily at home on an outpatient basis for the first five days of each period.

The primary measure was an 11-point pain intensity scale, averaged over the 5 day treatment period, which was administered once daily for present, worst, least and average pain intensity during the previous 24 hours. Secondary measures included an acute pain 0–100 point VAS, pain quality assessed with the McGill Pain Questionnaire, sleep assessed with the Leeds Sleep Evaluation Questionnaire, mood assessed with the POMS, quality of life assessed using the EQ-5D health outcome instrument. Subjective measures included 0–100 point VAS scales for high, relaxed, stressed and happy.

Over the first three hours after smoking marijuana, ratings of pain,

high, relaxation, stress, happiness and heart rate were recorded. During the five days of each study period, participants were contacted daily to administer questionnaires on pain intensity, sleep, medication and AEs. Subjects returned on the fifth day to complete questionnaires on pain quality, mood, quality of life and assessments of potency. At the end of the study, participants completed final adverse event reports and potency assessments.

The average daily pain intensity was significantly lower on 9.4% THC marijuana (5.4) than on placebo marijuana (6.1) ( $p = 0.023$ ). The 9.4% THC strength also produced more drowsiness, better sleep, with less anxiety and depression, compared to placebo (all  $p < 0.05$ ). However, there were no significant differences on POMS scores or on VAS scores for high, happy, relaxed or stressed between THC doses.

The most frequent drug-related adverse events reported in the group receiving 9.4% THC marijuana were headache, dry eyes, burning sensation, dizziness, numbness and cough. Reports of high and euphoria occurred on only three occasions, once in each dose of THC. There were no significant changes in vital signs, heart-rate variability, or renal function. One subject withdrew from the study due to increased pain during administration of 6% THC marijuana.

The authors conclude that smoked marijuana reduces neuropathic pain, improves mood and aids in sleep, but that smoking marijuana is not a preferable route of administration. The limitations of this study include: The lack of information on timing of assessments during the outpatient portion of the study and maintenance of subjects on other analgesic medication while being tested with marijuana. These limitations make it difficult to conclude that marijuana has analgesic properties on its own and that the actual AEs experienced during the study in response to marijuana are tolerable. However, the study produced positive results suggesting that marijuana should be studied further as an adjunct treatment for uncontrolled neuropathic pain.

Wilsey et al. (2013) conducted the most recent study entitled, "Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain". This study is the only one in this review that utilized vaporization as a method of marijuana administration. The subjects were 36 patients with a neuropathic pain disorder (CRPS, thalamic pain, spinal cord injury, peripheral neuropathy, radiculopathy, or nerve

injury) who were maintained on their current medications (opioids, anticonvulsants, antidepressants, and NSAIDs). Although subjects were required to have a history of marijuana use, they refrained from use of cannabinoids for 30 days before study sessions.

Subjects participated in three sessions in which they received 1.29% or 3.53% THC marijuana or placebo marijuana. The marijuana was vaporized using the Volcano vaporizer and a standardized cued-puff procedure: (1) "hold the vaporizer bag with one hand and put the vaporizer mouthpiece in their mouth" (30 seconds), (2) "get ready" (5 seconds), (3) "inhale" (5 seconds), (4) "hold vapor in lungs" (10 seconds), (5) "exhale and wait" before repeating puff cycle (40 seconds). Subjects inhaled 4 puffs at 60 minutes. At 180 minutes, the vaporizer was refilled with marijuana vapor and subjects were allowed to inhale 4 to 8 puffs using the cued procedure. Thus, cumulative dosing allowed for a range of 8 to 12 puffs in total for each session, depending on the subjects desired response and tolerance. The washout time between each session ranged from 3–14 days.

The primary outcome variable was spontaneous pain relief, as assessed using a 0–100 point VAS for current pain. Secondary measures included the Patient Global Impression of Change (PGIC), the Neuropathic Pain Scale (NPS), a 0–100 point VAS for allodynia. Acute pain threshold was measured with a thermal pain model. Subjective measures included 0–100 point unipolar VAS for any drug effect, good drug effect, bad drug effect, high, drunk, impaired, stoned, drug liking, sedated, confused, nauseated, desire more drug, anxious, down and hungry. Bipolar 0–100 point VAS included sad/happy, anxious/relaxed, jittery/calm, bad/good, paranoid/self-assured, and fearful/unafraid.

Neurocognitive assessments assessed attention and concentration, learning and memory, and fine motor speed.

A 30% reduction in pain was achieved in 61% of subjects who received the 3.53% THC marijuana, in 57% of subjects who received the 1.29% THC marijuana and in 26% of subjects who received the placebo marijuana ( $p = 0.002$  for placebo vs. 3.53% THC,  $p = 0.007$  for placebo vs 1.29% THC;  $p \leq 0.05$  1.29% THC vs. 3.53% THC). Both strengths of marijuana significantly decreased pain intensity, unpleasantness, sharpness, and deepness on the NPS, as well as pain ratings on the PGIC, compared to placebo. These effects on pain were maximal with cumulative dosing over

the course of the study session, with maximal effects at 180 minutes. There were no effects of marijuana compared to placebo on measures of allodynia or thermal pain. Subjects correctly identified the study treatment 63% of the time for placebo, 61% of the time for 1.29% THC, and 89% of the time for 3.53% THC.

On subjective measures, marijuana produced dose-dependent increases compared to placebo on ratings for: any drug effect, good drug effect, drug liking, high, stoned, sedated, confused, and hungry. Both strengths of marijuana produced similar increases in drunk or impaired compared to placebo. In contrast, desire for drug was rated as higher for the 1.29% THC marijuana compared to the 3.53% THC marijuana. There were no changes compared to placebo for bad effect, nausea, anxiety, feeling down or any of the bipolar mood assessments. There was dose-dependent impairment on learning and memory from marijuana compared to placebo, but similar effects between the two strengths of marijuana on attention.

The authors conclude that vaporization of relatively low doses of marijuana can produce improvements in analgesia in neuropathic pain patients, especially when patients are allowed to titrate their exposure. However, this individualization of doses may account for the general lack of difference between the two strengths of marijuana. No data were presented regarding the total amount of THC consumed by each subject, so it is difficult to determine a proper dose-response evaluation. Additional limitations of this study are the inclusion of subjects with many forms of neuropathic pain and maintenance of subjects on other analgesic medication while being tested with marijuana. These limitations make it difficult to conclude that marijuana has analgesic properties on its own. It is also difficult to determine if any particular subset of neuropathic pain conditions would benefit specifically from marijuana administration. However, the study produced positive results suggesting that marijuana should be studied further as an adjunct treatment for uncontrolled neuropathic pain.

### 3.2 Appetite Stimulation in HIV

Two randomized, double-blind, placebo-controlled Phase 2 studies examined the effects of smoked marijuana on appetite in HIV-positive subjects (Haney et al., 2005; Haney et al., 2007). Table 2 of the Appendix summarizes both studies.

The first study, conducted by Haney et al. (2005) is entitled, “Dronabinol and marijuana in HIV+ marijuana smokers: Acute effects on caloric intake and mood”. The subjects were 30 HIV-positive patients who were maintained on two antiretroviral medications and either had clinically significant decreases in lean muscle mass<sup>34</sup> (low-BIA group, n = 15) or normal lean muscle mass (normal-BIA group, n = 15). All subjects had a history of smoking marijuana at least twice weekly for 4 weeks prior to entry into the study. On average, individuals had smoked 3 marijuana cigarettes per day, 5–6 times per week for 10–12 years.

Subjects participated in 8 sessions that tested the acute effects of 0, 10, 20, and 30 mg dronabinol oral capsules and marijuana cigarettes with 0%, 1.8%, 2.8%, and 3.9% THC concentration by weight, using a double-dummy design (with only one active drug per session). The doses of dronabinol are higher than those doses typically prescribed for appetite stimulation in order to help preserve the blinding. There was a one-day washout period between test sessions.

Marijuana was administered using a standardized cued procedure: (1) “light the cigarette” (30 seconds), (2) “prepare” (5 seconds), (3) “inhale” (5 seconds), (4) “hold smoke in lungs” (10 seconds), and (5) “exhale.” Each subject smoked three puffs in this manner, with a 40-second interval between each puff.

Caloric intake was used as a surrogate measure for weight gain. Subjects received a box containing a variety of food and beverage items and were told to record consumption of these items following that day’s administration of the test drug. Subjective measures included 0–100 point VAS for feel drug effect, good effect, bad effect, take drug again, drug liking, hungry, full, nauseated, thirsty, desire to eat. Neurocognitive measures and vital signs were monitored.

The low BIA group consumed significantly more calories in the 1.8% and 3.9% THC marijuana conditions ( $p < 0.01$ ) and the 10, 20, and 30 mg dronabinol conditions ( $p < 0.01$ ) compared with the placebo condition. In contrast, in the normal BIA group, neither marijuana nor dronabinol significantly affected caloric intake. This lack of effect may be accountable, however, by the fact that this group consumed approximately 200 calories

more than the low BIA group under baseline conditions.

Ratings of high and good drug effect were increased by all drug treatments in both the low-BIA and normal-BIA groups, except in response to the 10 mg dose of dronabinol. The 3.9% THC marijuana increased ratings of good drug effect, drug liking and desire to smoke again compared with placebo. Ratings of sedation were increased in both groups by 10 and 30 mg dronabinol, and in the normal BIA group by the 2.8% THC marijuana. Ratings of stimulation were increased in the normal BIA group by 2.8% and 3.9% THC marijuana and by 20 mg dronabinol. Increases in ratings of forgetfulness, withdrawn, dreaming, clumsy, heavy limbs, heart pounding, jittery, and decreases in ratings of energetic, social, and talkative were reported in the normal BIA group with 30 mg dronabinol. There were no significant changes in vital signs or performance on neurocognitive measures in response to marijuana. Notably, the time course of subjective effects peaked quickly and declined thereafter for smoked marijuana, while oral dronabinol responses took longer to peak and persisted longer. Additionally, marijuana but not dronabinol produced dry mouth and thirst.

In general, AEs reported in this study were low in both drug conditions for both subject groups. In the low BIA group, nausea was reported by one subject in both the 10 and 20 mg dronabinol conditions, while an uncomfortable level of intoxication was produced by the 30 mg dose in two subjects. There were no AEs reported in this group following marijuana at any dose. In the normal BIA group, the 30 mg dose of dronabinol produced an uncomfortable level of intoxication in three subjects and headache in one subject, while the 3.9% marijuana produced diarrhea in one subject.

The authors conclude that smoked marijuana can acutely increase caloric intake in low BIA subjects without significant cognitive impairment. However, it is possible that the low degree of cognitive impairment reported in this study may reflect the development of tolerance to cannabinoids in this patient population, since all individuals had current histories of chronic marijuana use. Additional limitations in this study include not utilizing actual weight gain as a primary measure. However, the study produced positive results suggesting that marijuana should be studied further as a treatment for appetite stimulation in HIV patients.

<sup>34</sup> Lean muscle mass was assessed using bioelectrical impedance analysis (BIA). The low-BIA group was classified with having <90% BIA, and the normal-BIA group was classified with having >90% BIA.

A second study conducted by Haney et al. (2007) is entitled, "Dronabinol and marijuana in HIV-positive marijuana smokers: Caloric intake, mood, and sleep". The design of this study was nearly identical to the one conducted by this laboratory in 2005 (see above), but there was no stratification of subjects by BIA. The subjects were 10 HIV-positive patients who were maintained on two antiretroviral medications and had a history of smoking marijuana at least twice weekly for 4 weeks prior to entry into the study. On average, individuals had smoked 3 marijuana cigarettes per day, 5 times per week for 19 years.

Subjects participated in 8 sessions that tested the acute effects of 0, 5 and 10 mg dronabinol oral capsules and marijuana cigarettes with 0, 2.0% and 3.9% THC concentration by weight, using a double-dummy design (with 4 sessions involving only one active drug and 4 interspersed placebo sessions). Both drug and placebo sessions lasted for 4 days each, with active drug administration occurring 4 times per day (every 4 hours). Testing occurred in two 16-day inpatient stays. In the intervening outpatient period, subjects were allowed to smoke marijuana prior to re-entry to the study unit for the second inpatient stay.

Marijuana was administered using a standardized cued procedure: (1) "light the cigarette" (30 seconds), (2) "prepare" (5 seconds), (3) "inhale" (5 seconds), (4) "hold smoke in lungs" (10 seconds), and (5) "exhale." Each subject smoked three puffs in this manner, with a 40-second interval between each puff.

Caloric intake was used as a surrogate measure for weight gain, but subjects were also weighed throughout the study (a measure which was not collected in the 2005 study by this group). Subjects received a box containing a variety of food and beverage items and were told to record consumption of these items following that day's administration of the test drug. Subjective measures included 0–100 point VAS for drug effect, good effect, bad effect, take drug again, drug liking, hungry, full, nauseated, thirsty, desire to eat. Neurocognitive measures and vital signs were monitored. Sleep was assessed using both the Nightcap sleep monitoring system and selected VAS measures related to sleep.

Both 5 and 10 mg dronabinol ( $p < 0.008$ ) and 2.0% and 3.9% THC marijuana ( $p < 0.01$ ) dose-dependently increased caloric intake compared with placebo. This increase was generally accomplished through increases in incidents of eating, rather than an increase in the calories consumed in each incident. Subjects also gained

similar amounts of weight after the highest dose of each cannabinoid treatment: 1.2 kg (2.6 lbs) after 4 days of 10 mg dronabinol, and 1.1 kg (2.4 lbs) after 4 days of 3.9% THC marijuana. The 3.9% THC marijuana dose also increased the desire to eat and ratings of hunger.

Ratings of good drug effect, high, drug liking, and desire to smoke again were significantly increased by 10 mg dronabinol and 2.0% and 3.9% THC marijuana doses compared to placebo. Both marijuana doses increased ratings of stimulated, friendly, and self-confident. The 10 mg dose of dronabinol increased ratings of concentration impairment, and the 2.0% THC marijuana dose increased ratings of anxious. Dry mouth was induced by 10 mg dronabinol (10 mg) and 2.0% THC marijuana. There were no changes in neurocognitive performance or objective sleep measures from administration of either cannabinoid. However, 3.9% THC marijuana increased subjective ratings of sleep.

The authors conclude that both dronabinol and smoked marijuana increase caloric intake and produce weight gain in HIV-positive patients. However, it is possible that the low degree of cognitive impairment reported in this study may reflect the development of tolerance to cannabinoids in this subject population, since all individuals had current histories of chronic marijuana use. This study produced positive results suggesting that marijuana should be studied further as a treatment for appetite stimulation in HIV patients.

### 3.3 Spasticity in Multiple Sclerosis

Only one randomized, double-blind, placebo-controlled Phase 2 study examined the effects of smoked marijuana on spasticity in MS.

This study was conducted by Corey-Bloom et al. (2012) and is entitled, "Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial". The subjects were 30 patients with MS-associated spasticity and had moderate increase in tone (score  $\geq 3$  points on the modified Ashworth scale). Participants were allowed to continue other MS medications, with the exception of benzodiazepines. Eighty percent of subjects had a history of marijuana use and 33% had used marijuana within the previous year.

Subjects participated in two 3-day test sessions, with an 11 day washout period. During each test session they smoked a 4.0% THC marijuana cigarette once per day or a placebo cigarette once per day. Smoking occurred through a

standardized cued-puff procedure: (1) Inhalation for 5 seconds, (2) breath-hold and exhalation for 10 seconds, (3) pause between puffs for 45 seconds. Subjects completed an average of four puffs per cigarette.

The primary outcome measure was change in spasticity on the modified Ashworth scale. Additionally, subjects were assessed using a VAS for pain, a timed walk, and cognitive tests (Paced Auditory Serial Addition Test) and AEs.

Treatment with 4.0% THC marijuana reduced subject scores on the modified Ashworth scale by an average of 2.74 points more than placebo ( $p < 0.0001$ ) and reduced VAS pain scores compared to placebo ( $p = 0.008$ ). Scores on the cognitive measure decreased by 8.7 points more than placebo ( $p = 0.003$ ). However, marijuana did not affect scores for the timed walk compared to placebo. Marijuana increased rating of feeling high compared to placebo.

7 subjects did not complete the study due to adverse events (two subjects felt uncomfortably "high", two had dizziness and one had fatigue). Of those 7 subjects who withdrew, 5 had little or no previous experience with marijuana. When the data were re-analyzed to include these drop-out subjects, with the presumption they did not have a positive response to treatment, the effect of marijuana was still significant on spasticity.

The authors conclude that smoked marijuana had usefulness in reducing pain and spasticity associated with MS. It is concerning that marijuana-naïve subjects dropped out of the study because they were unable to tolerate the psychiatric AEs induced by marijuana. The authors suggest that future studies should examine whether different doses can result in similar beneficial effects with less cognitive impact. However, the current study produced positive results suggesting that marijuana should be studied further as an adjunct treatment for spasticity in MS patients.

### 3.4 Asthma

Tashkin et al. (1974) examined bronchodilation in 10 subjects with bronchial asthma in the study entitled, "Acute Effects of Smoked Marijuana and Oral  $\Delta^9$ -Tetrahydrocannabinol on Specific Airway Conductance in Asthmatic Subjects". The study was a double-blind, placebo-controlled, crossover design. All subjects were clinically stable at the time of the study; four subjects were symptom free, and six subjects had chronic symptoms of mild to moderate severity. Subjects were tested with 0.25ml of isoproterenol HCl prior to the study to ensure they responded to bronchodilator

medications. Subjects were not allowed to take bronchodilator medication within 8 hours prior to the study. Previous experience with marijuana was not required for participation in the study, but 7 of the 10 subjects reported previous use of marijuana at a rate of less than 1 marijuana cigarette per month. No subjects reported marijuana use within 7 days of the study.

The study consisted of four test sessions with an interval of at least 48 hours between sessions. On two test sessions subjects smoked 7 mg/kg of body weight of either marijuana, with 2% THC concentration by weight, or placebo marijuana. During the other two test sessions, subjects ingested capsules with either 15 mg of synthetic THC or placebo. Marijuana was administered using a uniform smoking technique: subjects inhaled deeply for 2–4 seconds, held smoke in lungs for 15 seconds, and resumed normal breathing for approximately 5 seconds. The author did not provide a description of the number of puffs taken at any smoking session. The authors state that the smoking procedure was repeated until the cigarette was consumed, which took approximately 10 minutes.

The outcome measure used was specific airway conductance (SGaw), as calculated using measurements of thoracic gas volume (TGV) and airway resistance (Raw) using a variable-pressure body plethysmograph. Additionally, an assessment of degree of intoxication was administered only to those subjects reporting previous marijuana use. This assessment consisted of subjects rating “how ‘high’ they felt” on a scale of 0–7, 7 representing “the ‘highest’ they had ever felt after smoking marijuana”.

Marijuana produced a significant increase of 33–48% in average SGaw compared to both baseline and placebo ( $P < 0.05$ ). This significant increase in SGaw lasted for at least 2 hours after administration. The average TGV significantly decreased by 4–13% compared to baseline and placebo ( $P < 0.05$ ). The author stated that all subjects reported feelings of intoxication after marijuana administration.

The authors conclude that marijuana produced bronchodilation in clinically stable asthmatic subjects with minimal to moderate bronchospasms. Study limitations include: inclusion of subjects with varying severity of asthmatic symptoms, use of SGaw to measure lung responses to marijuana administration, and administration of smoke to asthmatic subjects. Smoke delivers a number of harmful substances and is not an optimal delivery symptom, especially for asthmatic patients. FEV1

via spirometry is the gold standard to assess changes in lung function, pre and post asthma treatment, by pharmacotherapy. SGaw has been shown to be a valid tool in bronchoconstriction lung assessment; however, since the FEV1 method was not utilized, it is unclear whether these results would correlate if the FEV1 method had been employed.

### 3.5 Glaucoma

Two randomized, double-blind, placebo-controlled Phase 2 clinical studies examined smoked marijuana in glaucoma (Crawford and Merritt, 1979; Merritt et al., 1980). In both studies, intraocular pressure (IOP) was significantly reduced 30 minutes after smoking marijuana. Maximal effects occurred 60–90 minutes after smoking, with IOP returning to baseline within 3–4 hours. These two studies were included in the 1999 IOM report on the medical uses of marijuana. Because our independent analysis of these studies concurred with the conclusions from the 1999 IOM report, these studies will not be discussed in further detail in this review. No recent studies have been conducted examining the effect of inhaled marijuana on IOP in glaucoma patients. This lack of recent studies may be attributed to the conclusions made in the 1999 IOM report that while cannabinoids can reduce intraocular pressure (IOP), the therapeutic effects require high doses that produce short-lasting responses, with a high degree of AEs. This high degree of AEs means that the potential harmful effects of chronic marijuana smoking may outweigh its modest benefits in the treatment of glaucoma.

### 3.6 Conclusions

Of the eleven randomized, double-blind, placebo-controlled Phase 2 clinical studies that met the criteria for review (see Sections 2.2 and 2.3), ten studies administered marijuana through smoking, while one study utilized marijuana vaporization. In these eleven studies, there were five different therapeutic indications: five examined chronic neuropathic pain, two examined appetite stimulation in HIV patients, two examined glaucoma, one examined spasticity in MS, and one examined asthma.

There are limited conclusions that can be drawn from the data in these published studies evaluating marijuana for the treatment of different therapeutic indications. The analysis relied on published studies, thus information available about protocols, procedures, and results were limited to documents published and widely available in the

public domain. The published studies on medical marijuana are effectively proof-of-concept studies. Proof-of-concept studies provide preliminary evidence on a proposed hypothesis regarding a drug’s effect. For drugs under development, the effect often relates to a short-term clinical outcome being investigated. Proof-of-concept studies serve as the link between preclinical studies and dose ranging clinical studies. Therefore, proof-of-concept studies are not sufficient to demonstrate efficacy of a drug because they provide only preliminary information about the effects of a drug. Although these studies do not provide evidence that marijuana is effective in treating a specific, recognized disorder, these studies do support future larger well-controlled studies to assess the safety and efficacy of marijuana for a specific medical indication. Overall, the conclusions below are preliminary, based on very limited evidence.

#### 3.6.1 Conclusions for Chronic Neuropathic Pain

In subjects with chronic neuropathic pain who are refractory to other pain treatments, five proof-of-concept studies produced positive results regarding the use of smoked marijuana for analgesia. However, the subjects in these studies continued to use their current analgesic drug regime, and thus no conclusions can be made regarding the potential efficacy of marijuana for neuropathic pain in patients not taking other analgesic drugs. Subjects also had numerous forms of neuropathic pain, making it difficult to identify whether a specific set of symptoms might be more responsive to the effects of marijuana. It is especially concerning that some marijuana-naïve subjects had intolerable psychiatric responses to marijuana exposure at analgesic doses.

#### 3.6.2 Conclusions for Appetite Stimulation in HIV

In subjects who were HIV-positive, two proof-of-concept studies produced positive results with the use of both dronabinol and smoked marijuana to increase caloric intake and produce weight gain in HIV-positive patients. However, the amount of THC in the marijuana tested in these studies is four times greater than the dose of dronabinol typically tested for appetite stimulation (10 mg vs. 2.5 mg; Haney et al., 2005). Thus, it is possible that the low degree of AEs reported in this study may reflect the development of tolerance to cannabinoids in this patient population, since all individuals had current histories of chronic marijuana use. Thus, individuals with little prior

exposure to marijuana may not respond similarly and may not be able to tolerate sufficient marijuana to produce appetite stimulation.

### 3.6.3 Conclusions for Spasticity in MS

In subjects with MS, a proof of concept study produced positive results using smoked marijuana as a treatment for pain and symptoms associated with treatment-resistant spasticity. The subjects in this study continued to take their current medication regimen, and thus no conclusions can be made regarding the potential efficacy of marijuana when taken on its own. It is also concerning that marijuana-naïve subjects dropped out of the study because they were unable to tolerate the psychiatric AEs induced by marijuana. The authors suggest that future studies should examine whether different doses can result in similar beneficial effects with less cognitive impact.

### 3.6.4 Conclusions for Asthma

In subjects with clinically stable asthma, a proof of concept study produced positive results of smoked marijuana producing bronchodilation. However, in this study marijuana was administered at rest and not while experiencing bronchospasms. Additionally, the administration of marijuana through smoking introduces harmful and irritating substances to the subject, which is undesirable especially in asthmatic patients. Thus the results suggest marijuana may have bronchodilator effects, but it may also have undesirable adverse effects in subjects with asthma.

### 3.6.5 Conclusions for Glaucoma

As noted in Sections 3.5, the two studies that evaluated smoked marijuana for glaucoma were conducted decades ago, and they have been thoroughly evaluated in the 1999 IOM report. The 1999 IOM report concludes that while the studies with marijuana showed positive results for reduction in IOP, the effect is short-lasting, requires a high dose, and is associated with many AEs. Thus, the potential harmful effects may outweigh any modest benefit of marijuana for this condition. We agree with the conclusions drawn in the 1999 IOM report.

## 3.7 Design Challenges for Future Studies

The positive results reported by the studies discussed in this review support the conduct of more rigorous studies in the future. This section discusses methodological challenges that have occurred in clinical studies with smoked marijuana. These design issues

should be addressed when larger-scale clinical studies are conducted to ensure that valid scientific data are generated in studies evaluating marijuana's safety and efficacy for a particular therapeutic use.

### 3.7.1 Sample Size

The ability for results from a clinical study to be generalized to a broader population is reliant on having a sufficiently large study sample size. However, as noted above, all of the 11 studies reviewed in this document were early Phase 2 proof of concept studies for efficacy and safety. Thus, the sample sizes used in these studies were inherently small, ranging from 10 subjects per treatment group (Tashkin et al., 1974; Haney et al., 2007) to 25 subjects per treatment group (Abrams et al., 2007). These sample sizes are statistically inadequate to support a showing of safety or efficacy. FDA's recommendations about sample sizes for clinical trials can be found in the *Guidance for Industry: E9 Statistical Principles for Clinical Trials (1998)*.<sup>35</sup> For example, "the number of subjects in a clinical trial should always be large enough to provide a reliable answer to the questions addressed. This number is usually determined by the primary objective of the trial. The method by which the sample size is calculated should be given in the protocol, together with the estimates of any quantities used in the calculations (such as variances, mean values, response rates, event rates, difference to be detected)." (pg. 21). Other clinical FDA *Guidance for Industry*<sup>36</sup> may also contain recommendations regarding the appropriate number of subjects that should be investigated for a specific medical indication.

### 3.7.2 Marijuana Dose Standardization

Dose standardization is critical for any clinical study in order to ensure that each subject receives a consistent exposure to the test drug. The *Guidance for Industry: Botanical Drug Products (2004)*<sup>37</sup> provides specific information on the development of botanical drug products. Specifically, this guidance

<sup>35</sup> The *Guidance for Industry: E9 Statistical Principles for Clinical Trials* can be found at: [www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073137.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073137.pdf).

<sup>36</sup> Other *Guidances for Industry* can be found at: [www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064981.htm](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064981.htm).

<sup>37</sup> The *Guidance for Industry: Botanical Drug Products* can be found at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070491.pdf>.

includes information about the need for well-characterized and consistent chemistry for the botanical plant product and for consistent and reliable dosing. Specifically for marijuana studies, dose standardization is important because if marijuana leads to plasma levels of cannabinoids that are significantly different between subjects, this variation may lead to differences in therapeutic responsiveness or in the prevalence of psychiatric AEs.

In most marijuana studies discussed in this review, investigators use a standardized cued smoking procedure. In this procedure, a subject is instructed to inhale marijuana smoke for 5 seconds, hold the smoke in the lungs for 10 seconds, exhale and breathe normally for 40 seconds. This process is repeated to obtain the desired dose of the drug. However, this procedure may not lead to equivalent exposure to marijuana and its constituent cannabinoids, based on several factors:

- Intentional or unintentional differences in the depth of inhalation may change the amount of smoke in the subject's lungs.
- Smoking results in loss from side stream smoke, such that the entire dose is not delivered to the subject.
- There may be differences in THC concentration along the length of a marijuana cigarette. According to Tashkin et al. (1991), the area of the cigarette closest to the mouth tends to accumulate a higher concentration of THC, but this section of the cigarette is not smoked during a study.

For example, Wilsey et al. (2008) used this standardized smoking procedure. The reported mean (range) of marijuana cigarettes consumed was 550 mg (200–830mg) for the low strength marijuana (3.5% THC) and 490 mg (270–870mg) for the high strength marijuana (7% THC). This wide range of amounts of marijuana cigarette smoked by the individual subjects, even with standardized smoking procedure and controlled number of puffs, supports the issues with delivering consistent doses with smoke marijuana.

In other marijuana studies that do not use a cued smoking procedure, subjects are simply told to smoke the marijuana cigarette over a specific amount of time (usually 10 minutes) without further instruction (Crawford and Merritt, 1979; Merritt et al., 1980; Ellis et al., 2009). The use of a nonstandardized procedure may lead to non-equivalent exposures to marijuana and its constituent cannabinoids between subjects because of additional factors that are not listed above, such as:

- Differences in absorption and drug response if subjects (especially

marijuana-naïve ones) are not instructed to hold marijuana smoke in their lungs for a certain period of time.

- Prolonged periods between puffs may increase loss to side stream smoke.
- Subjects may attempt to smoke the marijuana cigarette in the way they would smoke a tobacco cigarette, which relies primarily on short, shallow puffs.

In both standardized and non-standardized smoking procedures, subjects may seek to control the dose of THC through self-titration (Crawford and Merritt, 1979; Merritt et al., 1980; Tashkin et al., 1974; Abrams et al., 2007; Ellis et al., 2009). Self-titration involves an individual moderating the amount of marijuana smoke inhaled over time in order to obtain a preferred level of psychoactive or clinical response. The ability of an individual to self-titrate by smoking is one reason given by advocates of “medical marijuana” in support of smoking of marijuana rather than through its ingestion via edibles. However, for research purposes, self-titration interferes with the ability to maintain consistent dosing levels between subjects, and thus, valid comparisons between study groups.

All of these factors can make the exact dose of cannabinoids received by a subject in a marijuana study difficult to determine with accuracy. Testing whether plasma levels of THC or other cannabinoids are similar between subjects following the smoking procedure would establish whether the procedure is producing appropriate results. Additionally, studies could be conducted to determine if vaporization can be used to deliver consistent doses of cannabinoids from marijuana plant material. Specifically, vaporization devices that involve the collection of vapors in an enclosed bag or chamber may help with delivery of consistent doses of marijuana. Thus, more information could be collected on whether vaporization is comparable to or different than smoking in terms of producing similar plasma levels of THC in subjects using identical marijuana plant material.

### 3.7.3 Acute vs. Chronic Therapeutic Marijuana Use

The studies that were reviewed administered the drug for short durations lasting no longer than 5 days (Abrams et al., 2007; Ellis et al., 2009; Ware et al., 2010). Thus all studies examined the short-term effect of marijuana administration for therapeutic purposes. However, many of the medical conditions that have been studied are persistent or expected to last the rest of a patient’s life. Therefore, data on chronic exposure to smoked

marijuana in clinical studies is needed. In this way, more information will be available regarding whether tolerance, physical dependence, or specific adverse events develop over the course of time with continuing use of therapeutic marijuana.

### 3.7.4 Smoking as a Route of Administration

As has been pointed out by the IOM and other groups, smoking is not an optimum route of administration for marijuana-derived therapeutic drug products, primarily because introducing the smoke from a burnt botanical substance into the lungs of individuals with a disease state is not recommended when their bodies may be physically compromised. The 1999 IOM report on medicinal uses of marijuana noted that alternative delivery methods offering the same ability of dose titration as smoking marijuana will be beneficial and may limit some of the possible long-term health consequences of smoking marijuana. The primary alternative to smoked marijuana is vaporization, which can reduce exposure to combusted plant material containing cannabinoids. The only study to use vaporization as the delivery method was Wilsey et al. (2013). The results from Wilsey et al. (2013) showed a similar effect of decreased pain as seen in the other studies using smoking as the delivery method (Ware et al., 2010; Wilsey et al., 2008). This similar effect of decrease pain supports vaporization as a possibly viable route to administer marijuana in research, while potentially limiting the risks associated with smoking.

### 3.7.5 Difficulty in Blinding of Drug Conditions

An adequate and well-controlled clinical study involves double-blinding, where both the subjects and the investigators are unable to tell the difference between the test treatments (typically consisting of at least a test drug and placebo) when they are administered. All of the studies reviewed in this document administered study treatments under double-blind conditions and thus were considered to have an appropriate study design.

However, even under the most rigorous experimental conditions, blinding can be difficult in studies with smoked marijuana because the rapid onset of psychoactive effects readily distinguishes active from placebo marijuana. The presence of psychoactive effects also occurs with other drugs. However, most other drugs have a similar psychoactive effect with substances with similar mechanisms of

actions. These substances can be used as positive controls to help maintain blinding to the active drug being tested. Marijuana on the other hand, has a unique set of psychoactive effects which makes the use of appropriate positive controls difficult (Barrett et al., 1995). However, two studies did use Dronabinol as a positive control drug to help maintain blinding (Haney et al., 2005; Haney et al., 2007).

When blinding is done using only placebo marijuana, the ability to distinguish active from placebo marijuana may lead to expectation bias and an alteration in perceived responsiveness to the therapeutic outcome measures. With marijuana-experienced subjects, for example, there may be an early recognition of the more subtle cannabinoid effects that can serve as a harbinger of stronger effects, which is less likely to occur with marijuana-naïve subjects. To reduce this possibility, investigators have tested doses of marijuana other than the one they were interested in experimentally to maintain the blind (Ware et al., 2010).

Blinding can also be compromised by differences in the appearance of marijuana plant material based on THC concentration. Marijuana with higher concentrations of THC tends to be heavier and seemingly darker, with more “tar-like” substance. Subjects who have experience with marijuana have reported being able to identify marijuana from placebo cigarettes by sight alone when the plant material in a cigarette was visible (Tashkin et al., 1974; Ware et al., 2010). Thus, to maintain a double-blind design, many studies obscure the appearance of plant material by closing both ends of the marijuana cigarette and placing it in an opaque plastic tube.

While none of these methods to secure blinding may be completely effective, it is important to reduce bias as much as possible to produce consistent results between subjects under the same experimental conditions.

### 3.7.6 Prior Marijuana Experience

Marijuana use histories in test subjects may influence outcomes, related to both therapeutic responsiveness and psychiatric AEs. Marijuana-naïve subjects may also experience a marijuana drug product as so aversive that they would not want to use the drug product. Thus, subjects’ prior experience with marijuana may affect the conduct and results of studies.

Most of the studies reviewed in this document required that subjects have a history of marijuana use (see tables in Appendix that describe specific

requirements for each study). However, in studies published in the scientific literature, the full inclusion criteria with regard to specific amount of experience with marijuana may not be provided. For those studies that do provide inclusion criteria, acceptable experience with marijuana can range from once in a lifetime to use multiple times a day.

The varying histories of use might affect everything from scores on adverse event measures, safety measures, or efficacy measures. Additionally, varying amounts of experience can impact cognitive effect measures assessed during acute administration studies. For instance, Schreiner and Dunn (2012) contend cognitive deficits in heavy marijuana users continue for approximately 28 days after cessation of smoking. Studies requiring less than a month of abstinence prior to the study may still see residual effects of heavy use at baseline and after placebo marijuana administration, thus showing no significant effects on cognitive measures. However, these same measurements in occasional or naïve marijuana users may demonstrate a significant effect after acute marijuana administration. Therefore, the amount of experience and the duration of abstinence of marijuana use are important to keep in mind when analyzing results for cognitive and other adverse event measures. Lastly, a study population with previous experience with marijuana may underreport the incidence and severity of adverse events. Because most studies used subjects with prior marijuana experience, we are limited in our ability to generalize the results, especially for safety measures, to marijuana naïve populations.

Five of 11 studies reviewed in this document included both marijuana-naïve and marijuana-experienced subjects (Corey-Bloom et al., 2012; Ellis et al., 2009; Ware et al., 2010; Merritt et al., 1980; Tashkin et al., 1974). Since the number of marijuana-naïve subjects in these studies was low, it was not possible to conduct a separate analysis compared to experienced users. However, systematically evaluating the effect of marijuana experience on study outcomes is important, since many patients who might use a marijuana product for a therapeutic use will be marijuana-naïve.

Research shows that marijuana-experienced subjects have a higher ability to tolerate stronger doses of oral dronabinol than marijuana-naïve subjects (Haney et al., 2005). Possibly, this increased tolerance is also the case when subjects smoke or vaporize marijuana. Thus, studies could be

conducted that investigate the role of marijuana experience in determining tolerability of and responses to a variety of THC concentrations in marijuana.

#### 3.7.7 Inclusion and Exclusion Criteria

For safety reasons, all clinical studies have inclusion and exclusion criteria that restrict the participation of individuals with certain medical conditions. For studies that test marijuana, these criteria may be based on risks associated with exposure to smoked material and the effects of THC. Thus, most studies investigating marijuana require that subjects qualify for the study based on restrictive symptom criteria such that individuals do not have other symptoms that may be known to interact poorly with cannabinoids.

Similarly, clinical studies with marijuana typically exclude individuals with cardiac or pulmonary problems, as well as psychiatric disorders. These exclusion criteria are based on the well-known effects of marijuana smoke to produce increases in heart rate and blood pressure, lung irritation, and the exacerbation of psychiatric disturbances in vulnerable individuals. Although these criteria are medically reasonable for research protocols, it is likely that future marijuana products will be used in patients who have cardiac, pulmonary or psychiatric conditions. Thus, individuals with these conditions should be evaluated, whenever possible.

Additionally, all studies reviewed in this document allowed the subjects to continue taking their current regimen of medications. Thus all results evaluated marijuana as an adjunct treatment for each therapeutic indication.

#### 3.7.8 Number of Female Subjects

A common problem in clinical research is the limited number of females who participate in the studies. This problem is present in the 11 studies reviewed in this document, in which one study did not include any female subjects (Ellis et al., 2009), and three studies had a low percentage of female subjects (Abrams et al., 2007; Haney et al., 2005; Haney et al., 2007). However, each of these four studies investigated an HIV-positive patient population, where there may have been a larger male population pool from which to recruit compared to females.

Since there is some evidence that the density of CB1 receptors in the brain may vary between males and females (Crane et al., 2012), there may be differing therapeutic or subjective responsiveness to marijuana. Studies using a study population that is equal parts male and female may show whether and

how the effects of marijuana differ between male and female subjects.

#### 4. References

1999. *Marijuana and Medicine: Assessing the Science Base*. Washington, DC: National Academy Press.
- Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, and Schambelan M. 2003. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. *Annals of Internal Medicine* 139 (4): 258–266.
- Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, and Petersen KL. 2007. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. *Neurology* 68 (7): 515–521.
- Appendino G, Chianese G, Tagliatalata-Scafati O. 2011. Cannabinoids: occurrence and medicinal chemistry. *Curr Med Chem*. 18(7):1085–99.
- Barrett RL, Wiley JL, Balster RL, and Martin BR. 1995. Pharmacological specificity of  $\Delta^9$ -tetrahydrocannabinol discrimination in rats. *Psychopharmacology* 118(4): 419–424.
- Chait LD, and Pierrri J. 1989. Some physical characteristics of NIDA marijuana cigarettes. *Addictive Behaviors* 14 (1): 61–67.
- Chang AE, Shiling DJ, Stillman RC, Godlberg NH, Seipp CA, Barofsky I, Simon RM, and Rosenberg SA. 1979. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. *Annals of Internal Medicine* 91: 819–824.
- Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, and Gouaux B. 2012. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *Canadian Medical Association Journal* 184 (10): 1143–1150.
- Crane NA, Schuster RM, Fusar-Poli P, and Gonzalez R. 2012. Effects of Cannabis on Neurocognitive Functioning: Recent Advances, Neurodevelopmental Influences, and Sex Differences. *Neuropsychology Review*.
- Crawford WJ, and Merritt JC. 1979. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. *International Journal of Clinical Pharmacology and Biopharmacy* 17 (5): 191–196.
- Ellis RJ, Toperoff W, Vaida F, Van Den Brande G, Gonzales J, Gouaux B, Bentley H, and Atkinson JH. 2009. Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. *Neuropsychopharmacology* 34 (3): 672–680.
- Flom MC, Adams AJ, and Jones RT. 1975. Marijuana smoking and reduced pressure in human eyes: drug action or epiphenomenon? *Investigative Ophthalmology* 14(1): 52–55.
- Foltin RW, Brady JV, and Fischamn MW. 1986. Behavioral analysis of marijuana

- effects on food intake in humans. *Pharmacology Biochemistry and Behavior* 25: 577–582.
- Foltin RW, Fischman MW, and Byrne MF. 1988. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. *Appetite* 11: 1–14.
- Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, and Domino EF. 1994. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. *Clinical Pharmacology and Therapeutics* 55 (3): 324–328.
- Greenwald MK and Stitzer ML. 2000. Antinociceptive, subjective, and behavioral effects of smoked marijuana in humans. *Drug and Alcohol Dependence* 59: 261–275.
- Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, and Foltin RW. 2007. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. *Journal of Acquired Immune Deficiency Syndromes* (1999) 45 (5): 545–554.
- Haney M, Rabkin J, Gunderson E, and Foltin RW. 2005. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. *Psychopharmacology* 181 (1): 170–178.
- Hill SY, Schwin R, Goodwin DW, and Powell BJ. 1974. Marijuana and pain. *Journal of Pharmacology and Experimental Therapeutics* 188(2): 415–418.
- Jampel H. 2010. American glaucoma society position statement: marijuana and the treatment of glaucoma. *Journal of Glaucoma* 19 (2): 75–76.
- Merritt JC, Crawford WJ, Alexander PC, Anduze AL, and Gelbart SS. 1980. Effect of marijuana on intraocular and blood pressure in glaucoma. *Ophthalmology* 87 (3): 222–228.
- Milstein SL, MacCannell KL, Karr GW, and Clark S. 1974. Marijuana produced changes in cutaneous sensitivity and affect: users and non-users. *Pharmacology Biochemistry and Behavior* 2:367–374.
- Milstein SL, MacCannell K, Karr G, and Clark S. 1975. Marijuana-produced changes in pain tolerance: Experiences and non-experienced subjects. *Int. Pharmacopsychiat* 10: 177–182.
- Naftali T, Schleider LB, Dotan I, Lansky EP, Benjaminov FS, and Konikoff FM. 2013. Cannabis induces a clinical response in patients with Crohn's disease: A prospective placebo-controlled study. *Clinical Gastroenterology and Hepatology* 11: 1276–1280.
- Russo E, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, and Kirlin KA. 2002. Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis. *Journal of Cannabis Therapeutics* 2 (1): 3–57.
- Soderpalm AHV, Schuster A, and de Wit H. 2001. Antiemetic efficacy of smoked marijuana subjective and behavioral effects on nausea induced by syrup of ipecac. *Pharmacology Biochemistry and Behavior* 69: 343–350.
- Tashkin DP, Gliederer F, Rose J, Chang P, Hui KK, Yu JL, and Wu TC. 1991. Tar, CO and delta 9THC delivery from the 1st and 2nd halves of a marijuana cigarette. *Pharmacology Biochemistry and Behavior* 40 (3): 657–661.
- Tashkin DP, Shapiro BJ, Lee YE, Harper CE. 1975. Effects of smoked marijuana in experimentally induced asthma. *American Review of Respiratory Disease* 112: 377–386.
- Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, and Abramson I. 2007. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. *Anesthesiology* 107 (5): 785–796.
- Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, and Collet JP. 2010. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *Canadian Medical Association Journal* 182 (14): E694–E701.
- Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, and Fishman S. 2008. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *J. Pain* 9 (6): 506–521.
- Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, and Donaghe H. 2013. Low-dose vaporized cannabis significantly improves neuropathic pain. *J. Pain* 14(2):136–48.



## Appendix (Tables)

Table 1: Randomized, controlled, double-blind trials examining smoked marijuana in treatment of neuropathic pain

Author & Date Indication	Subjects (n) Completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type Duration	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
Abrams et al. (2007) <i>HIV-Sensory Neuropathy; Neuropathic Pain</i>	Marijuana Group: 25/27 22 males 5 females  Placebo Group: 25/28 26 males 2 females  <u>Inclusion Criteria:</u> -documented HIV -documented HIV-SN -pain score $\geq 30$ mm VAS -prior marijuana use of six or more times in lifetime  <u>Previous Marijuana Experience:</u> -marijuana group: 21 current users -placebo group: 19 current users  <u>Exclusion Criteria:</u> -substance abuse (including tobacco) -family history of neuropathy due to causes not HIV related -use of isoniazid,	NIDA marijuana, smoked 0%, 3.65% THC  <u>Smoking Procedure:</u> -signal light cued smoking of marijuana cigarette with each puff consisting of: 1) 5s inhale smoke, 2) 10s hold smoke in lungs 3) 40s exhale and breath normally 4) repeat procedure for desired number of puffs # of puffs not specified, only specified that subjects smoked the entire marijuana/placebo cigarette  On 1 <sup>st</sup> and last day of intervention period BID. For all other days TID	Parallel Group  5-day treatment period	VAS daily pain score	-52% of the marijuana group showed >30% decrease in pain score compared to 24% of placebo group. -Marijuana group had significantly greater reduction in daily pain score than placebo group.  -NNT=3.6	-Rating for adverse events of anxiety, sedation, disorientation, confusion, and dizziness were significantly higher in the marijuana group compared to placebo group. -Marijuana and placebo groups showed a reduction in total mood disturbance on POMS.  AEs: -1 grade 3 dizziness in marijuana group -2 grade 3 anxiety, 1 in each group.

Author & Date Indication	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type Duration	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
Ellis et al. (2009) <i>HIV Sensory Neuropathy; Neuropathic Pain</i>	dapson, or metronidazole within 8 weeks of enrollment 28/34 28 males <u>Inclusion Criteria:</u> -documented HIV -documented neuropathic pain refractory to $\geq 2$ analgesics -pain score $\geq 5$ on pain intensity subscale of DDS <u>Previous Marijuana Experience:</u> -27 subjects had previous experience -63% of subjects had no exposure for >1 year before study <u>Exclusion Criteria:</u> -current DSM-IV substance abuse disorder -lifetime history of dependence on marijuana -previous psychosis with or intolerance to cannabinoids -concurrent use of approved cannabinoid medications -positive UDS for	NIDA marijuana, smoked 0%, 1%, 2%, 4%, 6%, 8% THC <u>Smoking Procedures:</u> - Verbally cued smoking of marijuana cigarette with each puff consisting of: 1) 5s inhale smoke, 2) 10s hold smoke in lungs 3) 40s exhale and breath normally 4) repeat procedure for desired number of puffs -unknown number of puffs QID	Crossover Dose-titration (on 1 <sup>st</sup> day) 2, 5-day treatment phase, with 2-week washout period	Pain magnitude on DDS	-Pain reduction was significantly greater after marijuana compared to placebo.  -NNT=3.5	-Mood disturbance, quality of life, and psychological disability improved for both marijuana and placebo. -Moderate to severe adverse events were more common with marijuana than placebo. -HIV disease parameters did not differ for marijuana or placebo. -Adverse events included: concentration difficulties, fatigue, sleepiness or sedation, increased duration of sleep, reduced salivation, and thirst. These adverse events were more frequent in marijuana compared to placebo.  <u>Withdrawals for drug related reasons:</u> -1 cannabis-naïve subject had acute cannabis-induced psychosis -1 subjects developed an intractable smoking-related cough during marijuana administration

Author & Date Indication	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type Duration	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
Wilsey et al. (2008) <i>Neuropathic pain; Various Causes</i>	cannabinoids during wash-in week -serious medical conditions that affect safety -alcohol or drug dependence within 12 months of study 32/38 20 males 18 females <u>Inclusion Criteria:</u> -CRPS type I, spinal cord injury, peripheral neuropathy, or nerve damage -previous marijuana use <u>Previous Marijuana Experience:</u> -median (range) time from previous exposure: 1.7 years (31 days to 30 years) -median (range) exposure duration: 2 years (1 day to 22 years). <u>Exclusion Criteria:</u> -no marijuana or cannabinoid medication use for 30 days prior to study; confirmed by UDS	NIDA marijuana, smoked 0%, 3.55%, 7% THC <u>Smoking Procedure:</u> Verbally cued smoking of marijuana cigarette with each puff consisting of: 1) 5s inhale smoke, 2) 10s hold smoke in lungs 3) 40s exhale and breath normally 4) repeat procedure for desired number of puffs Cumulative dosing procedure: -escalate the number of puffs from 2 to 4 puffs over 3 smoking sessions with 1 hour between sessions	Crossover 3, 6-hour sessions, with 3-day between sessions	VAS spontaneous pain intensity	-A significant decrease in pain intensity for both strengths of marijuana compared to placebo	-7% THC marijuana significantly decreased functioning on neurocognitive measures compared to placebo. -Subjective effects were greater for 7% THC marijuana than 3.55% THC marijuana with significantly more ratings of good drug effect, bad drug effect, feeling high, feeling stoned, impaired, sedation, confusion, and hunger compared to placebo.

Author & Date Indication	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type Duration	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
Ware et al. (2010) <i>Post-traumatic or postsurgical neuropathic pain</i>	<ul style="list-style-type: none"> <li>-severe depression</li> <li>-history of schizophrenia or bipolar depression</li> <li>-uncontrolled hypertension, cardiovascular disease, and pulmonary disease</li> <li>-active substance abuse</li> </ul> <p>21/23 11 males 12 females</p> <p><u>Inclusion Criteria:</u></p> <ul style="list-style-type: none"> <li>-neuropathic pain for <math>\geq 3</math> months caused by trauma or surgery</li> <li>-allodynia and hyperalgesia</li> <li>-pain score <math>&gt;4</math>cm VAS</li> <li>-no marijuana use for 1 year prior to study</li> <li>-stable analgesic regimen</li> <li>-normal liver and renal function</li> </ul> <p><u>Previous Marijuana Experience:</u></p> <ul style="list-style-type: none"> <li>-18 subjects had used marijuana before</li> </ul> <p><u>Exclusion Criteria:</u></p> <ul style="list-style-type: none"> <li>-pain due to cancer or nociceptive causes</li> <li>-significant cardiac or</li> </ul>	<p>TID</p> <p>NIDA placebo; Prairie Plant System Inc. (Canada) marijuana, smoked 0%, 2.5%, 6%, 9.4% THC</p> <p>(25 mg of marijuana/placebo plant material was placed in opaque gelatin capsules)</p> <p><u>Smoking Procedures:</u></p> <ol style="list-style-type: none"> <li>-1) Break one capsule open and tip content into the bowl of a titanium pipe</li> <li>2) light marijuana material</li> <li>3) 5s inhale smoke</li> <li>4) 10s hold smoke in lungs</li> <li>5) Exhale</li> </ol> <p>1 puff burned all 25 mg of plant material</p>	<p>Crossover</p> <p>4, 5-day out-patient* treatment phase, with 9-day washout periods</p>	<p>Pain intensity on 11-item NRS</p>	<p>-Average daily pain intensity was significantly lower after 9.4% THC compared to placebo.</p>	<p>-Anxiety and depression were significantly improved with 9.4% THC compared to placebo.</p> <p>-No significant difference between placebo and 9.4% THC for subjective effects.</p> <p><u>AEs:</u></p> <ul style="list-style-type: none"> <li>-248 mild AEs were reported</li> <li>-6 moderate AEs were reported: 2 fall, 1 increased pain, 1 numbness, 1 drowsiness, 1 pneumonia</li> <li>-Most frequently reported drug-related AEs for 9.4% THC: headache, dry eyes, burning sensation, dizziness, numbness, and cough.</li> </ul> <p><u>Withdrawals for drug related reason:</u></p> <ul style="list-style-type: none"> <li>-1 subject had increased pain after 6% THC administration</li> <li>-1 subject tested positive for cannabinoids in urine test during placebo treatment</li> </ul>

Author & Date Indication	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type Duration	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
<p>Wilsey et al. (2013)</p> <p><i>Neuropathic Pain; Various Causes</i></p>	<p>pulmonary disease</p> <p>-current substance abuse or dependence (including marijuana)</p> <p>-history of psychotic disorders</p> <p>-current suicidal ideations</p> <p>36/39</p> <p>28 males</p> <p>11 females</p> <p><u>Inclusion Criteria:</u></p> <p>-CRPS type 1, thalamic pain, spinal cord injury, peripheral neuropathy, radiculopathy, or nerve injury</p> <p>-previous marijuana use</p> <p><u>Previous Marijuana Experience:</u></p> <p>- median (range) time from last exposure prior to screening: 9.6 years (1 day to 45 years)</p> <p>-16 current marijuana users and 23 past users</p> <p>-# smoked daily: 6</p> <p>-# used approx. once every 2 weeks: 8</p> <p>-current users, 6 past users</p> <p>-# used once every 4 weeks or less: 2</p> <p>current</p>	<p>TID</p> <p>Intermediate doses were used to help maintain blinding</p> <p>NIDA marijuana, vaporized</p> <p>0%, 1.29%, 3.53% THC</p> <p><u>Smoking Procedures:</u></p> <p>- Verbally cued inhalation of vaporized material in the balloon with each puff consisting of:</p> <ol style="list-style-type: none"> <li>1) 5s inhale vapors,</li> <li>2) 10s hold vapors in lungs</li> <li>3) 40s exhale and breath normally</li> <li>4) repeat procedure for desired number of puffs</li> </ol> <p>BID</p> <p>Cumulative &amp; Flexible Dosing: -1<sup>st</sup> drug admin. consisted of 4 puffs from balloon.</p>	<p>Crossover</p> <p>3, 6-hour sessions, with at least 3 days between sessions</p>	<p>VAS</p> <p>spontaneous pain intensity</p>	<p>-Number of subjects that showed a 30% reduction in pain intensity was significantly greater for both strengths of marijuana compared to placebo.</p> <p>-Both strengths of marijuana showed a similar significant decrease in pain compared to placebo.</p> <p>-NNT=3.2 for 1.29% THC marijuana vs. placebo.</p> <p>-NNT=2.9 for 3.53% THC marijuana vs. placebo.</p>	<p>-Scores for feeling stoned, feeling high, like the drug effect, feeling sedated, and feeling confused were significantly greater for 3.53% THC marijuana compared to 1.29% THC marijuana, and for both strengths of marijuana compared to placebo.</p> <p>-Scores for feeling drunk and feeling impaired are significantly greater in both strengths of marijuana compared to placebo.</p> <p>-Scores for desired more of the drug were significantly greater for 1.29% THC marijuana compared to placebo, with no significant difference seen for 3.53% THC marijuana.</p> <p>-3.53% THC marijuana had significantly worse performance than 1.29% THC marijuana for learning and memory.</p> <p>-Both strengths of marijuana significantly reduced scores on attention compared to placebo.</p>

Author & Date <i>Indication</i>	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type <i>Duration</i>	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
	users, 12 past users  <u>Exclusion Criteria:</u> -no marijuana or cannabinoid medication use for 30 days prior to study; confirmed by UDS -severe depression -suicidal ideations -diagnoses of serious mental illness -uncontrolled hypertension, cardiovascular disease, or chronic pulmonary disease -active substance abuse	-Followed 2 hours later by 2 <sup>nd</sup> drug admin. -2 <sup>nd</sup> drug admin. consisted of 4 to 8 puffs from balloon; number of puffs taken was left up to the subject so they could self-titrate to their target does, which balanced desired response and tolerance levels.				

\*Out-patient: subjects were given enough doses of marijuana/placebo to last the 5-day treatment phase, and then were sent home for the remainder of the treatment phase. AE=Adverse Event; BID=drug administered two times per day; CRPS=complex regional pain syndrome; DDS=Descriptor Differential Scale; NIDA=National Institute of Drug Abuse; NNT=Number Needed to Treat; NRS=Numeric Rating Scale; QID=drug administered four times per day; THC=delta-9-tetrahydrocannabinol; TID=drug administered three times per day; UDS=urine drug screen; VAS=Visual Analog Scale.

Table 2: Randomized, controlled, double-blind trials examining smoked marijuana in treatment of appetite stimulation in HIV/AIDS

Author & Date Indication	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type Duration	Primary Outcome Measure	Results (summary)	Adverse events/AEs
Haney et al. (2005) <i>HIV+ with either normal muscle mass (Normal-BIA) or clinically significant loss of muscle mass (Low-BIA)</i>	Low-BIA: 15/17 12 males 3 females Normal-BIA: 15/18 15 males  Inclusion Criteria: -21-50 years of age -prescribed at least 2 antiretroviral medications -currently under the care of a physician for HIV management -medically and psychiatrically stable -smoke marijuana $\geq$ 2x/week for past 4 weeks	NIDA marijuana, smoked 0%, 1.8%, 2.8%, 3.9% THC  Dronabinol, oral 0, 10, 20, 30mg  Double-dummy drug admin. Procedures: -only 1 active dose per session -one dronabinol/placebo capsule followed 1 hour later by marijuana/placebo smoking	Crossover  8, 7-hour session, with at least 1 day between sessions	No primary outcome measure is specified  Related outcome measure was caloric intake	-In Low-BIA all dronabinol doses and 1.8% and 3.9% THC marijuana significantly increased caloric intake compared with placebo.  -Ratings of high and good drug effect were significantly increased for all strengths of marijuana and all doses of dronabinol except 10mg dronabinol. -3.9% THC significantly increased ratings of dry mouth and thirsty compared to placebo. -Low-BIA group showed no significant adverse event ratings, and in the normal-BIA group the only significant adverse events in response to marijuana included: diarrhea after 3.9% THC marijuana. -Dronabinol had more incidences of adverse events at all doses compared to marijuana.	
	Previous Marijuana Experience: -mean (SD) # of days/week of marijuana use: Low-BIA= 6 (2); Normal-BIA=5 (2) -mean (SD) # marijuana cigarettes/day: Low-BIA=3 (2); Normal-BIA=3 (1) -mean (SD) years of marijuana use: Low-BIA=12.2 (8.3);	Smoking Procedures: Verbally cued smoking of marijuana cigarette with each puff consisting of: 1) 5s inhale smoke, 2) 10s hold smoke in lungs 3) 40s exhale and breath normally				

Author & Date <i>Indication</i>	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type <i>Duration</i>	Primary Outcome Measure	Results (summary)	Adverse events/AEs
Haney et al. (2007) <i>HIV+</i>	<p>Normal-BIA=10.8 (2.6)</p> <p><u>Exclusion Criteria:</u> -diagnosis of nutritional malabsorption, major depression, dementia, chronic diarrhea, weakness, fever, significant pulmonary disease -an opportunistic infection within past 3 months -obesity -use of steroids within past 3 weeks -drug dependence (excluding marijuana or nicotine)</p>	<p>4) repeat for 3 puffs per smoking session QD</p> <p>NIDA marijuana, smoked 0%, 2%, 3.9% THC</p> <p>Dronabinol, oral 0, 5, 10mg</p> <p>Double-dummy drug admin. Procedures: -only 1 active dose per session -one dronabinol/placebo</p>	<p>Crossover 2, 16-day treatment phases, with 5-10 days between phases Each 16-day treatment phase consisted of 2, 4-day active drug</p>	<p>No primary outcome measure is specified Related outcome measures were Caloric Intake &amp; Body Weight</p>	<p>-Both strengths of marijuana significantly increased caloric intake compared to placebo. -3.9% THC marijuana significantly increased body weight compared to placebo.</p>	<p>-Both strengths of marijuana significantly increased ratings of: good drug effect, high, mellow, stimulate, friendly, and self-confident. Only 2% THC marijuana significantly increased ratings of anxious. -Both strengths of marijuana significantly increased subjective measures for satisfied sleep and estimated time of sleep.</p>



Author & Date Indication	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type Duration	Primary Outcome Measure	Results (summary)	Adverse events/AEs
	<p>2x/week for the past 4 weeks</p> <p><u>Previous Marijuana Experience:</u></p> <p>-mean (SD) # of days/week of marijuana use: 4.6 (0.6)</p> <p>-mean (SD) # marijuana cigarettes/day: 3.2 (0.8)</p> <p>-mean (SD) years of marijuana use: 18.6 (3.3)</p> <p><u>Exclusion Criteria:</u></p> <p>-diagnosis of nutritional malabsorption, major depression, dementia, chronic diarrhea, weakness, fever, significant pulmonary disease</p> <p>-an opportunistic infection within past 3 months</p> <p>-obesity</p> <p>-use of steroids within past 3 weeks</p> <p>-drug dependence (excluding marijuana or nicotine)</p>	<p>capsule followed 1 hour later by marijuana/placebo smoking</p> <p><u>Smoking Procedures:</u></p> <p>Light cued smoking of marijuana cigarette with each puff consisting of:</p> <ol style="list-style-type: none"> <li>1) 5s inhale</li> <li>smoke,</li> <li>2) 10s hold smoke in lungs</li> <li>3) 40s exhale and breath normally</li> <li>4) repeat for 3 puffs per smoking session</li> </ol> <p>QID</p>	<p>period with 4-day placebo period between active drug periods.</p>			

AE= Adverse Event; BIA= Bioelectric Impedance Analysis; NIDA= National Institute of Drug Abuse; QD= drug administered one time per day; QID= drug administered four times per day; THC= delta-9-tetrahydrocannabinol

Table 3: Randomized, controlled, double-blind trails examining smoked marijuana in treatment of spasticity in Multiple Sclerosis

Author & Date <i>Indication</i>	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type <i>Duration</i>	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
Corey- Bloom et al. (2012)	30/37 11 males 19 females	NIDA marijuana, smoked 0%, 4% THC	Crossover  2, 3-day <i>treatment periods, with 11 day washout period</i>	Spasticity on the Modified Ashworth Scale	-Smoking marijuana significantly reduced spasticity scores compared to placebo	-Marijuana reduced scores on cognitive measure compared to placebo. -Marijuana significantly increased perceptions of “highness” compared to placebo  <u>Withdrawals for drug-related reasons:</u> -2 subjects felt uncomfortably high -2 dizziness -1 fatigue
<i>Multiple Sclerosis; Spasticity</i>	<u>Inclusion Criteria:</u> -documented MS -spasticity -moderate increase in tone (score $\geq 3$ on modified Ashworth scale  <u>Previous Marijuana Experience:</u> -24 subjects had previous exposure to marijuana -10 subjects used marijuana within the year  <u>Exclusion Criteria:</u> -no marijuana smoking for $\leq 1$ month prior to screening -psychiatric disorder (other than depression) -history of substance use -substantial neurological disease other than MS -severe or unstable	<u>Smoking Procedure:</u> smoking of marijuana cigarette with each puff consisting of: 1) 5s inhale smoke, 2) 10s hold smoke in lungs 3) 45s exhale and breath normally 4) repeat for an average of 4 puffs per smoking session  QD				

Author & Date <i>Indication</i>	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type <i>Duration</i>	Primary Outcome Measure	Primary Outcome Measure Results	Adverse events/AEs
	medical illnesses -known pulmonary disorders -using high dose narcotic medication for pain -using benzodiazepines to control spasticity					

AE= Adverse Event; MS= Multiple Sclerosis; NIDA=National Institute of Drug Abuse; QD=drug administered one time per day; THC=delta-9-tetrahydrocannabinol

Table 4: Randomized, controlled, double-blind trails examining smoked marijuana in treatment of intraocular pressure in Glaucoma

Author & Date Indication	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type Duration	Primary Outcome Measure	Results (summary)	Adverse events/AEs
Crawford & Merritt (1979) <i>Hypertensive and Normotensive Glaucoma</i>	HT group: 8 4 males 4 females  NT group: 8 4 males 4 females  <u>Inclusion Criteria:</u> -documented glaucoma  Previous <u>Marijuana Experience:</u> -all were marijuana naïve  <u>Exclusion Criteria:</u> -coronary artery disease	NIDA marijuana, smoked 0%, 2.8% THC  <u>Smoking Procedure:</u> -instructed to inhale 20 times deeply and retain smoke in lungs -smoke marijuana/placebo cigarette in 5 minutes  QD	Crossover  4, 1-day sessions, no time between sessions	No primary outcome measure is specified  Related outcome measure was IOP	-Marijuana decreased IOP by 37-44% from baseline. -The maximal decrease in IOP was significantly greater in HT (-14mmHg) than NT (-9mmHg) after marijuana .	-Placebo marijuana increased heart rate for 10 minutes in both groups. -The maximal increase in heart rate was significantly greater in NT than HT after marijuana. -The maximal decrease in blood pressure was significantly greater in HT than NT after marijuana.
Merritt et al. (1980) <i>Glaucoma</i>	18 12 males 6 females (31 glaucoma eyes, analyzed results for each eye)  <u>Inclusion Criteria:</u> -documented glaucoma  Previous <u>Marijuana Experience:</u> -9 subjects had used marijuana at least once  <u>Exclusion Criteria:</u>	NIDA marijuana, smoked 0%, 2% THC  <u>Smoking Procedure:</u> -None described -smoked 1 marijuana/placebo cigarette over 10-20 minutes  QD	Crossover  2, 1-day sessions	No primary outcome measure is specified  Related outcome measure was IOP	-Marijuana significantly decreased IOP compared to placebo  -Marijuana significantly decreased heart rate compared to placebo  -Blood pressure significantly decreased after marijuana -All subjects experienced hunger, thirst, euphoria, drowsy, and feeling cold -Observed adverse events were greater in marijuana naïve subjects than in subjects with prior marijuana experience.	-Marijuana significantly increased heart rate compared to placebo -Blood pressure significantly decreased after marijuana -All subjects experienced hunger, thirst, euphoria, drowsy, and feeling cold -Observed adverse events were greater in marijuana naïve subjects than in subjects with prior marijuana experience.  <u>AEs:</u> -5 subjects postural hypotension

Author & Date Indication	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Type Duration	Primary Outcome Measure	Results (summary)	Adverse events/AEs
	-cardiac, neurological, and psychiatric dysfunction					-8 subjects anxiety with tachycardia and palpitations

AE= Adverse Event; HT=Hypertensive; IOP=Intraocular pressure; NIDA=National Institute of Drug Abuse; NT=Normotensive; QD=drug administered one time per day; THC=delta-9-tetrahydrocannabinol

Table 5: Randomized, controlled, double-blind trails examining smoked marijuana in treatment of asthma

Author & Date Indication	Subjects (n) completed/randomized Subject characteristics	Drugs Admin. Methods	Study Design Duration	Primary Outcome Measure	Results (summary)	Adverse events/AEs
Tashkin et al. (1974) <i>Bronchial Asthma</i>	10 5 males 5 females  <u>Inclusion Criteria:</u> -diagnosis of bronchial asthma -asthma relieved by bronchodilator medication -clinically stable  <u>Previous Marijuana Experience:</u> -7 subjects had previous exposure to marijuana -amount of exposure <1 cigarette/month  <u>Exclusion Criteria:</u> -no marijuana use $\leq$ 7 days of study -psychiatric illness	NIMH (NIDA) marijuana, smoked 0%, 2% THC  Dronabinol, oral 0, 15mg  Dosing is 7mg/kg of body weight of plant material  <u>Smoking Procedure:</u> smoking of marijuana cigarette with each puff consisting of: 1) 2-4s deep inhale smoke, 2) 15s hold smoke in lungs 3) 5s exhale and breath normally 4) repeat till entire cigarette is smoked  QD	Crossover  4, 1-day sessions, with at least 48 hours between sessions	No primary outcome measure is specified  Related outcome measure was sGaw	-Marijuana significantly increased sGaw (33-48%) compared to placebo and baseline	-Marijuana initially significantly increased pulse rate compared to placebo, and then at 90 minutes pulse rate was significantly decreased compared to baseline. -All subjects felt intoxicated after marijuana.

AE= Adverse Event; NIDA=National Institute of Drug Abuse; QD=drug administered one time per day; sGaw=Specific Airway Conductance; THC=delta-9-tetrahydrocannabinol

**U.S. Department of Justice—Drug Enforcement Administration**

**Schedule of Controlled Substances: Maintaining Marijuana in Schedule I of the Controlled Substances Act**

**Background, Data, and Analysis: Eight Factors Determinative of Control and Findings Pursuant to 21 U.S.C. 812(b)**

Prepared by: Office of Diversion  
Control, Drug and Chemical  
Evaluation Section, Washington, DC  
20537

July 2016

**Background**

On December 17, 2009, Bryan Krumm, CNP, submitted a petition to the Drug Enforcement Administration (DEA) to initiate proceedings for a repeal of the rules or regulations that place marijuana<sup>38</sup> in schedule I of the Controlled Substances Act (CSA). The petition requests that marijuana be rescheduled in any schedule other than schedule I of the CSA. The petitioner claims that:

1. Marijuana has accepted medical use in the United States;
  2. Studies have shown that smoked marijuana has proven safety and efficacy;
  3. Marijuana is safe for use under medical supervision; and
  4. Marijuana does not have the abuse potential for placement in schedule I.
- The DEA accepted this petition for filing on April 3, 2010.

The Attorney General may by rule transfer a drug or other substance between schedules of the CSA if she finds that such drug or other substance has a potential for abuse, and makes the findings prescribed by 21 U.S.C. 812(b) for the schedule in which such drug is to be placed. 21 U.S.C. 811(a)(1). The Attorney General has delegated this responsibility to the Acting Administrator of the DEA. 28 CFR 0.100(b).

In accordance with 21 U.S.C. 811(b), after gathering the necessary data, the DEA submitted the petition and

necessary data to the Department of Health and Human Services (HHS) on May 6, 2011, and requested that HHS provide a scientific and medical evaluation and scheduling recommendation for marijuana. In documents dated June 3 and June 25, 2015, the acting Assistant Secretary for Health of the HHS<sup>39</sup> recommended to the DEA that marijuana continue to be controlled in Schedule I of the CSA, and provided to the DEA its scientific and medical evaluation titled “Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act.” The HHS’s recommendations are binding on the DEA as to scientific and medical matters. 21 U.S.C. 811(b).

Before initiating proceedings to reschedule a substance, the CSA requires the Acting Administrator to determine whether the HHS scheduling recommendation, scientific and medical evaluation, and “all other relevant data” constitute substantial evidence that the drug should be rescheduled as proposed. 21 U.S.C. 811(b). The Acting Administrator must determine whether there is substantial evidence to conclude that the drug meets the criteria for placement in another schedule based on the criteria set forth in 21 U.S.C. 812(b). The CSA requires that both the DEA and the HHS consider the eight factors specified by Congress in 21 U.S.C. 811(c). This document lays out those considerations and is organized according to the eight factors. As DEA sets forth in detail below, the evidence shows:

1. *Actual or relative potential for abuse.* Marijuana has a high potential for abuse. Preclinical and clinical data show that it has reinforcing effects characteristic of drugs of abuse. National databases on actual abuse show marijuana is the most widely abused drug, including significant numbers of substance abuse treatment admissions. Data on marijuana seizures show widespread availability and trafficking.

2. *Scientific evidence of its pharmacological effect.* The scientific understanding of marijuana, cannabinoid receptors, and the endocannabinoid system continues to be studied and elucidated. Marijuana

produces various pharmacological effects, including subjective (e.g., euphoria, dizziness, disinhibition), cardiovascular, acute and chronic respiratory, immune system, and prenatal exposure effects, as well as behavioral and cognitive impairment.

3. *Current scientific knowledge.* There is no currently accepted medical use for marijuana in the United States. Marijuana sources are derived from numerous cultivated strains and may have different levels of  $\Delta^9$ -THC and other cannabinoids. Under the five-element test for currently accepted medical use discussed in more detail below and upheld by the Court of Appeals for the District of Columbia in *Alliance for Cannabis Therapeutics v. DEA*, 15 F.3d 1131, 1135 (D.C. Cir. 1994) (hereinafter “ACT”), there is no complete scientific analysis of marijuana’s chemical components; there are not adequate safety studies; there are not adequate and well-controlled efficacy studies; there is not a consensus of medical opinion concerning medical applications of marijuana; and the scientific evidence regarding marijuana’s safety and efficacy is not widely available. To date, scientific and medical research has not progressed to the point that marijuana has a currently accepted medical use, even under conditions where its use is severely restricted.

4. *History and current pattern of abuse.* Marijuana continues to be the most widely used illicit drug. In 2014, there were 22.2 million current users. There were also 2.6 million new users, most of whom were less than 18 years of age. During the same period, marijuana was the most frequently identified drug exhibit in federal, state, and local forensic laboratories.

5. *Scope, duration, and significance of abuse.* Abuse of marijuana is widespread and significant. In 2014, for example, an estimated 6.5 million people aged 12 or older used marijuana on a daily or almost daily basis over a 12-month period. In addition, a significant proportion of all admissions for substance abuse treatment are for marijuana/hashish as their primary drug of abuse. In 2013, 16.8% of all such admissions—281,991 over the course of the year—were for primary marijuana/hashish abuse.

6. *Risk, if any, to public health.* Together with the health risks outlined in terms of pharmacological effects above, public health risks from acute use of marijuana include impaired psychomotor performance, impaired driving, and impaired performance on tests of learning and associative processes. Chronic use of marijuana

<sup>38</sup> The Controlled Substances Act (CSA) defines marijuana as the following: “All parts of the plant *Cannabis sativa L.*, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin. Such term does not include the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted there from), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. 21 U.S.C. 802(16). Note that “marihuana” is the spelling originally used in the CSA. This document uses the spelling that is more common in current usage, “marijuana.”

<sup>39</sup> As set forth in a memorandum of understanding entered into by the HHS, the Food and Drug Administration (FDA), and the National Institute on Drug Abuse (NIDA), the FDA acts as the lead agency within the HHS in carrying out the Secretary’s scheduling responsibilities under the CSA, with the concurrence of the NIDA. 50 FR 9518, Mar. 8, 1985. The Secretary of the HHS has delegated to the Assistant Secretary for Health of the HHS the authority to make domestic drug scheduling recommendations.

poses a number of other risks to the public health including physical as well as psychological dependence.

7. *Psychic or physiological dependence liability.* Long-term, heavy use of marijuana can lead to physical dependence and withdrawal following discontinuation, as well as psychic or psychological dependence. In addition, a significant proportion of all admissions for treatment for substance abuse are for primary marijuana abuse; in 2013, 16.8% of all admissions were for primary marijuana/hashish abuse, representing 281,991 individuals.

8. *Immediate precursor.* Marijuana is not an immediate precursor of any controlled substance.

As specified in 21 U.S.C. 812(b)(1), in order for a substance to be placed in schedule I, the Acting Administrator must find that:

A. The drug or other substance has a high potential for abuse.

B. The drug or other substance has no currently accepted medical use in treatment in the United States.

C. There is a lack of accepted safety for use of the drug or other substance under medical supervision.

To be classified in another schedule under the CSA (e.g., II, III, IV, or V), a substance must have a “currently accepted medical use in treatment in the United States.” 21 U.S.C. 812(b)(2)–(5). A substance also may be placed in schedule II if it is found to have “a currently accepted medical use with severe restrictions.” 21 U.S.C. 812(b)(2). If a controlled substance has no such currently accepted medical use, it must be placed in schedule I. *See* Notice of Denial of Petition, 66 FR 20038 (Apr. 18, 2001) (“Congress established only one schedule—schedule I—for drugs of abuse with ‘no currently accepted medical use in treatment in the United States’ and ‘lack of accepted safety for use . . . under medical supervision.’”).

A drug that is the subject of an approved new drug application (NDA) or abbreviated new drug application (ANDA) under Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), is considered to have a currently accepted medical use in treatment in the United States for purposes of the CSA. The HHS stated in its review, however, that FDA has not approved any NDA for marijuana for any indication.

In the absence of NDA or ANDA approval, DEA has established a five-element test for determining whether the drug has a currently accepted medical use in treatment in the United States. Under this test, a drug will be considered to have a currently accepted medical use only if the following five elements are satisfied:

1. The drug’s chemistry is known and reproducible;

2. There are adequate safety studies;

3. There are adequate and well-controlled studies proving efficacy;

4. The drug is accepted by qualified experts; and

5. The scientific evidence is widely available.

57 FR 10499, 10506 (March 26, 1992). *See also* ACT, 15 F.3d at 1135.

As discussed in Factor 3, below, HHS concluded, and DEA agrees, that the scientific evidence is insufficient to demonstrate that marijuana has a currently accepted medical use under the five-element test. The evidence was insufficient in this regard also when the DEA considered petitions to reschedule marijuana in 1992 (57 FR 10499),<sup>40</sup> in 2001 (66 FR 20038), and in 2011 (76 FR 40552).<sup>41</sup> Little has changed since 2011 with respect to the lack of clinical evidence necessary to establish that marijuana has a currently accepted medical use. No studies have scientifically assessed the efficacy and full safety profile of marijuana for any specific medical condition.

The limited existing clinical evidence is not adequate to warrant rescheduling of marijuana under the CSA. To the contrary, the data in this scheduling review document show that marijuana continues to meet the criteria for schedule I control under the CSA for the following reasons:

1. Marijuana has a high potential for abuse.

2. Marijuana has no currently accepted medical use in treatment in the United States.

3. Marijuana lacks accepted safety for use under medical supervision.

#### **Factor 1: The Drug’s Actual or Relative Potential for Abuse**

Marijuana is the most commonly abused illegal drug in the United States. It is also the most commonly used illicit drug by high school students in the United States. Further, marijuana is the most frequently identified drug by state, local and federal forensic laboratories. Marijuana’s main psychoactive ingredient,  $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC),<sup>42</sup> is an effective reinforcer in laboratory animals, including primates and rodents. These animal studies both predict and support the observations that marijuana produces reinforcing effects in humans. Such reinforcing

effects can account for the repeated abuse of marijuana.

#### *A. Indicators of Abuse Potential*

The HHS has concluded in its document, “Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act,” that marijuana has a high potential for abuse. The finding of “abuse potential” is critical for control under the Controlled Substances Act (CSA). Although the term is not defined in the CSA, guidance in determining abuse potential is provided in the legislative history of the Act (Comprehensive Drug Abuse Prevention and Control Act of 1970, H.R. Rep. No. 91–1444, 91st Cong., Sess. 2 (1970), reprinted in 1970 U.S.C.A.N. 4566, 4603). Accordingly, the following items are indicators that a drug or other substance has potential for abuse:

- *There is evidence that individuals are taking the drug or drugs containing such a substance in amounts sufficient to create a hazard to their health or to the safety of other individuals or of the community; or*

- *There is significant diversion of the drug or drugs containing such a substance from legitimate drug channels; or*

- *Individuals are taking the drug or drugs containing such a substance on their own initiative rather than on the basis of medical advice from a practitioner licensed by law to administer such drugs in the course of his professional practice; or*

- *The drug or drugs containing such a substance are new drugs so related in their action to a drug or drugs already listed as having a potential for abuse to make it likely that the drug will have the same potentiality for abuse as such drugs, thus making it reasonable to assume that there may be significant diversions from legitimate channels, significant use contrary to or without medical advice, or that it has a substantial capability of creating hazards to the health of the user or to the safety of the community.*

Of course, evidence of actual abuse of a substance is indicative that a drug has a potential for abuse.

In its recommendation, the HHS analyzed and evaluated data on marijuana as applied to each of the above four criteria. The analysis presented in the recommendation (HHS, 2015) is discussed below:

1. *There is evidence that individuals are taking the drug or drugs containing such a substance in amounts sufficient to create a hazard to their health or to the safety of other individuals or of the community.*

<sup>40</sup> *See Alliance for Cannabis Therapeutics v. DEA*, 15 F.3d 1131 (D.C. Cir. 1994).

<sup>41</sup> *See Americans for Safe Access v. DEA*, 706 F.3d 438 (D.C. Cir. 2013)(rhg den. 2013).

<sup>42</sup> The terms  $\Delta^9$ -THC and THC are used interchangeably throughout this document.



The HHS stated that some individuals are taking marijuana in amounts sufficient to create a hazard to their health and to the safety of other individuals and the community. Data from national databases on actual abuse of marijuana support the idea that a large number of individuals use marijuana. In its recommendation (HHS, 2015), the HHS presented data from the National Survey on Drug and Health (NSDUH) of the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Monitoring the Future (MTF) survey of the National Institute on Drug Abuse (NIDA), and the DEA has since updated this information. The most recent data from SAMHSA's NSDUH in 2014 reported that marijuana was the most used illicit drug. Among Americans aged 12 years and older, an estimated 22.2 million Americans used marijuana within the past month according to the 2014 NSDUH. In 2004, an estimated 14.6 million individuals reported using marijuana within the month prior to the study. The estimated rates in 2014 thus reflect an increase of approximately 7.6 million individuals over a 10-year period. According to the 2013 NSDUH report, an estimated 19.8 million individuals reported using marijuana. Thus, over a period of one year (2013 NSDUH–2014 NSDUH), there was an estimated increase of 2.4 million individuals in the United States using marijuana.

The results from the 2015 Monitoring the Future survey of 8th, 10th, and 12th grade students indicate that marijuana was the most widely used illicit drug in these age groups. Current monthly use was 6.5% of 8th graders, 14.8% of 10th graders, and 21.3% of 12th graders. The Treatment Episode Data Set (TEDS) in 2013 reported that marijuana abuse was the primary factor in 16.8 percent of non-private substance-abuse treatment facility admissions. In 2011, SAMHSA's Drug Abuse Warning Network (DAWN) reported that marijuana was mentioned in 36.4% (455,668 out of approximately 1.25 million) of illicit drug-related Emergency Department (ED) visits.

Data on the extent and scope of marijuana abuse are presented under Factors 4 and 5 of this analysis. Discussion of the health effects of marijuana is presented under Factor 2, and the assessment of risk to the public health posed by acute and chronic marijuana abuse is presented under Factor 6 of this analysis.

*2. There is significant diversion of the drug or drugs containing such a substance from legitimate drug channels.*

In accordance with the CSA, the only lawful source of marijuana in the United

States is that produced and distributed for research purposes under the oversight of NIDA and in conformity with United States obligations under the Single Convention on Narcotic Drugs.<sup>43</sup> The HHS stated that there is a lack of significant diversion from legitimate drug sources, but that this is likely due to high availability of marijuana from illicit sources. Marijuana is not an FDA-approved drug product. Neither a New Drug Application (NDA) nor a Biologics License Application (BLA) has been approved for marketing in the United States. However, the marijuana used for nonclinical and clinical research represents a very small amount of the total amount of marijuana available in the United States and therefore information about marijuana diversion from legitimate sources is limited or not available.

The DEA notes that the magnitude of the demand for illicit marijuana is evidenced by information from a number of databases presented under Factor 4. Briefly, marijuana is the most commonly used illegal drug in the United States. It is also the most commonly used illicit drug by American high schoolers. Marijuana is the most frequently identified drug in state, local, and federal forensic laboratories, with increasing amounts of both domestically grown and of illicitly smuggled marijuana.

Given that marijuana has long been the most widely trafficked and abused controlled substance in the United States, and that all aspects of such illicit activity are entirely outside of the closed system of distribution mandated by the CSA, it may well be the case that there is little thought given to diverting marijuana from the small supplies produced for legitimate research purposes. Thus, the lack of data indicating diversion of marijuana from legitimate channels to the illicit market is not indicative of a lack of potential for abuse of the drug.

*3. Individuals are taking the drug or drugs containing such a substance on their own initiative rather than on the basis of medical advice from a practitioner licensed by law to administer such drugs in the course of his professional practice.*

The HHS stated that the FDA has not evaluated or approved an NDA or BLA for marijuana for any therapeutic indication. Consistent with federal law, therefore, an individual legitimately can take marijuana based on medical advice from a practitioner only by participating

in research that is being conducted under an Investigational New Drug (IND) application. The HHS noted that there are several states as well as the District of Columbia which have passed laws allowing for individuals to use marijuana for purported "medical" use under certain circumstances, but data are not available yet to determine the number of individuals using marijuana under these state laws. Nonetheless, according to 2014 NSDUH data, 22.2 million American adults currently use marijuana (SAMHSA, 2015a). Based on the large number of individuals who use marijuana and the lack of an FDA-approved drug product, the HHS concluded that the majority of individuals using marijuana do so on their own initiative rather than by following medical advice from a licensed practitioner.

*4. The drug or drugs containing such a substance are new drugs so related in their action to a drug or drugs already listed as having a potential for abuse to make it likely that the drug will have the same potentiality for abuse as such drugs, thus making it reasonable to assume that there may be significant diversions from legitimate channels, significant use contrary to or without medical advice, or that it has a substantial capability of creating hazards to the health of the user or to the safety of the community.*

Marijuana and its primary psychoactive ingredient,  $\Delta^9$ -THC, are controlled substances in schedule I under the CSA.

The HHS stated that one approved, marketed drug product contains synthetic  $\Delta^9$ -THC, also known as dronabinol, and another approved, marketed drug product contains a cannabinoid-like synthetic compound that is structurally related to  $\Delta^9$ -THC, the main active component in marijuana. Both products are controlled under the CSA.

Marinol is a schedule III drug product containing synthetic  $\Delta^9$ -THC (dronabinol) formulated in sesame oil in soft gelatin capsules. Marinol was approved by the FDA in 1985 for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who did not respond to conventional anti-emetic treatments. In 1992, FDA approved Marinol for the treatment of anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS). Marinol was originally placed into schedule II and later rescheduled to schedule III under the CSA due to the low reports of abuse relative to marijuana.

<sup>43</sup> See 76 FR 51403, 51409–51410 (2011) (discussing cannabis controls required under the Single Convention).

Cesamet is a drug product containing the schedule II substance nabilone, a synthetic substance structurally related to  $\Delta^9$ -THC. Cesamet was approved for marketing by the FDA in 1985 for the treatment of nausea and vomiting associated with cancer chemotherapy. All other naturally occurring cannabinoids in marijuana and their synthetic equivalents with similar chemical structure and pharmacological activity are already included as schedule I drugs under the CSA.

### B. Abuse Liability Studies

In addition to the indicators suggested by the CSA's legislative history, data as to preclinical and clinical abuse liability studies, as well as actual abuse, including clandestine manufacture, trafficking, and diversion from legitimate sources, are considered in this factor.

Abuse liability evaluations are obtained from studies in the scientific and medical literature. There are many preclinical measures of a drug's effects that when taken together provide an accurate prediction of the human abuse liability. Clinical studies of the subjective and reinforcing effects in humans and epidemiological studies provide quantitative data on abuse liability in humans and some indication of actual abuse trends. Both preclinical and clinical studies have clearly demonstrated that marijuana and  $\Delta^9$ -THC possess the attributes associated with drugs of abuse: They function as a positive reinforcer to maintain drug-seeking behavior, they function as a discriminative stimulus, and they have dependence potential.

Preclinical and most clinical abuse liability studies have been conducted with the psychoactive constituents of marijuana, primarily  $\Delta^9$ -THC and its metabolite, 11-hydroxy- $\Delta^9$ -THC.  $\Delta^9$ -THC's subjective effects are considered to be the basis for marijuana's abuse liability. The following studies provide a summary of that data.

#### 1. Preclinical Studies

$\Delta^9$ -THC, the primary psychoactive component in marijuana, is an effective reinforcer in laboratory animals, including primates and rodents, as these animals will self-administer  $\Delta^9$ -THC. These animal studies both predict and support the observations that  $\Delta^9$ -THC, whether smoked as marijuana or administered by other routes, produces reinforcing effects in humans. Such reinforcing effects can account for the repeated abuse of marijuana.

#### a. Drug Discrimination Studies

The drug discrimination paradigm is used as an animal model of human subjective effects (Solinas et al., 2006) and is a method where animals are able to indicate whether a test drug is able to produce physical or psychological changes similar to a known drug of abuse. Animals are trained to press one bar (in an operant chamber) when they receive a known drug of abuse and another bar when they receive a placebo. When a trained animal receives a test drug, if the drug is similar to the known drug of abuse, it will press the bar associated with the drug.

Discriminative stimulus effects of  $\Delta^9$ -THC have specificity for the pharmacological effects of cannabinoids found in marijuana (Balster and Prescott, 1992; Browne and Weissman, 1981; Wiley et al., 1993; Wiley et al., 1995). As mentioned by the HHS, the discriminative stimulus effects of cannabinoids appear to be unique because abused drugs of other classes including stimulants, hallucinogens, opioids, benzodiazepines, barbiturates, NMDA antagonists, and antipsychotics do not fully substitute for  $\Delta^9$ -THC.

Laboratory animals including monkeys (McMahon et al., 2009), mice (McMahon et al., 2008), and rats (Gold et al., 1992) are able to discriminate cannabinoids from other drugs and placebo. The major active metabolite of  $\Delta^9$ -THC, 11-hydroxy- $\Delta^9$ -THC, generalizes to  $\Delta^9$ -THC (Browne and Weissman, 1981). In addition, according to the HHS, twenty-two other cannabinoids found in marijuana also substitute for  $\Delta^9$ -THC. At least one cannabinoid, CBD, does not substitute for  $\Delta^9$ -THC in rats (Vann et al., 2008).

#### b. Self-Administration Studies

Animal self-administration behavior associated with a drug is a commonly used method for evaluating if the drug produces rewarding effects and for predicting abuse potential (Balster, 1991; Balster and Bigelow, 2003). Drugs that are self-administered by animals are likely to produce rewarding effects in humans. As mentioned in the HHS review document, earlier attempts to demonstrate self-administration of  $\Delta^9$ -THC were unsuccessful and confounded by diet restrictions, animal restraint, and known analgesic activity of  $\Delta^9$ -THC at testing doses (Tanda and Goldberg, 2003; Justinova et al., 2003). Self-administration of  $\Delta^9$ -THC was first demonstrated by Tanda et al. (2000). Tanda et al. (2000) showed that squirrel monkeys that were initially trained to self-administer cocaine (30  $\mu$ g/kg, i.v.) self-administered 2  $\mu$ g/kg  $\Delta^9$ -THC (i.v.)

and at a rate of 30 injections per one hour session. Tanda et al. (2000) used a lower dose of  $\Delta^9$ -THC that was rapidly delivered (0.2 ml injection over 200 ms) than in previous self-administration studies such that analgesic activity of  $\Delta^9$ -THC was not a confounding factor. The authors also stated that the doses were comparable to those doses used by humans who smoke marijuana. A CB1 receptor antagonist (SR141716) blocked this rewarding effect of THC.

Justinova et al. (2003) were able to demonstrate self-administration of  $\Delta^9$ -THC in drug-naïve squirrel monkeys (no previous exposure to other drugs). The authors tested the monkeys with several doses of  $\Delta^9$ -THC (1, 2, 4, 8, and 16  $\mu$ g/kg, i.v.) and found that the maximal rates of self-administration were observed with the 4  $\mu$ g/kg/infusion. Subsequently, Braida et al. (2004) reported that rats will self-administer  $\Delta^9$ -THC when delivered intracerebroventricularly (i.c.v.), but only at the lowest doses tested (0.01–0.02  $\mu$ g/infusion, i.c.v.).

Self-administration behavior with  $\Delta^9$ -THC was found to be antagonized in rats and squirrel monkeys by rimonabant (SR141716A, CB1 antagonist) and the opioid antagonists (naloxone and naltrexone) (Tanda et al., 2000; Braida et al., 2004; Justinova et al., 2004).

#### c. Conditioned Place Preference Studies

Conditioned place preference (CPP) is a behavioral assay where animals are given the opportunity to spend time in two distinct environments: one where they previously received a drug and one where they received a placebo. If the drug is reinforcing, animals in a drug-free state will choose to spend more time in the environment paired with the drug when both environments are presented simultaneously.

CPP has been demonstrated with  $\Delta^9$ -THC in rats but only at low doses (0.075–1.0 mg/kg, i.p.; Braida et al., 2004). Rimonabant (0.25–1.0 mg/kg, i.p.) and naloxone (0.5–2.0 mg/kg, i.p.) antagonized  $\Delta^9$ -THC-mediated CPP (Braida et al., 2004). However, in another study with rats, rimonabant was demonstrated to induce CPP at doses ranging from 0.25–3.0 mg/kg (Cheer et al., 2000). Mice without  $\mu$ -opioid receptors did not exhibit CPP to  $\Delta^9$ -THC (paired with 1 mg/kg  $\Delta^9$ -THC, i.p.) (Ghozland et al., 2002).

#### 2. Clinical Studies

In its scientific review (HHS, 2015), the HHS provided a list of common subjective psychoactive responses to cannabinoids based on information from several references (Adams and Martin, 1996; Gonzalez, 2007; Hollister, 1986;

Hollister, 1988; Institute of Medicine, 1982). Furthermore, Maldonado (2002) characterized these subjective responses as pleasurable to most humans and are generally associated with drug-seeking and/or drug-taking. Later studies (Scherrer et al., 2009; Zeiger et al., 2010) reported that high levels of positive psychoactive effects correlate with increased marijuana use, abuse, and dependence. The list of the common subjective psychoactive effects provided by the HHS (HHS, 2015) is presented below:

(1) *Disinhibition, relaxation, increased sociability, and talkativeness.*

(2) *Increased merriment and appetite, and even exhilaration at high doses.*

(3) *Enhanced sensory perception, which can generate an increased appreciation of music, art, and touch.*

(4) *Heightened imagination, which can lead to a subjective sense of increased creativity.*

(5) *Initial dizziness, nausea, tachycardia, facial flushing, dry mouth, and tremor.*

(6) *Disorganized thinking, inability to converse logically, time distortions, and short-term memory impairment.*

(7) *Ataxia and impaired judgment, which can impede driving ability or lead to an increase in risk-taking behavior.*

(8) *Illusions, delusions, and hallucinations that intensify with higher doses.*

(9) *Emotional lability, incongruity of affect, dysphoria, agitation, paranoia, confusion, drowsiness, and panic attacks, which are more common in inexperienced or high-dosed users.*

The HHS mentioned that marijuana users prefer higher concentrations of the principal psychoactive component ( $\Delta^9$ -THC) over lower concentrations. In a clinical study with marijuana users ( $n = 12$ , usage ranged from once a month to 4 times a week), subjects were given a choice of 1.95%  $\Delta^9$ -THC marijuana or 0.63%  $\Delta^9$ -THC marijuana after sampling both marijuana cigarettes in two choice sessions. The marijuana cigarette with high THC was chosen in 21 out of 24 choice sessions or 87.5% of the time (Chait and Burke, 1994). Furthermore, in a double-blind study, frequent marijuana users ( $n = 11$ , usage at least 2 times per month with at least 100 occasions) when given a low-dose of oral  $\Delta^9$ -THC (7.5 mg) were able to distinguish the psychoactive effects better than occasional users ( $n = 10$ , no use within the past 4 years with 10 or fewer lifetime uses) and also experienced fewer sedative effects (Kirk and de Wit, 1999).

Marijuana has also been recognized by scientific experts to have withdrawal symptoms (negative reinforcement)

following moderate and heavy use. As discussed further in Factor 7, the DEA notes that the American Psychiatric Association's (APA) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) included a list of withdrawal symptoms following marijuana [cannabis] use (DSM-5, 2013).

### *C. Actual Abuse of Marijuana—National Databases Related to Marijuana Abuse and Trafficking*

Marijuana continues to be the most widely used illicit drug. Evidence of actual abuse can be defined by episodes/mentions in databases indicative of abuse/dependence. The HHS provided in its recommendation (HHS, 2015) information relevant to actual abuse of marijuana including data results from the National Survey on Drug Use and Health (NSDUH), a Monitoring the Future (MTF) survey, the Drug Abuse Warning Network (DAWN), and the Treatment Episode Data Set (TEDS). These data sources provide quantitative information on many factors related to abuse of a particular substance, including incidence and patterns of use, and profile of the abuser of specific substances. The DEA is providing updated information from these databases in this discussion. The DEA also includes data on trafficking and illicit availability of marijuana from DEA databases including the National Forensic Laboratory Information System (NFLIS) and the National Seizure System (NSS), formerly the Federal-wide Drug Seizure System (FDSS), as well as other sources of data specific to marijuana, including the Potency Monitoring Project and the Domestic Cannabis Eradication and Suppression Program (DCE/SP).

#### 1. National Survey on Drug Use and Health (NSDUH)

The National Survey on Drug Use and Health (NSDUH) is conducted annually by the Department of Health and Human Service's Substance Abuse and Mental Health Services Administration (SAMHSA). SAMHSA is the primary source of estimates of the prevalence and incidence of pharmaceutical drugs, illicit drugs, alcohol, and tobacco use in the United States. The survey is based on a nationally representative sample of the civilian, non-institutionalized population 12 years of age and older. The survey excludes homeless people who do not use shelters, active military personnel, and residents of institutional group quarters such as jails and hospitals.

According to the 2014 NSDUH report, marijuana was the most commonly used and abused illicit drug. That data showed that there were 22.2 million people who were past month users (8.4%) among those aged 12 and older in the United States. (Note: NSDUH figures on marijuana use include hashish use; the relative proportion of hashish use to marijuana use is very low). Marijuana had the highest rate of past-year dependence or abuse in 2014. The NSDUH report estimates that 3.0 million people aged 12 or older used an illicit drug for the first time in 2014; a majority (70.3%) of these past year initiates reported that their first drug used was marijuana. Among those who began using illicit drugs in the past year, 65.6%, 70.3%, and 67.6% reported marijuana as the first illicit drug initiated in 2012, 2013, and 2014 respectively. In 2014, the average age of marijuana initiates among 12- to 49-year-olds was 18.5 years. These usage rates and demographics are relevant in light of the risks presented.

Marijuana had the highest rate of past year dependence or abuse of any illicit drug in 2014. The 2014 NSDUH report stated that 4.2 million persons were classified with substance dependence or abuse of marijuana in the past year (representing 1.6% of the total population aged 12 or older, and 59.0% of those classified with illicit drug dependence or abuse) based on criteria specified in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV).

Among past year marijuana users age 12 or older, 18.5% used marijuana on 300 or more days within the previous 12 months in 2014. This translates into 6.5 million people using marijuana on a daily or almost daily basis over a 12-month period, significantly more than the estimated 5.7 million daily or almost daily users in just the year before. Among past month marijuana users, 41.6% (9.2 million) used the drug on 20 or more days in the past month, a significant increase from the 8.1 million who used marijuana 20 days or more in 2013.

#### 2. Monitoring the Future (MTF)

Monitoring the Future (MTF) is an ongoing study which is funded under a series of investigator-initiated competing research grants from the National Institute on Drug Abuse (NIDA). MTF tracks drug use trends among American adolescents in the 8th, 10th, and 12th grades. According to its 2015 survey results, marijuana was the most commonly used illicit drug, as was the case in previous years. Approximately 6.5% of 8th graders,

14.8% of 10th graders, and 21.3% of 12th graders surveyed in 2015 reported marijuana use during the past month prior to the survey. A number of high school students in 2015 also reported daily use in the past month, including 1.1%, 3.0%, and 6.0% of 8th, 10th, and 12th graders, respectively.

### 3. Drug Abuse Warning Network (DAWN), Emergency Department (ED) Visits

The Drug Abuse Warning Network (DAWN) is a public health surveillance system that monitors drug-related hospital emergency department (ED) visits to track the impact of drug use, misuse, and abuse in the United States. For the purposes of DAWN, the term “drug abuse” applies if the following conditions are met: (1) The case involved at least one of the following: use of an illegal drug, use of a legal drug contrary to directions, or inhalation of a non-pharmaceutical substance; and (2) the substance was used for one of the following reasons: because of drug dependence, to commit suicide (or attempt to commit suicide), for recreational purposes, or to achieve other psychic effects. Importantly, many factors can influence the estimates of ED visits, including trends in overall use of a substance as well as trends in the reasons for ED usage. For instance, some drug users may visit EDs for life-threatening issues while others may visit to seek care for detoxification because they needed certification before entering treatment. Additionally, DAWN data do not distinguish the drug responsible for the ED visit from other drugs that may have been used concomitantly. As stated in a DAWN report, “Since marijuana/hashish is frequently present in combination with other drugs, the reason for the ED visit may be more relevant to the other drug(s) involved in the episode.”

In 2011, marijuana was involved in 455,668 ED visits out of 2,462,948 total

ED visits involving all abuse or misuse in the United States and out of 1.25 million visits involving abuse or misuse of illicit drugs (excluding alcohol-related visits), as estimated by DAWN. This is lower than the number of ED visits involving cocaine (505,224) and higher than the number of ED visits involving heroin (258,482) and stimulants (e.g., amphetamine, methamphetamine) (159,840). Visits involving the other major illicit drugs, such as MDMA, GHB, LSD and other hallucinogens, PCP, and inhalants, were much less frequent, comparatively.

In young patients, marijuana is the illicit drug most frequently involved in ED visits, according to DAWN estimates, with 240.2 marijuana-related ED visits per 100,000 population ages 12 to 17, 443.8 per 100,000 population ages 18 to 20, and 446.9 per 100,000 population ages 21 to 24.

### 4. Treatment Episode Data Set (TEDS) System

The Treatment Episode Data Set (TEDS) system is part of the SAMHSA Drug and Alcohol Services Information System and is a national census of annual admissions to state licensed or certified, or administratively tracked, substance abuse treatment facilities. The TEDS system contains information on patient demographics and substance abuse problems of admissions to treatment for abuse of alcohol and/or drugs in facilities that report to state administrative data systems. For this database, the primary substance of abuse is defined as the main substance of abuse reported at the time of admission. TEDS also allows for the recording of two other substances of abuse (secondary and tertiary).

In 2011, the TEDS system included 1,928,792 admissions to substance abuse treatment; in 2012 there were 1,801,385 admissions; and in 2013 there were 1,683,451 admissions. Marijuana/hashish was the primary substance of

abuse for 18.3% (352,397) of admissions in 2011; 17.5% (315,200) in 2012; and 16.8% (281,991) in 2013. Of the 281,991 admissions for marijuana/hashish treatment in 2013, 24.3% used marijuana/hashish daily. Among those treated for marijuana/hashish as the primary substance in 2013, 27.4% were ages 12 to 17 years and 29.7% were ages 18 to 24 years. Those admitted for marijuana/hashish were mostly male (72.6%) and non-Hispanic (82.2%). Non-hispanic whites (43.2%) represented the largest ethnic group of marijuana admissions.

### 5. Forensic Laboratory Data

Data on marijuana seizures from federal, state, and local forensic laboratories have indicated that there is significant trafficking of marijuana. The National Forensic Laboratory System (NFLIS) is a program sponsored by the Drug Enforcement Administration’s Office of Diversion Control. NFLIS systematically collects drug identification results and associated information from drug exhibits encountered by law enforcement and analyzed in federal, state, and local forensic laboratories. NFLIS is a comprehensive information system that includes data from 278 individual forensic laboratories that report more than 91% of the drug caseload in the U.S. NFLIS captures data for all drugs and chemicals identified and reported by forensic laboratories. More than 1,700 unique substances are represented in the NFLIS database.

Data from NFLIS showed that marijuana was the most frequently identified drug in federal, state, and local laboratories from January 2004 through December 2014. Marijuana accounted for between 29.47% and 34.84% of all drug exhibits analyzed annually during that time frame (Table 1).

**Table 1. NFLIS Federal, State and Local Forensic Laboratory Data of Marijuana Reports (other than hashish)**

Year	Reports	Percent of Total Reports
2004	454,582	34.42%
2005	483,134	32.53%
2006	520,060	32.55%
2007	525,668	33.66%
2008	526,420	34.07%
2009	536,888	34.30%
2010	544,418	34.91%
2011	495,937	33.42%
2012	485,591	32.02%
2013	452,839	30.70%
2014	432,989	29.27%
2015*	341,162	26.73%

NFLIS database queried 03-23-2016, by date of submission, all drugs reported

\*2015 data are still being reported to NFLIS due to normal lag time.

Since 2004, the total number of reports of marijuana and the amount of marijuana encountered federally has remained high (see data from Federal-wide Drug Seizure System and Domestic Cannabis Eradication and Suppression Program below).

#### 6. Federal-Wide Drug Seizure System

The Federal-wide Drug Seizure System (FDSS) contains information about drug seizures made within the jurisdiction of the United States by the Drug Enforcement Administration, the

Federal Bureau of Investigation, United States Customs and Border Protection, and United States Immigration and Customs Enforcement. It also records maritime seizures made by the United States Coast Guard. Drug seizures made by other Federal agencies are included in the FDSS database when drug evidence custody is transferred to one of the agencies identified above. FDSS is now incorporated into the National Seizure System (NSS), which is a repository for information on

clandestine laboratory and contraband (chemicals and precursors, currency, drugs, equipment and weapons). FDSS reports total federal drug seizures [in kilograms (kg)] of substances such as cocaine, heroin, MDMA, methamphetamine, and cannabis (marijuana and hashish). The yearly volume of cannabis seized (Table 2), consistently exceeding a thousand metric tons per year, shows that cannabis is very widely trafficked in the United States.

**Table 2. Total Federal Seizures of Cannabis (Expressed in Kg)**  
(Source: NSS, U.S. Seizures, EPIC System Portal, queried 08-05-2015)

	2010	2011	2012	2013	2014
<b>Cannabis</b>	<b>4,071,328</b>	<b>3,622,256</b>	<b>2,756,439</b>	<b>2,622,494</b>	<b>1,768,277</b>
Marijuana	4,070,850	3,621,322	2,754,457	2,618,340	1,767,741
Hashish	478	934	1,982	4,154	536

#### 7. Potency Monitoring Project


The University of Mississippi's Potency Monitoring Project (PMP), through a contract with the National Institute on Drug Abuse (NIDA), analyzes and compiles data on the

$\Delta^9$ -THC concentrations of marijuana, hashish and hash oil samples provided by DEA regional laboratories and by state and local police agencies. After 2010, PMP has analyzed only marijuana samples provided by DEA regional laboratories. As indicated in Figure 1,

the percentage of  $\Delta^9$ -THC increased from 1995 to 2010 with an average THC content of 3.75% in 1995 and 9.53% in 2010. In examining marijuana samples only provided by DEA laboratories, the average  $\Delta^9$ -THC content was 3.96% in 1995 in comparison to 11.16% in 2015.

**Figure 1. Average Percentage of  $\Delta^9$ -THC in Samples of Seized Marijuana (1995 – 2015)\***

(Source: The University of Mississippi Potency Monitoring Program, Quarterly Report # 131)



\*PMP discontinued analysis of state samples after 2010.

\*\*Data for 2015 are incomplete. Figure 1 contains percentage of  $\Delta^9$ -THC data through Dec. 22. Due to lack of funding, 4,177 samples haven't yet been analyzed.

#### 8. The Domestic Cannabis Eradication and Suppression Program

The Domestic Cannabis Eradication and Suppression Program (DCE/SP) was established in 1979 to reduce the supply of domestically cultivated marijuana in the United States. The program was designed to serve as a partnership between federal, state, and local

agencies. Only California and Hawaii were active participants in the program at its inception. However, by 1982 the program had expanded to 25 states and by 1985 all 50 states were participants. Cannabis is cultivated in remote locations and frequently on public lands and illicitly grown in all states. Data provided by the DCE/SP (Table 3) show

that in the United States in 2014, there were 3,904,213 plants eradicated in outdoor cannabis cultivation areas compared to 2,597,798 plants in 2000. Significant quantities of marijuana were also eradicated from indoor cultivation operations. There were 396,620 indoor plants eradicated in 2014 compared to 217,105 eradicated in 2000.

**Table 3. Domestic Cannabis Eradication, Outdoor and Indoor Plants Seized, 2000–2014** (Source: Domestic Cannabis Eradication/Suppression Program)

	2000	2001	2002	2003	2004
<b>Outdoor</b>	2,597,798	3,068,632	3,128,800	3,427,923	2,996,144
<b>Indoor</b>	217,105	236,128	213,040	223,183	203,896
<b>Total</b>	2,814,903	3,304,760	3,341,840	3,651,106	3,200,040

	2005	2006	2007	2008	2009
<b>Outdoor</b>	3,938,151	4,830,766	6,599,599	7,562,322	9,980,038
<b>Indoor</b>	270,935	400,892	434,728	450,986	414,604
<b>Total</b>	4,209,086	5,231,658	7,034,327	8,013,308	10,394,642

	2010	2011	2012	2013	2014
<b>Outdoor</b>	9,866,766	6,226,288	3,631,582	4,033,513	3,904,213
<b>Indoor</b>	462,419	509,231	302,377	361,727	396,620
<b>Total</b>	10,329,185	6,735,519	3,933,959	4,395,240	4,300,833

The recent statistics from these various surveys and databases show that marijuana continues to be the most commonly used illicit drug, with considerable rates of heavy abuse and dependence. They also show that marijuana is the most readily available illicit drug in the United States.

#### **Petitioners' Major Comment in Relation to Factor 1 and the Government's Responses**

(1) The petitioner states on pages 1–2 of the petition that “[p]ure THC (Marinol), the primary psychoactive ingredient in marijuana has been placed in Schedule III. However, unlike Marinol, marijuana has other cannabinoids that help to mitigate the psychoactive effects of THC and reduce the potential for abuse. Therefore, the THC in marijuana can not have the high potential for abuse required for placement in Schedule I.”

First, the petitioners failed to review the indicators of abuse potential, as discussed in the legislative history of the CSA. The petitioners did not use data on marijuana usage, diversion, psychoactive properties, and dependence in their evaluation of marijuana abuse potential. The HHS and the DEA discuss those indicators above in this factor. HHS's evaluation of the full range of data led HHS and DEA to conclude that marijuana has a high potential for abuse.

Second, the HHS indicated that modulating effects of the other cannabinoids in marijuana on  $\Delta^9$ -THC have not been demonstrated in controlled studies. Specifically, HHS concluded in its 8-factor analysis that

“any possible mitigation of delta-9-THC's psychoactive effects by CBD will not occur for most marijuana users.”

Marinol was rescheduled from schedule II to schedule III on July 2, 1999 (64 FR 35928, DEA 1999). In assessing Marinol, HHS compared Marinol to marijuana on several aspects of abuse potential and found that major differences between the two, such as formulation, availability, and usage, contribute to differences in abuse potential. The psychoactive effects from smoking are generally more rapid and intense than those that occur through oral administration (HHS, 2015; Wesson and Washburn, 1990; Hollister and Gillespie, 1973). Therefore, as concluded by both the HHS and the DEA, the delayed onset of action and longer duration of action from an oral dose of Marinol may contribute in limiting the abuse potential of Marinol relative to marijuana, which is most often smoked. The HHS also stated that the extraction and purification of dronabinol from the encapsulated sesame oil mixture of Marinol is highly complex and difficult and that the presence of sesame oil mixture may preclude the smoking of Marinol-laced cigarettes.

Additionally, the FDA approved a New Drug Application (NDA) for Marinol, indicating a legitimate medical use for Marinol in the United States and allowing for Marinol to be rescheduled into schedule II and subsequently into schedule III of the CSA. The HHS mentioned that marijuana and Marinol differ on a wide variety of factors and these differences are major reasons for

differential scheduling of marijuana and Marinol. Marijuana, as discussed more fully in Factors 3 and 6, does not have a currently accepted medical use in the United States, is highly abused, and has a lack of accepted safety.

Finally, the DEA notes that under the CSA, for a substance to be placed in schedule II, III, IV, or V, it must have a currently accepted medical use in treatment in the United States.<sup>44</sup> As DEA has previously stated, Congress established only one schedule, schedule I, for drugs of abuse with “no currently accepted medical use in treatment in the United States.” 76 FR 40552 (2011). Thus, any attempt to compare the relative abuse potential of schedule I substance to that of a substance in another schedule is inconsequential since a schedule I substance must remain in schedule I until it has been found to have a currently accepted medical use in treatment in the United States.

#### **Factor 2: Scientific Evidence of the Drug's Pharmacological Effects, if Known**

The HHS stated that there are large amounts of scientific data on the neurochemistry, mechanistic effects, toxicology, and pharmacology of marijuana. A scientific evaluation, as conducted by the HHS and the DEA, of marijuana's neurochemistry, human and animal behavioral pharmacology, central nervous system effects, and other pharmacological effects (e.g. cardiovascular, immunological effects) is presented below.

<sup>44</sup> See *Americans for Safe Access*, 706 F.3d at 440.

## Neurochemistry

Marijuana contains numerous constituents such as cannabinoids that have a variety of pharmacological actions. The HHS stated that different marijuana samples derived from various cultivated strains may differ in their chemical constituents including  $\Delta^9$ -THC and other cannabinoids. Therefore marijuana products from different strains will have different biological and pharmacological effects. The chemical constituents of marijuana are discussed further in Factor 3.

The primary site of action for cannabinoids such as  $\Delta^9$ -THC is at the cannabinoid receptor. Two cannabinoid receptors, CB1 and CB2, have been identified and characterized (Battista et al., 2012; Piomelli, 2005) and are G-protein-coupled receptors. Activation of these inhibitory G-protein-coupled receptors inhibits adenylate cyclase activity, which prevents conversion of ATP to cyclic AMP. Cannabinoid receptor activation also results in inhibition of N- and P/Q-type calcium channels and activates inwardly rectifying potassium channels (Mackie et al., 1995; Twitchell et al., 1997). The HHS mentioned that inhibition of N-type calcium channels decreases neurotransmitter release and this may be the underlying mechanism in the ability of cannabinoids to inhibit acetylcholine, norepinephrine and glutamate from specific areas of the brain. These cellular actions may underlie the antinociceptive and psychoactive effects of cannabinoids.  $\Delta^9$ -THC acts as an agonist at cannabinoid receptors.

CB1 receptors are primarily found in the central nervous system and are located mainly in the basal ganglia, hippocampus and cerebellum of the brain (Howlett et al., 2004). CB1 receptors are also located in peripheral tissues such as the immune system (De Petrocellis and Di Marzo, 2009), but the concentration of CB1 receptors there is considerably lower than in the central nervous system (Herkenham et al., 1990; 1992). CB2 receptors are found primarily in the immune system and predominantly in B lymphocytes and natural killer cells (Bouaboula et al., 1993). CB2 receptors are also found in the central nervous system, primarily in the cerebellum and hippocampus (Gong et al., 2006).

Two endogenous ligands to the cannabinoid receptors, anandamide and arachidonyl glycerol (2-AG), were identified in 1992 (Devane et al., 1992) and 1995 (Mechoulam et al., 1995), respectively. Anandamide is a low-efficacy agonist (Brievogel and Childers,

2000) and 2-AG is a high efficacy agonist (Gonsiorek et al., 2000) to the cannabinoid receptors. These endogenous ligands are present in both the central nervous system and in the periphery (HHS, 2015).

$\Delta^9$ -THC and cannabidiol (CBD) are two of the major cannabinoids in marijuana.  $\Delta^9$ -THC is the major psychoactive cannabinoid (Wachtel et al., 2002).  $\Delta^9$ -THC has similar affinity for CB1 and CB2 receptors and acts as a weak agonist at CB2 receptors. The HHS indicated that activation of CB1 receptors mediates psychotropic effects of cannabinoids. CBD has low affinity for both CB1 and CB2 receptors. CBD has antagonistic effects at CB1 receptors, and some inverse agonistic properties at CB2 receptors.

## Animal Behavioral Effects

Animal abuse potential studies (drug discrimination, self-administration, conditioned place preference) are discussed more fully in Factor 1. Briefly, it was consistently demonstrated that  $\Delta^9$ -THC, the primary psychoactive component in marijuana, and other cannabinoids in marijuana have a distinct drug discriminative profile. In addition, animals self-administer  $\Delta^9$ -THC, and  $\Delta^9$ -THC in low doses produces conditioned place preference.

## Central Nervous System Effects

### *Psychoactive Effects*

The clinical psychoactive effects of marijuana are discussed more fully in Factor 1. Briefly, the psychoactive effects from marijuana use are considered pleasurable and associated with drug-seeking or drug-taking (HHS, 2015; Maldonado, 2002). Further, it was noted by HHS that marijuana users prefer higher concentrations of the principal psychoactive component ( $\Delta^9$ -THC) over lower concentrations (HHS, 2015).

Studies have evaluated psychoactive effects of THC in the presence of high CBD, CBC, or CBN ratios. Even though some studies suggest that CBD may decrease some of  $\Delta^9$ -THC's psychoactive effects, the HHS found that the ratios of CBD to  $\Delta^9$ -THC administered in the studies were not comparable to the amounts found in marijuana used by most people (Dalton et al., 1976; Karniol et al., 1974; Zwardi et al., 1982). In fact, the CBD ratios in these studies are significantly higher than the CBD found in most marijuana currently found on the streets (Mehmedic et al., 2010). HHS indicated that most of the marijuana available on the street has a high THC and low CBD content and therefore any

lessening of THC's psychoactive effects by CBD will not occur for most marijuana users (HHS, 2015). Dalton et al. (1976) reported that when volunteers smoked cigarettes with a ratio of 7 CBD to 1  $\Delta^9$ -THC (0.15 mg/kg CBD and 0.025 mg/kg  $\Delta^9$ -THC), there was a significant decrease in ratings of acute subjective effects and achieving a "high" in comparison to smoking  $\Delta^9$ -THC alone. In oral administration studies, the subjective effects and anxiety produced by combination of CBD and THC in a ratio of at least 1:2 CBD to  $\Delta^9$ -THC (15, 30, 60 mg CBD to 30 mg  $\Delta^9$ -THC; Karniol et al., 1974) or a ratio of 2:1 CBD to  $\Delta^9$ -THC (1 mg/kg CBD to 0.5 mg/kg  $\Delta^9$ -THC; Zuardi et al., 1982) are less than those produced by  $\Delta^9$ -THC administered alone.

In one study (Ilan et al., 2005), the authors calculated the naturally occurring concentrations of CBC and CBD in marijuana cigarettes with either 1.8 or 3.6%  $\Delta^9$ -THC by weight. The authors varied the concentrations of CBC and CBD for each concentration of  $\Delta^9$ -THC in the marijuana cigarettes. Administrations in healthy marijuana users (n=23) consisted of either: (1) Low CBC (0.1% by weight) and low CBD (0.2% by weight); (2) high CBC (0.5% by weight) and low CBD; (3) low CBC and high CBD (1.0% by weight); or 4) high CBC and high CBD and the users were divided into low  $\Delta^9$ -THC (1.8% by weight) and high  $\Delta^9$ -THC (3.6% by weight) groups. Subjective psychoactive effects were significantly greater for all groups in comparison to placebo and there were no significant differences in effects among the treatments (Ilan et al., 2005).

The HHS also referred to a study with  $\Delta^9$ -THC and cannabidiol (CBD) (Karniol et al., 1975). In this study, oral administration of either 12.5, 25, or 50 mg CBD combined with 25 mg  $\Delta^9$ -THC (ratio of at least 1:2 CBD to  $\Delta^9$ -THC) significantly increased subjective psychoactive ratings of  $\Delta^9$ -THC compared to  $\Delta^9$ -THC alone (Karniol et al., 1975).

### *Behavioral Impairment*

Several factors may influence marijuana's behavioral effects including the duration (chronic or short term), frequency (daily, weekly, or occasionally), and amount of use (heavy or moderate). Researchers have examined how long behavioral impairments persist following chronic marijuana use. These studies used self-reported histories of exposure duration, frequency, and amount of marijuana use, and administered several performance and cognitive tests at different time points following



marijuana abstinence. According to HHS, behavioral impairments may persist for up to 28 days of abstinence in chronic marijuana users.

Psychoactive effects of marijuana can lead to behavioral impairment including cognitive decrements and decreased ability to operate motor vehicles (HHS, 2015). Block et al. (1992) evaluated cognitive measures in 48 healthy male subjects following smoking a marijuana cigarette that contained 2.57% or 19 mg  $\Delta^9$ -THC by weight or placebo. Each subject participated in eight sessions (four sessions with marijuana; four sessions with placebo) and several cognitive and psychomotor tests were administered (e.g. verbal recall, facial recognition, text learning, reaction time). Marijuana significantly impaired performances in most of these cognitive and psychomotor tests (Block et al., 1992).

Ramaekers et al. (2006) reported that in 20 recreational users of marijuana, acute administration of 250  $\mu$ g/kg and 500  $\mu$ g/kg  $\Delta^9$ -THC in smoked marijuana resulted in dose-dependent impairments in cognition, motor impulsivity, motor control (tracking impairments), and risk taking. In another study (Kurzthaler et al., 1999), when 290  $\mu$ g/kg  $\Delta^9$ -THC was administered via a smoked marijuana cigarette in 30 healthy volunteers with no history of substance abuse there were significant impairments of motor speed and accuracy. Furthermore, administration of 3.95%  $\Delta^9$ -THC in a smoked marijuana cigarette increased the latency in a task of simulated braking in a vehicle (Liguori et al., 1998). The HHS noted that the motor impairments reported in these studies (Kurzthaler et al., 1999; Liguori et al., 1998) are critical skills needed for operating a vehicle.

As mentioned in the HHS document, some studies examined the persistence of the behavioral impairments immediately after marijuana administration. Some of marijuana's acute effects may still be present for at least 24 hours after the acute psychoactive effects have subsided. In a brief communication, Heishmann et al. (1990) reported that there were cognitive impairments (digit recall and arithmetic tasks) in two out of three experienced marijuana smokers for 24 hours after smoking marijuana cigarettes containing 2.57%  $\Delta^9$ -THC. However, Fant et al. (1998) evaluated subjective effects and performance measures for up to 25 hours in 10 healthy males after exposure to either 1.8% or 3.6%  $\Delta^9$ -THC in marijuana cigarettes. Peak decrements in subjective and performance measures were noted within 2 hours of marijuana exposure

but there were minimal residual alterations in subjective or performance measures at 23–25 hours after exposure.

Persistence of behavioral impairments following repeated and chronic use of marijuana has also been investigated and was reviewed in the HHS document (HHS, 2015). In particular, researchers examined how long behavioral impairments last following chronic marijuana use. In studies examining persistence of effects in chronic and heavy marijuana users, there were significant decrements in cognitive and motor function tasks in all studies of up to 27 days, and in most studies at 28 days (Solowij et al., 2002; Messinis et al., 2006; Lisdahl and Price, 2012; Pope et al., 2002; Bolla et al., 2002; Bolla et al., 2005). In studies that followed heavy marijuana users for longer than 28 days and up to 20 years of marijuana abstinence, cognitive and psychomotor impairments were no longer detected (Fried et al., 2005; Lyons et al., 2004; Tait et al., 2011). For example, Fried et al. (2005) reported that after 3 months of abstinence from marijuana, any deficits in intelligence (IQ), memory, and processing speeds following heavy marijuana use were no longer observed (Fried et al., 2005). In a meta-analysis that examined non-acute and long-lasting effects of marijuana, any deficits in neurocognitive performance that were observed within the first month were no longer apparent after approximately one month of abstinence (Schreiner and Dunn, 2012). HHS further notes that in moderate marijuana users deficits in decision-making skills were not observed after 25 days of abstinence and additionally IQ, immediate memory and delayed memory skills were not significantly impacted as observed with heavy and chronic marijuana users (Fried et al., 2005; HHS, 2015)

As mentioned in the HHS document (HHS, 2015), the intensity and persistence of neurological impairment from chronic marijuana use also may be dependent on the age of first use. In two separate smaller scale studies (less than 100 participants per exposure group), Fontes et al. (2011) and Gruber et al. (2012) compared neurological function in early onset (chronic marijuana use prior to age 15 or 16) and late onset (chronic marijuana use after age 15 or 16) heavy marijuana users and found that there were significant deficits in executive neurological function in early onset users which were not observed or were less apparent in late onset users. In a prospective longitudinal birth cohort study following 1,037 individuals (Meier et al., 2012), a significant decrease in IQ and

neuropsychological performance was observed in adolescent-onset users and persisted even after abstinence from marijuana for at least one year. However, Meier et al (2012) reported in there was no significant change in IQ in adult-onset users.

The HHS noted that there is some evidence that the severity of the persistent neurological impairments may also be due in part to the amount of marijuana usage. In the study mentioned above, Gruber et al. (2012) found that the early onset users consumed three times as much marijuana per week and used it twice as often as late onset users. Meier et al. (2012) reported in their study, mentioned above, that there was a correlation between IQ deficits in adolescent onset users and the increased amount of marijuana used.

#### *Behavioral Effects of Prenatal Exposure*

In studies that examined effects of prenatal marijuana exposure, many of the pregnant women also used alcohol and tobacco in addition to marijuana. Even though other drugs were used in conjunction with marijuana, there is evidence of an association between heavy prenatal marijuana exposure and deficits in some cognitive function. There have been two prospective longitudinal birth cohort studies following individuals prenatally exposed to marijuana from birth until adulthood: The Ottawa Prenatal Prospective Study (OPPS; Fried et al., 1980), and the Maternal Health Practices and Child Development Project (MHPCD; Day et al., 1985). Both longitudinal studies report that heavy prenatal marijuana use is associated with decreased performance on tasks assessing memory, verbal and quantitative reasoning in 4-year-olds (Fried and Watkinson, 1990) and in 6 year olds (Goldschmidt et al., 2008). In subsequent studies with the OPPS cohort, deficits in sustained attention were reported in children ages 6 and 13–16 years (Fried et al., 1992; Fried, 2002) and deficits in executive neurological function were observed in 9- and 12-year-old children (Fried et al., 1998). DEA further notes that with the MHPCD cohort, follow-up studies reported an increased rate of delinquent behavior (Day et al., 2011) and decreased achievement test scores (Goldschmidt et al., 2012) at age 14. When the MHPCD cohort was followed to age 22, there was a marginal ( $p = 0.06$ ) increase in psychosis with prenatal marijuana exposure and early onset of marijuana use (Day et al., 2015).

### *Association of Marijuana Use With Psychosis*

There has been extensive research to determine whether marijuana usage is associated with development of schizophrenia or other psychoses, and the HHS indicated that the available data do not suggest a causative link between marijuana and the development of psychosis (HHS, 2015; Minozzi et al., 2010). As mentioned in the HHS review (HHS, 2015), numerous large scale longitudinal studies demonstrated that subjects who used marijuana do not have a greater incidence of psychotic diagnoses compared to non-marijuana users (van Os et al., 2002; Fergusson et al., 2005; Kuepper et al., 2011). Further, the HHS commented that when analyzing the available data examining the association between marijuana and psychosis, it is critical to differentiate whether the patients in a study are already diagnosed with psychosis or if the individuals have a limited number of symptoms associated with psychosis without qualifying for a diagnosis of the disorder.

As mentioned by the HHS, some of the studies examining the association between marijuana and psychosis utilized non-standard methods to categorize psychosis and these methods did not conform to the criteria in the Diagnostic and Statistical Manual (DSM-5) or the International Classification of Diseases (ICD-10) and would not be appropriate for use in evaluating the association between marijuana use and psychosis. For example, researchers characterized psychosis as “schizophrenic cluster” (Maremmanni et al., 2004), “subclinical psychotic symptoms” (van Gastel et al., 2012), “pre-psychotic clinical high risk” (van der Meer et al., 2012), and symptoms related to “psychosis vulnerability” (Griffith-Lending et al., 2012).

The HHS discussed an early epidemiological study conducted by Andreasson et al. (1987), which examined the link between psychosis and marijuana use. In this study, about 45,000 18- and 19-year-old male Swedish subjects provided detailed information on their drug-taking history and 274 of these subjects were diagnosed with schizophrenia over a 14-year period (1969–1983). Out of the 274 subjects diagnosed with psychosis, 21 individuals (7.7%) had used marijuana more than 50 times, while 197 individuals (72%) never used marijuana. As presented by the authors (Andreasson et al., 1987), individuals who claimed to take marijuana on more

than 50 occasions were 6 times more likely to be diagnosed with schizophrenia than those who had never consumed the drug. The authors concluded that marijuana users who are vulnerable to developing psychoses are at the greatest risk for schizophrenia. In a 35 year follow up to the subjects evaluated in Andreasson et al. (1987), Manrique-Garcia et al. (2012) reported similar findings. In the follow up study, 354 individuals developed schizophrenia. Of those, 32 individuals (9%) had used marijuana more than 50 times and were 6.3 times more likely to develop schizophrenia. 255 of the 354 individuals (72%) never used marijuana.

The HHS also noted that many studies support the assertion that psychosis from marijuana usage may manifest only in individuals already predisposed to development of psychotic disorders. Marijuana use may precede diagnosis of psychosis (Schimmelmann et al., 2011), but most reports indicate that prodromal symptoms of schizophrenia are observed prior to marijuana use (Schiffman et al., 2005). In a review examining gene-environmental interaction between marijuana exposure and the development of psychosis, it was concluded that there is some evidence to support that marijuana use may influence the development of psychosis but only for susceptible individuals (Pelayo-Teran et al., 2012).

Degenhardt et al. (2003) modeled the prevalence of schizophrenia against marijuana use across eight birth cohorts in individuals born during 1940 to 1979 in Australia. Even though there was an increase in marijuana use in the adult subjects over this time period, there was not an increase in diagnoses of psychosis for these same subjects. The authors concluded that use of marijuana may increase schizophrenia only in persons vulnerable to developing psychosis.

### **Cardiovascular and Autonomic Effects**

The HHS stated that acute use of marijuana causes an increase in heart rate (tachycardia) and may increase blood pressure (Capriotti et al., 1988; Benowitz and Jones, 1975). There is some evidence that associates the increased heart rate from  $\Delta^9$ -THC exposure with excitation of the sympathetic and depression of the parasympathetic nervous systems (Malinowska et al., 2012). Tolerance to tachycardia develops with chronic exposure to marijuana (Jones, 2002; Sidney, 2002).

Prolonged exposure to  $\Delta^9$ -THC results in a decrease in heart rate (bradycardia) and hypotension (Benowitz and Jones,

1975). These effects are thought to be mediated through peripherally located, presynaptic CB1 receptor inhibition of norepinephrine release with possible direct activation of vascular cannabinoid receptors (Wagner et al., 1998; Pacher et al., 2006).

As stated in the HHS recommendation (HHS, 2015), marijuana exposure causes orthostatic hypotension (fainting-like feeling; sudden drop in blood pressure upon standing up) and tolerance can develop to this effect upon repeated, chronic exposure (Jones, 2002). Tolerance to orthostatic hypotension is potentially related to plasma volume expansion, but tolerance does not develop to supine hypotensive effects (Benowitz and Jones, 1975).

Marijuana smoking, particularly by those with some degree of coronary artery or cerebrovascular disease, poses risks such as increased cardiac work, increased catecholamines and carboxyhemoglobin, myocardial infarction and postural hypotension (Benowitz and Jones, 1981; Hollister, 1988; Mittleman et al., 2001; Malinowska et al., 2012). However, electrocardiographic changes were minimal after administration of large cumulative doses of  $\Delta^9$ -THC (Benowitz and Jones, 1975)

The DEA notes two recent reports that reviewed several case studies on marijuana and cardiovascular complications (Panayiotides, 2015; Hackam, 2015). Panayiotides (2015) reported that approximately 25.6% of the cardiovascular cases from marijuana use resulted in death from data provided by the French Addictovigilance Network during the period of 2006–2010. Several case studies on marijuana usage and cardiovascular events were discussed and it was concluded that although a causal link cannot be established due to not knowing exact amounts of marijuana used in the cases and confounding variables, the available evidence supports a link between marijuana and cardiotoxicity. Hackham (2015) reviewed 34 case reports or case series reports of marijuana and stroke/ ischemia in 64 stroke patients and reported that in 81% of the cases there was a temporal relationship between marijuana usage and stroke or ischemic event. The author concluded that collective analysis of the case reports supports a causal link between marijuana use and stroke.

### **Respiratory Effects**

The HHS stated that transient bronchodilation is the most typical respiratory effect of acute exposure to marijuana (Gong et al., 1984). In a recent

longitudinal study, information on marijuana use and pulmonary data function were collected from 5,115 individuals over 20 years from 4 communities in the United States (Oakland, CA; Chicago, IL; Minneapolis, MN; Birmingham, AL) (Pletcher et al., 2012). Of the 5,115 individuals, 795 individuals reported use of only marijuana (without tobacco). The authors reported that occasional use of marijuana (7 joint-years for lifetime or 1 joint/day for 7 years or 1 joint/week for 49 years) does not adversely affect pulmonary function. Pletcher et al. (2012) further concluded that there is some preliminary evidence suggesting that heavy marijuana use may have a detrimental effect on pulmonary function, but the sample size of heavy marijuana users in the study was too small. Further, as mentioned in the HHS recommendation document (HHS, 2015), long-term use of marijuana may lead to chronic cough, increased sputum, as well as increased frequency of chronic bronchitis and pharyngitis (Adams and Martin, 1996; Hollister, 1986).

The HHS stated that the evidence that marijuana may lead to cancer of the respiratory system is inconsistent, with some studies suggesting a positive correlation while others do not (Lee and Hancox, 2011; Tashkin, 2005). The HHS noted a case series that reported lung cancer occurrences in three marijuana smokers (age range 31–37 years) with no history of tobacco smoking (Fung et al., 1999). Furthermore, in a case-control study (n = 173 individuals with squamous cell carcinoma of the head and neck; n = 176 controls; Zhang et al., 1999), prevalence of marijuana use was 9.7% in controls and 13.9% in cases and the authors reported that marijuana use may dose-dependently interact with mutagenic sensitivity, cigarette smoking, and alcohol use to increase risk associated with head and neck cancers (Zhang et al., 1999). However, in a large clinical study with 1,650 subjects, no positive correlation was found between marijuana use and lung cancer (Tashkin et al., 2006). This finding held true regardless of the extent of marijuana use when both tobacco use and other potential confounding factors were controlled. The HHS concluded that new evidence suggests that the effects of smoking marijuana on respiratory function and cancer are different from the effects of smoking tobacco (Lee and Hancox, 2011).

The DEA further notes the publication of recent review articles critically evaluating the association between marijuana and lung cancer. Most of the reviews agree that the association is

weak or inconsistent (Huang et al., 2015; Zhang et al., 2015; Gates et al., 2014; Hall and Degenhardt, 2014). Huang et al. (2015) identified and reviewed six studies evaluating the association between marijuana use and lung cancer and the authors concluded that an association is not supported most likely due to the small amounts of marijuana smoked in comparison to tobacco. Zhang et al. (2015) examined six case control studies from the US, UK, New Zealand, and Canada within the International Lung Cancer Consortium and found that there was a weak association between smoking marijuana and lung cancer in individuals who never smoked tobacco, but precision of the association was low at high marijuana exposure levels. Hall and Degenhardt (2014) noted that even though marijuana smoke contains several of the same carcinogens and co-carcinogens as tobacco smoke (Roth et al., 1998) and has been found to be mutagenic and carcinogenic in the mouse skin test, epidemiological studies have been inconsistent, but more consistent positive associations have been reported in case control studies. Finally Gates et al. (2014), reviewed the studies evaluating marijuana use and lung cancer and concluded that there is evidence that marijuana produces changes in the respiratory system (precursors to cancer) that could lead to lung cancer, but overall association is weak between marijuana use and lung cancer especially when controlling for tobacco use.

## Endocrine System

### *Reproductive Hormones*

The HHS stated that administration of marijuana to humans does not consistently alter the endocrine system. In a controlled human exposure study (n = 4 males), subjects were acutely administered smoked marijuana containing 2.8%  $\Delta^9$ -THC or placebo and an immediate significant decrease in luteinizing hormone and an increase in cortisol was reported in the subjects that smoked marijuana (Cone et al., 1986). Furthermore, as cited by the HHS, two later studies (Dax et al., 1989; Block et al., 1991) reported no changes in hormone levels. Dax et al. (1989) recruited male volunteers (n = 17) that were occasional or heavy users of marijuana. Following exposure to smoked  $\Delta^9$ -THC (18 mg/cigarette) or oral  $\Delta^9$ -THC (10 mg three times per day for three days and on the morning of the fourth day), the subjects in that study showed no changes in plasma adrenocorticotrophic hormone (ACTH), cortisol, prolactin, luteinizing hormone,

or testosterone levels. Additionally, Block et al. (1991) compared plasma hormone levels amongst non-users as well as infrequent, moderate, and frequent users of marijuana (n = 93 men and 56 women) and found that chronic use of marijuana (infrequent, moderate, and frequent users) did not significantly alter concentrations of testosterone, luteinizing hormone, follicle stimulating hormone, prolactin, or cortisol.

The HHS noted that there is a discrepancy in the effect of marijuana on female reproductive system functionality between animals and humans (HHS, 2015). Female rhesus monkeys that were administered 2.5 mg/kg  $\Delta^9$ -THC, i.m., during days 1–18 of the menstrual cycle had reduced progesterone levels and ovulation was suppressed (Asch et al., 1981). However, women who smoked marijuana (1 gram marijuana cigarette with 1.8%  $\Delta^9$ -THC) during the periovulatory period (24–36 hours prior to ovulation) did not exhibit changes in reproductive hormone levels or their menstrual cycles (Mendelson and Mello, 1984). In a review article by Brown and Dobs (2002), the authors state that endocrine changes observed with marijuana are no longer observed with chronic administration and this may be due to drug tolerance.

### *Reproductive Cancers*

The HHS stated that recent studies support a possible association between frequent, long-term marijuana use and increased risk of testicular germ cell tumors. In a hospital-based case-control study, the frequency of marijuana use was compared between testicular germ cell tumor (TGCT) patients (n = 187) and controls (n = 148) (Trabert et al., 2011). TGCT patients were more likely to be frequent marijuana users than controls with an odds ratio (OR) of 2.2 (95% confidence limits of 1.0–5.1) and were less likely to be infrequent or short-term users with odds ratios of 0.5 and 0.6, respectively in comparison to controls (Trabert et al., 2011). The DEA further notes that in two population-based case-control studies (Daling et al., 2009; Lacson et al., 2012), marijuana use was compared between patients diagnosed with TGCT and matched controls in Washington State or Los Angeles County. In both studies, it was reported that TCGT patients were twice as likely as controls to use marijuana. Authors of both studies concluded that marijuana use is associated with an elevated risk of TGCT (Daling et al., 2009; Lacson et al., 2012).

The HHS cited a study (Sarfraz et al., 2005) demonstrating that WIN 55,212–2 (a mixed CB1/CB2 agonist) induces apoptosis (one form of cell death) in

prostate cancer cells and decreases expression of androgen receptors and prostate specific antigens, suggesting a potential therapeutic value for cannabinoid agonists in the treatment of prostate cancer, an androgen-stimulated type of carcinoma.

#### *Other hormones (e.g. Thyroid, Appetite)*

In more recent studies, as cited by the HHS, chronic marijuana use by subjects (n = 39) characterized as dependent on marijuana according to the ICD-10 criteria did not affect serum levels of thyroid hormones: TSH (thyrotropin), T4 (thyroxine), and T3 (triiodothyronine) (Bonnet, 2013). With respect to appetite hormones, in a pilot study with HIV-positive males, smoking marijuana dose-dependently increased plasma levels of ghrelin and leptin and decreased plasma levels of peptide YY (Riggs et al., 2012).

The HHS stated that  $\Delta^9$ -THC reduces binding of the corticosteroid dexamethasone in hippocampal tissue from adrenalectomized rats and acute  $\Delta^9$ -THC releases corticosterone, with tolerance developing to this effect with chronic administration (Eldridge et al., 1991). These data suggest that  $\Delta^9$ -THC may interact with the glucocorticoid receptor system.

#### **Immune System**

The HHS stated that cannabinoids alter immune function but that there can be differences between the effects of synthetic, natural, and endogenous cannabinoids (Croxford and Yamamura, 2005; Tanasescu and Constantinescu, 2010).

The HHS noted that there are conflicting results in animal and human studies with respect to cannabinoid effects on immune functioning in subjects with compromised immune systems. Abrams et al. (2003) examined the effects of marijuana and  $\Delta^9$ -THC in 62 HIV-1-infected patients. Subjects received one of three treatments, three times a day: smoked marijuana cigarette containing 3.95%  $\Delta^9$ -THC, oral tablet containing  $\Delta^9$ -THC (2.5 mg oral dronabinol), or oral placebo. There were no changes in CD4+ and CD8+ cell counts, HIV RNA levels, or protease inhibitor levels in any of the treatment groups (Abrams et al., 2003). Therefore, use of cannabinoids showed no short-term adverse virologic effects in individuals with compromised immune systems. Conversely, Roth et al. (2005) reported that in immunodeficient mice implanted with human blood cells infected with HIV, exposure to  $\Delta^9$ -THC *in vivo* suppresses immune function, increases HIV co-receptor expression,

and acts as a cofactor to enhance HIV replication.

The DEA notes two recent clinical studies reporting a decrease in cytokine and interleukin levels following marijuana use. Keen et al. (2014) compared the differences in the levels of IL-6 (interleukin-6), a proinflammatory cytokine, amongst non-drug users (n = 78), marijuana only users (n = 46) and marijuana plus other drug users (n = 45) in a community-based sample of middle-aged African Americans (Keen et al., 2014). After adjusting for confounders, analyses revealed that lifetime marijuana only users had significantly lower IL-6 levels than the nonuser group. Further, Sexton et al. (2014) compared several immune parameters in healthy individuals and subjects with multiple sclerosis (MS) and found that the chronic use of marijuana resulted in reduced monocyte migration, and decreased levels of CCL2 and IL-17 in both healthy and MS groups.

The DEA also notes a review suggesting that  $\Delta^9$ -THC suppresses the immune responses in experimental animal models and *in vitro* and that these changes may be primarily mediated through the CB2 cannabinoid receptor (Eisenstein and Meissler, 2015).

#### **Factor 3: The State of the Current Scientific Knowledge Regarding the Drug or Substance**

##### **Chemistry**

The HHS stated that marijuana, also known as *Cannabis sativa L.*, is part of the Cannabaceae plant family and is one of the oldest cultivated crops. The term “marijuana” is generally used to refer to a mixture of the dried flowering tops and leaves from *Cannabis*. Marijuana users primarily smoke the marijuana leaves, but individuals also ingest marijuana through food infused with marijuana and its extracts. *Cannabis sativa* is the primary species of *Cannabis* that is illegally marketed in the United States. Marijuana is one of three major derivatives sold as separate illicit products, the other two being hashish and hash oil. Hashish is composed of the dried and compressed cannabinoid-rich resinous material of *Cannabis* and is found as balls and cakes as well as other forms. Individuals may break off pieces and place them into a pipe to smoke. Hash oil, a viscous brown or amber colored liquid, is produced by solvent extraction of cannabinoids from *Cannabis* and contains approximately 50% cannabinoids. One to two drops of hash oil on a cigarette has been reported to

produce the equivalent of a single marijuana cigarette (DEA, 2015).

Different marijuana samples are derived from numerous cultivated strains and may have different chemical compositions including levels of  $\Delta^9$ -THC and other cannabinoids (Appendino et al., 2011). A consequence of having different chemical compositions in the various marijuana samples is that there will be significant differences in safety, biological, pharmacological, and toxicological profiles and therefore, according to the HHS, all *Cannabis* strains cannot be considered collectively because of the variations in chemical composition. Furthermore, the concentration of  $\Delta^9$ -THC and other cannabinoids present in marijuana may vary due to growing conditions and processing of the plant after harvesting. For example, the plant parts collected such as flowers, leaves and stems can influence marijuana's potency, quality, and purity (Adams and Martin, 1996; Agurell et al., 1984; Mechoulam, 1973). Variations in marijuana harvesting have resulted in potencies ranging from a low of 1 to 2% up to a high of 17% as indicated by cannabinoid content. The concentration of  $\Delta^9$ -THC averages approximately 12% by weight in a typical marijuana mixture of leaves and stems. However, some specifically grown and selected marijuana samples can contain 15% or greater  $\Delta^9$ -THC (Appendino et al., 2011). As a result, the  $\Delta^9$ -THC content in a 1 gram marijuana cigarette can range from as little as 3 milligrams to 150 milligrams or more. In a systematic review conducted by Cascini et al. (2012), it was reported that marijuana's  $\Delta^9$ -THC content has increased significantly from 1979–2009.

Since there is considerable variability in the cannabinoid concentrations and chemical constituency among marijuana samples, the interpretation of clinical data with marijuana is complicated. A primary issue is the lack of consistent concentrations of  $\Delta^9$ -THC and other substances in marijuana which complicates the interpretation of the effects of different marijuana constituents. An added issue is that the non-cannabinoid components in marijuana may potentially modify the overall pharmacological and toxicological properties of various marijuana strains and products.

Various *Cannabis* strains contain more than 525 identified natural constituents including cannabinoids, 21 (or 22) carbon terpenoids found in the plant, as well as their carboxylic acids, analogues, and transformation products (Agurell et al., 1984; 1986; Mechoulam, 1973; Appendino et al., 2011). To date,

more than 100 cannabinoids have been characterized (ElSohly and Slade, 2005; Radwan et al., 2009; Appendino et al., 2011), and most major cannabinoid compounds occurring naturally have been identified. There are still new and comparably more minor cannabinoids being characterized (Pollastro et al., 2011). The majority of the cannabinoids are found in *Cannabis*. One study reported accumulation of two cannabinoids, cannabigerol and its corresponding acid, in *Helichrysum* (*H. umbraculigerum*) which is a non-*Cannabis* source (Appendino et al., 2011).

Of the cannabinoids found in marijuana,  $\Delta^9$ -THC (previously known as  $\Delta^1$ -THC) and delta-8-tetrahydrocannabinol ( $\Delta^8$ -THC,  $\Delta^6$ -THC) have been demonstrated to produce marijuana's psychoactive effects. Psychoactive effects from marijuana usage have been mainly attributed to  $\Delta^9$ -THC because  $\Delta^9$ -THC is present in significantly more quantities than  $\Delta^8$ -THC in most marijuana varieties. There are only a few marijuana strains that contain  $\Delta^8$ -THC in significant amounts (Hively et al., 1966).  $\Delta^9$ -THC is an optically active resinous substance that is extremely lipophilic. The chemical name for  $\Delta^9$ -THC is (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo-[b,d]pyran-1-ol, or (-)-delta9-(trans)-tetrahydrocannabinol. The (-)-trans  $\Delta^9$ -THC isomer is pharmacologically 6 to 100 times more potent than the (+)-trans isomer (Dewey et al., 1984).

Other relatively well-characterized cannabinoids present in marijuana include cannabidiol (CBD), cannabichromene (CBC), and cannabinol (CBN). CBD and CBC are major cannabinoids in marijuana and are both lipophilic. The chemical name for CBD is 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol and the chemical name for CBC is 2-methyl-2-(4-methylpent-3-enyl)-7-pentyl-5-chromenol. CBN is a minor naturally-occurring cannabinoid with weak psychoactivity and is also a major metabolite of  $\Delta^9$ -THC. The chemical name for CBN is 6,6,9-trimethyl-3-pentyl-benzo[c]chromen-1-ol.

In summary, marijuana has several strains with high variability in the concentrations of  $\Delta^9$ -THC, the main psychoactive component, as well as other cannabinoids and compounds. Marijuana is not a single chemical and does not have a consistent and reproducible chemical profile with predictable or consistent clinical effects. In the HHS recommendation for marijuana scheduling (HHS, 2015), it

was recommended that investigators consult a guidance for industry entitled, *Botanical Drug Products*,<sup>45</sup> which provides information on the approval of botanical drug products. Specifically, in order to investigate marijuana in support of a New Drug Application (NDA), clinical studies under an Investigational New Drug (IND) application should include "consistent batches of a particular marijuana product for [a] particular disease." (HHS, 2015). Furthermore, the HHS noted that investigators must provide data meeting the requirements for new drug approval as stipulated in 21 CFR 314.50 (HHS, 2015).

#### Human Pharmacokinetics

Pharmacokinetics of marijuana in humans is dependent on the route of administration and formulation (Adams and Martin, 1996; Agurell et al., 1984; Agurell et al., 1986). Individuals primarily smoke marijuana as a cigarette (weighing between 0.5 and 1 gram) or in a pipe. More recently, vaporizers have been used as another means for individuals to inhale marijuana. Marijuana may also be ingested orally in foods or as an extract in ethanol or other solvents. Pharmacokinetic studies with marijuana focused on evaluating the absorption, metabolism, and elimination profile of  $\Delta^9$ -THC and other cannabinoids (Adams and Martin, 1996; Agurell et al., 1984; Agurell et al., 1986).

#### Absorption and Distribution of Inhaled Marijuana Smoke

There is high variability in the pharmacokinetics of  $\Delta^9$ -THC and other cannabinoids from smoked marijuana due to differences in individual smoking behavior even under controlled experimental conditions (Agurell et al., 1986; Herning et al., 1986; Huestis et al., 1992a). Experienced marijuana users can titrate and regulate the dose by holding marijuana smoke in their lungs for an extended period of time resulting in increased psychoactive effects by prolonging absorption of the smoke. This property may also help explain why there is a poor correlation between venous levels of  $\Delta^9$ -THC and the intensity of effects and intoxication (Agurell et al., 1986; Barnett et al., 1985; Huestis et al., 1992a). The HHS recommended that puff and inhalation volumes should be tracked in experimental studies because the concentration of cannabinoids can vary at different stages of smoking.

$\Delta^9$ -THC from smoked marijuana is rapidly absorbed within seconds.

Psychoactive effects are observed immediately following absorption with measurable neurological and behavioral changes for up to 6 hours (Grotenhermen, 2003; Hollister, 1986; Hollister, 1988).  $\Delta^9$ -THC is distributed to the brain in a rapid and efficient manner. Bioavailability of  $\Delta^9$ -THC from marijuana (from a cigarette or pipe) ranges from 1 to 24% with the fraction absorbed rarely exceeding 10 to 20% (Agurell et al., 1986; Hollister, 1988). The low and variable bioavailability of  $\Delta^9$ -THC is due to loss in side-stream smoke, variation in individual smoking behaviors and experience, incomplete absorption of inhaled smoke, and metabolism in lungs (Herning et al., 1986; Johansson et al., 1989). After cessation of smoking,  $\Delta^9$ -THC venous levels decline within minutes and continue to decline to about 5% to 10% of the peak level within an hour (Agurell et al., 1986; Huestis et al., 1992a; Huestis et al., 1992b).

#### Absorption and Distribution of Orally Administered Marijuana

Following oral administration of  $\Delta^9$ -THC or marijuana, onset of effects start within 30 to 90 minutes, peak after 2 to 3 hours and effects remain for 4 to 12 hours (Grotenhermen, 2003; Adams and Martin, 1996; Agurell et al., 1984; Agurell et al., 1986). Dose titration of  $\Delta^9$ -THC from orally ingested marijuana is difficult for users in comparison to smoked or inhaled marijuana due to the delay in the onset of effects. Oral bioavailability of  $\Delta^9$ -THC, either in its pure form or in marijuana, is low and variable with a range from 5% to 20% (Agurell et al., 1984; Agurell et al., 1986). There is also inter- and intra-subject variability of orally administered  $\Delta^9$ -THC under experimental conditions and even under repeated dosing experiments (HHS, 2015). The HHS noted that in bioavailability studies using radiolabeled  $\Delta^9$ -THC,  $\Delta^9$ -THC plasma levels following oral administration of  $\Delta^9$ -THC were low relative to plasma levels after inhaled or intravenously administered  $\Delta^9$ -THC. The low and variable bioavailability of orally administered  $\Delta^9$ -THC is due to first pass hepatic elimination from blood and erratic absorption from stomach and bowel (HHS, 2015).

#### Metabolism and Excretion of Cannabinoids From Marijuana

Studies evaluating cannabinoid metabolism and excretion focused on  $\Delta^9$ -THC because it is the primary psychoactive component in marijuana.

$\Delta^9$ -THC is metabolized via microsomal hydroxylation and oxidation to both active and inactive

<sup>45</sup> Available at <http://www.fda.gov/Drugs/default.htm> under Guidance (Drugs).

metabolites (Lemberger et al., 1970; Lemberger et al., 1972a; Lemberger et al., 1972b; Agurell et al., 1986; Hollister, 1988). Metabolism of  $\Delta^9$ -THC is consistent among frequent and infrequent marijuana users (Agurell et al., 1986). The primary active metabolite of  $\Delta^9$ -THC following oral ingestion is 11-hydroxy- $\Delta^9$ -THC which is equipotent to  $\Delta^9$ -THC in producing marijuana-like subjective effects (Agurell et al., 1986; Lemberger and Rubin, 1975). Metabolite levels following oral administration may be greater than that of  $\Delta^9$ -THC and may contribute greatly to the pharmacological effects of oral  $\Delta^9$ -THC or marijuana.

Plasma clearance of  $\Delta^9$ -THC approximates hepatic blood flow at a rate of approximately 950 ml/min or greater. Rapid clearance of  $\Delta^9$ -THC from blood is primarily due to redistribution to other tissues in the body rather than to metabolism (Agurell et al., 1984; Agurell et al., 1986). Outside of the liver, metabolism in most tissues is considerably slow or does not occur. The elimination half-life of  $\Delta^9$ -THC ranges from 20 hours to between 10 and 13 days (Hunt and Jones, 1980). Lemberger et al. (1970) reported that the half-life of  $\Delta^9$ -THC ranged from 23–28 hours in heavy marijuana users and up to 60 to 70 hours in naïve users. The long elimination half-life of  $\Delta^9$ -THC is due to slow release of  $\Delta^9$ -THC and other cannabinoids from tissues and subsequent metabolism. Inactive carboxy metabolites of  $\Delta^9$ -THC have terminal half-lives of 50 hours to 6 days or more and serve as long-term markers in urine tests for marijuana use.

Most of the absorbed  $\Delta^9$ -THC dose is eliminated in the feces and about 33% in urine. The glucuronide metabolite of  $\Delta^9$ -THC is excreted as the major urine metabolite along with 18 non-conjugated metabolites (Agurell et al., 1986).

#### Research Status and Test of Currently Accepted Medical Use for Marijuana

According to the HHS, there are numerous human clinical studies with marijuana in the United States under FDA-regulated IND applications. Results of small clinical exploratory studies have been published in the medical literature. Approval of a human drug for marketing, however, is contingent upon FDA approval of a New Drug Application (NDA) or a Biologics License Application (BLA). According to the HHS, the FDA has not approved any drug product containing marijuana for marketing.

The HHS noted that a drug may be found to have a medical use in treatment in the United States for

purposes of the CSA if the drug meets the five elements described by the DEA in 1992. Those five elements “are both necessary and sufficient to establish a prima facie case of currently accepted medical use” in treatment in the United States.” (57 FR 10499, 10504 (March 26, 1992)). This five-element test, which the HHS and DEA have utilized in all such analyses for more than two decades, has been upheld by the Court of Appeals. *ACT*, 15 F.3d at 1135. The five elements that characterize “currently accepted medical use” for a drug are summarized here and expanded upon in the discussion below:

1. *The drug's chemistry must be known and reproducible;*
2. *There must be adequate safety studies;*
3. *There must be adequate and well-controlled studies proving efficacy;*
4. *The drug must be accepted by qualified experts; and*
5. *Scientific evidence must be widely available.*

In its review (HHS, 2015), the HHS evaluated the five elements with respect to the currently available research for marijuana. The HHS concluded that marijuana does not meet any of the five elements—all of which must be demonstrated to find that a drug has a “currently accepted medical use.” A brief summary of the HHS’s evaluation is provided below.

*Element #1: The drug's chemistry must be known and reproducible.*

*“The substance's chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official compendia, as defined by section 201(j) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321(j), is sufficient generally to meet this requirement.” 57 FR 10499, 10506 (March 26, 1992).*

As defined by the CSA, marijuana includes all species of the genus *Cannabis*, including all strains therein.<sup>46</sup> Chemical constituents

<sup>46</sup> Although the CSA definition of marijuana refers only to the species “*Cannabis sativa* L.,” federal courts have consistently ruled that all species of the genus *cannabis* are included in this definition. See *United States v. Kelly*, 527 F.2d 961, 963–964 (9th Cir. 1976) (collecting and examining cases). The Single Convention (article 1, par. 1(c)) likewise defines the “cannabis plant” to mean “any plant of the genus *Cannabis*.” As explained above in the attachment titled “Preliminary Note Regarding Treaty Considerations,” 21 U.S.C. 811(d)(1) provides that, where a drug is subject to control under the Single Convention, the DEA Administrator must control the drug under the schedule he deems most appropriate to carry out such treaty obligations, without regard to the findings required by 21 U.S.C. 811(a) or 812(b) and without regard to the procedures prescribed by 21 U.S.C. 811(a) and (b).

including  $\Delta^9$ -THC and other cannabinoids vary significantly in marijuana samples derived from different strains (Appendino et al., 2011). As a result, there will be significant differences in safety, biological, pharmacological, and toxicological parameters amongst the various marijuana samples. Due to the variation of the chemical composition in marijuana samples, it is not possible to reproduce a standardized dose when considering all strains together. The HHS does advise that if a specific *Cannabis* strain is cultivated and processed under controlled conditions, the plant chemistry may be consistent enough to derive reproducible and standardized doses.

*Element #2: There must be adequate safety studies.*

*“There must be adequate pharmacological and toxicological studies, done by all methods reasonably applicable, on the basis of which it could fairly and responsibly be concluded, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, that the substance is safe for treating a specific, recognized disorder.” 57 FR 10499, 10506 (March 26, 1992).*

The HHS stated that there are no adequate safety studies on marijuana. As indicated in their evaluation of Element #1, the considerable variation in the chemistry of marijuana complicates the safety evaluation. The HHS concluded that marijuana does not satisfy Element #2 for having adequate safety studies such that medical and scientific experts may conclude that it is safe for treating a specific ailment.

*Element #3: There must be adequate and well-controlled studies of efficacy.*

*“There must be adequate, well-controlled, well-designed, well-conducted and well-documented studies, including clinical investigations, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, on the basis of which it could be fairly and responsibly concluded by such experts that the substance will have the intended effect in treating a specific, recognized disorder.” 57 FR 10499, 10506 (March 26, 1992).*

As indicated in the HHS’s review of marijuana (HHS, 2015), there are no adequate or well-controlled studies that prove marijuana’s efficacy. The FDA independently reviewed (FDA, 2015) publicly available clinical studies on marijuana published prior to February 2013 to determine if there were appropriate studies to determine marijuana’s efficacy (please refer to FDA, 2015 and HHS, 2015 for more

details). After review, the FDA determined that out of the identified articles, including those identified through a search of bibliographic references and 566 abstracts located on PubMed, 11 studies met the *a priori* selection criteria, including placebo control and double-blinding. FDA and HHS critically reviewed each of the 11 studies to determine if the studies met accepted scientific standards. FDA and HHS concluded that these studies do not “currently prove efficacy of marijuana” for any therapeutic indication due to limitations in the study designs. The HHS indicated that these studies could be used as proof of concept studies, providing preliminary evidence on a proposed hypothesis involving a drug’s effect.

*Element #4: The drug must be accepted by qualified experts.*

*“[A] consensus of the national community of experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, accepts the safety and effectiveness of the substance for use in treating a specific, recognized disorder. A material conflict of opinion among experts precludes a finding of consensus.” 57 FR 10499, 10506 (March 26, 1992).*

The HHS concluded that there is currently no evidence of a consensus among qualified experts that marijuana is safe and effective in treating a specific and recognized disorder. The HHS indicated that medical practitioners who are not experts in evaluating drugs cannot be considered qualified experts (HHS, 2015; 57 FR 10499, 10505). Further, the HHS noted that the 2009 American Medical Association (AMA) report entitled, “Use of Cannabis for Medicinal Purposes” does not conclude that there is a currently accepted medical use for marijuana. HHS also pointed out that state-level “medical marijuana” laws do not provide evidence of such a consensus among qualified experts.

*Element #5: The scientific evidence must be widely available.*

*“In the absence of NDA approval, information concerning the chemistry, pharmacology, toxicology, and effectiveness of the substance must be reported, published, or otherwise widely available, in sufficient detail to permit experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, to fairly and responsibly conclude the substance is safe and effective for use in treating a specific, recognized disorder.” 57 FR 10499, 10506 (March 26, 1992).*

The HHS concluded that the currently available data and information on

marijuana is not sufficient to allow scientific scrutiny of the chemistry, pharmacology, toxicology, and effectiveness. In particular, scientific evidence demonstrating the chemistry of a specific *Cannabis* strain that could provide standardized and reproducible doses is not available.

#### **Petitioners’ Major Comments in Relation to Factor 3 and the Government’s Responses**

(1) The petitioner states on page 2 of the petition, “*Marijuana has accepted medical use in the United States. Thirteen states accept the safety of marijuana for medical use . . . . Marijuana has been accepted as having medical use by dozens of professional medical and nursing organizations throughout the U.S. . . . Even the American Medical Association has now accepted the safety and efficacy of cannabinoid medicines and supports removal of marijuana from schedule I of the CSA in order to support further research.*”

As noted above, the HHS concluded that there is currently no evidence of a consensus among qualified experts that marijuana is safe and effective in treating a specific and recognized disorder, as required by the established standards. HHS pointed out that state-level “medical marijuana” laws do not provide evidence of such a consensus among qualified experts. HHS also indicated that medical practitioners who are not experts in evaluating drugs cannot be considered qualified experts (HHS, 2015; 57 FR 10499, 10505).

Further, the HHS pointed out that the 2009 AMA report entitled, “Use of Cannabis for Medicinal Purposes” does not conclude that there is a currently accepted medical use for marijuana. Instead, the AMA, like several other professional and medical associations, recommended further testing with marijuana to determine its medicinal value. The AMA official policy on medicinal use of marijuana is as follows: “*Our AMA urges that marijuana’s status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternative delivery methods. This should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product.*” (AMA, 2009). The DEA further notes that the 2013 AMA House of Delegates report states that, “*cannabis is a dangerous drug and as*

*such is a public health concern.*” (AMA, 2013).

(2) The petitioner asserts on page 3 of the petition that, “*Several recent studies of smoked marijuana have confirmed the safety and efficacy of smoked marijuana for medical use.*”

The HHS, in its scientific and medical evaluation, reviewed marijuana clinical studies evaluating therapeutic properties and concluded that there is not enough data to confirm the safety and efficacy of smoked marijuana for use in treating a specific and recognized disorder. Relevant to efficacy, for instance, the HHS concluded, for instance, that “smoking marijuana currently has not been shown to allow delivery of consistent and reproducible doses,” and that the bioavailability of the delta-9 -THC from marijuana in a cigarette or pipe can range from 1 percent to 24 percent with the fraction absorbed rarely exceeding 10 to 20%. Issues relating to the safety of smoked marijuana were discussed above in Factor 2.

(3) On page 3, the petitioner states that “*marijuana has been determined to be safe for use under medical supervision by the DEA’s own administrative law judge.*”

As described above, in the absence of NDA or ANDA approval, DEA has established a five-element test for determining whether the drug has a currently accepted medical use in treatment in the United States. 57 FR 10499, 10506 (March 26, 1992)). See also *ACT*, 15 F.3d at 1135. In response to this petition, HHS concluded, and DEA agrees, that the scientific evidence is insufficient to demonstrate that marijuana has a currently accepted medical use under the five-element test. The evidence was insufficient in this regard also when the DEA considered petitions to reschedule marijuana in 1992 (57 FR 10499), in 2001 (66 FR 20038), and in 2011 (76 FR 40552). Little has changed since 2011 with respect to the lack of clinical evidence necessary to establish that marijuana has a currently accepted medical use. No studies have scientifically assessed the efficacy and full safety profile of marijuana for any specific medical condition.

#### **Factor 4: Its History and Current Pattern of Abuse**

Marijuana continues to be the most widely used illicit drug. In 2013, an estimated 24.6 million Americans age 12 or older were current (past month) illicit drug users. Of those, 19.8 million were current (past month) marijuana users. As of 2013, an estimated 114.7 million Americans age 12 and older had

used marijuana or hashish in their lifetime and 33.0 million had used it in the past year.

According to the NSDUH estimates, 3.0 million people age 12 or older used an illicit drug for the first time in 2014. Marijuana initiates totaled 2.6 million in 2014. Nearly half (46.8%) of the 2.6 million new users were less than 18 years of age. In 2014, marijuana was used by 82.2% of current (past month) illicit drug users. In 2014, among past year marijuana users age 12 or older, 18.5% used marijuana on 300 or more days within the previous 12 months. This translates into 6.5 million people using marijuana on a daily or almost daily basis over a 12-month period, a significant increase from the 3.1 million daily or almost daily users in 2006 and from the 5.7 million in just the previous year. In 2014, among past month marijuana users, 41.6% (9.2 million people) used the drug on 20 or more days in the past month, a significant increase from the 8.1 million in 2013.

Marijuana is also the illicit drug with the highest numbers of past year dependence or abuse in the U.S. population. According to the 2014 NSDUH report, of the 7.1 million persons aged 12 or older who were classified with illicit drug dependence or abuse, 4.2 million of them abused or were dependent on marijuana (representing 59.0% of all those classified with illicit drug dependence or abuse and 1.6% of the total U.S. non-institutionalized population aged 12 or older).

According to the 2015 Monitoring the Future (MTF) survey, marijuana is used by a large percentage of American youths, and is the most commonly used illicit drug among American youth. Among students surveyed in 2015, 15.5% of 8th graders, 31.1% of 10th graders, and 44.7% of 12th graders reported that they had used marijuana in their lifetime. In addition, 11.8%, 25.4%, and 34.9% of 8th, 10th, and 12th graders, respectively, reported using marijuana in the past year. A number of high school students reported daily use in the past month, including 1.1%, 3.0%, and 6.0% of 8th, 10th, and 12th graders, respectively.

The prevalence of marijuana use and abuse is also indicated by criminal investigations for which drug evidence was analyzed in federal, state, and local forensic laboratories, as discussed above in Factor 1. The National Forensic Laboratory System (NFLIS), a DEA program, systematically collects drug identification results and associated information from drug cases submitted to and analyzed by federal, state, and local forensic laboratories. NFLIS data

shows that marijuana was the most frequently identified drug from January 2001 through December 2014. In 2014, marijuana accounted for 29.3% (432,989) of all drug exhibits in NFLIS.

The high consumption of marijuana is being fueled by increasing amounts of domestically grown marijuana as well as increased amounts of foreign source marijuana being illicitly smuggled into the United States. In 2014, the Domestic Cannabis Eradication and Suppression Program (DCE/SP) reported that 3,904,213 plants were eradicated in outdoor cannabis cultivation areas compared to 2,597,798 in 2000, as shown above in Table 3. Significant quantities of marijuana were also eradicated from indoor cultivation operations. There were 396,620 indoor plants eradicated in 2014 compared to 217,105 eradicated in 2000. As shown in Table 2 above, in 2014, the National Seizure System (NSS) reported seizures of 1,767,741 kg of marijuana.

#### **Factor 5: The Scope, Duration, and Significance of Abuse**

Abuse of marijuana is widespread and significant. As previously noted, according to the NSDUH, in 2014, an estimated 117.2 million Americans (44.2%) age 12 or older had used marijuana or hashish in their lifetime, 35.1 million (13.2%) had used it in the past year, and 22.2 million (8.4%) had used it in the past month. Past year and past month marijuana use has increased significantly since 2013. Past month marijuana use is highest among 18–21 year olds and it declines among those 22 years of age and older. In 2014, an estimated 18.5% of past year marijuana users age 12 or older used marijuana on 300 or more days within the past 12 months. This translates into 6.5 million persons using marijuana on a daily or almost daily basis over a 12-month period. In 2014, an estimated 41.6% (9.2 million) of past month marijuana users age 12 or older used the drug on 20 or more days in the past month (SAMHSA, NSDUH). Chronic use of marijuana is associated with a number of health risks (see Factors 2 and 6).

Furthermore, the average percentage of  $\Delta^9$ -THC in seized marijuana has increased over the past two decades (The University of Mississippi Potency Monitoring Project). Additional studies are needed to clarify the impact of greater potency, but one study shows that higher levels of  $\Delta^9$ -THC in the body are associated with greater psychoactive effects (Harder and Rietbrock, 1997), which can be correlated with higher abuse potential (Chait and Burke, 1994).

TEDS data show that in 2013, marijuana/hashish was the primary

substance of abuse in 16.8% of all admissions to substance abuse treatment among patients age 12 and older. TEDS data also show that marijuana/hashish was the primary substance of abuse for 77.0% of all 12- to 14-year-olds admitted for drug treatment and 75.5% of all 15- to 17-year-olds admitted for drug treatment in 2013. Among the 281,991 admissions to drug treatment in 2013 in which marijuana/hashish was the primary drug, the average age at admission was 25 years and the peak age cohort was 15 to 17 years (22.5%). Thirty-nine percent of the 281,991 primary marijuana/hashish admissions (35.9%) were under the age of 20.

In summary, the recent statistics from these various surveys and databases (see Factor 1 for more details) demonstrate that marijuana continues to be the most commonly used illicit drug, with large incidences of heavy use and dependence in teenagers and young adults.

#### **Factor 6: What, if Any, Risk There Is to the Public Health**

In its recommendation, the HHS discussed public health risks associated with acute and chronic marijuana use in Factor 6. Public health risks as measured by emergency department visits and drug treatment admissions are discussed by HHS and DEA in Factors 1, 4, and 5. Similarly, Factor 2 discusses marijuana's pharmacology and presents some of the adverse health effects associated with use. Marijuana use may affect the physical and/or psychological functioning of an individual user, but may also have broader public impacts including driving impairments and fatalities from car accidents.

#### **Risks From Acute Use of Marijuana**

As discussed in the HHS review document (HHS, 2015), acute use of marijuana impairs psychomotor performance including motor control and impulsivity, risk taking and executive function (Ramaekers et al., 2004; Ramaekers et al., 2006). In a minority of individuals using marijuana, dysphoria, prolonged anxiety, and psychological distress may be observed (Haney et al., 1999). The DEA further notes a recent review of acute marijuana effects (Wilkinson et al., 2014) that reported impaired neurological function including altered perception, paranoia, delayed response time, and memory deficits.

In its recommendation, HHS references a meta-analysis conducted by Li et al. (2012) where the authors concluded that psychomotor impairments associated with acute marijuana usage have also been



associated with increased risk of car accidents with individuals experiencing acute marijuana intoxication (Li et al., 2012; HHS, 2015). The DEA further notes more recent studies examining the risk associated with marijuana use and driving. Younger drivers (under 21) have been characterized as the highest risk group associated with marijuana use and driving (Whitehill et al., 2014). Furthermore, in 2013, marijuana was found in 13% of the drivers involved in automobile-related fatal accidents (McCartt, 2015). The potential risk of automobile accidents associated with marijuana use appears to be increasing since there has been a steady increase in individuals intoxicated with marijuana over the past 20 years (Wilson et al., 2014). However, a recent study commissioned by the National Highway Traffic Safety Administration (NHTSA) reported that when adjusted for confounders (e.g., alcohol use, age, gender, ethnicity), there was not a significant increase in crash risk (fatal and nonfatal, n = 2,682) associated with marijuana use (Compton and Berning, 2015).

The DEA also notes recent studies examining unintentional exposures of children to marijuana (Wang et al., 2013; 2014). Wang et al. (2013) reviewed emergency department (ED) visits at a children's hospital in Colorado from January 1, 2005 to December 31, 2011. As stated by the authors, in 2000 Colorado passed Amendment 20 which allowed for the use of marijuana. Following the passage of "a new Justice Department policy" instructing "federal prosecutors not to seek arrest of medical marijuana users and suppliers as long as they conform to state laws" (as stated in Wang et al., 2013), 14 patients in Colorado under the age of 12 were admitted to the ED for the unintended use of marijuana over a 27 month period. Prior to the passage of this policy, from January 1, 2005 to September 30, 2009 (57 months), there were no pediatric ED visits due to unintentional marijuana exposure (Wang et al., 2013). The DEA also notes a larger scale evaluation of pediatric exposures using the National Poison Data System (Wang et al., 2014). That study reported that there were 985 unintentional marijuana exposures in children (9 years and younger) between January 1, 2005 to December 31, 2011. The authors stratified the ED visits by states with laws allowing medical use of marijuana, states transitioning to legalization for medical use, and states with no such laws. Out of the 985 exposures, 495 were in non-legal states (n=33 states), 93 in transitional states

(n=8 states), and 396 in "legal" states (n=9 states). The authors reported that there was a twofold increase (OR = 2.1) in moderate or major effects in children with unintentional marijuana use and a threefold increase (OR = 3.4) in admissions to critical care units in states allowing medical use of marijuana, in comparison to non-legal states.

#### **Risks Associated With Chronic Use of Marijuana**

The HHS noted that a major risk from chronic marijuana use is a distinctive withdrawal syndrome, as described in the 2013 DSM-5. The HHS analysis also quoted the following description of risks associated with marijuana [cannabis] abuse from the DSM-5:

*Individuals with cannabis use disorder may use cannabis throughout the day over a period of months or years, and thus may spend many hours a day under the influence. Others may use less frequently, but their use causes recurrent problems related to family, school, work, or other important activities (e.g., repeated absences at work; neglect of family obligations). Periodic cannabis use and intoxication can negatively affect behavioral and cognitive functioning and thus interfere with optimal performance at work or school, or place the individual at increased physical risk when performing activities that could be physically hazardous (e.g. driving a car; playing certain sports; performing manual work activities, including operating machinery). Arguments with spouses or parents over the use of cannabis in the home, or its use in the presence of children, can adversely impact family functioning and are common features of those with cannabis use disorder. Last, individuals with cannabis use disorder may continue using marijuana despite knowledge of physical problems (e.g. chronic cough related to smoking) or psychological problems (e.g. excessive sedation or exacerbation of other mental health problems) associated with its use. (HHS 2015, page 34).*

The HHS stated that chronic marijuana use produces acute and chronic adverse effects on the respiratory system, memory and learning. Regular marijuana smoking can produce a number of long-term pulmonary consequences, including chronic cough and increased sputum (Adams and Martin, 1996), and histopathologic abnormalities in bronchial epithelium (Adams and Martin, 1996).

#### **Marijuana as a "Gateway Drug"**

The HHS reviewed the clinical studies evaluating the gateway hypothesis in marijuana and found them to be limited. The primary reasons were: (1) Recruited participants were influenced by social, biological, and economic factors that contribute to

extensive drug abuse (Hall and Lynskey, 2005), and (2) most studies testing the gateway drug hypothesis for marijuana use the determinative measure *any use of an illicit drug* rather than applying DSM-5 criteria for drug abuse or dependence (DSM-5, 2013).

The HHS cited several studies where marijuana use did not lead to other illicit drug use (Kandel and Chen, 2000; von Sydow et al., 2002; Nace et al., 1975). Two separate longitudinal studies with adolescents using marijuana did not demonstrate an association with use of other illicit drugs (Kandel and Chen, 2000; von Sydow et al., 2002).

It was noted by the HHS that, when evaluating the gateway hypothesis, differences appear when examining use versus abuse or dependence of other illicit drugs. Van Gundy and Rebellon (2010) reported that there was a correlation between marijuana use in adolescence and other illicit drug use in early adulthood, but when examined in terms of drug abuse of other illicit drugs, age-linked stressors and social roles were confounders in the association. Degenhardt et al. (2009) reported that marijuana use often precedes use of other illicit drugs, but dependence involving drugs other than marijuana frequently correlated with higher levels of illicit drug abuse. Furthermore, Degenhardt et al. (2010) reported that in countries with lower prevalence of marijuana usage, use of other illicit drugs before marijuana was often documented.

Based on these studies among others, the HHS concluded that although many individuals with a drug abuse disorder may have used marijuana as one of their first illicit drugs, this does not mean that individuals initiated with marijuana inherently will go on to become regular users of other illicit drugs.

#### **Factor 7: Its Psychic or Physiological Dependence Liability**

##### **Physiological (Physical) Dependence in Humans**

The HHS stated that heavy and chronic use of marijuana can lead to physical dependence (DSM-5, 2013; Budney and Hughes, 2006; Haney et al., 1999). Tolerance is developed following repeated administration of marijuana and withdrawal symptoms are observed as following discontinuation of marijuana usage (HHS, 2015).

The HHS mentioned that tolerance can develop to some of marijuana's effects, but does not appear to develop with respect to the psychoactive effects. It is believed that lack of tolerance to

psychoactive effects may relate to electrophysiological data demonstrating that chronic  $\Delta^9$ -THC administration does not affect increased neuronal firing in the ventral tegmental area, a brain region that plays a critical role in drug reinforcement and reward (Wu and French, 2000). Humans can develop tolerance to marijuana's cardiovascular, autonomic, and behavioral effects (Jones et al., 1981). Tolerance to some behavioral effects appears to develop with heavy and chronic use, but not with occasional usage. Ramaekers et al. (2009) reported that following acute administration of marijuana, occasional marijuana users still exhibited impairments in tracking and attention tasks whereas performance of heavy users on the these tasks was not affected. In a follow-up study with the same subjects that participated in the study by Ramaekers et al. (2009), a neurophysiological assessment was conducted where event-related potentials (ERPs) were measured using electroencephalography (EEG) (Theunissen et al., 2012). Similar to the earlier results, the heavy marijuana users (n = 11; average of 340 marijuana uses per year) had no changes in their ERPs with the acute marijuana exposure. However, occasional users (n = 10; average of 55 marijuana uses per year) had significant decreases in the amplitude of an ERP component (categorized as P100) on tracking and attention tasks and ERP amplitude change is indicative of a change in brain activity (Theunissen et al., 2012).

The HHS indicated that down-regulation of cannabinoid receptors may be a possible mechanism for tolerance to marijuana's effects (Hirvonen et al., 2012; Gonzalez et al., 2005; Rodriguez de Fonseca et al., 1994; Oviedo et al., 1993).

As indicated by the HHS, the most common withdrawal symptoms in heavy, chronic marijuana users are sleep difficulties, decreased appetite or weight loss, irritability, anger, anxiety or nervousness, and restlessness (Budney and Hughes, 2006; Haney et al., 1999). As reported by HHS, most marijuana withdrawal symptoms begin within 24–48 hours of discontinuation, peak within 4–6 days, and last for 1–3 weeks.

The HHS pointed out that the American Psychiatric Association's (APA's) Diagnostic and Statistical Manual of Mental Disorders—5 (DSM–5) included a list of withdrawal symptoms following marijuana [cannabis] use (DSM–5, 2013). The DEA notes that a DSM–5 working group report indicated that marijuana withdrawal symptoms were added to DSM–5 (they were not previously

included in DSM–IV) because marijuana withdrawal has now been reliably presented in several studies (Hasin et al., 2013). In short, marijuana withdrawal signs are reported in up to one-third of regular users and between 50% and 90% of heavy users (Hasin et al., 2013). According to DSM–5 criteria, in order to be characterized as having marijuana withdrawal, an individual must develop at least three of the seven symptoms within one week of decreasing or stopping the heavy and prolonged use (DSM–5, 2013). These seven symptoms are: (1) Irritability; anger or aggression, (2) nervousness or anxiety, (3) sleep difficulty, (4) decreased appetite or weight loss, (5) restlessness, (6) decreased mood, (7) somatic symptoms causing significant discomfort (DSM–5, 2013).

#### Psychological (Psychic) Dependence in Humans

High levels of psychoactive effects such as positive reinforcement correlate with increased marijuana abuse and dependence (Scherrer et al., 2009; Zeiger et al., 2010). Epidemiological marijuana use data reported by NSDUH, MTF, and TEDS support this assertion as presented in the HHS 2015 review of marijuana and updated by the DEA. According to the findings in the 2014 NSDUH survey, an estimated 9.2 million individuals 12 years and older used marijuana daily or almost daily (20 or more days within the past month). In the 2015 MTF report, daily marijuana use (20 or more days within the past 30 days) in 8th, 10th, and 12th graders is 1.1%, 3.0%, and 6.0%, respectively.

The 2014 NSDUH report stated that 4.2 million persons were classified with dependence on or abuse of marijuana in the past year (representing 1.6% of the total population age 12 or older, and 59.0% of those classified with illicit drug dependence or abuse) based on criteria specified in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM–IV). Furthermore, of the admissions to licensed substance abuse facilities, as presented in TEDS, marijuana/hashish was the primary substance of abuse for; 18.3% (352,297) of 2011 admissions; 17.5% (315,200) of 2012 admissions; and 16.8% (281,991) of 2013 admissions. Of the 281,991 admissions in 2013 for marijuana/hashish as the primary substance, 24.3% used marijuana/hashish daily. Among admissions to treatment for marijuana/hashish as the primary substance in 2013, 27.4% were ages 12 to 17 years and 29.7% were ages 20 to 24 years.

#### Factor 8: Whether the Substance is an Immediate Precursor of a Substance Already Controlled Under the CSA

Marijuana is not an immediate precursor of another controlled substance.

#### Determination

After consideration of the eight factors discussed above and of the HHS's Recommendation, the DEA finds that marijuana meets the three criteria for placing a substance in schedule I of the CSA under 21 U.S.C. 812(b)(1):

1. Marijuana has a high potential for abuse.

The HHS concluded that marijuana has a high potential for abuse based on a large number of people regularly using marijuana, its widespread use, and the vast amount of marijuana that is available through illicit channels.

Marijuana is the most abused and trafficked illicit substance in the United States. Approximately 22.2 million individuals in the United States (8.4% of the United States population) were past month users of marijuana according to the 2014 NSDUH survey. A 2015 national survey (Monitoring the Future) that tracks drug use trends among high school students showed that by 12th grade, 21.3% of students reported using marijuana in the past month, and 6.0% reported having used it daily in the past month. In 2011, SAMHSA's Drug Abuse Warning Network (DAWN) reported that marijuana was mentioned in 36.4% of illicit drug-related emergency department (ED) visits, corresponding to 455,668 out of approximately 1.25 million visits. The Treatment Episode Data Set (TEDS) showed that 16.8% of non-private substance-abuse treatment facility admissions in 2013 were for marijuana as the primary drug.

Marijuana has dose-dependent reinforcing effects that encourage its abuse. Both clinical and preclinical studies have demonstrated that marijuana and its principle psychoactive constituent,  $\Delta^9$ -THC, possess the pharmacological attributes associated with drugs of abuse. They function as discriminative stimuli and as positive reinforcers to maintain drug use and drug-seeking behavior. Additionally, use of marijuana can result in psychological dependence.

2. Marijuana has no currently accepted medical use in treatment in the United States.

The HHS stated that the FDA has not approved an NDA for marijuana. The HHS noted that there are opportunities for scientists to conduct clinical research with marijuana and there are active INDs for marijuana, but marijuana

does not have a currently accepted medical use in the United States, nor does it have an accepted medical use with severe restrictions.

FDA approval of an NDA is not the sole means through which a drug can be determined to have a “currently accepted medical use” under the CSA. Applying the five-part test summarized below, a drug has a currently accepted medical use if all of the following five elements have been satisfied. As detailed in the HHS evaluation and as set forth below, none of these elements has been fulfilled for marijuana:

i. The drug’s chemistry must be known and reproducible

Chemical constituents including  $\Delta^9$ -THC and other cannabinoids in marijuana vary significantly in different marijuana strains. In addition, the concentration of  $\Delta^9$ -THC and other cannabinoids may vary between strains. Therefore the chemical composition among different marijuana samples is not reproducible. Due to the variation of the chemical composition in marijuana strains, it is not possible to derive a standardized dose. The HHS does advise that if a specific *Cannabis* strain is cultivated and processed under controlled conditions, the plant chemistry may be consistent enough to derive standardized doses.

ii. There must be adequate safety studies

There are not adequate safety studies on marijuana for use in any specific, recognized medical condition. The considerable variation in the chemistry of marijuana results in differences in safety, biological, pharmacological, and toxicological parameters amongst the various marijuana samples.

iii. There must be adequate and well-controlled studies proving efficacy

There are no adequate and well-controlled studies that determine marijuana’s efficacy. In an independent review performed by the FDA of publicly available clinical studies on marijuana (FDA, 2015), FDA concluded that these studies do not have enough information to “currently prove efficacy of marijuana” for any therapeutic indication.

iv. The drug must be accepted by qualified experts

At this time, there is no consensus of opinion among experts concerning the medical utility of marijuana for use in treating specific recognized disorders.

v. The scientific evidence must be widely available

The currently available data and information on marijuana is not sufficient to address the chemistry, pharmacology, toxicology, and

effectiveness. The scientific evidence regarding marijuana’s chemistry with regard to a specific cannabis strain that could be formulated into standardized and reproducible doses is not currently available.

3. There is a lack of accepted safety for use of marijuana under medical supervision.

Currently, there are no FDA-approved marijuana products. The HHS also concluded that marijuana does not have a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. According to the HHS, the FDA is unable to conclude that marijuana has an acceptable level of safety in relation to its effectiveness in treating a specific and recognized disorder due to lack of evidence with respect to a consistent and reproducible dose that is contamination free. The HHS indicated that marijuana research investigating potential medical use should include information on the chemistry, manufacturing, and specifications of marijuana. The HHS further indicated that a procedure for delivering a consistent dose of marijuana should also be developed. Therefore, the HHS concluded that marijuana does not have an acceptable level of safety for use under medical supervision.

## References

- Abrams DI, Hilton JF, Reiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M (2003). Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. *Ann Intern Med* 139(4):258–266.
- Adams IB, Martin BR (1996). Cannabis: Pharmacology and toxicology in animals and humans. *Addiction* 91:1585–1614.
- Agurell S, Dewey WL, and Willetts RE (eds.) (1984). *The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects*. New York: Academic Press
- Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L (1986). Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on man. *Pharmacol Rev* 38(1):21–43.
- American College of Physicians [ACP]. (2008). Supporting Research Into the Therapeutic Role of Marijuana. Philadelphia: American College of Physicians; 2008: Position Paper (Available from American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106).
- American Medical Association [AMA]. (2009a). Use of Cannabis for Medical Purposes. *Report of the Council on Science and Public Health* 3.
- American Medical Association [AMA]. (2009b). AMA Policy: Medical Marijuana. H-95–952 Medical Marijuana.
- American Medical Association [AMA]. (2013). 2013 Interim Meeting. American Medical Association House of Delegates (1–13). Accessed at [www.ama-assn.org/assets/meeting/2013i/113-refcommk-annotated.pdf](http://www.ama-assn.org/assets/meeting/2013i/113-refcommk-annotated.pdf).
- American Society of Addiction Medicine [ASAM]. (2014). *New York Times* calls for legalization of marijuana, ASAM strongly objects. Accessed at [www.asam.org/docs/default-source/pressreleases/asam-press-release-nytimes-editorial-marijuana-2014-7-27.pdf?sfvrsn=2](http://www.asam.org/docs/default-source/pressreleases/asam-press-release-nytimes-editorial-marijuana-2014-7-27.pdf?sfvrsn=2).
- Andreasson S, Allebeck P, Engström A, Rydberg U (1987). Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. *Lancet* 1:483–483.
- Appendino G, Chianese G, Tagliatalata-Scafati O (2011). Cannabinoids: occurrence and medicinal chemistry. *Curr Med Chem* 18(7):1085–1099.
- Asch RH, Smith CG, Siler-Khodr TM, Pauerstein CJ (1981). Effects of delta 9-tetrahydrocannabinol during the follicular phase of the rhesus monkey (*Macaca mulatta*). *J Clin Endocrinol Metab* 52(1):50–55.
- Balster RL (1991). Drug abuse potential evaluation in animals. *Br J Addict* 86(12):1549–1558.
- Balster RL, Prescott WR (1992). Delta9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. *Neurosci Biobehav Res* 16(1):55–62.
- Balster RL, Bigelow GE (2003). Guidelines and methodological reviews concerning drug abuse liability assessment. *Drug Alcohol Depend* 70:S13–S40.
- Barnett G, Licko V, Thompson T (1985). Behavioral pharmacokinetics of marijuana. *Psychopharmacology* 85(1):51–56.
- Benowitz NL, Jones RT (1975). Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. *Clin Pharmacol Ther* 18(3):287–297.
- Benowitz NL, Jones RT (1981). Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. *J Clin Pharmacol* 21(8–9 Suppl):214S–223S.
- Block RI, Farinpour R, Schlechte JA (1991). Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. *Drug Alcohol Depend* 28(2):121–128.
- Block RI, Farinpour R, Braverman K (1992). Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. *Pharmacol Biochem Behav* 43(3):907–917.
- Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL (2002). Dose-related neurocognitive effects of marijuana use. *Neurology* 59:1337–1343.
- Bolla KI, Eldreth DA, Matochik JA, Cadet JL (2005). Neural substrates of faulty decision-making in abstinent marijuana users. *NeuroImage* 26:480–492.

23. Bonnet U (2013). Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function. *Pharmacopsychiatry* 46(1):35–36.
24. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P (1993). Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem* 214(1):173–180.
25. Braida D, Iosue S, Pegorini S, Sala M (2004). Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. *Eur J Pharmacol* 506(1):63–69.
26. Brievogel CS, Childers SR (2000). Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. *J Pharmacol Exp Ther* 295(1):328–336.
27. Brown TT, Dobs AS (2002). Endocrine effects of marijuana. *J Clin Pharmacol* 42(11 Suppl):90S–96S.
28. Browne RG, Weisman A (1981). Discriminative stimulus properties of delta 9-tetrahydrocannabinol: Mechanistic studies. *J Clin Pharmacol* 21(8–9 Suppl):227S–234S.
29. Budney AJ, Hughes JR (2006). The cannabis withdrawal syndrome. *Curr Opin Psychiatry* 19(3):233–238.
30. Capriotti RM, Foltin RW, Brady JV, Fischman MW (1988). Effects of marijuana on the task-elicited physiological response. *Drug Alcohol Depend* 21(3):183–187.
31. Cascini F, Aiello C, Di Tanna G (2012). Increasing delta-9-tetrahydrocannabinol  $\Delta$ -9-THC content in herbal cannabis over time: systematic review and meta-analysis. *Curr Drug Abuse Rev* 5(1):32–40.
32. Chait LD, Burke KA (1994). Preference for “high” versus low-potency marijuana. *Pharmacol Biochem Behav* 7:357–364.
33. Cheer JF, Kendall DA, Marsden CA (2000). Cannabinoid receptors and reward in the rat: a conditioned place preference study. *Psychopharmacology (Berl)* 151(1):25–30.
34. Compton RP, Berning A (2015). Drug and Alcohol Crash Risk. *Traffic Safety Facts Research Note*. DOT HS 812 117. Washington, DC: National Highway Traffic Safety Administration.
35. Cone EJ, Johnson RE, Moore JD, Roache JD (1986). Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. *Pharmacol Biochem Behav* 24(6):1749–1754.
36. Croxford JL, Yamamura T (2005). Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? *J Neuroimmunol* 166(1–2):3–18.
37. Daling JR, Doody DR, Sun X, Trabert BL, Weiss NS, Chen C, Biggs ML, Starr JR, Dey SK, Schwartz SM (2009). Association of marijuana use and the incidence of testicular germ cell tumors. *Cancer*. 115(6):1215–1223.
38. Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB (1976). Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. *Clin Pharmacol Ther* 19(3):300–309.
39. Dax EM, Pilotte NS, Adler WH, Nagel JE, Lange WR (1989). The effects of 9-enetetrahydrocannabinol on hormone release and immune function. *J Steroid Biochem* 34(1–6):263–270.
40. Day NL, Wagener DK, Taylor PM (1985). Measurement of substance use during pregnancy: methodologic issues. *NIDA Res Monogr* 59:36–47.
41. Day NL, Leech SL, Goldschmidt L (2011). The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioning. *Neurotoxicol Teratol* 33(1):129–136.
42. Day NL, Goldschmidt L, Day R, Larkby C, Richardson GA (2015). Prenatal marijuana exposure, age of marijuana initiation, and the development of psychotic symptoms in young adults. *Psychol Med* 45(8):1779–1787.
43. Degenhardt L, Hall W, Lynskey M (2003). Testing hypotheses about the relationship between cannabis use and psychosis. *Drug Alcohol Depend* 71(1):37–48.
44. Degenhardt L, Hall WD, Lynskey M, McGrath J, McLaren J, Calabria B, Whiteford H, Vos T (2009). Should burden of disease estimates include cannabis use as a risk factor for psychosis? *PLoS Medicine*. 6(9):e1000133.
45. Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neumark Y, Sampson N, Alonso J, Angermeyer M, Anthony JC, Bruffaerts R, et al (2010). Evaluating the drug use “gateway” theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. *Drug Alcohol Depend* 108(1–2):84–97.
46. De Petrocellis PL, Di Marzo V (2009). An introduction to the endocannabinoid system: From the early to the latest concepts. *Best Pract Res Clin Endocrinol Metab* 23(1):1–15.
47. Department of Health and Human Services [HHS] (2015). Basis for the recommendation for maintaining marijuana in Schedule I of the Controlled Substances Act.
48. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258(5090):1946–1949.
49. Dewey WL, Martin BR, May EL (1984). Cannabinoid stereoisomers: pharmacological effects. In Smith DF. (Ed.) *CRC Handbook of stereoisomers: drugs in psychopharmacology*, 317–26 (Boca Raton, FL, CRC Press).
50. Drug Enforcement Administration (2015). *Drugs of Abuse*.
51. DSM–5 (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association. Washington, DC: American Psychiatric Publishing.
52. Eisenstein TK, Meissler JJ (2015). Effects of cannabinoids on T-cell function and resistance to infection. *J Neuroimmune Pharmacol* 10(2):204–216.
53. Eldridge JC, Murphy LL, Landfield PW (1991). Cannabinoids and the hippocampal glucocorticoid receptor: Recent findings and possible significance. *Steroids* 56(5):226–231.
54. ElSohly MA, Slade D (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. *Life Sci* 78:539–548.
55. Fant RV, Heishman SJ, Bunker EB, Pickworth WB (1998). Acute and residual effects of marijuana in humans. *Pharmacol Biochem Behav* 60(4):777–784.
56. Federal Register (1992). “Marijuana Scheduling Petition; Denial of Petition; Remand”—Drug Enforcement Administration, Final Order. *Fed Registr* 57(59):10499–10508.
57. Federal Register (1999). “Rescheduling of the Food and Drug Administration Approved Product Containing Synthetic Dronabinol [(–)-delta 9-(trans)-Tetrahydrocannabinol] in Sesame Oil and Encapsulated in Soft Gelatin Capsules From Schedule II to Schedule III; Final Rule.” *Fed Registr* 64(127):35928–35930.
58. Federal Register (2001). “Notice of Denial of Petition: Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act.” *Fed Registr* 66(75):20038–20076.
59. Fergusson DM, Horwood LJ, Ridder EM (2005). Tests of causal linkages between cannabis use and psychotic symptoms. *Addiction*. 100(3):354–366.
60. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL (2011). Cannabis use before age 15 and subsequent executive functioning. *Br J Psychiatry* 198(6):442–447.
61. Fried PA, Watkinson B, Grant A, Knights RM (1980). Changing patterns of soft drug use prior to and during pregnancy: a prospective study. *Drug Alcohol Depend* 6(5):323–343.
62. Fried PA, Watkinson B (1990). 36- and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes and alcohol. *J Dev Behav Pediatr* 11:49–58.
63. Fried PA, Watkinson B, Gray R (1992). A follow-up study of attentional behavior in 6-year-old children exposed prenatally to marijuana, cigarettes and alcohol. *Neurotoxicol Teratol* 14:299–311.
64. Fried PA, Watkinson B, Gray R (1998). Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marijuana. *Neurotoxicol Teratol* 20(3):293–306.
65. Fried PA (2002). Adolescents prenatally exposed to marijuana: Examination of facets of complex behaviors and comparisons with the influence of in utero cigarettes. *J Clin Pharmacol* 42(11 Suppl):97S–102S.
66. Fried PA, Watkinson B, Gray R (2005). Neurocognitive consequences of

- marihuana—a comparison with pre-drug performance. *Neurotoxicol Teratol* 27(2):231–239.
67. Fung M, Gallagher C, Machtay M (1999). Lung and aero-digestive cancers in young marijuana smokers. *Tumori* 85(2):140–142.
68. Gates P, Jaffe A, Copeland J (2014). Cannabis smoking and respiratory health: Consideration of the literature. *Respirology* 19(5):655–662.
69. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R (2002). Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. *J Neurosci* 22(3):1146–1154.
70. Gold LH, Balster RL, Barrett RL, Britt DT, Martin BR (1992). A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. *J Pharmacol Exp Ther* 262(2):479–486.
71. Goldschmidt L, Richardson GA, Willford JA, Day NL (2008). Prenatal marijuana exposure and intelligence test performance at age 6. *J Am Acad Child Adolesc Psychiatry* 47(3):254–263.
72. Goldschmidt L, Richardson GA, Willford JA, Severtson SG, Day NL (2012). School achievement in 14-year-old youths prenatally exposed to marijuana. *Neurotoxicol Teratol* 34(1):161–167.
73. Gong H Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ (1984). Acute and subacute bronchial effects of oral cannabinoids. *Clin Pharmacol Ther* 35(1):26–32.
74. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR (2006). Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. *Brain Res* 1071(1):10–23.
75. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide. *Mol Pharmacol* 57(5):1045–1050.
76. Gonzalez R (2007). Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. *Neuropsychol Rev* 17(3):347–361.
77. Gonzalez S, Cebeira M, Fernandez-Ruiz J (2005). Cannabinoid tolerance and dependence: A review of studies in laboratory animals. *Pharmacol Biochem Behav* 81(2):300–318.
78. Griffith-Lendering MF, Wigman JT, Prince van Leeuwen A, Huijbregts SC, Huizink AC, Ormel J, Verhulst FC, van Os J, Swaab H, Vollebergh WA (2013). Cannabis use and vulnerability for psychosis in early adolescence—a TRAILS study. *Addiction* 108(4):733–740.
79. Grotenhermen F (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet* 42(4):327–360.
80. Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE (2012). Age of onset of marijuana use and executive function. *Psychol Addict Behav* 26(3):496–506.
81. Hackam DG (2015). Cannabis and stroke: Systematic appraisal of case reports. *Stroke* 46(3):852–856.
82. Hall WD, Lynskey M (2005). Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. *Drug Alcohol Rev* 24(1):39–48.
83. Hall W, Degenhardt L (2014). The adverse health effects of chronic cannabis use. *Drug Test Anal* 6(1–2):39–45.
84. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999). Abstinence symptoms following smoked marijuana in humans. *Psychopharmacology (Berl)* 141(4):395–404.
85. Harder S, Rietbrock S (1997). Concentration-effect relationship of delta-9-tetrahydrocannabinol and prediction of psychotropic effects after smoking marijuana. *International Journal of Clinical Pharmacology and Therapeutics*. 35(4):155–159.
86. Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF (2013). DSM-5 criteria for substance use disorders: Recommendations and rationale. *Am J Psychiatry* 170(8):834–851.
87. Heishman SJ, Huestis MA, Henningfield JE, Cone EJ (1990). Acute and residual effects of marijuana: Profiles of plasma THC levels, physiological, subjective, and performance measures. *Pharmacol Biochem Behav* 37(3):561–565.
88. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990). Cannabinoid receptor localization in brain. *Proc Natl Acad Sci* 87:1932–1936.
89. Herkenham M (1992). Cannabinoid receptor localization in brain: Relationship to motor and reward systems. *Ann N Y Acad Sci* 654:19–32.
90. Herning RI, Hooker WD, Jones RT (1986). Tetrahydrocannabinol content and differences in marijuana smoking behavior. *Psychopharmacology (Berl)* 90(2):160–162.
91. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB (2012). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. *Mol Psychiatry* 17(6):643–649.
92. Hively RL, Mosher WA, Hoffman FW (1966). Isolation of trans- $\Delta^9$ -tetrahydrocannabinol from marihuana. *J Am Chem Soc* 88:1832–1833.
93. Hollister LE, Gillespie HK (1973). Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration. *Clin Pharmacol Ther* 14(3):353–357.
94. Hollister LE (1986). Health aspects of cannabis. *Pharmacological Rev* 3:1–20.
95. Hollister LE (1988). Cannabis (Literature review). *Acta Psychiatr Scand (Suppl)* 78:108–118.
96. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ (2004). Cannabinoid physiology and pharmacology: 30 years of progress. *Neuropharmacology* 47 Suppl:345–358.
97. Huang YH, Zhang ZF, Tashkin DP, Feng B, Straif K, Hashibe K (2015). An epidemiologic review of marijuana and cancer: An update. *Cancer Epidemiol Biomarkers Prev* 24(1):15–31.
98. Huestis MA, Sampson AH, Holicky BJ, Benningfield JE, Cone EJ (1992a). Characterization of the absorption phase of marijuana smoking. *Clin Pharmacol Ther* 52:31–41.
99. Huestis MA, Benningfield JE, Cone EJ (1992b). Blood Cannabinoids. 1. Absorption of THC and formation of 11-OH-THC and THC COOH during and after smoking marijuana. *J Anal Toxicol* 16(5):276–282.
100. Hunt CA, Jones RT (1980). Tolerance and disposition of tetrahydrocannabinol in man. *J Pharmacol Exp Ther* 215(1):35–44.
101. Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H (2005). Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. *Behav Pharmacol* 16(5–6):487–496.
102. Institute of Medicine (1982). Division of Health Sciences Policy. Marijuana and Health: Report of a Study by a Committee of the Institute of Medicine, Division of Health Sciences Policy. Washington, DC: National Academy Press, 1982.
103. Institute of Medicine (1999). Division of Neuroscience and Behavioral Health. Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press, 1999.
104. Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK (1989). Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. *Eur J Clin Pharmacol* 37(3):273–277.
105. Jones RT, Benowitz NL, Heming RI (1981). Clinical relevance of cannabis tolerance and dependence. *J Clin Pharmacol* 21:143S–152S.
106. Jones RT (2002). Cardiovascular system effects of marijuana. *J Clin Pharmacol* 42(11Suppl):58S–63S.
107. Justinova Z, Tanda G, Redhi GH, Goldberg SR (2003). Self-administration of delta9-tetrahydrocannabinol (THC) by drug naïve squirrel monkeys. *Psychopharmacology (Berl)* 169(2):135–140.
108. Justinova Z, Tanda G, Munzar P, Goldberg SR (2004). The opioid antagonist naltrexone reduces the reinforcing effects of delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. *Psychopharmacology (Berl)* 173(1–2):186–194.
109. Kandel D (1975). Stages in adolescent involvement in drug use. *Science* 190:912–914.
110. Kandel DB, Chen K (2000). Types of marijuana users by longitudinal course. *J Stud Alcohol* 61(3):367–378.
111. Karniol IG, Shirakawa I, Kasinski N, Pfefferman A, Carlini EA (1974). Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. *Eur J Pharmacol* 28(1):172–177.
112. Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE (1975). Effects of delta9-tetrahydrocannabinol and cannabiniol in man. *Pharmacology* 13(6):502–512.

113. Keen L 2nd, Pereira D, Latimer W (2014). Self-reported lifetime marijuana use and interleukin-6 levels in middle-aged African Americans. *Drug Alcohol Depend* 140:156–160.
114. Kirk JM, de Wit H (1999). Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. *Pharmacol Biochem Behav* 63(1):137–142.
115. Kuepper R, van Os J, Lieb R, Wittchen HU, Henquet C (2011). Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. *Psychol Med* 41(10):2121–2129.
116. Kurtzthaler I, Hummer M, Miller C, Sperner-Unterwieser B, Gunther V, Wechdorn H, Battista HJ, Fleischhacker WW (1999). Effects of cannabis use on cognitive functions and driving ability. *J Clin Psychiatry* 60(6):395–399.
117. Lacson JC, Carroll JD, Tuazon E, Castela E, Bernstein L, Cortessis VK (2012). Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. *Cancer* 118:5374–5383.
118. Lee MH, Hancox RJ (2011). Effects of smoking cannabis on lung function. *Exp Rev Respir Med* 5(4):537–546.
119. Lemberger L, Silberstein SD, Axelrod J, Kopin IJ (1970). Marijuana: Studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. *Science* 70:1320–1322.
120. Lemberger L, Weiss JL, Watanabe AM, Galanter IM, Wyatt RJ, Cardon PV (1972a). Delta-9-tetrahydrocannabinol: Temporal correlation of the psychological effects and blood levels after various routes of administration. *New Eng J Med* 286(13):685–688.
121. Lemberger L, Crabtree RE, Rowe HM (1972b). 11-Hydroxy-delta-9-tetrahydrocannabinol: Pharmacology, disposition and metabolism of a major metabolite of marijuana in man. *Science* 77:62–63.
122. Lemberger L, Rubin A (1975). The physiologic disposition of marijuana in man. *Life Sci* 17:1637–1642.
123. Li M-C, Brady JE, DiMaggio CJ, Lusardi AR, Tzong, KY, Li G (2012). Marijuana use and motor vehicle crashes. *Epidemiologic Rev* 34:65–72.
124. Liguori A, Gatto CP, Robinson JH (1998). Effects of marijuana on equilibrium, psychomotor performance, and simulated driving. *Behav Pharmacol* 9(7):599–609.
125. Lisdahl KM, Price JS (2012). Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. *J Int Neuropsychol Soc* 18(4):678–688.
126. Lyons MJ, Bar JL, Panizzon MS, Toomey R, Eisen S, Xian H, Tsuang MT (2004). Neuropsychological consequences of regular marijuana use: a twin study. *Psychol Med* 34(7):1239–1250.
127. Mackie K, Lai Y, Westenbroek R, Mitchell R (1995). Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. *J Neurosci* 15(10):6552–6561.
128. Maldonado R (2002). Study of cannabinoid dependence in animals. *Pharmacol Ther* 95(2):153–164.
129. Malinowska B, Baranowska-Kuczko M, Schlicker E (2012). Triphasic blood pressure responses to cannabinoids: Do we understand the mechanism? *Br J Pharmacol* 165(7):2073–2088.
130. Manrique-Garcia E, Zammit S, Dalman C, Hemmingston T, Andreasson S, Allebeck P (2012). Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. *Psychol Med* 42(6):1321–1328.
131. Marenmani I, Lazzeri A, Pacini M, Lovrecic M, Placidi GF, Perugi G (2004). Diagnostic and symptomatological features in chronic psychotic patients according to cannabis use status. *J Psychoactive Drugs* 36(2):235–241.
132. McCart AT (2015). Marijuana and driving in the United States: Prevalence, risks, and laws. Presented at the Casualty Actuarial Society Spring Meeting. Colorado Springs, CO. May 19, 2015.
133. McMahon LR, Ginsburg BC, Lamb RJ (2008). Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice. *Psychopharmacology (Berl)* 198(4):487–495.
134. McMahon LR (2009). Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta-9-tetrahydrocannabinol. *Psychopharmacology (Berl)* 203(2):219–228.
135. Mechoulam R (1973). Cannabinoid chemistry. In Mechoulam, R. (ed.) *Marijuana*, pp.2–88 (New York, NY, Academic Press, Inc.).
136. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE., Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol* 50(1):83–90.
137. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly MA (2010). Potency trends of Δ<sup>9</sup>-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. *J Forensic Sci* 55(5):1209–1217.
138. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci USA* 109(40):E2657–E2664.
139. Mendelson JH, Mello NK (1984). Effects of marijuana on neuroendocrine hormones in human males and females. *NIDA Res Monogr* 44:97–114.
140. Messinis L, Kyprianidou A, Malefaki S, Papathanasopoulos P (2006). Neuropsychological deficits in long-term frequent cannabis users. *Neurology* 66:737–739.
141. Minozzi S, Davoli M, Bargagli AM, Amato L, Vecchi S, Perucci CA (2010). An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. *Drug Alcohol Rev* 29(3):304–317.
142. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE (2001). Triggering myocardial infarction by marijuana. *Circulation* 103:2805–2809.
143. Nace EP, Meyers AL, Rothberg JM, Maleson F (1975). Addicted and nonaddicted drug users. A comparison of drug usage patterns. *Arch Gen Psychiatry* 32(1):77–80.
144. Oviedo A, Glowa J, Herkenham M (1993). Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study. *Brain Res* 616:293–302.
145. Pacher P, Batkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev* 58(3):389–462.
146. Panayiotides IM (2015). What is the association between cannabis consumption and cardiovascular complications. *Subst Abuse* 9:1–3.
147. Pelayo-Teran JM, Suarez-Pinilla P, Chadi N, Crespo-Pacorro B (2012). Gene-environment interactions underlying the effect of cannabis in first episode psychosis. *Curr Pharm Des* 18(32):5024–5035.
148. Piomelli D (2005). The endocannabinoid system: A drug discovery perspective. *Curr Opin Investig* 6(7):672–679.
149. Pletcher MJ, Vittinghoff E, Kalhan R, Richman J, Safford M, Sidney S, Lin F, Kertesz S (2012). Association between marijuana exposure and pulmonary function over 20 years. *Journal of the American Medical Association*. 307(2):173–181.
150. Pollastro F, Tagliatalata-Scafati O, Allara M, Munoz E, Di Marzo V, De Petrocellis L, Appendino G (2011). Bioactive prenylogous cannabinoid from fiber hemp (*Cannabis sativa*). *J Nat Prod*. 74(9):2019–2022.
151. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2002). Cognitive measures in long-term cannabis users. *J Clin Pharmacol* 42(11 Suppl):41S–47S.
152. Radwan MM, ElSohly MA, Slade D, Ahmed SA, Khan IA, Ross SA (2009). Biologically active cannabinoids from high-potency Cannabis sativa. *J Nat Prod* 72(5):906–911.
153. Ramaekers JG, Berghaus G, van Laar M, Drummer OH (2004). Dose related risk of motor vehicle crashes after cannabis use. *Drug and Alcohol Dependence*. 73(2):109–119.
154. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR (2006). High-potency marijuana impairs executive functions and inhibitory motor control.

- Neuropsychopharmacology* 31(10):2296–2303.
155. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW., Moeller MR (2009). Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. *J Psychopharmacol* 23(3):266–277.
  156. Riggs PK, Vaida F, Rossi SS, Sorkin LS, Gouaux B, Grant I, Ellis RJ (2012). A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. *Brain Res* 1431:46–52.
  157. Rodriguez de Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA (1994). Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. *Pharmacol Biochem Behav* 47(1):33–40.
  158. Roth MD, Arora A, Barsky SH, Kleeup EC, Simmons M, Tashkin DP (1998). Airway inflammation in young marijuana and tobacco smokers. *American Journal of Respiratory and Crit Care Med* 157:928–937.
  159. Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC (2005). Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL–SCID mouse. *Life Sci* 77(14):1711–1722.
  160. Russo E, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, Kirilin KA (2001). Chronic cannabis use in the compassionate investigational new drug program: An examination of benefits and adverse effects of legal clinical cannabis. *J Cannabis Ther* 2:3–57.
  161. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H (2005). Cannabinoid receptor as a novel target for the treatment of prostate cancer. *Cancer Res* 65(5):1635–1641.
  162. Scherrer JF, Grant JD, Duncan AE, Sartor CE, Haber JR, Jacob T, Bucholz KK (2009). Subjective effects to cannabis are associated with use, abuse and dependence after adjusting for genetic and environmental influences. *Drug Alcohol Depend* 105(1–2):76–82.
  163. Schifman J, Nakamura B, Earleywine MJ, LaBrie J (2005). Symptoms of schizotypy precede cannabis use. *Psychiatry Res* 134(1):37–42.
  164. Schimmelmann BG, Conus P, Cotton SM, Kupferschmid S, Karow A, Schultze-Lutter F, McGorry PD, Lambert M (2011). Cannabis use disorder and age at onset of psychosis—a study in first episode patients. *Schizophr Res* 129(1):52–56.
  165. Schreiner AM, Dunn ME (2012). Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis. *Exp Clin Psychopharmacol* 20(5):420–429.
  166. Sexton M, Cudaback E, Abdullah RA, Finnell J, Mischley LJ, Rozga M, Lichtman AH, Stella N (2014). Cannabis use by individuals with multiple sclerosis: Effects on specific immune parameters. *Inflammopharmacology* 22(5):295–303.
  167. Sidney S (2002). Cardiovascular consequences of marijuana use. *J Clin Pharmacol* 42(11Suppl):64S–70S.
  168. Solinas M, Panlilio LV, Justinova Z, Yasar S, Goldberg SR (2006). Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. *Nat Protoc* 1(3):1194–1206.
  169. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J (2002). Marijuana Treatment Project Research Group. Cognitive functioning of long-term heavy cannabis users seeking treatment. *Journal of the American Medical Association* 287(9):1123–1131.
  170. Substance Abuse and Mental Health Services Administration (2013). *Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits*. HHS Publication No. (SMA) 13–4760, DAWN Series D–39. Rockville, MD.
  171. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2015a). Results from the 2014 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD.
  172. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2015b). *Treatment Episode Data Set (TEDS): 2003–2013. National Admissions to Substance Abuse Treatment Services*. BHSIS Series S–75, HHS Publication No. (SMA) 15–4934. Rockville, MD.
  173. Tait RJ, MacKinnon A, Christensen H (2011). Cannabis use and cognitive functioning: 8-year trajectory in a young adult cohort. *Addiction* 106(12):2195–2203.
  174. Tanasescu R, Constantinescu CS (2010). Cannabinoids and the immune system: An overview. *Immunobiology* 215(8):588–597.
  175. Tanda G, Munzar P, Goldberg SR (2000). Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. *Nat Neurosci* 3(11):1073–1074.
  176. Tanda G, Goldberg SR (2003). Cannabinoids: Reward, dependence, and underlying neurochemical mechanisms—a review of recent preclinical data. *Psychopharmacology (Berl)* 169(2):115–134.
  177. Tashkin DP (2005). Smoked marijuana as a cause of lung injury. *Monaldi Arch Chest Dis* 63(2):93–100.
  178. Tashkin DP, Zhang ZF, Greenland S, Cozen W, Mack TM, and Morgenstern H (2006). Marijuana use and lung cancer: Results of a case-control study. *American Thoracic Society International Conference*. Abstract A777.
  179. Theunissen EL, Kauert GF, Toennes SW., Moeller MR, Sambeth A, Blanchard MM, Ramaekers JG (2012). Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. *Psychopharmacology (Berl)* 220(2):341–350.
  180. Trabert B, Sigurdson AJ, Sweeney AM, Strom SS, McGlynn KA (2011). Marijuana use and testicular germ cell tumors. *Cancer* 117(4):848–853.
  181. Twitchell W, Brown S, Mackie K (1997). Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. *J Neurophysiol* 78(1):43–50.
  182. U.S. Food and Drug Administration (FDA), Center for Drug and Evaluation Research, Controlled Substances Staff (2015). *The Medical Application of Marijuana: A Review of Published Clinical Studies*. March 19, 2015.
  183. van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MW, de Haan L (2012). Cannabis use in patients at clinical high risk of psychosis: Impact on prodromal symptoms and transition to psychosis. *Curr Pharm Des* 18(32):5036–5044.
  184. van Gastel WA, Wigman JT, Monshouwer K, Kahn RS, van Os J, Boks MP, Volleburch WA (2012). Cannabis use and subclinical positive psychotic experiences in early adolescence: Findings from a Dutch survey. *Addiction* 107(2):381–387.
  185. Van Gundy K, Rebellon CJ (2010). A Life-course Perspective on the “Gateway Hypothesis.” *J Health Soc Behav* 51(3):244–259.
  186. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. (2002). Cannabis use and psychosis: A longitudinal population-based study. *Am J Epi* 156(4):319–327.
  187. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL (2008). Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of  $\Delta(9)$ -tetrahydrocannabinol. *Drug Alcohol Depend* 94(1–3):191–198.
  188. Volkow ND, Baler RD, Compton WM, Weiss SR (2014). Adverse health effects of marijuana use. *N Engl J Med* 370(23):2219–2227.
  189. von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen HU (2002). What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. *Drug Alcohol Depend* 68(1):49–64.
  190. Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H (2002). Comparison of the subjective effects of  $\Delta(9)$ -tetrahydrocannabinol and marijuana in humans. *Psychopharmacology (Berl)* 161(4):331–339.
  191. Wagner JA, Varga K, Kunos G (1998). Cardiovascular actions of cannabinoids and their generation during shock. *J Mol Med* 76(12):824–836.
  192. Wang GS, Roosevelt G, Heard K (2013). Pediatric marijuana exposures in a medical marijuana state. *JAMA Pediatr* 167(7):630–633.
  193. Wang GS, Roosevelt G, Le Lait MC, Martinez EM, Bucher-Bartelson B, Bronstein AC, Heard K (2014). Association of unintended pediatric exposures with decriminalization of marijuana in the United States. *Ann Emerg Med* 63(6):684–689.
  194. Wang T, Collet JP, Shapiro S, Ware MA (2008). Adverse effects of medical cannabinoids: A systematic review. *CMAJ* 178(13):1669–1678.

195. Wesson DR, Washburn P (1990). Current patterns of drug abuse that involve smoking. *NIDA Res Monogr* 99:5–11.
196. Whitehill JM, Rivara FP, Moreno MA (2014). Marijuana-using drivers, alcohol-using drivers, and their passengers: Prevalence and risk factors among underage college students. *JAMA Pediatr* 168(7):618–624.
197. Wiley JL, Barrett RL, Britt DL, Balster RL, Martin BR (1993). Discriminative stimulus effects of  $\Delta$  9-tetrahydrocannabinol and  $\Delta$  9-11-tetrahydrocannabinol in rats and rhesus monkeys. *Neuropharmacology* 32(4):359–365.
198. Wiley JL, Huffman JW, Balster RL, Martin BR (1995). Pharmacological specificity of the discriminative stimulus effects of  $\Delta$  9-tetrahydrocannabinol in rhesus monkeys. *Drug Alcohol Depend* 40(1):81–86.
199. Wilkinson ST, Radhakrishnan R, D'Souza DC (2014). Impact of cannabis use on the development of psychotic disorders. *Curr Addict Rep* 1(2):115–128.
200. Wilson FA, Stimpson JP, Pagán JA (2014). Fatal crashes from drivers testing positive for drugs in the U.S., 1993–2010. *Public Health Rep* 129(4):342–350.
201. Wu X, French ED (2000). Effects of chronic  $\Delta$ 9-tetrahydrocannabinol on rat midbrain dopamine neurons: An electrophysiological assessment. *Neuropharmacology* 39(3):391–398.
202. Zeiger JS, Haberstick BC, Corley RP, Ehringer MA, Crowley TJ, Hewitt JK, Hopfer CJ, Stallings MC, Young SE., Rhee SH (2010). Subjective effects to marijuana associated with marijuana use in community and clinical subjects. *Drug Alcohol Depend* 109(1–3):161–66.
203. Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, Hsu TC, Schantz, SP (1999). Marijuana use and increased risk of squamous cell carcinoma of the head and neck. *Cancer Epidemiol Biomarkers Prev* 8(12):1071–1078.
204. Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, Woll PJ, Orlow I, Cox B on behalf of the Cannabis and Respiratory Disease Research Group of New Zealand, Brhane Y, Liu G, Hung RJ (2015). Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. *Int J Cancer* 136(4):894–903.
205. Zwardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982). Action of cannabidiol on the anxiety and other effects produced by  $\Delta$  9-THC in normal subject. *Psychopharmacology (Berl)* 76(3):245–250.

[FR Doc. 2016–17960 Filed 8–11–16; 8:45 am]

**BILLING CODE 4410–09–P**



# **Exhibit 4**

Tariff Act of 1930. On February 4, 1992, the Commission scheduled a public hearing in connection therewith for March 26, 1992. On March 17, 1992, the Commission received notice of withdrawal from the only scheduled witness for the hearing scheduled for March 26, 1992. Therefore, the public hearing in connection with this investigation (scheduled to be held beginning at 9:30 a.m. on March 26, 1992, at the U.S. International Trade Commission Building, 500 E Street, SW., Washington DC), is cancelled.

**EFFECTIVE DATE:** March 20, 1992.

**FOR FURTHER INFORMATION CONTACT:** Edward Carroll (202-205-1819), Office of Public Affairs, U.S. International Trade Commission. Hearing impaired persons can obtain information on this study by contacting the Commission's TDD terminal on (202-205-1810).

By order of the Commission.

Dated: March 24, 1992.

**Kenneth R. Mason,**

*Secretary.*

[FR Doc. 92-7160 Filed 3-25-92; 8:45 am]

**BILLING CODE 7020-02-M**

**INTERSTATE COMMERCE COMMISSION**

[Finance Docket No. 32016]

**Sioux & Western Railroad Co.— Construction Exemption—Charles County, Mo; Notice**

**AGENCY:** Interstate Commerce Commission.

**ACTION:** Notice of exemption.

**SUMMARY:** Pursuant to 49 U.S.C. 10505, the Interstate Commerce Commission conditionally exempts from the prior approval requirements of 49 U.S.C. 10901 the construction by the Sioux & Western Railroad Company of approximately 2 miles of rail line between the Sioux Plant and a Union Pacific Railroad Company line in Charles County, MO.

**DATES:** The exemption will not become effective until the environmental process is completed. At that time, the Commission will issue a further decision addressing the environmental matters and establishing an effective date for the exemption, if appropriate. Petitions to reopen must be filed by April 15, 1992.

**ADDRESSES:** Send pleadings referring to Finance Docket No. 32016 to:

- (1) Office of the Secretary, Case Control Branch, Interstate Commerce Commission, Washington, DC 20423.
- (2) Petitioner's representative: John R. Molm, Esquire, Troutman, Sanders, Lockerman and Ashmore, 1400 Candler Building, 127 Peachtree Street, NE., Atlanta, GA 30303.

**FOR FURTHER INFORMATION CONTACT:** Joseph H. Dettmar, (202) 927-5660, (TDD for hearing impaired: (202) 927-5712.

**SUPPLEMENTARY INFORMATION:** Additional information is contained in the Commission's decision. To purchase a copy of the full decision, write to, call, or pick up in person from: Dynamic Concepts, Inc., room 2229, Interstate Commerce Commission Building, Washington, DC 20423. Telephone: (202) 289-4357/4359. (Assistance for the hearing impaired is available through TDD services (202) 927-5721.)

Decided: March 11, 1992.

By the Commission, Chairman Philbin, Vice Chairman McDonald, Commissioners Simmons, Phillips, and Emmett.

**Sidney L. Strickland, Jr.,**

*Secretary.*

[FR Doc. 92-7017 Filed 3-25-92; 8:45 am]

**BILLING CODE 7035-01-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. 86-22]

**Marijuana Scheduling Petition; Denial of Petition; Remand**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Final order.

**SUMMARY:** This is a final order of the Administrator of the Drug Enforcement Administration (DEA) concluding the plant material marijuana has no currently accepted medical use and denying the petition of the National Organization for Reform of Marijuana Laws (NORML) to reschedule marijuana from Schedule I to Schedule II of the Controlled Substances Act.

**EFFECTIVE DATE:** March 26, 1992.

**FOR FURTHER INFORMATION CONTACT:** Office of Congressional and Public Affairs, 202-307-7363.

**SUPPLEMENTARY INFORMATION:**

**Background**

On December 21, 1989, the former Administrator of DEA, following rulemaking on the record, which included a hearing before an administrative law judge, issued a final order concluding the plant material marijuana has no currently accepted medical use, and denying the petition of NORML to reschedule marijuana from Schedule I to Schedule II of the Controlled Substances Act. 54 FR 63767. On April 26, 1991, the United States Court of Appeals for the District of Columbia Circuit remanded the matter to the Administrator for clarification of

DEA's interpretation of the term "currently accepted medical use in treatment in the United States." *Alliance for Cannabis Therapeutics v. DEA*, 930 F.2d 936.

Following a review of the entire record in this matter, and a comprehensive re-examination of the relevant statutory standard, I conclude that marijuana has no currently accepted medical use and must remain in Schedule I. Further hearings are unnecessary since the record is extraordinarily complete, all parties had ample opportunity and wide latitude to present evidence and to brief all relevant issues, and the narrow question on remand centers exclusively on this Agency's legal interpretation of a statutorily-created standard.

**Summary of the Decision**

Does the marijuana plant have any currently accepted medical use in treatment in the United States, within the meaning of the Federal Controlled Substances Act, 21 U.S.C. 801, *et seq.*? Put simply, is marijuana good medicine for illnesses we all fear, such as multiple sclerosis (MS), glaucoma and cancer?

The answer might seem obvious based simply on common sense. Smoking causes lung cancer and other deadly diseases. Americans take their medicines in pills, solutions, sprays, shots, drops, creams and sometimes in suppositories, but never by smoking. No medicine prescribed for us today is smoked.

With a little homework, one can learn that marijuana has been rejected as medicine by the American Medical Association, the National Multiple Sclerosis Society, the American Glaucoma Society, the American Academy of Ophthalmology the American Cancer Society. Not one American health association accepts marijuana as medicine.

For the last half century, drug evaluation experts at the United States Food and Drug Administration (FDA) have been responsible for protecting Americans from unsafe and ineffective new medicines. Relying on the same scientific standards used to judge all other drugs, FDA experts repeatedly have rejected marijuana for medical use.

Yet claims persist that marijuana has medical value. Are these claims true, What are the facts?

Between 1987 and 1988, DEA and NORML, under the guidance of an administrative law judge, collected all relevant information on this subject. Stacked together it stands nearly five feet high. Is there reliable scientific evidence that marijuana is medically

effective. If it has medical value, do its benefits outweigh its risks? What do America's top medical and scientific experts say? Would they prescribe it for their patients, their families, their friends?

As the current Administrator of Drug Enforcement, and as a former United States District Judge, I have made a detailed review of the evidence in this record to find the answers.

There are significant short-term side effects and long-term risks linked to smoking marijuana. Marijuana is likely to be more cancer-causing than tobacco; damages brain cells; causes lung problems, such as bronchitis and emphysema; may weaken the body's antibacterial defenses in the lungs; lowers overall blood pressure, which could adversely affect the supply of blood to the head; causes sudden drops in blood pressure (orthostatic hypotension), rapid heart beat (tachycardia), and heart palpitations; suppresses luteinizing hormone secretion in women, which affects the production of progesterone, an important female hormone; causes anxiety and panic in some users because of its mind-altering effects; produces dizziness, trouble with thinking, trouble with concentrating, fatigue, and sleepiness; and impairs motor skills.

As a plant, marijuana can contain bacteria capable of causing serious infections in humans, such as salmonella enteritidis, Klebsiella pneumoniae, group D Streptococcus and pathogenic aspergillus.

Several of these risk stand out. The immune systems of cancer patients are weakened by radiation and chemotherapy, leaving them susceptible to infection. If they experiment with marijuana to control nausea, they risk weakening their immune systems further and exposing themselves to the infection-causing bacteria in the plant. It is estimated, for example, that at Memorial Sloan-Kettering Cancer Center 60 patients die each year from pathogenic aspergillus infections.

Glaucoma patients face possible blindness caused by very high fluid pressures within their eyes. If they experiment with marijuana to lower their eye fluid pressure, it can cause dramatic drops in their blood pressure and reduce the blood supply to their heads. Glaucoma experts testified this reduced the blood supply to the optic nerves and could speed up, rather than slow down, their loss of eyesight.

MS, glaucoma and cancer patients who have undiagnosed heart problems risk heart palpitations, very rapid heart beats and sudden dramatic drops in

blood pressure if they experiment with marijuana. For MS and glaucoma patients who must take medications for the rest of their lives, experimenting with marijuana poses the additional risks of lung cancer, emphysema, bladder cancer and leukemia.

Many risks remain unknown. Marijuana contains over 400 separately identified chemicals. No one knows all the effects of burning these chemicals together and inhaling the burnt mix. Are these risks outweighed by medical benefits?

There are scientific studies showing pure THC (Delta-9-Tetrahydrocannabinol), one of the many chemicals found in marijuana, has some effect in controlling nausea and vomiting. Pure THC is pharmaceutically made in a clean capsule form, called Marinol, and is available for use by the medical community. More information on Marinol can be found in the "Physicians' Desk Reference," available in most libraries.

Since marijuana contains THC, you might think marijuana also would be effective. However, the effect of taking a drug in combination with other chemicals is seldom the same as taking just the pure drug. As already noted, marijuana contains over 400 other chemicals, not just THC. There are no reliable scientific studies that show marijuana to be significantly effective in controlling nausea and vomiting. People refer to the Sallan study as proving marijuana's effectiveness. They are mistaken. The Sallan study involved pure THC, not marijuana. People refer to the Chang study to support marijuana's effectiveness. They also are mistaken. Doctor Chang tested the combination of pure THC and marijuana to treat nausea and vomiting. The preliminary results he got were probably due to the THC, not the marijuana. Because he tested the combination, we cannot tell just what effects can be attributed to marijuana alone. People cite a third study, done by Doctor Levitt, as proof marijuana is effective. They are mistaken. Doctor Levitt compared marijuana to THC in controlling nausea and vomiting, and he concluded that THC was the more effective drug.

A librarian can help locate copies of these studies should you want to see them for yourself. Sallan, et al., "Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy," 293 New England Journal of Medicine 795-797 (1975); Chang, et al., "Delta-9-Tetrahydrocannabinol as an Antiemetic in Cancer Patients Receiving High-Dose Methotrexate," 91 Annals of Internal Medicine 819-824 (1979); Levitt, et al.,

"Randomized Double Blind Comparison of Delta-9-Tetrahydrocannabinol (THC) and Marijuana As Chemotherapy Antiemetics," (Meeting Abstract) 3 Proceedings of the Annual Meeting of the American Society of Clinical Oncology 91 (1984).

During the 1970's and 1980's, a number of states set up research programs to give marijuana to cancer and glaucoma patients, on the chance it might help. Some people point to these programs as proof of marijuana's usefulness. Unfortunately, all research is not necessarily good scientific research. These state programs failed to follow responsible scientific methods. Patients took marijuana together with their regular medicines, so it is impossible to say whether marijuana helped them. Observations or results were not scientifically measured. Procedures were so poor that much critical research data were lost or never recorded. Although these programs were well-intentioned, they are not scientific proof of anything.

Some people refer to a study by Doctor Thomas Ungerleider as proof marijuana reduced nausea in bone marrow transplant patients. Unfortunately, Doctor Ungerleider neglected to follow responsible scientific methods in his study. Like the state programs, it proves nothing. Doctor Ungerleider chose not to publish his study evidently because of its serious weaknesses. He admitted as much when questioned under oath.

Those who say there are reliable scientific studies showing marijuana is an effective drug for treating nausea and vomiting are wrong. No such studies exist.

Our nation's top cancer experts reject marijuana for medical use. Doctor David S. Ettinger, a professor of oncology at the Johns Hopkins University School of Medicine, an author of over 100 scholarly articles on cancer treatment, and a nationally respected cancer expert, testified:

There is no indication that marijuana is effective in treating nausea and vomiting resulting from radiation treatment or other causes. No legitimate studies have been conducted which make such conclusions.

Doctor Richard J. Gralla, a professor of medicine at Cornell University Medical College, an associate attending physician at the Memorial Sloan-Kettering Cancer Center, and an expert in cancer research, testified:

Most experts would say, and our studies support, that the cannabinoids in general are not very effective against the major causes of nausea and vomiting.

Doctor Gralla added:

I have found that because of the negative side effects and problems associated with marijuana \* \* \*. most medical oncologists and researchers have little interest in marijuana for the treatment of nausea and vomiting in their patients.

Doctor John Laszlo, Vice President of Research for the American Cancer Society, an expert who has spent 37 years researching cancer treatments, and who has written a leading textbook on the subject, "Antiemetics and Cancer Chemotherapy," testified there is not enough scientific evidence to justify using marijuana to treat nausea and vomiting. Not one nationally-recognized cancer expert could be found to testify on marijuana's behalf.

To be an effective treatment for glaucoma, a drug must: (i) Lower the pressure within the eye (intraocular pressure), (ii) for prolonged periods of time, and (iii) actually preserve sight (visual fields). Five scientific studies are cited as evidence marijuana is an effective glaucoma treatment. Those who cite these studies are mistaken. These studies tested pure THC, not marijuana. W.D. Purnell and J.M. Gregg, "Delta-9-Tetrahydrocannabinol, Euphoria and Intraocular Pressure in Man," 7 *Annals of Ophthalmology* 921-923 (1975); M. Perez-Reyes, D. Wagner, M.E. Wall, and K.H. Davis, "Intravenous Administration of Cannabinoids on Intraocular Pressure," *The Pharmacology of Marijuana* 829-832 (M.C. Braude and S. Szara eds. 1976); J.C. Merritt, S.M. McKinnon, J.R. Armstrong, G. Hatem, and L.A. Reid, "Oral Delta-9-Tetrahydrocannabinol in Hyperogeneous Glaucomas," 12 *Annals of Ophthalmology* 947 (1980); K. Green and M. Roth, "Ocular Effects of Topical Administration of Delta-9-Tetrahydrocannabinol in Man," 100 *Archives of Ophthalmology* 265-267 (1982); and W.M. Jay and K. Green, "Multiple-Drop Study of Topically Applied 1% Delta-9-Tetrahydrocannabinol in Human Eyes," 101 *Archives of Ophthalmology* 591-593 (1983).

Three studies show very heavy doses of marijuana, taken for short periods of time, can reduce eye pressure. R.S. Hepler, I.M. Frank, and T.J. Ungerleider, "Pupillary Constriction After Marijuana Smoking," 74 *American Journal of Ophthalmology* 1185-1190 (1972); R.S. Hepler, I.M. Frank, and R. Petrus, "Ocular Effects of Marijuana Smoking," *The Pharmacology of Marijuana* 815-824 (1976); and J.C. Merritt, W.J. Crawford, P.C. Alexander, A.L. Anduze and S.S. Gelbart, "Effect of Marijuana on Intraocular and Blood Pressure in

Glaucoma," 87 *Ophthalmology* 222-228 (1980)

Unusually large doses of marijuana were needed in these three studies to achieve the desired effect. Heavy marijuana use produces dizziness, trouble with thinking, impaired motor skills, fatigue and sleepiness. The 1976 study by Doctors Hepler, Frank and Petrus emphasized "Our subjects were sometimes too sleepy to permit measurement of intraocular pressures \* \* \* 3 hours after intoxication." If a glaucoma patient were to smoke marijuana 8 to 10 times every day for the rest of his life, would he be alert and energetic enough to live a relatively normal life? Would he develop other diseases? No scientific studies exist to answer these questions. Robert Randall claims to have saved his sight by smoking 8 to 10 marijuana cigarettes every day. Under oath he admits he stays at home most days, follows no daily schedule or routine, and has not held a regular job in over 15 years. He also has avoided having a comprehensive medical examination since 1975.

No scientific studies have shown marijuana can reduce eye pressure over long periods of time.

No scientific studies have shown marijuana can save eyesight.

America's top glaucoma experts reject marijuana as medicine. Doctor Keith Green is a professor of Ophthalmology who serves, or has served, on the editorial boards of eight prestigious eye journals (*Ophthalmic Research*, *Oftalmology Abstracts*, *Current Eye Research*, *Experimental Eye Research*, *Investigative Ophthalmology*, *American Journal of Ophthalmology*, *Archives of Ophthalmology*, and *Survey of Ophthalmology*). Doctor Green has conducted extensive basic and clinical research using marijuana and THC to treat glaucoma patients. He has authored over 200 books or research articles in ophthalmology and is a highly respected expert on this subject. Doctor Green testified:

There is no scientific evidence \* \* \* that indicates that marijuana is effective in regulating the progression of symptoms associated with glaucoma. \* \* \* It is clear that there is no evidence that marijuana use prevents the progression of visual loss in glaucoma. \* \* \* The quantities of the drug required to reduce intraocular pressure in glaucoma sufferers are large, and would require the inhalation of at least six marijuana cigarettes each day. \* \* \* Smoking is not a desirable form of treatment for many reasons \* \* \* [M]arijuana . . . has little potential future as a glaucoma medication.

Doctor George Spaeth is the Director of the Glaucoma Service at Wills Eye Hospital in Philadelphia, the largest service in the United States devoted to researching and treating glaucoma and to teaching other doctors about this disease. Doctor Spaeth is President of the American Glaucoma Society. He is a professor of ophthalmology, the editor of a scholarly eye journal (*Ophthalmic Surgery*), and the author of over 200 research articles on glaucoma. He testified:

I have not found any documentary evidence which indicates that a single patient has had his or her natural history of the disease altered by smoking marijuana.

Amputees and victims of MS can suffer from extreme muscle spasms. It is claimed marijuana is useful in treating spasticity. Three unusually small, inconclusive studies have tried using pure THC, not marijuana, to treat spasticity. D.J. Petro and C. Ellenberger, "Treatment of Human Spasticity with Delta-9-Tetrahydro-cannabinol," 21 *Journal of Clinical Pharmacology* 413S-416S (1981) (included only nine patients). Two of the studies are mere abstracts, or short digests, without much detail. Hanigan, Destee & Troung *Abstr. B45, Clin. Pharmacol. Ther.* 198 (1986) (included only five patients), and Sandyk, Cannoe, Stern and Snider *Abstr. PP 331, 36 Neurology* 342 (1986) (included only three patients).

No scientific studies exist which test marijuana to relieve spasticity.

National experts on MS reject marijuana as medicine. Doctor Kenneth P. Johnson is Chairman of the Department of Neurology at the University of Maryland School of Medicine. He manages that Maryland Center for MS, one of the most active MS research and treatment centers in the United States. He sits on the editorial boards of noted medical journals related to MS (*Neurology* and *Journal of Neuroimmunology*). He is the author of over 100 scientific and medical articles on MS. Doctor Johnson has spent most of his long career researching MS and has diagnosed and treated more than 6,000 patients with MS. Doctor Johnson testified:

At this time, I am not aware of \* \* \* any legitimate medical research in which marijuana was used to treat the symptoms of multiple sclerosis. \* \* \* To conclude that marijuana is therapeutically effective without conducting rigorous testing would be professionally irresponsible.

Doctor Stephen Reingold is Assistant Vice President of Research for the National Multiple Sclerosis Society, which spends over \$7 million each year

on MS research. Only the Federal Government spends more. Doctor Reingold testified:

I could find no actual published research which has used marijuana \* \* \* In the existing research using THC, the results were inconclusive \* \* \* In the absence of any well-designed, well-controlled research \* \* \*, the National Multiple Sclerosis Society \* \* \* does not endorse or advocate its use \* \* \*.

Doctor Donald H. Silberberg is Chairman of the Department of Neurology at the University of Pennsylvania School of Medicine and Chief of the Neurology Service at the Hospital of Pennsylvania. Doctor Silberberg is on the editorial board of *Annals of Neurology* and is President of the National Medical Advisory Board for the National Multiple Sclerosis Society. He has been actively researching and treating MS for most of his career, has written over 130 medical articles on MS and is Co-Director of a large MS research center at the University of Pennsylvania. Doctor Silberberg testified:

I have not found any legitimate medical or scientific works which show that marijuana \* \* \* is medically effective in treating multiple sclerosis or spasticity. \* \* \* The long-term treatment of the symptoms of multiple sclerosis through the use of marijuana could be devastating. \* \* \* [T]he use of (marijuana), especially for long-term treatment \* \* \* would be worse than the original disease itself.

The only favorable evidence that could be found by NORML and DEA consists of stories by marijuana users who claim to have been helped by the drug. Scientists call these stories anecdotes. They do not accept them as reliable proofs. The FDA's regulations, for example, provide that in deciding whether a new drug is a safe and effective medicine, "isolated case reports \* \* \* will not be considered." 21 CFR 314.126(e). Why do scientists consider stories from patients and their doctors to be unreliable?

First, sick people are not objective scientific observers, especially when it comes to their own health. We all have heard of the placebo effect. Patients have a tendency to respond to drugs as they believe is expected of them. Imagine how magnified this placebo effect can be when a suffering person experiments on himself, praying for some relief. Many stories no doubt are due to the placebo effect, not to any real medical effects of marijuana.

Second, most of the stories come from people who took marijuana at the same time they took prescription drugs for their symptoms. For example, Robert Randall claims marijuana has saved his

sight, yet he has taken standard glaucoma drugs continuously since 1972. There is no objective way to tell from these stories whether it is marijuana that is helpful, or the proven, traditional medicines. Even these users can never know for sure.

Third, any mind-altering drug that produces euphoria can make a sick person think he feels better. Stories from patients who claim marijuana helps them may be the result of the mind-altering effects of the drug, not the results of improvements in their conditions.

Fourth, long-time abusers of marijuana are not immune to illness. Many eventually get cancer, glaucoma, MS and other diseases. People who become dependent on mind-altering drugs tend to rationalize their behavior. They invent excuses, which they can come to believe, to justify their drug dependence. Stories of marijuana's benefits from sick people with a prior history of marijuana abuse may be based on rationalizations caused by drug dependence, not on any medical benefits caused by the drug. Robert Randall, for example, admits under oath to becoming a regular user in 1968, four years before he showed the first signs of, and was diagnosed as having, glaucoma. Since then he has smoked marijuana 8 to 10 times every day.

A century ago many Americans relied on stories to pick their medicines, especially from snake oil salesmen. Thanks to scientific advances and to the passage of the Federal Food, Drug and Cosmetic Act (FDCA) in 1906, 21 U.S.C. 301 *et seq.*, we now rely on rigorous scientific proof to assure the safety and effectiveness of new drugs. Mere stories are not considered an acceptable way to judge whether dangerous drugs should be used as medicines.

There are doctors willing to testify that marijuana has medical uses NORML found over a dozen to testify in this case. We have a natural tendency to believe doctors. We assume their opinions are entitled to respect. But what if a doctor is giving an opinion beyond his professional competence? Evaluating the safety and effectiveness of drugs is a specialized area. Does the doctor have this specialized expertise? Is he familiar with all the published scientific studies? Or is he improperly basing his opinion on mere stories or anecdotal evidence? Does he really know what he is talking about? Does he have a personal motive to exaggerate or lie? Questions like these led the United States Supreme Court, in 1973, to warn about the opinions of doctors concerning the value of drugs as medicine, when not supported by rigorous scientific

testing, *Weinberger v. Hynson, Etc.*, 412 U.S. 609, 639:

[I]mpressions or beliefs of physicians, no matter how fervently held, are treacherous.

Nearly half the doctors who testified for NORML are psychiatrists. They do not specialize in treating or researching cancer, glaucoma or MS. One is a general practitioner who works as a wellness counselor at a health spa. Under oath he admits to using every illegal, mind-altering drug he has ever studied, and he prides himself on recommending drugs that would never be recommended by medical schools or reputable physicians. Another is a general practitioner who quit practicing in 1974. He admits he has not kept up on new medical and scientific information about marijuana for 18 years.

Only one of the doctors called by NORML is a nationally-recognized expert. Doctor John C. Merritt is a board-certified ophthalmologist and researcher who has authored articles on the use of marijuana and cannabinoids to reduce eye pressure. He is in private practice and sees mostly children who suffer from glaucoma. Doctor Merritt testified, "[M]arijuana is a highly effective IOP-lowering drug which may be of critical value to some glaucoma patients who, without marijuana, would progressively go blind." The last scientific study using marijuana in glaucoma patients, published by Doctor Merritt in 1979, concluded:

It is because of the frequency and severity with which the untoward events occurred that marijuana inhalation is not an ideal therapeutic modality for glaucoma patients.

One year later, in 1980, Doctor Merritt gave the following testimony, under oath, before the United States Congress, House Select Committee on Narcotics Abuse and Control:

For me to sit here and say that the lowering pressure effects occurred repeatedly, day in and day out, I have no data, and neither does anyone else, and that is the real crux of the matter. When we are talking about treating a disease like glaucoma, which is a chronic disease, the real issue is, does the marijuana repeatedly lower the intraocular pressure? I have shown you no \* \* \* studies, and to my knowledge there is no data to that effect.

Doctor Merritt was unable to explain, under oath, the contradictory positions he has taken on this subject.

Each of NORML's doctors testified his opinion is based on the published scientific studies. With one exception, none of them could identify under oath the scientific studies they swore they relied on. Only one had enough knowledge to discuss the scientific technicalities involved. Eventually, each

one admitted he was basing his opinion on anecdotal evidence, on stories he heard from patients, and on his impressions about the drug.

Sadly, Doctor Ivan Silverberg, an oncologist from San Francisco, exaggerated while on the witness stand. At first he swore "there is voluminous medical research which shows marijuana is effective in easing nausea and vomiting." Pushed on cross-examination to identify this voluminous research, Doctor Silverberg replied, "Well \* \* \*, I'm going to have to back off a little bit from that." How far would Doctor Silverberg back off? Was he aware, at least, of the approximate number of scientific studies that have been done using marijuana to treat nausea? Under oath, he replied, "I would doubt very few. But, no, I'm not."

Beyond doubt, the claims that marijuana is medicine are false, dangerous and cruel.

Sick men, women and children can be fooled by these claims and experiment with the drug. Instead of being helped, they risk serious side effects. If they neglect their regular medicines while trying marijuana, the damage could be irreversible. It is a cruel hoax to offer false hope to desperately ill people.

Those who insist marijuana has medical uses would serve society better by promoting or sponsoring more legitimate scientific research, rather than throwing their time, money and rhetoric into lobbying, public relations campaigns and perennial litigation.

#### Clarification of Currently Accepted Medical Use

The Controlled Substances Act of 1970 divides the universe of all drugs of abuse into five sets or schedules. Drugs in Schedule I are subject to the most severe controls, because they have a high potential for abuse and no currently accepted medical use in treatment in the United States. 21 U.S.C. 812 (b)(1). Drugs of abuse which have currently accepted medical use in treatment in the United States are placed in Schedules II, III, IV and V. Regrettably, the Controlled Substances Act does not speak directly to what is meant by "currently accepted medical use."

A century before the Controlled Substances Act was enacted, the determination of what drugs to accept as medicine was totally democratic and totally standardless. Each patient and each physician was free to decide for himself, often based on no more than anecdotal evidence. This state of affairs became unsatisfactory to a majority of the American people. In 1906, Congress intervened with the passage of the Food, Drug and Cosmetic Act (FDCA). A shift

began away from anecdotal evidence to objectively conducted scientific research, away from uninformed opinions of lay persons and local doctors to expert opinions of specialists trained to evaluate the safety and effectiveness of drugs, and away from totally democratic decision-making to oversight by the Federal Government.

By 1969, Congress had developed detailed Federal statutory criteria under the FDCA to determine whether drugs are acceptable for medical use. Those deemed acceptable can be marketed nationally. Those deemed unacceptable are subject to Federal seizure if marketed interstate. The FDCA is a very complex regulatory scheme not easily summarized. However, it is fair to say that drugs falling into one of four FDCA categories were accepted by Congress for medical use.

First, Congress accepted new drugs which have been approved by FDA's experts as safe and effective for use in treatment, based on substantial scientific evidence. 21 U.S.C. 321(p) and 355 (so-called "NDA-approved drugs").

Second, Congress accepted those drugs "generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective," based on substantial scientific evidence. 21 U.S.C. 321(p) and 355; *Weinberger v. Bentex Pharmaceuticals, Inc.*, 412 U.S. 645 (1973). An acronym for this category is "human GRASE drugs" (Generally Recognized As Safe and Effective). These drugs achieve acceptance through rigorous scientific proof, through a past history of widespread use in treatment in the United States, and through recognition by a consensus of drug experts outside the FDA.

Third, Congress accepted for use in veterinary medicine those drugs "generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective," based on substantial scientific evidence. 21 U.S.C. 321(w) and 355. An acronym for these is "animal GRASE drugs." They achieve acceptance through rigorous scientific evidence and through recognition by a consensus of drug experts outside the FDA. Unlike human GRASE drugs, animal GRASE drugs need not have a past history of widespread use.

Finally, Congress accepted those drugs marketed prior to 1938 which had been subject to the 1906 provisions of the FDCA, provided these very old drugs retain their exact formulations and are never promoted for new uses. 21 U.S.C. 321(p) and (w). These are politically

"grandfathered" drugs. They need not meet modern standards for safety and effectiveness.

A fifth group of drugs was accepted for research use only, not for use in treatment of patients. 21 U.S.C. 355(i) (so-called "IND or approved investigational new drugs").

Drugs intended for medical use and shipped interstate are subject to Federal seizure under the FDCA if they do not fit within one of the above accepted sets or groupings. It seems fair to say that seizable drugs were rejected by Congress for medical uses.

In enacting the Controlled Substances Act in 1970, could Congress have intended to create a totally new Federal standard for determining whether drugs have accepted medical uses? Or did Congress intend to rely on standards it had developed over the prior 64 years under the FDCA? There is nothing in the Controlled Substances Act, its legislative history, or its purposes that would indicate Congress intended to depart radically from existing Federal law.

Indeed, it seems likely that the core standards developed under the FDCA represent a long-term consensus of expert medical and scientific opinion concerning when a drug should be accepted by anyone as safe and effective for medical use.

Fortunately, there is a way to corroborate what Congress intended. Congress did more than just announce criteria for scheduling drugs of abuse under the Controlled Substances Act: Congress applied those criteria to an initial listing of drugs that it placed into the original five schedules of the Act.

NDA-approved drugs were placed by Congress into Schedules II, III, IV and V of the Act. For example, pethidine (also known as meperidine) received New Drug Application (NDA) approval in 1942. Congress put it into Schedule II(b)(14). Methamphetamine had an approved NDA. Congress put it into Schedule III(a)(3). I am not aware of any drug with an approved NDA that Congress originally put into Schedule I.

Drugs with medical uses, but without approved NDA's also were placed by Congress into Schedules II, III, IV and V. For example, cocaine was put into Schedule II(a)(4). Codeine combinations were put into Schedules III(d)(1) and V. Morphine combinations were put into Schedule III(d)(8). Phenobarbital was put into Schedule IV(11). Barbiturates were put into Schedule III(b)(1). Amphetamines were put into Schedule III(a)(1).

The Court of Appeals for the First Circuit was correct when it decided in

*Grinspoon v. DEA*, 828 F.2d 881 (1987) that NDA approval is not the only method by which drugs can achieve Federal recognition as having medical uses. Congress put both GRASE drugs and pre-1938-grandfathered drugs into Schedules II, III, IV and V of the CSA.

Drugs recognized under the FDCA for research use only, not for use in treatment, such as alphacetylmethadol and marijuana, were placed by Congress into Schedule I.

Unfortunately, Federal records are not complete enough to do a comprehensive mathematical mapping, tracing every drug in the initial Controlled Substances Act schedules back to its legal status under the FDCA. Nevertheless, determining legislative intent does not require mathematical certainty. Probability based on circumstantial evidence, on samplings, and on inductive reasoning can suffice, especially when there is nowhere else to turn.

The pattern of initial scheduling of drugs in the Controlled Substance Act, viewed in light of the prior legal status of these drugs under the FDCA, convinces me that Congress equated the term "currently accepted medical use in treatment in the United States" as used in the Controlled Substances Act with the core FDCA standards for acceptance of drugs for medical use.

This is not to say that every FDCA requirement for GRASE status, or for NDA approval, is pertinent to scheduling determinations under the Controlled Substances Act. There are differences. But the core FDCA criteria appear to have guided the Congress in the decisions it made concerning the initial scheduling of drugs in the Act.

These same core FDCA criteria served as the basis for an eight-point test used by my predecessor as Administrator to describe drugs with currently accepted medical uses. 54 FR 53783 (December 29, 1989):

1. Scientifically determined and accepted knowledge of its chemistry;
2. The toxicology and pharmacology of the substance in animals;
3. Establishment of its effectiveness in humans through scientifically designed clinical trials;
4. General availability of the substance and information regarding the substance and its use;
5. Recognition of its clinical use in generally accepted pharmacopeia, medical references, journals or textbooks;
6. Specific indications for the treatment of recognized disorders;
7. Recognition of the use of the substance by organizations or associations of physicians; and

8. Recognition and use of the substance by a substantial segment of the medical practitioners in the United States.

Some uncertainty remains over the precise meaning and application of parts of this test. Therefore, the Court of Appeals for the District of Columbia Circuit remanded these proceedings for a further explanation. In addition to addressing those parts of the test that concerned the Court of Appeals, it would be useful to clarify the entire test, pinpoint its origins, and identify which elements are both necessary and sufficient to establish a prima facie case of currently accepted medical use. This is not an effort to change the substantive law. The statutory meaning of currently accepted medical use remains the same as enacted by Congress in 1970. My purpose simply is to clarify this Agency's understanding of the law.

#### *A. The Drug's Chemistry Must Be Known and Reproducible*

The ability to recreate a drug in standardized dosages is fundamental to testing that drug and to using it as a medicine. Knowing the composition, properties, methods of production, and methods of analysis of a drug is essential to reproducing it in standardized dosages. To be GRASE or to receive NDA approval, a drug's chemistry must be known and reproducible. See *e.g.*, 21 CFR 314.50(d)(1) and 314.126(b)(7)(d); *Dorovic v. Richardson*, 749 F.2d 242, 251 (7th Cir. 1973). The listing of a drug in a current edition of one of the official compendia normally satisfies this requirement. 21 U.S.C. 321(j); 21 CFR 314.50(d)(1).

The first element of our eight-point test, namely, "scientifically determined and accepted knowledge of its chemistry," should be clarified to read:

The substance's chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official compendia, as defined by section 201(j) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321(j), is sufficient generally to meet this requirement.

Acceptance of this knowledge will be discussed elsewhere.

#### *B. There Must Be Adequate Safety Studies*

No drug can be considered safe in the abstract. Safety has meaning only when judged against the intended use of the drug, its known effectiveness, its known and potential risks, the severity of the illness to be treated, and the availability of alternative therapies. *Hess & Clark Division of Rhodia, Inc. v. FDA*, 495 F.2d 975, 993 (D.C. Cir. 1974). To know the

risks, there must be adequate studies, by all methods reasonably applicable, to show the pharmacological and toxicological effects of the drug. 21 CFR 314.125(b)(2). This includes animal studies and clinical trials in large numbers of humans. 21 CFR 312.21. The studies need not be well-controlled, but they must be adequate. *Edison Pharmaceuticals Co. v. FDA*, 600 F.2d 831 (D.C. Cir. 1979). Short term (acute) studies of a drug intended to treat long-term (chronic) illnesses, such as glaucoma or MS, are clearly inadequate. *United States v. Naremcro, Inc.*, 553 F.2d 1138, 1143 (8th Cir. 1977). The second element of our eight-point test, namely, "the toxicology and pharmacology of the substance in animals," should be clarified as follows:

There must be adequate pharmacological and toxicological studies, done by all methods reasonably applicable, on the basis of which it could fairly and responsibly be concluded, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, that the substance is safe for treating a specific, recognized disorder.

It must be emphasized that while the existence of adequate safety tests is a separate analytical question, the ultimate determination of whether a drug is safe for a specific use is not a distinct issue. Safety and effectiveness are inextricably linked in a risks-benefits calculation. A determination that a drug is ineffective is tantamount to a determination that it is unsafe. *United States v. Rutherford*, 442 U.S. 544 (1970).

The scheduling criteria of the Controlled Substances Act appear to treat the lack of medical use and lack of safety as separate considerations. Prior rulings of this Agency purported to treat safety as a distinct factor. 53 FR 5156 (February 22, 1988). In retrospect, this is inconsistent with scientific reality. Safety cannot be treated as a separate analytical question.

#### *C. There Must Be Adequate and Well-Controlled Studies Proving Efficacy*

Since 1962, Congress has prohibited the FDA to approve an NDA unless the applicant submits adequate, well-controlled, well-designed, well-conducted, and well-documented studies, performed by qualified investigators, which prove the efficacy of a drug for its intended use. 21 U.S.C. 355(d); 21 CFR 314.126. Similarly, a drug cannot be considered GRASE unless it is supported by this same quantity and quality of scientific proof. 21 CFR 314.200(e)(i); *Weinberger v. Hynson, Etc.*, 412 U.S. 609, 629 (1973).

Studies involving related, but not identical, drugs are irrelevant. *United States v. Articles of Food & Drug*, 518 F.2d 743, 747 (5th Cir. 1975). Studies involving the same drug combined with other drugs are irrelevant. *United States v. Articles of Drug \* \* \* Promise Toothpaste*, 826 F.2d 564, 570 (7th Cir. 1987). *Incomplete studies are insufficient. United States v. Articles of Food & Drug*, *supra*. Uncontrolled studies are insufficient. 21 U.S.C. 355(d); *Cooper Labs v. FDA*, 501 F.2d 772, 778 (D.C. Cir. 1974). Statistically insignificant studies are insufficient. 21 CFR 312.21, 314.50(d)(6) and 314.126(b)(7). Poorly designed studies are insufficient. 21 CFR 314.126(b)(2). Poorly conducted studies are insufficient. 21 CFR part 58—Good Laboratory Practices. Poorly documented studies are insufficient. 21 CFR 312.58 and 314.200(e)(4). Studies by investigators who are not qualified, both to conduct and to evaluate them are insufficient. 21 U.S.C. 355(d). Moreover, since scientific reliability requires a double examination with similar results, one valid study is insufficient. There must be two or more valid studies which corroborate each other. See 1 J. O'Reilly "Food and Drug Administration" 13-55 n.12 (1985).

Lay testimonials, impressions of physicians, isolated case studies, random clinical experience, reports so lacking in details they cannot be scientifically evaluated, and all other forms of anecdotal proof are entirely irrelevant. 21 CFR 314.126(e); *Weingerger v. Hynson, Etc.*, 412 U.S. 609, 630 (1973).

Element three of our eight-point test, namely, "establishment of its effectiveness in humans through scientifically designed clinical trials," should be restated as:

There must be adequate, well-controlled, well-designed, well-conducted and well-documented studies, including clinical investigations, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, on the basis of which it could fairly and responsibly be concluded by such experts that the substance will have the intended effect in treating a specific, recognized disorder.

#### D. Acceptance by Qualified Experts Is Required

The opinions of lay persons are totally irrelevant to whether a drug is GRASE or meets NDA requirements. The observations and opinions of medical practitioners who are not experts in evaluating drugs also are irrelevant to whether a drug is GRASE or meets NDA requirements. *Weinberger v. Hynson, Etc.*, 412 U.S. 609, 619 (1973). By explicit

requirements in the FDCA since 1938, the only body of opinion that counts is that of experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs. 21 U.S.C. 321 (p) and (w).

From this, one would conclude that expert acceptance of a drug as safe and effective for its intended use is essential to a drug having a currently accepted medical use under the CSA. How widespread must this expert acceptance be?

To be GRASE, a drug must be "generally recognized" among experts as safe and effective for its intended use. The drug must be known or familiar to the national community of relevant experts. *United States v. Articles of Drug \* \* \* Furestrol Vaginal Suppositories*, 294 F. Supp. 1307, 1309 (N.D. Ga. 1968) *aff'd*, 415 F.2d 390 (5th Cir. 1969). To determine if a drug is known to the community of experts, courts have looked to whether there is widely available scientific literature about the drug, *Premo Pharmaceutical Laboratories, Inc. v. United States*, 629 F.2d 795, 803 (2d Cir. 1980), whether it is widely taught in medical schools, *Lemmon Pharmaceuticals Co. v. Richardson*, 319 F. Sup. 375, 378 (E.D. Pa. 1970), and whether it is widely discussed by experts. *United States v. Bentex Ulcerine*, 469 F. 2d 875, 880 (5th Cir. 1972).

The recognition of a drug as GRASE need not be universal. General recognition is sufficient. *United States v. 41 Cartons \* \* \* Ferro-Lac*, 420 F.2d 1126, 1132 (5th Cir. 1970). The Supreme Court has interpreted this to mean a consensus of experts is familiar with and accepts a drug as safe and effective. *Weinberger v. Hynson, Etc.*, 412 U.S. 609, 629 (1973). However, if there is a serious dispute among the experts, a drug cannot be considered GRASE. *United States v. An Article of Food \* \* \* Coco Rico*, 752 F.2d 11, 15 (1st Cir. 1985); *Merrit Corp. v. Folsom*, 165 F. Supp. 418, 421 (D.D.C. 1958).

During the NDA process, the FDA may reach out to the expert community for its views. 21 CFR 314.103(c)(3). The FDA need not determine that a drug is generally known and accepted by the expert community. Nor must the FDA develop a consensus of opinion among outside experts. The FDA has both the experts and the statutory mandate to resolve conflicts over the safety and efficacy of new drugs. *Weinberger v. Bentex Pharmaceuticals, Inc.*, 412 U.S.C. 638, 653 (1973).

In drafting the Controlled Substances Act, Congress appears to have accommodated, rather than chosen from these different FDCA standards. Clearly,

the Controlled Substances Act does not authorize the Attorney General, nor by delegation the DEA Administrator, to make the ultimate medical and policy decision as to whether a drug should be used as medicine. Instead, he is limited to determining whether others accept a drug for medical use. Any other construction would have the effect of reading the word "accepted" out of the statutory standard. Since Congress recognized NDA-approved drugs as having currently accepted medical uses, without any need for a national consensus of experts, FDA acceptance of a drug through the NDA process would seem to satisfy the Controlled Substances Act. And, since Congress recognized GRASE drugs as having currently accepted medical uses, without the need for NDA approval, acceptance of a drug by a national consensus of experts also would seem to satisfy the Act.

When a drug lacks NDA approval and is not accepted by a consensus of experts outside FDA, it cannot be found by the Attorney General or his delegate to have a currently accepted medical use. To do so would require the Attorney General to resolve complex scientific and medical disputes among experts, to decide the ultimate medical policy question, rather than merely determine whether the drug is accepted by others.

Because the recognition of a drug by non-experts is irrelevant to GRASE status, to NDA approval, and to currently accepted medical use under the Controlled Substances Act, points seven and eight of our eight-point test should be combined and restated as follows:

The drug has a New Drug Application (NDA) approved by the Food and Drug Administration pursuant to the Food, Drug and Cosmetic Act, 21 U.S.C. 355. Or, a consensus of the national community of experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, accepts the safety and effectiveness of the substance for use in treating a specific, recognized disorder. A material conflict of opinion among experts precludes a finding of consensus.

This restatement also incorporates the component of part one of our eight-point test concerning "accepted knowledge of its chemistry."

#### E. The Scientific Evidence Must Be Widely Available

Nothing in the FDCA, nor in FDA's regulations, requires that scientific evidence supporting an NDA be published. This stems from the fact that a consensus of experts outside FDA is



not required for NDA approval. In contrast, most courts have held that a drug cannot be considered GRASE unless the supporting scientific evidence appears in the published scientific and medical literature. Without published studies, it would be difficult for the community of experts outside FDA to develop an informed acceptance of a drug for medical use. *Cooper Labs Inc. v. FDA*, 501 F.2d 772, 786 (D.C. Cir. 1974).

Point four of the eight-point test focuses, in part, on the "general availability of information regarding the substance and its use." This should be clarified to read:

In the absence of NDA approval, information concerning the chemistry, pharmacology, toxicology and effectiveness of the substance must be reported, published, or otherwise widely available, in sufficient detail to permit experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, to fairly and responsibly conclude the substance is safe and effective for use in treating a specific, recognized disorder.

#### F. General Availability of a Drug Is Irrelevant

The second component of point four of the eight-point test involves the "general availability of the substance" for use in treatment. The second component of point eight focuses on "use of the substance by a substantial segment of the medical practitioners in the United States." These elements justifiably concerned the Court of Appeals, leading to the remand in this case.

Under the FDCA, a human GRASE drug must have a material history of past use in treatment in the United States. 21 U.S.C. 321(p)(2) (which has \* \* \*, otherwise than in such investigations, been used to a material extent or a material time); *Weinberger v. Hynson, Etc.*, 412 U.S. 609, 631 (1973). Rigorous scientific proofs and current unanimous acceptance by the medical and scientific community are not enough for a human drug to be GRASE. *Tri-Bio Labs, Inc. v. United States*, 836 F.2d 135, 142 n.8 (3d Cir. 1987). The general availability of a drug for use in treatment is a factor courts have considered to determine if a human drug is GRASE.

In contrast, a drug can achieve current acceptance for human medical use through the NDA process without a past history of use in treatment. Also, animal drugs can become accepted as GRASE without any past history of medical use. Given this conflict in FDCA standards, which did Congress choose when drafting the CSA?

As the Court of Appeals points out, requiring a material history of past use in treatment before recognizing a drug as having a currently accepted medical use, would permanently freeze all Schedule I drugs into Schedule I. 930 F.2d at 940. Clearly, Congress did not intend this result. Moreover, the use of the word "currently" before the term "accepted medical use" would indicate Congress rejected the human GRASE requirement of past material use in treatment. I conclude that the general availability of a drug is irrelevant to whether it has a currently accepted medical use in treatment within the meaning of the Controlled Substances Act.

#### G. Recognition in Generally Accepted Texts Is Irrelevant

Point five of the eight-point test deals with "recognition of its clinical use in generally accepted pharmacopeia, medical references, journals or textbooks." The listing of a drug in an official compendium is sufficient to show its chemistry is scientifically established. This appears in my clarification to point one. The requirement that information concerning the chemistry, pharmacology, toxicology and effectiveness of the substance be reported, published or otherwise widely available, is explained adequately in revised point four. To the extent the scheduling of a drug directly influences its recognition in publications, this element is subject to the same criticism identified by the Court of Appeals concerning point four. Therefore, this should not be treated as a distinct requirement.

#### H. Specific, Recognized Disorders Are the Referent

It is impossible to judge the safety and effectiveness of a drug except in relation to a specific intended use. A drug cannot obtain NDA approval or GRASE status except in relation to the treatment of a specific, recognized disorder. This is an essential aspect of whether a drug has currently accepted medical use. Rather than standing alone, this requirement will be more clearly understood by incorporating it into the other critical elements.

To summarize, the five necessary elements of a drug with currently accepted medical use in treatment in the United States are:

#### (i) The Drug's Chemistry Must Be Known and Reproducible

The substance's chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official

compendia, as defined by section 201(j) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321(j), is sufficient generally to meet this requirement.

#### (ii) There Must Be Adequate Safety Studies

There must be adequate pharmacological and toxicological studies done by all methods reasonably applicable on the basis of which it could fairly and responsibly be concluded, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, that the substance is safe for treating a specific, recognized disorder.

#### (iii) There Must Be Adequate and Well-Controlled Studies Proving Efficacy

There must be adequate, well-controlled, well-designed, well-conducted and well-documented studies, including clinical investigations, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs on the basis of which it could fairly and responsibly be concluded by such experts, that the substance will have its intended effect in treating a specific, recognized disorder.

#### (iv) The Drug Must Be Accepted by Qualified Experts

The drug must have a New Drug Application (NDA) approved by the Food and Drug Administration, pursuant to the Food, Drug and Cosmetic Act, 21 U.S.C. 355. Or, a consensus of the national community of experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, must accept the safety and effectiveness of the substance of use in treating a specific, recognized disorder. A material conflict of opinion among experts precludes a finding of consensus.

#### (v) The Scientific Evidence Must Be Widely Available

In the absence of NDA approval, information concerning the chemistry, pharmacology, toxicology and effectiveness of the substance must be reported, published, or otherwise widely available in sufficient detail to permit experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, to fairly and responsibly conclude the substance is safe and effective for use in treating a specific, recognized disorder.

Together these five elements constitute prima facie evidence that a drug has currently accepted medical use in treatment in the United States. In the interest of total clarity, let me emphasize those proofs that are irrelevant to the determination of currently accepted medical use, and that will not be considered by the Administrator:

- (i) Isolated case reports;
- (ii) Clinical impressions of practitioners;
- (iii) Opinions of persons not qualified by scientific training and experience to evaluate the safety and effectiveness of the substance at issue;
- (iv) Studies or reports so lacking in detail as to preclude responsible scientific evaluation;

(v) Studies or reports involving drug substances other than the precise substance at issue;

(vi) Studies or reports involving the substance at issue combined with other drug substances;

(vii) Studies conducted by persons not qualified by scientific training and experience to evaluate the safety and effectiveness of the substance at issue;

(viii) Opinions of experts based entirely on unrevealed or unspecified information;

(ix) Opinions of experts based entirely on theoretical evaluations of safety or effectiveness.

#### *Bad Medicine By Any Standard*

My predecessor as DEA Administrator developed and relied upon an eight-point test to determine whether marijuana has accepted medical uses. 54 FR 53783 (December 29, 1989):

1. Scientifically determined and accepted knowledge of its chemistry;
2. the toxicology and pharmacology of the substance in animals;
3. Establishment of its effectiveness in humans through scientifically designed clinical trials;
4. General availability of the substance and information regarding the substance and its use;
5. Recognition of its clinical use in generally accepted pharmacopeia, medical references, journals or textbooks;
6. Specific indications for the treatment of recognized disorders;
7. Recognition of the use of the substance by organizations or associations of physicians; and
8. Recognition and use of the substance by a substantial segment of the medical practitioners in the United States.

The Court of Appeals remanded the decision of my predecessor for clarification of what role factors (4), (5) and (8) of the initial eight-point test played in his reasoning. For ease of discussion, these factors can be divided as follows:

(4)(a) General availability of the substance \* \* \*;

(4)(b) General availability of \* \* \* information regarding the substance and its use;

(5) Recognition of its clinical use in generally accepted pharmacopeia, medical references, journals or textbooks;

(8)(a) Recognition \* \* \* of the substance by a substantial segment of the medical practitioners in the United States; and

(8)(b) [U]se of the substance by a substantial segment of the medical practitioners in the United States.

I have found no evidence indicating initial factors (4)(a) or (8)(b) played any role in my predecessor's decision. In light of my understanding of the legal standard involved, these factors are irrelevant to whether marijuana has a currently accepted medical use.

My predecessor emphasized the lack of scientific evidence of marijuana's

effectiveness, and the limited data available on its risks, as reflected in the published scientific studies. He also emphasized the importance of this data to the conclusions reached by experts concerning the drug. 54 FR 53783. I take this to mean that, under initial factor (4)(b), he believed the information available to experts is insufficient for them responsibly and fairly to conclude the marijuana is safe and effective for use as medicine.

Marijuana is not recognized as medicine in generally accepted pharmacopeia, medical references and textbooks, as noted by my predecessor. 54 FR 53784. I take this to mean, under initial factor (5), that he determined that marijuana's chemistry is neither known, nor reproducible, as evidenced by its absence from the official pharmacopeia. Finally, my predecessor concluded, under initial factor (8)(a), that the vast majority of physicians does not accept marijuana as having medical use. 54 FR 53784. Along the way, he found that highly respected oncologists and antiemetic researchers reject marijuana for use in controlling nausea and vomiting, 54 FR 53777, that experts experienced in researching glaucoma medications reject marijuana for use in treating glaucoma, 54 FR 53779, and that noted neurologists who specialize in treating and conducting research in spasticity reject marijuana for use by MS patients, 54 FR 53780. I take this to mean my predecessor found no national consensus of qualified experts accepts marijuana's value as medicine.

Certainly I cannot know my predecessor's unstated reasoning. However, I have reviewed the entire record *de novo*, and I am convinced that his application of the initial eight-point test to this record correctly resulted in the conclusion that marijuana has no currently accepted medical use in treatment in the United States. Therefore, I adopt in their entirety the findings of facts and conclusions of law reached by the former Administrator in his final order of December 21, 1989, 54 FR 53767.

Pursuant to the remand of the Court of Appeals, I have condensed and clarified the initial standard into a five-point test. My application of the refined, five-point test to this record is set out briefly below.

First, marijuana's chemistry is neither fully known, nor reproducible. Thus far, over 400 different chemicals have been identified in the plant. The proportions and concentrations differ from plant to plant, depending on growing conditions, age of the plant, harvesting and storage factors. THC levels can vary from less than 0.2% to over 10%. It is not known

how smoking or burning the plant material affects the composition of all these chemicals. It is not possible to reproduce the drug in dosages which can be considered standardized by any currently accepted scientific criteria. Marijuana is not recognized in any current edition of the official compendia. 21 U.S.C. 321(j).

Second, adequate safety studies have not been done. All reasonably applicable pharmacological and toxicological studies have not been carried out. Most of the chronic animal studies have been conducted with oral or intravenous THC, not with marijuana. Pharmacological data on marijuana's bioavailability, metabolic pathways and pharmacokinetics is inadequate. Studies in humans are too small and too few. Sophisticated epidemiological studies of marijuana use in large populations are required, similar to those done for tobacco use. Far too many questions remain unknown for experts fairly and responsibly to conclude marijuana is safe for any use.

Third, there are no adequate, well-controlled scientific studies proving marijuana is effective for anything.

Fourth, marijuana is not accepted for medical use in treatment by even a respectable minority, much less a consensus, of experts trained to evaluate drugs. The FDA's expert drug evaluators have rejected marijuana for medical use. No NDA has been approved by FDA for marijuana. The testimony of nationally recognized experts overwhelmingly rejects marijuana as medicine, compared to the scientifically empty testimony of the psychiatrists, a wellness counselor and general practitioners presented by NORML.

Fifth, given my conclusions on points one, two and three, it follows that the published scientific evidence is not adequate to permit experts to fairly and responsibly conclude that marijuana is safe and effective for use in humans.

A failure to meet just one of the five points precludes a drug from having a currently accepted medical use. Marijuana fails all five points of the test.

NORML has argued, unsuccessfully, that the legal standard for currently accepted medical use should be whether a respectable minority of physicians accepts the drug. The key to this medical malpractice defense is that the minority opinion must be recognized as respectable, as competent, by members of the profession.

In the absence of reliable evidence adequately establishing marijuana's chemistry, pharmacology, toxicology and effectiveness, no responsible physician could conclude that marijuana

is safe and effective for medical use. To quote Doctor Kenneth P. Johnson, Chairman of the Department of Neurology at the University of Maryland, and the author of over 100 scientific and medical articles on MS: "To conclude that marijuana is therapeutically effective without conducting rigorous testing would be professionally irresponsible."

By any modern scientific standard, marijuana is no medicine.

Under the authority vested in the Attorney General by section 201(a) of the Controlled Substances Act, 21 U.S.C. 811(a), and delegated to the Administrator of the Drug Enforcement Administration by regulations of the Department of Justice, 28 CFR 0.100(b), the Administrator hereby orders that marijuana remain in Schedule I as listed in 21 CFR 1308.11(d)(14).

Dated: March 18, 1992.

**Robert C. Bonner,**

*Administrator.*

[FR Doc. 92-8714 Filed 3-25-92; 8:45 am]

BILLING CODE 4410-09-M

## NUCLEAR REGULATORY COMMISSION

### ENVIRONMENTAL PROTECTION AGENCY

#### Proposed Guidance Document on the Testing of Mixed Radioactive and Hazardous Waste

**AGENCIES:** Nuclear Regulatory Commission, Environmental Protection Agency.

**ACTION:** Notice of availability and request for public comment.

**SUMMARY:** The Nuclear Regulatory Commission (NRC) and the Environmental Protection Agency (EPA) are jointly issuing a proposed guidance document on the testing of mixed radioactive and hazardous waste (mixed waste). This guidance document was developed to assist mixed waste generators in identifying and performing the testing required under the Federal regulations that implement the Resource Conservation and Recovery Act Subtitle C hazardous waste program and to ensure that employee radiation exposures are maintained As Low As Reasonably Achievable (ALARA). The agencies are soliciting comments from interested members of the regulated community, the States, and the public.

Interested individuals may provide the agencies with their comments on the proposed guidance document by forwarding their written comments to the NRC at the address listed in the "ADDRESSES" section. Interested parties

may also participate in a public meeting being held to solicit oral comments on the proposed guidance document. Interested individuals will be given an opportunity to speak for fifteen minutes at this meeting. This time allowance may be extended, on request for good cause, if the schedule of speakers permits this extension.

**DATES:** The agencies will accept written comments until May 26, 1992.

Individuals submitting comments after this date cannot be assured that the agencies will be able to afford their comments full consideration in any revisions that may be made to the proposed guidance document.

The public meeting to solicit oral comments on the proposed guidance document will be held on April 14, 1992, from 8:30 a.m. until 4:30 p.m. at the Mayflower/Stouffer Hotel, New York Room 1127 Connecticut Avenue NW., Washington, DC 20036, telephone (202) 347-3000.

**ADDRESSES:** Copies of the proposed guidance document may be obtained by contacting Dominick A. Orlando, NRC Mixed Waste Project Manager, Division of Low-Level Waste Management and Decommissioning, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555, telephone (301) 504-2566.

Written comments on the proposed guidance document should be directed to David L. Meyer, Chief, Regulatory Publications Branch, Division of Freedom of Information and Publications Service, Office of Administration, U.S. Nuclear Regulatory Commission, Washington, DC 20555 or hand delivered to the Commission's offices at 7920 Norfolk Avenue, Bethesda, MD between the hours of 7:45 a.m. and 4:14 p.m. on Federal workdays.

Requests to speak at the public meeting should be submitted, in writing, to EPA. The written request should be addressed to Reid Rosnick, Mixed Waste Coordinator, Permits and State Programs Branch, Office of Solid Waste (OS-342), U.S. Environmental Protection Agency, 401 M Street SW., Washington, DC 20460. Interested speakers should include in the written request a statement identifying the topics to be addressed in their presentations, the names and affiliations of the individual(s) that will speak, and the amount of time the speaker(s) will require. A transcript of the oral proceedings will be included in the record for this action.

**FOR FURTHER INFORMATION CONTACT:** Dominick A. Orlando, Mixed Waste Project Manager, Division of Low-Level

Waste Management and Decommissioning, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555, telephone (303) 504-2566 or; Reid Rosnick, Mixed Waste Coordinator, Permits and State Programs Division, Office of Solid Waste, U.S. Environmental Protection Agency, 401 M Street SW., Washington, DC 20460, telephone (202) 260-4755.

Dated at Rockville, MD this 19th day of March, 1992.

For the U.S. Nuclear Regulatory Commission.

**Robert M. Bernero,**

*Director, Office of Nuclear Material Safety and Safeguards.*

For the U.S. Environmental Protection Agency.

**Sylvia K. Lowrance,**

*Director, Office of Solid Waste.*

[FR Doc. 92-7031 Filed 3-25-92; 8:45 am]

BILLING CODE 7590-01-M

## OFFICE OF MANAGEMENT AND BUDGET

### Circular No. A-76: Performance of Commercial Activities; Amendment

**AGENCY:** Office of Management and Budget.

**ACTION:** Issuance of Transmittal Memorandum No. 11, amending OMB Circular No. A-76, "Performance of Commercial Activities."

**SUMMARY:** This notice contains Transmittal No. 11, dated February \_\_\_\_\_, 1992, to OMB Circular No. A-76, "Performance of Commercial Activities."

This Transmittal Memorandum updates the Federal pay raise assumptions and inflation factors used for computing the Government's in-house personnel and non-pay cost increases for Fiscal Years 1992 through 1997. The Federal pay raise assumptions and the non-pay category rates are contained in the President's Budget for Fiscal Year 1993. The factors contained in OMB Circular No. A-76, Transmittal Memorandum No. 10, dated February 28, 1991, are outdated.

The revision does not require any agency to (1) create or maintain a duplicate control/monitoring/reporting system or (2) adopt any additional controls, not presently in compliance with Federal Acquisition Regulations (FAR).

**FOR FURTHER INFORMATION CONTACT:** Mr. David Childs, Federal Services Branch, General Management Division.